PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rochon, PA; Gurwitz, JH				Rochon, PA; Gurwitz, JH			Prescribing for seniors - Neither too much nor too little	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; REPLACEMENT; WOMEN		Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; Univ Toronto, Dept Med, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of Toronto; University of Toronto	Rochon, PA (corresponding author), Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Barakat K, 1999, LANCET, V353, P955, DOI 10.1016/S0140-6736(98)07114-1; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Handa VL, 1996, J AM GERIATR SOC, V44, P1; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Josse R, 1996, CAN MED ASSOC J, V155, P1113; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MYERS MG, 1995, GUIDELINES TREATMENT; National Osteoporosis Foundation, 1998, PHYS GUID PREV TREAT; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spurgeon D, 1999, BRIT MED J, V318, P961, DOI 10.1136/bmj.318.7189.961b; Steinbrook R, 1998, NEW ENGL J MED, V338, P1541, DOI 10.1056/NEJM199805213382111; TAMBLYN R, 1999, EVALUATION IMPACT RE	24	90	94	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					113	115		10.1001/jama.282.2.113	http://dx.doi.org/10.1001/jama.282.2.113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411177				2023-01-03	WOS:000081376800002
J	Soll, R				Soll, R			Consensus and controversy over resuscitation of the newborn infant	LANCET			English	Editorial Material							NEONATAL RESUSCITATION		Univ Vermont, Coll Med, Dept Paediat, Burlington, VT 05405 USA	University of Vermont	Soll, R (corresponding author), Univ Vermont, Coll Med, Dept Paediat, Burlington, VT 05405 USA.							Edwards AD, 1998, ARCH DIS CHILD-FETAL, V78, pF85, DOI 10.1136/fn.78.2.F85; Ginsberg HG, 1998, CLIN PERINATOL, V25, P1; Guyer B, 1998, PEDIATRICS, V102, P1333, DOI 10.1542/peds.102.6.1333; HEIN HA, 1993, PEDIATRICS, V91, P496; Kamenir SA, 1997, J TROP PEDIATRICS, V43, P170, DOI 10.1093/tropej/43.3.170; Kattwinkel J, 1999, CIRCULATION, V99, P1927, DOI 10.1161/01.CIR.99.14.1927; Nadkarni V, 1997, CIRCULATION, V95, P2185, DOI 10.1161/01.CIR.95.8.2185; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; SAUGSTAD OD, 1996, PRENAT NEONAT MED, V1, P26; TYSON JE, 1995, SEMIN PERINATOL, V19, P98, DOI 10.1016/S0146-0005(05)80030-8; *WHO, 1997, WORLD HLTH REP 1995, P21; Wiswell Thomas, 1998, Pediatric Research, V43, p203A; Zhu X. Y., 1997, SMJ, V38, P485	13	8	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					4	5		10.1016/S0140-6736(99)00149-X	http://dx.doi.org/10.1016/S0140-6736(99)00149-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406355				2023-01-03	WOS:000081243200004
J	Stevenson, GT				Stevenson, GT			Immunotherapy of non-metastatic complication of malignant disease	LANCET			English	Editorial Material									Univ Southampton, Tenovus Res Lab, Southampton SO16 6YD, Hants, England	University of Southampton	Stevenson, GT (corresponding author), Univ Southampton, Tenovus Res Lab, Southampton SO16 6YD, Hants, England.							Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; GLYNN LE, 1964, AUTOIMMUNITY; HOLLINSHEAD A, 1988, CANCER, V62, P1662, DOI 10.1002/1097-0142(19881015)62:8<1662::AID-CNCR2820620835>3.0.CO;2-X; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; SISKIND GW, 1974, FED PROC, V33, P1886; WARREN HS, 1988, CRC CR REV IMMUNOL, V8, P83	6	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 30	1999	353	9150					340	340		10.1016/S0140-6736(05)74942-4	http://dx.doi.org/10.1016/S0140-6736(05)74942-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950433				2023-01-03	WOS:000078437000003
J	Tomlin, PJ				Tomlin, PJ			A memorable incident - When is a spade not a spade	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1999	318	7178					256	256						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915741				2023-01-03	WOS:000078292300034
J	Bliss, DZ; Johnson, S; Savik, K; Clabots, CR; Willard, K; Gerding, DN				Bliss, DZ; Johnson, S; Savik, K; Clabots, CR; Willard, K; Gerding, DN			Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding	ANNALS OF INTERNAL MEDICINE			English	Article						Clostridium difficile; diarrhea; enteral feeding; hospitalization; Clostridium infections	CRITICALLY ILL PATIENTS; MICROBIAL-CONTAMINATION; ENTERAL FEEDS; COLONIZATION; INFECTION; SYSTEMS; HYPOALBUMINEMIA; ENVIRONMENT; DELIVERY; SEVERITY	Background: Clostridium difficile is the most common infectious cause of nosocomial diarrhea, but its role in diarrhea associated with tube feeding has not been rigorously investigated. Objective: To determine the incidence of C. difficile acquisition and C. difficile-associated diarrhea in tube-fed and non-tube-fed patients. Design: Prospective cohort study. Setting: A university-affiliated Veterans Affairs Medical Center. Patients: 76 consecutive hospitalized, tube-fed patients and 76 hospitalized, non-tube-fed patients. The two cohorts were matched for age, unit location, duration of hospitalization before surveillance, and severity of illness. Measurements: Incidence of C. difficile acquisition, incidence of C, difficile-associated diarrhea, and C. difficile restriction endonuclease analysis typing results. Results: More tube-fed patients than non-tube-fed patients acquired C. difficile (15 of 76 patients [20%] compared with 6 of 76 patients [8%]; P = 0.03) and developed C. difficile-associated diarrhea (7 of 76 patients [9%] compared with 1 of 76 patients [1%]; P = 0.03). The mean proportion (+/-SD) of surveillance days with diarrhea was greater for tube-fed patients after the development of C. difficile-associated diarrhea than for tube-fed patients without this diarrhea (0.68 +/- 0.4 compared with 0.22 +/- 0.2 [95% CI for the mean difference, 0.08 to 0.84]). Postpyloric tube feeding (odds ratio, 3.14 [CI, 1.008 to 9.77]) and duration of surveillance (odds ratio, 1.08 [CI, 1.0009 to 1.16]) were risk factors for the acquisition of C. difficile. Nineteen restriction endonuclease analysis types of C. difficile were identified from 20 patients. Conclusions: Hospitalized, tube-fed patients, especially those receiving postpyloric tube feeding, are at greater risk for the acquisition of C. difficile and the development of C. difficile-associated diarrhea than are hospitalized, non-tube-fed patients. Clinicians should test for C. difficile in tube-fed patients with diarrhea.	Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; Vet Affairs Chicago Healthcare Syst, Chicago, IL 60611 USA; Vet Affairs Med Ctr, Res Serv 151, Minneapolis, MN 55417 USA; Northwestern Univ, Sch Med, Chicago, IL USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Northwestern University	Bliss, DZ (corresponding author), Univ Minnesota, Sch Nursing, 6-101 Weaver Densford Hall,308 Dr Johnson & Gerdi, Minneapolis, MN 55455 USA.	bliss@tc.umn.edu		Johnson, Stuart/0000-0001-9548-229X	NINR NIH HHS [1F32-NR06746] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [F32NR006746] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ANDERSON KR, 1984, JPEN-PARENTER ENTER, V8, P673, DOI 10.1177/0148607184008006673; ANDERTON A, 1993, CLIN NUTR, V12, P16; ANDERTON A, 1990, CLIN NUTR, V9, P157, DOI 10.1016/0261-5614(90)90048-W; ANDERTON A, 1988, J HOSP INFECT, V11, P364, DOI 10.1016/0195-6701(88)90090-4; BETTIN K, 1994, INFECT CONT HOSP EP, V15, P697; BLISS DZ, 1992, AM J CLIN NUTR, V55, P753, DOI 10.1093/ajcn/55.3.753; BRINSON RR, 1987, CRIT CARE MED, V15, P506, DOI 10.1097/00003246-198705000-00011; BRINSON RR, 1988, CRIT CARE MED, V16, P130, DOI 10.1097/00003246-198802000-00007; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CLABOTS CR, 1989, J CLIN MICROBIOL, V27, P2386, DOI 10.1128/JCM.27.10.2386-2387.1989; CLABOTS CR, 1993, 33 INT C ANTI AG CHE; CROCKER KS, 1986, AM J INFECT CONTROL, V14, P250, DOI 10.1016/0196-6553(86)90037-4; DONIUS MA, 1993, JPEN-PARENTER ENTER, V17, P461, DOI 10.1177/0148607193017005461; EDES TE, 1990, AM J MED, V88, P91, DOI 10.1016/0002-9343(90)90454-L; FREEDLAND CP, 1989, JPEN-PARENTER ENTER, V13, P18, DOI 10.1177/014860718901300118; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; GOTTSCHLICH MM, 1988, JPEN-PARENTER ENTER, V12, P338, DOI 10.1177/0148607188012004338; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; Holdeman L.V., 1975, ANAEROBE LAB MANUAL; HORN SD, 1986, MED CARE, V24, P159, DOI 10.1097/00005650-198602000-00007; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY TWJ, 1983, CRIT CARE MED, V11, P7, DOI 10.1097/00003246-198301000-00003; Keohane P P, 1983, Clin Nutr, V1, P259, DOI 10.1016/0261-5614(83)90003-1; KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42; KOTILAINEN HR, 1983, P ROSS LABORATORIES, P16; LEVY J, 1989, JPEN-PARENTER ENTER, V13, P228, DOI 10.1177/0148607189013003228; MALAMOULADAS H, 1983, J CLIN PATHOL, V36, P88, DOI 10.1136/jcp.36.1.88; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; METCALF AM, 1986, CLIN GASTROENTEROL, V15, P705; MICKSCHL DB, 1990, HEART LUNG, V19, P362; PETERSON LR, 1986, AM J CLIN PATHOL, V86, P208, DOI 10.1093/ajcp/86.2.208; ROLFE RD, 1983, INFECT IMMUN, V42, P480, DOI 10.1128/IAI.42.2.480-486.1983; ROLFE RD, 1984, INFECT IMMUN, V45, P185, DOI 10.1128/IAI.45.1.185-191.1984; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SCHROEDER P, 1983, JPEN-PARENTER ENTER, V7, P364, DOI 10.1177/0148607183007004364; SIEGEL DL, 1990, JAMA-J AM MED ASSOC, V263, P979, DOI 10.1001/jama.263.7.979; THURN J, 1990, J HOSP INFECT, V15, P203, DOI 10.1016/0195-6701(90)90028-M; WAGNER DR, 1994, JPEN-PARENTER ENTER, V18, P453, DOI 10.1177/0148607194018005453; WILSON KH, 1985, J INFECT DIS, V151, P355, DOI 10.1093/infdis/151.2.355; YANNELLI B, 1988, AM J INFECT CONTROL, V16, P246, DOI 10.1016/S0196-6553(88)80003-8; ZIMMARO DM, 1989, JPEN-PARENTER ENTER, V13, P117, DOI 10.1177/0148607189013002117	47	206	210	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1012	+		10.7326/0003-4819-129-12-199812150-00004	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	147DC	9867755				2023-01-03	WOS:000077471900003
J	Christie, JD; Rosen, IM; Bellini, LM; Inglesby, TV; Lindsay, J; Alper, A; Asch, DA				Christie, JD; Rosen, IM; Bellini, LM; Inglesby, TV; Lindsay, J; Alper, A; Asch, DA			Prescription drug use and self-prescription among resident physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE	Context.-Self-prescription is common among practicing physicians, but little is known about the practice among resident physicians. Objective.-To determine prescription drug use and self-prescription among US resident physicians. Design and Setting.-Anonymous mail survey of all resident physicians in 4 US categorical internal medicine training programs in February 1997. Main Outcome Measures.-Self-reported use of health care services and prescription medications and how they were obtained. Results.-A total of 316 (83%) of 381 residents responded; 244 residents (78%) reported using at least 1 prescription medicine and 162 residents (52%) reported self-prescribing medications. Twenty-five percent of all medications and 42% of self-prescribed medications were obtained from a sample cabinet; 7% of all medications and 11% of self-prescribed medications were obtained directly from a pharmaceutical company representative. Conclusions.-Self-prescription is common among resident physicians. Although self-prescription is difficult to evaluate, the source of these medications and the lack of oversight of medication use raise questions about the practice.	Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Johns Hopkins University; Stanford University; Tulane University	Asch, DA (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, 3641 Locust Walk, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X				Allibone A, 1981, J R Coll Gen Pract, V31, P728; Asch DA, 1996, EPIDEMIOLOGY, V7, P550, DOI 10.1097/00001648-199609000-00020; CHAMBERS R, 1992, BRIT J GEN PRACT, V42, P153; CHAMBERS RM, 1993, FAM PRACT, V10, P416, DOI 10.1093/fampra/10.4.416; MCCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805; Selley P, 1988, Health Trends, V20, P128; WACHTEL TJ, 1995, J GEN INTERN MED, V10, P261, DOI 10.1007/BF02599883; Westfall JM, 1997, JAMA-J AM MED ASSOC, V278, P141, DOI 10.1001/jama.278.2.141	8	60	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1253	1255		10.1001/jama.280.14.1253	http://dx.doi.org/10.1001/jama.280.14.1253			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786376	Bronze			2023-01-03	WOS:000076357900032
J	Behringer, W; Kittler, H; Sterz, F; Domanovits, H; Schoerkhuber, W; Holzer, M; Mullner, M; Laggner, AN				Behringer, W; Kittler, H; Sterz, F; Domanovits, H; Schoerkhuber, W; Holzer, M; Mullner, M; Laggner, AN			Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome	ANNALS OF INTERNAL MEDICINE			English	Article						epinephrine; neurologic manifestations; cardiopulmonary resuscitation; dose-response relationship, drug; outcome and process assessment (health care)	HOSPITAL CARDIAC-ARREST; VENTRICULAR-FIBRILLATION; BLOOD-FLOW; PERFUSION-PRESSURE; STANDARD; CPR; MODEL; NOREPINEPHRINE; IMPROVES; SEVERITY	Background: Epinephrine is the drug of choice in advanced cardiac life support, but it can have deleterious side effects after restoration of spontaneous circulation. Objective: To investigate the association between the cumulative epinephrine dose used in advanced cardiac life support and neurologic outcome after cardiac arrest. Design: Retrospective cohort study. Setting: University hospital. Patients: Adults admitted to the emergency department with witnessed, nontraumatic, normothermic ventricular fibrillation cardiac arrest and unsuccessful initial defibrillation. Measurements: Functional neurologic outcome was regularly assessed by cerebral performance category (CPC) within 6 months after cardiac arrest. A CPC of 1 or 2 was defined as favorable recovery. Results: Among 178 enrolled patients, the median cumulative epinephrine dose administered was 4 mg (range, 0 to 50 mg). In 151 patients (84%), spontaneous circulation was restored; 63 of these 151 patients (42%) had favorable neurologic recovery. Patients with an unfavorable CPC received a significantly higher cumulative dose of epinephrine than did patients with a favorable CPC (4 mg compared with 1 mg; P < 0.001). This finding persisted after stratification by duration of resuscitation. After possible cofounders were controlled for, the cumulative epinephrine dose remained an independent predictor of unfavorable neurologic outcome. Conclusions: The results indicate that an increasing cumulative dose of epinephrine administered during resuscitation is independently associated with unfavorable neurologic outcome after ventricular fibrillation cardiac arrest.	Univ Vienna, Sch Med, Vienna, Austria	University of Vienna	Sterz, F (corresponding author), Vienna Gen Hosp, Univ Clin, Dept Emergency Med, Waehringerguertel 18-20-6-D, A-1090 Vienna, Austria.		Kittler, Harald/K-7574-2013; Kittler, Harald/AAK-1502-2020	KITTLER, HARALD/0000-0002-0051-8016				Altman DG, 1991, PRACTICAL STAT MED R; *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2205; [Anonymous], 1986, Am J Emerg Med, V4, P72; BARTON C, 1991, ANN EMERG MED, V20, P722, DOI 10.1016/S0196-0644(05)80830-3; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEER RJ, 1994, RESUSCITATION, V27, P189, DOI 10.1016/0300-9572(94)90032-9; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; BROWN CG, 1990, RESUSCITATION, V19, P1, DOI 10.1016/0300-9572(90)90094-U; BRUNETTE DD, 1990, ANN EMERG MED, V19, P8, DOI 10.1016/S0196-0644(05)82130-4; CALLAHAM M, 1991, JAMA-J AM MED ASSOC, V265, P1117, DOI 10.1001/jama.265.9.1117; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CHOUX C, 1995, RESUSCITATION, V29, P3, DOI 10.1016/0300-9572(94)00810-3; Crile G, 1906, J EXP MED, V8, P713, DOI 10.1084/jem.8.6.713; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; GOETTING MG, 1991, ANN EMERG MED, V20, P22, DOI 10.1016/S0196-0644(05)81112-6; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; JENNETT B, 1975, LANCET, V1, P480; LINDNER KH, 1989, CRIT CARE MED, V17, P437, DOI 10.1097/00003246-198905000-00012; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; LINDNER KH, 1991, AM J EMERG MED, V9, P27, DOI 10.1016/0735-6757(91)90008-8; LITTLE RA, 1985, Q J MED, V54, P133; LIVESAY JJ, 1978, J THORAC CARDIOV SUR, V76, P244; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; MARTENS PR, 1993, RESUSCITATION, V25, P227, DOI 10.1016/0300-9572(93)90119-B; MARWICK TH, 1988, LANCET, V2, P66; MULLER CP, 1989, EXP HEMATOL, V17, P1; NG AY, 1990, AM J EMERG MED, V8, P87, DOI 10.1016/0735-6757(90)90190-B; OLSON DW, 1989, ANN EMERG MED, V18, P250, DOI 10.1016/S0196-0644(89)80408-1; ONEIL BJ, 1994, CRIT CARE MED, V22, P194, DOI 10.1097/00003246-199402000-00006; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1962, JAMA-J AM MED ASSOC, V182, P283; REDDING JS, 1968, JAMA-J AM MED ASSOC, V203, P93; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; RIVERS EP, 1994, CHEST, V106, P1499, DOI 10.1378/chest.106.5.1499; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; RUBERTSSON S, 1995, CRIT CARE MED, V23, P1984, DOI 10.1097/00003246-199512000-00007; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STUEVEN HA, 1989, RESUSCITATION, V17, pS71, DOI 10.1016/0300-9572(89)90092-0; SUGA H, 1983, CIRC RES, V53, P306, DOI 10.1161/01.RES.53.3.306; TANG W, 1991, CIRCULATION, V84, P2101, DOI 10.1161/01.CIR.84.5.2101; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; WORTSMAN J, 1993, CRIT CARE MED, V21, P692, DOI 10.1097/00003246-199305000-00012	49	102	108	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					450	456		10.7326/0003-4819-129-6-199809150-00004	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735082				2023-01-03	WOS:000075892100003
J	Ruiz-Arguello, MB; Goni, FM; Alonso, A				Ruiz-Arguello, MB; Goni, FM; Alonso, A			Vesicle membrane fusion induced by the concerted activities of sphingomyelinase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE DILUTION KINETICS; PHASE-TRANSITIONS; CELLULAR-RESPONSES; LIPOSOME FUSION; CUBIC PHASES; DIACYLGLYCEROL; MECHANISMS; CERAMIDE; LIPIDS; PHOSPHATIDYLETHANOLAMINE	When vesicles composed of an equimolar mixture of sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and cholesterol are treated with phospholipase C, phospholipid hydrolysis occurs without major changes in vesicle architecture. In the same way, addition of sphingomyelinase leads only to sphingomyelin cleavage. However, when both enzymes are added together, their joint hydrolytic activities give rise to leakage-free vesicle aggregation, lipid mixing, and aqueous contents mixing, i.e. vesicle fusion, The contribution of both enzymes is unequal, the main role of sphingomyelinase being the production of relatively large amounts of ceramide that will facilitate the lamellar-to-nonlamellar transition in the formation of the fusion pore, whereas phospholipase C provides mainly a localized, asymmetric, high concentration of diacylglycerol that constitutes the trigger for the fusion process. The lipidic endproducts of both enzymes cooperate in destabilizing and fusing the membranes in a way that is never achieved through the action of any of the enzymes individually, nor by the products themselves when premixed with the other lipids during liposome preparation. Thus the enzymes appear to be coupled through their reaction products. This is the first observation of membrane fusion induced by the concerted activities of two enzymes. Besides, considering that both diacylglycerol and ceramide are important metabolites involved in cell signaling, it may also provide new ideas in the exploration of "cross-talk" phenomena between different signal transduction pathways.	Univ Basque Country, Dept Bioquim, CSIC, Unidad Asociada,Grp Biomembranas, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country	Alonso, A (corresponding author), Univ Basque Country, Dept Bioquim, CSIC, Unidad Asociada,Grp Biomembranas, Aptdo 644, E-48080 Bilbao, Spain.	gbpaliza@lg.ehu.es	Alonso, Alicia/E-5310-2012; Goni, Felix M/M-5425-2015	Alonso, Alicia/0000-0002-2730-7470; Goni, Felix M/0000-0001-6270-9216				Basanez G, 1997, BIOPHYS J, V72, P2630, DOI 10.1016/S0006-3495(97)78906-9; Basanez G, 1996, BIOPHYS J, V70, P2299, DOI 10.1016/S0006-3495(96)79795-3; Basanez G, 1998, BIOCHEMISTRY-US, V37, P3901, DOI 10.1021/bi9728497; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Bottcher C, 1961, ANAL CHIM ACTA, V1061, P297; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; CHERNOMORDIK L, 1995, BIOPHYS J, V69, P922, DOI 10.1016/S0006-3495(95)79966-0; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; Fanani ML, 1997, MOL MEMBR BIOL, V14, P25, DOI 10.3109/09687689709048166; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; GOMEZMUNOZ A, 1997, SPHINGOLIPID MEDIATE, P103; GUNTHERAUSBORN S, 1995, J BIOL CHEM, V270, P29279; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; KOZLOV GV, 1983, PHYS REV B, V28, P255, DOI 10.1103/PhysRevB.28.255; Luzzati V, 1997, CURR OPIN STRUC BIOL, V7, P661, DOI 10.1016/S0959-440X(97)80075-9; MALLABIABARRENA A, 1995, CELL, V83, P667, DOI 10.1016/0092-8674(95)90177-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MONCK JR, 1994, NEURON, V12, P707, DOI 10.1016/0896-6273(94)90325-5; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; NIEVA JL, 1995, FEBS LETT, V368, P143, DOI 10.1016/0014-5793(95)00631-I; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	35	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22977	22982		10.1074/jbc.273.36.22977	http://dx.doi.org/10.1074/jbc.273.36.22977			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722520	hybrid			2023-01-03	WOS:000075778100020
J	Emanuel, LL				Emanuel, LL			Facing requests for physician-assisted suicide - Toward a practical and principled clinical skill set	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVE EUTHANASIA; PATIENT REQUESTS; MEDICAL-CARE; RESUSCITATE; HYDRATION; NUTRITION; ATTITUDES; DECISIONS; ORDERS; STATE	Requests for physician-assisted suicide are not a new phenomenon, and many physicians are likely to face this challenging situation. This article proposes for professionals an 8-step approach to respond to requests for physician-assisted suicide. The approach seeks to identify and treat the root causes of the request and aims to present a plan for consistent application of a set of clinical skills. Justification for the steps requires only 2 noncontentious principles: the patient should be free of unwanted intervention, and the physician is obligated to provide suffering patients with comfort care. Care based on these 2 principles alone does not include physician-assisted suicide. The approach does, however, justify patient refusal of oral intake in specific circumstances. The approach could resolve a majority of requests for physician-assisted suicide and should be tested further for clinical efficacy.	Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	American Medical Association	Emanuel, LL (corresponding author), Amer Med Assoc, Inst Eth, 515 N State St, Chicago, IL 60610 USA.							Alpert HR, 1998, J GEN INTERN MED, V13, P175, DOI 10.1046/j.1525-1497.1998.00052.x; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Edelstein L., 1967, ANCIENT MED; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL EJ, 1998, ANN M 1998 AM SOC CL; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Emanuel LL, 1995, HASTINGS CENT REP, V25, pS14, DOI 10.2307/3527851; EMANUEL LL, 1996, CONT INTERNAL MED, V8, P10; EMANUEL LL, 1998, REGULATING WE DIE; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; Glick SM, 1997, AM J MED, V102, P294, DOI 10.1016/S0002-9343(97)00016-8; Gloth F M 3rd, 1994, Md Med J, V43, P511; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; Kamisar Y, 1998, MINN LAW REV, V82, P895; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koenig HG, 1996, ARCH INTERN MED, V156, P2240, DOI 10.1001/archinte.156.19.2240; KOUENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MOORE FD, 1997, HARVARD ALUMNI M SEP, P3; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; SAUNDERS CM, 1978, MANAGEMENT TERMINAL, P194; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STANLEY J, 1997, QUEST DIE DIGNITY; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1997, AM MED NEWS     0113, V40, P56; 1997, AM MED NEWS     0113, V40, P3; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	46	62	62	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					643	647		10.1001/jama.280.7.643	http://dx.doi.org/10.1001/jama.280.7.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110ME	9718058				2023-01-03	WOS:000075384300035
J	Pastan, S; Bailey, J				Pastan, S; Bailey, J			Medical progress - Dialysis therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AMBULATORY PERITONEAL-DIALYSIS; STAGE RENAL-DISEASE; ANAPHYLACTOID REACTIONS; PATIENT MORTALITY; HEMODIALYSIS; SURVIVAL; MORBIDITY; ACCESS; MEMBRANES; DIALYZERS		Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA USA	Emory University	Pastan, S (corresponding author), Emory Clin, 25 Prescott St,Suite 4441, Atlanta, GA 30308 USA.		Pastan, Stephen/AAC-6622-2022					ABUELO JG, 1993, SEMIN DIALYSIS, V6, P59, DOI 10.1111/j.1525-139X.1993.tb00257.x; AHMED KR, 1997, NUTR MANAGEMENT RENA, P563; [Anonymous], 1997, AM J KIDNEY DIS S, V30, pS137; BERGSTROM J, 1993, KIDNEY INT, V44, P1048, DOI 10.1038/ki.1993.347; Besarab A, 1996, SEMIN DIALYSIS, V9, pS21; Bloembergen W E, 1996, Adv Ren Replace Ther, V3, P201; BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177; Bregman H.D.J., 1994, HDB DIALYSIS, V2nd ed., P149; Charra B, 1996, AM J NEPHROL, V16, P35, DOI 10.1159/000168968; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; CHERTOW GM, 1997, NUTR MANAGEMENT RENA, P257; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; CHURCHILL DN, 1995, DIALYSIS MEMBRANES S, P60; CIMOCHOWSKI GE, 1990, NEPHRON, V54, P154, DOI 10.1159/000185837; CONVERSE RL, 1992, J CLIN INVEST, V90, P1657, DOI 10.1172/JCI116037; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; DAUGIRDAS JT, 1985, AM J NEPHROL, V5, P163, DOI 10.1159/000166927; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; DIAMOND SM, 1987, AM J KIDNEY DIS, V9, P3, DOI 10.1016/S0272-6386(87)80155-5; DUMLER F, 1992, AM J KIDNEY DIS, V19, P49, DOI 10.1016/S0272-6386(12)70202-0; Eknoyan G, 1996, SEMIN DIALYSIS, V9, P24, DOI 10.1111/j.1525-139X.1996.tb00897.x; FARIAS MG, 1994, KIDNEY INT, V46, P1392, DOI 10.1038/ki.1994.410; FEIG PU, 1981, NEPHRON, V27, P25, DOI 10.1159/000182015; Feldman HI, 1996, JAMA-J AM MED ASSOC, V276, P620, DOI 10.1001/jama.276.8.620; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; Flanigan MJ, 1997, AM J KIDNEY DIS, V29, P383, DOI 10.1016/S0272-6386(97)90199-2; Friedman EA, 1996, JAMA-J AM MED ASSOC, V275, P1118, DOI 10.1001/jama.275.14.1118; Goldie SJ, 1996, AM J KIDNEY DIS, V28, P86, DOI 10.1016/S0272-6386(96)90135-3; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HAKIM RM, 1984, NEW ENGL J MED, V311, P878, DOI 10.1056/NEJM198410043111403; Hakim RM, 1996, KIDNEY INT, V50, P566, DOI 10.1038/ki.1996.350; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HENRICH WL, 1982, AM J KIDNEY DIS, V2, P349, DOI 10.1016/S0272-6386(82)80093-0; HENRICH WL, 1984, NEW ENGL J MED, V310, P19, DOI 10.1056/NEJM198401053100105; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; *HLTH CAR FIN ADM, 1997, 1996 ANN REP ESRD CO, P35; *HLTH CAR FIN ADM, 1997, 1997 ANN REP ESRD CO, P19; Ikizler TA, 1996, KIDNEY INT, V50, P343, DOI 10.1038/ki.1996.323; Indridason O S, 1995, Curr Opin Nephrol Hypertens, V4, P307, DOI 10.1097/00041552-199507000-00004; Ing TS, 1997, AM J KIDNEY DIS, V30, P859; Ismail N, 1996, AM J NEPHROL, V16, P60, DOI 10.1159/000168972; Jacobs C, 1997, NEPHROL DIAL TRANSPL, V12, P38, DOI 10.1093/ndt/12.1.38; JOST CMT, 1993, KIDNEY INT, V44, P606, DOI 10.1038/ki.1993.287; Keane WF, 1996, PERITON DIALYSIS INT, V16, P557; LAZARUS JM, 1994, AM J KIDNEY DIS, V24, P1019, DOI 10.1016/S0272-6386(12)81077-8; Levin A, 1996, J AM SOC NEPHROL, V7, P242; LOWRIE EG, 1983, KIDNEY INT, pS1; LYSAGHT MJ, 1989, T AM SOC ART INT ORG, V35, P784; MANN JFE, 1995, NEPHROL DIAL TRANSPL, V10, P80, DOI 10.1093/ndt/10.supp2.80; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P10; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P1; McLaughlin K, 1997, AM J KIDNEY DIS, V29, P553, DOI 10.1016/S0272-6386(97)90337-1; *NAT I DIAB DIG KI, 1995, REN DAT SYST USRDS 1; *NAT I DIAB DIG KI, 1997, REN DAT SYST USRDS 1; NOLPH KD, 1994, PERITON DIALYSIS INT, V14, P261; NOLPH KD, 1996, CURR NEPHRO, V19, P281; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Pascual M, 1996, KIDNEY INT, V49, P309, DOI 10.1038/ki.1996.47; PEGUES DA, 1992, KIDNEY INT, V42, P1232, DOI 10.1038/ki.1992.409; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; RADERMACHER J, 1995, CLIN NEPHROL, V44, pS56; RADOVICH JM, 1995, CONTRIB NEPHROL, V113, P11; Rocco MV, 1996, AM J KIDNEY DIS, V28, P250, DOI 10.1016/S0272-6386(96)90308-X; RODBY RA, 1994, AM J KIDNEY DIS, V23, P401, DOI 10.1016/S0272-6386(12)81003-1; ROSBOROUGH DC, 1993, SEMIN DIALYSIS, V6, P260, DOI 10.1111/j.1525-139X.1993.tb00155.x; Sang GLS, 1997, AM J KIDNEY DIS, V29, P669, DOI 10.1016/S0272-6386(97)90118-9; Scarpioni L, 1996, Perit Dial Int, V16 Suppl 1, pS275; SELGAS R, 1989, PERITON DIALYSIS INT, V9, P329; SLATOPOLSKY E, 1986, NEW ENGL J MED, V315, P157, DOI 10.1056/NEJM198607173150304; STIVELMAN JC, 1995, J AM SOC NEPHROL, V6, P1256; Sukhatme VP, 1996, KIDNEY INT, V49, P1161, DOI 10.1038/ki.1996.167; Tokars JI, 1997, ASAIO J, V43, P108, DOI 10.1097/00002480-199701000-00019; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; Twardowski ZJ, 1996, PERITON DIALYSIS INT, V16, pS6; VANSTONE JC, 1980, T AM SOC ART INT ORG, V26, P383; VERRESEN L, 1994, KIDNEY INT, V45, P1497, DOI 10.1038/ki.1994.195; VIGLINO G, 1989, PERITON DIALYSIS INT, V9, P165; Wanten GJA, 1996, PERITON DIALYSIS INT, V16, P352; WING AJ, 1978, BRIT MED J, V2, P853, DOI 10.1136/bmj.2.6141.853; Winston JA, 1996, J AM SOC NEPHROL, V7, P1; 1997, AM J KIDNEY DIS S2, V2, pS1	86	197	202	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1998	338	20					1428	1437		10.1056/NEJM199805143382006	http://dx.doi.org/10.1056/NEJM199805143382006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM667	9580651				2023-01-03	WOS:000073563700006
J	Walsh, BW; Kuller, LH; Wild, RA; Paul, S; Farmer, M; Lawrence, JB; Shah, AS; Anderson, PW				Walsh, BW; Kuller, LH; Wild, RA; Paul, S; Farmer, M; Lawrence, JB; Shah, AS; Anderson, PW			Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; MYOCARDIAL-INFARCTION; ADJUVANT TAMOXIFEN; LY139481 HCL; PLASMA; CHOLESTEROL; TRIAL; RISK; REPLACEMENT	Context.-Raloxifene is a selective estrogen receptor modulator that has estrogen-agonistic effects on bone and estrogen-antagonistic effects on breast and uterus. Objective.-To identify the effects of raloxifene on markers of cardiovascular risk in postmenopausal women, and to compare them with those induced by hormone replacement therapy (HRT). Design.-Double-blind, randomized, parallel trial. Setting.-Eight sites in the United States. Participants.-390 healthy postmenopausal women recruited by advertisement. Intervention.-Participants were randomized to receive 1 of 4 treatments: raloxifene, 60 mg/d; raloxifene, 120 mg/d; HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 2.5 mg/d); or placebo. Main Outcome Measures.-Change and percent change from baseline of lipid levels and coagulation parameters after 3 months and 6 months of treatment. Results.-At the last visit completed, compared with placebo, both dosages of raloxifene significantly lowered low-density lipoprotein cholesterol (LDL-C) by 12% (P < .001), similar to the 14% reduction with HRT (P < .001), Both dosages of raloxifene significantly lowered lipoprotein(a) by 7% to 8% (P < .001), less than the 19% decrease with HRT (P < .001). Raloxifene increased high-density lipoprotein-2 cholesterol (HDL2-C) by 15% to 17% (P < .05), less than the 33% increase with HRT (P <.001), Raloxifene did not significantly change high-density lipoprotein cholesterol (HDL-C), triglycerides, or plasminogen activator inhibitor-1 (PAI-1); whereas HRT increased HDL-C by 11% and triglycerides by 20%, and decreased PAI-1 by 29% (for all, P < .001). Raloxifene significantly lowered fibrinogen by 12% to 14% (P < .001), unlike HRT, which had no effect. Neither treatment changed fibrinopeptide A or prothrombin fragment 1 and 2. Conclusions.-Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides. In contrast to HRT, raloxifene had no effect on HDL-C and PAI-1, and a lesser effect on HDL2-C and lipoprotein(a). Further clinical trials are necessary to determine whether these favorable biochemical effects are associated with protection against cardiovascular disease.	Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Clin Studies, St Petersburg, FL USA	Harvard University; Brigham & Women's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Oklahoma System; University of Oklahoma Health Sciences Center; Eli Lilly	Walsh, BW (corresponding author), Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA.	bwwalsh@bics.bwh.harvard.edu						Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123; Bjarnason NH, 1997, CIRCULATION, V96, P1964, DOI 10.1161/01.CIR.96.6.1964; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BRYANT HU, 1993, J BONE MINER RES, V8, pS123; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; CHMIELEWSKA J, 1986, CLIN CHEM, V32, P482; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; CONSTANTINO JP, 1997, JNCI-J NATL CANCER I, V89, P776; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Draper MW, 1996, J BONE MINER RES, V11, P835; DRAPER MW, 1993, P 4 INT S OST CONS D, P119; EFRON B, 1981, ANN STAT, V9, P586, DOI 10.1214/aos/1176345462; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Grese TA, 1997, J MED CHEM, V40, P146, DOI 10.1021/jm9606352; GREY AB, 1995, J CLIN ENDOCR METAB, V80, P3191, DOI 10.1210/jc.80.11.3191; JOHANNES CB, 1994, AM J EPIDEMIOL, V140, P439, DOI 10.1093/oxfordjournals.aje.a117266; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Kauffman RF, 1997, J PHARMACOL EXP THER, V280, P146; KAUFFMAN RF, 1995, DRUG NEWS PERSPECT, V8, P531; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Mannucci PM, 1996, ARCH INTERN MED, V156, P1806, DOI 10.1001/archinte.156.16.1806; MARCOVINA SM, 1994, LAB MEASUREMENT LIPI, P239; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; PELZER H, 1991, THROMB HAEMOSTASIS, V65, P153; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SORIA J, 1980, THROMB RES, V20, P425, DOI 10.1016/0049-3848(80)90281-9; STEIN EA, 1994, TIETZ TXB CLIN CHEM, P1085; TRINDER P, 1981, ANN CLIN BIOCHEM, V18, P64, DOI 10.1177/000456328101800202; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	35	546	564	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1998	279	18					1445	1451		10.1001/jama.279.18.1445	http://dx.doi.org/10.1001/jama.279.18.1445			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL718	9600478	Bronze			2023-01-03	WOS:000073463500033
J	Blendon, RJ; Young, JT				Blendon, RJ; Young, JT			The public and the war on illicit drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This article presents what Americans think about the policies subsumed under the label of the "War on Drugs." It is based on an analysis of 47 national surveys conducted between 1978 and 1997. The major results are that most Americans rely on the mass media for information about the scope of the drug abuse problem; Americans do not think that the Wars on Drugs have succeeded, but they do not want to quit on these efforts; weak support exists for increasing funding for drug treatment; support for preventive education has increased during the 1990s; criminal justice responses remain very popular; for many, illicit drug use is a moral rather than a public health issue; the public supports allowing physicians to prescribe marijuana for severe illness, but opposes the general legalization of marijuana and other illicit drugs; and needle exchange programs are supported by a bare majority, but only when they are told that the American Medical Association supports these programs.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02215 USA.							[Anonymous], 1996, NY TIMES; [Anonymous], 1996, WASHINGTON POST; [Anonymous], 1995, US TODAY; [Anonymous], 1988, WASHINGTON POST; [Anonymous], 1996, CBS NEWS POLL; BUCKLEY W, 1996, NATL REV        0212; Canadian Institute of Public Opinion (CIPO), 1990, GALLUP POLL; Danielian LH, 1989, COMMUNICATION CAMPAI, P29; Davis James A., GEN SOCIAL SURVEYS 1; *FED AM SCI, 1997, PRINC PRACT DRUG POL; FRIEDMAN M, 1998, NY TIMES        0111, V149, P19; HART PD, 1994, DRUG STRATEGIES; *LINDSM FDN, 1997, LAK RES POLL; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P946, DOI 10.1001/jama.278.11.946; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MAGINNIS RL, 1997, AM ASSESS MED MARIJU; MERRIAM JE, 1989, COMMUNICATION CAMPAI, P21; Newsweek, 1995, NEWSWEEK; *OFF APP STUD, 1997, 17 DAWN OFF APPL STU; *PRINC SURV RES AS, 1995, HJ KAIS FAM FDN POLL; Reese S, 1989, COMMUNICATION CAMPAI, P29, DOI DOI 10.1080/08838158909364073; *ROP CTR PUBL OP R, 1990, PARTN DRUG FREE AM G; *ROP CTR PUBL OP R, 1996, ABC NEWS POLL; SOROS G, 1997, WASHINGTON POST 0202; Specter M, 1990, WASHINGTON POST; *SUBST AB MENT HLT, 1997, NAT ADM SUBST AB TRE; *SUBST AB MENT HLT, 1997, PREL FIL 1996 NAT HO; *SUBST AB MENT HLT, 1996, 18 SUBST AB MENT HLT; U. S. Bureau of the Census, 1996, STAT ABSTR US; *U VIRG, 1997, POST MOD PROJ; YANKELOVICH, 1997, TIME             JUN; YANKELOVICH, 1993, TIME; 1996, CBS NEWS POLL    OCT; 1997, CBS NEWS POLL; 1996, NEWSWEEK POLL; 1996, WASHINGTON POST 0703; 1997, ABC WASHINGTON POST; 1986, CBS NEWS NY TIMES; 1995, CNN US TODAY     AUG	39	71	71	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					827	832		10.1001/jama.279.11.827	http://dx.doi.org/10.1001/jama.279.11.827			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515986				2023-01-03	WOS:000072417600012
J	Patton, J				Patton, J			Breathing life into protein drugs - Inhalation of therapeutic macromolecules is a feasible, natural, more people-friendly, delivery system.	NATURE BIOTECHNOLOGY			English	Article									Inhale Therapeut Syst, San Carlos, CA 94070 USA		Patton, J (corresponding author), Inhale Therapeut Syst, 150 Ind Rd, San Carlos, CA 94070 USA.							Adjei A., 1997, INHALATION DELIVERY; EVERARD ML, 1995, THORAX, V50, P746, DOI 10.1136/thx.50.7.746; FOLKESSON HG, 1990, ACTA PHYSIOL SCAND, V139, P347, DOI 10.1111/j.1748-1716.1990.tb08933.x; HINDLE M, 1995, INT J PHARM, P116; ILLUM L, 1997, INHALATION DELIVERY, P135; Lalor C.B., 1997, INHALATION DELIVERY, P235; MACKAY M, 1994, RESP DRUG DELIVERY, V4, P31; NIVEN RW, INHALATION DELIVERY, P151; ORIORDAN TG, 1994, AM J RESP CRIT CARE, V149, P214, DOI 10.1164/ajrccm.149.1.8111585; Patton J.S., 1994, RESP DRUG DELIVERY, P65; Patton JS, 1996, ADV DRUG DELIVER REV, V19, P3, DOI 10.1016/0169-409X(95)00113-L; SETO D, 1997, DRUG DELIVERY IND	12	37	48	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					141	143		10.1038/nbt0198-141	http://dx.doi.org/10.1038/nbt0198-141			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487516				2023-01-03	WOS:000071831300021
J	Goldman, A				Goldman, A			ABC of palliative care - Special problems of children	BRITISH MEDICAL JOURNAL			English	Review									Great Ormond St Hosp Children, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Goldman, A (corresponding author), Great Ormond St Hosp Children, Great Ormond St, London WC1N 3JH, England.							*ACT ROYAL COLL PR, 1997, HLTH GUID DEV CHILDR; *ROYAL COLL PAED C, 1997, PREV CONTR PAIN CHIL	2	53	54	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					49	52		10.1136/bmj.316.7124.49	http://dx.doi.org/10.1136/bmj.316.7124.49			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451269	Green Published			2023-01-03	WOS:000071377900027
J	Aguilar, L; Ortega-Pierres, G; Campos, B; Fonseca, R; Ibanez, M; Wong, C; Farfan, N; Naciff, JM; Kaetzel, MA; Dedman, JR; Baeza, I				Aguilar, L; Ortega-Pierres, G; Campos, B; Fonseca, R; Ibanez, M; Wong, C; Farfan, N; Naciff, JM; Kaetzel, MA; Dedman, JR; Baeza, I			Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHATIDATE; LIPOSOMES; LIPIDS; ANTIBODIES; PHASES	Hexagonal phase (H-II)-preferring lipids such as phosphatidate, cardiolipin, and phosphatidylserine form nonbilayer molecular arrangements in lipid bilayers. While their presence in biological membranes has not been established, in vitro studies suggest that alterations in membrane properties modify their function. In this study, antiphospholipid monoclonal antibodies were developed against nonbilayer structures. One of the monoclonal antibodies identifies nonplanar surfaces in Liposomes and in membranes of cultured cells. These results are the first evidence that natural membranes maintain a fragile balance between bilayer and nonbilayer Lipid arrangements. Therefore, these antibodies can be used to evaluate the role of H-II-preferring lipids in the modulation of membrane activities, Our studies demonstrated that nonplanar surfaces are highly immunogenic, Although these structures are normally transient, their formation can be stabilized by temperature variations, drugs, antibiotics, apolar peptides, and divalent cations, Our studies demonstrated that abnormal exposure of nonbilayer arrangements may induce autoimmune responses as found in the antiphospholipid syndrome.	Inst Politecn Nacl, Natl Sch Biol Sci, Dept Biochem, Mexico City 06401, DF, Mexico; Ctr Res & Adv Studies, Dept Genet & Mol Biol, Mexico City 07000, DF, Mexico; Ctr Res & Adv Studies, Dept Chem, Mexico City 07000, DF, Mexico; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	Instituto Politecnico Nacional - Mexico; University System of Ohio; University of Cincinnati	Baeza, I (corresponding author), Inst Politecn Nacl, Natl Sch Biol Sci, Dept Biochem, Apartado Postal 4-897,Admon 4, Mexico City 06401, DF, Mexico.			Ibanez Hernandez, Miguel Angel Antonio/0000-0003-4013-6888; Aguilar Faisal, J. Leopoldo/0000-0003-0519-3254	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHERSON RA, 1996, ANTIPHOSPHOLIPID SYN, P1; BAEZA I, 1995, BIOCHEM CELL BIOL, V73, P289, DOI 10.1139/o95-036; BAEZA I, 1994, J MOL EVOL, V39, P560, DOI 10.1007/BF00160401; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; CULLIS PR, 1991, MEMBRANE FUSION, P65; DARZYNKIEWICZ Z, 1990, FLOW CYTOMETRY SHORT, P290; Epand RM, 1996, CHEM PHYS LIPIDS, V81, P101, DOI 10.1016/0009-3084(96)02575-3; FENSKE DB, 1993, CHEM PHYS LIPIDS, V64, P143, DOI 10.1016/0009-3084(93)90063-9; Ibanez M, 1996, BIOCHEM CELL BIOL, V74, P633, DOI 10.1139/o96-068; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Kinnunen PKJ, 1996, CHEM PHYS LIPIDS, V81, P151, DOI 10.1016/0009-3084(96)02579-0; LAFLEUR M, 1990, BIOCHEM CELL BIOL, V68, P1, DOI 10.1139/o90-001; LEE YC, 1993, BIOPHYS J, V65, P1429, DOI 10.1016/S0006-3495(93)81206-2; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; Naciff JM, 1996, AM J PHYSIOL-CELL PH, V271, pC2004; ORTEGAPIERRES G, 1984, PARASITOLOGY, V88, P359, DOI 10.1017/S0031182000054603; Rauch J, 1998, THROMB HAEMOSTASIS, V80, P936; RAUSCH J, 1990, P NATL ACAD SCI USA, V87, P4112; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; SMAAL EB, 1987, BIOCHIM BIOPHYS ACTA, V897, P453, DOI 10.1016/0005-2736(87)90442-1; Verkleij AJ, 1991, MEMBRANE FUSION, P155; Wegener J, 1996, CHEM PHYS LIPIDS, V81, P229, DOI 10.1016/0009-3084(96)02585-6	23	34	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	1999	274	36					25193	25196		10.1074/jbc.274.36.25193	http://dx.doi.org/10.1074/jbc.274.36.25193			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235QN	10464237	hybrid			2023-01-03	WOS:000082554200002
J	Weers, PMM; Narayanaswami, V; Kay, CM; Ryan, RO				Weers, PMM; Narayanaswami, V; Kay, CM; Ryan, RO			Interaction of an exchangeable apolipoprotein with phospholipid vesicles and lipoprotein particles - Role of leucines 32, 34, and 95 in Locusta migratoria apolipophorin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN SECONDARY STRUCTURE; A-I; LIPID TRANSPORT; CONFORMATIONAL ADAPTATIONS; CIRCULAR-DICHROISM; MANDUCA-SEXTA; BINDING; NMR; DIMYRISTOYLPHOSPHATIDYLCHOLINE	Apolipophorin III (apoLp-III) from Locusta migratoria is an exchangeable apolipoprotein that binds reversibly to lipid surfaces. In the lipid-free state this 164-residue protein exists as a bundle of five elongated amphipathic alpha-helices, Upon lipid binding, apoLp-III undergoes a significant conformational change, resulting in exposure of its hydrophobic interior to the lipid environment. On the basis of x-ray crystallographic data (Breiter, D. R., Kanost, M. R., Benning, M. M., Wesenberg, G., Law, J. H., Wells, M. A, Rayment, I., and Holden, H. M. (1991) Biochemistry 30, 603-608), it was proposed that hydrophobic residues, present in loops that connect helices 1 and 2 (Leu-32 and Leu-34) and helices 3 and 4 (Leu-95), may function in initiation of lipid binding. To examine this hypothesis, mutant apoLp-IIIs were designed wherein the three Leu residues were replaced by Arg, individually or together. Circular dichroism spectroscopy and temperature and guanidine hydrochloride denaturation studies showed that the mutations did not cause major changes in secondary structure content or stability. In lipid binding assays, addition of apoLp-III to phospholipid vesicles caused a rapid clearance of vesicle turbidity due to transformation to discoidal complexes. L34R and L32R/L34R/L95R apoLp-IIIs displayed a much stronger interaction with lipid vesicles than wild-type apoLp-III. Furthermore, it was demonstrated that the mutant apoLp-IIIs retained their ability to bind to lipoprotein particles. However, in lipoprotein competition binding assays, the mutants displayed an impaired ability to initiate a binding interaction when compared with wild-type apoLp-III, The data indicate that the loops connecting helices 1 and 2 and helices 3 and 4 are critical regions in the protein, contributing to recognition of hydrophobic defects on lipoprotein surfaces by apoLp-III.	Univ Alberta, Heritage Med Res Ctr 328, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Prot Engn Network Excellence, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Ryan, RO (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.			Narayanaswami, Vasanthy/0000-0001-7088-4057				BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CHEUNG MC, 1987, J LIPID RES, V28, P913; DEMEL RA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P151, DOI 10.1016/0005-2760(92)90091-9; DOLPHIN PJ, 1992, STRUCTURE FUNCTION A, P295; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Jonas A., 1992, STRUCTURE FUNCTION A, P217; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; Little C., 1981, METHOD ENZYMOL, V71, P725; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MANTULIN WW, 1980, J BIOL CHEM, V255, P8185; Narayanaswami V, 1996, ARCH BIOCHEM BIOPHYS, V334, P143, DOI 10.1006/abbi.1996.0439; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; NARAYANASWAMI V, 1995, BIOCHEMISTRY-US, V34, P11822, DOI 10.1021/bi00037a021; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Pace C N, 1986, Methods Enzymol, V131, P266; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; SUREWICZ WK, 1986, J BIOL CHEM, V261, P6191; VANDERHORST DJ, 1991, EUR J BIOCHEM, V196, P509; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; Wang JJ, 1998, PROTEIN SCI, V7, P336; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; WANG JJ, 1992, BIOCHEMISTRY-US, V31, P8706, DOI 10.1021/bi00152a004; WEERS PMM, 1993, BIOL CHEM H-S, V374, P863, DOI 10.1515/bchm3.1993.374.7-12.863; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; Weers PMM, 1998, BBA-LIPID LIPID MET, V1393, P99, DOI 10.1016/S0005-2760(98)00063-0; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	52	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21804	21810		10.1074/jbc.274.31.21804	http://dx.doi.org/10.1074/jbc.274.31.21804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419496	hybrid			2023-01-03	WOS:000081721100049
J	Kwakkel, G; Wagenaar, RC; Twisk, JWR; Lankhorst, GJ; Koetsier, JC				Kwakkel, G; Wagenaar, RC; Twisk, JWR; Lankhorst, GJ; Koetsier, JC			Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial	LANCET			English	Article							FUNCTIONAL STATUS; ACTIVITIES INDEX; NATURAL-HISTORY; REHABILITATION; RECOVERY; CLASSIFICATION; INFARCTION	Background We investigated the effects of different intensities of arm and leg rehabilitation training on the functional recovery of activities of daily living (ADL), walking ability, and dexterity of the paretic arm, in a single-blind randomised controlled trial. Methods Within 14 days after stroke onset, 101 severely disabled patients with a primary middle-cerebral-artery stroke were randomly assigned to: a rehabilitation programme with emphasis on arm training; a rehabilitation programme with emphasis on leg training; or a control programme in which the arm and leg were immobilised with an inflatable pressure splint. Each treatment regimen was applied for 30 min, 5 days a week during the first 20 weeks after stroke. In addition, all patients underwent a basic rehabilitation programme. The main outcome measures were ability in ADL (Barthel index), walking ability (functional ambulation categories), and dexterity of the paretic arm (Action Research arm test) at 6, 12, 20, and 26 weeks. Analyses were by intention to treat. Findings At week 20, the leg-training group (n=31) had higher scores than the control group (n=37) for ADL ability (median 19 [IQR 16-20] vs 16 [10-19], p<0.05), walking ability (4 [3-5] vs 3 [1-4], p<0.05), and dexterity (2 [0-56] vs 0 [0-2], p<0.01). The arm-training group (n=33) differed significantly from the control group only in dexterity (9 [0-39] vs 0 [0-2], p<0.01). There were no significant differences in these endpoints at 20 weeks between the arm-training and leg-training groups. Interpretation Greater intensity of leg rehabilitation improves functional recovery and health-related functional status, whereas greater intensity of arm rehabilitation results in small improvements in dexterity, providing further evidence that exercise therapy primarily induces treatment effects on the abilities at which training is specifically aimed.	Vrije Univ Amsterdam, Univ Hosp, Dept Phys Therapy, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Res Inst Fundamental & Clin Human Movement Sci, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Phys Therapy, Boston, MA 02215 USA; Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Boston University; Vrije Universiteit Amsterdam	Kwakkel, G (corresponding author), Vrije Univ Amsterdam, Univ Hosp, Dept Phys Therapy, POB 7057, NL-1007 MB Amsterdam, Netherlands.	g.kwakkel@azvu.nl						[Anonymous], 1989, STROKE, V20, P1407; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Collen F M, 1990, Int Disabil Stud, V12, P6; de Haan R, 1993, Ned Tijdschr Geneeskd, V137, P917; DEELMAN BG, 1981, SAN TEST APHASIA TES; ERDMAN RAM, 1993, PSYCHOL REP, V72, P1027, DOI 10.2466/pr0.1993.72.3.1027; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GRESHAM GE, 1986, STROKE, V17, P358, DOI 10.1161/01.STR.17.3.358; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; HUNT SM, 1981, J EPIDEMIOL COMMUN H, V35, P297, DOI 10.1136/jech.35.4.297; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; KALRA L, 1993, J AM GERIATR SOC, V41, P396, DOI 10.1111/j.1532-5415.1993.tb06947.x; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; KWAKKEL G, 1998, DYNAMICS FUNCTIONAL, P69; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; POOLE JL, 1990, OCCUP THER J RES, V10, P360, DOI 10.1177/153944929001000605; Post MWM, 1996, ARCH PHYS MED REHAB, V77, P440, DOI 10.1016/S0003-9993(96)90031-3; ROBICHAUD JA, 1992, PHYS THER, V72, P176, DOI 10.1093/ptj/72.3.176; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; SKILBECK CE, 1983, J NEUROL NEUROSUR PS, V46, P5, DOI 10.1136/jnnp.46.1.5; SUNDERLAND A, 1994, J NEUROL NEUROSUR PS, V57, P856, DOI 10.1136/jnnp.57.7.856; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WADE DT, 1989, HDB CLIN NEUROLOGY, V11, P233; WAGENAAR RC, 1990, SCAND J REHABIL MED, V22, P1; WAGENAAR RC, 1991, J REHABILITATION SCI, V4, P61; Wardlaw JM, 1996, J NEUROL, V243, P274, DOI 10.1007/BF00868526; WEILLER C, 1993, ANN NEUROL, V33, P181	35	608	640	2	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					191	196		10.1016/S0140-6736(98)09477-X	http://dx.doi.org/10.1016/S0140-6736(98)09477-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	217MU	10421300				2023-01-03	WOS:000081504200010
J	Ranieri, VM; Suter, PM; Tortorella, C; De Tullio, R; Dayer, JM; Brienza, A; Bruno, F; Slutsky, AS				Ranieri, VM; Suter, PM; Tortorella, C; De Tullio, R; Dayer, JM; Brienza, A; Bruno, F; Slutsky, AS			Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-EXPIRATORY PRESSURE; TUMOR-NECROSIS-FACTOR; TIDAL VOLUME; PROTECTIVE-VENTILATION; PERSISTENT ELEVATION; ALVEOLAR MACROPHAGES; PULMONARY-EDEMA; LUNG INJURY; ARDS; CYTOKINES	Context Studies have shown that an inflammatory response may be elicited by mechanical ventilation used for recruitment or derecruitment of collapsed lung units or to overdistend alveolar regions, and that a lung-protective strategy may reduce this response. Objective To test the hypothesis that mechanical ventilation induces a pulmonary and systemic cytokine response that can be minimized by limiting recruitment or derecruitment and overdistention. Design and Setting Randomized controlled trial in the intensive care units of 2 European hospitals from November 1995 to February 1998, with a 28-day follow-up. Patients Forty-four patients (mean [SD] age, 50 [18] years) with acute respiratory distress syndrome were enrolled, 7 of whom were withdrawn due to adverse events. Interventions After admission, volume-pressure curves were measured and bronchoalveolar lavage and blood samples were obtained. Patients were randomized to either the control group (n = 19). tidal volume to obtain normal values of arterial carbon dioxide tension (35-40 mm Hg) and positive end-expiratory pressure (PEEP) producing the greatest improvement in arterial oxygen saturation without worsening hemodynamics; or the lung-protective strategy group (n = 18), tidal volume and PEEP based on the volume-pressure curve. Measurements were repeated 24 to 30 and 36 to 40 hours after randomization. Main Outcome Measures Pulmonary and systemic concentrations of inflammatory mediators approximately 36 hours after randomization. Results Physiological characteristics and cytokine concentrations were similar in both groups at randomization. There were significant differences (mean [SD]) between the control and lung-protective strategy groups in tidal volume (11.1 [1.3] vs 7.6 [1.1] mL/kg), end-inspiratory plateau pressures (31.0 [4.5] vs 24.6 [2.4] cm H2O), and PEEP (6.5 [1.7] vs 14.8 [2.7] cm H2O) (P<.001), Patients in the control group had an in crease in bronchoalveolar lavage concentrations of interleukin (IL) 1 beta, IL-6, and IL-1 receptor agonist and in both bronchoalveolar lavage and plasma concentrations of tumor necrosis factor (TNF) alpha, IL-6, and TNF-alpha receptors over 36 hours (P<.05 for all). Patients in the lung-protective strategy group had a reduction in bronchoalveolar lavage concentrations of polymorphonuclear cells, TNF-alpha, IL-1 beta, soluble TNF-alpha receptor 55, and IL-8, and in plasma and bronchoalveolar lavage concentrations of IL-6, soluble TNF-alpha receptor 75, and IL-1 receptor antagonist (P<.05). The concentration of the inflammatory mediators 36 hours after randomization was significantly lower in the lung-protective strategy group than in the control group (P<.05). Conclusions Mechanical ventilation can induce a cytokine response that may be attenuated by a strategy to minimize overdistention and recruitment/derecruitment of the lung, Whether these physiological improvements are associated with improvements in clinical end points should be determined in future studies.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Bari, Osped Policlin, Ist Anestesiol & Rianimaz, Bari, Italy; Univ Bari, Osped Policlin, Serv Pneumol, Bari, Italy; Univ Bari, Osped Policlin, Dipartimento Med Interna, Bari, Italy; Univ Geneva, Hop Cantonal Univ Geneva, Div Surg Intens Care, Geneva, Switzerland; Univ Geneva, Hop Cantonal Univ Geneva, Div Immunol & Allergy, Geneva, Switzerland	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Geneva; University of Geneva	Ranieri, VM (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Room 656A,600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Slutsky, Arthur/M-3325-2019; Slutsky, Arthur S/A-6013-2008; Ranieri, Marco/AFX-8152-2022	Slutsky, Arthur S/0000-0002-6063-3876; Tortorella, Cosimo/0000-0002-4504-9313				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; CHIUMELLO D, 1998, AM J RESP CRIT CARE, V157, pA45; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Douzinas EE, 1997, AM J RESP CRIT CARE, V155, P53, DOI 10.1164/ajrccm.155.1.9001289; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; HAMILTON PP, 1983, J APPL PHYSIOL, V55, P131, DOI 10.1152/jappl.1983.55.1.131; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; Hudson LD, 1998, NEW ENGL J MED, V338, P385, DOI 10.1056/NEJM199802053380609; KAWANO T, 1987, J APPL PHYSIOL, V62, P27, DOI 10.1152/jappl.1987.62.1.27; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Meduri GU, 1998, AM J RESP CRIT CARE, V158, P1432; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; Meduri GU, 1997, CHEST, V112, P1154, DOI 10.1378/chest.112.5.1154; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; MICHIE HR, 1990, ARCH SURG-CHICAGO, V125, P531; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Nahum A, 1997, CRIT CARE MED, V25, P1733, DOI 10.1097/00003246-199710000-00026; Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040, DOI 10.1152/ajplung.1998.275.6.L1040; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; Schwartz MD, 1996, CRIT CARE MED, V24, P1285, DOI 10.1097/00003246-199608000-00004; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; VANOTTEREN GM, 1995, AM J RESP CELL MOL, V13, P399, DOI 10.1165/ajrcmb.13.4.7546769; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U	42	1269	1341	1	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					54	61		10.1001/jama.282.1.54	http://dx.doi.org/10.1001/jama.282.1.54			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404912	Bronze			2023-01-03	WOS:000081195800029
J	Parker, RA; Delbanco, TL; Foley, K				Parker, RA; Delbanco, TL; Foley, K			A 44-year-old woman with severe pain at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CANCER PAIN; MANAGEMENT; METHADONE; MORPHINE; CARE; NARCOTICS; ATTITUDES		Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Parker, RA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brokline Ave,LY318, Boston, MA 02215 USA.							American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; BRUERA E, 1987, CANCER TREAT REP, V71, P67; BRUERA E, 1993, CLIN AUDIT PALLIATIV, P61; Buckman R., 1998, PRACTICAL GUIDE COMM; Capello C F, 1998, J Palliat Med, V1, P155, DOI 10.1089/jpm.1998.1.155; Carron A T, 1999, Ann Intern Med, V130, P82; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSEM NH, 1991, MASSACHUSETTS GEN HO, P343; Cherny N I, 1994, J Palliat Care, V10, P57; Cherny N I, 1994, J Palliat Care, V10, P71; CHERNY NI, 1996, HEMATOL ONCOL, P235; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; CHRISTAKIS NA, 1996, NEW ENGL J MED, V1, P3; DAALEMAN TP, 1994, J FAM PRACTICE, V39, P564; Doyle D, 1998, OXFORD TXB PALLIATIV; ELLIOTT K, 1995, NEUROPSYCHOPHARMACOL, V13, P347, DOI 10.1038/sj.npp.1380294; Ellis MR, 1999, J FAM PRACTICE, V48, P105; Foley K.M, 1991, NEW PHARMACOTHERAPY, P181; Foley Kathleen M., 1997, P2807; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Foley KM, 1998, J CLIN ONCOL, V16, P3213, DOI 10.1200/JCO.1998.16.10.3213; Foley KM, 1993, OXFORD TXB PALLIATIV, P148; FORREST WH, 1977, NEW ENGL J MED, V296, P712, DOI 10.1056/NEJM197703312961303; FOX WP, 1995, PSYCHO-ONCOL, V4, P87; *GALL I, 1997, SPIR BEL DYING PROC; GIBSON R, 1998, J PALLIAT MED, V1, P415; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; Jacox A, 1994, CLIN PRACTICE GUIDEL; JADAD A, 1998, TOPICS PALLIATIVE CA, P31; LEVIN DN, 1985, CANCER, V56, P2337, DOI 10.1002/1097-0142(19851101)56:9<2337::AID-CNCR2820560935>3.0.CO;2-W; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LIPSYTE R, 1998, COUNTRY ILLNESS COMF; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656; MOULIN D, 1998, NEUROPATHIC CANC PAI, V2; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RP, 1998, TXB PALLIATIVE MED, P361; PORTER J, 1980, NEW ENGL J MED, V302, P123; Posner J.B., 1995, NEUROLOGICAL COMPLIC; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; VENTAFRIDDA V, 1987, CANCER, V59, P851; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3; World Health Organization, 1990, CANC PAIN REL PALL C; 1998, CBS NEWS POLL   0420	51	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1937	1945		10.1001/jama.281.20.1937	http://dx.doi.org/10.1001/jama.281.20.1937			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349898				2023-01-03	WOS:000080427300034
J	Greenspan, SL; Greenspan, FS				Greenspan, SL; Greenspan, FS			The effect of thyroid hormone on skeletal integrity	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MINERAL DENSITY; LEVOTHYROXINE SUPPRESSIVE THERAPY; TERM L-THYROXINE; FORMER HYPERTHYROID PATIENTS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; SUBCLINICAL HYPERTHYROIDISM; REPLACEMENT THERAPY; TREATMENT GUIDELINES; CALCIUM HOMEOSTASIS	Background: Thyroid disease and osteoporosis are common problems often managed by primary care physicians, Despite many studies, confusion still exists about the effect of thyroid hormone on skeletal health. Purpose: To review evidence on. the effect of thyroid hormone(from hyperthyroidism, exogenous or endogenous suppression of thyroid-stimulating hormone [TSH], and thyroid hormone replacement therapy) on skeletal integrity. Data Sources: A MEDLINE search of papers published between 1966 and 1997. Data Selection: Cross-sectional studies, longitudinal studies, and meta-analyses that had appropriate control groups (patients matched for age, sex, and menopausal status), made comparisons with established databases, or defined thyroid state by TSH level or thyroid hormone dose were reviewed. Data Extraction and Synthesis: Data synthesis was not straightforward because of changes in doses and types of thyroid hormone preparations; changes in definitions of thyroid hormone replacement therapy and suppressive therapies; problems with study design; differences in skeletal sites assessed (hip, spine, forearm, or heel) and techniques used to measure bone mineral density; and inclusion of heterogenous and changing thyroid disease states. Overall, hyperthyroidism and use of thyroid hormone to suppress TSH because of thyroid cancer, goiters, or nodules seem to have an adverse effect on bone, especially in postmenopausal women; the largest effect is on cortical bone. Thyroid hormone replacement seems to have a minimal clinical effect on bone. Conclusion: Women with a history of hyperthyroidism or TSH suppression by thyroid hormone should have skeletal status assessed by bone mineral densitometry, preferably at a site containing cortical bone, such as the hip or forearm.	Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Greenspan, SL (corresponding author), Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab, E-GZ-800,330 Brookline Ave, Boston, MA 02215 USA.				NCRR NIH HHS [MO1-RR01032] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; Baran DT, 1997, CALCIFIED TISSUE INT, V61, P433, DOI 10.1007/s002239900362; Bauer DC, 1997, J CLIN ENDOCR METAB, V82, P2931, DOI 10.1210/jc.82.9.2931; BURMEISTER LA, 1992, J CLIN ENDOCR METAB, V75, P344, DOI 10.1210/jc.75.2.344; CAMPOSPASTOR MM, 1993, BONE MINER, V21, P1, DOI 10.1016/S0169-6009(08)80115-8; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; *DEP HLTH HUM SERV, 1998, FED REGISTER, V63, P34321; DEROSA G, 1995, HORM METAB RES, V27, P503, DOI 10.1055/s-2007-980012; *DIAGN THER TECHN, 1992, JAMA-J AM MED ASSOC, V261, P917; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; DUNCAN WE, 1994, THYROID, V4, P183, DOI 10.1089/thy.1994.4.183; ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv-7-4-379; ESCALANTE DA, 1995, AM J MED, V98, P374, DOI 10.1016/S0002-9343(99)80316-7; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FLORKOWSKI CM, 1993, NEW ZEAL MED J, V106, P443; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; FRANKLYN J, 1994, CLIN ENDOCRINOL, V41, P425, DOI 10.1111/j.1365-2265.1994.tb02572.x; FRANKLYN JA, 1995, THYROID, V5, P359, DOI 10.1089/thy.1995.5.359; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GARTON M, 1994, CLIN ENDOCRINOL, V41, P747, DOI 10.1111/j.1365-2265.1994.tb02789.x; Genant HK, 1996, J BONE MINER RES, V11, P707; Gharib H, 1998, ANN INTERN MED, V128, P386, DOI 10.7326/0003-4819-128-5-199803010-00008; GIANNINI S, 1994, CLIN SCI, V87, P593, DOI 10.1042/cs0870593; Gorres G, 1996, EUR J NUCL MED, V23, P690, DOI 10.1007/BF00834532; GRANT DJ, 1993, CLIN ENDOCRINOL, V39, P529, DOI 10.1111/j.1365-2265.1993.tb02404.x; GRANT DJ, 1995, CLIN ENDOCRINOL, V43, P339, DOI 10.1111/j.1365-2265.1995.tb02041.x; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; HAWKINS F, 1994, CALCIFIED TISSUE INT, V54, P16, DOI 10.1007/BF00316283; KLEE GG, 1993, CLIN LAB MED, V13, P673, DOI 10.1016/S0272-2712(18)30432-3; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; Kung AWC, 1996, J CLIN ENDOCR METAB, V81, P1232, DOI 10.1210/jc.81.3.1232; KUNG AWC, 1993, CLIN ENDOCRINOL, V39, P535, DOI 10.1111/j.1365-2265.1993.tb02405.x; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; Langdahl BL, 1996, THYROID, V6, P161; Langdahl BL, 1996, THYROID, V6, P169; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; LEHMKE J, 1992, CLIN ENDOCRINOL, V36, P511, DOI 10.1111/j.1365-2265.1992.tb02254.x; Lima N, 1997, THYROID, V7, P691, DOI 10.1089/thy.1997.7.691; LIPS P, 1998, AM J MED, V103, pS3; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MARCOCCI C, 1994, J CLIN ENDOCR METAB, V78, P818, DOI 10.1210/jc.78.4.818; Marcocci C, 1997, J BONE MINER RES, V12, P72, DOI 10.1359/jbmr.1997.12.1.72; MCDERMOTT MT, 1995, CALCIFIED TISSUE INT, V56, P521, DOI 10.1007/BF00298581; MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889-8529(18)30338-4; MUDDE AH, 1992, CLIN ENDOCRINOL, V37, P35, DOI 10.1111/j.1365-2265.1992.tb02280.x; MULLER CG, 1995, THYROID, V5, P81, DOI 10.1089/thy.1995.5.81; *NAT OST FDN, 1998, PHYS GUID PREV TREAT, P1; Nguyen TT, 1997, J BONE MINER RES, V12, P1092, DOI 10.1359/jbmr.1997.12.7.1092; Papini E, 1998, J CLIN ENDOCR METAB, V83, P780, DOI 10.1210/jc.83.3.780; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PIOLI G, 1992, ACTA ENDOCRINOL-COP, V126, P238, DOI 10.1530/acta.0.1260238; POOR G, 1995, J BONE MINER RES, V10, P1900; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; Ridgway EC, 1998, ANN INTERN MED, V128, P403, DOI 10.7326/0003-4819-128-5-199803010-00010; ROSEN CJ, 1992, J CLIN ENDOCR METAB, V75, P1531, DOI 10.1210/jc.75.6.1531; Rosen HN, 1998, J CLIN ENDOCR METAB, V83, P2324, DOI 10.1210/jc.83.7.2324; ROSEN HN, 1993, J CLIN ENDOCR METAB, V77, P664, DOI 10.1210/jc.77.3.664; Ross Douglas S., 1996, P1016; ROSS DS, 1993, AM J MED, V95, P385, DOI 10.1016/0002-9343(93)90307-B; ROSS DS, 1994, THYROID, V4, P319, DOI 10.1089/thy.1994.4.319; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; Saggese G, 1996, EUR J PEDIATR, V155, P452, DOI 10.1007/BF01955180; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SCHNEIDER DL, 1994, JAMA-J AM MED ASSOC, V271, P1245, DOI 10.1001/jama.271.16.1245; SCHNEIDER DL, 1995, ARCH INTERN MED, V155, P2005, DOI 10.1001/archinte.155.18.2005; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; Singer PA, 1996, ARCH INTERN MED, V156, P2165, DOI 10.1001/archinte.156.19.2165; SOLOMON BL, 1993, THYROID, V3, P17, DOI 10.1089/thy.1993.3.17; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOH SH, 1985, ARCH INTERN MED, V145, P883, DOI 10.1001/archinte.145.5.883; TOH SH, 1990, J BONE MINER RES, V5, P463, DOI 10.1002/jbmr.5650050507; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P209; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VONRECKLINGHAUS.D, 1891, FIBROSE DEFORMIEREND, P1; Wartofsky L, 1997, ENDOCRINOLOGIST, V7, P322, DOI 10.1097/00019616-199707050-00007; WEJDA B, 1995, J INTERN MED, V237, P241, DOI 10.1111/j.1365-2796.1995.tb01172.x; Werner SC, 1978, THYROID, P965; WERNER SC, 1978, THYROID, P525	81	158	168	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					750	758		10.7326/0003-4819-130-9-199905040-00016	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00016			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357695				2023-01-03	WOS:000080062300007
J	Ahmad, N; Gupta, S; Mukhtar, H				Ahmad, N; Gupta, S; Mukhtar, H			Involvement of retinoblastoma (Rb) and E2F transcription factors during photodynamic therapy of human epidermoid carcinoma cells A431	ONCOGENE			English	Article						photodynamic therapy; cell cycle; retinoblastoma (pRb); E2F	MOUSE LYMPHOMA-CELLS; CYCLE PROGRESSION; INDUCED ABLATION; CANCER-CELLS; NITRIC-OXIDE; APOPTOSIS; INDUCTION; PROTEINS; KINASE; PHOTOSENSITIZERS	Photodynamic therapy (PDT), a promising new therapeutic modality for the management of a variety of solid malignancies and many non-malignant diseases, is a bimodal therapy using a porphyrin based photosensitizing chemical and visible light. The proper understanding of the mechanism of PDT-mediated cancer cell-kill may result in improving the efficacy of this treatment modality. Earlier we have shown (PI oc. Natl, Acad. Sci, USA; 95: 6977-6982, 1998) that silicon phthalocyanine (Pc4)-PDT results in an induction of the cyclin kinase inhibitor WAF1/CIP1/p21 which, by inhibiting cyclins (E and DI) and cyclin dependent kinases (cdk2 and cdk6), results in a G0/G1-phase arrest followed by apoptosis in human epidermoid carcinoma cells A431. We have also demonstrated the generation of nitric oxide during PDT-mediated apoptosis (Cancer Res.; 58: 1785-1788, 1998), Retinoblastoma (pRb) and E2F family transcription factors are important proteins, which regulate the G1-->S transition in the cell cycle. Here, we pro, ide evidence for the involvement of pRb-E2F/DP machinery as an important contributor of PDT-mediated cell cycle arrest and apoptosis, Western blot analysis demonstrated a decrease in the hyper-phosphorylated form of pRb at 3, 6 and 12 h post-PDT with a relative increase in hypo-phosphorylated pRb, Western blot analysis also revealed that PDT-caused decrease in phosphorylation of pRb occurs at serine-780, The ELISA data demonstrated a time dependent accumulation of hypo-phosphorylated pRb by PDT, This response was accompanied with down-regulation in the protein expression of all five E2F (1-5) family transcription factors, and their heterodimeric partners DP1 and DP2, These results suggest that Pc4-PDT of A431 cells results in a down regulation of hyper-phosphorylated pRb protein with a relative increase in hypo-phosphorylated pRb that, in turn, compromises with the availability of free E2F, We suggest that these events result in a stoppage of the cell cycle progression at G1-->S transition thereby leading to a G0/G1 phase arrest and a subsequent apoptotic cell death, These data provide an evidence for the involvement of pRb-E2F/DP machinery in PDT-mediated cell cycle arrest leading to apoptosis.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.			Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [P30 CA 43703, R01 CA51802, P01 CA 48735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, P01CA048735, R01CA051802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; BenHur E, 1997, PHOTOCHEM PHOTOBIOL, V65, P456, DOI 10.1111/j.1751-1097.1997.tb08589.x; Bowen C, 1998, CANCER RES, V58, P3275; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Goldberg Y, 1996, ONCOGENE, V12, P893; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V54, P1093, DOI 10.1111/j.1751-1097.1991.tb02133.x; Granville DJ, 1997, CELL DEATH DIFFER, V4, P623, DOI 10.1038/sj.cdd.4400286; Gupta S, 1998, CANCER RES, V58, P1785; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUNA MC, 1994, CANCER RES, V54, P1374; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TOM R, 1997, J NATL CANCER I, V89, P112; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x	41	28	33	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1891	1896		10.1038/sj.onc.1202493	http://dx.doi.org/10.1038/sj.onc.1202493			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086343				2023-01-03	WOS:000079090000012
J	Hurwitz, B				Hurwitz, B			Commentary: Bevan's covenant continues intact	BRITISH MEDICAL JOURNAL			English	Editorial Material									Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England	Imperial College London	Hurwitz, B (corresponding author), Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.							*DEP HLTH, 1998, 1 CLASS SERV; *GEN PRACT COMM, 1998, PRIM CAR GROUPS; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; *NAT HLTH SERV EX, 1998, PRESCR INC SCHEM; *NAT HLTH SERV EX, 1998, DEV PRIM CAR GROUPS; Prayle D, 1998, J MED ETHICS, V24, P93, DOI 10.1136/jme.24.2.93; TOWSE A, 1997, GUIDELINES EVALUATIO	7	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1365	1365						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9882107				2023-01-03	WOS:000077081600025
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Barron, HV; Breen, T; Rundle, AC; Sloan, MA; French, W; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Barron, HV; Breen, T; Rundle, AC; Sloan, MA; French, W; Rogers, WJ		Participants Natl Registry Myocardial Infarc	Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; tissue plasminogen activator; hemorrhage; cerebral; hypertension; angioplasty; transluminal; percutaneous coronary	THROMBOLYTIC THERAPY; STROKE; TRIAL	Background: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarction has been unequivocally shown. However, thrombolysis is related to bleeding complications, including intracranial hemorrhage. Objective: To determine the frequency of and risk factors for intracranial hemorrhage after recombinant tissue-type plasminogen activator (tPA) given for acute myocardial infarction in patients receiving usual care. Design: Large national registry of patients who have had acute myocardial infarction. Setting: 1484 U.S. hospitals. Patients: 71 073 patients who had had acute myocardial infarction from 1 June 1994 to 30 September 1996, received tPA as the initial reperfusion strategy, and did not receive a second dose of any thrombolytic agent. Measurement: Intracranial hemorrhage confirmed by computed tomography or magnetic resonance imaging. Results: 673 patients (0.95%) were reported to have had intracranial hemorrhage during hospitalization for acute myocardial infarction; 625 patients (0.88%) had the event confirmed by computed tomography or magnetic resonance imaging. Of the 625 patients with confirmed intracranial hemorrhage, 331 (53%) died during hospitalization. An additional 158 patients (25.3%) who survived to hospital discharge had residual neurologic deficit. In multivariable models for the main effects of candidate risk factors, older age, female sex, black ethnicity, systolic blood pressure of 140 mm Hg or more, diastolic blood pressure of 100 mm Hg or more, history of stroke, tPA dose more than 1.5 mg/kg, and lower body weight were significantly associated with intracranial hemorrhage. Conclusions: Intracranial hemorrhage is a rare but serious complication of tPA in patients with acute myocardial infarction. Appropriate drug dosing may reduce the risk for this complication. Other therapies, such as primary coronary angioplasty, may be preferable in patients with acute myocardial infarction who have a history of stroke.	Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA 01608 USA; Fallon Healthcare Syst, Worcester, MA 01608 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Genentech Inc, Med Affairs, San Francisco, CA 94080 USA; Harbin Clin, Dept Neurosci, Rome, GA 30165 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alabama System; University of Alabama Birmingham	Gurwitz, JH (corresponding author), Univ Massachusetts, Sch Med, Meyers Primary Care Inst, 100 Cent St, Worcester, MA 01608 USA.							[Anonymous], 1997, PHYS DESK REF, P1723; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Becker, 1995, J Thromb Thrombolysis, V2, P231; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Betriu A, 1997, NEW ENGL J MED, V336, P1621; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Gurwitz JH, 1997, JAMA-J AM MED ASSOC, V277, P1723, DOI 10.1001/jama.277.21.1723; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIMAN NS, 1993, CIRCULATION, V88, P17; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	17	162	167	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					597	+		10.7326/0003-4819-129-8-199810150-00002	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786806				2023-01-03	WOS:000076431800001
J	Salit, SA; Kuhn, EM; Hartz, AJ; Vu, JM; Mosso, AL				Salit, SA; Kuhn, EM; Hartz, AJ; Vu, JM; Mosso, AL			Hospitalization costs associated with homelessness in New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOCIOECONOMIC-STATUS; PHYSICAL HEALTH; ADULTS	Background Homelessness is believed to be a cause of health problems and high medical costs, but data supporting this association have been difficult to obtain. We compared lengths of stay and reasons for hospital admission among homeless and other low-income persons in New York City to estimate the hospitalization costs associated with homelessness. Methods We obtained hospital-discharge data on 18,864 admissions of homeless adults to New York City's public general hospitals (excluding admissions for childbirth) and 383,986 nonmaternity admissions of other low-income adults to all general hospitals in New York City during 1992 and 1993. The differences in length of stay were adjusted for diagnosis-related group, principal diagnosis, selected coexisting illnesses, and demographic characteristics. Results Of the admissions of homeless people, 51.5 percent were for treatment of substance abuse or mental illness, as compared with 22.8 percent for I the other low-income patients, and another 19.7 percent of the admissions of homeless people were for trauma, respiratory disorders, skin disorders, and infectious diseases (excluding the acquired immunodeficiency syndrome [AIDS]), many of which are potentially preventable medical conditions. For the homeless, 80.6 percent of the admissions involved either a principal or a secondary diagnosis of substance abuse or mental illness - roughly twice the rates for the other patients. The homeless patients stayed 4.1 days, or 36 percent, longer per admission on average than the other patients, even after adjustments were made for differences in the rates of substance abuse and mental illness and other clinical and demographic characteristics. The costs of the additional days per discharge averaged $4,094 for psychiatric patients, $3,370 for patients with AIDS, and $2,414 for all types of patients. Conclusions Homelessness is associated with substantial excess costs per hospital stay in New York City. Decisions to fund housing and supportive services for the homeless should take into account the potential of these services to reduce the high costs of hospitalization in this population. (C) 1998, Massachusetts Medical Society.	New York City Hlth & Hosp Corp, New York, NY USA; Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; Univ Iowa, Dept Family Med, Iowa City, IA USA; Univ Iowa, Publ Policy Ctr, Iowa City, IA USA	Medical College of Wisconsin; University of Iowa; University of Iowa	Salit, SA (corresponding author), United Hosp Fund, Empire State Bldg,350 5th Ave,23rd Fl, New York, NY 10118 USA.							[Anonymous], AM STAT; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1990, SAFETY NET HLTH SOCI; BRICKNER PW, 1987, HLTH CARE HOMELESS P; Committee on Health Care for Homeless People, 1988, HOM HLTH HUM NEEDS; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P3132; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; HOLLOWAY L, 1996, NY TIMES        0831, pA1; Jencks Christopher, 1994, HOMELESS; Kennedy Randy, 1997, NEW YORK TIMES  1210, pB1; *NY CIT HUM RES AD, 1995, HRA FACTS AUG 1995; ROPERS RH, 1987, SOC SCI MED, V24, P669, DOI 10.1016/0277-9536(87)90310-8; ROSENHECK R, 1993, HOSP COMMUNITY PSYCH, V44, P1166; ROSSI P, 1989, DOWN OUT AM ORIGINS; *SAS I, 1989, SAS STAT US GUID VER, V2; STRUENING EL, 1990, J SOC ISSUES, V46, P65, DOI 10.1111/j.1540-4560.1990.tb01799.x; WRIGHT JD, 1987, HOMELESSNESS HLTH	20	218	218	3	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1734	1740		10.1056/NEJM199806113382406	http://dx.doi.org/10.1056/NEJM199806113382406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT654	9624194				2023-01-03	WOS:000074109800006
J	Morton, CC				Morton, CC			US dialysis survival strategy	ANNALS OF INTERNAL MEDICINE			English	Article																			0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					514	516		10.7326/0003-4819-128-6-199803150-00039	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499351				2023-01-03	WOS:000072414700036
J	Nightingale, SL				Nightingale, SL			Generic substitution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							U.S. Food and Drug Administration, APPROVED DRUG PRODUC	1	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2023-01-03	WOS:000072192800006
J	Yaffe, K; Sawaya, G; Lieberburg, I; Grady, D				Yaffe, K; Sawaya, G; Lieberburg, I; Grady, D			Estrogen therapy in postmenopausal women - Effects on cognitive function and dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HORMONE REPLACEMENT THERAPY; ALZHEIMERS-DISEASE; OLDER WOMEN; BASAL FOREBRAIN; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; ESTRADIOL PROTECTS; MONOAMINE-OXIDASE; GONADAL-STEROIDS; CAROTID-ARTERY	Context.-Several studies have suggested that estrogen replacement therapy in postmenopausal women improves cognition, prevents development of dementia, and improves the severity of dementia, while other studies have not found a benefit of estrogen use, Objective.-To determine whether postmenopausal estrogen therapy improves cognition, prevents development of dementia, or improves dementia severity. Data Sources.-We performed a literature search of studies published from January 1966 through June 1997, using MEDLINE, manually searched bibliographies of articles identified, and consulted experts. Study Selection.-Studies that evaluated biological mechanisms of estrogen's effect on the central nervous system and studies that addressed the effect of estrogen on cognitive function or on dementia. Data Extraction.-We reviewed studies for methods, sources of bias, and outcomes and performed a meta-analysis of the 10 studies of postmenopausal estrogen use and risk of dementia using standard meta-analytic methods. Data Synthesis.-Biochemical and neurophysiologic studies suggest several mechanisms by which estrogen may affect cognition: promotion of cholinergic and serotonergic activity in specific brain regions, maintenance of neural circuitry, favorable lipoprotein alterations, and prevention of cerebral ischemia. Five observational studies and 8 trials have addressed the effect of estrogen on cognitive function in nondemented postmenopausal women, Cognition seems to improve in perimenopausal women, possibly because menopausal symptoms improve, but there is no clear benefit in asymptomatic women. Ten observational studies have measured the effect of postmenopausal estrogen use on risk of developing dementia. Meta-analysis of these studies suggests a 29% decreased risk of developing dementia among estrogen users, but the findings of the studies are heterogeneous. Four trials of estrogen therapy in women with Alzheimer disease have been conducted and have had primarily positive results, but most have been small, of short duration, nonrandomized, and uncontrolled. Conclusions.-There are plausible biological mechanisms by which estrogen might lead to improved cognition, reduced risk for dementia, or improvement in the severity of dementia. Studies conducted in women, however, have substantial methodologic problems and have produced conflicting results. Large placebo-controlled trials are required to address estrogen's role in prevention and treatment of Alzheimer disease and other dementias. Given the known risks of estrogen therapy, we do not recommend estrogen for the prevention or treatment of Alzheimer disease or other dementias until adequate trials have been completed.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA; Athena Neurosci Inc, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yaffe, K (corresponding author), Univ Calif San Francisco, Vet Adm Med Ctr, 111G,4150 Clement St, San Francisco, CA 94121 USA.	kyaffe@itsa.ucsf.edu						AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; APPLEBAUMBOWDEN D, 1989, J LIPID RES, V30, P1895; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; AYLWARD M, 1973, INT RESEARCH COMMUNI, V1, P30; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CALDWELL BM, 1952, J GERONTOL, V7, P228; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COBB JL, 1995, NEUROLOGY, V45, P1707, DOI 10.1212/WNL.45.9.1707; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Coronary Drug Project Research Group, 1981, N ENGL J MED, V304, P612; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; DOHANICH GP, 1994, BEHAV NEUROSCI, V108, P988, DOI 10.1037/0735-7044.108.5.988; Drachman DA, 1997, NEW ENGL J MED, V336, P1245, DOI 10.1056/NEJM199704243361710; EGELAND GM, 1991, PREV MED, V20, P343, DOI 10.1016/0091-7435(91)90033-Z; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; GANGAR KF, 1991, LANCET, V338, P839; Gibbs RB, 1997, BRAIN RES, V749, P143, DOI 10.1016/S0006-8993(96)01375-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GOULD E, 1990, J NEUROSCI, V10, P1286; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hackman B W, 1976, Curr Med Res Opin, V4, P303, DOI 10.1185/03007997609109322; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HONJO H, 1992, J STEROID BIOCHEM, V41, P633, DOI 10.1016/0960-0760(92)90395-Y; HONJO H, 1989, J STEROID BIOCHEM, V34, P521; HONJO H, 1995, HORM METAB RES, V27, P204, DOI 10.1055/s-2007-979941; Honjo H., 1993, J JPN MENOPAUSE SOC, V1, P167; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; KIMURA D, 1995, HORM BEHAV, V29, P312, DOI 10.1006/hbeh.1995.1022; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; KLAIBER EL, 1979, ARCH GEN PSYCHIAT, V36, P550; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; LUINE VN, 1975, BRAIN RES, V86, P293, DOI 10.1016/0006-8993(75)90704-0; MATSUMOTO A, 1991, PSYCHONEUROENDOCRINO, V16, P25, DOI 10.1016/0306-4530(91)90069-6; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORTEL KF, 1995, J NEUROPSYCH CLIN N, V7, P334; MORTIMER JA, 1998, NEUROLOGY S4, V43, pS39; OHKURA T, 1994, ENDOCR J, V41, P361, DOI 10.1507/endocrj.41.361; OMALLEY CA, 1987, BRAIN RES, V403, P389, DOI 10.1016/0006-8993(87)90082-5; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PaganiniHill A, 1996, J AM GERIATR SOC, V44, P818, DOI 10.1111/j.1532-5415.1996.tb03740.x; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PALMER AM, 1993, J NEURAL TRANSM-GEN, V91, P135, DOI 10.1007/BF01245229; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; POIRIER MF, 1985, NEUROPSYCHOBIOLOGY, V14, P165, DOI 10.1159/000118222; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; Rauramo L, 1975, Front Horm Res, V3, P94; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; SIMPKINS JW, 1994, NEUROBIOL AGING, V15, pS195; Srivastava RAK, 1996, BIOCHEM MOL BIOL INT, V38, P91; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; SUMNER BEH, 1995, J STEROID BIOCHEM, V54, P15, DOI 10.1016/0960-0760(95)00075-B; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; THOMSON J, 1977, J ENDOCRINOL, V72, P395, DOI 10.1677/joe.0.0720395; Yaffe K, 1997, ARCH NEUROL-CHICAGO, V54, P1110, DOI 10.1001/archneur.1997.00550210044011	89	713	733	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					688	695		10.1001/jama.279.9.688	http://dx.doi.org/10.1001/jama.279.9.688			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496988				2023-01-03	WOS:000072192800034
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Users and practitioners of complementary medicine	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									COWARD R, 1989, WHOLE TRUTH; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FURNHAM A, 1998, COMPLEMENTARY MED OB, P71; Mills S., 1997, PROFESSIONAL ORG COM; *RES COUNC COMPL M, 1998, PUBL US COMPL MED OV; SHARMA U, 1995, COMPLEMENTARY MED TO; THOMAS K, 1995, NATL SUVEY ACCESS CO; Thomas KJ, 1993, METHODOLOGICAL STUDY; Wearn AM, 1998, J ROY SOC MED, V91, P465, DOI 10.1177/014107689809100904	9	127	132	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					836	838		10.1136/bmj.319.7213.836	http://dx.doi.org/10.1136/bmj.319.7213.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496832	Green Published			2023-01-03	WOS:000082865200030
J	Gianakos, D				Gianakos, D			Conversations with Stella	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Lynchburg Family Practice Residency, Lynchburg, VA 24501 USA		Gianakos, D (corresponding author), Lynchburg Family Practice Residency, Lynchburg, VA 24501 USA.	dean.gianakos@centrahealth.com							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					698	699		10.7326/0003-4819-130-8-199904200-00020	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215570				2023-01-03	WOS:000079786600013
J	Farre, R; Hernandez, L; Montserrat, JM; Rotger, M; Ballester, E; Navajas, D				Farre, R; Hernandez, L; Montserrat, JM; Rotger, M; Ballester, E; Navajas, D			Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea	LANCET			English	Article							APNEA		Univ Barcelona, Fac Med, Dept Ciencies Fisiol 1, Unitat Biofis & Bioengn, E-08026 Barcelona, Spain; Hosp Clin Barcelona, Serv Pneumol & Allergia Resp, Barcelona, Spain; Inst Invest Biomed August Pi Sunyer, Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Farre, R (corresponding author), Univ Barcelona, Fac Med, Dept Ciencies Fisiol 1, Unitat Biofis & Bioengn, E-08026 Barcelona, Spain.		Farre, Ramon/L-2664-2017; Navajas, Daniel/E-4233-2010	Farre, Ramon/0000-0002-9084-7824; Navajas, Daniel/0000-0001-7150-9363; MONTSERRAT, Josep Maria/0000-0003-3098-4605				Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Stradling J, 1997, LANCET, V349, P201, DOI 10.1016/S0140-6736(96)08166-4; SULLIVAN CE, 1981, LANCET, V1, P862; Wright J, 1997, BRIT MED J, V314, P851	5	71	71	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1154	1154		10.1016/S0140-6736(99)01056-9	http://dx.doi.org/10.1016/S0140-6736(99)01056-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209985				2023-01-03	WOS:000079858400019
J	Bridge, DT; Gilbert, J				Bridge, DT; Gilbert, J			An international work exchange: better than a midlife crisis	BRITISH MEDICAL JOURNAL			English	Article									Royal Perth Hosp, Perth, WA 6001, Australia; Exeter & Dist Hospice, Exeter EX2 5JJ, Devon, England	Royal Perth Hospital; University of Western Australia	Bridge, DT (corresponding author), Royal Perth Hosp, X2213, Perth, WA 6001, Australia.							FEEHALLY J, 1994, J ROY COLL PHYS LOND, V28, P372; HANDYSIDES S, 1994, BRIT MED J, V308, P114, DOI 10.1136/bmj.308.6921.114; JARECKY RK, 1986, J MED EDUC, V61, P803; VEALE D, 1992, BRIT J HOSP MED, V48, P671; Vickman L, 1996, ANN EMERG MED, V27, P668, DOI 10.1016/S0196-0644(96)70174-9; WOOD JB, 1994, BRIT MED J, V308, P1029, DOI 10.1136/bmj.308.6935.1029	6	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1709	1710		10.1136/bmj.317.7174.1709	http://dx.doi.org/10.1136/bmj.317.7174.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857136	Green Published			2023-01-03	WOS:000077742300024
J	Ben-Tovim, DI; Esterman, A				Ben-Tovim, DI; Esterman, A			Zero progress with hypochondriasis	LANCET			English	Editorial Material							CONTROLLED TRIAL		Flinders Med Ctr, Dept Psychiat, Bedford Pk, SA 5042, Australia; Flinders Med Ctr, Dept Clin Epidemiol & Hlth Outcomes, Bedford Pk, SA 5042, Australia	Flinders Medical Centre; Flinders Medical Centre	Ben-Tovim, DI (corresponding author), Flinders Med Ctr, Dept Psychiat, Bedford Pk, SA 5042, Australia.		Esterman, Adrian J/D-1042-2009	Esterman, Adrian/0000-0001-7324-9171				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Balint M., 1964, DOCTOR HIS PATIENT I; Barsky AJ, 1996, PSYCHOSOMATICS, V37, P48, DOI 10.1016/S0033-3182(96)71598-0; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; Fallon BA, 1996, PSYCHOPHARMACOL BULL, V32, P607; LEFF GP, 1988, PSYCHIAT GLOBAL TRAN; Mayou RA, 1997, PSYCHOL MED, V27, P1021, DOI 10.1017/S0033291797005254; Papageorgiou C, 1998, PSYCHOL MED, V28, P193, DOI 10.1017/S0033291797005825; Warwick HMC, 1996, BRIT J PSYCHIAT, V169, P189, DOI 10.1192/bjp.169.2.189	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1798	1799		10.1016/S0140-6736(05)79884-6	http://dx.doi.org/10.1016/S0140-6736(05)79884-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WE	9851376				2023-01-03	WOS:000077337900004
J	Barr, H				Barr, H			Gastrointestinal tumours: let there be light	LANCET			English	Editorial Material							HIGH-GRADE DYSPLASIA; ND-YAG LASER; PHOTODYNAMIC THERAPY; ESOPHAGEAL CANCER; BARRETTS-ESOPHAGUS; MULTICENTER; JAPANESE		Gloucestershire Royal & Cranfield Univ, Inst Med Sci, Gloucester Gastroenterol Grp, Gloucester GL1 3NN, England	Cranfield University	Barr, H (corresponding author), Gloucestershire Royal & Cranfield Univ, Inst Med Sci, Gloucester Gastroenterol Grp, Gloucester GL1 3NN, England.							BARR H, 1987, PHOTOCHEM PHOTOBIOL, V46, P795, DOI 10.1111/j.1751-1097.1987.tb04850.x; Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; BARR H, 1990, BRIT J SURG, V77, P93, DOI 10.1002/bjs.1800770132; Ell C, 1998, GUT, V43, P345, DOI 10.1136/gut.43.3.345; Gossner L, 1998, GASTROENTEROLOGY, V114, P448, DOI 10.1016/S0016-5085(98)70527-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROSJEAN P, 1998, EUR J SURG ONCOL, V24, P234; Hayata Y, 1996, LASER MED SCI, V11, P255, DOI 10.1007/BF02134916; HEIER SK, 1995, GASTROENTEROLOGY, V109, P63, DOI 10.1016/0016-5085(95)90269-4; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P507, DOI 10.1016/S0016-5107(95)70002-1; Ortner MAEJ, 1998, GASTROENTEROLOGY, V114, P536, DOI 10.1016/S0016-5085(98)70537-2; Overholt BF, 1997, GASTROINTEST ENDOSC, V45, P206, DOI 10.1016/S1052-5157(18)30308-8; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SIBILLE A, 1995, GASTROENTEROLOGY, V108, P337, DOI 10.1016/0016-5085(95)90058-6	15	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1242	1244		10.1016/S0140-6736(05)70484-0	http://dx.doi.org/10.1016/S0140-6736(05)70484-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788451				2023-01-03	WOS:000076573800005
J	Wang, W; Smith, DK; Moulding, K; Chen, HM				Wang, W; Smith, DK; Moulding, K; Chen, HM			The dependence of membrane permeability by the antibacterial peptide cecropin B and its analogs, CB-1 and CB-3, on liposomes of different composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; ANTIMICROBIAL PEPTIDES; PHOSPHOLIPID-VESICLES; SOLUTION CONFORMATION; INSECT IMMUNITY; LIPID VESICLES; DEFENSINS; PROTEINS; BINDING; SPECIFICITY	A natural antibacterial peptide, cecropin B (CB), and designed analogs, CB-1 and CB-3, were synthesized. The three peptides have different structural characteristics, with CB having one hydrophobic and one amphipathic alpha-helix, CB-1 having two amphipathic alpha-helices, and CB-3 having two hydrophobic cy-helices. These differences were used as the rationale for a study of their efficacy in breaking liposomes with different combinations of phosphatidic acid and phosphatidylcholine. Biosensor binding measurements and encapsulating dye leakage studies showed that the higher binding affinity of CB and CB-1 to the polar heads of lipids is not necessary for the peptides to be more effective at lysing lipid bilayers, especially when Liposomes have a higher phosphatidic acid content. Kinetic studies, by intrinsic and extrinsic fluorescence stopped-flow measurements, revealed two transitional steps in liposome breakage by CB and CB-1, although only one kinetic step was found for CB-3. Circular dichroism stopped-flow measurements, monitoring the formation of secondary structure in the peptides, found one kinetic step for the interaction of all of the peptides with the liposomes. Also, the cu-helical motif of the peptides was maintained after interacting with the liposomes. Based on these results, the mechanisms of liposome lysis by CB, CB-1, and CB-3 are discussed.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Peoples R China	Hong Kong University of Science & Technology	Wang, W (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Peoples R China.	bchmc@ust.hk		Smith, David/0000-0003-3608-0586				Barlett G.R., 1959, J BIOL CHEM, V234, P466; BenTal N, 1996, BIOPHYS J, V71, P3046, DOI 10.1016/S0006-3495(96)79498-5; BenTal N, 1997, BIOPHYS J, V73, P1717, DOI 10.1016/S0006-3495(97)78203-1; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN HM, 1991, J MOL BIOL, V220, P771, DOI 10.1016/0022-2836(91)90116-N; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DURELL SR, 1992, BIOPHYS J, V63, P1623, DOI 10.1016/S0006-3495(92)81730-7; FINK J, 1989, INT J PEPT PROT RES, V33, P412; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GOMES AV, 1993, BIOCHEMISTRY-US, V32, P5365, DOI 10.1021/bi00071a011; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; IWAI H, 1993, EUR J BIOCHEM, V217, P639, DOI 10.1111/j.1432-1033.1993.tb18287.x; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Javadpour MM, 1997, BIOCHEMISTRY-US, V36, P9540, DOI 10.1021/bi961644f; JAYNES J M, 1989, Peptide Research, V2, P157; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Ladokhin AS, 1997, BIOPHYS J, V72, P794, DOI 10.1016/S0006-3495(97)78713-7; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, VThird, DOI 10.1007/978-0-387-46312-4; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LICHTENSTEIN A, 1991, J CLIN INVEST, V88, P93, DOI 10.1172/JCI115310; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; Mancheno JM, 1996, BIOCHEMISTRY-US, V35, P9892, DOI 10.1021/bi953058c; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASSON L, 1994, ANAL BIOCHEM, V218, P405, DOI 10.1006/abio.1994.1199; MERRIFIELD RB, 1994, CIBA F SYMP, V186, P5; Moore AJ, 1996, J ANTIMICROB CHEMOTH, V37, P1077, DOI 10.1093/jac/37.6.1077; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; SEKIGNCHI M, 1994, ATLAS HUMAN TUMOR CE, P300; Silvestro L, 1997, BIOCHEMISTRY-US, V36, P11452, DOI 10.1021/bi9630826; SIPOS D, 1992, EUR J BIOCHEM, V209, P163, DOI 10.1111/j.1432-1033.1992.tb17273.x; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10301, DOI 10.1021/bi970176m; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	46	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27438	27448		10.1074/jbc.273.42.27438	http://dx.doi.org/10.1074/jbc.273.42.27438			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765273	hybrid			2023-01-03	WOS:000076448000060
J	Ganzini, L; Johnston, WS; McFarland, BH; Tolle, SW; Lee, MA				Ganzini, L; Johnston, WS; McFarland, BH; Tolle, SW; Lee, MA			Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOPELESSNESS; LIFE; ILL; OUTPATIENTS; EUTHANASIA; DEPRESSION; FAMILIES; QUALITY; HISTORY; IMPACT	Background and Methods Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that causes gradual paralysis, respiratory failure, and death, usually within three to five years after it has been diagnosed. Between 1995 and 1997, we surveyed patients with this disease in Oregon and Washington, as well as their family care givers, in order to determine their attitudes toward assisted suicide. Patients were considered to be willing to contemplate assisted suicide if they agreed with the statement, "Under some circumstances I would consider taking a prescription for a medicine whose sole purpose was to end my life," and disagreed with the statement, "I would never request or take a prescription for a medication whose sole purpose was to end my life." The Oregon Death with Dignity Act, which legalized physician-assisted suicide, was approved by Oregon voters in 1994 but did not go into effect until October 1997, after data collection for this study had been completed. Results Of 140 eligible persons with ALS, 100 (71 percent) agreed to participate in the study, as did 91 family care givers. The mean age of the patients with ALS was 54 years; the mean duration of illness since the diagnosis was 2.8 years. Fifty-six patients (56 percent) said they would consider assisted suicide, and 44 of the 56 agreed with the statement, "If physician-assisted suicide were legal, I would request a lethal prescription from a physician." One patient would have taken the medication immediately, and 36 would have kept it for future use. As compared with the patients who were opposed to assisted suicide, those who would consider it were mure likely to be men, had a higher level of education, were less likely to be religious, had higher scores for hopelessness, and rated their quality of life as lower. In 66 of 91 instances (73 percent), care givers and patients had the same attitude toward assisted suicide. Conclusions In Oregon and Washington, a majority of persons with ALS whom we surveyed would consider assisted suicide. Many would request a prescription for a lethal dose of medication well before they intended to use it. (N Engl J Med 1998;339: 967-73.) (C)1998, Massachusetts Medical Society.	Vet Affairs Med Ctr, Mental Hlth Div P 7 1DMH, Portland, OR 97207 USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; Providence ElderPlace, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Mental Hlth Div P 7 1DMH, Portland, OR 97207 USA.		Johnston, Wendy S/E-2491-2013	Johnston, Wendy S/0000-0002-4330-5563; McFarland, Bentson/0000-0001-9149-5616				ARMITAGE P, 1987, STAT METHOS MED RES; BATTIN MP, 1995, ACAD MED, V70, P583; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CASSEL C, 1980, DIAGNOSIS TREATMENT, P325; Cherny N I, 1994, J Palliat Care, V10, P71; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fleiss J. L., 1981, STAT METHODS RATES P, V2; HENDIN H, 1997, SEDUCED DEATH DOCTOR; LEE BC, 1997, OREGON HLTH LAW MANU, V2; Lord FM, 1968, STAT THEORIES MENTAL; MASSIE MJ, 1994, J PAIN SYMPTOM MANAG, V9, P325, DOI 10.1016/0885-3924(94)90192-9; MILTON N, 1995, ISSUES LAW MED, V11, P123; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Moberg D. O., 1965, OLDER PEOPLE THEIR S, P125; PEARLMAN RA, 1991, J GERONTOL, V46, pM31, DOI 10.1093/geronj/46.2.M31; RINGEL SP, 1993, NEUROLOGY, V43, P1316, DOI 10.1212/WNL.43.7.1316; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	29	231	232	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					967	973		10.1056/NEJM199810013391406	http://dx.doi.org/10.1056/NEJM199810013391406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124MW	9753713	Bronze			2023-01-03	WOS:000076186900006
J	Maclure, M; Dormuth, C; Naumann, T; McCormack, J; Rangno, R; Whiteside, C; Wright, JM				Maclure, M; Dormuth, C; Naumann, T; McCormack, J; Rangno, R; Whiteside, C; Wright, JM			Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia	LANCET			English	Article							ESSENTIAL-HYPERTENSION; RISK; MANAGEMENT; SOCIETY; TRIALS	Background The way in which dissemination of evidence changes medical practice needs td be better understood. Controversy about calcium-channel blockers (CCB) in the past 3 years has provided a natural experiment, enabling assessment of the impact of media stories, a national warning letter, a teleconference, small group workshops, and newsletters on first-line prescribing of antihypertensive drugs. Methods We included all physicians (4403) in British Columbia who prescribed a thiazide diuretic, beta-blocker, inhibitor of angiotensin-converting enzyme (ACE), or CCB as the first antihypertensive agent for 36 507 residents aged 66 years and over, with no previous or concurrent sign of underlying cardiovascular disease. We used a database covering all prescriptions to elderly people to measure the change in proportion of newly treated patients who received each class of drug as first-line therapy. We used a matched cohort design for assessment of the teleconference and workshops, a randomised community design for the newsletters, and time-series analysis for the media impacts. Findings The proportion of patients who received a CCB as first-line therapy declined gradually from 22% in early 1994 to 15% in late 1996. This proportion was not affected by two waves of adverse news about CCBs in 1995, but fell by 5% for 5 months and by 3% for 1 month after two waves in 1996. The proportion of patients who received either a CCB or an ACE inhibitor as first-fine therapy, contrary to guidelines, was still 42% overall in 1996. The workshops and newsletters were followed by shifts from first-line CCB to first-line thiazide prescribing. Interpretation Changes in prescribing practices occur gradually with the accumulation of small impacts from educational interventions and lay media attention.	British Columbia Minist Hlth, Victoria, BC V8W 3C8, Canada; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Victoria, Dept Econ, Victoria, BC V8W 2Y2, Canada; Lions Gate Hosp, N Vancouver, BC, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1W5, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Family Practice, Vancouver, BC, Canada	Harvard University; Harvard T.H. Chan School of Public Health; University of Victoria; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Maclure, M (corresponding author), British Columbia Minist Hlth, 1515 Blanshard St, Victoria, BC V8W 3C8, Canada.	mmaclure@bcsc02.gov.bc.ca		Dormuth, Colin/0000-0001-8577-8783; McCormack, James/0000-0002-7801-5515				Barnett AA, 1996, LANCET, V347, P313; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Dean M, 1996, LANCET, V348, P951, DOI 10.1016/S0140-6736(05)65348-2; FREEMANTLE N, 1998, COCHRANE LIB; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; *HLTH PROT BRANCH, 1996, DEAR DOCTOR, V44, P1; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; MARWICK C, 1996, JAMA-J AM MED ASSOC, V275, P638; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Myers MG, 1996, CAN MED ASSOC J, V155, P772; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, 1996, AM J HYPERTENS, V9, P1429; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BZ, 1995, CIRCULATION, V91, P925; REUTER, 1995, VANCOUVER SUN   0311, pA15; ROTHMAN K, 1986, MODERN EPIDEMIOLOGY, P173; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SOUMERAI SB, 1992, MILBANK Q, V70, P155, DOI 10.2307/3350088; *THER IN, 1995, THERAPEUTICS LETT, V8; *THER IN, 1995, THERAPEUTICS LETT, V7; THOMSON MA, 1998, COCHRANE LIB; *WHO, 1993, J HYPERTENS, V11, P906	30	58	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					943	948		10.1016/S0140-6736(97)11390-3	http://dx.doi.org/10.1016/S0140-6736(97)11390-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752816				2023-01-03	WOS:000076002200009
J	Levine, JD				Levine, JD			New directions in pain research: Molecules to maladies	NEURON			English	Editorial Material							DORSAL-ROOT GANGLIA; NERVE GROWTH-FACTOR; SENSORY NEURONS; SPINAL-CORD; INDUCED HYPERALGESIA; ANALGESIA; MORPHINE; INJURY; HYPERSENSITIVITY; LOCALIZATION		Univ Calif San Francisco, Natl Inst, Hlth Pain Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Levine, JD (corresponding author), Univ Calif San Francisco, Natl Inst, Hlth Pain Ctr, San Francisco, CA 94143 USA.							Abbadie C, 1997, J NEUROSCI, V17, P8049; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Allen BJ, 1997, J NEUROSCI, V17, P5921; Amir R, 1997, J PHYSIOL-LONDON, V501, P183, DOI 10.1111/j.1469-7793.1997.183bo.x; BELKNAP JK, 1995, LIFE SCI, V57, pPL117, DOI 10.1016/0024-3205(95)02040-P; Benedetti F, 1996, PAIN, V64, P535, DOI 10.1016/0304-3959(95)00179-4; Bergmann I, 1997, EUR J NEUROSCI, V9, P18, DOI 10.1111/j.1460-9568.1997.tb01349.x; BING Z, 1991, NEUROSCIENCE, V44, P693, DOI 10.1016/0306-4522(91)90088-6; Birbaumer N, 1997, J NEUROSCI, V17, P5503; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CERVERO F, 1992, TRENDS NEUROSCI, V15, P374, DOI 10.1016/0166-2236(92)90182-8; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cicero TJ, 1996, J PHARMACOL EXP THER, V279, P767; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; Craig AD, 1996, NATURE, V384, P258, DOI 10.1038/384258a0; DEVOR M, 1993, J NEUROSCI, V13, P1976; DUGGAN AW, 1986, NEUROSCI LETT, V68, P134, DOI 10.1016/0304-3940(86)90243-0; Dyck PJ, 1997, NEUROLOGY, V48, P501, DOI 10.1212/WNL.48.2.501; England S, 1996, J PHYSIOL-LONDON, V495, P429, DOI 10.1113/jphysiol.1996.sp021604; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; Gold MS, 1996, P NATL ACAD SCI USA, V93, P1108, DOI 10.1073/pnas.93.3.1108; Gu JGG, 1997, NATURE, V389, P749, DOI 10.1038/39639; HINGTGEN CM, 1995, J NEUROSCI, V15, P5411; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Ji RR, 1996, REGUL PEPTIDES, V66, P179, DOI 10.1016/S0167-0115(96)00101-2; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; LAUTENBACHER S, 1993, PAIN, V53, P255, DOI 10.1016/0304-3959(93)90221-A; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; Ma QP, 1997, NEUROREPORT, V8, P807, DOI 10.1097/00001756-199703030-00001; Ma QP, 1996, PAIN, V67, P97, DOI 10.1016/0304-3959(96)03105-3; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCLACHLAN EM, 1993, NATURE, V363, P543, DOI 10.1038/363543a0; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; Nicol GD, 1997, J NEUROPHYSIOL, V77, P167, DOI 10.1152/jn.1997.77.1.167; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; Robbins WR, 1998, ANESTH ANALG, V86, P579, DOI 10.1097/00000539-199803000-00027; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Stucky CL, 1997, J NEUROSCI, V17, P4398; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; WATKINS LR, 1994, BRAIN RES, V639, P283, DOI 10.1016/0006-8993(94)91742-6; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; YU SS, 1993, J BIOL CHEM, V268, P337	48	16	22	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0896-6273			NEURON	Neuron	APR	1998	20	4					649	654		10.1016/S0896-6273(00)81005-3	http://dx.doi.org/10.1016/S0896-6273(00)81005-3			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZK649	9581758	Bronze			2023-01-03	WOS:000073346500005
J	Passalacqua, G; Albano, M; Fregonese, L; Riccio, A; Pronzato, C; Mela, GS; Canonica, GW				Passalacqua, G; Albano, M; Fregonese, L; Riccio, A; Pronzato, C; Mela, GS; Canonica, GW			Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis	LANCET			English	Article							DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; EPITHELIAL-CELLS; RHINITIS; ASTHMA; PARIETARIA; CHALLENGE; EFFICACY; ICAM-1	Background Non-injective routes of immunotherapy are thought to be valuable therapeutic options for respiratory allergy. We investigated the clinical efficacy and the effects of sublingual/oral immunotherapy on conjunctival allergic inflammation in patients with mite-induced respiratory allergy. Methods We used a double-blind placebo-controlled design. 20 patients with mite-induced rhinoconjunctivitis (six of whom also had mild asthma) were randomly assigned sublingual/oral immunotherapy (n=10) or placebo (n=10) for 2 years. We assessed symptom score by diary cards and inflammatory-cell infiltrate, and expression of intercellular adhesion molecule 1 (ICAM-1) in the conjunctiva after specific allergen challenge at enrolment and after 12 and 24 months of treatment. Findings We found significantly lower symptom scores in the immunotherapy group than in the placebo group in most of the winter months (p=0.05). Compared with the placebo group, inflammatory-cell infiltration after conjunctival challenge, and ICAM-1 expression on conjunctival epithelium decreased significantly in the first year of treatment in the immunotherapy group (p=0.04 and p=0.02, respectively). These effects were also seen for the minimum persistent inflammation, in symptom-free patients exposed constantly to allergens (p=0.02). Serum concentrations of eosinophil cationic protein decreased significantly (p=0.04). Immunotherapy was well tolerated and compliance was good. Interpretation Our results suggest that this immunotherapy is clinically effective in rhinoconjunctivitis and that it decreases the immune-mediated inflammatory responses to the allergen.	Univ Genoa, Dept Internal Med, DIMI, Allergy & Clin Immunol Serv, I-16132 Genoa, Italy; Univ Genoa, Dept Internal Med, DIMI, Lab Clin Informat, I-16132 Genoa, Italy	University of Genoa; University of Genoa	Canonica, GW (corresponding author), Univ Genoa, Dept Internal Med, DIMI, Allergy & Clin Immunol Serv, V Benedetto XV 6, I-16132 Genoa, Italy.		Mela, Giuseppe S/F-6072-2010; canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; RICCIO, ANNA MARIA/0000-0001-8392-533X				BAGNASCO M, 1997, J ALLERGY CLIN IMMUN, V100, P121; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; FELIZIANI V, 1995, ALLERGOL IMMUNOPATH, V23, P173; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; MALLING HJ, 1993, ALLERGY          S14, V48, P1; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; Passalacqua G, 1996, J INVEST ALLERG CLIN, V6, P81; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25	20	222	230	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					629	632		10.1016/S0140-6736(97)07055-4	http://dx.doi.org/10.1016/S0140-6736(97)07055-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500318				2023-01-03	WOS:000072364200008
J	Lidegaard, O				Lidegaard, O			Commentary: Oral contraceptives and myocardial infarction: reassuring new findings	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark	University of Copenhagen; Herlev & Gentofte Hospital	Lidegaard, O (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1583	1584						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428552				2023-01-03	WOS:000080913100020
J	Johnstone, P; Zolese, G				Johnstone, P; Zolese, G			Systematic review of the effectiveness of planned short hospital stays for mental health care	BRITISH MEDICAL JOURNAL			English	Article							2-YEAR FOLLOW-UP; LONG HOSPITALIZATION; PSYCHIATRIC-CARE; FAMILIES; SCHIZOPHRENICS	Objective To determine the effectiveness of planned short hospital stays versus standard care for people with serious mental illness. Design Systematic review of all randomised controlled trials comparing planned short hospital stay versus long hospital stay or standard care for people with serious mental illness. Subjects Four trials enrolled 628 patients. Main outcomes measures Relapse; readmission; death (suicides and all causes); violent incidents (self, others, property); lost to follow up; premature discharge; delayed discharge; mental state (not improved); social functioning; patient satisfaction, quality of life, self esteem, and psychological wellbeing; family burden; imprisonment; employment status; independent living; total cost of care; and average length of hospital stay. Results Patients allocated to planned short hospital stays had no more readmissions (in four trials, odds ratio 0.93, 95% confidence interval 0.66 to 1.29 with no heterogeneity between trials), no more losses to follow up (in three trials of 404 patients, 1.09, 0.62 to 1.91 with no heterogeneity between trials), and more successful discharges on time (in three trials of 404 patients, 0.47, 0.27 to 0.85) than patients allocated long hospital stays or standard care. Some evidence showed that patients allocated planned short hospital stay were no more likely to leave hospital prematurely and had a greater chance of being employed than those allocated long hospital stay or standard care. Data on mental, social, and family outcomes could not be summated, and there were few or no data on patient satisfaction, deaths, violence, criminal behaviour, and costs. Conclusion The effectiveness of care in mental hospitals is important to patients, carers, and policy makers. Despite inadequacies in the data, this review suggests that planned short hospital stays do not encourage a "revolving door" pattern of care for people with serious mental illness and may be more effective than standard care. Further pragmatic trials are needed on the most effective organisation and delivery of care in mental hospitals.	Berkshire Hlth Author, Reading RG30 2BA, Berks, England; Pathfinder Mental Hlth Serv NHS Trust, London SW17 7DJ, England		Johnstone, P (corresponding author), Berkshire Hlth Author, Reading RG30 2BA, Berks, England.							ADAMS CE, 1998, COCHRANE COLLABORATI; Beck A, 1997, BRIT J PSYCHIAT, V170, P247, DOI 10.1192/bjp.170.3.247; BURHAN AS, 1969, HOSP COMMUNITY PSYCH, V20, P369; CAFFEY EM, 1971, ARCH GEN PSYCHIAT, V24, P81; *DEP HLTH, 1994, REP INQ CAR TREATM C; GLICK ID, 1976, AM J PSYCHIAT, V133, P515; GLICK ID, 1974, ARCH GEN PSYCHIAT, V30, P363; GLICK ID, 1976, AM J PSYCHIAT, V133, P509; GLICK ID, 1975, AM J PSYCHIAT, V132, P385; GLICK ID, 1976, ARCH GEN PSYCHIAT, V33, P78; GLICK ID, 1977, ARCH GEN PSYCHIAT, V34, P314; Goffman E., 1961, ASYLUM ESSAYS SOCIAL; HARGREAVES WA, 1977, ARCH GEN PSYCHIAT, V34, P305; HERZ MI, 1976, AM J PSYCHIAT, V133, P795; HERZ MI, 1975, AM J PSYCHIAT, V132, P413; HERZ MI, 1979, ARCH GEN PSYCHIAT, V36, P701; HERZ MI, 1977, AM J PSYCHIAT, V134, P502; HIRSCH SR, 1979, BRIT MED J, V1, P442, DOI 10.1136/bmj.1.6161.442; KNIGHTS A, 1980, BRIT J PSYCHIAT, V137, P170, DOI 10.1192/bjp.137.2.170; MATTES JA, 1977, J NERV MENT DIS, V165, P387, DOI 10.1097/00005053-197712000-00004; MATTES JA, 1979, J NERV MENT DIS, V167, P175, DOI 10.1097/00005053-197903000-00007; REBEL S, 1976, AM J PSYCHIAT, V133, P518; ROSEN B, 1976, ARCH GEN PSYCHIAT, V33, P1316; Sackett D, 1994, COCHRANE COLLABORATI; TODD NA, 1976, BRIT J PSYCHIAT, V129, P424, DOI 10.1192/bjp.129.5.424; Wing JK, 1970, I SCHIZOPHRENIA; 1998, TIMES            JUL, P4	27	48	48	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1387	1390		10.1136/bmj.318.7195.1387	http://dx.doi.org/10.1136/bmj.318.7195.1387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334748	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000080524700026
J	Kelsen, DP; Ginsberg, R; Pajak, TF; Sheahan, DG; Gunderson, L; Mortimer, J; Estes, N; Haller, DG; Ajani, J; Kocha, W; Minsky, BD; Roth, JA				Kelsen, DP; Ginsberg, R; Pajak, TF; Sheahan, DG; Gunderson, L; Mortimer, J; Estes, N; Haller, DG; Ajani, J; Kocha, W; Minsky, BD; Roth, JA			Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	33rd Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 17-21, 1997	DENVER, CO	Amer Soc Clin Oncol			SQUAMOUS-CELL CARCINOMA; CLINICAL-TRIALS; THERAPY; ADENOCARCINOMA; CHEMORADIOTHERAPY; RADIOTHERAPY	Background We performed a multi-institutional randomized trial comparing preoperative chemotherapy followed by surgery with surgery alone for patients with local and operable esophageal cancer. Methods Preoperative chemotherapy for patients randomly assigned to the chemotherapy group included three cycles of cisplatin and fluorouracil. Surgery was performed two to four weeks after the completion of the third cycle; patients also received two additional cycles of chemotherapy after the operation. Patients randomly assigned to the immediate-surgery group underwent the same surgical procedure. The main end point was overall survival. Results Of the 440 eligible patients with adequate data, 213 were assigned to receive preoperative chemotherapy and 227 to undergo immediate surgery. After a median possible study time of 55.4 months, there were no significant differences between the two groups in median survival: 14.9 months for the patients who received preoperative chemotherapy and 16.1 months for those who underwent immediate surgery (P=0.53). At one year, the survival rate was 59 percent for those who received chemotherapy and 60 percent for those who had surgery alone; at two years, survival was 35 percent and 37 percent, respectively. The toxic effects of chemotherapy were tolerable, and the addition of chemotherapy did not appear to increase the morbidity or mortality associated with surgery. There were no differences in survival between patients with squamous-cell carcinoma and those with adenocarcinoma. Weight loss was a significant predictor of poor outcome (P=0.03). With the addition of chemotherapy, there was no change in the rate of recurrence at locoregional or distant sites. Conclusions Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus. (N Engl J Med 1998;339:1979-84.) (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Radiat Therapy Oncol Grp, Stat Off, Philadelphia, PA USA; Univ Pittsburgh, Pittsburgh, PA USA; Mayo Clin, Rochester, MN USA; Washington Univ, St Louis, MO USA; Univ Kansas, Lawrence, KS 66045 USA; Univ Penn, Philadelphia, PA 19104 USA; MD Anderson Canc Ctr, Houston, TX USA; Univ Western Ontario, London, ON, Canada	Memorial Sloan Kettering Cancer Center; Radiation Therapy Oncology Group (RTOG); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; Washington University (WUSTL); University of Kansas; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; Western University (University of Western Ontario)	Kelsen, DP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.			Mortimer, Joanne/0000-0002-2935-1934	NATIONAL CANCER INSTITUTE [U10CA037422, U10CA021661, U10CA032115] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJANI JA, 1994, J NATL CANCER I, V86, P1086, DOI 10.1093/jnci/86.14.1086; AlSarraf, 1997, J CLIN ONCOL, V15, P866; AlSarraf M, 1997, J CLIN ONCOL, V15, P277, DOI 10.1200/JCO.1997.15.1.277; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Bosset JF, 1997, NEW ENGL J MED, V337, P161, DOI 10.1056/NEJM199707173370304; COX DR, 1972, J R STAT SOC B, V34, P187; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; ILSON DH, 1994, SEMIN ONCOL, V21, P493; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEN DP, 1995, CHEST, V107, pS224, DOI 10.1378/chest.107.6_Supplement.224S; KOK TC, 1997, P AN M AM SOC CLIN, V16, pA277; LEPRISE E, 1994, CANCER, V73, P1779; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Sposto R, 1997, STAT MED, V16, P695, DOI 10.1002/(SICI)1097-0258(19970330)16:6<695::AID-SIM436>3.0.CO;2-C; URBA S, 1997, P AN M AM SOC CLIN, V16, pA277; Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	22	1018	1051	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1998	339	27					1979	1984		10.1056/NEJM199812313392704	http://dx.doi.org/10.1056/NEJM199812313392704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	152XX	9869669	Bronze			2023-01-03	WOS:000077803800004
J	Monane, M; Matthias, DM; Nagle, BA; Kelly, MA				Monane, M; Matthias, DM; Nagle, BA; Kelly, MA			Improving prescribing patterns for the elderly through an online drug utilization review intervention - A system linking the physician, pharmacist, and computer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INAPPROPRIATE MEDICATION USE; EXPLICIT CRITERIA	Context.- Pharmacotherapy is among the most powerful interventions to improve health outcomes in the elderly. However, since some medications are less appropriate for older patients, systems approaches to improving pharmacy care may be an effective way to reduce inappropriate medication use. Objective.-To determine whether a computerized drug utilization review (DUR) database linked to a telepharmacy intervention can improve suboptimal medication use in the elderly. Design.-Population-based cohort design, April 1, 1996, through March 31, 1997, Setting.-Ambulatory care. Patients.-A total of 23 269 patients aged 65 years acid older throughout the United States receiving prescription drug benefits from a large pharmaceutical benefits manager during a 12-month period. Intervention.- Evaluation of provider prescribing through a computerized online DUR database using explicit criteria to identify potentially inappropriate drug use in the elderly. Computer alerts triggered telephone calls to physicians by pharmacists with training in geriatrics, whereby principles of geriatric pharmacology were discussed along with therapeutic substitution options. Main Outcome Measures.-Contact rate with physicians and change rate to suggested drug regimen. Results.-A total of 43 007 alerts were triggered. From a total of 43 007 telepharmacy calls generated by the alerts, we were able to reach 19 368 physicians regarding 24 266 alerts (56%). Rate of change to a more appropriate therapeutic agent was 24% (5860), but ranged from 40% for long half-life benzodiazepines to 2% to 7% for drugs that theoretically were contraindicated by patients' self-reported history. Except for rate of change of beta-blockers in patients with chronic obstructive pulmonary disease, all rates of change were significantly greater than the expected baseline 2% rate of change. Conclusions.-Using a system integrating computers, pharmacists, and physicians, our large-scale intervention improved prescribing patterns and quality of care and thus provides a population-based approach to advance geriatric clinical pharmacology. Future research should focus on the demonstration of improved health outcomes resulting from improved prescribing choices for the elderly.	Merck Medco Managed Care LLC, Dept Med Affairs, Montvale, NJ 07645 USA; Merck Medco Managed Care LLC, Dept Hlth & Utilizat Management, Montvale, NJ 07645 USA		Monane, M (corresponding author), Merck Medco Managed Care LLC, Dept Med Affairs, 100 Summit Ave, Montvale, NJ 07645 USA.	mark_monane@merck.com						BAUM C, 1984, JAMA-J AM MED ASSOC, V251, P1293, DOI 10.1001/jama.251.10.1293; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; *GEN ACC OFF, 1995, GAOHEHS95152; GROVES RE, 1985, AM J HOSP PHARM, V42, P316, DOI 10.1093/ajhp/42.2.316; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Hanlon JT, 1995, THERAPEUTICS ELDERLY, P212; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; SARTOR F, 1995, AM J EPIDEMIOL, V141, P782, DOI 10.1093/oxfordjournals.aje.a117502; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; STEWART RB, 1994, DRUG AGING, V4, P449, DOI 10.2165/00002512-199404060-00002; STEWART RB, 1989, MED CLIN N AM, V73, P1551, DOI 10.1016/S0025-7125(16)30616-2; STUCK AE, 1994, ARCH INTERN MED, V154, P2195; WILCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292	22	154	164	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1249	1252		10.1001/jama.280.14.1249	http://dx.doi.org/10.1001/jama.280.14.1249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127NR	9786375	Bronze			2023-01-03	WOS:000076357900031
J	Kiser, PF; Wilson, G; Needham, D				Kiser, PF; Wilson, G; Needham, D			A synthetic mimic of the secretory granule for drug delivery	NATURE			English	Article							MAST-CELL; VESICLES; ACCUMULATION; PRODUCTS	Secretory cells contain submicroscopic granules composed of a polyanionic polymer network that is collapsed owing to the presence of hydronium ions and weak base cations(1-3). The network is encapsulated within a lipid membrane, and functions as a vehicle for the osmotically inert storage of a variety of granule-bound endogenous mediator species, such as histamine, serotonin and proteases. These species are excreted from the granule and thence from the cell in response to external biochemical signals(1-4) Hydrogels that swell and shrink in response to external stimuli might serve as synthetic analogues of secretory granules(5,6). Here we describe the systematic engineering of multi-component, environmentally responsive hydrogel microspheres, coated with a lipid bilayer to mimic more closely the natural secretory granule. These microspheres exhibit pH- and ion-dependent volume phase transitions and ion-sensitive exchange of bound cations when the encapsulating lipid membrane is porated. We stimulated poration electrically in individual microgel particles immobilized and manipulated with a micropipette. This system could find use for the triggered release of encapsulated drugs in the body.	Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA; Access Pharmaceut, Dallas, TX 75207 USA; Glynn Wilson Grp, Issaquah, WA 98027 USA	Duke University	Needham, D (corresponding author), Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA.	david.needham@duke.edu	Kiser, Patrick F/C-2843-2014	Kiser, Patrick F/0000-0002-3868-7122; Needham, David/0000-0002-0082-9148				CHEN Y, 1994, MICROSPHERES REGIONA, P2; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; EICHENBAUM G, IN PRESS MACROMOLECU; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1997, Patent No. 5654006; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; KASHIWABARA M, 1995, COLLOID POLYM SCI, V273, P339, DOI 10.1007/BF00652347; KISER P, 1997, P AM CHEM SOC DIV PO, V76, P226; MADDEN TD, 1990, CHEM PHYS LIPIDS, V53, P37, DOI 10.1016/0009-3084(90)90131-A; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; NEEDHAM D, 1989, BIOPHYS J, V55, P1001, DOI 10.1016/S0006-3495(89)82898-X; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; RICKA J, 1984, MACROMOLECULES, V17, P2916, DOI 10.1021/ma00142a081; VERDUGO P, 1995, P INT S CONTR REL BI, P114; WU NZ, 1993, CANCER RES, V53, P3765	20	239	244	5	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					459	462		10.1038/28822	http://dx.doi.org/10.1038/28822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697768				2023-01-03	WOS:000075080400046
J	Pittet, D; Harbarth, S				Pittet, D; Harbarth, S			What techniques for diagnosis of ventilator-associated pneumonia?	LANCET			English	Editorial Material									Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Geneva; Harvard University; Harvard T.H. Chan School of Public Health	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland.							Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Flaherty JP, 1996, INFECT CONT HOSP EP, V17, P236; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; Pittet D, 1998, HOSP INFECT, P381; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					83	84		10.1016/S0140-6736(98)85005-8	http://dx.doi.org/10.1016/S0140-6736(98)85005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672269				2023-01-03	WOS:000074775100005
J	Brizel, DM; Albers, ME; Fisher, SR; Scher, RL; Richtsmeier, WJ; Hars, V; George, SL; Huang, AT; Prosnitz, LR				Brizel, DM; Albers, ME; Fisher, SR; Scher, RL; Richtsmeier, WJ; Hars, V; George, SL; Huang, AT; Prosnitz, LR			Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; RANDOMIZED TRIAL; RADIOTHERAPY; RECURRENCE; SURVIVAL; LARYNX	Background Radiotherapy is often the primary treatment for advanced head and neck cancer, but the rates of locoregional recurrence are high and survival is poor. We investigated whether hyperfractionated irradiation plus concurrent chemotherapy (combined treatment) is superior to hyperfractionated irradiation alone. Methods Patients with advanced head and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice daily, for a total of 7500 cGy. Patients in the combined-treatment group received 125 cGy twice daily, for a total of 7000 cGy, and five days of treatment with 12 mg of cisplatin per square meter of body-surface area per day and 600 mg of fluorouracil per square meter per day during weeks 1 and 6 of irradiation. Two cycles of cisplatin and fluorouracil were given to most patients after the completion of radiotherapy. Results of 122 patients who underwent randomization, 116 were included in the analysis. Most patients in both treatment groups had unresectable disease. The median follow-up was 41 months (range, 19 to 86). At three years the rate of overall survival was 55 percent in the combined-therapy group and 34 percent in the hyperfractionation group (P=0.07). The relapse-free survival rate was higher in the combined-treatment group (61 percent vs. 41 percent, P=0.08). The rate of locoregional control of disease at three years was 70 percent in the combined-treatment group and 44 percent in the hyperfractionation group (P=0.01). Confluent mucositis developed in 77 percent and 75 percent of the two groups, respectively. Severe complications occurred in three patients in the hyperfractionation group and five patients in the combined-treatment group. Conclusions Combined treatment for advanced head and neck cancer is more efficacious and not more toxic than hyperfractionated irradiation alone. (C) 1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Community & Family Med, Div Biometry, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Brizel, DM (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 3085, Durham, NC 27710 USA.			Brizel, David/0000-0001-9828-4790	NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NCI NIH HHS [CA14236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Beahrs OH, 1988, MANUAL STAGING CANC; Bourhis J, 1996, ANTICANCER RES, V16, P2397; BRIZEL DM, 1994, INT J RADIAT ONCOL, V28, P213, DOI 10.1016/0360-3016(94)90160-0; CAPLAN RJ, 1994, INT J RADIAT ONCOL, V29, P1183, DOI 10.1016/0360-3016(94)90416-2; Dubray B, 1996, RADIOLOGY, V201, P553, DOI 10.1148/radiology.201.2.8888257; FU KK, 1987, J CLIN ONCOL, V5, P1410, DOI 10.1200/JCO.1987.5.9.1410; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; GRIEM KL, 1996, 4 INT C HEAD NECK CA, P118; Harari PM, 1997, J CLIN ONCOL, V15, P2050, DOI 10.1200/JCO.1997.15.5.2050; HORIOT JC, 1992, RADIOTHER ONCOL, V25, P231, DOI 10.1016/0167-8140(92)90242-M; Horiot JC, 1997, RADIOTHER ONCOL, V44, P111, DOI 10.1016/S0167-8140(97)00079-0; HORIOT JC, 1995, EUR J CANCER, V31, P69; HORIOT JC, 1996, RADIOTHER ONCOL S1, V40, P106; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNEE R, 1985, RADIOTHER ONCOL, V4, P1, DOI 10.1016/S0167-8140(85)80055-4; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; MUNRO AJ, 1995, BRIT J CANCER, V71, P83, DOI 10.1038/bjc.1995.17; NG CE, 1987, BRIT J CANCER, V56, P301, DOI 10.1038/bjc.1987.193; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P515, DOI 10.1016/0360-3016(86)90058-1; PARSONS JT, 1989, HEAD NECK-J SCI SPEC, V11, P400, DOI 10.1002/hed.2880110504; PARSONS JT, 1988, INT J RADIAT ONCOL, V14, P649, DOI 10.1016/0360-3016(88)90085-5; PETERS LJ, 1992, PRINCIPLES PRACTICE, P97; WANG CC, 1986, INT J RADIAT ONCOL, V12, P3, DOI 10.1016/0360-3016(86)90407-4; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	28	900	922	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1798	1804		10.1056/NEJM199806183382503	http://dx.doi.org/10.1056/NEJM199806183382503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632446	Bronze			2023-01-03	WOS:000074197500003
J	Chase, M; Chung, RY; Chiocca, EA				Chase, M; Chung, RY; Chiocca, EA			An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy	NATURE BIOTECHNOLOGY			English	Article						gene therapy; herpes simplex virus type 1; prodrug activation	GENE-THERAPY; BRAIN-TUMORS; DNA-SYNTHESIS; VIRUS MUTANT; P53 GENE; CANCER; GLIOMAS; CELLS; ADENOVIRUS; ACTIVATION	Herpes simplex viruses type 1 (HSV-1) with an inactivated viral ribonucleotide reductase (Hsrr, ICP6) were designed to target tumor cells with upregulated mammalian ribonucleotide reductase (mRR), an enzyme whose expression is regulated by the p16/pRB tumor suppressor pathway. A recombinant HSV-1 was generated by knock-out of Hsrr and insertion of the rat CYP2B1 transgene responsible for the bioactivation of the prodrugs, cyclophosphamide and ifosfamide. The mutant virus replicated selectively in rat and human tumor cells that express mRR. Addition of cyclophosphamide potentiated oncolytic effects against cultured tumor cells and subcutaneous tumor xenografts established in athymic mice.	Harvard Univ, Sch Med, Mol Neurooncol Labs, Neurosurg Serv,Massachusetts Gen Hosp, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Chiocca, EA (corresponding author), Harvard Univ, Sch Med, Mol Neurooncol Labs, Neurosurg Serv,Massachusetts Gen Hosp, CNY6, Charlestown, MA 02129 USA.	Chiocca@helix.MGH.Harvard.edu						BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; Carroll NM, 1997, J SURG RES, V69, P413, DOI 10.1006/jsre.1997.5089; CHAMBERS R, 1995, P NATL ACAD SCI USA, V92, P1411, DOI 10.1073/pnas.92.5.1411; CHEN L, 1995, CANCER RES, V55, P581; Chen L, 1996, CANCER RES, V56, P1331; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLARKE L, 1989, CANCER RES, V49, P2344; COLVIN OM, 1993, CANC MED, P733; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GOPFERICH A, 1994, PHARMACEUT RES, V11, P1568, DOI 10.1023/A:1018901619230; KESARI S, 1995, LAB INVEST, V73, P636; LORENCE RM, 1994, JNCI-J NATL CANCER I, V86, P1228, DOI 10.1093/jnci/86.16.1228; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Marais R, 1996, CANCER RES, V56, P4735; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MINETA T, 1994, CANCER RES, V54, P3936; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MROZ PJ, 1993, HUM GENE THER, V4, P589, DOI 10.1089/hum.1993.4.5-589; MULDOON LL, 1995, AM J PATHOL, V147, P1840; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; NILAVER G, 1995, P NATL ACAD SCI USA, V92, P9829, DOI 10.1073/pnas.92.21.9829; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Rodriguez R, 1997, CANCER RES, V57, P2559; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Ueki K, 1996, CANCER RES, V56, P150; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wei MX, 1995, CLIN CANCER RES, V1, P1171; WEI MX, 1994, HUM GENE THER, V5, P969, DOI 10.1089/hum.1994.5.8-969	38	153	168	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1998	16	5					444	448		10.1038/nbt0598-444	http://dx.doi.org/10.1038/nbt0598-444			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	ZL948	9592392				2023-01-03	WOS:000073489600028
J	Emanuel, EJ; Emanuel, LL				Emanuel, EJ; Emanuel, LL			The promise of a good death	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; OF-LIFE QUESTIONNAIRE; ADVANCE DIRECTIVES; TERMINAL CARE; CANCER PAIN; EUTHANASIA; ATTITUDES; ILLNESS; HOSPICE; NEEDS		NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Assoc, Div Eth Stand, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10 Room 1C118, Bethesda, MD 20892 USA.	eemanuel@nih.gov						*AG HLTH CAR POL R, 1994, AHCPR PUBL; ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Aries P, 1981, HOUR OUR DEATH; *ASS PALL MED ROYA, 1993, PALL MED CURR; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BREITBART W, 1995, J PAIN SYMPTOM MANAG, V10, P131, DOI 10.1016/0885-3924(94)00075-V; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BROOK DB, IN PRESS HOSPICE J; Bruera E, 1991, J Palliat Care, V7, P6; Cassel, 1991, NATURE SUFFERING GOA; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Cohen SR, 1996, CANCER-AM CANCER SOC, V77, P576, DOI 10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0; Cohen SR, 1997, PALLIATIVE MED, V11, P3; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DONNELLY S, 1995, SEMIN ONCOL, V22, pS67; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; EMANUEL EJ, 1998, J CLIN ONCOL, V17, P1628; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EMANUEL LL, 1991, JAMA-J AM MED ASSOC, V325, P3288; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; *I MED, 1997, APPR DEATH IMPR CAR; KANE RL, 1984, LANCET, V1, P890; KINSELLA TD, 1994, BRIT MED J, V308, P1332; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; Kubler-Ross E., 1970, DEATH DYING; KUTNER L, 1969, INDIANA LAW J, V44, P539; Mount B M, 1994, J Palliat Care, V10, P24; MOUNT BM, 1983, J CHRON DIS, V36, P731, DOI 10.1016/0021-9681(83)90068-1; *NAT HOSP ORG, 1997, HOSP FACT SHEET; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PHILLIPS DP, 1988, LANCET, V2, P728; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; QUILL TE, 1996, MIDWIFE DYING PROCES, P202; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SEAL C, 1994, YEAR DEATH; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; STODDARD S, 1974, HOSPICE MOVEMENT BET; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERMAAS PJ, 1996, NEW ENGL J MED, V335, P1691; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *VTTAS HEALTHC, 1995, MISS VITAS QUAL IND; WEEKS JC, IN PRESS JAMA; Welch T., 1985, OUTPATIENT MANAGEMEN; World Health Organization, 1990, CANC PAIN REL PALL C; [No title captured]	60	323	329	2	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY	1998	351			2			21	29		10.1016/S0140-6736(98)90329-4	http://dx.doi.org/10.1016/S0140-6736(98)90329-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP168	9606363				2023-01-03	WOS:000073724100005
J	Jacobson, J				Jacobson, J			After the miracle	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					906	906		10.1001/jama.279.12.906	http://dx.doi.org/10.1001/jama.279.12.906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544753				2023-01-03	WOS:000072563600011
J	Ferreira, F; Ebner, C; Kramer, B; Casari, G; Briza, P; Kungl, AJ; Grimm, R; Jahn-Schmid, B; Breiteneder, H; Kraft, D; Breitenbach, M; Rheinberger, H; Scheiner, O				Ferreira, F; Ebner, C; Kramer, B; Casari, G; Briza, P; Kungl, AJ; Grimm, R; Jahn-Schmid, B; Breiteneder, H; Kraft, D; Breitenbach, M; Rheinberger, H; Scheiner, O			Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy	FASEB JOURNAL			English	Article						major birch pollen allergen; Bet v 1 mutants; IgE binding epitopes; allergen-specific T cell clones; hypoallergens	BIRCH POLLEN ALLERGEN; T-CELL CLONES; BET-V-I; 4 RECOMBINANT ISOFORMS; MAJOR ALLERGEN; INTERLEUKIN-4 PRODUCTION; PROTEIN ANTIGENICITY; OVERLAPPING PEPTIDES; ESCHERICHIA-COLI; ATOPIC PATIENTS	Specific immunotherapy is an efficient treatment for patients suffering from type I allergy. The mechanisms underlying successful immunotherapy are assumed to operate at the level of T helper cells, leading to a modulation of the immune response to allergens. During immunotherapy, increasing doses of allergens are given on a regular basis, and the beneficial effects for the patient depend on the concentration of allergen used. On the other hand, the risk of IgE-mediated anaphylactic side effects also increase with the amount of allergen applied per injection. Therefore, we have proposed the use of hypoallergenic (low IgE binding activity) forms of allergens for immunotherapy. We evaluated by site-directed mutagenesis the contributions of individual amino acid residues/positions for IgE binding to Bet v 1, the major allergen of birch pollen. We found that IgE binding to Bet v 1 depended on at least six amino acid residues/positions. Immunoblot analyses and inhibition experiments showed that the multiple-point Bet v 1 mutant exhibited extremely low reactivity with serum IgE from birch pollen-allergic patients. In vivo (skin prick) tests showed that the potency of the multiple-point mutant to induce typical urticarial type I reactions in pollen-allergic patients was significantly lower than for wild-type Bet v 1. Proliferation assays of allergen-specific T cell clones demonstrated that these six amino acid exchanges in the Bet v 1 sequence did not influence T cell recognition. Thus, the Bet v I six-point mutant displayed significantly reduced IgE binding activity, but conserved T cell activating capacity, which is necessary for immunomodulation. The approach described here may be generally applied to produce allergen variants to be used in a safe therapy form of immediate-type allergies.	Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria; European Mol Biol Lab, D-69012 Heidelberg, Germany; Novartis Forschungsinst, A-1235 Vienna, Austria; Hewlett Packard Analyt Grp, D-76337 Waldbronn, Germany; Univ Vienna, Inst Allgemeine & Expt Pathol, A-1090 Vienna, Austria	Salzburg University; European Molecular Biology Laboratory (EMBL); Novartis; Hewlett-Packard; University of Vienna	Ferreira, F (corresponding author), Salzburg Univ, Inst Genet & Allgemeine Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	fatima.ferreira@mh.sbg.ac.at	Ferreira, Fatima/E-4889-2011; Briza, Peter/D-7309-2012; Ferreira, Fatima/AAB-4321-2019	Ferreira, Fatima/0000-0003-0989-2335; Briza, Peter/0000-0002-4941-6782; Ferreira, Fatima/0000-0003-0989-2335; Kungl, Andreas/0000-0003-3362-797X				BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P135; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; DREBORG S, 1985, ALLERGY S4, V40, P55; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Faber C, 1996, J BIOL CHEM, V271, P19243, DOI 10.1074/jbc.271.32.19243; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; IPSEN H, 1989, EPITOPES ATOPIC ALLE, P3; JACOBS S, 1959, NATURE, V183, P262, DOI 10.1038/183262a0; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kungl AJ, 1996, BIOCHEM BIOPH RES CO, V223, P187, DOI 10.1006/bbrc.1996.0867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rothbard J B, 1989, Int Immunol, V1, P479, DOI 10.1093/intimm/1.5.479; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith AM, 1997, INT ARCH ALLERGY IMM, V113, P99, DOI 10.1159/000237517; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; VANREGENMORTEL MHV, 1986, TRENDS BIOCHEM SCI, V11, P36, DOI 10.1016/0968-0004(86)90230-6; Vrtala S, 1997, INT ARCH ALLERGY IMM, V113, P246, DOI 10.1159/000237560; WEISS C, 1993, J BIOL CHEM, V268, P19574; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	57	235	263	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					231	242		10.1096/fasebj.12.2.231	http://dx.doi.org/10.1096/fasebj.12.2.231			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472988	Bronze			2023-01-03	WOS:000071848400011
J	Moffett, JK; Torgerson, D; Bell-Syer, S; Jackson, D; Llewlyn-Phillips, H; Farrin, A; Barber, J				Moffett, JK; Torgerson, D; Bell-Syer, S; Jackson, D; Llewlyn-Phillips, H; Farrin, A; Barber, J			Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences	BRITISH MEDICAL JOURNAL			English	Article							COPING STRATEGIES; FITNESS PROGRAM; FOLLOW-UP; DISABILITY; THERAPY; BELIEFS	Objective To evaluate effectiveness of an exercise programme in a community setting for patients with low back pain to encourage a return to normal activities. Design Randomised controlled trial of progressive exercise programme compared with usual primary care management Patients' preferences for type of management were elicited independently of randomisation. Participants 187 patients aged 18-60 years with mechanical low back pain of 4 weeks to 6 months' duration. Interventions Exercise classes led by a physiotherapist that included strengthening exercises for all main muscle groups, stretching exercises, relaxation session, and brief education on back care. A cognitive-behavioural approach was used. Main outcome measures Assessments of debilitating effects of back pain before and after intervention and at 6 months and 1 year later. Measures included Poland disability questionnaire, Aberdeen back pain scale, pain diaries, and use of healthcare services. Results At 6 weeks after randomisation, the intervention group improved marginally more than the control group on the disability questionnaire and reported less distressing pain. At 6 months and 1 year, the intervention group showed significantly greater improvement in the disability questionnaire score (mean difference in changes 1.35, 95% confidence interval 0.13 to 2.57). At 1 year, the intervention group also showed significantly greater improvement in the Aberdeen back pain scale (4.44, 1.01 to 7.87) and reported only 378 days off work compared with 607 in the control group. The intervention group used fewer healthcare resources. Outcome was not influenced by patients' preferences. Conclusions The exercise class was more clinically effective than traditional general practitioner management, regardless of patient preference, and was cost effective.	Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ York, Dept Hlth Sci & Clin Evaluat, York YO1 5DD, N Yorkshire, England; Univ London, Imperial Coll, Sch Med, Dept Med Stat & Evaluat, London WC1E 7HU, England	University of York - UK; University of York - UK; Imperial College London; University of London	Moffett, JK (corresponding author), Univ Hull, Inst Rehabil, Hull HU3 2PG, N Humberside, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Farrin, Amanda/0000-0002-2876-0584; Barber, Julie/0000-0001-5762-762X				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Clement S, 1998, BRIT MED J, V317, P78; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; CROFT PR, 1997, LOW BACK PAIN; Efron B., 1993, INTRO BOOTSTRAP; ESTLANDER A, 1989, SCAND J BEHAV THER, V18, P56; FAAS A, 1993, SPINE, V18, P1388; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; HOLMES JA, 1990, HEALTH PSYCHOL, V9, P577, DOI 10.1037/0278-6133.9.5.577; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; McPherson K, 1997, J ROY SOC MED, V90, P652, DOI 10.1177/014107689709001205; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; RUTA DA, 1994, SPINE, V19, P1887, DOI 10.1097/00007632-199409000-00004; SLADE PD, 1983, BEHAV RES THER, V21, P409, DOI 10.1016/0005-7967(83)90010-4; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WADDELL G, 1996, LOW BACK PAIN EVIDEN; WILLIAMS DA, 1991, PAIN, V46, P185, DOI 10.1016/0304-3959(91)90074-8; [No title captured]	24	211	215	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					279	283		10.1136/bmj.319.7205.279	http://dx.doi.org/10.1136/bmj.319.7205.279			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426734	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000081909100018
J	Sadetzki, S; Modan, B				Sadetzki, S; Modan, B			Epidemiology as a basis for legislation: how far should epidemiology go?	LANCET			English	Editorial Material							RADIATION		Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Stanley Steyer Inst Canc Epidemiol, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University	Modan, B (corresponding author), Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel.							BROWN WMC, 1955, LANCET, V1, P1283; CRAWFORD GM, 1951, NEW ENGL J MED, V245, P726, DOI 10.1056/NEJM195111082451904; DAMESHEK W, 1957, JAMA-J AM MED ASSOC, V163, P838, DOI 10.1001/jama.1957.02970450040010; HARDER D, 1995, DIGNITY DISCOVERY RA; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; *ICRP, 1992, ICRP PUBL, V59; KAPLAN I I, 1957, Can Med Assoc J, V76, P43; LANGE RD, 1954, BLOOD, V9, P574, DOI 10.1182/blood.V9.6.574.574; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; MARCH HC, 1950, AM J MED SCI, V220, P282, DOI 10.1097/00000441-195022030-00007; March HC., 1944, RADIOLOGY, V43, P275, DOI DOI 10.1148/43.3.275; Modan B, 1975, Harefuah, V88, P541; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1987, MED ONCOL TUMOR PHAR, V4, P141; MOLONEY WC, 1995, SCIENCE, V121, P308; RON E, 1984, ISRAEL J MED SCI, V20, P1164; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; RON E, 1982, AM J EPIDEMIOL, V16, P149; *US DHEW, 1964, PHS PUBL; VETTER RJ, 1993, HEALTH PHYS, V64, P115; WERNER A, 1968, PHYS MED BIOL, V13, P247, DOI 10.1088/0031-9155/13/2/310; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P320	22	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2238	2239		10.1016/S0140-6736(98)12327-9	http://dx.doi.org/10.1016/S0140-6736(98)12327-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10393003				2023-01-03	WOS:000081091300045
J	Chen, Y; Schindler, M; Simon, SM				Chen, Y; Schindler, M; Simon, SM			A mechanism for tamoxifen-mediated inhibition of acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; DEFECTIVE ACIDIFICATION; PHOSPHOLIPID-VESICLES; CHLORIDE CHANNELS; LOCAL-ANESTHETICS; PROTON TRANSPORT; CYSTIC-FIBROSIS; RESISTANT CELLS; BONE-RESORPTION; H+-ATPASE	Tamoxifen has been reported to inhibit acidification of cytoplasmic organelles in mammalian cells. Here, the mechanism of this inhibition is investigated using in vitro assays on isolated organelles and liposomes. Tamoxifen inhibited ATP-dependent acidification in organelles from a variety of sources, including isolated microsomes from mammalian cells, vacuoles from Saccharomyces cerevisiae, and inverted membrane vesicles from Escherichia coli. Tamoxifen increased the ATPase activity of the vacuolar proton ATPase but decreased the membrane potential (V-m) generated by this proton pump, suggesting that tamoxifen may act by increasing proton permeability. In liposomes, tamoxifen increased the rate of pH dissipation. Studies comparing the effect of tamoxifen on pH gradients using different salt conditions and with other known ionophores suggest that tamoxifen affects transmembrane pH through two independent mechanisms. First, as a lipophilic weak base, it partitions into acidic vesicles, resulting in rapid neutralization. Second, it mediates coupled, electroneutral transport of proton or hydroxide with chloride. An understanding of the biochemical mechanism(s) for the effects of tamoxifen that are independent of the estrogen receptor could contribute to predicting side effects of tamoxifen and in designing screens to select for estrogen-receptor antagonists without these side effects.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Rockefeller University; Michigan State University	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave, New York, NY 10021 USA.	simon@rockvax.rockefeller.edu		Simon, Sanford/0000-0002-8615-4224	NATIONAL CANCER INSTITUTE [R01CA081257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81257] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Altan N, 1999, P NATL ACAD SCI USA, V96, P4432, DOI 10.1073/pnas.96.8.4432; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BERMAN E, 1995, LEUKEMIA, V9, P1631; BERMAN E, 1991, BLOOD, V77, P818; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; CHATTERJEE M, 1990, BRIT J CANCER, V62, P712, DOI 10.1038/bjc.1990.365; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; EHRING GR, 1994, J GEN PHYSIOL, V104, P1129, DOI 10.1085/jgp.104.6.1129; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; Goulian M, 1998, BIOPHYS J, V74, P328, DOI 10.1016/S0006-3495(98)77790-2; GREENBERG DA, 1987, CANCER RES, V47, P70; GRUNER SM, 1991, ANN NY ACAD SCI, V625, P685, DOI 10.1111/j.1749-6632.1991.tb33902.x; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; JORDAN VC, 1995, P SOC EXP BIOL MED, V208, P144; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kellen J. A., 1996, TAMOXIFEN ANTIESTROG; Ladokhin AS, 1995, BIOPHYS J, V69, P1964, DOI 10.1016/S0006-3495(95)80066-4; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rostovtseva TK, 1998, BIOPHYS J, V75, P1783, DOI 10.1016/S0006-3495(98)77620-9; SATO K, 1977, TOHOKU J EXP MED, V123, P185, DOI 10.1620/tjem.123.185; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V599, P150, DOI 10.1016/0005-2736(80)90064-4; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; SEELIG A, 1988, BIOCHIM BIOPHYS ACTA, V939, P267, DOI 10.1016/0005-2736(88)90070-3; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Song JB, 1996, J PHARMACOL EXP THER, V277, P1444; SUN XC, 1992, J BIOL CHEM, V267, P19147; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Weinlander G, 1997, J CANCER RES CLIN, V123, P452, DOI 10.1007/BF01372550; Williams JP, 1996, J BIOL CHEM, V271, P12488, DOI 10.1074/jbc.271.21.12488; Williams JP, 1997, J CELL BIOCHEM, V66, P358, DOI 10.1002/(SICI)1097-4644(19970901)66:3<358::AID-JCB8>3.3.CO;2-K; WISEMAN H, 1993, FEBS LETT, V330, P53, DOI 10.1016/0014-5793(93)80918-K; WISEMAN H, 1994, TRENDS PHARMACOL SCI, V15, P83, DOI 10.1016/0165-6147(94)90283-6; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	48	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18364	18373		10.1074/jbc.274.26.18364	http://dx.doi.org/10.1074/jbc.274.26.18364			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373441	hybrid			2023-01-03	WOS:000081056700033
J	Klomp, HM; Spincemaille, GHJJ; Steyerberg, EW; Habbema, JDF; van Urk, H				Klomp, HM; Spincemaille, GHJJ; Steyerberg, EW; Habbema, JDF; van Urk, H		ESES study grp	Spinal-cord stimulation in critical limb ischaemia: a randomised trial	LANCET			English	Article							PERIPHERAL VASCULAR-DISEASE; ELECTRICAL-STIMULATION; BLOOD-FLOW; LEG ISCHEMIA; PAIN; SCS; IMPROVEMENT; THERAPY	Background For patients with critical limb ischaemia, spinal-cord stimulation has been advocated for the treatment of ischaemic pain and the prevention of amputation. We compared the efficacy of the addition of spinal-cord stimulation to best medical treatment in a randomised controlled trial. Methods 120 patients with critical limb ischaemia not suitable for vascular reconstruction were randomly assigned either spinal-cord stimulation in addition to best medical treatment or best medical treatment alone. Primary outcomes were mortality and amputation. The primary endpoint was limb survival at 2 years. Findings The mean (SD) age of the patients was 72.6 years (10.3). Median (IQR) follow-up was 605 days (244-1171). 40 (67%) of 60 patients in the spinal-cord-stimulator group and 41 (68%) of 60 patients in the standard group were alive at the end of the study, (p=0.96). There were 25 major amputations in the spinal-cord-stimulator group and 29 in the standard group, (p=0.47). The hazard ratio for survival at 2 years without major amputation in the spinal-cord stimulation group compared with the standard group was 0.96 (95% CI 0.61-1.51). Interpretation Spinal-cord-stimulation in addition to best medical care does not prevent amputation in patients with critical limb ischaemia.	De Wever Hosp, Atruim Med Centrum, Dept Neurosurg, Heerlen, Netherlands; Univ Hosp Rotterdam Dijkzigt, Dept Surg, NL-3015 GD Rotterdam, Netherlands; Erasmus Univ, Ctr Clin Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam	Klomp, HM (corresponding author), Univ Hosp Rotterdam Dijkzigt, Dept Gen Surg H926, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		; Steyerberg, Ewout/C-1509-2018	Klomp, Houke/0000-0003-4999-8783; Steyerberg, Ewout/0000-0002-7787-0122				AUGUSTINSSON LE, 1985, ANN SURG, V202, P104, DOI 10.1097/00000658-198507000-00017; BELCH JF, 1994, PHARMACOTHERAPY CRIT; BRACALE GC, 1989, PACE, V12, P695, DOI 10.1111/j.1540-8159.1989.tb02717.x; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; BROSETA J, 1986, J NEUROSURG, V64, P71, DOI 10.3171/jns.1986.64.1.0071; BUNT TJ, 1991, SEMIN VASC SURG, V4, P216; COOK AW, 1976, NEW YORK STATE J MED, V76, P366; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; DORMANDY JA, 1986, VASCULAR SURG ISSUES; Drummond MF, 1992, METHODS EC EVALUATIO; EssinkBot ML, 1996, QUAL LIFE RES, V5, P91, DOI 10.1007/BF00435973; FIUME D, 1989, PACE, V12, P698, DOI 10.1111/j.1540-8159.1989.tb02718.x; JACOBS MJH, 1990, VASC MED REV, V1, P215; JACOBS MJHM, 1990, J VASC SURG, V12, P354, DOI 10.1067/mva.1990.22787; Jivegard L, 1987, Eur J Vasc Surg, V1, P345, DOI 10.1016/S0950-821X(87)80062-2; JIVEGARD LEH, 1995, EUR J VASC ENDOVASC, V9, P421, DOI 10.1016/S1078-5884(05)80010-3; KEMPCZINSKI RF, 1995, VASCULAR SURG; KLOMP HM, 1995, EUR J VASC ENDOVASC, V10, P478, DOI 10.1016/S1078-5884(05)80172-8; LOGERFO FW, 1991, J VASC SURG, V13, P518, DOI 10.1016/0741-5214(91)90310-Q; MEGLIO M, 1981, J NEUROSURG, V54, P821, DOI 10.3171/jns.1981.54.6.0821; NACHBUR B, 1994, EUR J VASCULAR SURG, V8, P383, DOI 10.1016/S0950-821X(05)80954-5; Norgren L, 1990, Eur J Vasc Surg, V4, P463, DOI 10.1016/S0950-821X(05)80784-4; Norgren L, 1990, Eur J Vasc Surg, V4, P449, DOI 10.1016/S0950-821X(05)80781-9; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; RIVERS SP, 1986, SURGERY, V99, P759; RUTHERFORD RB, 1991, CIRCULATION, V83, P6; SAMPERE CT, 1989, PACE, V12, P273, DOI 10.1111/j.1540-8159.1989.tb02659.x; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; STEEDMAN SM, 1992, CLIN J PAIN, V8, P204, DOI 10.1097/00002508-199209000-00004; STEUDE U, 1991, VASCULAR SURG, V25, P569; TALLIS RC, 1983, J NEUROL NEUROSUR PS, V46, P478, DOI 10.1136/jnnp.46.6.478; TROENG T, 1993, THEOR SURG, V8, P115; VANDERKLOOT WA, 1989, MPQ DLV CEN STANDARD; ZUCCO F, 1994, SPINAL CORD STIMULAT, P183	34	120	126	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1999	353	9158					1040	1044		10.1016/S0140-6736(98)05069-7	http://dx.doi.org/10.1016/S0140-6736(98)05069-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LQ	10199350				2023-01-03	WOS:000079614000009
J	Mofenson, LM				Mofenson, LM			Short-course zidovudine for prevention of perinatal infection	LANCET			English	Editorial Material							CLINICAL-TRIAL; TRANSMISSION; AFRICA		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; MOFENSON LM, IN PRESS AIDS; Rouse DJ, 1997, AM J OBSTET GYNECOL, V176, P617, DOI 10.1016/S0002-9378(97)70557-X; Scholl TO, 1997, AM J EPIDEMIOL, V146, P134, DOI 10.1093/oxfordjournals.aje.a009244; SEMBA R, 1998, 3 INT S GLOB STRAT P; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; World Health Organization, 1997, COV MAT CAR LIST AV	16	50	51	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					766	767		10.1016/S0140-6736(99)90028-4	http://dx.doi.org/10.1016/S0140-6736(99)90028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459952				2023-01-03	WOS:000079089100002
J	Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP				Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP			Medical progress - Transfusion medicine - Second of two parts - Blood conservation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE NORMOVOLEMIC HEMODILUTION; INTRAOPERATIVE AUTOLOGOUS TRANSFUSION; TOTAL-HIP-ARTHROPLASTY; RADICAL PROSTATECTOMY; COST-EFFECTIVENESS; ORTHOPEDIC-SURGERY; PERIOPERATIVE HEMODILUTION; VIRUS INACTIVATION; CARDIAC OPERATIONS; RANDOMIZED TRIAL		Washington Univ, Sch Med, Dept Med, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC USA; So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA	Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Dartmouth College	Goodnough, LT (corresponding author), Washington Univ, Sch Med, Dept Med, Div Lab Med, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.		kanter, michael howard/W-2753-2019					AUBUCHON JP, 1994, JAMA-J AM MED ASSOC, V272, P1210, DOI 10.1001/jama.272.15.1210; AUBUCHON JP, 1994, VOX SANG, V66, P176, DOI 10.1111/j.1423-0410.1994.tb00306.x; AXELROD FB, 1989, TRANSFUSION, V29, P677, DOI 10.1046/j.1537-2995.1989.29890020438.x; BELL K, 1992, TRANSFUSION MED, V2, P295, DOI 10.1111/j.1365-3148.1992.tb00173.x; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; Blum LN, 1998, TRANSFUSION, V38, P891, DOI 10.1046/j.1537-2995.1998.38998409012.x; BOVILL DF, 1986, ORTHOPEDICS, V9, P1403; BRECHER ME, 1994, TRANSFUSION, V34, P176, DOI 10.1046/j.1537-2995.1994.34294143950.x; Brecher ME, 1997, TRANSFUSION, V37, P1070, DOI 10.1046/j.1537-2995.1997.371098016448.x; BRECHER ME, IN PRESS TRANSFUSION; Charlton M, 1998, HEPATOLOGY, V28, P839, DOI 10.1002/hep.510280335; CLAGETT GP, IN PRESS J VASC SURG; CLEMENTS DH, 1992, J BONE JOINT SURG AM, V74A, P646, DOI 10.2106/00004623-199274050-00003; Cohen JA, 1996, TRANSFUSION, V36, P1036; COHEN JA, 1995, TRANSFUSION, V35, P640, DOI 10.1046/j.1537-2995.1995.35895357894.x; ENG J, 1990, EUR J CARDIO-THORAC, V4, P595, DOI 10.1016/1010-7940(90)90018-U; FARIS PM, 1991, J BONE JOINT SURG AM, V73A, P1169, DOI 10.2106/00004623-199173080-00005; Faris PM, 1991, J BONE JOINT SURG AM, V73, P15801; Goodnough L T, 1997, Hematology, V2, P413, DOI 10.1080/10245332.1997.11746363; Goodnough Lawrence T., 1996, American Journal of Medicine, V101, p33S, DOI 10.1016/S0002-9343(96)00167-2; GOODNOUGH LT, 1995, J LAB CLIN MED, V126, P57; Goodnough LT, 1996, J VASC SURG, V24, P213, DOI 10.1016/S0741-5214(96)70096-4; GOODNOUGH LT, 1994, UROLOGY, V44, P226; GOODNOUGH LT, 1992, VOX SANG, V63, P96, DOI 10.1111/j.1423-0410.1992.tb02493.x; GOODNOUGH LT, 1992, TRANSFUSION, V32, P441, DOI 10.1046/j.1537-2995.1992.32592327718.x; GOODNOUGH LT, 1994, AM J CLIN PATHOL, V101, P354; Goodnough LT, 1996, VOX SANG, V71, P133, DOI 10.1046/j.1423-0410.1996.7130133.x; GOODNOUGH LT, 1989, TRANSFUSION, V29, P821, DOI 10.1046/j.1537-2995.1989.29990070188.x; GOODNOUGH LT, 1990, VOX SANG, V59, P65, DOI 10.1111/j.1423-0410.1990.tb05010.x; GOODNOUGH LT, 1994, ANESTH ANALG, V78, P932; Goodnough LT, 1998, VOX SANG, V75, P128, DOI 10.1159/000030973; GOODNOUGH LT, IN PRESS VOX SANG; Grass JA, 1998, BLOOD, V91, P2180, DOI 10.1182/blood.V91.6.2180.2180_2180_2188; HEALY JC, 1994, ARCH PATHOL LAB MED, V118, P465; Kanter MH, 1996, JAMA-J AM MED ASSOC, V276, P798, DOI 10.1001/jama.276.10.798; Kasper SM, 1998, TRANSFUSION, V38, P669, DOI 10.1046/j.1537-2995.1998.38798346636.x; Kasper SM, 1998, ANESTH ANALG, V87, P284, DOI 10.1097/00000539-199808000-00009; Kasper SM, 1997, TRANSFUSION, V37, P1058, DOI 10.1046/j.1537-2995.1997.371098016445.x; Klein HG, 1998, TRANSFUSION, V38, P102, DOI 10.1046/j.1537-2995.1998.38198141508.x; Larocque BJ, 1997, TRANSFUSION, V37, P463, DOI 10.1046/j.1537-2995.1997.37597293874.x; Larocque BJ, 1998, TRANSFUSION, V38, P932, DOI 10.1046/j.1537-2995.1998.381098440857.x; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; Linden JV, 1997, TRANSFUSION, V37, P455, DOI 10.1046/j.1537-2995.1997.37597293872.x; LORENTZ A, 1991, ANAESTHESIST, V40, P205; Loscalzo J, 1997, J LAB CLIN MED, V129, P580, DOI 10.1016/S0022-2143(97)90191-8; Ma ZM, 1997, CLIN CHEM, V43, P1732; MARGOLISNUNNO H, 1994, TRANSFUSION, V34, P802, DOI 10.1046/j.1537-2995.1994.34994378283.x; Mercuriali F, 1996, CURR MED RES OPIN, V13, P465, DOI 10.1185/03007999609115227; MERCURIALI F, 1993, TRANSFUSION, V33, P55, DOI 10.1046/j.1537-2995.1993.33193142311.x; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; MONK TG, 1995, TRANSFUSION, V35, P559, DOI 10.1046/j.1537-2995.1995.35795357877.x; Monk TG, 1997, ANESTH ANALG, V85, P953, DOI 10.1097/00000539-199711000-00001; MONK TG, IN PRESS ANESTHESIOL; MOROFF G, 1992, BLOOD CELLS, V18, P43; Napier JAF, 1997, BRIT J ANAESTH, V78, P768, DOI 10.1093/bja/78.6.768; NESS PM, 1992, TRANSFUSION, V32, P226, DOI 10.1046/j.1537-2995.1992.32392213805.x; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; RITTER MA, 1994, J BONE JOINT SURG AM, V76A, P35, DOI 10.2106/00004623-199401000-00005; ROBERTS SR, 1991, AM J SURG, V162, P477, DOI 10.1016/0002-9610(91)90265-F; SCHAFF HV, 1978, J THORAC CARDIOV SUR, V75, P632; Schmied H, 1998, ANESTH ANALG, V86, P387, DOI 10.1097/00000539-199802000-00032; Scott MG, 1997, CLIN CHEM, V43, P1724; Thomas MJG, 1996, TRANSFUSION, V36, P633, DOI 10.1046/j.1537-2995.1996.36796323063.x; THURER RL, 1979, ANN THORAC SURG, V27, P500, DOI 10.1016/S0003-4975(10)63358-9; TOY PTCY, 1993, TRANSFUSION, V33, P721, DOI 10.1046/j.1537-2995.1993.33994025020.x; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; UMLAS J, 1994, TRANSFUSION, V34, P402, DOI 10.1046/j.1537-2995.1994.34594249051.x; VOAK D, 1993, TRANSFUSION MED, V3, P307, DOI 10.1111/j.1365-3148.1993.tb00067.x; WAGNER SJ, 1993, PHOTOCHEM PHOTOBIOL, V57, P819, DOI 10.1111/j.1751-1097.1993.tb09217.x; WARD HB, 1993, ANN THORAC SURG, V56, P137, DOI 10.1016/0003-4975(93)90418-H; White KL, 1997, ANESTH ANALG, V84, pS58; WILLIAMSON KR, 1991, TRANSFUSION, V31, P662, DOI 10.1046/j.1537-2995.1991.31791368347.x; WINSLOW RM, 1995, NAT MED, V1, P1212, DOI 10.1038/nm1195-1212; WODA R, 1992, CAN J ANAESTH, V39, P290, DOI 10.1007/BF03008792; YAMADA AH, 1993, J UROLOGY, V149, P73, DOI 10.1016/S0022-5347(17)36002-0; YOMTOVIAN R, 1992, J BONE JOINT SURG AM, V74A, P1265, DOI 10.2106/00004623-199274080-00021; 1996, TRANSFUSION, V36, P667	81	220	230	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					525	533		10.1056/NEJM199902183400706	http://dx.doi.org/10.1056/NEJM199902183400706			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021474				2023-01-03	WOS:000078680100006
J	Hira, K; Fukui, T; Endoh, A; Rahman, M; Maekawa, M				Hira, K; Fukui, T; Endoh, A; Rahman, M; Maekawa, M			Influence of superstition on the date of hospital discharge and medical cost in Japan: retrospective and descriptive study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	2nd Asian-Pacific Congress of Epidemiology	JAN   28, 1998	TOKYO, JAPAN				PLACEBO	Objectives To determine the influence of superstition about Taian (a lucky day)-Butsumetsu tan unlucky day) on decision to leave hospital. To estimate the costs of the effect of this superstition. Design Retrospective and descriptive study. Setting University hospital in Kyoto,Japan. Subjects Patients who were discharged alive from Kyoto University Hospital from 1 April 1992 to 31 March 1995, Main outcome measures Mean number, age, and hospital stay of patients discharged on each day of six day cycle. Results The mean number, age, and hospital stay of discharged patients were highest on Taian and lowest on Butsumetsu (25.5 v 19.3 patients/day, P = 0.0001; 43.9 v 41.4 years, P = 0.0001; and 43.1 v 33.3 days, P = 0.0001 respectively). The effect of this difference on the hospital's costs was estimated to be 7.4 million yen (pound 31 000). Conclusion The superstition influenced the decision to leave hospital, contributing to higher medical care costs in Japan. Although hospital stays need to be kept as short as possible to minimise costs, doctors should not ignore the possible psychological effects on patients' health caused by dismissing the superstition.	Kyoto Univ, Dept Gen Med & Clin Epidemiol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Human & Environm Studies, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Hira, K (corresponding author), Kyoto Univ, Dept Gen Med & Clin Epidemiol, Sakyo Ku, Kyoto 6068507, Japan.							BLACHER RS, 1983, GEN HOSP PSYCHIAT, V5, P279, DOI 10.1016/0163-8343(83)90007-5; DOBRILLA G, 1994, DIGEST DIS, V12, P368, DOI 10.1159/000171471; EDWARD A, 1990, HUM BEHAV, P64; KAKU K, 1975, AM J PUBLIC HEALTH, V65, P170, DOI 10.2105/AJPH.65.2.170; KAKU K, 1972, SOC BIOL, V19, P60, DOI 10.1080/19485565.1972.9987966; KAKU K, 1975, ANN HUM BIOL, V2, P391, DOI 10.1080/03014467500001011; KAKU K, 1975, ANN HUM BIOL, V2, P111, DOI 10.1080/03014467500000651; KIM YS, 1979, J BIOSOC SCI, V11, P457, DOI 10.1017/S0021932000012530; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; *ORG EC COOP DEV, 1993, OECD HLTH SYST FACTS, P215; REISS RE, 1988, OBSTET GYNECOL, V71, P270; SCANLON TJ, 1993, BRIT MED J, V307, P1584, DOI 10.1136/bmj.307.6919.1584; SCOTT R, 1994, BRIT MED J, V309, P1691, DOI 10.1136/bmj.309.6970.1691; *STAT INF DEP, 1993, PAT SURV, P566; *SURV DEP I SOC IN, 1997, DRUG TAR; UCHIDA M, 1991, CALENDARS TALE 12 MO, P106	17	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1680	1683		10.1136/bmj.317.7174.1680	http://dx.doi.org/10.1136/bmj.317.7174.1680			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	151VX	9857123	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000077742300009
J	Newdick, C				Newdick, C			Primary care groups and the right to prescribe	BRITISH MEDICAL JOURNAL			English	Article									Univ Reading, Dept Law, Reading RG6 6AH, Berks, England	University of Reading	Newdick, C (corresponding author), Univ Reading, Dept Law, Reading RG6 6AH, Berks, England.							*AUD COMM, 1994, PRESCR IMPR RAT PRES, P27; *DEP HLTH, 1995, VAR HLTH WHAT DOH NH; *GEN MED COUNC, 1994, RES CONSTR CONTR PRO; HUNTER DJ, 1992, SOC SCI MED, V35, P557, DOI 10.1016/0277-9536(92)90349-U; Klein RDP, 1996, MANAGING SCARCITY PR; Light DW, 1997, BRIT MED J, V315, P112, DOI 10.1136/bmj.315.7100.112; MOONEY G, 1988, MED ETHICS EC HLTH C; Newdick C, 1998, J Contemp Health Law Policy, V14, P335; NEWDICK C, 1995, WHO SHOULD WE TREAT, P178; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; *SECR STAT HLTH, 1997, CMND 3807; *SECR STAT HLTH, 1998, 1 CLASS SERV QUAL NH; Stevens A, 1991, Health Trends, V23, P20; TOWSE A, 1998, GUIDELINES EC EVALUA; WEBSTER C, 1998, NATL HLTH SERVICE PO, P30; WEST P, 1998, MANAGED CARE MODEL U	16	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1998	317	7169					1361	1364		10.1136/bmj.317.7169.1361	http://dx.doi.org/10.1136/bmj.317.7169.1361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HH	9812936	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000077081600024
J	Studdert, DM; Eisenberg, DM; Miller, FH; Curto, DA; Kaptchuk, TJ; Brennan, TA				Studdert, DM; Eisenberg, DM; Miller, FH; Curto, DA; Kaptchuk, TJ; Brennan, TA			Medical malpractice implications of alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUPUNCTURE; TRIALS; METAANALYSIS; HEALTH; PAIN	Although use of alternative therapies in the United States is widespread and growing, little is known about the malpractice experience of practitioners who deliver these therapies or about the legal principles that govern the relationship between conventional and alternative medicine. Using data from malpractice insurers, we analyzed the claims experience of chiropractors, massage therapists, and acupuncturists for 1990 through 1996, We found that claims against these practitioners occurred less frequently and typically involved injury that was less severe than claims against physicians during the same period. Physicians who may be concerned about their own exposure to liability for referral of patients for alternative treatments can draw some comfort from these findings. However, liability for referral is possible in certain situations and should be taken seriously. Therefore, we review relevant legal principles and case law to understand how malpractice law is likely to develop in this area. We conclude by suggesting some questions for physicians to ask themselves before referring their patients to alternative medicine practitioners.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res,Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Law, Boston, MA 02115 USA; Boston Univ, Sch Law, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston University	Eisenberg, DM (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U2AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baer H A, 1992, Med Anthropol, V13, P369; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; Blecher MB, 1997, HOSP HEALTH NETWORK, V71, P50; BLECHER MB, 1997, CRAINS CHICAGO  0127, P4; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; COHEN MH, 1996, ARIZ L REV, V38, P83; COVALESKI J, 1997, BESTS REV PC     APR, P61; DUFF C, 1997, WALL STREET J   0414, pB1; EDLIN M, 1997, MANAGED HLTH     JUN, P14; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; *FED CHIR LIC BOAR, 1997, OFF DIR CHIR LIC PRA; FIELDS DH, 1996, NY TIMES        1017, P26; Firshein J, 1995, Bus Health, V13, P28; GONZALES M, 1997, SOCIOECONOMIC CHARAC, P39; GRANDINETTI DA, 1997, MED ECON, V74, P73; Greely H T, 1996, Health Matrix Clevel, V6, P53; HALL MA, 1994, NEW YORK U LAW REV, V69, P693; HILTS PJ, 1996, NY TIMES        0102, P10; HOBSON SM, 1989, INDIANA LAW J, V64, P737; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; Morreim E. H., 1995, WIDENER LAW S J, V1, P89; *NIH OFF ALT MED, 1998, PROGR AR RES DEV INV; Orentlicher David, 1996, Univ Richmond Law Rev, V30, P155; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; *PHYS INS ASS AM, 1997, PIAA DAT SHAR REP 19; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; WHITAKER B, 1996, NY TIMES        1124, P11; 1997, WALL STREET J   0403, P1; 1991, NCAHF NEWSLETTE 1121, P1; 1996, NATL UNDERWRITE 1126, P18	38	73	73	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1610	1615		10.1001/jama.280.18.1610	http://dx.doi.org/10.1001/jama.280.18.1610			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820265				2023-01-03	WOS:000076852000030
J	Poenisch, C				Poenisch, C			Occasional notes - Merian Frederick's story	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Poenisch, C (corresponding author), 16463 Sutters Lane Ct, Northville, MI 48167 USA.							Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406	1	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					996	998		10.1056/NEJM199810013391411	http://dx.doi.org/10.1056/NEJM199810013391411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753718				2023-01-03	WOS:000076186900011
J	Powell-Braxton, L; Veniant, M; Latvala, RD; Hirano, KI; Won, WB; Ross, J; Dybdal, N; Zlot, CH; Young, SG; Davidson, NO				Powell-Braxton, L; Veniant, M; Latvala, RD; Hirano, KI; Won, WB; Ross, J; Dybdal, N; Zlot, CH; Young, SG; Davidson, NO			A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet	NATURE MEDICINE			English	Article							E-DEFICIENT MICE; APOLIPOPROTEIN-E; KNOCKOUT MICE; RECEPTOR; LESIONS; LACKING; EXPRESSION; CLEARANCE; APOBEC-1; CELLS	Mutations in the low density lipoprotein (LDL) receptor gene cause familial hypercholesterolemia, a human disease characterized by premature atherosclerosis and markedly elevated plasma levels of LDL cholesterol and apolipoprotein (apo) B100. In contrast, mice deficient for the LDL receptor (Ldlr(-/-)) have only mildly elevated LDL cholesterol levels and little atherosclerosis. This difference results from extensive editing of the hepatic apoB mRNA in the mouse, which limits apoB100 synthesis in favor of apoB48 synthesis. We have generated Ldlr(-/-) mice that cannot edit the apoB mRNA and therefore synthesize exclusively apoB100. These mice had markedly elevated LDL cholesterol and apoB100 levels and developed extensive atherosclerosis on a chow diet. This authentic model of human familiar hypercholesterolemia will provide a new tool for studying atherosclerosis.	Genentech Inc, Cardiovasc Res, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Roche Holding; Genentech; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Chicago	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.			Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL 18577, HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180, P01HL018577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DAVIDSON NO, 1995, RNA, V1, P3; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Kim E, 1998, J CLIN INVEST, V101, P1468; Kim E, 1998, J LIPID RES, V39, P703; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1996, CIRCULATION, V94; NAKAMURA Y, 1994, RHODIUM EX, V6, P14; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sanan DA, 1998, P NATL ACAD SCI USA, V95, P4544, DOI 10.1073/pnas.95.8.4544; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	33	162	170	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					934	938		10.1038/nm0898-934	http://dx.doi.org/10.1038/nm0898-934			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	9701246				2023-01-03	WOS:000075107400037
J	Richards, SH; Coast, J; Gunnell, DJ; Peters, TJ; Pounsford, J; Darlow, MA				Richards, SH; Coast, J; Gunnell, DJ; Peters, TJ; Pounsford, J; Darlow, MA			Randomised controlled trial comparing effectiveness and acceptability of an early discharge, hospital at home scheme with acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; STATE	Objective: to compare effectiveness and acceptability of early discharge to a hospital at home scheme with that of routine discharge from acute hospital. Design: Pragmatic randomised controlled trial. Setting: Acute hospital wards and community in north of Bristol, with a catchment population of about 224 000 people. Subjects: 241 hospitalised but medically stable elderly patients who fulfilled criteria for early discharge to hospital at home scheme and who consented to participate. Interventions: Patients' received hospital at home care or routine hospital care. Main outcome measures: Patients' quality of life, satisfaction, and physical functioning assessed at 4 weeks and 3 months after randomisation to treatment; length of stay in hospital and in hospital at home scheme after randomisation; mortality at 3 months. Results: There were no significant differences in patient mortality, quality of life, and physical functioning between the two arms of the trial at 4 weeks or 3 months. Only one of 11 measures of patient satisfaction was significantly different: hospital at home patients perceived higher levels of involvement in decisions. Length of stay for those receiving routine hospital care was 62% (95% confidence interval 51% to 75%) of length of stay in hospital at home scheme. Conclusions: The early discharge hospital at home scheme was similar to routine hospital discharge in terms of effectiveness and acceptability. Increased length of stay associated with the scheme must be interpreted with caution because of different organisational characteristics of the services.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Frenchay Hosp, Day Hosp, Bristol BS16 1LE, Avon, England; Hosp Home, Downend Clin, Bristol BS16 5TW, Avon, England	University of Bristol	Richards, SH (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	suzanne.richards@bris.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Richards, Suzanne/0000-0003-1416-0569; Peters, Tim/0000-0003-2881-4180; Coast, Joanna/0000-0002-3537-5166				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Closset J, 1995, ACTA GASTRO-ENT BELG, V58, P373; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; Coast J, 1996, BRIT MED J, V312, P162; Collin C, 1988, Int Disabil Stud, V10, P61; COSTAIN D, 1992, HOSP HOME CARE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fulop NJ, 1997, J ROY SOC MED, V90, P212, DOI 10.1177/014107689709000408; GOULD MM, 1995, BR J HLTH CARE MANAG, V1, P809; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P1241; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; MAHONEY F I, 1965, Md State Med J, V14, P61; Marks L, 1990, HOME HOSP CARE REDRA; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; *OFF POP CENS SURV, 1994, GEN HOUS SURV RES 19; Peters TJ, 1998, J EPIDEMIOL COMMUN H, V52, P59, DOI 10.1136/jech.52.1.59; PRYOR GA, 1989, J BONE JOINT SURG BR, V71, P471, DOI 10.1302/0301-620X.71B3.2722942; SCHULTEN JHG, 1992, FUNCTIONAL STATUS AS	19	100	102	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1796	1801		10.1136/bmj.316.7147.1796	http://dx.doi.org/10.1136/bmj.316.7147.1796			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624070	Green Published			2023-01-03	WOS:000074286300029
J	Shajahan, PM; Cavanagh, JTO				Shajahan, PM; Cavanagh, JTO			Admission for depression among men in Scotland, 1980-95: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Shajahan, PM (corresponding author), Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland.							BECK P, 1994, BRIT MED J, V308, P789, DOI 10.1136/bmj.308.6931.789; GEDDES JR, 1993, BRIT J PSYCHIAT, V163, P620, DOI 10.1192/bjp.163.5.620; POUNDER DJ, 1991, FORENSIC SCI INT, V51, P79, DOI 10.1016/0379-0738(91)90207-Y; WEISSMAN MM, 1993, J AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F	4	9	9	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1496	1497		10.1136/bmj.316.7143.1496	http://dx.doi.org/10.1136/bmj.316.7143.1496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP020	9582135	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000073707700024
J	Klein, JL; Millman, GC				Klein, JL; Millman, GC			Prospective, hospital based study of fever in children in the United Kingdom who had recently spent time in the tropics	BRITISH MEDICAL JOURNAL			English	Article									Northwick Pk & St Marks NHS Trust, Childrens Serv Directorate, Harrow HA1 3UJ, Middx, England	Imperial College London	Klein, JL (corresponding author), 177 Purves Rd,Kensal Rise, London NW10 5TH, England.							Brabin BJ, 1997, ARCH DIS CHILD, V77, P76, DOI 10.1136/adc.77.1.76; DOHERTY JF, 1995, QJM-INT J MED, V88, P277; SHINGADIA D, 1996, CURR PAEDIAT, V6, P108	3	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1425	1426		10.1136/bmj.316.7142.1425	http://dx.doi.org/10.1136/bmj.316.7142.1425			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572752	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000073651600028
J	Miller, FG; Meier, DE				Miller, FG; Meier, DE			Voluntary death: A comparison of terminal dehydration and physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EUTHANASIA; HYDRATION; NUTRITION	The controversial issue of legalizing physician-assisted suicide should be considered in light of legally available alternative methods of voluntary death. The increasingly polarized debate over this issue has failed to give due attention to an alternative: terminal dehydration. By voluntarily forgoing food and water, competent patients with terminal or incurable illness can escape intolerable, irremediable conditions without requiring transformation of the law and medical ethics. Terminal dehydration offers substantial advantages over physician-assisted suicide with respect to self-determination, access, professional integrity, and social implications but also has distinctive drawbacks as a humane means of voluntary death. This article analyzes clinical, ethical, and policy issues related to terminal dehydration compared with physician-assisted suicide.	Univ Virginia, Charlottesville, VA USA; Mt Sinai Sch Med, New York, NY USA	University of Virginia; Icahn School of Medicine at Mount Sinai	Meier, DE (corresponding author), Mt Sinai Med Ctr, POB 1070, New York, NY 10029 USA.							Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Cherny N I, 1994, J Palliat Care, V10, P31; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Donelan K, 1996, JAMA-J AM MED ASSOC, V276, P1346, DOI 10.1001/jama.276.16.1346; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; KASS LR, 1989, PUBLIC INTEREST, P25; LANGRETH R, 1996, WALL STREET J    OCT, V7, pA2; Meisel Alan, 1992, Kennedy Institute of Ethics Journal, V2, P309; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Miller FG, 1997, CAMB Q HEALTHC ETHIC, V6, P78, DOI 10.1017/S0963180100007635; MILLER FG, 1996, BIOLAW LEGAL ETHICAL, pS136; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS; Pellegrino E D, 1992, J Clin Ethics, V3, P95; Powell T, 1996, J LAW MED ETHICS, V24, P54, DOI 10.1111/j.1748-720X.1996.tb01833.x; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; SHAVELSON L, 1995, CHOSEN DEATH DYING C; Starr P., 1982, SOCIAL TRANSFORMATIO; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271	27	51	52	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					559	562		10.7326/0003-4819-128-7-199804010-00007	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZE539	9518401				2023-01-03	WOS:000072803500007
J	Muskin, PR				Muskin, PR			The request to die - Role for a psychodynamic perspective on physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT REQUESTS; PRIMARY-CARE; VOLUNTARY EUTHANASIA; WASHINGTON-STATE; ATTITUDES; DEPRESSION; MANAGEMENT; LIFE; PAIN; PSYCHIATRISTS	Published reports indicate that 2.5% of deaths in the Netherlands are the result of euthanasia or physician-assisted suicide, It is not known how many patients make these requests in the United States, but the issue has gained considerable attention, including that of the Supreme Court. The focus of the writing and discussion regarding the request to die has been on a patient's capacity. There has not been an adequate focus on the possible meanings contained within the request to die, A patient's request to die is a situation that requires the physician to engage in a dialogue to understand what the request means, including whether the request arises from a clinically significant depression or inadequately treated pain. This article outlines some of the thoughts and emotions that could underlie the patient's request to die. Recommendations are made regarding the role of the primary care physician and the role of the psychiatric consultant in the exploration of the meaning of the request.	Columbia Univ Coll Phys & Surg, Columbia Presbyterian Med Ctr, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Psychoanalyt Ctr Training & Res, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University	Muskin, PR (corresponding author), Columbia Univ Coll Phys & Surg, Columbia Presbyterian Med Ctr, Dept Psychiat, 622 W 168th St,Mailbox 427, New York, NY 10032 USA.							ADMIRAAL P, COMMUNICATION; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P326; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; Battin M P, 1991, Crisis, V12, P73; BECK AT, 1985, AM J PSYCHIAT, V142, P559; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; BREITBART W, 1990, ADV PAIN RES THER, V16, P399; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; CAVANAUGH S, 1984, MANUAL PSYCHIATRIC C, P211; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Cleeland C S, 1987, Oncology (Williston Park), V1, P19; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; DRUSS RG, 1995, PSYCHOL ILLNESS; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; Eissler K., 1955, PSYCHIAT DYING PATIE; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; Ganzini L, 1996, AM J PSYCHIAT, V153, P1469; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; GOLDSTEIN WN, 1991, AM J PSYCHIAT, V148, P153; HELIG S, 1988, SAN FRANCISCO MED, V61, P24; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; HENDIN H, 1997, SEDUCED DEATH DOCTOR; HUYSE FJ, 1993, HOSP COMMUNITY PSYCH, V44, P733; Jacox A, 1994, AHCPR PUBLICATION; Kohut H., 1971, ANAL SELF SYSTEMATIC; Kohut H., 1977, ANAL SELF; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Leiser RJ, 1996, NEW ENGL J MED, V335, P972; LO B, 1988, W J MED, V49, P211; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MASSIE MJ, 1987, MED CLIN N AM, V71, P243, DOI 10.1016/S0025-7125(16)30868-9; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; McKeogh M, 1997, NEW ENGL J MED, V337, P56, DOI 10.1056/NEJM199707033370118; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; Muskin Philip R., 1995, P69; NIETZSCHE F, 1993, COLUMBIA DICT QUOTAT; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; Roberts LW, 1997, PSYCHOSOMATICS, V38, P459, DOI 10.1016/S0033-3182(97)71423-3; Roter D L, 1994, JAMA, V271, P80, DOI 10.1001/jama.271.1.80; Roter D.L., 1992, DOCTORS TALKING PATI; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SHERBOURNE CD, 1994, AM J PSYCHIAT, V151, P1777; Sontag S., 1978, ILLNESS METAPHOR; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	56	80	80	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					323	328		10.1001/jama.279.4.323	http://dx.doi.org/10.1001/jama.279.4.323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT472	9450720				2023-01-03	WOS:000071607000043
J	Sattar, N; Perera, M; Small, M; Lumsden, MA				Sattar, N; Perera, M; Small, M; Lumsden, MA			Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes	LANCET			English	Article								C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 mu g with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.	Glasgow Royal Infirm Univ NHS Trust, Clin Biochem, Glasgow G4 0SF, Lanark, Scotland; Gartnavel Gen Hosp, Ctr Diabet, Glasgow G4 0SF, Lanark, Scotland; Queen Mothers Hosp, Dept Obstet & Gynaecol, Glasgow G4 0SF, Lanark, Scotland		Sattar, N (corresponding author), Glasgow Royal Infirm Univ NHS Trust, Clin Biochem, Glasgow G4 0SF, Lanark, Scotland.							CANTATORE FP, 1995, CLIN RHEUMATOL, V14, P157, DOI 10.1007/BF02214935; KAFONEK SD, 1994, DRUGS, V47, P16, DOI 10.2165/00003495-199400472-00005; Kluft C, 1999, LANCET, V353, P1274, DOI 10.1016/S0140-6736(05)66951-6; Maseri A, 1997, NEW ENGL J MED, V336, P1014, DOI 10.1056/NEJM199704033361409; SITTERI PK, 1977, ANN NY ACAD SCI, V286, P384	5	77	79	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					487	488		10.1016/S0140-6736(99)02079-6	http://dx.doi.org/10.1016/S0140-6736(99)02079-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465182				2023-01-03	WOS:000081896100022
J	Rosner, F				Rosner, F			Can an amulet cure leukemia?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		PREUSS J, 1993, BIBLICAL TALMUDIC ME, P146; Rosner F, 1999, MT SINAI J MED, V66, P102; ZIMMELS HJ, 1952, MAGICIANS THEOLOGIAN, P135	3	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					307	307		10.1001/jama.282.4.307	http://dx.doi.org/10.1001/jama.282.4.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432013				2023-01-03	WOS:000081596800001
J	Chin, AE; Hedberg, K; Higginson, GK; Fleming, DW				Chin, AE; Hedberg, K; Higginson, GK; Fleming, DW			Legalized physician-assisted suicide in Oregon - The first year's experience	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; ATTITUDES	Background and Methods On October 27, 1997, Oregon legalized physician-assisted suicide. We collected data on all terminally ill Oregon residents who received prescriptions for lethal medications under the Oregon Death with Dignity Act and who died in 1998. The data were obtained from physicians' reports, death certificates, and interviews with physicians. We compared persons who took lethal medications prescribed under the act with those who died from similar illnesses but did not receive prescriptions for lethal medications. Results Information on 23 persons who received prescriptions for lethal medications was reported to the Oregon Health Division; 15 died after taking the lethal medications, 6 died from underlying illnesses, and 2 were alive as of January 1, 1999. The median age of the 15 patients who died after taking lethal medications was 69 years; 8 were male, and all 15 were white. Thirteen of the 15 patients had cancer. The case patients and controls were similar with regard to sex, race, urban or rural residence, level of education, health insurance coverage, and hospice enrollment. No case patients or control patients expressed concern about the financial impact of their illness. One case patient and 15 control patients expressed concern about inadequate control of pain (P=0.10). The case patients were more likely than the control patients to have never married (P=0.04) and were more likely to be concerned about loss of autonomy due to illness (P=0.01) and loss of control of bodily functions (P=0.02). At death, 21 percent of the case patients and 84 percent of the control patients were completely disabled (P<0.001). Conclusions During the first year of legalized physician-assisted suicide in Oregon, the decision to request and use a prescription for lethal medication was associated with concern about loss of autonomy or control of bodily functions, not with fear of intractable pain or concern about financial loss. In addition, we found that the choice of physician-assisted suicide was not associated with level of education or health insurance coverage. (N Engl J Med 1999;340:577-83.) (C)1999, Massachusetts Medical Society.	Oregon Hlth Div, Portland, OR 97232 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), Oregon Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.							ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; *CTR HLTH STAT OR, 1997, OR VIT STAT COUNTY D; DEAN A, 1995, EPI INFO VERSION 6 W; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; *DRUG ENF AG DRUG, 1998, 4 DEP JUST DRUG ENF, P43; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; HALEY K, 1998, OREGON DEATH DIGNITY, P40; HEDBERG K, 1998, OREGON DEATH DIGNITY, P43; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; O'Keefe Mark, 1997, OREGONIAN       1019, pA1; OKEEFE M, 1994, OREGONIAN       1204, pA1; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PELLEGRINO ED, 1998, REGULATING WE DIE ET, P71; Preston T. A., 1996, J PHARM CARE PAIN SY, V4, P183; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009	20	211	211	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1999	340	7					577	583		10.1056/NEJM199902183400724	http://dx.doi.org/10.1056/NEJM199902183400724			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168FD	10021482				2023-01-03	WOS:000078680100039
J	Santini, JT; Cima, MJ; Langer, R				Santini, JT; Cima, MJ; Langer, R			A controlled-release microchip	NATURE			English	Article							DELIVERY SYSTEMS; DRUG DELIVERY	Much previous work in methods of achieving complex drug-release patterns has focused on pulsatile release from polymeric materials in response to specific stimuli(1), such as electric(2-5) or magnetic(6,7) fields, exposure to ultrasound(7,8), light(9) or enzymes(10), and changes in pH(11) or temperature(12-14), An alternative method for achieving pulsatile release involves using microfabrication technology to develop active devices that incorporate micrometre-scale pumps, valves and flow channels to deliver liquid solutions(15,16). Here we report a solid-state silicon microchip that can provide controlled release of single or multiple chemical substances on demand. The release mechanism is based on the electrochemical dissolution of thin anode membranes covering microreservoirs filled with chemicals in solid, liquid or gel form. We have conducted proof-of-principle release studies with a prototype microchip using gold and saline solution as a model electrode material and release medium, and we have demonstrated controlled, pulsatile release of chemical substances with this device.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Langer, R (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1994, POLYM DRUGS DRUG ADM, P98; EDELMAN ER, 1985, J BIOMED MATER RES, V19, P67, DOI 10.1002/jbm.820190107; FISCHELGHODSIAN F, 1988, P NATL ACAD SCI USA, V85, P2403, DOI 10.1073/pnas.85.7.2403; FRANKENTHAL RP, 1982, J ELECTROCHEM SOC, V129, P1192, DOI 10.1149/1.2124085; Gravesen P., 1993, Journal of Micromechanics and Microengineering, V3, P168, DOI 10.1088/0960-1317/3/4/002; HEPEL M, 1994, POLYM DRUGS DRUG ADM, P79; HOFFMAN A S, 1986, Journal of Controlled Release, V4, P213; Jaeger RC, 1988, INTRO MICROELECTRONI; JIRAN E, 1992, THIN SOLID FILMS, V208, P23, DOI 10.1016/0040-6090(92)90941-4; KOST J, 1989, P NATL ACAD SCI USA, V86, P7663, DOI 10.1073/pnas.86.20.7663; KOST J, 1991, ADV DRUG DELIVER REV, V6, P19; Kost J, 1990, PULSED SELF REGULATE, P3; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MATHIOWITZ E, 1989, J MEMBRANE SCI, V40, P67, DOI 10.1016/S0376-7388(00)80913-8; Merchant B, 1998, BIOLOGICALS, V26, P49, DOI 10.1006/biol.1997.0123; MILLER LL, 1988, MOL CRYST LIQ CRYST, V160, P297, DOI 10.1080/15421408808083024; Okano K, 1990, PULSED SELF REGULATE, P17; SHOJI S, 1994, J MICROMECH MICROENG, V4, P157, DOI 10.1088/0960-1317/4/4/001; SIEGEL RA, 1988, J CONTROL RELEASE, V8, P179, DOI 10.1016/0168-3659(88)90044-2; Wolf S, 1986, SILICON PROCESSING V, V1, P531; WU BM, 1997, THESIS MIT, P25	22	702	747	4	186	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 28	1999	397	6717					335	338		10.1038/16898	http://dx.doi.org/10.1038/16898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	162BE	9988626	Green Submitted			2023-01-03	WOS:000078324600045
J	Singer, PA; Martin, DK; Kelner, M				Singer, PA; Martin, DK; Kelner, M			Quality end-of-life care - Patients' perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; FAMILY MEMBERS; PREFERENCES	Context Quality end-of-life care is increasingly recognized as an ethical obligation of health care providers, both clinicians and organizations. However, this concept has not been examined from the perspective of patients. Objective To identify and describe elements of quality end-of-life care from the patient's perspective. Design Qualitative study using in-depth, open-ended, face-to-face interviews and content analysis. Setting Toronto, Ontario. Participants A total of 126 participants from 3 patient groups: dialysis patients (n = 48), people with human immunodeficiency virus infection (n = 40), and residents of a long-term care facility (n = 38). Outcome Measures Participants' views on end-of-life issues. Results Participants identified 5 domains of quality end-of-life care: receiving adequate pain and symptom management, avoiding inappropriate prolongation of dying, achieving a sense of control, relieving burden, and strengthening relationships with loved ones. Conclusion These domains, which characterize patients' perspectives on end-of-life care, can serve as focal points for improving the quality of end-of-life care.	Univ Toronto, Joint Ctr Bioeth, Dept Med, Toronto, ON M5G 1L4, Canada; Univ Toronto, Inst Human Dev Life Course & Aging, Toronto, ON M5G 1L4, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, Dept Med, 88 Coll St, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca						Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; BLUSTEIN J, 1993, HASTINGS CTR REP MAY, P6; BYOCK I, 1997, DYING WELL PEACE POS, P4311; CLEARY PD, 1997, JAMA-J AM MED ASSOC, V278, P608; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; Feinstein AR., 1967, CLIN JUDGMENT; Field MJ, 1997, APPROACHING DEATH IM; Fischer GS, 1997, ARCH INTERN MED, V157, P801, DOI 10.1001/archinte.157.7.801; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HARDWIG J, 1990, HASTINGS CENT REP, P5; HIGH DM, 1994, HASTINGS CENT REP, V24, pS16, DOI 10.2307/3563476; KELNER MJ, 1995, SOC SCI MED, V4, P537; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lindemann Nelson H, 1995, PATIENT FAMILY; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manning P. K., 1998, COLLECTING INTERPRET, P463; MARTIN DK, IN PRESS ARCH INTERN; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; Singer PA, 1997, J GEN INTERN MED, V12, P729, DOI 10.1046/j.1525-1497.1997.07157.x; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1998, CAN MED ASSOC J, V159, P159; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Strauss A., 1990, BASICS GROUNDED THEO; Strauss A., 1994, HDB QUALITATIVE RES, DOI DOI 10.1007/BF00988593; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	31	798	806	2	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					163	168		10.1001/jama.281.2.163	http://dx.doi.org/10.1001/jama.281.2.163			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	155VJ	9917120				2023-01-03	WOS:000077966800037
J	Koga, J; Yamauchi, T; Shimura, M; Ogawa, N; Oshima, K; Umemura, K; Kikuchi, M; Ogasawara, N				Koga, J; Yamauchi, T; Shimura, M; Ogawa, N; Oshima, K; Umemura, K; Kikuchi, M; Ogasawara, N			Cerebrosides A and C, sphingolipid elicitors of hypersensitive cell death and phytoalexin accumulation in rice plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE RESISTANCE RESPONSE; HOST-PATHOGEN INTERACTIONS; SCHIZOPHYLLUM-COMMUNE; ANTIFUNGAL ACTIVITY; FUNCTIONAL MOIETY; TOBACCO PLANTS; GENE; CERAMIDE; PROTEIN; GANGLIOSIDES	When plants interact with certain pathogens, they protect themselves by generating various chemical and physical barriers called the hypersensitive response. These barriers are induced by molecules called elicitors that are produced by pathogens. In the present study, the most active elicitors of the hypersensitive response in rice were isolated from the rice pathogenic fungus Magnaporthe grisea, and their structures were identified as cerebrosides A and C, sphingolipids that were previously isolated as inducers of cell differentiation in the fungus Schizophyllum commune. Treatment of rice leaves with cerebroside A induced the accumulation of antimicrobial compounds (phytoalexins), cell death, and increased resistance to subsequent infection by compatible pathogens. The degradation products of cerebroside A (fatty acid methyl ester, sphingold base, and glucosyl sphingoid base) showed no elicitor activity. Hydrogenation of the 8E-double bond in the sphingold base moiety or the 3E-double bond in the fatty acid moiety of cerebroside A did not alter the elicitor activity, whereas hydrogenation of the 4E-double bond in the sphingold base moiety led to a 12-fold decrease in elicitor activity. Furthermore, glucocerebrosides hom Gaucher's spleen consisting of (E)-4-sphingenine and cerebrosides hom rice bran mainly consisting of (4E,8E)-4,8-sphingadienine and (4E,8Z)-4,8-sphingadienine showed no elicitor activity. These results indicate that the methyl group at C-9 and the 4E-double bond in the sphingoid base moiety of cerebrosides A and C are the key elements determining the elicitor activity of these compounds. This study is the first to show that sphingolipids have elicitor activity in plants.	Meiji Seika Kaisha Ltd, Biosci Labs, Sakado, Saitama 3500289, Japan; Plant Biol Def Syst Labs, Niigata 9590422, Japan; Denka Seiken Co Ltd, Div Res & Dev, Niigata 9591836, Japan	Meiji Holdings Co., Ltd.; Denka Company Limited	Koga, J (corresponding author), Meiji Seika Kaisha Ltd, Biosci Labs, 5-3-1 Chiyoda, Sakado, Saitama 3500289, Japan.			Koga, Jinichiro/0000-0003-2106-9894				BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOSTOCK RM, 1981, SCIENCE, V212, P67, DOI 10.1126/science.212.4490.67; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CARTWRIGHT D, 1977, NATURE, V267, P511, DOI 10.1038/267511a0; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Dixon R A, 1990, Adv Genet, V28, P165; FUJINO Y, 1985, AGR BIOL CHEM TOKYO, V49, P2753, DOI 10.1080/00021369.1985.10867139; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KAWAI G, 1989, BIOCHIM BIOPHYS ACTA, V1001, P185; KAWAI G, 1983, BIOCHIM BIOPHYS ACTA, V754, P243, DOI 10.1016/0005-2760(83)90138-8; KAWAI G, 1985, AGR BIOL CHEM TOKYO, V49, P2137, DOI 10.1080/00021369.1985.10867040; KAWAI G, 1986, J BIOL CHEM, V261, P779; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KEEN NT, 1975, SCIENCE, V187, P74, DOI 10.1126/science.187.4171.74; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Koga J, 1997, PHYTOCHEMISTRY, V44, P249, DOI 10.1016/S0031-9422(96)00534-1; KOGA J, 1995, TETRAHEDRON, V51, P7907, DOI 10.1016/0040-4020(95)00423-6; Koga Jinichiro, 1998, Annals of the Phytopathological Society of Japan, V64, P97, DOI 10.3186/jjphytopath.64.97; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MATSUMOTO K, 1980, Annals of the Phytopathological Society of Japan, V46, P307, DOI 10.3186/jjphytopath.46.307; MIDLAND SL, 1993, J ORG CHEM, V58, P2940, DOI 10.1021/jo00063a007; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; Mittler R, 1996, PLANT CELL, V8, P1991, DOI 10.1105/tpc.8.11.1991; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; OBATA K, 1977, NATURE, V266, P369, DOI 10.1038/266369a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SHARP JK, 1984, J BIOL CHEM, V259, P1321; SHARP JK, 1984, J BIOL CHEM, V259, P1312; SITRIN RD, 1988, J ANTIBIOT, V41, P469, DOI 10.7164/antibiotics.41.469; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	49	123	138	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31985	31991		10.1074/jbc.273.48.31985	http://dx.doi.org/10.1074/jbc.273.48.31985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822670	hybrid			2023-01-03	WOS:000077207000052
J	Hacke, W; Kaste, M; Fieschi, C; von Kummer, R; Davalos, A; Meier, D; Larrue, V; Bluhmki, E; Davis, S; Donnan, G; Schneider, D; Diez-Tejedor, E; Trouillas, P				Hacke, W; Kaste, M; Fieschi, C; von Kummer, R; Davalos, A; Meier, D; Larrue, V; Bluhmki, E; Davis, S; Donnan, G; Schneider, D; Diez-Tejedor, E; Trouillas, P		Second European Australasian Acute Stroke Study	Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)	LANCET			English	Article							ACUTE ISCHEMIC STROKE; TIME	Background Thrombolysis for acute ischaemic stroke has been investigated in several clinical trials, with variable results. We have assessed the safety and efficacy of intravenous thrombolysis with alteplase (0.9 mg/kg bodyweight) within 6 h of stroke onset. Methods This non-angiographic, randomised, double-blind, trial enrolled 800 patients in Europe, Australia, and New Zealand, Computed tomography was used to exclude patients with signs of major infarction. Alteplase (n=409) and placebo (n=391) were randomly assigned with stratification for time since symptom onset (0-3 h or 3-6 h). The primary endpoint was the modified Rankin scale (mRS) at 90 days, dichotomised for favourable (score 0-1) and unfavourable (score 2-6) outcome. Analyses were by intention to treat. Findings 165 (40.3%) alteplase-group patients and 143 (36.6%) placebo-group patients had favourable mRS outcomes (absolute difference 3.7%, p=0.277). In a post-hoc analysis of mRS scores dichotomised far death or dependency, 222 (54.3%) alteplase-group and 180 (46.0%) placebo-group patients had favourable outcomes (score 0-2; absolute difference 8.3%, p=0.024). Treatment differences were similar whether patients were treated within 3 h or 3-6 h, 85 (10.6%) patients died, with no difference between treatment groups at day 90+/-14 days (43 alteplase, 42 placebo). Symptomatic intracranial haemorrhage occurred in 36 (8.8%) alteplase-group patients and 13 (3.4%) placebo-group patients. Interpretation The results do not confirm a statistical benefit for alteplase. However, we believe the trend towards efficacy should be interpreted in the light ui evidence from previous trials. Despite the increased risk of intracranial haemorrhage, thrombolysis with alteplase at a dose of 0.9 mg/kg in selected patients may lead to a clinically relevant improvement in outcome.	Heidelberg Univ, Sch Med, Dept Neurol, D-69120 Heidelberg, Germany; Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland; Univ Rome, Dept Neurol, Rome, Italy; Univ Dresden, Dept Neuroradiol, Dresden, Germany; Univ Hosp Girona, Dept Neurol, Girona, Spain; Boehringer Ingelheim KG, Dept Clin Res, Ingelheim, Germany; Boehringer Ingelheim KG, Dept Stat, Ingelheim, Germany; Univ Toulouse, Dept Neurol, Toulouse, France; Univ Melbourne, Dept Neurol, Parkville, Vic 3052, Australia; Univ Leipzig, Dept Neurol, Leipzig, Germany; Univ Madrid, Dept Neurol, Madrid, Spain; Univ Lyon, Dept Neurol, Lyon, France	Ruprecht Karls University Heidelberg; University of Helsinki; Sapienza University Rome; Technische Universitat Dresden; Boehringer Ingelheim; Boehringer Ingelheim; Universite de Toulouse; University of Melbourne; Leipzig University	Hacke, W (corresponding author), Heidelberg Univ, Sch Med, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	werner_hacke@ukl.unl-heldelberg.de	DONNAN, GEOFFREY A/A-9947-2008; von Kummer, Rüdiger/AAA-4478-2019; Davis, Stephen M/L-5260-2013; Hacke, Werner/ABE-8661-2020	von Kummer, Rüdiger/0000-0003-0119-4604; Davis, Stephen M/0000-0003-0962-2300; Kaste, Markku/0000-0001-6557-6412; Donnan, Geoffrey/0000-0001-6324-3403				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Azzimondi G, 1997, STROKE, V28, P537, DOI 10.1161/01.STR.28.3.537; BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; Brott T, 1997, STROKE, V28, P1530, DOI 10.1161/01.STR.28.8.1530; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; Fisher M, 1996, NEUROLOGY, V47, P884, DOI 10.1212/WNL.47.4.884; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HACKE W, IN PRESS STROKE; Hommel M, 1996, NEW ENGL J MED, V335, P145; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MULT AC STROK TRI, 1995, LANCET, V356, P1509; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; Ronning OM, 1998, STROKE, V29, P586, DOI 10.1161/01.STR.29.3.586; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Steiner T, 1998, CEREBROVASC DIS, V8, P198, DOI 10.1159/000015851; von Kummer R, 1998, STROKE, V29, P310; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214	19	2530	2652	1	74	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1245	1251		10.1016/S0140-6736(98)08020-9	http://dx.doi.org/10.1016/S0140-6736(98)08020-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788453				2023-01-03	WOS:000076573800007
J	Glasier, A; Baird, D				Glasier, A; Baird, D			The effects of self-administering emergency contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Emergency postcoital contraception prevents pregnancy, but it must be prescribed by a doctor and taken within 72 hours of intercourse. It has been proposed that emergency contraception be made available without a prescription. We undertook a study to learn how women might behave if given a supply of emergency contraceptive pills to keep at home. Methods We assigned 553 women to be given a replaceable supply of hormonal emergency contraceptive pills to take home (the treatment group) and 530 women to use emergency contraception obtained by visiting a doctor (the control group). The frequency of use of emergency contraception, the use of other contraceptives, and the incidence of unwanted pregnancy were determined in both groups of women one year later. Results The results for 549 women in the treatment group and 522 women in the control group were available for analysis. Three hundred seventy-nine of the women in the treatment group (69 percent) and 326 of the women in the control group (62 percent) contributed detailed information at followup. One hundred eighty of the women in the treatment group (47 percent) used emergency contraception at least once. Among those who returned the study questionnaire, 98 percent used emergency contraception correctly. There were no serious adverse effects. Eighty-seven women in the control group (27 percent) used emergency contraception at least once (P<0.001 for the comparison with the treatment group). The women in the treatment group were not more likely to use emergency contraception repeatedly. Their use of other methods of contraception was no different from that of the women in the control group. There were 18 unintended pregnancies in the treatment group and 25 in the control group (relative risk, 0.7; 95 percent confidence interval, 0.4 to 1.2), Conclusions Making emergency contraception more easily obtainable does no harm and may reduce the rate of unwanted pregnancies. [N Engl J Med 1998;339:1-4.) (C) 1998, Massachusetts Medical Society.	Univ Edinburgh, Dept Obstet & Gynaecol, Edinburgh EH4 1NL, Midlothian, Scotland; Edinburgh Healthcare Natl Hlth Serv Trust, Edinburgh, Midlothian, Scotland	University of Edinburgh	Glasier, A (corresponding author), Univ Edinburgh, Dept Obstet & Gynaecol, 18 Dean Terr, Edinburgh EH4 1NL, Midlothian, Scotland.							*DEP HLTH HUM SERV, 1997, FED REGISTER, V62, P8610; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; GLASIER A, 1995, PROVISION EMERGENCY, P16; Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857; Williams C, 1996, BRIT MED J, V312, P463, DOI 10.1136/bmj.312.7029.463a; Wright DW, 1986, BR J FAM PLANN, V12, P88; 1992, PHARM J, V249, P530	8	237	240	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					1	4		10.1056/NEJM199807023390101	http://dx.doi.org/10.1056/NEJM199807023390101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647872				2023-01-03	WOS:000074500000001
J	Rogers, A; Entwistle, V; Pencheon, D				Rogers, A; Entwistle, V; Pencheon, D			Managing demand - A patient led NHS: Managing demand at the interface between lay and primary care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; MEDICATION; SERVICES; ILLNESS		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; Univ Forvie Site, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Manchester; University of York - UK; University of Cambridge	Rogers, A (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				ALONZO AA, 1984, SOC SCI MED, V19, P499, DOI 10.1016/0277-9536(84)90045-5; ANCTIL B, 1996, JOINT COMMISSION J Q, V2, P345; BALXTER M, 1986, J ROY COLL GEN PRACT, V33, P256; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DEAN K, 1986, SOC SCI MED, V22, P275, DOI 10.1016/0277-9536(86)90076-6; DEAN K, 1986, HLTH PROMOTION, V2, P133; EYLES J, 1990, SOCIAL EFFECTS HLTH; FLEMING GV, 1984, MED CARE, V22, P950, DOI 10.1097/00005650-198410000-00007; Free C, 1998, BRIT MED J, V316, P380, DOI 10.1136/bmj.316.7128.380; FREWER LJ, 1994, PUBLIC UNDERST SCI, V2, P112; Gurwitz JH, 1995, HEALTH SERV RES, V30, P672; Hassell K, 1997, FAM PRACT, V14, P498, DOI 10.1093/fampra/14.6.498; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; JESSON J, 1994, ETHNIC MINORITY CONS, P66; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; PEARSON M, 1993, HEALTH SOC CARE COMM, V1, P11; ROGERS A, IN PRESS HLTH PLACE; ROGERS A, IN PRESS DEMANDING P; *SECR STAT HLTH, 1998, NEW NHS; Shipman C, 1997, FAM PRACT, V14, P503, DOI 10.1093/fampra/14.6.503; STACEY M, 1984, ECON IND DEMOCRACY, V5, P157, DOI 10.1177/0143831X8452002	24	37	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1816	+		10.1136/bmj.316.7147.1816	http://dx.doi.org/10.1136/bmj.316.7147.1816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV258	9624078	Green Published			2023-01-03	WOS:000074286300035
J	Goyder, EC; McNally, PG; Drucquer, M; Spiers, N; Botha, JL				Goyder, EC; McNally, PG; Drucquer, M; Spiers, N; Botha, JL			Shifting of care for diabetes from secondary to primary care, 1990-5: review of general practices	BRITISH MEDICAL JOURNAL			English	Review									Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm NHS Trust, Dept Endocrinol & Diabet, Leicester LE1 5WW, Leics, England; S Wigston Hlth Ctr, Leicester LE8 2SE, Leics, England	University of Leicester	Goyder, EC (corresponding author), Univ Sydney, Dept Publ Hlth & Community Med, Edward Ford Bldg A27, Sydney, NSW 2006, Australia.		Goyder, Elizabeth E/A-2146-2010	Goyder, Elizabeth E/0000-0003-3691-1888				Alexander WD, 1997, LANCET, V349, P578, DOI 10.1016/S0140-6736(97)80134-1; Krans HMJ, 1992, DIABETES CARE RES EU; LEESE B, 1995, BRIT MED J, V311, P546, DOI 10.1136/bmj.311.7004.546; LOWY A, 1993, BRIT MED J, V307, P413, DOI 10.1136/bmj.307.6901.413; Marks L., 1996, COUNTING COST REAL I	5	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1505	1506		10.1136/bmj.316.7143.1505	http://dx.doi.org/10.1136/bmj.316.7143.1505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582142	Green Published			2023-01-03	WOS:000073707700032
J	Cooper, A; Spencer, C; Whitehead, MI; Ross, D; Barnard, GJR; Collins, WP				Cooper, A; Spencer, C; Whitehead, MI; Ross, D; Barnard, GJR; Collins, WP			Systemic absorption of progesterone from Progest cream in postmenopausal women	LANCET			English	Article							ORAL PROGESTERONE		Univ London Kings Coll Hosp, Menopause Clin, London SE5 8RX, England; Churchill Clin, Amarant Trust, London, England; Southampton Univ Hosp Trust, Dept Chem Pathol, Endocrine Unit, Southampton, Hants, England; Univ London Kings Coll, Sch Med & Dent, Acad Dept Obstet & Gynaecol, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of London; King's College London	Whitehead, MI (corresponding author), Univ London Kings Coll Hosp, Menopause Clin, Denmark Hill, London SE5 8RX, England.							KESNER JS, 1994, STEROIDS, V59, P205, DOI 10.1016/0039-128X(94)90029-9; LANE G, 1983, BRIT MED J, V287, P1241, DOI 10.1136/bmj.287.6401.1241; Lee J.R., 1990, INT CLIN NUTR REV, V10, P384; PADWICK ML, 1986, FERTIL STERIL, V46, P402	4	47	67	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1255	1256		10.1016/S0140-6736(05)79323-5	http://dx.doi.org/10.1016/S0140-6736(05)79323-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643756				2023-01-03	WOS:000073283600022
J	Nightingale, SL				Nightingale, SL			Promotional practices of pharmacy benefits management companies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2023-01-03	WOS:000072192800004
J	Horton, R				Horton, R			ICRF: from mayhem to meltdown	LANCET			English	Editorial Material																			0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1043	1044		10.1016/S0140-6736(05)70449-9	http://dx.doi.org/10.1016/S0140-6736(05)70449-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213542				2023-01-03	WOS:A1997YA73400003
J	Durham, SR; Walker, SM; Varga, EM; Jacobson, MR; O'Brien, F; Noble, W; Till, SJ; Hamid, QA; Nouri-Aria, KT				Durham, SR; Walker, SM; Varga, EM; Jacobson, MR; O'Brien, F; Noble, W; Till, SJ; Hamid, QA; Nouri-Aria, KT			Long-term clinical efficacy of grass-pollen immunotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED IMMUNOTHERAPY; T-CELL CLONES; DOUBLE-BLIND; HAY-FEVER; ALLERGEN IMMUNOTHERAPY; MESSENGER-RNA; FOLLOW-UP; RAGWEED IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; RUSH IMMUNOTHERAPY	Background Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment. Methods We conducted a randomized, double-blind, placebo-controlled trial of the discontinuation of immunotherapy for grass-pollen allergy in patients in whom three to four years of this treatment had previously been shown to be effective. During the three years of this trial, primary outcome measures were scores for seasonal symptoms and the use of rescue medication. Objective measures included the immediate conjunctival response and the immediate and late skin responses to allergen challenge; Cutaneous-biopsy specimens obtained 24 hours after intradermal allergen challenge were examined for T-cell infiltration and the presence of cytokine-producing T helper cells (T(H)2 cells) (as evidenced by the presence of interleukin-4 messenger RNA). A matched group of patients with hay fever who had not received immunotherapy was followed as a control for the natural course of the disease. Results Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it. Symptom scores in both treatment groups (median areas under the curve in 1995, 921 for continuation of immunotherapy and 504 for discontinuation of immunotherapy; P=0.60) were markedly lower than those in the group that had not received immunotherapy (median value in 1995, 2863). Although there was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression. Conclusions immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity. (N Engl J Med 1999; 341:468-75.) (C) 1999 Massachusetts Medical Society.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Upper Resp Med, London SW3 6LY, England; Royal Brompton & Harefield Batl Hlth Serv Trust, Allergy Clin, London, England; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; McGill University	Durham, SR (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Upper Resp Med, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013; Noble, Wendy/C-3756-2009	Walker, Samantha/0000-0001-5503-8258; Noble, Wendy/0000-0002-7898-4295; Jacobson, Mikila/0000-0002-2921-6169; Till, Stephen/0000-0003-4518-3093				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; ARMITAGE P, 1994, STAT METHODS MED RES, P448; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; Chanez P, 1996, ALLERGY, V51, P850; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; FRANKLAND AW, 1954, LANCET, V1, P1055; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HOLGATE ST, 1991, CLIN EXP ALLERGY, V21, P11, DOI 10.1111/j.1365-2222.1991.tb01758.x; IMADA M, 1995, IMMUNOLOGY, V85, P373; *INT RHIN MAN WORK, 1994, ALLERGY S19, V49, P34; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; McKean J. W., 1977, ACM Transactions on Mathematical Software, V3, P183, DOI 10.1145/355732.355740; MOQBEL R, 1995, J IMMUNOL, V155, P4939; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P88, DOI 10.1016/0091-6749(90)90227-U; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PASTORELLO EA, 1992, ALLERGY, V47, P281, DOI 10.1111/j.1398-9995.1992.tb02054.x; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; 1998, ALLERGY S, V44, P1	48	1027	1076	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					468	475		10.1056/NEJM199908123410702	http://dx.doi.org/10.1056/NEJM199908123410702			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441602	Bronze			2023-01-03	WOS:000081962600002
J	Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER				Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER			Analysis of questions asked by family doctors regarding patient care	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; INFORMATION NEEDS; CLINICAL QUESTIONS; PHYSICIANS	Objectives To characterise the information needs of: family doctors by collecting the questions they asked about patient care during consultations and to classify these in ways that would be useful to developers of knowledge bases. Design Observational study in which investigators visited doctors for two half days and collected their questions. Taxonomies were developed to characterise the clinical topic and generic type of information sought for each question. Setting Eastern Iowa. Participants Random sample of 103 family doctors. Main outcome measures Number of questions posed, pursued, and answered; topic and generic type of information sought for each question; time spent pursuing answers; information resources used. Results Participants asked a total of 1101 questions. Questions about drug prescribing obstetrics and gynaecology, and adult infectious disease were most common and comprised 36% of all questions. The taxonomy of generic questions included 69 categories; the three most common types, comprising 24% of all questions, were "What is the cause of symptom X?" "What is the dose of drug X?" and "How should I manage disease or finding X?" Answers to most questions (702, 64%) were not immediately pursued, but, of those pursued, most (318, 80%) were answered. Doctors spent an average of less than 2 minutes pursuing an answer, and they used readily available print and human resources. Only two questions led to a formal literature search. Conclusions Family doctors in this study did not pursue answers to most of their questions. Questions about patient care can be organised into a limited number of generic types, which could help guide the efforts of knowledge base developers.	Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA; Amer Coll Phys, Amer Soc Internal Med, Philadelphia, PA USA; Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA; Moses Cone Hosp Family Med Residency, Greensboro, NC USA; Univ Iowa, Student Hlth Serv, Iowa City, IA USA	University of Iowa; American College of Physicians; Michigan State University; Moses Cone Memorial Hospital; University of Iowa	Ely, JW (corresponding author), Univ Iowa, Coll Med, Dept Family Med, 200 Hawkins Dr,01291-D PFP, Iowa City, IA 52242 USA.		Bergus, George/AAS-9522-2021	Levy, Barcey/0000-0002-3315-4116				Chambliss ML, 1996, J FAM PRACTICE, V43, P140; CIMINO JJ, 1993, B MED LIBR ASSOC, V81, P195; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; EBELL MH, 1998, MD COMPUTING, V15, P189; ELY JW, 1992, J FAM PRACTICE, V35, P265; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; GORMAN PN, 1994, B MED LIBR ASSOC, V82, P140; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Haug JD, 1997, B MED LIBR ASSOC, V85, P223; Henderson AR, 1997, EVIDENCE BASED MED P; HUTH EJ, 1994, ANN INTERN MED, V120, P889, DOI 10.7326/0003-4819-120-10-199405150-00012; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; REYNOLDS RD, 1995, J FAM PRACTICE, V41, P583; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Shaughnessy AF, 1998, J FAM PRACTICE, V47, P425; Smith R, 1996, BRIT MED J, V313, P1062; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; VERHOEVEN AAH, 1995, B MED LIBR ASSOC, V83, P85; WILSON SR, 1989, USE CRITICAL INCIDEN; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	23	338	343	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					358	361		10.1136/bmj.319.7206.358	http://dx.doi.org/10.1136/bmj.319.7206.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435959	Bronze, Green Published			2023-01-03	WOS:000082001700021
J	Winter, B; Cohen, S				Winter, B; Cohen, S			Withdrawal of treatment	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Nottingham NG7 2UH, England; UCL Hosp, London, England	University of Nottingham; University College London Hospitals NHS Foundation Trust; University of London; University College London	Winter, B (corresponding author), Univ Nottingham Hosp, Nottingham NG7 2UH, England.								0	30	32	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					306	308		10.1136/bmj.319.7205.306	http://dx.doi.org/10.1136/bmj.319.7205.306			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426751	Green Published			2023-01-03	WOS:000081909100034
J	Ely, EW; Evans, GW; Haponik, EF				Ely, EW; Evans, GW; Haponik, EF			Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	95th International Conference of the American-Thoracic-Society	APR 23-29, 1999	SAN DIEGO, CA	Amer Thorac Soc		respiration, artificial; age factors; intensive care units; outcome and process assessment (health care); health resources	ILL HOSPITALIZED ADULTS; NEW-YORK-STATE; RESPIRATORY-FAILURE; AGE; MORTALITY; SURVIVAL; SUPPORT; IMPACT; LIFE; PREFERENCES	Background: It has been argued that life support for the elderly should be limited to conserve resources. As this population increases, so will the importance of evaluating appropriate use of mechanical ventilation in this group. Objective: To determine whether age has an independent effect on the outcomes of patients treated with mechanical ventilation after admission to an intensive care unit (ICU). Design: Prospective cohort study. Setting: University-based tertiary care medical center. Patients: 63 patients 75 years of age or older and 237 patients younger than 75 years of age enrolled from medical and coronary ICUs. Measurements: In-hospital mortality rate, duration of mechanical ventilation, lengths of stay in the ICU and in the hospital, and cost of care. Results: Median duration of mechanical ventilation was 4.2 days (interquartile range, 2.1 to 9.3 days) for patients 75 years of age or older and 6.4 days (interquartile range, 3.4 to 11.4 days) for patients younger than 75 years of age (P = 0.14). When the length of time required to "pass" a daily screening test of weaning variables was used as an indicator of recovery from respiratory failure, elderly patients passed earlier than younger patients (risk ratio, 1.58 [95% CI, 1.13 to 2.22]; P = 0.03). The cost of ICU care was lower for older ($12 822 [CI, $9821 to $26 313] than for younger ($19 316 [CI, $9699 to $39 950]) patients (P = 0.03). Median hospital costs tended to be lower in the older group ($21 292 compared with $29 049; P = 0.17). After adjustment for ethnicity, sex, and severity of illness in a multivariate logistic regression analysis, patient age of 75 years or older was predictive of 1 less day on the ventilator (CI, -2.8 to 1.2 days). Lengths of stay in the ICU (beta-coefficient, -0.5 days [CI, -3.0 to 2.7 days]) and in the hospital (beta-coefficient, 0.3 days [CI, -3.7 to 5.5 days]) did not differ for persons 75 years of age or older after these adjustments (P > 0.1). Intensive care unit and hospital costs, however, were lower for elderly persons (P = 0.02). The in-hospital mortality rate was 38.1% among elderly patients and 38.8% among younger patients (P > 0.2); Cox proportional hazards analysis confirmed that survival did not differ between the two groups (relative risk for older patients, 0.82 [CI, 0.52 to 1.29]). Conclusions: After adjustment for severity of illness, elderly patients spent similar time on mechanical ventilation and in the ICU and hospital but had a lower cost of care than younger patients. These outcomes are not explained by differences in mortality rate and suggest that mechanical ventilation should not be restricted in elderly patients with respiratory failure on the basis of chronologic age.	Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA	Vanderbilt University; Wake Forest University	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, 913 Oxford House, Nashville, TN 37232 USA.		Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172				Baltussen R, 1996, HEALTH ECON, V5, P227, DOI 10.1002/(SICI)1099-1050(199605)5:3<227::AID-HEC198>3.3.CO;2-P; Barrett-Connor E, 1998, JAMA-J AM MED ASSOC, V279, P622, DOI 10.1001/jama.279.8.622; Blouin AS, 1996, J NURS ADMIN, V26, P3, DOI 10.1097/00005110-199611000-00001; BOULT C, 1993, J AM GERIATR SOC, V41, P811, DOI 10.1111/j.1532-5415.1993.tb06175.x; Campion EW, 1998, NEW ENGL J MED, V338, P1064, DOI 10.1056/NEJM199804093381512; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DARDAINE V, 1995, AGING-CLIN EXP RES, V7, P221, DOI 10.1007/BF03324339; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; ELPERN EH, 1989, CHEST, V96, P1120, DOI 10.1378/chest.96.5.1120; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Fried TR, 1996, J GEN INTERN MED, V11, P257, DOI 10.1007/BF02598264; Giugliano RP, 1998, ARCH INTERN MED, V158, P1113, DOI 10.1001/archinte.158.10.1113; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; GRACEY DR, 1992, CHEST, V101, P211, DOI 10.1378/chest.101.1.211; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HEUSER MD, 1992, ARCH INTERN MED, V152, P1683, DOI 10.1001/archinte.152.8.1683; Hobbs FB, 1995, 65 PLUS US; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kurek CJ, 1998, CHEST, V114, P214, DOI 10.1378/chest.114.1.214; Kurek CJ, 1997, CRIT CARE MED, V25, P983, DOI 10.1097/00003246-199706000-00015; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, P295; PAPADAKIS MA, 1993, WESTERN J MED, V159, P659; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; STAUFFER JL, 1993, CHEST, V104, P1222, DOI 10.1378/chest.104.4.1222; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; SWINBURNE AJ, 1993, ARCH INTERN MED, V153, P1657, DOI 10.1001/archinte.153.14.1657; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; WITEK TJ, 1985, ARCH INTERN MED, V145, P235, DOI 10.1001/archinte.145.2.235; Yuen E J, 1995, Am J Med Qual, V10, P76, DOI 10.1177/0885713X9501000203; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	54	132	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					96	+		10.7326/0003-4819-131-2-199907200-00004	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	217QD	10419447				2023-01-03	WOS:000081509700003
J	Shelly, MP; Nightingale, P				Shelly, MP; Nightingale, P			ABC of intensive care - Respiratory support	BRITISH MEDICAL JOURNAL			English	Article									Withington Hosp, Manchester M20 8LR, Lancs, England		Shelly, MP (corresponding author), Withington Hosp, Manchester M20 8LR, Lancs, England.								0	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1674	1677		10.1136/bmj.318.7199.1674	http://dx.doi.org/10.1136/bmj.318.7199.1674			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373174	Green Published			2023-01-03	WOS:000081105600032
J	Thiemann, DR; Coresh, J; Oetgen, WJ; Powe, NR				Thiemann, DR; Coresh, J; Oetgen, WJ; Powe, NR			The association between hospital volume and survival after acute myocardial infarction in elderly patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; CORONARY ANGIOPLASTY VOLUME; SHORT-TERM MORTALITY; THROMBOLYTIC THERAPY; CARDIOLOGISTS; PHYSICIAN; OUTCOMES; MODELS; TRIAL; CARE	Background Patients with chest pain thought to be due to acute coronary ischemia are typically taken by ambulance to the nearest hospital. The potential benefit of field triage directly to a hospital that treats a large number of patients with myocardial infarction is unknown. Methods We conducted a retrospective cohort study of the relation between the number of Medicare patients with myocardial infarction that each hospital in the study treated (hospital volume) and longterm survival among 98,898 Medicare patients 65 years of age or older. We used proportional-hazards methods to adjust for clinical, demographic, and health-system-related variables, including the availability of invasive procedures, the specialty of the attending physician, and the area of residence of the patient (rural, urban, or metropolitan). Results The patients in the quartile admitted to hospitals with the lowest volume were 17 percent more likely to die within 30 days after admission than patients in the quartile admitted to hospitals with the highest volume (hazard ratio, 1.17; 95 percent confidence interval, 1.09 to 1.26; P<0.001), which resulted in 2.3 more deaths per 100 patients. The crude mortality rate at one year was 29.8 percent among the patients admitted to the lowest-volume hospitals, as compared with 27.0 percent among those admitted to the highest-volume hospitals. There was a continuous inverse dose-response relation between hospital volume and the risk of death. In an analysis of subgroups defined according to age, history of cardiac disease, Killip class of infarction, presence or absence of contraindications to thrombolytic therapy, and time from the onset of symptoms, survival at high-volume hospitals was consistently better than at low-volume hospitals. The availability of technology for angioplasty and bypass surgery was not independently associated with overall mortality. Conclusions Patients with acute myocardial infarction who are admitted directly to hospitals that have more experience treating myocardial infarction, as reflected by their case volume, are more likely to survive than are patients admitted to low-volume hospitals. (N Engl J Med 1999;340:1640-8.) (C) 1999. Massachusetts Medical Society.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21287 USA; Johns Hopkins Univ, Program Med Technol & Practice Assessment, Baltimore, MD 21287 USA; Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA; Maryland Healthcare Associates, Clinton, MD USA; Delmarva Fdn Med Care, Easton, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Thiemann, DR (corresponding author), Johns Hopkins Univ, Dept Med, Carnegie 568, Baltimore, MD 21287 USA.				NCRR NIH HHS [RR00035, RR00072] Funding Source: Medline; PHS HHS [K01 A600561] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM HOSP ASS, 1997, 1994 ANN SURV HOSP D; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; *CENS BUR, 1992, CENS POP HOUS 1990 S; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP AGR EC RES SE, 1997, ZIPFIP FIL; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; Jollis JG, 1998, NEW ENGL J MED, V338, P983, DOI 10.1056/NEJM199804023381410; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Phibbs CS, 1996, JAMA-J AM MED ASSOC, V276, P1054, DOI 10.1001/jama.276.13.1054; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; *STAT, 1997, STATA VERS 5 0; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; *TX MED FDN, 1998, COOP CARD PROJ; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632	38	307	311	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1640	1648		10.1056/NEJM199905273402106	http://dx.doi.org/10.1056/NEJM199905273402106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341277				2023-01-03	WOS:000080494200006
J	Monaghan, J				Monaghan, J			Time to add chemotherapy to radiotherapy for cervical cancer	LANCET			English	Editorial Material									Queen Elizabeth Hosp, Dept Gynecol Oncol, Gateshead NE9 6SX, Tyne & Wear, England		Monaghan, J (corresponding author), Queen Elizabeth Hosp, Dept Gynecol Oncol, Gateshead NE9 6SX, Tyne & Wear, England.							GROGAN M, 1999, 30 ANN M SOC GYN ONC; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502	4	11	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1288	1289		10.1016/S0140-6736(99)00073-2	http://dx.doi.org/10.1016/S0140-6736(99)00073-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218522				2023-01-03	WOS:000080278100004
J	Kandela, P				Kandela, P			Sketches from the Lancet	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 13	1999	353	9152					601	601		10.1016/S0140-6736(05)75668-3	http://dx.doi.org/10.1016/S0140-6736(05)75668-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10029022				2023-01-03	WOS:000078670200069
J	Fitzgerald, FT				Fitzgerald, FT			Curiosity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA	University of California System; University of California Davis	Fitzgerald, FT (corresponding author), Univ Calif Davis, Med Ctr, Dept Internal Med, Box 179002, Sacramento, CA 95817 USA.								0	47	48	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					70	72		10.7326/0003-4819-130-1-199901050-00015	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890857				2023-01-03	WOS:000077744500014
J	Seale, C				Seale, C			Theories and studying the care of dying people	BRITISH MEDICAL JOURNAL			English	Article									Univ London Goldsmiths Coll, Dept Sociol, London SE14 6NW, England	University of London; Goldsmiths University London	Seale, C (corresponding author), Univ London Goldsmiths Coll, Dept Sociol, London SE14 6NW, England.							[Anonymous], YEAR DEATH; Baruch G., 1981, SOCIOLOGY HLTH ILLNE, V3, P275, DOI DOI 10.1111/1467-9566.EP10486851; Cartwright A., 1990, NATURAL HIST SURVEY; Danforth L.M., 1982, DEATH RITUALS RURAL; Giddens A., 1990, CONSEQUENCES MODERNI; Kubler-Ross E., 1970, DEATH DYING; LONG SO, 1982, SOC SCI MED, V16, P2101, DOI 10.1016/0277-9536(82)90259-3; Melzack R, 1989, CHALLENGE PAIN; Metcalf P., 1991, CELEBRATIONS DEATH; Seale C, 1996, AGEING SOC, V16, P75, DOI 10.1017/S0144686X00003147; SEALE C, 1995, SOCIOL HEALTH ILL, V17, P376, DOI 10.1111/1467-9566.ep10933327; SEALE C, 1995, SOCIOLOGY, V29, P597, DOI 10.1177/0038038595029004003; Seale C, 1998, CONSTRUCTING DEATH S; Silverman D., 2014, INTERPRETING QUALITA, V5th ed.; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661	15	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1518	1520		10.1136/bmj.317.7171.1518	http://dx.doi.org/10.1136/bmj.317.7171.1518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WJ	9831588	Green Published			2023-01-03	WOS:000077338300040
J	Mejicano, GC; Maki, DG				Mejicano, GC; Maki, DG			Infections acquired during cardiopulmonary resuscitation: Estimating the risk and defining strategies for prevention	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; HEPATITIS-C VIRUS; TO-MOUTH RESUSCITATION; CREUTZFELDT-JAKOB-DISEASE; HOSPITAL CARDIAC-ARREST; AIDS-RELATED COMPLEX; B IMMUNE GLOBULIN; OCCUPATIONAL RISK; CYTOMEGALO-VIRUS	Purpose: To estimate the risk for acquiring an infectious disease during cardiopulmonary resuscitation (CPR) or CPR training and to identify strategies to minimize that risk. Data Sources: English-language articles published since 1965 were identified through a search of the MEDLINE database and selected bibliographies. Study Selection: Studies that contained information about transmission of infectious organisms, particularly HIV and other bloodborne viruses that might be transmitted through mouth-to-mouth ventilation, contact exposures, and needlesticks during CPR. Data Extraction: Descriptive and analytic data from each study. Data Synthesis: Fear of acquiring infection, especially HIV infection, can delay prompt initiation of mouth-to-mouth ventilation. Although pathogens can be isolated from the saliva of infected persons, salivary transmission of bloodborne viruses is unusual and transmission of infection has been rare: Only 15 documented cases have been reported. Most of these cases involved a bacterial pathogen, such as Neisseria meningitidis. Transmission of hepatitis B virus, hepatitis C virus, or cytomegalovirus during CPR has not been reported; all three reported cases of HIV infection acquired during resuscitation of an infected patient resulted from high-risk cutaneous exposures. There have been no reports of infection acquired during CPR training. Simple infection-control measures, including use of barrier devices, can reduce the risk for acquisition of an infectious disease during CPR and CPR training. Postexposure protocols can further protect potential rescuers and trainees. Conclusions: The benefit of initiating lifesaving resuscitation in a patient in cardiopulmonary arrest greatly outweighs the risk for secondary infection in the rescuer or the patient. Nevertheless, use of simple infection-control measures during CPR and CPR training can reduce a very low level of risk even further.	Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Maki, DG (corresponding author), Univ Wisconsin Hosp & Clin, 600 Highland Ave, Madison, WI 53792 USA.							ABE K, 1991, LANCET, V337, P248, DOI 10.1016/0140-6736(91)92222-N; ACHONG MR, 1980, AM HEART J, V100, P759, DOI 10.1016/0002-8703(80)90248-3; ADLER SP, 1986, PEDIATR INFECT DIS J, V5, P239, DOI 10.1097/00006454-198603000-00016; AHLFORS K, 1981, ACTA PAEDIATR SCAND, V70, P819, DOI 10.1111/j.1651-2227.1981.tb06233.x; AHMAD F, 1990, LANCET, V335, P787, DOI 10.1016/0140-6736(90)90898-F; AKAHANE Y, 1992, LANCET, V339, P1059, DOI 10.1016/0140-6736(92)90585-Q; ALTER HJ, 1977, INFECT IMMUN, V16, P928, DOI 10.1128/IAI.16.3.928-933.1977; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1996, Med Lett Drugs Ther, V38, P35; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, JAMA-J AM MED ASSOC, V268, P2184, DOI DOI 10.1001/JAMA.1992.03490160054025; [Anonymous], [No title captured]; BALCAREK KB, 1990, JAMA-J AM MED ASSOC, V263, P840, DOI 10.1001/jama.263.6.840; BALFOUR CL, 1986, JAMA-J AM MED ASSOC, V256, P1909, DOI 10.1001/jama.256.14.1909; BALLARD JL, 1986, PEDIATR INFECT DIS J, V5, P198, DOI 10.1097/00006454-198603000-00007; Ballew KA, 1997, BRIT MED J, V314, P1462, DOI 10.1136/bmj.314.7092.1462; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Becker LB, 1997, ANN EMERG MED, V30, P654, DOI 10.1016/S0196-0644(97)70085-4; Berg RA, 1997, CIRCULATION, V95, P1635; BERGER JR, 1993, NEUROLOGY, V43, P205, DOI 10.1212/WNL.43.1_Part_1.205; BERNOULLI C, 1977, LANCET, V1, P478; Bierens JJLM, 1996, RESUSCITATION, V32, P185, DOI 10.1016/0300-9572(96)00943-4; BLENKHARN JI, 1990, RESUSCITATION, V19, P151, DOI 10.1016/0300-9572(90)90038-G; BLUMENFIELD M, 1987, GEN HOSP PSYCHIAT, V9, P58, DOI 10.1016/0163-8343(87)90103-4; BRADY MT, 1986, AM J INFECT CONTROL, V14, P197, DOI 10.1016/0196-6553(86)90117-3; BRADY MT, 1987, INFECT CONT HOSP EP, V8, P329, DOI 10.1017/S0195941700066431; Brenner B, 1996, RESUSCITATION, V32, P5, DOI 10.1016/0300-9572(96)00966-5; BRENNER B, 1994, RESUSCITATION, V28, P185, DOI 10.1016/0300-9572(94)90063-9; Brenner BE, 1996, RESUSCITATION, V31, P17, DOI 10.1016/0300-9572(95)00905-1; BRENNER BE, 1993, ARCH INTERN MED, V153, P1763, DOI 10.1001/archinte.153.15.1763; BRETTLER DB, 1992, BLOOD, V80, P540; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUDDINGH GJ, 1953, PEDIATRICS, V11, P595; CANCIOBELLO TP, 1982, J INFECT DIS, V146, P652, DOI 10.1093/infdis/146.5.652; Cardo DM, 1997, INFECT DIS CLIN N AM, V11, P331, DOI 10.1016/S0891-5520(05)70359-7; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; CAVALCANTE N J F, 1991, AIDS Care, V3, P311, DOI 10.1080/09540129108253078; *CDC, 1978, 42 CDC, P34; Centers for Disease Control (CDC), 1983, MMWR Morb Mortal Wkly Rep, V32, P101; CHANDRA NC, 1994, INSTRUCTORS MANUAL B; COHEN HJ, 1985, ANN INTERN MED, V102, P136, DOI 10.7326/0003-4819-102-1-136_2; COMROE JH, 1979, AM REV RESPIR DIS, V119, P1025; CONTE JE, 1983, NEW ENGL J MED, V309, P740, DOI 10.1056/NEJM198309223091228; COUZIGOU P, 1993, GUT, V324, pS59; CREANGE A, 1995, ANN NEUROL, V38, P269, DOI 10.1002/ana.410380223; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V262, P2732; CURREY CJ, 1990, ACAD MED, V65, P472, DOI 10.1097/00001888-199007000-00015; CYDULKA R K, 1991, Journal of Emergency Medicine, V9, P317, DOI 10.1016/0736-4679(91)90373-N; DAVIS GE, 1978, J MAINE MED ASSOC, V69, P214; DEMMLER GJ, 1986, PEDIATR INFECT DIS J, V5, P605, DOI 10.1097/00006454-198609000-00032; DRUMMOND JA, 1986, JAMA-J AM MED ASSOC, V256, P2342, DOI 10.1001/jama.1986.03380170058010; DUFFY P, 1974, NEW ENGL J MED, V290, P692; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; DWORSKY ME, 1983, NEW ENGL J MED, V309, P950, DOI 10.1056/NEJM198310203091604; *ECRI, 1992, ECRI HEALTHC HAZ MAT, P5; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EMBIL JA, 1975, CAN MED ASSOC J, V113, P627; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; FELDMAN HA, 1972, J AMER MED ASSOC, V220, P1107, DOI 10.1001/jama.220.8.1107; Figura N, 1996, LANCET, V347, P1342, DOI 10.1016/S0140-6736(96)90996-4; FINKELHOR RS, 1980, JAMA-J AM MED ASSOC, V243, P650; FLOWERS RH, 1988, INFECT CONT HOSP EP, V9, P491, DOI 10.2307/30146544; FONS MP, 1994, J AM DENT ASSOC, V125, P713, DOI 10.14219/jada.archive.1994.0114; FRIED MW, 1992, GASTROENTEROLOGY, V102, P1306; FRIEDLAND GH, 1986, NEW ENGL J MED, V314, P344, DOI 10.1056/NEJM198602063140604; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Gerberding J L, 1989, Infect Dis Clin North Am, V3, P735; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; GLASER JB, 1985, ARCH INTERN MED, V145, P1653, DOI 10.1001/archinte.145.9.1653; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; GREENBERG MD, 1983, ANN EMERG MED, V12, P194, DOI 10.1016/S0196-0644(83)80576-9; GROOPMAN JE, 1984, SCIENCE, V226, P447, DOI 10.1126/science.6093247; HART CA, 1993, J MED MICROBIOL, V39, P3, DOI 10.1099/00222615-39-1-3; HATHERLEY LI, 1986, INFECT CONT HOSP EP, V7, P452, DOI 10.1017/S0195941700064948; HEILMAN KM, 1965, NEW ENGL J MED, V273, P1035, DOI 10.1056/NEJM196511042731908; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1995, PRINCIPLES PRACTICE, P2632; HENDERSON DK, 1993, PREVENTION CONTROL N, P42; HENDRICKS AA, 1980, JAMA-J AM MED ASSOC, V243, P257, DOI 10.1001/jama.243.3.257; HEPTONSTALL J, 1995, OCCUPATIONAL HIV SUM; HESS D, 1990, Respiratory Care, V35, P800; HO DD, 1985, NEW ENGL J MED, V313, P1606; HO M, 1990, REV INFECT DIS, V12, pS701; Hodgin L, 1992, Occup Health Saf, V61, P58; HODGIN L, 1992, OCCUP HEALTH SAF, V61, P58; HOLLINGER FB, 1992, GASTROENTEROLOGY, V102, P1426, DOI 10.1016/0016-5085(92)90791-V; Holmes SJ, 1996, J NEUROL NEUROSUR PS, V60, P333, DOI 10.1136/jnnp.60.3.333; Idris AH, 1996, ANN EMERG MED, V27, P569, DOI 10.1016/S0196-0644(96)70159-2; IDRIS AH, 1994, CIRCULATION, V90, P3063, DOI 10.1161/01.CIR.90.6.3063; IDRIS AH, 1994, RESUSCITATION, V28, P143, DOI 10.1016/0300-9572(94)90087-6; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JACOBSON JA, 1976, JAMA-J AM MED ASSOC, V236, P1053; Juip M, 1988, Nursing, V18, P48; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; Khajotia RR, 1997, ARCH INTERN MED, V157, P1901, DOI 10.1001/archinte.157.16.1901; KHAN AH, 1979, JAMA-J AM MED ASSOC, V241, P2701; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN R, 1993, LANCET, V341, P768, DOI 10.1016/0140-6736(93)90549-V; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LAWRENCE PJ, 1985, MED J AUSTRALIA, V143, P443, DOI 10.5694/j.1326-5377.1985.tb123133.x; Lee KH, 1996, CRIT CARE MED, V24, P2046, DOI 10.1097/00003246-199612000-00019; LEWANDOWSKI C, 1992, ANN EMERG MED, V21, P1353, DOI 10.1016/S0196-0644(05)81901-8; LIFSON AR, 1988, JAMA-J AM MED ASSOC, V259, P1353, DOI 10.1001/jama.259.9.1353; LIOU TC, 1992, J MED VIROL, V37, P197, DOI 10.1002/jmv.1890370309; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LOCKE CJ, 1995, ARCH INTERN MED, V155, P938, DOI 10.1001/archinte.155.9.938; LUCHT E, 1993, J MED VIROL, V39, P156, DOI 10.1002/jmv.1890390213; MACQUARRIE MB, 1974, JAMA-J AM MED ASSOC, V230, P723; Madama V C, 1991, Occup Health Saf, V60, P64; MADAMA VC, 1991, OCCUP HEALTH SAF, V60, P64; MADAMA VC, 1991, OCCUP HEALTH SAF, V60, P58; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARDER MZ, 1985, ORAL SURG ORAL MED O, V60, P372, DOI 10.1016/0030-4220(85)90258-0; MARTINEZLAGE JF, 1994, J NEUROL NEUROSUR PS, V57, P1091, DOI 10.1136/jnnp.57.9.1091; Mason M, 1991, Can J Cardiovasc Nurs, V2, P23; MCCORMICK JB, 1975, ANN INTERN MED, V83, P883, DOI 10.7326/0003-4819-83-6-883; MCCORMICK RD, 1991, AM J MED, V91, pS301, DOI 10.1016/0002-9343(91)90386-C; MCCORMICK RD, 1981, AM J MED, V70, P928, DOI 10.1016/0002-9343(81)90558-1; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCDONALD GB, 1976, GASTROINTEST ENDOSC, V22, P168, DOI 10.1016/S0016-5107(76)73735-0; McHugh M, 1990, Nurs Manage, V21, P37; MCNEIL EL, 1989, RESUSCITATION, V18, P1, DOI 10.1016/0300-9572(89)90107-X; MEMON AM, 1982, ANN EMERG MED, V11, P322, DOI 10.1016/S0196-0644(82)80135-2; MICHAEL AD, 1992, AM J EMERG MED, V10, P156; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MORRIS IM, 1975, LANCET, V2, P1152; MOSLEY JW, 1975, NEW ENGL J MED, V293, P729, DOI 10.1056/NEJM197510092931501; MURPH JR, 1991, JAMA-J AM MED ASSOC, V265, P603, DOI 10.1001/jama.265.5.603; NAKANO I, 1992, AM J GASTROENTEROL, V87, P1522; Newcombe RL, 1996, MED J AUSTRALIA, V164, P603, DOI 10.5694/j.1326-5377.1996.tb122203.x; NICKALLS RWD, 1986, BRIT MED J, V292, P1350, DOI 10.1136/bmj.292.6532.1350; NICKLIN G, 1980, JAMA-J AM MED ASSOC, V244, P2046, DOI 10.1001/jama.1980.03310180016016; NUMATA N, 1993, J MED VIROL, V41, P120, DOI 10.1002/jmv.1890410207; *OCC SAF HLTH ADM, 1993, POL PROC OCC EXP TUB; ORNATO JP, 1990, ANN EMERG MED, V19, P151, DOI 10.1016/S0196-0644(05)81800-1; ORNATO JP, 1989, J EMERGENCY CARE TRA, V18, P45; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PERRILLO RP, 1979, GASTROENTEROLOGY, V76, P1319; Pinkerton SD, 1997, ARCH INTERN MED, V157, P1972, DOI 10.1001/archinte.157.17.1972; POWELL E, 1985, AUST NZ J MED, V15, P717; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; PROSSER RL, 1990, JAMA-J AM MED ASSOC, V263, P3025, DOI 10.1001/jama.1990.03440220047025; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PUCHHAMMERSTOCKL E, 1994, J MED VIROL, V43, P143, DOI 10.1002/jmv.1890430208; Reed Elizabeth, 1993, Journal of Emergency Medicine, V11, P9, DOI 10.1016/0736-4679(93)90003-P; RICHMAN KM, 1993, J ACQ IMMUN DEF SYND, V6, P402; ROBERT LM, 1994, INFECT DIS CLIN N AM, V8, P319; ROSSI R, 1991, RESUSCITATION, V21, P103, DOI 10.1016/0300-9572(91)90082-A; SAHDEV P, 1994, ANN EMERG MED, V23, P823, DOI 10.1016/S0196-0644(94)70321-3; SANDE MA, 1986, NEW ENGL J MED, V314, P380, DOI 10.1056/NEJM198602063140609; SAVITEER SM, 1985, NEW ENGL J MED, V313, P1606; SCHUPFER PC, 1986, PEDIATR INFECT DIS J, V5, P677, DOI 10.1097/00006454-198611000-00015; SCOTT RM, 1980, J INFECT DIS, V142, P67, DOI 10.1093/infdis/142.1.67; SEEFF LB, 1978, ANN INTERN MED, V88, P285, DOI 10.7326/0003-4819-88-3-285; Sepkowitz KA, 1996, ANN INTERN MED, V125, P917, DOI 10.7326/0003-4819-125-11-199612010-00008; Sepkowitz KA, 1996, ANN INTERN MED, V125, P826, DOI 10.7326/0003-4819-125-10-199611150-00007; Sheard T, 1990, Nursing, V20, P43; SMITH JL, 1976, J INFECT DIS, V133, P705, DOI 10.1093/infdis/133.6.705; STEELMAN VM, 1994, AM J INFECT CONTROL, V22, P312, DOI 10.1016/0196-6553(94)90019-1; Stern A, 1994, JEMS, V19, P85; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; SUN D, 1995, SEMIN DERMATOL, V14, P205, DOI 10.1016/S1085-5629(05)80020-3; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; Teplow L, 1973, J Occup Med, V15, P427; Thomas DL, 1996, AM J MED, V100, P41, DOI 10.1016/S0002-9343(96)90009-1; TODD MA, 1980, JAMA-J AM MED ASSOC, V243, P331; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TOOKEY P, 1991, ARCH DIS CHILD, V66, P1009, DOI 10.1136/adc.66.9.1009; TSOUKAS CM, 1988, J ACQ IMMUN DEF SYND, V1, P505; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; TURNER R, 1982, PEDIATRICS, V70, P547; TYLER K, 1995, PRINCIPLES PRACTICE, P1674; VALENZUELA TD, 1991, ANN EMERG MED, V20, P90, DOI 10.1016/S0196-0644(05)81129-1; VANDYKE RB, 1984, PEDIATR INFECT DIS J, V3, P153, DOI 10.1097/00006454-198403000-00019; Vidmar L, 1996, LANCET, V347, P1762, DOI 10.1016/S0140-6736(96)90838-7; VILLAREJOS VM, 1974, NEW ENGL J MED, V291, P1375, DOI 10.1056/NEJM197412262912602; WAHN V, 1986, LANCET, V2, P694; WANG JT, 1992, J MED VIROL, V36, P28, DOI 10.1002/jmv.1890360106; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; Weiss SH, 1997, MED CLIN N AM, V81, P555, DOI 10.1016/S0025-7125(05)70531-9; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; West K, 1990, Occup Health Saf, V59, P28; Weston CFM, 1997, RESUSCITATION, V34, P27, DOI 10.1016/S0300-9572(96)01031-3; Wickham EA, 1996, BRIT MED J, V312, P988, DOI 10.1136/bmj.312.7037.988; YEAGER AS, 1975, J CLIN MICROBIOL, V2, P448; Yeager M, 1990, Occup Health Saf, V59, P51; YOUNG KC, 1993, J MED VIROL, V41, P55, DOI 10.1002/jmv.1890410112; 1997, MMWR MORB MORTAL WKL, V46, P620; 1995, MMWR MORB MORTAL WKL, V44, P929; 1997, MMWR MORB MORTAL WKL, V46, P1066; 1992, CLIN INFECT DIS, V14, P1179; 1987, MMWR MORB MORTAL WKL, V36, P285; 1990, MMWR MORB MORTAL WKL, V39, P17; 1990, CMAJ, V143, P1007; 1989, MMWR MORB MORTAL  S6, V38, P1; 1997, MMWR MORB MORTAL WKL, V46, P21; 1989, JAMA, V262, P2714; 1986, NURS LIFE, V6, P23; 1978, MMWR MORB MORTAL WKL, V27, P247; 1988, MMWR MORB MORTAL WKL, V37, P377; 1987, MMWR MORB MORTAL S2, V36, pS3; 1988, ANN EMERG MED, V17, P1249; 1984, INFECT CONTROL, V5, P242; 1982, MMWR MORB MORTAL WKL, V31, P577; 1996, MMWR MORB MORTAL WKL, V45, P468; 1996, MMWR MORB MORTAL WKL, V45, P295; 1990, CMAJ, V142, P547; 1978, MMWR MORB MORTAL WKL, V27, P132; 1992, JAMA, V268, P2171	214	68	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					813	828		10.7326/0003-4819-129-10-199811150-00014	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00014			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841588				2023-01-03	WOS:000076984800008
J	Hill, MD; Hachinski, V				Hill, MD; Hachinski, V			Stroke treatment: time is brain	LANCET			English	Article							ACUTE ISCHEMIC STROKE; PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; TEMPERATURE; INFARCTION; SAFETY	Treatments for stroke have traditionally consisted of supportive care and the prevention of complications. The evidence that is accumulating justifies a more aggressive approach. Experimental and clinical data show that there is a variable therapeutic window that may exceed 6-8 h;(1) that stroke units spare lives and reduce disability;(2) and that thrombolysis with recombinant tissue plasminogen activator (rtPA) makes a difference in acute stroke.(3) This article focuses on the ideal treatment of acute ischaemic stroke in the first 24 h.	Univ Toronto, Dept Neurol, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Western Ontario, Dept Neurol Sci, London, ON N6A 3K7, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Western University (University of Western Ontario)	Hill, MD (corresponding author), Univ Toronto, Dept Neurol, Toronto, ON M5B 1W8, Canada.		Hill, Michael D/C-9073-2012	Hill, Michael D/0000-0002-6269-1543				[Anonymous], 1998, JAMA, V279, P1265; [Anonymous], 1986, Arch Neurol, V43, P71; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Boiser JC, 1998, STROKE, V29, P305; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; CANDELISE L, 1995, LANCET, V346, P1509; CHAMORRO A, 1995, NEUROLOGY, V45, P861, DOI 10.1212/WNL.45.5.861; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; Demchuk AM, 1998, STROKE, V29, P273; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; GINSBERG MD, 1995, CEREBROVASCULAR DISEASES, P331; Grond M, 1998, STROKE, V29, P288; GROTTA J, 1997, NEW ENGL J MED, V337, P1309; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HACKE W, 1998, 23 INT JOINT C STROK; Hommel M, 1996, NEW ENGL J MED, V335, P145; HOSSMANN V, 1983, ARCH NEUROL-CHICAGO, V40, P803, DOI 10.1001/archneur.1983.04050120053007; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kwiatkowski TG, 1998, STROKE, V29, P288; Leira EC, 1998, STROKE, V29, P320; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARSH EE, 1989, NEUROLOGY, V39, P1631, DOI 10.1212/WNL.39.12.1631; Read SJ, 1998, STROKE, V29, P312; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P1306, DOI 10.1001/archneur.1996.00550120118026; Sacchetti ML, 1997, NEUROLOGY, V49, pS70, DOI 10.1212/WNL.49.5_Suppl_4.S70; Sandercock P, 1997, LANCET, V349, P1569; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Sharafuddin MJA, 1997, J VASC INTERV RADIOL, V8, P939, DOI 10.1016/S1051-0443(97)70690-0; Tanne D, 1998, STROKE, V29, P288; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Yoon BW, 1997, ARCH NEUROL-CHICAGO, V54, P741, DOI 10.1001/archneur.1997.00550180055012	36	18	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	1998	352			3			SIII10	SIII14						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133UP	9803956				2023-01-03	WOS:000076704700004
J	Pandolfe, WD; Butrym, JA				Pandolfe, WD; Butrym, JA			In the laboratory - When is homogenization the best processing choice?	NATURE BIOTECHNOLOGY			English	Editorial Material									APV Homogenizer Grp, Wilmington, MA USA		Pandolfe, WD (corresponding author), APV Homogenizer Grp, Wilmington, MA USA.		Di Stadio, Arianna/Q-2498-2017	Di Stadio, Arianna/0000-0001-5510-3814					0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1998	16	10					974	975		10.1038/nbt1098-974	http://dx.doi.org/10.1038/nbt1098-974			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126YQ	9788357				2023-01-03	WOS:000076323300036
J	Kaufman, JS; Reda, DJ; Fye, CL; Goldfarb, DS; Henderson, WG; Kleinman, JG; Vaamonde, CA				Kaufman, JS; Reda, DJ; Fye, CL; Goldfarb, DS; Henderson, WG; Kleinman, JG; Vaamonde, CA		Dept Vet Affairs Cooperative Study Grp Erythrop	Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; STAGE RENAL-DISEASE; MAINTENANCE HEMODIALYSIS; ANEMIC PATIENTS; PHARMACOKINETICS; CROSSOVER; PAIN; PHARMACODYNAMICS; INJECTION; DIALYSIS	Background Several studies have suggested that if recombinant human erythropoietin (epoetin) is administered subcutaneously rather than intravenously, a lower dose may be sufficient to maintain the hematocrit at a given level. Methods In a randomized, unblinded trial conducted at 24 hemodialysis units at Veterans Affairs medical centers, we assigned 208 patients who were receiving long-term hemodialysis and epoetin therapy to treatment with either subcutaneous or intravenous epoetin. The dose was initially reduced until the hematocrit was below 30 percent and then was gradually increased to a level that would maintain the hematocrit in the range of 30 to 33 percent for 26 weeks. We compared the average doses in the 26-week maintenance phase and the discomfort associated with the two routes of administration. Results For the 107 patients treated by the subcutaneous route, the average weekly dose of epoetin during the maintenance phase was 32 percent less than that for the 101 patients treated by the intravenous route (mean [+/- SD], 95.1 +/- 75.0 vs. 140.3 +/- 88.5 U per kilogram of body weight per week; P<0.001). Only one patient in the subcutaneous-therapy group withdrew from the study because of pain at the injection site, and 86 percent rated the pain associated with subcutaneous administration as ranging from absent to mild. Conclusions In patients receiving hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target range, with an average weekly dose of epoetin that is lower than with intravenous administration. (N Engl J Med 1998; 339:578-83.) (C) 1998, Massachusetts Medical Society.	Boston Vet Affairs Med Ctr, Boston, MA 02130 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Vet Affairs Cooperat Studies Program, Coordinating Ctr, Hines, IL USA; Vet Affairs Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA; New York Vet Affairs Med Ctr, New York, NY USA; NYU, Sch Med, Dept Med, New York, NY USA; Milwaukee Vet Affairs Med Ctr, Milwaukee, WI USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Miami Vet Affairs Med Ctr, Miami, FL USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA	Boston University; New York University; Medical College of Wisconsin; University of Miami	Kaufman, JS (corresponding author), Boston Vet Affairs Med Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.			, Domenic/0000-0003-1831-4270; Goldfarb, David/0000-0002-9215-1273				ALBITAR S, 1995, NEPHROL DIAL TRANSPL, V10, P40, DOI 10.1093/ndt/10.supp6.40; [Anonymous], 1997, Am J Kidney Dis, V30, pS192; BARCLAY PG, 1993, CLIN NEPHROL, V40, P277; BESARAB A, 1992, J AM SOC NEPHROL, V2, P1405; BROCKMOLLER J, 1992, BRIT J CLIN PHARMACO, V34, P499; CANAUD B, 1995, DIALYSIS TRANSPLANT, V24, P306; EIDEMAK I, 1992, NEPHROL DIAL TRANSPL, V7, P526; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FRENKEN LAM, 1991, BRIT MED J, V303, P288, DOI 10.1136/bmj.303.6797.288; GRANOLLERAS C, 1991, CLIN NEPHROL, V36, P294; HALSTENSON CE, 1991, CLIN PHARMACOL THER, V50, P702, DOI 10.1038/clpt.1991.210; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; Jensen JD, 1996, EUR J CLIN PHARMACOL, V50, P171, DOI 10.1007/s002280050088; KOOISTRA MP, 1991, BRIT J HAEMATOL, V79, P634, DOI 10.1111/j.1365-2141.1991.tb08093.x; MACDOUGALL IC, 1989, BRIT MED J, V299, P157, DOI 10.1136/bmj.299.6692.157; MCMAHON FG, 1990, BLOOD, V76, P1718; MUIRHEAD N, 1992, AM J NEPHROL, V12, P303, DOI 10.1159/000168464; PAGANINI EP, 1995, AM J KIDNEY DIS, V26, P331, DOI 10.1016/0272-6386(95)90654-1; Parker KP, 1997, J AM SOC NEPHROL, V8, P288; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; SALMONSON T, 1990, BRIT J CLIN PHARMACO, V29, P709, DOI 10.1111/j.1365-2125.1990.tb03692.x; SCHALLER R, 1994, ARTIF ORGANS, V18, P552, DOI 10.1111/j.1525-1594.1994.tb03378.x; STEFFENSEN G, 1992, BLOOD PURIFICAT, V10, P241, DOI 10.1159/000170054; STOCKENHUBER F, 1991, NEPHRON, V59, P399, DOI 10.1159/000186598; TAYLOR JE, 1994, CLIN NEPHROL, V41, P297; TOMSON CRV, 1992, NEPHROL DIAL TRANSPL, V7, P129, DOI 10.1093/oxfordjournals.ndt.a092082; Valderrabano F, 1996, KIDNEY INT, V50, P1373, DOI 10.1038/ki.1996.452; VEYS N, 1992, AM J NEPHROL, V12, P68, DOI 10.1159/000168420; Virot JS, 1996, AM J KIDNEY DIS, V28, P400, DOI 10.1016/S0272-6386(96)90498-9; Woolson RF, 1987, STAT METHODS ANAL BI; ZEHNDER C, 1991, NEPHRON, V57, P485, DOI 10.1159/000186357	31	223	231	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					578	583		10.1056/NEJM199808273390902	http://dx.doi.org/10.1056/NEJM199808273390902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718376	Bronze			2023-01-03	WOS:000075552900002
J	Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK				Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK			A national survey of physician-assisted suicide and euthanasia in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONCOLOGISTS; ATTITUDES; DEATH; ILL	Background Although there have been many studies of physician-assisted suicide and euthanasia in the United States, national data are lacking. Methods In 1996, we mailed questionnaires to a stratified probability sample of 3102 physicians in the 10 specialties in which doctors are most likely to receive requests from patients for assistance with suicide or euthanasia. We weighted the results to obtain nationally representative data. Results We received 1902 completed questionnaires (response rate, 61 percent). Eleven percent of the physicians said that under current legal constraints; there were circumstances in which they would be willing to hasten a patient's death by prescribing medication, and 7 percent said that they would provide a lethal injection; 36 percent and 24 percent, respectively, said that they would do so if it were legal. Since entering practice, 18.3 percent of the physicians (unweighted number, 320) reported having received a request from a patient for assistance with suicide and 11.1 percent (unweighted number, 196) had received a request for a lethal injection. Sixteen percent of the physicians receiving such requests (unweighted number, 42), or 3.3 percent of the entire sample, reported that they had written at least one prescription to be used to hasten death, and 4.7 percent (unweighted number, 59), said that they had administered at least one lethal injection. Conclusions A substantial proportion of physicians in the United States in the specialties surveyed report that they receive requests for physician-assisted suicide and euthanasia, and about 6 percent have complied with such requests at least once. (C)1998, Massachusetts Medical Society.	Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Chicago	Meier, DE (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Box 1070, New York, NY 10029 USA.				NATIONAL INSTITUTE OF NURSING RESEARCH [R03NR003109] Funding Source: NIH RePORTER; NINR NIH HHS [1RO3NR03109] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; CRANE D, 1977, SANCTITY SOCIAL LIFE; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; JOBE JB, 1989, AM J PUBLIC HEALTH, V79, P1053, DOI 10.2105/AJPH.79.8.1053; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; McKeogh M, 1997, NEW ENGL J MED, V337, P56, DOI 10.1056/NEJM199707033370118; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; MEIER DE, 1993, PHYSICIAN ASSISTED D; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; TAYLOR H, 1995, DOCTOR ASSISTED SUCI	22	366	367	2	69	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1193	1201		10.1056/NEJM199804233381706	http://dx.doi.org/10.1056/NEJM199804233381706			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554861	Bronze			2023-01-03	WOS:000073208400006
J	Matsuoka, K; Orci, L; Amherdt, M; Bednarek, SY; Hamamoto, S; Schekman, R; Yeung, T				Matsuoka, K; Orci, L; Amherdt, M; Bednarek, SY; Hamamoto, S; Schekman, R; Yeung, T			COPII-coated vesicle formation reconstituted with purified coat proteins and chemically defined liposomes	CELL			English	Article							GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLINOSITOL 4-KINASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; YEAST; TRANSPORT; COMPLEX; SEC23P	COPII vesicle formation requires only three coat assembly subunits: Sar1p, Sec13/31p, and Sec23/24p. PI 4-phosphate or PI 4,5-bisphosphate is required for the binding of these proteins to liposomes. The GTP-bound form of Sar1p recruits Sec23/24p to the liposomes as well as to the ER membranes, and this Sar1p-Sec23/24p complex is required for the binding of Sec13/31p. Ultrastructural analysis shows that the binding of COPII coat proteins to liposomes results in coated patches, coated buds, and coated vesicles of 50-90 nm in diameter. Budding proceeds without rupture of the donor liposome or vesicle product. These observations suggest that the assembly of the COPII coat on the ER occurs by a sequential binding of coat proteins to specific lipids and that this assembly promotes the budding of COPII-coated vesicles.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Taylor, Graham/A-4027-2012; Matsuoka, Ken/E-3215-2010					Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Waksman M, 1997, J BIOL CHEM, V272, P36; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	48	498	509	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					263	275		10.1016/S0092-8674(00)81577-9	http://dx.doi.org/10.1016/S0092-8674(00)81577-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568718	Bronze			2023-01-03	WOS:000073174000012
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - What is complementary medicine?	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England		Zollman, C (corresponding author), Res Council Complementary Med, London, England.							ERNST E, 1996, COMPLEMENTARY MED CR; LEWITH G, 1996, COMPLEMENTARY MED IN; VICKERS A, 1998, EXAMINING COMPLEMENT; Vincent C, 1997, COMPLEMENTARY MED RE; WOODHAM A, 1997, ENCY COMPLEMENTARY M	5	183	188	4	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					693	696		10.1136/bmj.319.7211.693	http://dx.doi.org/10.1136/bmj.319.7211.693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480829	Green Published			2023-01-03	WOS:000082636800028
J	Fox, AJ; Rowbotham, DJ				Fox, AJ; Rowbotham, DJ			Anaesthesia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							EVOKED POTENTIAL INDEX; NITROUS-OXIDE; LEVERING LARYNGOSCOPE; GENERAL-ANESTHESIA; BUPIVACAINE; ROPIVACAINE; DESFLURANE; SEVOFLURANE; ISOFLURANE; S(-)-BUPIVACAINE		Univ Leicester, Leicester Royal Infirm, Dept Anaesthesia, Leicester LE1 5WW, Leics, England	University of Leicester	Rowbotham, DJ (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Anaesthesia, Leicester LE1 5WW, Leics, England.	David.Rowbotham@leicester.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBRIGHT GA, 1979, ANESTHESIOLOGY, V51, P285, DOI 10.1097/00000542-197910000-00001; BENUMOF JL, 1992, ANESTH ANALG, V74, P313, DOI 10.1213/00000539-199202000-00034; Biebuyck JF, 1994, ANESTHESIOLOGY, V80, P906; Brain AIJ, 1997, BRIT J ANAESTH, V79, P699, DOI 10.1093/bja/79.6.699; BROCKWAY MS, 1991, BRIT J ANAESTH, V66, P31, DOI 10.1093/bja/66.1.31; Capouet V, 1996, BRIT J ANAESTH, V76, P54, DOI 10.1093/bja/76.1.54; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Cox CR, 1998, BRIT J ANAESTH, V80, P594, DOI 10.1093/bja/80.5.594; Cox CR, 1998, BRIT J ANAESTH, V80, P289, DOI 10.1093/bja/80.3.289; CRISTWOOD R, 1994, EXPERT OPINION INVES, V3, P1209; Diemunsch P, 1999, BRIT J ANAESTH, V82, P274, DOI 10.1093/bja/82.2.274; Doi M, 1997, BRIT J ANAESTH, V78, P180, DOI 10.1093/bja/78.2.180; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Elton CD, 1997, BRIT J ANAESTH, V79, P551, DOI 10.1093/bja/79.5.551; Gepts E, 1998, ANAESTHESIA, V53, P4, DOI 10.1111/j.1365-2044.1998.53s111.x; GHOURI AF, 1991, ANESTHESIOLOGY, V74, P419, DOI 10.1097/00000542-199103000-00005; Goto T, 1997, ANESTHESIOLOGY, V86, P1273, DOI 10.1097/00000542-199706000-00007; Gray JM, 1998, ANAESTHESIA, V53, P22, DOI 10.1111/j.1365-2044.1998.53s114.x; HOWELL CJ, 1999, COCHRANE LIB; JONES RM, 1990, BRIT J ANAESTH, V64, P3; KENNY G N C, 1992, Anesthesiology (Hagerstown), V77, pA328, DOI 10.1097/00000542-199209001-00328; Knudsen K, 1997, BRIT J ANAESTH, V78, P507, DOI 10.1093/bja/78.5.507; Lee DJH, 1996, BRIT J ANAESTH, V76, P780, DOI 10.1093/bja/76.6.780; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; MATHER LE, 1996, ANESTHESIOLOGY, V137, pF135; MAZOIT JX, 1993, ANESTH ANALG, V77, P477; McClure JH, 1996, BRIT J ANAESTH, V76, P300, DOI 10.1093/bja/76.2.300; MCCOY EP, 1993, ANAESTHESIA, V48, P516, DOI 10.1111/j.1365-2044.1993.tb07075.x; Mirakhur RK, 1998, ANAESTHESIA, V53, P1, DOI 10.1111/j.1365-2044.1998.53s170.x; Morton CPJ, 1997, BRIT J ANAESTH, V79, P3, DOI 10.1093/bja/79.1.3; Paris ST, 1997, BRIT J ANAESTH, V79, P280, DOI 10.1093/bja/79.3.280; PATEL SS, 1995, DRUGS, V50, P742, DOI 10.2165/00003495-199550040-00010; Petersen-Felix S, 1998, BRIT J ANAESTH, V81, P742, DOI 10.1093/bja/81.5.742; ROSENBERG PH, 1983, ANESTHESIOLOGY, V58, P95, DOI 10.1097/00000542-198301000-00014; RUSSELL D, 1995, BRIT J ANAESTH, V75, P562, DOI 10.1093/bja/75.5.562; Shende D, 1997, ANAESTHESIA, V52, P496, DOI 10.1111/j.1365-2044.1997.101-az0098.x; SILK JM, 1991, EUR J ANAESTH, P47; Smith I, 1996, BRIT J ANAESTH, V76, P435, DOI 10.1093/bja/76.3.435; Thompson JP, 1996, BRIT J ANAESTH, V76, P341, DOI 10.1093/bja/76.3.341; Tuckey JP, 1996, ANAESTHESIA, V51, P71, DOI 10.1111/j.1365-2044.1996.tb07658.x; ZWASS MS, 1992, ANESTHESIOLOGY, V76, P373, DOI 10.1097/00000542-199203000-00009	41	7	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	1999	319	7209					557	560		10.1136/bmj.319.7209.557	http://dx.doi.org/10.1136/bmj.319.7209.557			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463900	Green Published			2023-01-03	WOS:000082347200029
J	Miyata, T; Asami, N; Uragami, T				Miyata, T; Asami, N; Uragami, T			A reversibly antigen-responsive hydrogel	NATURE			English	Article							PHASE-TRANSITIONS; POLYMER GEL; RELEASE; GLUCOSE; COLLAPSE; PH	Stimuli-responsive hydrogels that undergo abrupt changes in volume in response to external stimuli such as pH, temperature and solvent composition have potential applications in biomedicine and the creation of 'intelligent' materials systems, for example as media for drug delivery, separation processes and protein immobilization. Hydrogels have been reported that respond to pH(1-3), temperature(4-13), electric fields(14-16) and saccharides(17-22). For some biomedical applications it would be very useful to have a material whose swelling response was dictated by a specific protein. Here we report such a material, which swells reversibly in a buffer solution in response to a specific antigen. The hydrogel was prepared by grafting the antigen and corresponding antibody to the polymer network, so that binding between the two introduces crosslinks in the network. Competitive binding of the free antigen triggers a change in gel volume owing to breaking of these non-covalent crosslinks. In addition, we show that the hydrogel displays shape-memory behaviour, and that stepwise changes in antigen concentration can induce pulsatile permeation of a protein through the network.	Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Osaka 5648680, Japan	Kansai University; Kansai University	Miyata, T (corresponding author), Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan.							AOKI T, 1994, MACROMOLECULES, V27, P947, DOI 10.1021/ma00082a010; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; FEIL H, 1991, J MEMBRANE SCI, V64, P283, DOI 10.1016/0376-7388(91)80099-R; Flory P.J., 1953, PRINCIPLES POLYM CHE; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; Kataoka K, 1998, J AM CHEM SOC, V120, P12694, DOI 10.1021/ja982975d; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Lee SJ, 1996, J MOL RECOGNIT, V9, P549, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<549::AID-JMR299>3.0.CO;2-C; Miyata T, 1996, MACROMOL CHEM PHYSIC, V197, P1135, DOI 10.1002/macp.1996.021970330; MIYATA T, 1994, MACROMOL CHEM PHYSIC, V195, P1111, DOI 10.1002/macp.1994.021950401; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; NATSUME T, 1994, J BIOL CHEM, V269, P31224; OBIDAT AA, 1996, PHARMACEUT RES, V13, P989; OBIDAT AA, 1997, BIOMATERIALS, V18, P801; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; SHOEMAKER SG, 1987, APPL BIOCHEM BIOTECH, V15, P11, DOI 10.1007/BF02798503; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1980, PHYS REV LETT, V45, P1636, DOI 10.1103/PhysRevLett.45.1636; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	26	935	972	14	676	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					766	769		10.1038/21619	http://dx.doi.org/10.1038/21619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391240				2023-01-03	WOS:000081101600049
J	Forster, A; Young, J; Langhorne, P				Forster, A; Young, J; Langhorne, P		Day Hosp Grp	Systematic review of day hospital care for elderly people	BRITISH MEDICAL JOURNAL			English	Review							COMPREHENSIVE GERIATRIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; LONG-TERM CARE; STROKE PATIENTS; COST-EFFECTIVENESS; REHABILITATION; DOMICILIARY; METAANALYSIS; OUTCOMES; HOME	Objective To examine the effectiveness of day hospital attendance in prolonging independent living for elderly people. Design Systematic review of 12 controlled clinical trials (available by January 1997) comparing day hospital care with comprehensive care (five trials), domiciliary care (four trials), or no comprehensive care (three trials). Subjects 2867 elderly people. Main outcome measures Death, institutionalisation, disability, global "poor outcome," and use of resources. Results Overall, there was no significant difference between day hospitals and alternative services for death, disability, or use of resources. However, compared with subjects receiving no comprehensive care, patients attending day hospitals had a lower odds of death or "poor" outcome (0.72, 95% confidence interval 0.53 to 0.99; P < 0.05) and functional deterioration (0.61, 0.38 to 0.97; P < 0.05). The day hospital group showed trends towards reductions in hospital bed use and placement in institutional care. Eight trials reported treatment costs, six of which reported that day hospital attendance was more expensive than other care, although only two analyses took into account cost of long term care. Conclusions Day hospital care seems to be an effective service for elderly people who need rehabilitation but may have no clear advantage over other comprehensive care. Methodological problems limit these conclusions, and further randomised trials are justifiable.	St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England; Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Forster, A (corresponding author), St Lukes Hosp, Dept Hlth Care Elderly, Bradford BD5 0NA, W Yorkshire, England.			young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				BURCH S, IN PRESS CLIN REHAB; CUMMINGS V, 1985, ARCH PHYS MED REHAB, V66, P86; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DONALDSON C, 1987, COMMUNITY MED, V9, P55; EAGLE DJ, 1991, CAN MED ASSOC J, V144, P699; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GLADMAN J, 1994, AGE AGEING, V23, P241, DOI 10.1093/ageing/23.3.241; GLADMAN JRF, 1993, J NEUROL NEUROSUR PS, V56, P960, DOI 10.1136/jnnp.56.9.960; HEDRICK SC, 1993, MED CARE, V31, pSS1; HUI E, 1995, STROKE, V26, P1616, DOI 10.1161/01.STR.26.9.1616; *NAT AUD OFF, 1994, NAT HLTH SERV DAY HO; PARKER SG, 1994, J ROY COLL PHYS LOND, V28, P428; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PITKALA K, 1991, ARCH GERONTOL GERI S, V2, P51; *RES UN ROYAL COLL, 1994, GER HOSP THEIR ROL G; SHERWOOD S, 1986, AM J PUBLIC HEALTH, V76, P38, DOI 10.2105/AJPH.76.1.38; SIU AL, 1994, J AM GERIATR SOC, V42, P1094, DOI 10.1111/j.1532-5415.1994.tb06215.x; SKELLIE FA, 1982, AM J PUBLIC HEALTH, V72, P353, DOI 10.2105/AJPH.72.4.353; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; TUCKER MA, 1984, BRIT MED J, V289, P1209, DOI 10.1136/bmj.289.6453.1209; Vetter N, 1989, DAY HOSP PILOT STUDY; WEILER PG, 1976, MED CARE, V14, P700, DOI 10.1097/00005650-197608000-00007; WEISSERT W, 1980, MED CARE, V18, P567, DOI 10.1097/00005650-198006000-00001; WOODFORDWILLIAM.E, 1962, GERONTOL CLIN, V4, P241, DOI 10.1159/000244750; YOUNG J, 1993, J ROY COLL PHYS LOND, V27, P252; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	26	59	62	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1999	318	7187					837	+		10.1136/bmj.318.7187.837	http://dx.doi.org/10.1136/bmj.318.7187.837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185DM	10092260	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000079652900023
J	Cash, J; Boyd, K				Cash, J; Boyd, K			Blood transfusion: Bayer's initiative	LANCET			English	Editorial Material									Univ Edinburgh, Royal Infirm, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Cash, J (corresponding author), Otterburn Pk, Edinburgh EH14 1JX, Midlothian, Scotland.							AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; ALTER HJ, 1988, VIRAL HEPATITIS LIVE, P537; Busch M P, 1994, Curr Opin Hematol, V1, P438; *DAN COUNC ETH, 1998, 1977 ANN REP; *NUFF COUNC BIOETH, 1998, MENT DIS ETH ETH CON	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 27	1999	353	9154					691	692		10.1016/S0140-6736(98)90048-4	http://dx.doi.org/10.1016/S0140-6736(98)90048-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073509				2023-01-03	WOS:000078966400007
J	Turrisi, AT; Kim, K; Blum, R; Sause, WT; Livingston, RB; Komaki, R; Wagner, H; Aisner, S; Johnson, DH				Turrisi, AT; Kim, K; Blum, R; Sause, WT; Livingston, RB; Komaki, R; Wagner, H; Aisner, S; Johnson, DH			Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHWEST-ONCOLOGY-GROUP; RANDOMIZED TRIAL; RADIATION-THERAPY; CHEMOTHERAPY; CARCINOMA; IRRADIATION; SURVIVAL; DISEASE	Background For small-cell lung cancer confined to one hemithorax (limited small-cell lung cancer), thoracic radiotherapy improves survival, but the best ways of integrating chemotherapy and thoracic radiotherapy remain unsettled. Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy. Methods We studied 417 patients with limited small-cell lung cancer. All the patients received four 21-day cycles of cisplatin plus etoposide. We randomly assigned these patients to receive a total of 45 Gy of concurrent thoracic radiotherapy, given either twice daily over a three-week period or once daily over a period of five weeks. Results Twice-daily treatment beginning with the first cycle of chemotherapy significantly improved survival as compared with concurrent once-daily radiotherapy (P = 0.04 by the log-rank test). After a median follow-up of almost 8 years, the median survival was 19 months for the once-daily group and 23 months for the twice-daily group. The survival rates for patients receiving once-daily radiotherapy were 41 percent at two years and 16 percent at five years. For patients receiving twice-daily radiotherapy, the survival rates were 47 percent at two years and 26 percent at five years. Grade 3 esophagitis was significantly more frequent with twice-daily thoracic radiotherapy, occurring in 27 percent of patients, as compared with 11 percent in the once-daily group (P < 0.001). Conclusions Four cycles of cisplatin plus etoposide and a course of radiotherapy (45 Gy, given either once or twice daily) beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year survival rates of 44 percent and 23 percent, a considerable improvement in survival rates over previous results in patients with limited small-cell lung cancer. (N Engl J Med 1999;340:265-71.) (C) 1999, Massachusetts Medical Society.	Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA; Univ Wisconsin, Madison, WI USA; St Vincents Med Ctr, New York, NY USA; LDS Hosp, Salt Lake City, UT USA; Univ Washington, Seattle, WA 98195 USA; MD Anderson Canc Ctr, Houston, TX USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Vanderbilt Univ, Nashville, TN USA	Medical University of South Carolina; University of Wisconsin System; University of Wisconsin Madison; Saint Vincents Hospital Manhattan; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Rutgers State University New Brunswick; Rutgers State University Medical Center; Vanderbilt University	Turrisi, AT (corresponding author), Med Univ S Carolina, Dept Radiat Oncol, 171 Ashley Ave, Charleston, SC 29425 USA.	turrisi@radonc.muse.edu	Johnson, David H./A-7437-2009		NATIONAL CANCER INSTITUTE [U10CA032102, U10CA023318, U10CA020319] Funding Source: NIH RePORTER; NCI NIH HHS [CA20319, CA23318, CA32102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIAGADA R, 1993, NEW ENGL J MED, V329, P1848, DOI 10.1056/NEJM199312163292504; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BUNN PA, 1987, ANN INTERN MED, V106, P655, DOI 10.7326/0003-4819-106-5-655; BUNN PA, 1995, J CLIN ONCOL, V13, P1632, DOI 10.1200/JCO.1995.13.7.1632; BUNN PA, 1995, J CLIN ONCOL, V13, P2860; CARNEY DN, 1983, CANCER RES, V43, P2806; Choi NC, 1998, J CLIN ONCOL, V16, P3528, DOI 10.1200/JCO.1998.16.11.3528; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1989, ANAL BINARY DATA, V2nd; FRYTAK S, 1991, LUNG CANCER S, V7, P157; GRECO FA, 1976, ANN INTERN MED, V85, P294, DOI 10.7326/0003-4819-85-3-294; Gregor A, 1997, J CLIN ONCOL, V15, P2840, DOI 10.1200/JCO.1997.15.8.2840; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; JOHNSON BE, 1991, P AN M AM SOC CLIN, V10, P240; JOHNSON DH, 1993, J CLIN ONCOL, V11, P879, DOI 10.1200/JCO.1993.11.5.879; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOMAKI R, 1985, AM J CLIN ONCOL-CANC, V8, P523, DOI 10.1097/00000421-198512000-00013; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LEBEAU B, 1996, P AN M AM SOC CLIN, V15, P383; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCCRACKEN JD, 1990, J CLIN ONCOL, V8, P892, DOI 10.1200/JCO.1990.8.5.892; MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336; NATALE RB, 1982, CANCER TREAT REV, V9, P91, DOI 10.1016/S0305-7372(82)80085-6; *NCI, 1998, COMM TOX CRIT; PAPAC RJ, 1987, INT J RADIAT ONCOL, V13, P993; PAPAC RJ, 1988, INT J RADIAT ONCOL, V14, P213; PEREZ CA, 1984, J CLIN ONCOL, V2, P1200, DOI 10.1200/JCO.1984.2.11.1200; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; SHANK B, 1985, CANCER-AM CANCER SOC, V56, P2771, DOI 10.1002/1097-0142(19851215)56:12<2771::AID-CNCR2820561209>3.0.CO;2-A; SIEROCKI JS, 1979, CANCER TREAT REP, V63, P1593; TAKADA M, 1996, P AN M AM SOC CLIN, V15, P372; Turrisi AT, 1987, P AN M AM SOC CLIN, V6, P172; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	34	1017	1054	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1999	340	4					265	271		10.1056/NEJM199901283400403	http://dx.doi.org/10.1056/NEJM199901283400403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161YU	9920950	Bronze			2023-01-03	WOS:000078318700003
J	Sugarman, J; Burk, L				Sugarman, J; Burk, L			Physicians' ethical obligations regarding alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; Duke Univ, Dept Philosophy, Durham, NC USA; Duke Univ, Dept Radiol, Durham, NC 27710 USA; Duke Univ, Off Integrat Med Educ, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University	Sugarman, J (corresponding author), Duke Univ, Med Ctr, Div Gen Internal Med, Box 3040, Durham, NC 27710 USA.			Sugarman, Jeremy/0000-0001-7022-8332				Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Barrett S, 1998, BIOMED ETH, P1; BRATMAN S, 1997, ALTERN THER, V3, P127; CALLAHAN D, 1996, HASTINGS CENT RE NOV, P9; CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Daly D, 1997, J Altern Complement Med, V3, P405, DOI 10.1089/acm.1997.3.405; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 1996, J MED ETHICS, V22, P197, DOI 10.1136/jme.22.4.197; Halperin E C, 1998, N C Med J, V59, P21; Hufford, 1995, Altern Ther Health Med, V1, P94; Hufford D J, 1997, Altern Ther Health Med, V3, P78; JENIKE MA, 1994, J GERIATR PSYCHIA S1, V7, P1; Kahn J. P., 1998, CONSENT SEEKING JUST; KOTTOW MH, 1992, J MED ETHICS, V18, P18, DOI 10.1136/jme.18.1.18; LYNOE N, 1992, SCAND J SOC MED, V20, P217, DOI 10.1177/140349489202000406; MACK RB, 1998, NC MED J, V59, P24; Macklin R, 1998, KENNEDY INST ETHIC J, V8, P1, DOI 10.1353/ken.1998.0005; Milan FB, 1998, J GEN INTERN MED, V13, P562, DOI 10.1046/j.1525-1497.1998.00168.x; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; VONBEHREN D, 1997, ARIZONA HLTH HORIZON, P16; *WORKSH ALT MED, 1995, ALT MED EXP MED HOR	24	37	37	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1623	1625		10.1001/jama.280.18.1623	http://dx.doi.org/10.1001/jama.280.18.1623			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820269				2023-01-03	WOS:000076852000035
J	Meng, ID; Manning, BH; Martin, WJ; Fields, HL				Meng, ID; Manning, BH; Martin, WJ; Fields, HL			An analgesia circuit activated by cannabinoids	NATURE			English	Article							ROSTRAL VENTROMEDIAL MEDULLA; RECEPTOR; BRAIN; PAIN; NEURONS; DELTA-9-TETRAHYDROCANNABINOL; ANTINOCICEPTION; MORPHINE; AGONIST	Although many anecdotal reports indicate that marijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sensation(1,2), studies of humans have produced inconsistent results(3-6). In animal studies, the apparent pain-suppressing effects of delta-9-THC and other cannabinoid drugs(7-12) are confounded by motor deficits(13,14). Here we show that a brainstem circuit that contributes to the pain-suppressing effects of morphine(15) is also required for the analgesic effects of cannabinoids. Inactivation of the rostral ventromedial medulla (RVM) prevents the analgesia but not the motor deficits produced by systemically administered cannabinoids, Furthermore, cannabinoids produce analgesia by modulating RVM neuronal activity in a manner similar to, but pharmacologically dissociable from, that of morphine. We also show that endogenous cannabinoids tonically regulate pain thresholds in part through the modulation of RVM neuronal activity. These results show that analgesia produced by cannabinoids and opioids involves similar brainstem circuitry and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Meng, ID (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Manning, Barton/AAD-2340-2021; Fields, Howard/ABG-9073-2020; Martin, William J/L-9033-2017	Martin, William J/0000-0002-2749-3365				BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BUXBAUM D, 1969, FED PROC, V28, P735; Cadas H, 1997, J NEUROSCI, V17, P1226; CLARK WC, 1981, J CLIN PHARM S, V21, P299; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dunn M, 1974, Paraplegia, V12, P175; FIELDS HL, 1983, NATURE, V306, P684, DOI 10.1038/306684a0; FIELDS HL, 1995, J NEUROPHYSIOL, V74, P1742, DOI 10.1152/jn.1995.74.4.1742; GOUGH AL, 1977, PSYCHOPHARMACOLOGY, V54, P87, DOI 10.1007/BF00426547; HEINRICHER MM, 1992, NEUROSCIENCE, V48, P533, DOI 10.1016/0306-4522(92)90400-V; Herzberg U, 1997, NEUROSCI LETT, V221, P157, DOI 10.1016/S0304-3940(96)13308-5; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; LIBMAN E, 1985, PERS INDIV DIFFER, V6, P169, DOI 10.1016/0191-8869(85)90106-0; LICHTMAN AH, 1991, BRAIN RES, V559, P309, DOI 10.1016/0006-8993(91)90017-P; Martin WJ, 1996, J NEUROSCI, V16, P6601; Martin WJ, 1998, NEUROSCI LETT, V242, P33, DOI 10.1016/S0304-3940(98)00044-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mikuriya Tod H, 1973, MARIJUANA MED PAPERS; Mitchell JM, 1998, NEUROSCIENCE, V87, P123, DOI 10.1016/S0306-4522(98)00119-5; MOSS DE, 1980, EUR J PHARMACOL, V61, P313, DOI 10.1016/0014-2999(80)90134-X; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; Pan ZZ, 1996, NEUROSCIENCE, V74, P855, DOI 10.1016/0306-4522(96)00179-0; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; RICHARDSON JD, 1998, J NEUROSCI, V518; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Roychowdhury SM, 1996, NEUROSCIENCE, V74, P863, DOI 10.1016/0306-4522(96)00180-7; SOFIA RD, 1973, J PHARMACOL EXP THER, V186, P646; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; UEKI S, 1980, TRENDS PHARMACOL SCI, V1, P126	31	298	305	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					381	383		10.1038/26481	http://dx.doi.org/10.1038/26481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759727				2023-01-03	WOS:000076083800053
J	Wernerman, J				Wernerman, J			Documentation of clinical benefit of specific aminoacid nutrients	LANCET			English	Editorial Material							SUPPLEMENTED PARENTERAL-NUTRITION; BONE-MARROW TRANSPLANTATION; IMMUNE-ENHANCING DIET; DOUBLE-BLIND; GLUTAMINE; TRIAL		Huddinge Univ Hosp, Dept Anaesthesiol & Intens Care, S-14186 Huddinge, Sweden	Karolinska Institutet	Wernerman, J (corresponding author), Huddinge Univ Hosp, Dept Anaesthesiol & Intens Care, S-14186 Huddinge, Sweden.							BOWER RH, 1995, CRIT CARE MED, V23, P436, DOI 10.1097/00003246-199503000-00006; CALDER PC, 1994, CLIN NUTR, V13, P2, DOI 10.1016/0261-5614(94)90003-5; DESMET SS, 1994, INTENS CARE MED, V20, P298; DUNHAM M, 1997, SHOCK S1, V7, P147; Griffiths RD, 1997, NUTRITION, V13, P295; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; LARSSON J, 1990, BRIT J SURG, V77, P413, DOI 10.1002/bjs.1800770418; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; Roth E, 1982, Clin Nutr, V1, P25, DOI 10.1016/0261-5614(82)90004-8; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; Tucker HN, 1996, NUTR REV, V54, P111; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	14	1	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					756	757		10.1016/S0140-6736(05)60675-7	http://dx.doi.org/10.1016/S0140-6736(05)60675-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737276				2023-01-03	WOS:000075762700005
J	Emanuel, EJ; Daniels, ER; Fairclough, DL; Clarridge, BR				Emanuel, EJ; Daniels, ER; Fairclough, DL; Clarridge, BR			The practice of euthanasia and physician-assisted suicide in the United States - Adherence to proposed safeguards and effects on physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACTIVE EUTHANASIA; WASHINGTON-STATE; CANCER-PATIENTS; ATTITUDES; NETHERLANDS; LIFE; END; EXPERIENCES; PREVALENCE; DECISIONS	Context.-Despite intense debates about legalization, there are few data examining the details of actual euthanasia and physician-assisted suicide (PAS) cases in the United States. Objective.-To determine whether the practices of euthanasia and PAS are consistent with proposed safeguards and the effect on physicians of having performed euthanasia or PAS. Design.-Structured in-depth telephone interviews. Setting and Participants.-Randomly selected oncologists;in the United States. Outcome Measures.-Adherence to primary and secondary safeguards for the practice of euthanasia and PAS; regret, comfort, and fear of prosecution from performing euthanasia or PAS. Results.-A total of 355 oncologists (72.6% response rate) were interviewed on euthanasia and PAS. On 2 screening questions, 56 oncologists (15.8%) reported participating in euthanasia or PAS; 53 oncologists (94.6% response rate) participated in in-depth interviews. Thirty-eight of 53 oncologists described clearly defined cases of euthanasia or PAS. Twenty-three patients (60.5%) both initiated and repeated their request for euthanasia or PAS, but 6 patients (15.8%) did not participate in the decision for euthanasia or PAS. Thirty-seven patients (97.4%) were experiencing unremitting pain or such poor physical functioning they could not perform self-care. Physicians sought consultation in 15 cases (39.5%), Overall, oncologists adhered to all 3 main safeguards in 13 cases (34.2%), (1) having the patient initiate and repeat the request for euthanasia or PAS, (2) ensuring the patient was experiencing extreme physical pain or suffering, and (3) consulting with a colleague. Those who adhered to the safeguards had known their patients longer and tended to be more religious. In 28 cases (73.7%), the family supported the decision. In all cases of pain, patients were receiving narcotic analgesia. Fifteen patients (39.5%) were enrolled in a hospice, While 19 oncologists (52.6%) received comfort from having helped a patient with euthanasia or PAS, 9 (23.7%) regretted having performed euthanasia or PAS, and 15(39.5%) feared prosecution. Conclusions.-Intractable pain or poor physical functioning seem to be nearly absolute requirements for physicians to perform euthanasia or PAS. Only one third of cases are performed consistently with proposed safeguards. For some patients, end-of-life care that includes opioid analgesia and hospice care does not obviate their desire for euthanasia or PAS. While the majority of physicians seem comforted by their actions, some experience adverse consequences from having performed euthanasia or PAS.	Dana Farber Canc Inst, Div Canc Prevent & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Amer Med Ctr, Ctr Canc Res, Ctr Res Methodol & Biometr, Denver, CO USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Boston	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Prevent & Control, Ctr Outcomes & Policy Res, 44 Biney St, Boston, MA 02115 USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1993, J FAM PRACTICE, V37, P123; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DEROGATIS LR, 1983, JAMA-J AM MED ASSOC, V249, P751, DOI 10.1001/jama.249.6.751; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 1996, ARCH INTERN MED, V156, P825, DOI 10.1001/archinte.156.8.825; Emanuel Ezekiel, 1997, Atl Mon, V279, P73; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GEVERS JKM, 1992, J MED ETHICS, V18, P138, DOI 10.1136/jme.18.3.138; KINSELLA TD, 1993, CAN MED ASSOC J, V148, P1921; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MANDERMAAS PJ, 1991, LANCET, V388, P669; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1998, DEATH DIGNITY MAKING; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	33	100	101	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					507	513		10.1001/jama.280.6.507	http://dx.doi.org/10.1001/jama.280.6.507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	108AY	9707132				2023-01-03	WOS:000075244900013
J	Pollock, AM; Vickers, N				Pollock, AM; Vickers, N			Deprivation and emergency admissions for cancers of colorectum, lung, and breast in south east England: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RATES; CONSULTATION; SURVIVAL; SURGERY; IMPACT	Objectives: To examine the relation between deprivation and acute emergency admissions for cancers of the colon, rectum, lung, and breast in south east England. Design: Ecological analysis with data from hospital episode statistics and 1991 census. Setting: North and South Thames Regional Health Authorities (population about 14 million), divided into 10 aggregations of 31 470 census enumeration districts (median population 462). Subjects: 146 639 admissions relating to 76 552 patients aged < 100 years on admission, resident in the Thames regions, admitted between 1 April 1992 and 31 March 1995. Results: Residents living in deprived areas were more likely to be admitted as emergencies and has ordinary inpatient admissions and less likely to be admitted as day cases. Adjusted odds of ordinary admissions from the most deprived tenth occurring as emergencies (relative to admissions from the most affluent tenth) were 2.29 (95% confidence interval 2.09 to 2.52) for colorectal cancer, 2.20 (1.99 to 2.43) for lung cancer, and 2.41 (2.17 to 2.67) for female breast cancer; adjusted odds of admissions as day cases were 0.70 (0.64 to 0.76), 0.50 (0.44 to 0.56), and 0.56 (0.50 to 0.62), respectively. Patients from deprived areas with lung or breast cancers were less likely to be recorded as having surgical interventions. Adjusted odds of patients fi-om the most deprived tenth receiving surgery were 0.88 (0.78 to 1.00), 0.58 (0.48 to 0.70), and 0.63 (0.56 to 0.71), respectively. Admissions for colorectal cancer from the most deprived areas were less likely to be to hospitals admitting 100 or more new patients a year; the opposite held true for breast cancer admissions. No association was found for lung cancer admissions. Conclusions: Earlier diagnostic and referral procedures in primary care in deprived areas are required if there are to be significant reductions in mortality from these cancers. A national information strategy is required to ensure the continued availability of population based data on NHS patients and to mandate standardised datasets from the private sector. Rationalisation of acute services, hospital mergers, and plans for bed closures must take into account the increased healthcare needs and inequities in access to treatment and care of residents in areas with high levels of deprivation Health authorities and primary care groups should re-examine their purchasing intentions, service reviews, and monitoring arrangements in the light of these findings.	St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London	Pollock, AM (corresponding author), UCL, Sch Publ Hlth, London WC1E 7HN, England.			pollock, allyson/0000-0002-7388-3110				BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; CHATURVEDI N, 1995, BRIT J GEN PRACT, V45, P127; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; *EXP ADV GROUP CAN, 1994, POL FRAM COMM CANC S; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GILL L, 1993, J EPIDEMIOL COMMUN H, V47, P316, DOI 10.1136/jech.47.4.316; *GOV STAT SERV, 1993, HOSP EP STAT 1989 19; LAMDEN KH, 1995, J PUBLIC HEALTH MED, V17, P63; *LIANG BUISS, 1996, LIANGS REV PRIV HLTH; MAJEED F, 1995, BRIT MED J, V310, P1674, DOI 10.1136/bmj.310.6995.1674a; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MCCORMICK A, 1994, MORBIDITY STAT GEN P; SCHRIJVERS CTM, 1995, CANCER-AM CANCER SOC, V75, P2946, DOI 10.1002/1097-0142(19950615)75:12<2946::AID-CNCR2820751223>3.0.CO;2-6; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SCHRIJVERS CTM, 1995, EUR J CANCER, V31A, P1660, DOI 10.1016/0959-8049(95)00272-K; SCHRIJVERS CTM, 1995, INT J CANCER, V63, P324, DOI 10.1002/ijc.2910630303; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; Townsend P, 1988, HLTH DEPRIVATION INQ	24	67	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					245	252		10.1136/bmj.317.7153.245	http://dx.doi.org/10.1136/bmj.317.7153.245			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677214	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000075081900021
J	Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P				Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P			Generation of coated intermediates of clathrin-mediated endocytosis on protein-free liposomes	CELL			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; HIGH-AFFINITY BINDING; NERVE-TERMINALS; ALPHA-ADAPTIN; GOLGI STACK; IN-VITRO; DYNAMIN; MEMBRANE; DOMAIN; TRANSPORT	Clathrin-coated buds and dynamin-coated tubules morphologically similar to corresponding structures observed in synaptic membranes can be generated on protein-free liposomes by incubation with cytosol, or with clathrin coat proteins and purified dynamin, respectively. Dynamin- and clathrin-coated intermediates may form independently of each other, despite the coupling between the two processes typically observed in synaptic membranes. Formation of both structures on liposomes can occur in the absence of nucleotides. These findings indicate that interfaces between lipids and cytosolic proteins are fully sufficient to deform lipids bilayers into buds and tubules. They suggest that a main function of membrane proteins is to act as positive and negative regulators of coat assembly, therefore controlling these processes in time and space.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993; Takei, Kohji/0000-0002-6555-9425	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHEN H, 1998, IN PRESS NATURE; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HAMA K, 1977, J NEUROCYTOL, V6, P361, DOI 10.1007/BF01178223; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HEUSER J, 1971, PROC R SOC SER B-BIO, V179, P247, DOI 10.1098/rspb.1971.0096; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LOVAS B, 1971, Z ZELLFORSCH MIK ANA, V121, P341, DOI 10.1007/BF00337638; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MORRIS MB, 1992, J CELL BIOCHEM, V48, P356, DOI 10.1002/jcb.240480404; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RAPAPORT I, 1997, EMBO J, V16, P2240; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617; YE W, 1991, J BIOL CHEM, V266, P4442; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	60	279	283	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					131	141		10.1016/S0092-8674(00)81228-3	http://dx.doi.org/10.1016/S0092-8674(00)81228-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674434	hybrid			2023-01-03	WOS:000074790800016
J	Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH				Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH			Congruence between decisions to initiate chiropractic spinal manipulation for low back pain and appropriateness criteria in North America	ANNALS OF INTERNAL MEDICINE			English	Article						low back pain; spine; chiropractic; manipulation, orthopedic; quality of health care	RANDOMIZED CLINICAL-TRIAL; NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CORONARY-ANGIOGRAPHY; NECK COMPLAINTS; MANUAL THERAPY; CAROTID ENDARTERECTOMY; OUTCOME MEASURES; PERSISTENT BACK; FOLLOW-UP	Background: Recent U.S. practice guidelines recommend spinal manipulation for some patients with low back pain. If followed, these guidelines are likely to increase the number of persons referred for chiropractic care. Concerns have been raised about the appropriate use of chiropractic care, but systematic data are lacking. Objective: To determine the appropriateness of chiropractors' decisions to use spinal manipulation for patients with low back pain. Design: Retrospective review of chiropractic office records against preset criteria for appropriateness that were developed from a systematic review of the literature and a nine-member panel of chiropractic and medical specialists. Appropriateness criteria reflect the expected balance between risk and benefit. Setting: 131 of 185 (71%) chiropractic offices randomly sampled from sites in the United States and Canada. Patients: 10 randomly selected records of patients presenting with low back pain from each office (1310 patients total). Measurements: Sociodemographic data on patients and chiropractors; use of health care services by patients; assessment of the decision to initiate spinal manipulation as appropriate, uncertain, or inappropriate. Results: Of the 1310 patients who sought chiropractic care for low back pain, 1088 (83%) had spinal manipulation. For 859 of these patients (79%), records contained data sufficient to determine whether care was congruent with appropriateness criteria. Care was classified as appropriate in 46% of cases, uncertain in 25% of cases, and inappropriate in 29% of cases. Patients who did not undergo spinal manipulation were less likely to have a presentation judged appropriate and were more likely to have a presentation judged inappropriate than were patients who did undergo spinal manipulation (P = 0.01). Conclusions: The proportion of chiropractic spinal manipulation judged to be congruent with appropriateness criteria is similar to proportions previously described for medical procedures; thus, the findings provide some reassurance about the appropriate application of chiropractic care. However, more than one quarter of patients were treated for indications that were judged inappropriate. The number of inappropriate decisions to use chiropractic spinal manipulation should be decreased.	Rand Corp, Santa Monica, CA 90401 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Los Angeles Coll Chiropract, Whittier, CA 90609 USA; Canadian Mem Chiropract Coll, Toronto, ON M4G 3E6, Canada	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shekelle, PG (corresponding author), Rand Corp, 1700 Main St,POB 2138, Santa Monica, CA 90401 USA.		Mior, Silvano A/L-4786-2015	Mior, Silvano A/0000-0001-6575-2797				BALLANTINE HT, 1972, NEW ENGL J MED, V286, P237, DOI 10.1056/NEJM197202032860504; BENGTSON A, 1994, JAMA-J AM MED ASSOC, V271, P1260, DOI 10.1001/jama.271.16.1260; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BIGOS SJ, 1992, AHCPR PUBLICATION; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BROOK RH, 1993, SCHWEIZ MED WSCHR, V123, P249; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1989, APPROPRIATENESS USE; CURTIS P, 1992, J FAM PRACTICE, V35, P551; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; FELLEGI IP, 1980, J AM STAT ASSOC, V75, P261, DOI 10.2307/2287444; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; Hurwitz EL, 1998, AM J PUBLIC HEALTH, V88, P771, DOI 10.2105/AJPH.88.5.771; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KAHN KL, 1988, J CLIN EPIDEMIOL, V41, P115, DOI 10.1016/0895-4356(88)90085-6; Kahn KL., 1992, EFFECTS DRG BASED PR, pxxiv 343; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOSECOFF J, 1987, MED CARE, V25, P196, DOI 10.1097/00005650-198703000-00003; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; Leape LL, 1996, ANN INTERN MED, V125, P8, DOI 10.7326/0003-4819-125-1-199607010-00003; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SHEKELLE PG, 1995, J MANIP PHYSIOL THER, V18, P265; SHEKELLE PG, 1991, APPROPRIATE USE SPIN; SHEKELLE PG, 1994, USE COSTS CHIROPRACT; SHEKELLE PG, IN PRESS INT J TECH; THOMAS DR, 1987, J AM STAT ASSOC, V82, P630, DOI 10.2307/2289475; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080	50	37	37	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					9	+		10.7326/0003-4819-129-1-199807010-00003	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653012				2023-01-03	WOS:000074513300002
J	Davidson, WS; Jonas, A; Clayton, DF; George, JM				Davidson, WS; Jonas, A; Clayton, DF; George, JM			Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHIPATHIC HELICAL PEPTIDES; CENTRAL-NERVOUS-SYSTEM; AMINO-ACID-SEQUENCE; APOLIPOPROTEIN A-I; CIRCULAR-DICHROISM; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SYNAPTIC VESICLES; BETA COMPONENT; BRAIN	alpha-Synuclein is a highly conserved presynaptic protein of unknown function. A mutation in the protein has been causally linked to Parkinson's disease in humans, and the normal protein is an abundant component of the intraneuronal inclusions (Lewy bodies) characteristic of the disease. alpha-Synuclein is also the precursor to an intrinsic component of extracellular plaques in Alzheimer's disease. The alpha-synuclein sequence is largely composed of degenerate 11-residue repeats reminiscent of the amphipathic alpha-helical domains of the exchangeable apolipoproteins. We hypothesized that alpha-synuclein should associate with phospholipid bilayers and that this lipid association should stabilize an alpha-helical secondary structure in the protein. We report that alpha-synuclein binds to small unilamellar phospholipid vesicles containing acidic phospholipids, but not to vesicles with a net neutral charge. We further show that the protein associates preferentially with vesicles of smaller diameter (20-25 nm) as opposed to larger (similar to 125 nm) vesicles. Lipid binding is accompanied by an increase in alpha-helicity from 3% to approximately 80%. These observations are consistent with a role in vesicle function at the presynaptic terminal.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	George, JM (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin, Urbana, IL 61801 USA.	j-george@uiuc.edu	George, Julia M/B-2169-2008; Clayton, David/B-2190-2008	George, Julia M/0000-0001-6194-6914; Clayton, David/0000-0002-6395-3488; Davidson, William/0000-0003-2756-2989	NATIONAL INSTITUTE ON AGING [R01AG013762] Funding Source: NIH RePORTER; NIA NIH HHS [1R01 AG13762] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRECKENRIDGE WC, 1973, BIOCHIM BIOPHYS ACTA, V320, P681, DOI 10.1016/0304-4165(73)90148-7; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; Hope MJ., 1993, LIPOSOME TECHNOLOGY, V1, P123; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JONAS A, 1989, J BIOL CHEM, V264, P4818; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LEVIN JM, 1988, BIOCHIM BIOPHYS ACTA, V955, P283, DOI 10.1016/0167-4838(88)90206-3; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MICHAELSON DM, 1983, BIOCHEM J, V211, P155, DOI 10.1042/bj2110155; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; NAKAJO S, 1994, MOL BRAIN RES, V27, P81, DOI 10.1016/0169-328X(94)90187-2; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; OKAZAKI H, 1961, J NEUROPATH EXP NEUR, V20, P237, DOI 10.1097/00005072-196104000-00007; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; THOMAS PD, 1988, BIOCHEM J, V254, P155, DOI 10.1042/bj2540155; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005	42	1197	1217	0	132	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 17	1998	273	16					9443	9449		10.1074/jbc.273.16.9443	http://dx.doi.org/10.1074/jbc.273.16.9443			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZH610	9545270	hybrid			2023-01-03	WOS:000073128800016
J	Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR				Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR			Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS CENTER; HEMOLYSIS; ANEMIA	Background Hemodialysis is a common but potentially hazardous procedure. From February 17 to 20, 1996, 116 of 130 patients (89 percent) at a dialysis center (dialysis center A) in Caruaru, Brazil, had visual disturbances, nausea, and vomiting associated with hemodialysis. By March 24, 26 of the patients had died of acute liver failure. Methods A case patient was defined as any patient undergoing dialysis at dialysis center A or Caruaru's other dialysis center (dialysis center B) during February 1996 who had acute liver failure. To determine the risk factors for and the source of the outbreak, we conducted a cohort study of the 130 patients at dialysis center A and the 47 patients at dialysis center B, reviewed the centers' water supplies, and collected water, patients' serum, and postmortem liver tissue for microcystin assays. Results One hundred one patients (all at dialysis center A) met the case definition, and 50 died. Affected patients who died were older than those who survived (median age, 47 vs. 35 years; P<0.001). Furthermore, all 17 patients undergoing dialysis on the Tuesday-, Thursday-, and Saturday-night schedule became ill, and 13 of them (76 percent) died. Both centers received water from a nearby reservoir. However, the water supplied to dialysis center B was treated, filtered, and chlorinated, whereas the water supplied to dialysis center A was not. Microcystins produced by cyanobacteria were detected in water from the reservoir and from dialysis center A and in serum and liver tissue of case patients. Conclusions Water used for hemodialysis can contain toxic materials, and its quality should therefore be carefully monitored. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Atlanta, GA 30333 USA; Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; Secretaria Saude Pernambuco, Recife, PE, Brazil; Hosp Barao Lucena, Recife, PE, Brazil; Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil	Centers for Disease Control & Prevention - USA; University System of Ohio; Wright State University Dayton; Universidade Federal do Rio de Janeiro	Jochimsen, EM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.		de oliveira e azevedo, sandra maria feliciano/G-8362-2015	de oliveira e azevedo, sandra maria feliciano/0000-0002-3046-0652				ALFREY AC, 1972, T AM SOC ART INT ORG, V18, P257; AN JS, 1994, TOXICON, V32, P1495, DOI 10.1016/0041-0101(94)90308-5; ARNOW PM, 1994, ANN INTERN MED, V121, P339, DOI 10.7326/0003-4819-121-5-199409010-00005; *ASS ADV MED INSTR, 1996, AAMI STAND REC PRACT, V3; AZEVEDO SMFO, 1994, J APPL PHYCOL, V6, P261, DOI 10.1007/BF02181936; BURWEN DR, 1995, KIDNEY INT, V48, P469, DOI 10.1038/ki.1995.315; CARMICHAEL WW, 1992, J APPL BACTERIOL, V72, P445, DOI 10.1111/j.1365-2672.1992.tb01858.x; Carmichael WW, 1997, ADV BOT RES, V27, P211; Dean A.G., 1994, EPI INFO VERSION 6 W; EATON JW, 1973, SCIENCE, V181, P463, DOI 10.1126/science.181.4098.463; *FOOD DRUG ADM, 1989, FDA SAF AL SOD AZ CO; FREEMAN RM, 1967, NEW ENGL J MED, V276, P1113, DOI 10.1056/NEJM196705182762003; GORDON SM, 1990, AM J NEPHROL, V10, P123, DOI 10.1159/000168066; GORDON SM, 1990, KIDNEY INT, V37, P110, DOI 10.1038/ki.1990.15; HOY RH, 1981, AM J HOSP PHARM, V38, P1512, DOI 10.1093/ajhp/38.10.1512; LEVIN NW, 1990, CLIN DIALYSIS, P172; MANZLER AD, 1970, ANN INTERN MED, V73, P409, DOI 10.7326/0003-4819-73-3-409; NICKEY WA, 1970, J AMER MED ASSOC, V214, P915, DOI 10.1001/jama.1970.03180050069020; ORRINGER EP, 1976, NEW ENGL J MED, V294, P1416, DOI 10.1056/NEJM197606242942602; PETRIE JJB, 1977, LANCET, V1, P1178; Rao PVL, 1996, TOXICOLOGY, V114, P29, DOI 10.1016/S0300-483X(96)03413-0; SCHREEDER MT, 1983, J CHRON DIS, V36, P581, DOI 10.1016/0021-9681(83)90146-7; Stotts RR, 1997, TOXICON, V35, P455, DOI 10.1016/S0041-0101(96)00120-1; Teixeira M da G, 1993, Bull Pan Am Health Organ, V27, P244; Tipple M A, 1991, ASAIO Trans, V37, P588; VELANDIA M, 1995, LANCET, V345, P1417, DOI 10.1016/S0140-6736(95)92603-8	26	833	890	3	179	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					873	878		10.1056/NEJM199803263381304	http://dx.doi.org/10.1056/NEJM199803263381304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516222				2023-01-03	WOS:000072669800004
J	Gazelle, G				Gazelle, G			The slow code - Should anyone rush to its defense?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; PHYSICIANS ATTITUDES; CARE; FUTILITY; PATIENT		Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Vanguard Medical Associates	Gazelle, G (corresponding author), Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1992, ANN INTERN MED, V117, P947; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FOWLER MDM, 1989, HEART LUNG, V18, P533; GOLDENRING J, 1979, NEW ENGL J MED, V300, P1058; Jonsen A., 1986, CLIN ETHICS PRACTICA; LANDRY FJ, 1992, ARCH INTERN MED, V152, P2305, DOI 10.1001/archinte.152.11.2305; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MULLER JH, 1992, SOC SCI MED, V34, P885, DOI 10.1016/0277-9536(92)90257-Q; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NEHER JO, 1988, J FAM PRACTICE, V27, P429; Nuland S.B., 1994, HOW WE DIE; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SAKLAYEN M, 1995, MEDICINE, V74, P163, DOI 10.1097/00005792-199507000-00001; Schneider A P 2nd, 1993, J Am Board Fam Pract, V6, P91; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZUGER A, 1989, JAMA-J AM MED ASSOC, V262, P2988	25	33	33	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					467	469		10.1056/NEJM199802123380712	http://dx.doi.org/10.1056/NEJM199802123380712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459653				2023-01-03	WOS:000071900100011
J	Lahdensuo, A				Lahdensuo, A			Guided self management of asthma - how to do it	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GENERAL-PRACTICE		Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland	Tampere University; Tampere University Hospital	Lahdensuo, A (corresponding author), Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland.	aarne.lahdensuo@tays.fi						*AM LUNG ASS WORK, 1998, STAND COMPR ASTHM ED; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BLAINEY AD, 1991, HLTH TRENDS, V22, P151; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; GIBSON PG, 1995, CHEST, V107, P1003, DOI 10.1378/chest.107.4.1003; GIBSON PG, 1999, COCHRANE LIB; Holgate ST, 1996, CLIN EXP ALLERGY, V26, P1; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; KLEIGER JH, 1979, J ASTHMA RES, V16, P93, DOI 10.3109/02770907909106618; Lahdensuo A, 1996, BRIT MED J, V312, P748; Liljas B, 1997, PATIENT EDUC COUNS, V32, pS97, DOI 10.1016/S0738-3991(97)00101-8; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; Partridge MR, 1997, PATIENT EDUC COUNS, V32, pS1, DOI 10.1016/S0738-3991(97)00103-1; PARTRIDGE MR, 1993, RES CLIN FORUMS, V15, P65	15	36	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1999	319	7212					759	760		10.1136/bmj.319.7212.759	http://dx.doi.org/10.1136/bmj.319.7212.759			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488007	Green Published			2023-01-03	WOS:000082701500024
J	Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP				Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP			Ethnic differences in use of hormone replacement therapy: community based survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England	St Georges University London; St Georges University London; St Georges University London	Cook, DG (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Cappuccio, Francesco/D-3028-2009; Cappuccio, Francesco Paolo/ABF-1094-2020	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Cook, Derek/0000-0002-9723-5759; Harris, Tess/0000-0002-8671-1553				BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; GRIFFITHS F, 1995, FAM PRACT, V12, P163, DOI 10.1093/fampra/12.2.163; TOBIAS JH, 1994, CLIN SCI, V87, P587, DOI 10.1042/cs0870587	5	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					610	611		10.1136/bmj.319.7210.610	http://dx.doi.org/10.1136/bmj.319.7210.610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473476	Bronze, Green Published			2023-01-03	WOS:000082460300020
J	Connelly, MT; Ferrari, N; Hagen, N; Inui, TS				Connelly, MT; Ferrari, N; Hagen, N; Inui, TS			Patient-identified needs for hormone replacement therapy counseling: A qualitative study	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN	Background: Numerous medical organizations, including the American College of Physicians, have recommended that women be counseled about postmenopausal hormone replacement therapy (HRT). Patients' perspectives on their counseling needs, however, have not been integrated into most counseling guides. Objective: To use patient self-reports to identify needs for HRT counseling. Design: Individual, in-depth patient interviews. Setting: Managed care organization. Patients: 26 women who had received an initial prescription for HRT. Measurements: Qualitative, consensus review of the content of interview transcripts. Results: On average, women reported 15 factors (range, 6 to 24 factors) as critical to their decision-making process. Although most women cited their physician's opinion (96%), reports in the media (81%), and experiences and opinions of friends (77%) as critical to their decisions about HRT, counseling recommendations address none of these concerns. Conclusions: Many women in a managed care organization who accepted a prescription for HRT identified counseling needs that are not included in widely used HRT guidelines.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Hlth Publicat Grp, Boston, MA 02215 USA; Brown & Toland Phys Serv Org, San Francisco, CA 94109 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Connelly, MT (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 203, Boston, MA 02215 USA.				AHRQ HHS [1F32HS00107-01] Funding Source: Medline; BHP HRSA HHS [2T32PE11001-06, 5T32PE11001-07] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		*AM COLL OBST GYN, 1998, AM COLL OBST GYN ED, V247, P1; Barry MJ, 1997, DIS MANAG CLIN OUTCO, V1, P5; Chan ECY, 1998, AM J MED, V105, P266, DOI 10.1016/S0002-9343(98)00257-5; CRABTREE BF, 1992, DOING QUALITATIVE RE, P41; Daley J, 1999, ANN INTERN MED, V130, P602, DOI 10.7326/0003-4819-130-7-199904060-00021; FEASLEY J, 1996, HLTH OUTCOMES OLDER; GRADY D, 1992, ANN INTERN MED, V117, P1038; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; Liao L, 1996, J GEN INTERN MED, V11, P373, DOI 10.1007/BF02600051; LIVINGSTON WW, 1994, J GEN INTERN MED, V9, P385, DOI 10.1007/BF02629518; MANSFIELD PK, 1998, HEALTH CARE WOMEN IN, V18, P55; Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459; O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Saver BG, 1997, AM J PREV MED, V13, P358, DOI 10.1016/S0749-3797(18)30155-7; Seto TB, 1996, J GEN INTERN MED, V11, P197, DOI 10.1007/BF02642475; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P829	18	37	37	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					265	268		10.7326/0003-4819-131-4-199908170-00005	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454947				2023-01-03	WOS:000082012500004
J	Ziouzenkova, O; Asatryan, L; Akmal, M; Tetta, C; Wratten, ML; Loseto-Wich, G; Jurgens, G; Heinecke, J; Sevanian, A				Ziouzenkova, O; Asatryan, L; Akmal, M; Tetta, C; Wratten, ML; Loseto-Wich, G; Jurgens, G; Heinecke, J; Sevanian, A			Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood - Relevance to atherogenesis caused by hemodialysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; ACCELERATED ATHEROSCLEROSIS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; LDL SUBFRACTION; GENERATION; PROTEINS; HYDROPEROXIDES; ERYTHROCYTES; SPECIFICITY	Human blood contains a form of minimally modified low density lipoprotein (LDL), termed LDL-, whose origin remains unknown. Exploring the mechanism of formation, we found that LDL- can be produced in plasma in the absence of oxygen following LDL incubation with oxidized hemoglobin species. A high degree of apolipoprotein B100 modification results from covalent association of hemoglobin with LDL involving dityrosine formation but not due to the malonaldehyde epitope formation. This was evidenced by the cross-reactivity of oxidized LDL with antibodies against hemoglobin that was accompanied by a 60-fold increase in dityrosine levels. In this study we found significantly higher LDL- levels in the blood of hemodialysis patients, perhaps contributing 60 their greatly increased risk of atherosclerosis. The mechanism of LDL- formation was studied during ex vivo blood circulation using a model system resembling clinical hemodialysis in terms of the induction of inflammatory responses. This circulation increased free hemoglobin and LDL- levels compared with non-circulated blood without appreciable lipid peroxidation, Pronounced increases in LDL- were found also during circulation of plasma supplemented with nanomolar hemoglobin levels. The increase in dityrosine content and presence of heme in LDL after blood circulation suggest that LDL is modified, in part, by hemoglobin-LDL conjugates containing heme, Thus, hemoglobin-mediated reactions leading to LDL oxidation in plasma can account for high LDL- levels in hemodialysis patients.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Div Nephrol, Los Angeles, CA 90033 USA; Bellco SPA, Clin & Lab Res Dept, I-41037 Mirandola, Italy; Washington Univ, Sch Med, St Louis, MO 63110 USA; Karl Franzens Univ Graz, A-8010 Graz, Austria	University of Southern California; University of Southern California; Washington University (WUSTL); University of Graz	Sevanian, A (corresponding author), 1985 Zonal Ave,PSC 612, Los Angeles, CA 90033 USA.	asevan@thevine.net	Ziouzenkova, Ouliana/B-3690-2012; Ziouzenkova, Ouliana/AAM-1971-2020; Jürgens, Günther/B-8818-2011	Ziouzenkova, Ouliana/0000-0003-2449-2591; 	FOGARTY INTERNATIONAL CENTER [F05TW005340] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050350] Funding Source: NIH RePORTER; FIC NIH HHS [1 F05 TW05340-01] Funding Source: Medline; NHLBI NIH HHS [HL50350] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Balagopalakrishna C, 1997, ADV EXP MED BIOL, V411, P337; Banni S, 1996, NEPHRON, V72, P177, DOI 10.1159/000188838; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bonomini M, 1997, NEPHRON, V75, P402, DOI 10.1159/000189577; CAZZOLATO G, 1991, FREE RADICAL BIO MED, V11, P247, DOI 10.1016/0891-5849(91)90120-R; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; DAUL AE, 1994, DEUT MED WOCHENSCHR, V119, P1263, DOI 10.1055/s-2008-1058831; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DELMASBEAUVIEUX MC, 1995, NEPHRON, V69, P404, DOI 10.1159/000188510; Demuth K, 1996, ARTERIOSCL THROM VAS, V16, P773, DOI 10.1161/01.ATV.16.6.773; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FORTIER N, 1988, BLOOD, V71, P1427; GIULIVI C, 1994, METHOD ENZYMOL, V231, P490; Giulivi C, 1998, FREE RADICAL BIO MED, V24, P269, DOI 10.1016/S0891-5849(97)00226-8; Greilberger J, 1997, ARTERIOSCL THROM VAS, V17, P2721, DOI 10.1161/01.ATV.17.11.2721; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HATTORI A, 1978, ARCH HISTOL JAPON, V41, P205, DOI 10.1679/aohc1950.41.205; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HODIS HN, 1994, J LIPID RES, V35, P669; Kim JG, 1997, FREE RADICAL BIO MED, V23, P251, DOI 10.1016/S0891-5849(96)00615-6; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; MAGGI E, 1994, KIDNEY INT, V45, P876, DOI 10.1038/ki.1994.115; MAIORINO M, 1994, FREE RADICAL BIO MED, V16, P661, DOI 10.1016/0891-5849(94)90067-1; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; MARESCA M, 1992, CELL BIOCHEM FUNCT, V10, P79, DOI 10.1002/cbf.290100203; Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a; Miller YI, 1996, ARCH BIOCHEM BIOPHYS, V326, P252, DOI 10.1006/abbi.1996.0073; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PAGANGA G, 1992, FEBS LETT, V303, P154, DOI 10.1016/0014-5793(92)80508-E; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RiceEvans C, 1996, FREE RADICAL RES, V25, P285, DOI 10.3109/10715769609149053; Sevanian A, 1997, J LIPID RES, V38, P419; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; Taccone-Galluci M, 1994, ASAIO J, V40, pM663, DOI 10.1097/00002480-199407000-00081; TETTA C, 1991, NEPHROL DIAL TRANSPL, V6, P24; VANDENBERG JJM, 1992, FREE RADICAL BIO MED, V12, P487, DOI 10.1016/0891-5849(92)90102-M; WINTERBOURN CC, 1985, HDB METHODS OXYGEN R; WONG SHY, 1987, CLIN CHEM, V33, P214; Yang CY, 1997, FREE RADICAL BIO MED, V23, P82, DOI 10.1016/S0891-5849(96)00624-7; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUKAWA S, 1995, NEPHROL DIAL TRANSPL, V10, P1	48	113	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18916	18924		10.1074/jbc.274.27.18916	http://dx.doi.org/10.1074/jbc.274.27.18916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383389	hybrid			2023-01-03	WOS:000081196300012
J	Pecoul, B; Chirac, P; Trouiller, P; Pinel, J				Pecoul, B; Chirac, P; Trouiller, P; Pinel, J			Access to essential drugs in poor countries - A lost battle?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Drugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis, Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs, These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.	Fdn Med Sans Frontieres, F-75011 Paris, France		Pecoul, B (corresponding author), Fdn Med Sans Frontieres, 8 Rue St Sabin, F-75011 Paris, France.	office@paris.msf.org						*CDCP, 1993, MORT DYS AFR FOLL UP; COLLSECK A, 1998, 12 INT C AIDS JUN 28; Correa CM, 1997, URUGUAY ROUND DRUGS; CROFTON J, 1997, WHOTB6210; DOUA F, 1987, AM J TROP MED HYG, V37, P525, DOI 10.4269/ajtmh.1987.37.525; Grabowski H, 1997, PHARMACOECONOMICS, V11, P389, DOI 10.2165/00019053-199711050-00002; *HARV SCH PUBL HLT, 1996, INT STRAT TROP DIS T; *INT FED PHARM MAN, 1997, INT PROP PAT PHARM; KADDAR M, 1995, REV PRECRIRE, V157, P844; LANJOUW JO, 1998, INTRO PHARM PROD PAT; LEGROS D, 1997, 24 INT SCI COUNC TRY; O'Brien KL, 1998, JAMA-J AM MED ASSOC, V279, P1175, DOI 10.1001/jama.279.15.1175; Olliario P, 1997, TROP MED INT HEALTH, V2, P113, DOI 10.1046/j.1365-3156.1997.d01-234.x; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; PAQUET C, 1993, LANCET, V342, P175, DOI 10.1016/0140-6736(93)91378-Y; Paquet C, 1995, Sante, V5, P181; PECOUL B, 1991, LANCET, V338, P862, DOI 10.1016/0140-6736(91)91511-R; PINEL J, 1997, MED MALADIES INFECT, V27, P1; ROZEK RP, 1998, EFF PAT PROT PRIC PH; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; TANDON BN, 1996, EPIDEMIOL INFECT, V117, P313; *TROP DIS RES, 1995, INV ER TROP DIS RES, P9; Trouiller P, 1996, Sante, V6, P299; TROUILLER P, 1998, 8 INT C INF DIS MAY; *UNICEF SUPPL DIV, 1995, ESS DRUGS PRIC LIST; VARAINE F, 1998, 8 INT C INF DIS MAY; Velasquez German, 1998, HLTH EC DRUGS DAP SE, P25; *WHO, 1997, B WKLY EPIDEMIOL REC, V72, P313; WHO, 1996, WHO TECHN REP SER, V863; *WHO, 1996, WHO DRUG INFORMATION, V4, P182; *WHO, 1992, WHODMPCFD92; World Health Organization, 1995, WHO DRUG INF, V9, P127; World Health Organization, 1998, WORLD HLTH STAT ANN	33	217	221	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					361	367		10.1001/jama.281.4.361	http://dx.doi.org/10.1001/jama.281.4.361			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929090				2023-01-03	WOS:000078111300036
J	Shlay, JC; Chaloner, K; Max, MB; Flaws, B; Reichelderfer, P; Wentworth, D; Hillman, S; Brizz, B; Cohn, DL				Shlay, JC; Chaloner, K; Max, MB; Flaws, B; Reichelderfer, P; Wentworth, D; Hillman, S; Brizz, B; Cohn, DL		Terry Beirn Community Programs Clinical Res AID	Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETIC NEUROPATHY; DESIPRAMINE; FLUOXETINE; RAT	Context.-Peripheral neuropathy is common in persons infected with the human immunodeficiency virus (HIV) but few data on symptomatic treatment are available. Objective.-To evaluate the efficacy of a standardized acupuncture regimen (SAR) and amitriptyline hydrochloride for the relief of pain due to HIV-related peripheral neuropathy in HIV-infected patients. Design.-Randomized, placebo-controlled, multicenter clinical trial. Each site enrolled patients into 1 of the following 3 options: (1) a modified double-blind 2 x 2 factorial design of SAR, amitriptyline, or the combination compared with placebo, (2) a modified double-blind design of an SAR vs control points, or (3) a double-blind design of amitriptyline vs placebo. Setting.-Terry Beirn Community Programs for Clinical Research on AIDS (HIV primary care providers) in 10 US cities. Patients.-Patients with HIV-associated, symptomatic, lower-extremity peripheral neuropathy. Of 250 patients enrolled, 239 were in the acupuncture comparison (125 in the factorial option and 114 in the SAR option vs control points option), and 136 patients were in the amitriptyline comparison (125 in the factorial option and 11 in amitriptyline option vs placebo option). Interventions.-Standarized acupuncture regimen vs control points, amitriptyline (75 mg/d) vs placebo, or both for 14 weeks. Main Outcome Measure.-Changes in mean pain scores at 6 and 14 weeks, using a pain scale ranging from 0.0 (no pain) to 1.75 (extremely intense), recorded daily. Results.-Patients in all 4 groups showed reduction in mean pain scores at 6 and 14 weeks compared with baseline values. For both the acupuncture and amitriptyline comparisons, changes in pain score were not significantly different between the 2 groups. At 6 weeks, the estimated difference in pain reduction for patients in the SAR group compared with those in the control points group (a negative value indicates a greater reduction for the "active" treatment) was 0.01 (95% confidence interval [CI], -0.11 to 0.12; P=.88) and for patients in the amitriptyline group vs those in the placebo group was -0.07 (95% CI, -0.22 to 0.08; P = .38). At 14 weeks, the difference for those in the SAR group compared with those in the control points group was -0.08 (95% CI, -0.21 to 0.06; P = .26) and for amitriptyline compared with placebo was 0.00 (95% CI, -0.18 to 0.19; P = .99). Conclusions.-In this study, neither acupuncture nor amitriptyline was more effective than placebo in relieving pain caused by HIV-related peripheral neuropathy.	Denver Community Program Clin Res AIDS, Denver, CO USA; Univ Minnesota, Sch Stat, St Paul, MN 55108 USA; NIAID, NIH, Bethesda, MD 20892 USA; NIDR, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA; Social & Sci Syst Inc, Rockville, MD USA	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Minnesota System; University of Minnesota Twin Cities; Social & Scientific Systems	Shlay, JC (corresponding author), Denver Publ Hlth, 605 Bannock St, Denver, CO 80204 USA.	jshlay@dhha.org	Chaloner, Kathryn/B-5090-2013					Agresti A, 1996, INTRO CATEGORIAL DAT; ARMINGTON K, 1997, AIDS CARE, V9, P52; Birch S, 1996, J Altern Complement Med, V2, P101, DOI 10.1089/acm.1996.2.101; CHAPMAN CR, 1990, MANAGEMEN TPAIN, P1805; DALAKAS M, 1988, ANN NEUROL, V23, pS28; DEYO RA, 1991, ADULT SPINE PRINCIPL, P1777; FAUCI AS, 1998, HARRISONS PRINCIPLES, P1790; GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803; GRACELY RH, 1978, PAIN, V5, P5, DOI 10.1016/0304-3959(78)90020-9; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; HEGARTY A, 1994, SEMIN NEUROL, V14, P213, DOI 10.1055/s-2008-1041080; Jett MF, 1997, PAIN, V69, P161, DOI 10.1016/S0304-3959(96)03231-9; KIEBURTZ Z, 1997, ANN NEUROL, V42, P429; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; LEE PK, 1975, JAMA-J AM MED ASSOC, V232, P1133, DOI 10.1001/jama.232.11.1133; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; Littell R.C., 1996, SAS SYSTEMS MIXED MO; MAX MB, 1994, PROG PAIN RES MANAG, V1, P229; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; MCQUAY HJ, 1993, ANAESTHESIA, V48, P281, DOI 10.1111/j.1365-2044.1993.tb06943.x; Newshan G, 1998, AIDS, V12, P219; NORTON GR, 1984, CAN J BEHAV SCI, V16, P22, DOI 10.1037/h0080774; OBRIEN PC, 1994, BIOMETRICS, V31, P511; OConnor J, 1981, ACUPUNCTURE COMPREHE; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; RICHARDSON PH, 1986, PAIN, V24, P15, DOI 10.1016/0304-3959(86)90023-0; Simpson DM, 1996, NEUROLOGY, V47, P1254, DOI 10.1212/WNL.47.5.1254; SIMPSON DM, 1994, ANN INTERN MED, V121, P769, DOI 10.7326/0003-4819-121-10-199411150-00008; SINDRUP SH, 1990, CLIN PHARMACOL THER, V47, P509, DOI 10.1038/clpt.1990.65; SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945, DOI 10.1001/archneur.1988.00520330023005; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; THOMSON R, 1982, BRIT J PSYCHIAT, V140, P64, DOI 10.1192/bjp.140.1.64; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; Vrethem M, 1997, CLIN J PAIN, V13, P313, DOI 10.1097/00002508-199712000-00009	39	202	213	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1590	1595		10.1001/jama.280.18.1590	http://dx.doi.org/10.1001/jama.280.18.1590			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820261	Bronze			2023-01-03	WOS:000076852000026
J	Wilt, TJ; Ishani, A; Stark, G; MacDonald, R; Lau, J; Mulrow, C				Wilt, TJ; Ishani, A; Stark, G; MacDonald, R; Lau, J; Mulrow, C			Saw palmetto extracts for treatment of benign prostatic hyperplasia - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SERENOA-REPENS; DOUBLE-BLIND; CLINICAL-TRIALS; FINASTERIDE; METAANALYSIS; PHYTOTHERAPY; PLACEBO; PERMIXON(R); HYPERTROPHY; EFFICACY	Objective.-To conduct a systematic review and, where possible, quantitative meta-analysis of the existing evidence regarding the therapeutic efficacy and safety of the saw palmetto plant extract, Serenoa repens, in men with symptomatic benign prostatic hyperplasia (BPH). Data Sources.-Studies were identified through the search of MEDLINE (1966-1997), EMBASE, Phytodok, the Cochrane Library, bibliographies of identified trials and review articles, and contact with relevant authors and drug companies, Study Selection.-Randomized trials were included if participants had symptomatic BPH, the intervention was a preparation of S repens alone or in combination with other phytotherapeutic agents, a control group received placebo or other pharmacological therapies for BPH, and the treatment duration was at least 30 days. Data Extraction.-Two investigators for each article (T.J.W,, A.I., G,S., and R.M.) independently extracted key data on design features, subject characteristics, therapy allocation, and outcomes of the studies. Data Synthesis.-A total of 18 randomized controlled trials involving 2939 men met inclusion criteria and were analyzed, Many studies did not report results in a method that permitted meta-analysis. Treatment allocation concealment was adequate in 9 studies; 16 were double-blinded. The mean study duration was 9 weeks (range, 4-48 weeks). As compared with men receiving placebo, men treated with S repens had decreased urinary tract symptom scores (weighted mean difference [WMD], -1.41 points [scale range, 0-19] [95% confidence interval (CI), -2.52 to -0.30] [n = 1 study]), nocturia (WMD, -0.76 times per evening [95% CI, -1.22 to -0.32] [n = 10 studies]), and improvement in self-rating of urinary tract symptoms; risk ratio for improvement (1.72 [:95% CI, 1.21-2.44] [n = 6 studies]), and peak urine flow (WMD, 1.93 mVs [95% CI, 0.72-3.14] [n = 8 studies]). Compared with men receiving finasteride, men treated with S repens had similar improvements in urinary tract symptom scores (WMD, 0.37 international Prostate Symptom Score points [scale range, 0-35] 1:95% CI, -0.45 to 1.19] [n =2 studiesl) and peak urine flow (WMD, -0.74 mL/s [95% CI, -1.66 to 0.18] [n = 2 studies]). Adverse effects due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride (4.9%) than with S repens (1.1%; P < .001). Withdrawal rates in men assigned to placebo, S repens, or finasteride were 7%, 9%, and 11%, respectively. Conclusions.-The existing literature on S repens for treatment of BPH is limited in terms of the short duration of studies and variability in study design, use of phytotherapeutic preparations, and reports of outcomes. However, the evidence suggests that S repens improves urologic symptoms and flow measures. Compared with finasteride, S repens produces similar improvement in urinary tract symptoms and urinary flow and was associated with fewer adverse treatment events. Further research is needed using standardized preparations of S repens to determine its long-term effectiveness and ability to prevent BPH complications.	Vet Affairs Med Ctr, Dept Vet Affairs, Cochrane Collaborat Review Grp Prostat Dis & Urol, Coordinating Ctr, Minneapolis, MN 55417 USA; Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis Vet Integrated Serv Network 13, Minneapolis, MN USA; New England Med Ctr, Boston, MA 02111 USA; Dept Vet Affairs, Cochrane Ctr, San Antonio, TX USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Tufts Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Wilt, TJ (corresponding author), Vet Affairs Med Ctr, Dept Vet Affairs, Cochrane Collaborat Review Grp Prostat Dis & Urol, Coordinating Ctr, 111-O,1 Vet Dr, Minneapolis, MN 55417 USA.	wilt.timothy@minneapolis.va.gov						Barry MJ, 1997, JAMA-J AM MED ASSOC, V278, P2178; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Boccafoschi C, 1983, UROLOGIA, V50, P1257; Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; BRAECKMAN J, 1997, EUR J CLIN RES, V9, P247; Buck AC, 1996, BRIT J UROL, V78, P325, DOI 10.1046/j.1464-410X.1996.00104.x; CARBIN BE, 1990, BRIT J UROL, V66, P639, DOI 10.1111/j.1464-410X.1990.tb07199.x; Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; CHAMPAULT G, 1984, BRIT J CLIN PHARMACO, V18, P461, DOI 10.1111/j.1365-2125.1984.tb02491.x; Chapple CR, 1996, EUR UROL, V29, P155; CHRISTENSEN MM, 1990, UROL CLIN N AM, V17, P509; COMAR OB, 1986, RIV ITALIANA BIOL ME, V6, P122; CUKIER J, 1985, CR THER PHARM CLIN, V4, P15; DESCOTES JL, 1995, CLIN DRUG INVEST, V9, P291, DOI 10.2165/00044011-199509050-00007; Di Silverio F, 1993, Minerva Urol Nefrol, V45, P143; DICKERSIN K, 1996, BRIT MED J, V12, P944; DISILVERIO F, 1992, EUR UROL, V21, P309; DREIKORN K, 1989, NEW DEV BIOSCIENCES, V5, P109; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Emili E, 1983, UROLOGIA, V50, P1042; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; GABRIC V, 1987, THERAPIEWOCHE, V37, P1775; Grasso Marco, 1995, Archivos Espanoles de Urologia, V48, P97; GUESS HA, 1992, EPIDEMIOL REV, V14, P131, DOI 10.1093/oxfordjournals.epirev.a036083; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAU J, 1996, METAANALYST VERSION; LAVORI PW, 1992, NEUROPSYCHOPHARMACOL, V6, P39; LOBELENZ J, 1992, THERAPEUTIKON, V6, P34; LOWE F, 1998, J UROL S, V159, pA986; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; MANDRESSI S, 1983, UROLOGIA, V50, P752; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P607, DOI 10.1001/jama.273.8.607; Mattei F. M., 1990, TW UROL NEPHROL, V2, P346; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; MCCONNELL JD, CLIN PRACTICE GUIDEL, V8; MCGUIRE E, 1987, NIH PUBLICATION, P221; Metzker H, 1996, UROLOGE B, V36, P292, DOI DOI 10.1007/S001310050033; OESTERLING JE, 1995, NEW ENGL J MED, V332, P99, DOI 10.1056/NEJM199501123320207; PERSICHELLI EP, 1986, UROLOGIA, V53, P696; Roehrborn CG, 1996, UROLOGY, V48, P406, DOI 10.1016/S0090-4295(96)00208-7; Roveda S., 1994, Archivio di Medicina Interna, V46, P61; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEMINO MA, 1992, ARCH ESP UROL, V45, P211; SMITH HR, 1986, BRIT J UROL, V58, P36, DOI 10.1111/j.1464-410X.1986.tb05424.x; Sokeland J, 1997, UROLOGE A, V36, P327, DOI 10.1007/s001200050106; STRAUCH G, 1994, EUR UROL, V26, P247; Tasca A, 1985, Minerva Urol Nefrol, V37, P87; *UPD SOFTW, 1996, REVM COMP PROGR VERS; Wasson JH, 1998, NEW ENGL J MED, V338, P612, DOI 10.1056/NEJM199802263380909; Weisser H, 1997, EUR UROL, V31, P97; 1998, INT MED WORLD REPORT, V13, P8	51	242	251	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1604	1609		10.1001/jama.280.18.1604	http://dx.doi.org/10.1001/jama.280.18.1604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820264				2023-01-03	WOS:000076852000029
J	Turrell, AR; Castleden, CM; Freestone, B				Turrell, AR; Castleden, CM; Freestone, B			Long stay care and the NHS: discontinuities between policy and practice	BRITISH MEDICAL JOURNAL			English	Article							PRIVATE NURSING-HOME; ELDERLY PEOPLE; RESIDENTIAL CARE; HOSPITALS		Univ Sheffield, Trent Inst Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England; Leicester Gen Hosp, Med Elderly Dept, Leicester LE5 4PW, Leics, England; Leicestershire Hlth Author, Leicester LE5 4QF, Leics, England	University of Sheffield; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Turrell, AR (corresponding author), Univ Sheffield, Trent Inst Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England.							ANDREW RA, 1988, J ROY COLL GEN PRACT, V38, P546; Benbow SJ, 1997, BRIT MED J, V314, P1868, DOI 10.1136/bmj.314.7098.1868; BLACK D, 1975, BRIT MED J, V815, P441; *BRIT GER SOC, 1997, MED CAR NURS HOM PAT; CARTWRIGHT A, 1991, AGE AGEING, V20, P271, DOI 10.1093/ageing/20.4.271; *CHART SOC PHYS PR, 1993, PHYSIOTHERAPY, V79, P404; Ferguson B, 1996, EFFECTIVE HLTH CARE, V2, P1; Greaves D, 1997, J MED ETHICS, V23, P77, DOI 10.1136/jme.23.2.77; HARRISON R, 1990, AGE AGEING, V19, P97, DOI 10.1093/ageing/19.2.97; HEPPLE J, 1989, AGE AGEING, V18, P61, DOI 10.1093/ageing/18.1.61; *HLTH COMM, 1996, 591 HC, V1; HUMPHREYS HI, 1986, J ROY COLL GEN PRACT, V36, P500; LIANG W, 1996, LAINGS REV PRIVATE H; Mattimore TJ, 1997, J AM GERIATR SOC, V45, P818, DOI 10.1111/j.1532-5415.1997.tb01508.x; PEET SM, 1995, BRIT MED J, V311, P1063, DOI 10.1136/bmj.311.7012.1063; SNAPE J, 1997, AGE AGEING, V26, P317; STERN MC, 1993, BRIT MED J, V306, P827, DOI 10.1136/bmj.306.6881.827; TAYLOR IC, 1994, ULSTER MED J, V63, P170; TURNER G, 1991, HLTH TRENDS, V22, P158; Victor C R, 1994, Qual Health Care, V3, P210, DOI 10.1136/qshc.3.4.210; WILLIAMS EI, 1992, BRIT J GEN PRACT, V42, P477	21	23	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					942	944						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756820				2023-01-03	WOS:000076409000040
J	Rajagopalan, M				Rajagopalan, M			The escape	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Ballarat Hlth Serv, Ballarat, Vic, Australia		Rajagopalan, M (corresponding author), Ballarat Hlth Serv, Box 577, Ballarat, Vic, Australia.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					67	68		10.7326/0003-4819-129-1-199807010-00015	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653003				2023-01-03	WOS:000074513300011
J	Best, PJM; Berger, PB; Miller, VM; Lerman, A				Best, PJM; Berger, PB; Miller, VM; Lerman, A			The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; FOLLOW-UP; CORONARY ATHEROSCLEROSIS; 17-BETA-ESTRADIOL; DISEASE; GROWTH; AORTA	Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-l. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin-l. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17 beta-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-l levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/ml (range, 0.2 to 14.1 nmol/ml) (P = 0.04). The mean baseline plasma endothelin-l level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-l was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-l. This may be one mechanism by which ERT provides cardiovascular benefit.	Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51736, HL07111-21D] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; DUBEY RK, 1994, J PHARMACOL EXP THER, V269, P402; Duckles SP, 1996, J PHARMACOL EXP THER, V279, P1; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; LERMAN A, 1995, CIRCULATION, V92, P2426, DOI 10.1161/01.CIR.92.9.2426; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Mathew V, 1996, MAYO CLIN PROC, V71, P769; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; POLDERMAN KH, 1993, ANN INTERN MED, V118, P429, DOI 10.7326/0003-4819-118-6-199303150-00006; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RODEHEFFER RJ, 1992, MAYO CLIN PROC, V67, P719, DOI 10.1016/S0025-6196(12)60795-2; ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; WEISSBERG PL, 1990, ATHEROSCLEROSIS, V85, P257, DOI 10.1016/0021-9150(90)90118-3; YLIKORKALA O, 1995, J CLIN ENDOCR METAB, V80, P3384, DOI 10.1210/jc.80.11.3384	20	174	178	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					285	288		10.7326/0003-4819-128-4-199802150-00006	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471931				2023-01-03	WOS:000072013400005
J	Gill, TM; Robison, JT; Tinetti, ME				Gill, TM; Robison, JT; Tinetti, ME			Difficulty and dependence: Two components of the disability continuum among community-living older persons	ANNALS OF INTERNAL MEDICINE			English	Article						activities of daily living; aged; disabled persons; independent living; geriatric assessment	PHYSICAL-DISABILITY; FUNCTIONAL STATUS; ADULTS; PREDICTORS; ELDERS; HEALTH; POPULATIONS; IMPAIRMENT; DESIGN; FALLS	Background: Although most epidemiologic studies have defined disability in basic activities of daily living (BADLs) as dependence, some investigators have argued that BADL disability should be defined as degree of difficulty. Objective: To determine whether the responses to questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than the response to either question alone. Setting: General community. Participants: 1065 persons 72 years of age and older. Measurements: On the basis of self-reported information collected at baseline, participants were categorized into three BADL groups: independent without difficulty, independent with difficulty, and dependent. Additional baseline information was collected on several measures of higher-level function and physical performance. Follow-up information was collected on regular home care visits and BADL function at 1 and 3 years and on hospitalizations, admissions to skilled-nursing facilities, and deaths over a 4-year period. Results: In a cross-sectional analysis, the proportion of participants with poor higher-level function and physical performance increased substantially across the three BADL groups. In a longitudinal analysis, the rates of hospitalization and regular home care visits for the independent without difficulty group, the independent with difficulty group, and the dependent group were 46%, 57%, and 72% (P < 0.001) and 17%, 30%, and 49% (P < 0.001), respectively; survival curves for admission to a skilled-nursing facility and death differed significantly for each pair-wise comparison. Among persons who were BADL independent, those with difficulty were significantly more likely to develop BADL dependence over a 3-year period than those without difficulty (31% compared with 18%; P < 0.001). Conclusions: In the assessment of BADL function in older persons, questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than either question alone.	Yale Univ, Sch Med, Genet Program, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Genet Program, Room 17B-TMP,POB 208025, New Haven, CT 06504 USA.		Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NIA NIH HHS [R01 AG-07449, P60 AG-10469, 5T32-AG00153] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469, R01AG007449, T32AG000153] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENVENUTI F, 1995, J AM GERIATR SOC, V43, P479, DOI 10.1111/j.1532-5415.1995.tb06092.x; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crawford SL, 1997, J AM GERIATR SOC, V45, P338, DOI 10.1111/j.1532-5415.1997.tb00950.x; DIPIETRO L, 1993, MED SCI SPORT EXER, V25, P628; DUNN JE, 1992, AM J PUBLIC HEALTH, V82, P395, DOI 10.2105/AJPH.82.3.395; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FERRUCCI L, 1991, J GERONTOL, V46, pM52, DOI 10.1093/geronj/46.2.M52; Ferrucci L, 1996, J CLIN EPIDEMIOL, V49, P1089, DOI 10.1016/0895-4356(96)00231-4; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fried LP, 1996, J GERONTOL A-BIOL, V51, pM206, DOI 10.1093/gerona/51A.5.M206; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X; JETTE AM, 1985, J CHRON DIS, V38, P59, DOI 10.1016/0021-9681(85)90008-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEIL JE, 1989, J CLIN EPIDEMIOL, V42, P521, DOI 10.1016/0895-4356(89)90148-0; Kempen GIJM, 1996, SOC SCI MED, V43, P1601, DOI 10.1016/S0277-9536(96)00057-3; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; REUBEN DB, 1995, J AM GERIATR SOC, V43, P936, DOI 10.1111/j.1532-5415.1995.tb05540.x; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; WIENER JM, 1990, J GERONTOL, V45, pS229, DOI 10.1093/geronj/45.6.S229	35	185	185	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					96	+		10.7326/0003-4819-128-2-199801150-00004	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR200	9441588				2023-01-03	WOS:000071470800003
J	Beral, V; Bull, D; Doll, R; Key, T; Peto, R; Reeves, G; Calle, EE; Heath, CW; Coates, RJ; Liff, JM; Franceschi, S; Talamini, R; Chantarakul, N; Koetsawang, S; Rachawat, D; Morabia, A; Schuman, L; Stewart, W; Szklo, M; Bain, C; Schofield, F; Siskind, V; Band, P; Coldman, AJ; Gallagher, RP; Hislop, TG; Yang, P; Duffy, SW; Kolonel, LM; Nomura, AMY; Oberle, MW; Ory, HW; Peterson, HB; Wilson, HG; Wingo, PA; Ebeling, K; Kunde, D; Nishan, P; Colditz, G; Martin, N; Pardthaisong, T; Silpisornkosol, S; Theetranont, C; Boosiri, B; Chutivongse, S; Jimakorn, P; Virutamasen, P; Wongsrichanalai, C; McMichael, AJ; Rohan, T; Ewertz, M; Adami, HO; Bergkvist, R; Persson, I; Paul, C; Skegg, DCG; Spears, GFS; Boyle, P; Evstifeeva, T; Daling, JR; Hutchinson, WB; Malone, K; Noonan, EA; Stanford, JL; Thomas, DB; Weiss, NS; White, E; Andrieu, N; Bramond, A; Clavel, F; Gairard, B; Lansac, J; Piana, L; Renaud, R; Fine, SRP; Cuevas, HR; Ontiveros, P; Palet, A; Salazar, SB; Aristizabal, N; Cuadros, A; Bachelor, A; Le, MG; Deacon, J; Peto, J; Taylor, CN; Modan, B; Ron, E; Friedman, GD; Hiatt, RA; Levi, F; Bishop, T; Kosmelj, K; PrimicZakelj, M; Ravnihar, B; Stare, J; Beeson, WL; Fraser, G; Bulbrook, RD; Cuzick, J; Fentiman, IS; Hayward, JL; Wang, DY; McPherson, K; Hanson, RL; Leske, MC; Mahoney, MC; Nasca, PC; Varma, AO; Weinstein, AL; Moller, TR; Olsson, H; Ranstam, J; Goldbohm, RA; vandenBrandt, PA; Apelo, RA; Baens, J; delaCruz, JR; Javier, B; Lacaya, LB; Ngelangel, CA; LaVecchia, C; Negri, E; Marubini, E; Ferraroni, M; Gerber, M; RIchardson, S; Segala, C; Gatei, D; Kenya, P; Kungu, A; Mati, JG; Brinton, LA; Hoover, R; Schairer, C; Spirtas, R; Lee, HP; Rookus, MA; vanLeeuwen, FE; Schoenberg, JA; Gammon, MD; Clarke, EA; Jones, L; Neil, A; Vessey, M; Yeates, D; Crossley, B; Hermon, C; Jones, S; Lewis, C; Collins, R; Mabuchi, K; Preston, D; Hannaford, P; Kay, C; RoseroBixby, L; Yuan, JM; Wei, HY; Yun, T; Zhiheng, C; Berry, G; Booth, JC; Jelihovsky, T; MacLennan, R; Shearman, R; Wang, QS; Baines, CJ; Miller, AB; Wall, C; Lund, E; Stalsberg, H; Katsouyanni, K; Trichopoulos, D; Dabancens, A; Martinez, L; Molina, R; Salas, O; Alexander, FE; Folsom, AR; Chilvers, CED; Bernstein, L; Haile, RW; PaganiniHill, A; Pike, MC; Ross, RK; Ursin, G; Yu, MC; Longnecker, MP; Newcomb, P; Bergkvist, L; Farley, TMN; Holck, S; Meirik, O				Beral, V; Bull, D; Doll, R; Key, T; Peto, R; Reeves, G; Calle, EE; Heath, CW; Coates, RJ; Liff, JM; Franceschi, S; Talamini, R; Chantarakul, N; Koetsawang, S; Rachawat, D; Morabia, A; Schuman, L; Stewart, W; Szklo, M; Bain, C; Schofield, F; Siskind, V; Band, P; Coldman, AJ; Gallagher, RP; Hislop, TG; Yang, P; Duffy, SW; Kolonel, LM; Nomura, AMY; Oberle, MW; Ory, HW; Peterson, HB; Wilson, HG; Wingo, PA; Ebeling, K; Kunde, D; Nishan, P; Colditz, G; Martin, N; Pardthaisong, T; Silpisornkosol, S; Theetranont, C; Boosiri, B; Chutivongse, S; Jimakorn, P; Virutamasen, P; Wongsrichanalai, C; McMichael, AJ; Rohan, T; Ewertz, M; Adami, HO; Bergkvist, R; Persson, I; Paul, C; Skegg, DCG; Spears, GFS; Boyle, P; Evstifeeva, T; Daling, JR; Hutchinson, WB; Malone, K; Noonan, EA; Stanford, JL; Thomas, DB; Weiss, NS; White, E; Andrieu, N; Bramond, A; Clavel, F; Gairard, B; Lansac, J; Piana, L; Renaud, R; Fine, SRP; Cuevas, HR; Ontiveros, P; Palet, A; Salazar, SB; Aristizabal, N; Cuadros, A; Bachelor, A; Le, MG; Deacon, J; Peto, J; Taylor, CN; Modan, B; Ron, E; Friedman, GD; Hiatt, RA; Levi, F; Bishop, T; Kosmelj, K; PrimicZakelj, M; Ravnihar, B; Stare, J; Beeson, WL; Fraser, G; Bulbrook, RD; Cuzick, J; Fentiman, IS; Hayward, JL; Wang, DY; McPherson, K; Hanson, RL; Leske, MC; Mahoney, MC; Nasca, PC; Varma, AO; Weinstein, AL; Moller, TR; Olsson, H; Ranstam, J; Goldbohm, RA; vandenBrandt, PA; Apelo, RA; Baens, J; delaCruz, JR; Javier, B; Lacaya, LB; Ngelangel, CA; LaVecchia, C; Negri, E; Marubini, E; Ferraroni, M; Gerber, M; RIchardson, S; Segala, C; Gatei, D; Kenya, P; Kungu, A; Mati, JG; Brinton, LA; Hoover, R; Schairer, C; Spirtas, R; Lee, HP; Rookus, MA; vanLeeuwen, FE; Schoenberg, JA; Gammon, MD; Clarke, EA; Jones, L; Neil, A; Vessey, M; Yeates, D; Crossley, B; Hermon, C; Jones, S; Lewis, C; Collins, R; Mabuchi, K; Preston, D; Hannaford, P; Kay, C; RoseroBixby, L; Yuan, JM; Wei, HY; Yun, T; Zhiheng, C; Berry, G; Booth, JC; Jelihovsky, T; MacLennan, R; Shearman, R; Wang, QS; Baines, CJ; Miller, AB; Wall, C; Lund, E; Stalsberg, H; Katsouyanni, K; Trichopoulos, D; Dabancens, A; Martinez, L; Molina, R; Salas, O; Alexander, FE; Folsom, AR; Chilvers, CED; Bernstein, L; Haile, RW; PaganiniHill, A; Pike, MC; Ross, RK; Ursin, G; Yu, MC; Longnecker, MP; Newcomb, P; Bergkvist, L; Farley, TMN; Holck, S; Meirik, O		Collaborative Group on Hormonal Factors in Breast Cancer	Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer	LANCET			English	Article							ORAL-CONTRACEPTIVE USE; REQUIRING PROLONGED OBSERVATION; ESTROGEN-PROGESTIN REPLACEMENT; POSTMENOPAUSAL WOMEN; MENOPAUSAL ESTROGEN; UNITED-STATES; RISK-FACTORS; EXOGENOUS ESTROGENS; BODY-MASS; ASSOCIATION	Background The Collaborative Group on Hormonal Factors in Breast Cancer has brought together and reanalysed about 90% of the worldwide epidemiological evidence on the relation between risk of breast cancer and use of hormone replacement therapy (HRT). Methods Individual data on 52 705 women with breast cancer and 108 411 women without breast cancer from 51 studies in 21 countries were collected, checked, and analysed centrally, The main analyses are based on 53 865 postmenopausal women with a known age al menopause, of whom 17 830 (33%) had used HRT at some time, The median age at first use was 48 years, and 34% of ever-users had used HRT for 5 years or longer, Estimates of the relative risk of breast cancer associated with the use of HRT were obtained after stratification of all analyses by study, age at diagnosis, time since menopause, body-mass index, parity, and the age a woman was when her first child was born. Findings Among current users of HRT or those who ceased use 1-4 years previously, the relative risk of having breast cancer diagnosed increased by a factor of 1.023 (95% CI 1.011-1.036; 2p=0.0002) for each year of use; the relative risk was 1.35 (1.21-1.49; 2p=0.00001) for women who had used HRT for 5 years or longer(average duration of use in this group 11 years), This increase is comparable with the effect on breast cancer of delaying menopause, since among never-users of HRT the relative risk of breast cancer increases by a factor of 1.028 (95% CI 1.021-1.034) for each year older at menopause, 5 or more years after cessation of HRT use, there was no significant excess of breast cancer overall or in relation to duration of use, These main findings did not vary between individual studies, Of the many factors examined that might affect the relation between breast cancer risk and use of HRT, only a woman's weight and body-mass index had a material effect: the increase in the relative risk of breast cancer associated with long durations of use in current and recent users was greater for women of lower than of higher weight or body-mass index, There was no marked variation in the results according to hormonal type or dose but little information was available about long durations of use of any specific preparation, Cancers diagnosed in women who had ever used HRT tended to be less advanced clinically than those diagnosed in never-users, In North America and Europe the cumulative incidence of breast cancer between the ages of 50 and 70 in never-users of HRT is about 45 per 1000 women, The cumulative excess numbers of breast cancers diagnosed between these ages per 1000 women who began use of HRT at age 50 and used it for 5, 10, and 15 years, respectively, are estimated to be 2 (95% CI 1-3), 6 (3-9), and 12 (5-20), Whether HRT affects mortality from breast cancer is not known. Interpretation The risk of having breast cancer diagnosed is increased in women using HRT and increases with increasing duration of use, This effect is reduced after cessation of use of HRT and has largely, if not wholly, disappeared after about 5 years, These findings should be considered in the context of the benefits and other risks associated with the use of HRT.			Beral, V (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, GIBSON BLDG, OXFORD OX2 6HE, ENGLAND.		Ursin, Giske/U-6637-2017; Negri, Eva Vanna Lorenza/AAC-5698-2019; Hiatt, Robert/AAQ-1537-2021; Ferraroni, Monica/D-6548-2017; Brinton, Louise A/G-7486-2015; franceschi, silvia/M-2452-2014; Fentiman, Ian S/I-7644-2019; Colditz, Graham/A-3963-2009; Boyle, Peter/A-4380-2014; Katsouyanni, Klea/D-4856-2014; Negri, Eva/B-7244-2013; Clavel-Chapelon, Francoise/G-6733-2014; Richardson, Sylvia T/G-4691-2015; Ranstam, Jonas/A-4386-2009; Fentiman, Ian/AAB-9886-2020	Ursin, Giske/0000-0002-0835-9507; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; Ferraroni, Monica/0000-0002-4542-4996; Brinton, Louise A/0000-0003-3853-8562; franceschi, silvia/0000-0003-4181-8071; Colditz, Graham/0000-0002-7307-0291; Boyle, Peter/0000-0001-6251-0610; Katsouyanni, Klea/0000-0002-0132-9575; Negri, Eva/0000-0001-9712-8526; Richardson, Sylvia T/0000-0003-1998-492X; Ranstam, Jonas/0000-0002-8287-7273; Ewertz, Marianne/0000-0002-5965-969X; Lund, Eiliv/0000-0002-8071-8711; Yuan, Jian-Min/0000-0002-4620-3108; Bishop, Tim/0000-0002-8752-8785; La Vecchia, Carlo/0000-0003-1441-897X; Szklo, Moyses/0000-0001-9433-6266				ALEXANDER FE, 1987, J EPIDEMIOL COMMUN H, V41, P101, DOI 10.1136/jech.41.2.101; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Calle EE, 1996, CONTRACEPTION, V54, pS1; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; Goodman MT, 1997, PREV MED, V26, P144, DOI 10.1006/pmed.1996.9979; HARRIS RE, 1992, J NATL CANCER I, V84, P1575, DOI 10.1093/jnci/84.20.1575; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KAY CR, 1988, BRIT J CANCER, V58, P675, DOI 10.1038/bjc.1988.285; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; LAVECCHIA C, 1992, INT J CANCER, V50, P161, DOI 10.1002/ijc.2910500131; LAVECCHIA C, 1995, BRIT J CANCER, V72, P244, DOI 10.1038/bjc.1995.310; LEE NC, 1987, J NATL CANCER I, V79, P1247; Levi F, 1996, EUR J CANCER PREV, V5, P259, DOI 10.1097/00008469-199608000-00006; LIPWORTH L, 1995, INT J CANCER, V62, P548, DOI 10.1002/ijc.2910620510; MARUBINI E, 1988, CANCER, V61, P173, DOI 10.1002/1097-0142(19880101)61:1&lt;173::AID-CNCR2820610129&gt;3.0.CO;2-P; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; MORABIA A, 1993, PREV MED, V22, P178, DOI 10.1006/pmed.1993.1015; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NGELANGEL CA, 1994, PHILIPP J INTERN MED, V32, P231; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RAVNIHAR B, 1988, NEOPLASMA, V35, P109; RAVNIHAR B, 1979, EUR J CANCER, V15, P395, DOI 10.1016/0014-2964(79)90074-4; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROOKUS MA, 1994, LANCET, V344, P844, DOI 10.1016/S0140-6736(94)92826-6; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SCHUURMAN AG, 1995, CANCER CAUSE CONTROL, V6, P416, DOI 10.1007/BF00052181; SEGALA C, 1991, BRIT J CANCER, V64, P919, DOI 10.1038/bjc.1991.427; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; TALAMINI R, 1985, INT J EPIDEMIOL, V14, P70, DOI 10.1093/ije/14.1.70; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMAS DB, 1990, BRIT J CANCER, V61, P110; Thomas HV, 1997, J NATL CANCER I, V89, P396, DOI 10.1093/jnci/89.5.396; URSIN G, 1992, EPIDEMIOLOGY, V3, P414, DOI 10.1097/00001648-199209000-00006; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; WANG DY, 1987, EUR J CANCER CLIN ON, V23, P1541, DOI 10.1016/0277-5379(87)90098-8; WEINSTEIN AL, 1993, INT J EPIDEMIOL, V22, P781, DOI 10.1093/ije/22.5.781; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	66	1987	2027	4	110	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	1997	350	9084					1047	1059		10.1016/s0140-6736(97)08233-0	http://dx.doi.org/10.1016/s0140-6736(97)08233-0			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213546	hybrid			2023-01-03	WOS:A1997YA73400007
J	Plaisance, P; Lurie, KG; Vicaut, E; Adnet, F; Petit, JL; Epain, D; Ecollan, P; Gruat, R; Cavagna, P; Biens, J; Payen, D				Plaisance, P; Lurie, KG; Vicaut, E; Adnet, F; Petit, JL; Epain, D; Ecollan, P; Gruat, R; Cavagna, P; Biens, J; Payen, D		French Active Compression-Decompression Card	A comparison of standard cardiopulmonary resuscitation and active compression-decompression resuscitation for out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR-FIBRILLATION; CPR; INSTRUCTOR; SURVIVAL; STUDENT; SYSTEM; TRIAL; MODEL	Background We previously observed that shortterm survival after out-of-hospital cardiac arrest was greater with active compression-decompression cardiopulmonary resuscitation (CPR) than with standard CPR. In the current study, we assessed the effects of the active compression-decompression method on one-year survival. Methods Patients who had cardiac arrest in the Paris metropolitan area or in Thionville, France, more than 80 percent of whom had asystole, were assigned to receive either standard CPR (377 patients) or active compression-decompression CPR (373 patients) according to whether their arrest occurred on an even or odd day of the month, respectively. The primary end point was survival at one year. The rate of survival to hospital discharge without neurologic impairment and the neurologic outcome were secondary end points. Results Both the rate of hospital discharge without neurologic impairment (6 percent vs. 2 percent, P = 0.01) and the one-year survival rate (5 percent vs. 2 percent, P = 0.03) were significantly higher among patients who received active compression-decompression CPR than among those who received stand ard CPR. AII patients who survived to one year had cardiac arrests that were witnessed. Nine of 17 one-year survivors in the active compression-decompression group and 2 of 7 in the standard group, respectively, initially had asystole or pulseless electrical activity. In 12 of the 17 survivors who had received active compression-decompression CPR, neurologic status returned to base line, as compared with 3 of 7 survivors who had received standard CPR (P = 0.34). Conclusions Active compression-decompression CPR performed during advanced life support significantly improved long-term survival rates among patients who had cardiac arrest outside the hospital. (N Engl J Med 1999;341:569-75.) (C)1999, Massachusetts Medical Society.	Lariboisiere Univ Hosp, Dept Anesthesiol & Crit Care, F-75475 Paris 10, France; Lariboisiere Univ Hosp, Serv Mobile Urgence & Reanimat, F-75475 Paris, France; Univ Minnesota, Cardiac Arrhythmia Ctr, Minneapolis, MN USA; Fernand Widal Hosp, Biophys Lab, Paris, France; Thionville Hosp, SMUR 57, Thionville, France; Lagny Hosp, Serv Aide Med Urgente, SMUR, SAMU 77, Lagny, France; La Pitie Salpetriere Univ Hosp, SMUR, Paris, France; La Pitie Salpetriere Univ Hosp, Dept Anesthesiol & Crit Care, SAMU 75, Paris, France; Pontoise Hosp, SMUR, SAMU 95, Pontoise, France; Montfermeil Hosp, SMUR, SAMU 93, Montfermeil, France; Aulnay Bois Hosp, SMUR, SAMU 93, Aulnay Sous Bois, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Minnesota System; University of Minnesota Twin Cities; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier Rene Dubos, Pontoise	Plaisance, P (corresponding author), Lariboisiere Univ Hosp, Dept Anesthesiol & Crit Care, 2 Rue Ambroise Pare, F-75475 Paris 10, France.							BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; CARLI PA, 1993, TXB TRAUMA ANESTHESI, P199; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2184; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; JANNIERE D, 1993, J EUR URGENCES, V6, P76; KIMMAN GP, 1994, RESUSCITATION, V28, P227, DOI 10.1016/0300-9572(94)90068-X; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; Luiz T, 1996, J CARDIOTHOR VASC AN, V10, P178, DOI 10.1016/S1053-0770(96)80234-5; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; Mauer D, 1996, RESUSCITATION, V33, P125, DOI 10.1016/S0300-9572(96)01006-4; MULLIE A, 1989, RESUSCITATION, V17, pS23, DOI 10.1016/0300-9572(89)90088-9; Nolan J, 1998, RESUSCITATION, V37, P119, DOI 10.1016/S0300-9572(98)00045-8; Panzer W, 1996, RESUSCITATION, V33, P117, DOI 10.1016/S0300-9572(96)01021-0; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; Plaisance P, 1997, CIRCULATION, V95, P955; Schneider T, 1996, RESUSCITATION, V32, P203, DOI 10.1016/0300-9572(96)00946-X; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHULTZ JJ, 1995, RESUSCITATION, V29, P23, DOI 10.1016/0300-9572(94)00812-T; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; SILFVAST T, 1990, AM J EMERG MED, V8, P359, DOI 10.1016/0735-6757(90)90097-J; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; Sunde K, 1997, RESUSCITATION, V34, P235, DOI 10.1016/S0300-9572(96)01087-8; THEURY O, 1997, REV SAMU, V6, P211; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; Wik L, 1996, RESUSCITATION, V32, P206, DOI 10.1016/0300-9572(96)82051-X	28	123	129	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					569	575		10.1056/NEJM199908193410804	http://dx.doi.org/10.1056/NEJM199908193410804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451462				2023-01-03	WOS:000082061500004
J	Abrahm, JL				Abrahm, JL		ACP ASIM End Life Care Consensus Panel	Management of pain and spinal cord compression in patients with advanced cancer	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSMUCOSAL FENTANYL CITRATE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTROLLED CLINICAL-TRIAL; QUALITY-OF-LIFE; TRANSDERMAL FENTANYL; EPIDURAL METASTASES; BREAKTHROUGH PAIN; BONE METASTASES; ORAL MORPHINE; BREAST-CANCER	General internists often care for patients with advanced cancer. These patients have substantial morbidity caused by moderate to severe pain and by spinal cord compression. With appropriate multidisciplinary care, pain can be controlled in 90% of patients who have advanced malignant conditions, and 90% of ambulatory patients with spinal cord compression can remain ambulatory. Guidelines have been developed for assessing and managing patients with these problems, but implementing the guidelines can be problematic for physicians who infrequently need to use them. This paper traces the last year of life of Mr. Simmons, a hypothetical patient who is dying of refractory prostate cancer. Mr. Simmons and his family interact with professionals from various disciplines during this year. Advance care planning is completed and activated. Practical suggestions are offered for assessment and treatment of all aspects of his pain, including its physical, psychological, social, and spiritual dimensions. The methods of pain relief used or discussed include nonpharmacologic techniques, nonopioid analgesics, opioids, adjuvant medications, radiation therapy, and radiopharmaceutical agents. Overcoming resistance to taking opioids; initiating, titrating, and changing opioid routes and agents; and preventing or relieving the side effects they induce are also covered. Data on assessment and treatment of spinal cord compression are reviewed. Physicians can use the techniques described to more readily implement existing guidelines and provide comfort and optimize quality of life for patients with advanced cancer.	Hosp Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrahm, JL (corresponding author), Hosp Univ Penn, 514 Maloney,3600 Spruce St, Philadelphia, PA 19104 USA.							Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.3.CO;2-D; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *AM PAIN SOC, 1992, PRINC AN US TREATM A; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; BAINES M, 1988, J PAIN SYMPTOM MANAG, V3, P815; BENSON H, 1974, PSYCHIATRY, V37, P37, DOI 10.1080/00332747.1974.11023785; Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593; BERGER AM, 1998, PRINCIPLES PRACTICE, P191; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN, P69; Breitbart W, 1997, PAIN, V72, P235, DOI 10.1016/S0304-3959(97)00039-0; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; Breitbart W, 1997, OXFORD TXB PALLIATIV, P933; BREITBART W, 1994, TXB PAIN, P825; BROOMHEAD A, 1997, P AN M AM SOC CLIN, V16, pA61; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; BRUERA E, 1994, J PAIN SYMPTOM MANAG, V9, P515, DOI 10.1016/0885-3924(94)90113-9; BRUERA E, 1997, P ASCO, V16, pA62; Bruera E D, 1985, J Palliat Care, V1, P46; *CANC PAIN ASS TRE, 1992, J CLIN ONCOL, V10, P1976; CARACINI A, 1997, OXFORD TXB PALLIATIV, P727; CHERNY NI, 1996, PAIN PALLIATIVE CARE; CHERNYSHEV AV, 1993, ZOOL ZH, V72, P11; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COBB CA, 1977, J NEUROSURG, V47, P653, DOI 10.3171/jns.1977.47.5.0653; Coleman RE, 1997, CANCER, V80, P1686, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.3.CO;2-T; COLEMAN RE, 1998, ASCO ED BOOK, P100; Coyle N, 1995, CANC PAIN MANAGEMENT, P89; Currow DC, 1997, J PAIN SYMPTOM MANAG, V13, P302, DOI 10.1016/S0885-3924(97)00079-1; Dalal S, 1998, J PAIN SYMPTOM MANAG, V16, P245, DOI 10.1016/S0885-3924(98)00084-0; DECONNO F, 1995, J CLIN ONCOL, V13, P1004, DOI 10.1200/JCO.1995.13.4.1004; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DOYLE D, 1997, OXFORD TXB PALLIATIV; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Ferrante FM, 1996, ANESTHESIOLOGY, V84, P1243; Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532-5415.1998.tb01084.x; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; FERRELLTORRY AT, 1993, CANCER NURS, V16, P93; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Foley Kathleen M., 1997, P2807; Foley KM, 1998, J CLIN ONCOL, V16, P3213, DOI 10.1200/JCO.1998.16.10.3213; FOLEY KM, 1997, OXFORD TXB PALLIATIV, P310; GLARE P, 1992, J PAIN SYMPTOM MANAG, V7, P369, DOI 10.1016/0885-3924(92)90092-V; Gloth F M 3rd, 1996, Am J Med, V101, p19S; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; HANKS G, 1997, OXFORD TXB PALLIATIV, P351; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; HEIMDAL K, 1992, J NEURO-ONCOL, V12, P141; HOLLAND JC, 1998, PSYCHO ONCOLOGY; Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; HOSKIN PJ, 1997, OXFORD TXB PALLIATIV, P267; INGHAM J, 1997, OXFORD TXB PALLIATIV, P203; JACOX A, 1994, ACHPR PUBLICATION; Janjan NA, 1997, CANCER-AM CANCER SOC, V80, P1628, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1; Kaiko R., 1996, Clinical Pharmacology and Therapeutics, V59, P130, DOI 10.1038/sj.clpt.1996.19; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; Kanner R M, 1981, Ann N Y Acad Sci, V362, P161, DOI 10.1111/j.1749-6632.1981.tb12804.x; Kaplan R, 1998, J CLIN ONCOL, V16, P3230, DOI 10.1200/JCO.1998.16.10.3230; Kreeger L, 1996, J PAIN SYMPTOM MANAG, V11, P1, DOI 10.1016/S0885-3924(96)90004-4; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277-5379(91)90257-E; Lichter I, 1996, HEMATOL ONCOL CLIN N, V10, P207, DOI 10.1016/S0889-8588(05)70335-X; LIPTON A, 1998, ASCO ED BOOK, P94; Loblaw DA, 1998, J CLIN ONCOL, V16, P1613, DOI 10.1200/JCO.1998.16.4.1613; Loscalzo M, 1996, HEMATOL ONCOL CLIN N, V10, P139, DOI 10.1016/S0889-8588(05)70331-2; LYSS AP, 1997, P AN M AM SOC CLIN, V16, pA41; MACDONALD N, 1997, PALLIATIVE MED CASE; Manfredi PL, 1996, J PAIN SYMPTOM MANAG, V11, P131, DOI 10.1016/0885-3924(95)00150-6; MARANZANO E, 1995, INT J RADIAT ONCOL, V32, P959, DOI 10.1016/0360-3016(95)00572-G; McCaffery M, 1992, Hosp J, V8, P121; McEwan AJB, 1997, SEMIN NUCL MED, V27, P165, DOI 10.1016/S0001-2998(97)80046-3; MCGUIRE DB, 1995, CANC PAIN MANAGEMENT, P1; *MED EC, 1998, RED BOOK; Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656; MERCADANTE S, 1998, PRINCIPLES PRACTICE, P191; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PAYNE R, 1998, PRINCIPLES PRACTICE, P61; PINOVER WH, 1998, PRINCIPLES PRACTICE, P603; PORTENOY RK, 1987, NEUROLOGY, V37, P134, DOI 10.1212/WNL.37.1.134; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; PORTENOY RK, 1989, CANCER, V64, P207; PORTER J, 1980, NEW ENGL J MED, V302, P123; POSNER JB, 1995, CONT NEUROLOGY SERIE, V45; Rhiner M, 1993, Cancer Pract, V1, P137; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; RIPAMONTI C, 1998, PRINCIPLES PRACTICE, P207; ROBINSON RG, 1993, SEMIN ONCOL, V20, P44; RODICHOK LD, 1986, ANN NEUROL, V20, P696, DOI 10.1002/ana.410200608; RODICHOK LD, 1981, AM J MED, V70, P1181, DOI 10.1016/0002-9343(81)90825-1; ROTH SH, 1989, RHEUM DIS CLIN N AM, V15, P479; Saunders C, 1983, LIVING DYING MANAGEM; Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574; SIEGAL T, 1989, SPINE, V14, P223, DOI 10.1097/00007632-198902000-00015; SORENSEN PS, 1994, EUR J CANCER, V30A, P22, DOI 10.1016/S0959-8049(05)80011-5; Spross J. A., 1995, CANC PAIN MANAGEMENT, P159; STOREY P, 1997, HOSPICE PALLIATIVE C; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U; SYRJALA KL, 1996, HYPNOSIS SUGGESTON T, P121; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Waller A, 1996, HDB PALLIATIVE CARE; WESTERLING D, 1982, EUR J CLIN PHARMACOL, V23, P59, DOI 10.1007/BF01061378; WILWERDING MB, 1995, SUPPORT CARE CANCER, V3, P135, DOI 10.1007/BF00365854; World Health Organization, 1996, CANC PAIN REL GUID O; WYCROSS RG, 1974, INT J CLIN PHARM, V7, P184; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; YOUNG RF, 1980, J NEUROSURG, V53, P741, DOI 10.3171/jns.1980.53.6.0741; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	115	34	34	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					37	46		10.7326/0003-4819-131-1-199907060-00009	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391814				2023-01-03	WOS:000081345200007
J	Winters, JC; Jorritsma, W; Groenier, KH; Sobel, JS; Meyboom-de Jong, B; Arendzen, HJ				Winters, JC; Jorritsma, W; Groenier, KH; Sobel, JS; Meyboom-de Jong, B; Arendzen, HJ			Treatment of shoulder complaints in general practice: long term results of a randomised, single blind study comparing physiotherapy, manipulation, and corticosteroid injection	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; DISORDERS		Univ Groningen, Dept Family Practice, NL-9713 AW Groningen, Netherlands; Rehabil Ctr Beatrixoord, Haren, Netherlands	University of Groningen; University of Groningen	Winters, JC (corresponding author), Nieuwe Schoolweg 2A, NL-9756 BB Glimmen, Netherlands.							vanderHeijden GJMG, 1997, BRIT MED J, V315, P25, DOI 10.1136/bmj.315.7099.25; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; VANDERWINDT DAWM, 1995, J CLIN EPIDEMIOL, V48, P691, DOI 10.1016/0895-4356(94)00170-U; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320	5	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1395	1396		10.1136/bmj.318.7195.1395	http://dx.doi.org/10.1136/bmj.318.7195.1395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334751	Green Published, Green Submitted			2023-01-03	WOS:000080524700030
J	Cobleigh, MA; Norlock, FE; Oleske, DM; Starr, A				Cobleigh, MA; Norlock, FE; Oleske, DM; Starr, A			Hormone replacement therapy and high S phase in breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DNA FLOW-CYTOMETRY; ESTROGEN-RECEPTOR STATUS; PROGNOSTIC FACTORS; RISK-FACTORS; WOMEN; CARCINOMA; PLOIDY; TUMOR; REGRESSION	Context Prolonged postmenopausal hormone replacement therapy (HRT) is associated with increased incidence of breast cancer and, paradoxically, reduced breast cancer mortality, The biological rationale for this discrepancy has not been explored. Objective To compare the prognostic characteristics of cancers arising in women who have used HRT with those in women who never have used HRT. Design Prospective cohort study from December 1989 to November 1996. Setting Teaching hospital in a large midwestern metropolitan area. Patients Cohort of 331 postmenopausal women who presented consecutively with 349 invasive breast cancers. Main outcome Measures Estrogen receptor (ER) status (ER positive vs ER negative) and S phase (low vs high) for current HRT users vs never users. Results The frequency of high S-phase fraction among cancers in women who were using HRT was markedly increased com pared with that in women who had never used HRT (adjusted odds ratio [OR], 2.82; 95% confidence interval [CI], 1.04-7.66). However, the greater frequency of high S-phase fraction was limited to women with ER-positive cancers (for HRT users vs never Users, OR, 5.25; 95% CI, 1.36-20.28; for ER-negative cancers in HRT users vs never users, OR, 1.08; 95% CI, 0.20-5.86). Conclusions Use of HRT appears to stimulate growth of ER-positive but not ER-negative breast cancer as measured by S-phase fraction. The prognostic significance of high S-phase fraction in current HRT users who have ER-positive tumors is unknown.	Rush Presbyterian St Lukes Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA	Rush University; Rush University; Rush University	Cobleigh, MA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Sect Med Oncol, 1725 W Harrison St,Suite 821, Chicago, IL 60612 USA.							BALSLEV I, 1994, INT J CANCER, V56, P16; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; BOSARI S, 1992, CANCER-AM CANCER SOC, V70, P1943, DOI 10.1002/1097-0142(19921001)70:7<1943::AID-CNCR2820700722>3.0.CO;2-Y; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COBLEIGH MA, 1998, CANC TREAT RES, V94, P210; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COOPER JA, 1989, BRIT J CANCER, V59, P119, DOI 10.1038/bjc.1989.24; DHODAPKAR MV, 1995, CANCER-AM CANCER SOC, V75, P43, DOI 10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#; EWERS SB, 1992, BREAST CANCER RES TR, V24, P115, DOI 10.1007/BF01961244; FUQUA SAW, 1996, DIS BREAST, P262; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Harvey SC, 1996, AM J ROENTGENOL, V167, P394, DOI 10.2214/ajr.167.2.8686614; HILDRETH NG, 1983, J NATL CANCER I, V70, P1027; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; HULKA BS, 1984, AM J EPIDEMIOL, V119, P692, DOI 10.1093/oxfordjournals.aje.a113790; JONES C, 1994, MED J AUSTRALIA, V161, P106, DOI 10.5694/j.1326-5377.1994.tb127340.x; LESSER ML, 1981, CANCER, V48, P299, DOI 10.1002/1097-0142(19810715)48:2<299::AID-CNCR2820480215>3.0.CO;2-2; LIPPMAN M, 1976, CANCER RES, V36, P4595; Magnusson C, 1996, BREAST CANCER RES TR, V38, P325, DOI 10.1007/BF01806152; MERKEL DE, 1993, CANCER, V72, P1926, DOI 10.1002/1097-0142(19930915)72:6<1926::AID-CNCR2820720622>3.0.CO;2-I; MUSS HB, 1989, CANCER, V64, P1894, DOI 10.1002/1097-0142(19891101)64:9<1894::AID-CNCR2820640923>3.0.CO;2-K; OREILLY SM, 1990, J CLIN ONCOL, V8, P2040, DOI 10.1200/JCO.1990.8.12.2040; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SQUITIERI R, 1994, J AM COLL SURGEONS, V178, P167; STAL O, 1993, J CLIN ONCOL, V11, P1717, DOI 10.1200/JCO.1993.11.9.1717; STANFORD JL, 1987, AM J EPIDEMIOL, V125, P184, DOI 10.1093/oxfordjournals.aje.a114519; TOIKKANEN S, 1989, BRIT J CANCER, V60, P693, DOI 10.1038/bjc.1989.342; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351; WINCHESTER DJ, 1990, ARCH SURG-CHICAGO, V125, P886; WITZIG TE, 1994, CANCER, V74, P1752, DOI 10.1002/1097-0142(19940915)74:6<1752::AID-CNCR2820740618>3.0.CO;2-5	32	34	35	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1528	1530		10.1001/jama.281.16.1528	http://dx.doi.org/10.1001/jama.281.16.1528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227323				2023-01-03	WOS:000079857400035
J	Chamberlain, G; Steer, P				Chamberlain, G; Steer, P			ABC of labour care - Labour in special circumstances	BRITISH MEDICAL JOURNAL			English	Review									Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England	Singleton Hospital; Imperial College London	Chamberlain, G (corresponding author), Singleton Hosp, Swansea SA2 8QA, W Glam, Wales.							ERIKIM M, 1993, GUIDE EFFECTIVE CARE, P145; James DK, 1999, HIGH RISK PREGNANCY; Maternal and Child Health Research Consortium, 2000, CONF ENQ STILLB DEAT; Mercey D, 1998, BMJ-BRIT MED J, V316, P241, DOI 10.1136/bmj.316.7127.241	4	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1124	1127		10.1136/bmj.318.7191.1124	http://dx.doi.org/10.1136/bmj.318.7191.1124			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10213729	Green Published			2023-01-03	WOS:000080166000031
J	Bleyer, AJ; Hylander, B; Sudo, H; Nomoto, Y; de la Torre, E; Chen, RA; Burkart, JM				Bleyer, AJ; Hylander, B; Sudo, H; Nomoto, Y; de la Torre, E; Chen, RA; Burkart, JM			An international study of patient compliance with hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY	Context International differences in compliance of patients undergoing hemodialysis are poorly characterized and could contribute to international survival differences. Objective To compare international differences in patient compliance with hemodialysis treatments. Design A prospective observational study of patients undergoing hemodialysis in 1995 and a cross-sectional survey of health care professionals caring for hemodialyzed patients in 1996. Setting and Patients Four dialysis centers in the southeastern United States with 415 patients undergoing hemodialysis, 1 center in Sweden with 84 patients, and 4 centers in Japan with 194 patients participated in the prospective observational study. In the cross-sectional survey, nurses and nephrologists from the United States (n = 49), Japan (n = 21), and Sweden (n = 16) responded to questions regarding the compliance of their patients undergoing hemodialysis. Main Outcome Measures Percentage of patients who miss a dialysis treatment and number of missed dialysis treatments. Results Of 415 US patients, 147 missed 699 treatments over a 6-month period (28.1 missed treatments per 100 patient-months or 2.3% of all prescribed treatments). During a 3-month period, there were 0 missed treatments per 100 patient-months for patients from Japan and 0 missed treatments per 100 patient-months for patients from Sweden (P<.001). In the cross-sectional survey, the mean (SD) estimated percentage of patients missing a treatment per month was 4% (3%) for the United States, 0% for Japan, and 0.1% (3%) for Sweden (P<.001). Conclusions Noncompliance is much more common in US patients undergoing hemodialysis than Swedish and Japanese patients. The implications of these results for international differences in survival deserve further study.	Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Winston Salem, NC 27157 USA; Karolinska Hosp, S-10401 Stockholm, Sweden; Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan	Wake Forest University; Wake Forest Baptist Medical Center; Karolinska Institutet; Karolinska University Hospital; Tokai University	Bleyer, AJ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ableyer@wfubmc.edu						Anderson GF, 1997, HEALTH AFFAIR, V16, P163, DOI 10.1377/hlthaff.16.6.163; Bleyer A J, 1996, Nephrol News Issues, V10, P35; BLEYER AJ, 1995, J AM SOC NEPHROL, V6, P593; Gaylin W, 1996, HASTINGS CENT REP, V26, P43, DOI 10.2307/3528763; KIMMEL PL, 1995, J AM SOC NEPHROL, V5, P1826; KITAGAWA T, 1995, AM J EPIDEMIOL, V142, P612; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Scarr S, 1996, SCAND J PSYCHOL, V37, P93, DOI 10.1111/j.1467-9450.1996.tb00642.x; SHERMAN RA, 1994, AM J KIDNEY DIS, V24, P921, DOI 10.1016/S0272-6386(12)81061-4; Tsukamoto Y, 1996, Med Law, V15, P195; *US REN DAT SYST, 1996, AM J KIDNEY DIS S2, V28, pS146; *US REN DAT SYST, 1996, USRDS 1996 ANN DAT R, P14; 1997, DIAL TRANSPLANTATION, V26, pL6	13	68	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1211	1213		10.1001/jama.281.13.1211	http://dx.doi.org/10.1001/jama.281.13.1211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	181VW	10199431	Bronze			2023-01-03	WOS:000079464400036
J	Aldridge, J; Measham, F				Aldridge, J; Measham, F			Sildenafil (Viagra) is used as a recreational drug in England	BRITISH MEDICAL JOURNAL			English	Letter									Appl Res Ctr, Social Policy Social Problems SPARC, Manchester M13 9PL, Lancs, England	University of Manchester	Aldridge, J (corresponding author), Appl Res Ctr, Social Policy Social Problems SPARC, Manchester M13 9PL, Lancs, England.			Measham, Fiona/0000-0002-9322-1931				KIRBY R, 1999, STUDENT BMJ, V7, P11; Parker H., 1998, ILLEGAL LEISURE NORM	2	57	58	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1999	318	7184					669	669		10.1136/bmj.318.7184.669	http://dx.doi.org/10.1136/bmj.318.7184.669			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10066221	Green Published			2023-01-03	WOS:000079089200049
J	Jardine, E; O'Toole, M; Paton, JY; Wallis, C				Jardine, E; O'Toole, M; Paton, JY; Wallis, C			Current status of long term ventilation of children in the United Kingdom: questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To identify the number and current location of children, aged 0 to 16 years, requiring long term ventilation in the United Kingdom, and to establish their underlying diagnoses and ventilatory needs. Design Postal questionnaires sent to consultant respiratory paediatricians and all lead clinicians of intensive care and special care baby units in the United Kingdom. Subjects AU children in the United Kingdom who, when medically stable, continue to need a mechanical aid for breathing. Results 141 children requiring long term ventilation were identified from the initial questionnaire. Detailed information was then obtained on 136 children from 30 units. Thirty three children (24%) required continuous positive pressure ventilation by tracheostomy over 24 hours, and 103 received ventilation when asleep by a non-invasive mask (n = 62; 46%), tracheostomy (n = 32; 24%), or negative pressure ventilation (n = 9; 7%). Underlying conditions included neuromuscular disease (n = 62; 46%), congenital central hypoventilation syndrome (n = 18; 13%), spinal injury (n = 16; 12%), craniofacial syndromes (n = 9; 7%), bronchopulmonary dysplasia (n = 6; 4%), and others (n = 25; 18%). 93 children were cared for ar home. 43 children remained in hospital because of home circumstances, inadequate funding, or lack of provision of home carers. 96 children were of school age and 43 were attending mainstream school. Conclusions A significant increase in the number of children requiring long term ventilation in the United Kingdom has occurred over the past decade. Contributing factors include improved technology, developments in paediatric non-invasive ventilatory support, and a change in attitude towards home care. Successful discharge home and return to school is occurring even for severely disabled patients. Funding and home carers are common obstacles to discharge.	Inst Child Hlth, London WC1N 3JH, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Glasgow	Wallis, C (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 3JH, England.	c.wallis@ich.ucl.ac.uk	Paton, James/B-9541-2008						0	97	101	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	1999	318	7179					295	299		10.1136/bmj.318.7179.295	http://dx.doi.org/10.1136/bmj.318.7179.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZH	9924054	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000078436700022
J	Krantz, A				Krantz, A			Diversification of the drug discovery process	NATURE BIOTECHNOLOGY			English	Editorial Material									Bullet Therapeut, San Mateo, CA USA		Krantz, A (corresponding author), Bullet Therapeut, San Mateo, CA USA.								0	26	27	3	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1998	16	13					1294	1294		10.1038/4243	http://dx.doi.org/10.1038/4243			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	143AH	9853592	Bronze			2023-01-03	WOS:000077232600003
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	20	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1714	1714		10.1016/S0140-6736(05)61500-0	http://dx.doi.org/10.1016/S0140-6736(05)61500-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853480				2023-01-03	WOS:000077110300071
J	Eskinazi, DP				Eskinazi, DP			Factors that shape alternative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ Coll Phys & Surg, Rosenthal Ctr Complementary & Alternat Med, New York, NY 10032 USA	Columbia University	Eskinazi, DP (corresponding author), Columbia Univ Coll Phys & Surg, Rosenthal Ctr Complementary & Alternat Med, 630 W 168th St,Box 75, New York, NY 10032 USA.							*ALT MED PROGR ADV, 1994, TRANSCR ALT MED PROG; BENFIELD H, 1991, HEAVEN EARTH GUIDE C, P5; BENVENISTE J, 1988, NATURE, V334, P291, DOI 10.1038/334291a0; BURKHOLTZ H, 1994, FDA FOLLIES, V12, P110; Chez RA, 1997, AM J OBSTET GYNECOL, V177, P1156, DOI 10.1016/S0002-9378(97)70033-4; Donden Yeshi, 1986, HLTH BALANCE INTRO T; EISENBERG DM, 1993, NEW ENGL J MED, V328, P245; ERNST E, 1996, COMPLEMENTARY MED OB; ESKINAZI D, BOTANICALS ROLE US H; ESKINAZI D, 1996, J ALTERN COMPLEM MED, V2, P1; FUGHBERMAN A, 1996, ALTERNATIVE MED WHAT, P50; JONAS W, 1995, M ALT MED PROGR ADV; Merriam-Webster's, 1993, MERRIAM WEBSTERS COL; *MILB MEM FUND, 1998, ENH ACC ALT MED; *NIH, 1995, ALT MED EXP MED HOR; *ROS CTR COMPL ALT, 1998, INF SHEET WHAT IS CO; SCHIFF M., 1995, MEMORY WATER; Sharma H.M., 1996, FUNDAMENTALS COMPLEM; SIEGFRIED JD, 1998, PHARMA NEWSL     JAN; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; WISE TA, 1986, HINDU SYSTEM MED, P1	21	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1621	1623		10.1001/jama.280.18.1621	http://dx.doi.org/10.1001/jama.280.18.1621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820268				2023-01-03	WOS:000076852000034
J	Poller, L; Shiach, CR; MacCallum, PK; Johansen, AM; Munster, AM; Magalhaes, A; Jespersen, J				Poller, L; Shiach, CR; MacCallum, PK; Johansen, AM; Munster, AM; Magalhaes, A; Jespersen, J		European Concerted Action Anticoagu	Multicentre randomised study of computerised anticoagulant dosage	LANCET			English	Article							MANAGEMENT; WARFARIN	Background The demand for anticoagulant treatment is increasing. We compared the benefits of computer generated anticoagulaant dosing with traditional dosing decided by experienced medical staff in achieving target international normalised ratios (INRs). Methods In five European centres we randomly assigned 285 patients in the stabilisation period and stabilised patients to the computer-generated-dose group (n=137) or traditional-dose group (n=148). Centres had a specialist interest in oral anticoagulation but no previous experience with computer-generated dosing. The computer program calculated doses and times to next visit. Our main endpoint was time spent in target INR range (Rosendaal method). Findings For all patients combined, computer-generated dosing was significantly beneficial overall in achieving target INR (p=0.004). The mean time within target INR range for all patients and ail ranges was 63.3% (SD 28.0) of days in the computer-generated-dose group compared with 53.2% (27.7) in the traditional-dose group. For the stabilisation patients alone, computer-generated doses led to a non-significant benefit in all INR ranges (p=0.06), whereas in the stable patients the benefit was significant (p=0.02). Interpretation The computer program gave better INR control than the experienced medical staff and at least similar standards to the specialised centres should be generally available. Clinical outcome and cost effectiveness remain to be assessed.	Univ Manchester, Dept Pathol Sci, ECAA Cent Facil, Manchester M13 9PT, Lancs, England; Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England; St Bartholomews & Royal London Sch Med, MRC, Epidemiol & Med Care Unit, London, England; Aker Sykehus, Dept Med A, Oslo, Norway; Cent Sygehuset, Dept Clin Biochem, Esbjerg, Denmark; Ctr Hosp VN de Gaia, Serv Imunohemoterapia, Vila Nova De Gaia, Portugal	University of Manchester; University of Manchester; University of London; Queen Mary University London	Poller, L (corresponding author), Univ Manchester, Dept Pathol Sci, ECAA Cent Facil, Stopford Bldg, Manchester M13 9PT, Lancs, England.			Munster, Anna-Marie Bloch/0000-0002-3398-3977				AGENO W, 1997, THROMB HAEMOSTASIS, V77, P701; Baglin T, 1998, J CLIN PATHOL, V51, P89, DOI 10.1136/jcp.51.2.89; COLVIN BT, 1990, J CLIN PATHOL, V43, P177; GALVIN M, 1994, P DAWN AC US GROUP M, P1; HIRSH J, 1995, CHEST S, V108, P231; LOELIGER EA, 1984, THROMB HAEMOSTASIS, V54, P514; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; RYAN PJ, 1989, BRIT MED J, V299, P1207, DOI 10.1136/bmj.299.6709.1207; SMITH SGW, 1989, BRIT MED J, V299, P1529; WILSON R, 1984, BRIT MED J, V289, P422, DOI 10.1136/bmj.289.6442.422	11	175	181	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 7	1998	352	9139					1505	1509		10.1016/S0140-6736(98)04147-6	http://dx.doi.org/10.1016/S0140-6736(98)04147-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136ME	9820298				2023-01-03	WOS:000076862300008
J	Ramsay, DJ; Bowman, MA; Greenman, PE; Jiang, SP; Kushi, LH; Leeman, S; Lin, KM; Moerman, DE; Schnoll, SH; Walker, M; Waternaux, C; Wisneski, LA				Ramsay, DJ; Bowman, MA; Greenman, PE; Jiang, SP; Kushi, LH; Leeman, S; Lin, KM; Moerman, DE; Schnoll, SH; Walker, M; Waternaux, C; Wisneski, LA		NIN Consensus Dev Panel Acupuncture	Acupuncture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELECTROACUPUNCTURE EA; CHINESE ACUPUNCTURE; POSTOPERATIVE PAIN; NERVE-STIMULATION; SMOKING CESSATION; STROKE PATIENTS; ANALGESIA; MORPHINE; SITES; RATS	Objective.-To provide clinicians, patients, and the general public with a responsible assessment of the use and effectiveness of acupuncture to treat a variety of conditions. Participants.-A nonfederal, nonadvocate, 12-member panel representing the fields of acupuncture, pain, psychology, psychiatry, physical medicine and rehabilitation, drug abuse, family practice, internal medicine, health policy, epidemiology, statistics, physiology, biophysics, and the representatives of the public. In addition, 25 experts from these same fields presented data to the panel and a conference audience of 1200. Presentations and discussions were divided into 3 phases over 2 1/2 days: (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session; (2) questions and statements from conference attendees during open discussion periods that were part of the public session; and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. The conference was organized and supported by the Office of Alternative Medicine and the Office of Medical Applications of Research, National institutes of Health, Bethesda, Md. Evidence.-The literature, produced from January 1970 to October 1997, was searched through MEDLINE, Allied and Alternative Medicine, EMBASE, and MANTIS, as well as through a hand search of 9 journals that were not indexed by the National Library of Medicine. An extensive bibliography of 2302 references was provided to the panel and the conference audience. Expert speakers prepared abstracts of their own conference presentations with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience. Consensus Process.-The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in the open forum and scientific literature. The panel composed a draft statement, which was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel's final revisions within a few weeks of the conference. The statement is available at http://consensus.nih.gov. Conclusions.-Acupuncture as a therapeutic intervention is widely practiced in the United States. Although there have been many studies of its potential usefulness, many of these studies provide equivocal results because of design, sample size, and other factors. The issue is further complicated by inherent difficulties in the use of appropriate controls, such as placebos and sham acupuncture groups. However, promising results have emerged, for example, showing efficacy of acupuncture in adult postoperative and chemotherapy nausea and vomiting and in postoperative dental pain. There are other situations, such as addiction, stroke rehabilitation, headache, menstrual cramps, tennis elbow, fibromyalgia, myofascial pain, osteoarthritis, low back pain, carpal tunnel syndrome, and asthma, in which acupuncture may be useful as an adjunct treatment or an acceptable alternative or be included in a comprehensive management program. Further research is likely to uncover additional areas where acupuncture interventions will be useful.	Univ Penn Hlth Syst, Dept Family Practice & Community Med, Philadelphia, PA USA; Univ Maryland, College Pk, MD 20742 USA; Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA; Assoc Asian Pacific Community Hlth Org, Oakland, CA USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA; Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02215 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Harbor Med Ctr, Res Ctr Psychobiol Ethnic, Torrance, CA 90509 USA; Univ Michigan, Dearborn, MI 48128 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Columbia Univ, Div Biostat, New York, NY USA; New York State Psychiat Inst, New York, NY 10032 USA; Amer Wholehealth, Bethesda Ctr, Bethesda, MD USA	University of Pennsylvania; University System of Maryland; University of Maryland College Park; Michigan State University; Michigan State University College of Osteopathic Medicine; University of Minnesota System; University of Minnesota Twin Cities; Boston University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Michigan System; University of Michigan; Virginia Commonwealth University; Columbia University; New York State Psychiatry Institute	Ramsay, DJ (corresponding author), Univ Maryland, College Pk, MD 20742 USA.		bowman, marjorie a/F-7235-2013; Vincent, Charles A/D-1134-2010	bowman, marjorie a/0000-0002-1945-9212; Vincent, Charles A/0000-0003-0270-0222				Asagai Yoshimi, 1994, Laser Therapy, V6, P195; BIRCH S, 1996, ACUPUNCTURE EFFICACY; Bullock M L, 1997, J Altern Complement Med, V3, P31, DOI 10.1089/acm.1997.3.31; BULLOCK ML, 1989, LANCET, V1, P1435; BULLOCK ML, 1987, ALCOHOL CLIN EXP RES, V11, P292, DOI 10.1111/j.1530-0277.1987.tb01310.x; CAHN AM, 1978, LANCET, V1, P182; Cassapakis C., 1995, P 3 S SOC AC RES SEP, P1; Chang FY, 1996, AM J CHINESE MED, V24, P185, DOI 10.1142/S0192415X96000244; CHEN XH, 1992, EUR J PHARMACOL, V211, P203; Cheng X. D., 1997, CHIN J IMMUNOL, V13, P68; CHRISTENSEN PA, 1989, BRIT J ANAESTH, V62, P258, DOI 10.1093/bja/62.3.258; ClavelChapelon F, 1997, PREV MED, V26, P25, DOI 10.1006/pmed.1996.9997; Diehl D L, 1997, J Altern Complement Med, V3, P119, DOI 10.1089/acm.1997.3.119; DU LN, IN PRESS CHIN J IMMU; DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508; DUNDEE JW, 1986, BRIT MED J, V293, P583, DOI 10.1136/bmj.293.6547.583; DUNDEE JW, 1991, CLIN PHARMACOL THER, V50, P78, DOI 10.1038/clpt.1991.106; DUNDEE JW, 1989, BRIT J ANAESTH, V63, P612, DOI 10.1093/bja/63.5.612; DUNDEE JW, 1991, POSTGRAD MED J, V67, P47; HAMMERSCHLAG R, 1997, COMPLEMENT THER MED, V5, P133; HAN JS, 1992, NEWS PHYSIOL SCI, V7, P176; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; He D, 1997, PREV MED, V26, P208, DOI 10.1006/pmed.1996.0125; HELMS JM, 1996, ACUPUNCTURE ENEGETIC; Hoizey D., 1988, HIST CHINESE MED; Jin HO, 1996, AM J PHYSIOL-GASTR L, V271, pG524, DOI 10.1152/ajpgi.1996.271.3.G524; JOHANSSON K, 1993, NEUROLOGY, V43, P2189, DOI 10.1212/WNL.43.11.2189; Kaptchuk T, 1983, WEB HAS NO WEAVER; KAPTCHUK TJ, IN PRESS B HIST MED; Konefal J., 1995, ALTERNATIVE MED J, V2, P8; Kosten, 1993, AM J ADDICTIONS, V2, P194; Lao L, 1996, J Altern Complement Med, V2, P27, DOI 10.1089/acm.1996.2.27; Lao L, 1996, J Altern Complement Med, V2, P23, DOI 10.1089/acm.1996.2.23; LAO LX, 1995, ORAL SURG ORAL MED O, V79, P423, DOI 10.1016/S1079-2104(05)80121-0; LI YY, 1992, AM J GASTROENTEROL, V87, P1372; LIAO SJ, 1994, PRINCIPLES PRACTICE; Lu Gwei- Djen, 1980, CELESTIAL LANCETS HI; Lytle C D, 1996, J Altern Complement Med, V2, P253, DOI 10.1089/acm.1996.2.253; MARTELETE M, 1985, ACUPUNCTURE ELECTRO, V10, P183, DOI 10.3727/036012985816714432; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; Naeser M A, 1996, J Altern Complement Med, V2, P211, DOI 10.1089/acm.1996.2.211; NAESER MA, 1994, ACUPUNCTURE ELECTRO, V19, P227, DOI 10.3727/036012994816357231; NAESER MA, 1927, ACUPUNCT ELECT RES, V19, P22794; Naeser MA, 1996, LASERS SURG MED S, V8, P7; *NIH TECHN ASS, 1996, J ALTERN COMPLEMENT, V2, P1; NORHEIM AJ, 1996, COMPLEMENT THER MED, V4, P8, DOI DOI 10.1016/S0965-2299(96)80049-5; PATEL M, 1989, INT J EPIDEMIOL, V18, P900, DOI 10.1093/ije/18.4.900; Porkert M., 1974, THEORETICAL FDN CHIN; PORTENOY RK, 1993, DRUG THER, V23, P41; SHLAY JC, IN PRESS JAMA; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; SINGH BB, 1997, COMPLEMENT THER MED, V5, P3; SUNG YF, 1977, ANESTH ANALG, V56, P473; Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Unschuld Paul O., 1985, MED CHINA HIST IDEAS; VINCENT C, 1995, J ROY SOC MED, V88, P199; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; WHITE AR, 1996, COCHRANE DATABASE SY; YANG QY, 1992, J REPROD MED, V1, P6; YANG SP, 1997, ACTA PHYSL SINICA, V49, P354; YANG SP, 1994, ACUPUNCTURE ELECTRO, V19, P9; YU J, 1995, CHIN J INTEGRATED TR, V1, P13; Zhang Y, 1996, ACUPUNCTURE ELECTRO, V21, P177, DOI 10.3727/036012996816356870; ZHU CB, 1995, ACTA PHARM SINIC, V16, P311; 1996, FED REG, V61, P64616; [No title captured]	68	834	852	8	216	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1998	280	17					1518	1524						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134RR	9809733				2023-01-03	WOS:000076757200026
J	McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G				McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G			Confidential inquiry into quality of care before admission to intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIOPULMONARY ARREST; AVOIDABLE FACTORS; CARDIAC-ARREST; HEAD-INJURY; DOCTORS; CONSULTANTS; DEATHS; MANAGEMENT; PHYSICIANS; RESPONSES	Objective: To examine the prevalence, nature, causes, and consequences of suboptimal care before admission to intensive care units, and to suggest possible solutions. Design: Prospective confidential inquiry on the basis of structured interviews and questionnaires. Setting: A large district general hospital and a teaching hospital. Subjects: A cohort of 100 consecutive adult emergency admissions, 50 in each centre. Main outcome measures: Opinions of two external assessors on quality of care especially recognition, investigation, monitoring, and management of abnormalities of airway, breathing, and circulation, and oxygen therapy and monitoring. Results: Assessors agreed that 20 patients were well managed (group 1) and 54 patients received suboptimal care (group 2), Assessors disagreed on quality of management of 26 patients (group 3). The casemix and severity of illness, defined by the acute physiology and chronic health evaluation (APACHE II) score, were similar between centres and the three groups. In groups 1, 2, and 3 intensive care mortalities were 5 (25%), 26 (48%), and 6 (23%) respectively (P = 0.04) (group 1 versus group 2, P = 0.07). Hospital mortalities were 7 (35%), 30 (56%), and 8 (31%) (P = 0.07) and standardised hospital mortality ratios (95% confidence intervals) were 1.23 (0.49 to 2.54), 1.4 (0.94 to 2.0), and 1.26 (0.54 to 2.48) respectively. Admission to intensive care was considered late in 37 (69%) patients in group 2. Overall, a minimum of 4.5% and a maximum of 41% of admissions were considered potentially avoidable. Suboptimal care contributed to morbidity or mortality in most instances. The main causes of suboptimal care were failure of organisation, lack of knowledge, failure to appreciate clinical urgency, lack of supervision, and failure to seek advice. Conclusions: The management of airway breathing, and circulation, and oxygen therapy and monitoring in severely ill patients before admission to intensive care units may frequently be suboptimal. Major consequences may include increased morbidity and mortality and requirement for intensive care. Possible solutions include improved teaching, establishment of medical emergency teams, and widespread debate on the structure and process of acute care.	Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England; Southampton Gen Hosp, Intens Care Unit, Southampton SO16 6YD, Hants, England; Broomfield Hosp, Chelmsford CM1 7ET, Essex, England; Royal Cornwall Hosp, Truro TR1 3L, Cornwall, England; Univ Portsmouth, Sch Math Studies, Portsmouth PO1 2EG, Hants, England	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Southampton; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Royal Cornwall Hospital; University of Portsmouth	McQuillan, P (corresponding author), Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England.							ALLAN A, 1994, CLIN INTENSIVE CARE, V5, P152; Altman DG, 1991, PRACTICAL STAT MED R; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BOYD O, 1993, LANCET, V341, P1573, DOI 10.1016/0140-6736(93)90706-M; Capewell S, 1996, BRIT MED J, V312, P991; Daffurn K, 1994, Intensive Crit Care Nurs, V10, P115, DOI 10.1016/0964-3397(94)90007-8; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; *DEPT HLTH UK, 1992, HLTH NAT; DILLNER L, 1995, BRIT MED J, V310, P757, DOI 10.1136/bmj.310.6982.757; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRANKLIN C, 1994, CRIT CARE MED, V22, P244, DOI 10.1097/00003246-199402000-00014; GEORGE AL, 1989, AM J MED, V87, P28; Goldhill DR, 1996, ANAESTHESIA, V51, P719, DOI 10.1111/j.1365-2044.1996.tb07882.x; GOULD TH, 1994, ANAESTHESIA, V49, P807; Hourihan F., 1995, CLIN INTENSIVE CARE, V6, P269, DOI [10.3109/tcic.6.6.269.272, DOI 10.3109/TCIC.6.6.269.272]; JEFFREYS RV, 1981, LANCET, V2, P459; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; MATHER HM, 1995, BRIT MED J, V311, P1060, DOI 10.1136/bmj.311.7012.1060; MCGLOIN H, 1997, CLIN INTENSIVE CARE, V8, P104; MONTGOMERY H, 1994, BRIT MED J, V309, P1551, DOI 10.1136/bmj.309.6968.1551; MOSS F, 1995, BRIT MED J, V310, P925, DOI 10.1136/bmj.310.6984.925; *NAT CONF ENQ PER, 1993, NAT CONF ENQ PER DEA; PALAZZO M, 1993, LANCET, V342, P307; PAPPACHAN VJ, 1997, CLIN INTENSIVE CARE, V8, P97; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; POPE A, 1960, PENGUIN DICT QUOTATI; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; *ROYAL COLL PHYS L, 1996, FUT PATT CAR GEN SPE; *ROYAL COLL SURG E, 1985, REP WORK PART MAN PA; SAX FL, 1987, CRIT CARE MED, V15, P510, DOI 10.1097/00003246-198705000-00012; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SIEGAL S, 1988, STAT BEHAV SCI; SMITH J, 1995, BRIT MED J, V310, P953, DOI 10.1136/bmj.310.6985.953; STONEHAM MD, 1994, LANCET, V344, P1339, DOI 10.1016/S0140-6736(94)90697-1; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNNELL RD, 1996, CLIN INTENSIVE CARE, V7, P55; 1994, REP CONF ENQ MAT DEA	42	603	623	3	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1853	1858						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632403				2023-01-03	WOS:000074686500015
J	Rogal, AP				Rogal, AP			Brignole	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Rogal, AP (corresponding author), 200 South St, Brookline, MA 02167 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					691	692		10.7326/0003-4819-128-8-199804150-00016	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537945				2023-01-03	WOS:000073052500012
J	Northover, J				Northover, J			Realism or nihilism in bowel cancer follow-up?	LANCET			English	Editorial Material							COLORECTAL-CANCER; COLON-CANCER; CEA; COST		St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Imperial College London	Northover, J (corresponding author), St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England.							Audisio RA, 1996, ANN SURG ONCOL, V3, P349, DOI 10.1007/BF02305664; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; COCHRANE JPS, 1980, BRIT MED J, V280, P593, DOI 10.1136/bmj.280.6214.593; FLETCHER RH, 1993, JAMA-J AM MED ASSOC, V270, P987, DOI 10.1001/jama.270.8.987; HAWARD R, 1997, IMPROVING OUTCOMES C; KIEVIT J, 1995, EUR J CANCER, V31A, P1222, DOI 10.1016/0959-8049(95)00155-C; MAKELA J, 1996, ARCH SURG-CHICAGO, V130, P1062; MARTIN EW, 1979, AM J SURG, V137, P167, DOI 10.1016/0002-9610(79)90137-5; MOERTEL C, 1978, JAMA-J AM MED ASSOC, V78, P1065; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; OHLSSON B, 1995, DIS COLON RECTUM, V38, P219; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; SUGARBAKER P, 1994, TUMORI, V31, P126; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837	15	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1074	1076		10.1016/S0140-6736(05)79375-2	http://dx.doi.org/10.1016/S0140-6736(05)79375-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660572				2023-01-03	WOS:000073090200004
J	De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP				De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP			Altered nociception, analgesia and aggression in mice lacking the receptor for substance P	NATURE			English	Article							STRESS-INDUCED ANALGESIA; PRIMARY SENSORY NEURONS; DORSAL HORN; SPINAL-CORD; RAT; ANTAGONIST; ACTIVATION; INHIBITION; INDUCTION; LOCALIZATION	The peptide neurotransmitter substance P modulates sensitivity to pain by activating the neurokinin-1 (NK-1) receptor, which is expressed by discrete populations of neurons throughout the central nervous system(1-4). Substance P is synthesized by small-diameter sensory 'pain' fibres(5), and release of the peptide into the dorsal horn of the spinal cord following intense peripheral stimulation(6) promotes central hyperexcitability and increased sensitivity to pain(7-10). However, despite the availability of specific NK-1 antagonists(4), the function of substance P in the perception of pain remains unclear Here we investigate the effect of disrupting the gene encoding the NK-1 receptor in mice, We found that the mutant mice were healthy and fertile, but the characteristic amplification ('wind up') and intensity coding of nociceptive reflexes was absent, Although substance P did not mediate the signalling of acute pain or hyperalgesia, it was essential for the full development of stress-induced analgesia and for an aggressive response to territorial challenge, demonstrating that the peptide plays an unexpected role in the adaptive response to stress.	MRC, Mol Neurobiol Lab, Div Neurobiol, Cambridge CB2 2QH, England; Univ Miguel Hernandez, Inst Neurociencias, Alicante 03080, Spain; Univ Alcala de Henares, Fac Med, Dept Fisiol, Madrid 28871, Spain; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad de Alcala; University of Edinburgh	Hunt, SP (corresponding author), MRC, Mol Neurobiol Lab, Div Neurobiol, Hills Rd, Cambridge CB2 2QH, England.	hunt@mrc-lmb.cam.ac.uk	de Felipe, Carmen/D-3813-2012; HUNT, STEPHEN P/C-1646-2008	Laird, Jennifer/0000-0001-6570-3995; Herrero, Juan F./0000-0003-1986-3482				Abbadie C, 1997, PAIN, V69, P101, DOI 10.1016/S0304-3959(96)03285-X; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; CERVERO F, 1985, J PHYSIOL-LONDON, V365, P223, DOI 10.1113/jphysiol.1985.sp015768; Chapman V, 1996, J NEUROPHYSIOL, V76, P1817, DOI 10.1152/jn.1996.76.3.1817; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; DUGGAN AW, 1988, BRAIN RES, V451, P261, DOI 10.1016/0006-8993(88)90771-8; HERRERO JF, 1993, BRIT J PHARMACOL, V110, P303, DOI 10.1111/j.1476-5381.1993.tb13809.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; LAIRD JMA, 1993, BRIT J PHARMACOL, V109, P713, DOI 10.1111/j.1476-5381.1993.tb13632.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MAENO H, 1993, MOL BRAIN RES, V18, P43, DOI 10.1016/0169-328X(93)90172-L; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; MANTYH PW, 1989, J NEUROSCI, V9, P258; MAREK P, 1992, BRAIN RES, V578, P197, DOI 10.1016/0006-8993(92)90248-8; MCCARTHY PW, 1989, NEUROSCIENCE, V28, P745, DOI 10.1016/0306-4522(89)90019-5; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; NOGUCHI K, 1992, J NEUROSCI, V12, P2563; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; SIEGEL A, 1995, AGGRESSIVE BEHAV, V21, P49, DOI 10.1002/1098-2337(1995)21:1<49::AID-AB2480210108>3.0.CO;2-2; VANDERAH TW, 1992, J PHARMACOL EXP THER, V262, P190; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7; YAKSH TL, 1994, TXB PAIN, P165; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	29	612	619	2	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					394	397		10.1038/32904	http://dx.doi.org/10.1038/32904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537323				2023-01-03	WOS:000072713600053
J	Holt, PG; Sly, PD; Smith, W				Holt, PG; Sly, PD; Smith, W			Sublingual immunotherapy for allergic respiratory disease	LANCET			English	Editorial Material									TVWT Inst Child Hlth Res, W Perth, WA 6872, Australia		Holt, PG (corresponding author), TVWT Inst Child Hlth Res, W Perth, WA 6872, Australia.		Sly, Peter D/F-1486-2010; Holt, Patrick G/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Holt, Patrick G/0000-0003-1193-0935				Barnes PJ, 1996, AM J RESP CRIT CARE, V154, P1227, DOI 10.1164/ajrccm.154.5.8912730; *BRIT SOC ALL CLIN, 1993, CLIN EXP ALLERGY  S3, V23, P1; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0	9	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					613	614		10.1016/S0140-6736(05)78425-7	http://dx.doi.org/10.1016/S0140-6736(05)78425-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500315				2023-01-03	WOS:000072364200005
J	Tyrer, P; Evans, K; Gandhi, N; Lamont, A; Harrison-Read, P; Johnson, T				Tyrer, P; Evans, K; Gandhi, N; Lamont, A; Harrison-Read, P; Johnson, T			Randomised controlled trial of two models of care for discharged psychiatric patients	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-ILLNESS; SCALE	Objective: To compare the clinical outcome and costs of care of psychiatric patients allocated to community multidisciplinary teams or to hospital based care programmes after discharge from inpatient care. Design: Randomised controlled trial. Setting: Inner London (Paddington and North Kensington) and outer London (Brent) psychiatric services. Subjects: 155 patients with severe mental illness with a previous admission within the past 2 years. Main outcome measures: Ratings of clinical psychopathology, depression, anxiety, and social functioning; comprehensive costs of health care. Results: Clinical outcomes were available for 133 patients and cost data for 144 patients after 1 year. The clinical outcomes of the two models of care were essentially similar, but admission to hospital was more likely in the hospital based care group and the costs of health care were 14% greater per patient than in the community group. This difference, however, was dwarfed by a twofold difference in the costs of care in the outer London services compared with those in inner London. This was explained largely by greater inpatient care for outer London patients (58 median bed days v 18 for inner London patients), more of which was provided by extracontractual referrals to other psychiatric hospitals as Brent had only 0.28/1000 beds available for acute adult patients compared with 0.82/1000 in Paddington and North Kensington over the period of the study. Conclusion: Aftercare by community teams for psychiatric patients with severe mental illness has a similar outcome to hospital based aftercare but with fewer admissions to hospital. When psychiatric bed requirements are insufficient for a population, however, neither form of aftercare is effective as greater use of hospital beds elsewhere swamps any advantage of community care programmes, with disintegration and discontinuity of psychiatric services leading to escalating costs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Paterson Ctr, Div Neurosci & Psychol Med, London W2 1PD, England; Cent Middlesex Hosp, Pk Royal Ctr Mental Hlth, London NW10 7NS, England; Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	Imperial College London; Imperial College London; MRC Biostatistics Unit; University of Cambridge	Tyrer, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Paterson Ctr, Div Neurosci & Psychol Med, London W2 1PD, England.	p.tyrer@ic.ac.uk						ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; CREED F, 1995, COMMUNITY PSYCHIAT A, P11; Department of Health, 1996, BUILD BRIDG GUID ARR; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; HOLLANDER D, 1994, PSYCHIAT B, V18, P532; HOULT J, 1984, ACTA PSYCHIAT SCAND, V69, P359, DOI 10.1111/j.1600-0447.1984.tb02506.x; KINGDON D.G, 1994, PSYCHIATRIC B, V18, P68; KNAPP M, 1994, BRIT J PSYCHIAT, V165, P195, DOI 10.1192/bjp.165.2.195; MARSHALL M, 1996, SCHIZOPHRENIA MODULE; MCGUFFIN P, 1993, OPCRIT VERSION 3 3 P; *MILMIS PROJ GROUP, 1995, PSYCHIAT B, V19, P276; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; SPITZER RL, 1987, STRUCTURAL CLIN INTE; Stein LI, 1980, ARCH GEN PSYCHIAT, V36, P1073; TYRER P, 1995, LANCET, V345, P756, DOI 10.1016/S0140-6736(95)90640-1; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; TYRER P, 1995, COMMUNITY PSYCHIAT A; TYRER P, 1995, EMERGENCY MENTAL HLT, P197; Tyrer P, 1990, MEASURING HUMAN PROB, P119; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	61	63	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					106	109						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR408	9462315				2023-01-03	WOS:000071492300018
J	Dennis, DT; Meltzer, MI				Dennis, DT; Meltzer, MI			Antibiotic prophylaxis after tick bites	LANCET			English	Editorial Material							LYME-DISEASE; MISDIAGNOSIS; PREVENTION		CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA	Dennis, DT (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FT COLLINS,CO, USA.		Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472				Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042	9	15	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1192		10.1016/S0140-6736(05)63449-6	http://dx.doi.org/10.1016/S0140-6736(05)63449-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652556				2023-01-03	WOS:A1997YD23800005
J	Larkin, M				Larkin, M			US online pharmacies strive for respectability	LANCET			English	Editorial Material																		1999, LANCET, V354, P138	1	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					782	782		10.1016/S0140-6736(05)76034-7	http://dx.doi.org/10.1016/S0140-6736(05)76034-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475233				2023-01-03	WOS:000082233000077
J	Singer, M; Little, R				Singer, M; Little, R			ABC of intensive care - Cutting edge	BRITISH MEDICAL JOURNAL			English	Article									UCL, Bloomsbury Inst Intens Care Med, London WC1E 6BT, England; Univ Manchester, NW Injury Res Ctr, Manchester M13 9PL, Lancs, England	University of London; University College London; University of Manchester	Little, R (corresponding author), UCL, Bloomsbury Inst Intens Care Med, London WC1E 6BT, England.		Singer, Mervyn/J-4425-2012	Singer, Mervyn/0000-0002-1042-6350					0	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					501	504		10.1136/bmj.319.7208.501	http://dx.doi.org/10.1136/bmj.319.7208.501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454407	Green Published			2023-01-03	WOS:000082199600029
J	Steer, P				Steer, P			ABC of labour care - Assessment of mother and fetus in labour	BRITISH MEDICAL JOURNAL			English	Review							ACTIVE MANAGEMENT		Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Sch Med, London, England	Imperial College London	Steer, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Sch Med, London, England.							*DEP HLTH, 1992, CHANG CHILDB; Ingermarsson J, 1993, FETAL HEART RATE MON; Maternal and Child Health Research Consortium, 2000, CONF ENQ STILLB DEAT; ODRISCOLL K, 1984, OBSTET GYNECOL, V63, P485; ODRISCOLL K, 1969, BMJ-BRIT MED J, V2, P477, DOI 10.1136/bmj.2.5655.477; ODRISCOLL K, 1973, BMJ-BRIT MED J, V3, P135, DOI 10.1136/bmj.3.5872.135; Spencer JAD, 1993, INTRAPARTUM FETAL SU; Westgren M, 1998, BRIT J OBSTET GYNAEC, V105, P29, DOI 10.1111/j.1471-0528.1998.tb09346.x	8	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1999	318	7187					858	+		10.1136/bmj.318.7187.858	http://dx.doi.org/10.1136/bmj.318.7187.858			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185DM	10092268	Green Published			2023-01-03	WOS:000079652900037
J	Greendale, GA; Lee, NP; Arriola, ER				Greendale, GA; Lee, NP; Arriola, ER			The menopause	LANCET			English	Review							HORMONE-REPLACEMENT THERAPY; LOW-DOSE ESTRADIOL; POSTMENOPAUSAL UROGENITAL ATROPHY; CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE; BONE-MINERAL DENSITY; ESTROGEN REPLACEMENT; URINARY-INCONTINENCE; SURGICAL MENOPAUSE; VAGINAL RING	Menopause is diagnosed after 12 months of amenorrhoea resulting from the permanent cessation of ovarian function. The mean age at menopause is 51 years. The perimenopause, a time of changing ovarian function, precedes the final menses by several years. The physiology and clinical manifestations of this transition to menopause are not well understood; however, some symptoms, such as hot flashes, certainty begin in the perimenopause. Causal associations between menopause and several symptoms and diseases are proposed. The evidence for these associations varies and is reviewed. Hormone replacement therapy can be directed-at symptom relief or at prevention or treatment of chronic diseases. Doses and routes of hormone replacement therapy vary by indication. Complications of hormone replacment therapy depend on the regimen used. Knowing the expected vaginal bleeding pattern for each hormone replacement therapy regimen is important, since unexpected bleeding may signal endometrial hyperplasia. Postmenopausal hormone therapy is a complex intervention that produces positive and negative specific health effects. Overall, based on observational studies, postmenopausal women who use hormones have a 30-50% lower all-cause mortality rate than those who do not use hormones. It is important to recognise that the value that individual women place on various health outcomes associated with hormone replacement therapy may differ. Thus, the decision to use hormone replacement therapy should be made jointly by each woman and her health-care provider, after careful consideration of possible benefits, risks, and her personal preferences.	Univ Calif Los Angeles, Sch Med, Div Geriatr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pharmaceut Serv, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Greendale, GA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Geriatr, 2339 PVUB,Box 951687, Los Angeles, CA 90095 USA.		Hilton, Paul/D-9300-2011; Hunter, Myra S/F-2133-2010	Hilton, Paul/0000-0002-2541-5195; 				*ACOG COMM OP, 1993, J GYNECOL OBSTET, V43, P89; *AM COLL OBST GYN, 1992, ACOG TECHN B, V166, P166; AMY JJ, 1993, INT J FERTIL, V38, P5; ARCHER DF, 1994, OBSTET GYNECOL, V83, P686; Avis Nancy E., 1994, Annals of Epidemiology, V4, P214; Ayton RA, 1996, BRIT J OBSTET GYNAEC, V103, P351, DOI 10.1111/j.1471-0528.1996.tb09741.x; BEYENE Y, 1986, CULT MED PSYCHIAT, V10, P47, DOI 10.1007/BF00053262; BOLAJI II, 1993, EUR J OBSTET GYN R B, V48, P61, DOI 10.1016/0028-2243(93)90054-G; Bourne T, 1997, INT J GYNECOL OBSTET, V56, P115, DOI 10.1016/S0020-7292(96)02813-5; Brinton LA, 1997, ENDOCRIN METAB CLIN, V26, P361, DOI 10.1016/S0889-8529(05)70252-8; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Casson PR, 1996, INT J FERTIL MENOP S, V41, P412; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; Cerin A, 1996, NEW ENGL J MED, V334, P668, DOI 10.1056/NEJM199603073341018; CHAI CU, 1997, THROMB HAEMOSTASIS, V78, P70; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIGNARELLI M, 1989, GYNECOL OBSTET INVES, V27, P34, DOI 10.1159/000293612; COBLEIGH MA, 1995, JAMA-J AM MED ASSOC, V273, P378; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Creasy G W, 1992, Obstet Gynecol Surv, V47, P654, DOI 10.1097/00006254-199209000-00026; CROOK D, 1997, BRIT J OBSTET GYNAEC, V104, pS4; Cumming RG, 1997, AM J EPIDEMIOL, V145, P242; Cushing KL, 1998, OBSTET GYNECOL, V91, P35, DOI 10.1016/S0029-7844(97)00577-2; DIOKNO AC, 1990, ARCH INTERN MED, V150, P197, DOI 10.1001/archinte.150.1.197; Dunn LB, 1997, ARCH DERMATOL, V133, P339, DOI 10.1001/archderm.133.3.339; ETTINGER B, 1994, OBSTET GYNECOL, V83, P693; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; Fantl JA, 1996, OBSTET GYNECOL, V88, P745; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; Ferenczy A, 1997, MATURITAS, V26, P219, DOI 10.1016/S0378-5122(97)01104-3; FIELD CS, 1993, AM J OBSTET GYNECOL, V168, P114, DOI 10.1016/S0002-9378(12)90897-2; Foster RH, 1997, DRUG AGING, V11, P309, DOI 10.2165/00002512-199711040-00006; FRANCESCHI S, 1990, TUMORI, V76, P439, DOI 10.1177/030089169007600505; Gelfand MM, 1997, CLIN THER, V19, P383, DOI 10.1016/S0149-2918(97)80125-7; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GILLET JY, 1994, MATURITAS, V19, P103, DOI 10.1016/0378-5122(94)90060-4; GINSBURG ES, 1994, OBSTET GYN CLIN N AM, V21, P381; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Grady D, 1997, J NATL CANCER I, V89, P1088, DOI 10.1093/jnci/89.15.1088; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greendale GA, 1997, ENDOCRIN METAB CLIN, V26, P261, DOI 10.1016/S0889-8529(05)70246-2; GREENDALE GA, 1996, J WOMENS HEALTH, V5, P445; Griebling TL, 1997, ENDOCRIN METAB CLIN, V26, P347, DOI 10.1016/S0889-8529(05)70251-6; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grodstein F, 1996, J AM DENT ASSOC, V127, P370, DOI 10.14219/jada.archive.1996.0208; HANSEN MA, 1991, BMJ-BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961; HAPELS AA, 1981, MATURITAS, V3, P321; HARRIS ST, 1991, ARCH INTERN MED, V151, P1980, DOI 10.1001/archinte.151.10.1980; HAY AG, 1994, BRIT J PSYCHIAT, V164, P513, DOI 10.1192/bjp.164.4.513; HICKOK LR, 1993, OBSTET GYNECOL, V82, P919; HINTON P, 1990, INT UROGYNECOL J, V1, P800; Hirvonen E, 1997, BRIT J OBSTET GYNAEC, V104, P19, DOI 10.1111/j.1471-0528.1997.tb11563.x; HIRVONEN E, 1995, MATURITAS, V21, P39, DOI 10.1016/0378-5122(94)00862-2; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNTER MS, 1990, PSYCHOSOM MED, V52, P357, DOI 10.1097/00006842-199005000-00009; JENSEN J, 1991, BAILLIERE CLIN OB GY, V5, P867, DOI 10.1016/S0950-3552(05)80294-9; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; KAUFERT PA, 1992, MATURITAS, V14, P143, DOI 10.1016/0378-5122(92)90006-P; KICOVIC PM, 1980, MATURITAS, V2, P275, DOI 10.1016/0378-5122(80)90029-8; Kornhauser C, 1997, J HUM HYPERTENS, V11, P405, DOI 10.1038/sj.jhh.1000420; Krall EA, 1997, AM J MED, V102, P536; KRONENBERG F, 1994, EXP GERONTOL, V29, P319, DOI 10.1016/0531-5565(94)90012-4; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; LAVECCHIA C, 1992, J EPIDEMIOL COMMUN H, V46, P234, DOI 10.1136/jech.46.3.234; LINDGREN R, 1993, ACTA OBSTET GYN SCAN, V72, P292, DOI 10.3109/00016349309068040; LINDSAY R, 1980, LANCET, V2, P1151; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MAGOS AL, 1985, OBSTET GYNECOL, V65, P496; MANSON JE, 1994, AM HEART J, V128, P1337, DOI 10.1016/0002-8703(94)90257-7; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; METCALF MG, 1979, NEW ZEAL MED J, V89, P45; METTLER L, 1991, MATURITAS, V14, P23, DOI 10.1016/0378-5122(91)90144-F; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MILSOM I, 1993, J UROLOGY, V149, P1459, DOI 10.1016/S0022-5347(17)36415-7; MYERS LS, 1990, J CLIN ENDOCR METAB, V70, P1124, DOI 10.1210/jcem-70-4-1124; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NACHTIGALL LE, 1994, FERTIL STERIL, V61, P178; Nachtigall LE, 1995, MATURITAS, V22, pS43, DOI 10.1016/0378-5122(95)00963-9; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P115, DOI 10.1016/S0002-9378(97)70448-4; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NILSSON K, 1992, MATURITAS, V15, P121, DOI 10.1016/0378-5122(92)90246-Z; Notelovitz M, 1997, MENOPAUSE, V4, P80; OSBORN M, 1988, BMJ-BRIT MED J, V296, P259; Pearlstein T, 1997, ENDOCRIN METAB CLIN, V26, P279, DOI 10.1016/S0889-8529(05)70247-4; Portaluppi F, 1997, HYPERTENSION, V29, P976, DOI 10.1161/01.HYP.29.4.976; POTTER JD, 1995, JNCI-J NATL CANCER I, V87, P1039, DOI 10.1093/jnci/87.14.1039; RAUDASKOSKI TH, 1995, AM J OBSTET GYNECOL, V172, P114, DOI 10.1016/0002-9378(95)90095-0; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; REKERS H, 1992, MATURITAS, V15, P101, DOI 10.1016/0378-5122(92)90244-X; Ross D, 1997, AM J OBSTET GYNECOL, V177, P937, DOI 10.1016/S0002-9378(97)70297-7; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; SCHMIDT G, 1994, GYNECOL OBSTET INVES, V38, P253, DOI 10.1159/000292492; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Schneider LS, 1997, AM J GERIAT PSYCHIAT, V5, P97; SEELEY DG, 1995, ARCH INTERN MED, V155, P293, DOI 10.1001/archinte.155.3.293; Sener AB, 1996, FERTIL STERIL, V65, P354; SHERWIN BB, 1985, PSYCHOSOM MED, V47, P339, DOI 10.1097/00006842-198507000-00004; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; SMITH P, 1993, MATURITAS, V16, P145, DOI 10.1016/0378-5122(93)90059-Q; SOBEL NB, 1994, OBSTET GYN CLIN N AM, V21, P299; Sowers MR, 1995, EPIDEMIOL REV, V17, P287, DOI 10.1093/oxfordjournals.epirev.a036194; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STONE SC, 1975, OBSTET GYNECOL, V45, P625, DOI 10.1097/00006250-197506000-00005; STUDD JWW, 1994, BRIT J OBSTET GYNAEC, V101, P787, DOI 10.1111/j.1471-0528.1994.tb11947.x; Sturdee DW, 1997, BRIT J OBSTET GYNAEC, V104, P1109, DOI 10.1111/j.1471-0528.1997.tb10932.x; Suhonen S, 1997, ACTA OBSTET GYN SCAN, V76, P145, DOI 10.3109/00016349709050071; TAITEL HF, 1995, INT J FERTIL MENOP S, V40, P207; THOMPSON B, 1973, J BIOSOC SCI, V5, P71, DOI 10.1017/S0021932000008956; VANDERMOOREN MJ, 1994, MATURITAS, V20, P175, DOI 10.1016/0378-5122(94)90014-0; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; VOOIJS GP, 1995, EUR J OBSTET GYN R B, V62, P101, DOI 10.1016/0301-2115(95)02170-C; WALTER S, 1978, UROL INT, V33, P135, DOI 10.1159/000280190; WATTS NB, 1995, OBSTET GYNECOL, V85, P529, DOI 10.1016/0029-7844(94)00448-M; WHITEHEAD MI, 1990, OBSTET GYNECOL, V75, pS59; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213; WREN BG, 1997, INT J GYNECOL CANCER, V4, P217; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	122	338	349	1	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 13	1999	353	9152					571	580		10.1016/S0140-6736(98)05352-5	http://dx.doi.org/10.1016/S0140-6736(98)05352-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	168BG	10028999				2023-01-03	WOS:000078670200043
J	Delbanco, T; Hartman, EE				Delbanco, T; Hartman, EE			A 40-year-old woman considering contraception, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Peterson HB, 1998, JAMA-J AM MED ASSOC, V279, P1651, DOI 10.1001/jama.279.20.1651	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1999	281	4					374	374		10.1001/jama.281.4.374	http://dx.doi.org/10.1001/jama.281.4.374			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158JB	9929092				2023-01-03	WOS:000078111300038
J	Dearnaley, DP; Khoo, VS; Norman, AR; Meyer, L; Nahum, A; Tait, D; Yarnold, J; Horwich, A				Dearnaley, DP; Khoo, VS; Norman, AR; Meyer, L; Nahum, A; Tait, D; Yarnold, J; Horwich, A			Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial	LANCET			English	Article							PELVIC RADIOTHERAPY; ACUTE TOXICITY; TECHNICAL ASPECTS; THERAPY; CARCINOMA; MORBIDITY	Background Radical radiotherapy is commonly used to treat localised prostate cancer. Late chronic side-effects limit the dose that can be given, and may be linked to the volume of normal tissues irradiated. Conformal radiotherapy allows a smaller amount of rectum and bladder to be treated, by shaping the high-dose volume to the prostate. We assessed the ability of this new technology to lessen the risk of radiation-related effects in a randomised controlled trial of conformal versus conventional radiotherapy. Methods We recruited men with prostate cancer for treatment with a standard dose of 64 Gy in daily 2 Gy fractions. The men were randomly assigned conformal or conventional radiotherapy treatment. The primary endpoint was the development of late radiation complications (>3 months after treatment) measured with the Radiation Therapy and Oncology Group (RTOG) score. Indicators of disease (cancer) control were also recorded. Findings In the 225 men treated, significantly fewer men developed radiation-induced proctitis and bleeding in the conformal group than in the conventional group (37 vs 56% greater than or equal to RTOG grade 1, p = 0.004; 5 vs 15% greater than or equal to RTOG grade 2, p = 0.01). There were no differences between groups in bladder function after treatment (53 vs 59% greater than or equal to grade 1, p = 0.34; 20 vs 23% greater than or equal to grade 2, p = 0.61). After median follow-up of 3.6 years there was no significant difference between groups in local tumour control (conformal 78% [95% CI 66-86], conventional 83% [69-90]). Interpretation Conformal techniques significantly lowered the risk of late radiation-induced proctitis after radiotherapy for prostate cancer. Widespread introduction of these radiotherapy treatment methods is appropriate. Our results are the basis for dose-escalation studies to improve local tumour control.	Royal Marsden NHS Trust, Dept Radiotherapy & Oncol, Sutton SM2 5PT, Surrey, England; Inst Canc Res, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Dearnaley, DP (corresponding author), Royal Marsden NHS Trust, Dept Radiotherapy & Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England.		Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; Nahum, Alan/0000-0002-6429-9502				[Anonymous], 1995, RADIOTHER ONCOL, V35, P17; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BURNET NG, 1992, LANCET, V339, P1570, DOI 10.1016/0140-6736(92)91833-T; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Dearnaley DP, 1997, LANCET, V349, P892, DOI 10.1016/S0140-6736(97)22013-1; FUKS Z, 1993, RADIOTHER ONCOL, V29, P219, DOI 10.1016/0167-8140(93)90250-C; HANKS GE, 1995, INT J RADIAT ONCOL, V31, P25, DOI 10.1016/0360-3016(94)00366-S; Hanks GE, 1998, INT J RADIAT ONCOL, V41, P501, DOI 10.1016/S0360-3016(98)00089-3; Huddart RA, 1996, RADIOTHER ONCOL, V39, P19, DOI 10.1016/0167-8140(96)01717-3; *INT COMM RAD UN M, 1993, 50 ICRU INT COMM RAD; Laverdiere J, 1997, INT J RADIAT ONCOL, V37, P247, DOI 10.1016/S0360-3016(96)00513-5; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; LEIBEL SA, 1994, INT J RADIAT ONCOL, V28, P55, DOI 10.1016/0360-3016(94)90141-4; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; MAYLES WPM, 1993, RADIOTHER ONCOL, V29, P184, DOI 10.1016/0167-8140(93)90245-4; Mettlin C, 1997, PROSTATE, V32, P221, DOI 10.1002/(SICI)1097-0045(19970801)32:3<221::AID-PROS9>3.0.CO;2-N; MIDDLETON RG, 1995, J UROLOGY, V154, P2144, DOI 10.1016/S0022-5347(01)66718-1; NEAL AJ, 1995, RADIOTHER ONCOL, V37, P29, DOI 10.1016/0167-8140(95)01619-R; Nguyen LN, 1998, UROLOGY, V51, P991, DOI 10.1016/S0090-4295(98)00028-4; NIEMIERKO A, 1993, INT J RADIAT ONCOL, V25, P135, DOI 10.1016/0360-3016(93)90156-P; OLDHAM M, 1995, BRIT J RADIOL, V68, P882, DOI 10.1259/0007-1285-68-812-882; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; Pollack A, 1996, INT J RADIAT ONCOL, V34, P555, DOI 10.1016/0360-3016(95)02103-5; SAILER SL, 1994, INT J RADIAT ONCOL, V30, P439, DOI 10.1016/0360-3016(94)90026-4; SANDLER HM, 1995, INT J RADIAT ONCOL, V33, P797, DOI 10.1016/0360-3016(95)00219-7; SHEARER RJ, 1992, BRIT J UROL, V69, P521, DOI 10.1111/j.1464-410X.1992.tb15601.x; Tait DM, 1997, RADIOTHER ONCOL, V42, P121, DOI 10.1016/S0167-8140(96)01870-1; TENHAKEN RK, 1989, INT J RADIAT ONCOL, V16, P193, DOI 10.1016/0360-3016(89)90029-1; VIJAYAKUMAR S, 1993, INT J RADIAT ONCOL, V25, P359, DOI 10.1016/0360-3016(93)90361-X; WILLIAMS MV, 1984, INT J RADIAT ONCOL, V10, P1703, DOI 10.1016/0360-3016(84)90532-7; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1	32	546	557	0	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 23	1999	353	9149					267	272		10.1016/S0140-6736(98)05180-0	http://dx.doi.org/10.1016/S0140-6736(98)05180-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MF	9929018				2023-01-03	WOS:000078292200008
J	Leach, RM; Rees, PJ; Wilmshurst, P				Leach, RM; Rees, PJ; Wilmshurst, P			ABC of oxygen - Hyperbaric oxygen therapy	BRITISH MEDICAL JOURNAL			English	Article									Royal Shrewsbury Hosp, Shrewsbury, England; Guys & St Thomass Hosp Trust, Dept Intens Care, London, England; Guys & St Thomass Hosp Trust, Dept Resp Med, London, England	Guy's & St Thomas' NHS Foundation Trust	Leach, RM (corresponding author), Guys & St Thomass Hosp Trust, Dept Intens Care, London, England.								0	249	256	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1140	1143						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784458				2023-01-03	WOS:000076755100037
J	Boyle, P; Horton, R; Radda, G; Sharp, D; Veronesi, U; Walker, AM				Boyle, P; Horton, R; Radda, G; Sharp, D; Veronesi, U; Walker, AM			Open debate on hormone-replacement therapy	LANCET			English	Editorial Material							METAANALYSIS		European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; The Lancet, London, England; MRC, London, England; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	IRCCS European Institute of Oncology (IEO); Harvard University; Harvard T.H. Chan School of Public Health	Boyle, P (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy.		Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610				[Anonymous], 1997, LANCET, V350, P675; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Naylor CD, 1997, BMJ-BRIT MED J, V315, P617, DOI 10.1136/bmj.315.7109.617; *NIH CONS DEV PAN, 1995, NIH CONS DEV C STAT	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					836	836		10.1016/S0140-6736(05)60003-7	http://dx.doi.org/10.1016/S0140-6736(05)60003-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742975				2023-01-03	WOS:000075857300005
J	Eccles, M; Freemantle, N; Mason, J				Eccles, M; Freemantle, N; Mason, J		N England Non-Steroidal Anti-Inflammat	North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL COMPLICATIONS; RHEUMATOID-ARTHRITIS; CONTROLLED TRIAL; DOUBLE-BLIND; OSTEOARTHRITIS; METAANALYSIS; PREVENTION; KNEE		Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.		Eccles, Martin P/AAD-4029-2020; Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				BRADLEY JD, 1992, J RHEUMATOL, V19, P1950; *BRIT MED ASS ROYA, 1996, BRIT NAT FORM; deCraen AJM, 1996, BRIT MED J, V313, P321, DOI 10.1136/bmj.313.7053.321; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; HAWKEY CJ, 1996, GUT               S1, V39, pW5; HAWKEY CJ, 1996, GUT               S1, V38, pT155; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Koch M, 1996, ARCH INTERN MED, V156, P2321, DOI 10.1001/archinte.156.20.2321; LEVINE LR, 1993, ARCH INTERN MED, V153, P2249; MCCORMICK A, 1995, MORBIDITY STAT G MB5; *N ENGL EV BAS GUI, 1997, NONST ANT DRUGS NSAI; PARR G, 1989, BRIT J CLIN PHARMACO, V27, P235, DOI 10.1111/j.1365-2125.1989.tb05356.x; PO LAW, 1998, BRIT MED J, V315, P1565; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904	18	114	118	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					526	530						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712607				2023-01-03	WOS:000075641400029
J	Bartus, RT; Tracy, MA; Emerich, DF; Zale, SE				Bartus, RT; Tracy, MA; Emerich, DF; Zale, SE			Sustained delivery of proteins for novel therapeutic products	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; RELEASE; MODEL		Alkermes Inc, Cambridge, MA 02139 USA	Alkermes	Bartus, RT (corresponding author), Alkermes Inc, 64 Sidney St, Cambridge, MA 02139 USA.							Bawa R., 1985, J CONTR RELEASE, V1, P259, DOI [10.1016/0168-3659(85)90002-1, DOI 10.1016/0168-3659(85)90002-1]; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Johnson OL, 1997, PHARM RES-DORDR, V14, P730, DOI 10.1023/A:1012142204132; Khan A, 1998, Patent No. [US 5 711 968, 5711968]; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; Lee HJ, 1997, J PHARMACOL EXP THER, V281, P1431; LEE VHL, 1991, ADV PARENTERAL SCI, V4, P691; NAFFAKH N, 1995, P NATL ACAD SCI USA, V92, P3194, DOI 10.1073/pnas.92.8.3194; Nieforth KA, 1996, CLIN PHARMACOL THER, V59, P636, DOI 10.1016/S0009-9236(96)90003-X; SALTZMAN WM, 1989, BIOPHYS J, V55, P163, DOI 10.1016/S0006-3495(89)82788-2; Tracy MA, 1998, BIOTECHNOL PROGR, V14, P108, DOI 10.1021/bp9701271; Wall D.A., 1995, DRUG DELIV, V2, P1, DOI DOI 10.3109/10717549509031346; WRIGHT JC, 1997, P INT S CONTR REL BI, V24, P59; Zale S. E., 1997, US Patent, Patent No. [5,674,534, 5674534]; Zhang Y, 1997, J BIOMED MATER RES, V34, P531, DOI 10.1002/(SICI)1097-4636(19970315)34:4<531::AID-JBM13>3.0.CO;2-F; [No title captured]	17	94	108	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1161	1162		10.1126/science.281.5380.1161	http://dx.doi.org/10.1126/science.281.5380.1161			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735031				2023-01-03	WOS:000075531200040
J	Bannon, MJ; Ross, EM				Bannon, MJ; Ross, EM			Administration of medicines in school: who is responsible?	BRITISH MEDICAL JOURNAL			English	Article							TEACHERS; ASTHMA; CHILDREN; EPILEPSY; ILLNESS; SERVICE; AGE		Northwick Pk Hosp, Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England; Univ London Kings Coll, Mary Sheridan Ctr, London SE11 4QW, England	Imperial College London; University of London; King's College London	Bannon, MJ (corresponding author), Northwick Pk Hosp, Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England.							ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; BAGNALL P, 1996, DIFFERENT LIGHT SCH; BANNON M. J., 1995, PROG COM CH HLTH, V1, P125; BANNON MJ, 1992, ARCH DIS CHILD, V67, P1467, DOI 10.1136/adc.67.12.1467; BEVIS M, 1990, ARCH DIS CHILD, V65, P622, DOI 10.1136/adc.65.6.622; Billingham K, 1998, BRIT MED J, V316, P406, DOI 10.1136/bmj.316.7129.406; *BMA COMM HLTH DOC, 1994, MED SCH; BRADBURY AJ, 1983, ARCH DIS CHILD, V58, P692, DOI 10.1136/adc.58.9.692; CASEY FA, 1994, ARCH DIS CHILD, V70, P382, DOI 10.1136/adc.70.5.382; CELANO MP, 1993, J LEARN DISABIL-US, V26, P23, DOI 10.1177/002221949302600103; CHETCUTI P, 1993, ARCH DIS CHILD, V68, P167, DOI 10.1136/adc.68.2.167; *DEP ED EMPL DEP H, 1996, SUPP PUP MED NEEDS S; Dyer J, 1996, Prof Nurse, V11, P518; Eboh W O, 1996, Br J Nurs, V5, P30; EISER C, 1995, ARCH DIS CHILD, V72, P302, DOI 10.1136/adc.72.4.302; FILIMORE EJ, 1997, ARCH DIS CHILD, V77, P420; FOX TK, 1991, PUBLIC HEALTH, V105, P399, DOI 10.1016/S0033-3506(05)80600-6; Leffert Nancy, 1993, Current Opinion in Pediatrics, V5, P429; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; *NHS MAN EX, 1992, PAT CHART PRIM HLTH; *NHS MAN EX, 1995, CHILDR CHART; PAPOLA P, 1994, PEDIATRICS, V94, P914; Polnay L, 1995, HLTH NEEDS SCH AGE C; STURNIOLO MG, 1994, ARCH DIS CHILD, V70, P424, DOI 10.1136/adc.70.5.424; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; VERITY CM, 1985, PAEDIAT PERSPECTIVES; WHITMORE K, 1984, PROGR CHILD HLTH, V1; 1991, CONTACT FAMILY DIREC	28	11	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1998	316	7144					1591	1593		10.1136/bmj.316.7144.1591	http://dx.doi.org/10.1136/bmj.316.7144.1591			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ495	9596602	Green Published			2023-01-03	WOS:000073867800031
J	Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ				Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ			Postmenopausal hormone use and risk for colorectal cancer and adenoma	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; estrogen replacement therapy; adenoma; colonoscopy; sigmoidoscopy	LARGE-BOWEL-CANCER; EXOGENOUS FEMALE HORMONES; COLON-CANCER; REPRODUCTIVE FACTORS; ESTROGEN-RECEPTOR; PROGESTERONE RECEPTORS; REPLACEMENT THERAPY; PROSPECTIVE COHORT; UNITED-STATES; CELL-LINES	Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [Cl, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with greater than or equal to 5 years of use. 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (greater than or equal to 1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Grodstein, F (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BURCH JC, 1975, ESTROGENS POST MENOP, P208; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CHUTE CG, 1991, EPIDEMIOLOGY, V2, P395, DOI 10.1097/00001648-199109000-00019; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CONCOLINO G, 1986, CANCER DETECT PREV, V9, P477; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS FG, 1989, INT J CANCER, V43, P587, DOI 10.1002/ijc.2910430409; DEVERDIER MG, 1992, CANCER CAUSE CONTROL, V3, P355, DOI 10.1007/BF00146889; FURNER SE, 1989, CANCER RES, V49, P4936; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HENDRICKSE CW, 1993, BRIT J SURG, V80, P636, DOI 10.1002/bjs.1800800531; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; JACOBSON JS, 1995, CANCER CAUSE CONTROL, V6, P513, DOI 10.1007/BF00054159; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; LOINTIER P, 1992, ANTICANCER RES, V12, P1327; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; MOROTOMI M, 1990, CANCER RES, V50, P3595; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; Peipins LA, 1997, CANCER EPIDEM BIOMAR, V6, P671; PETERS RK, 1990, BRIT J CANCER, V61, P741, DOI 10.1038/bjc.1990.166; Potter JD, 1996, CANCER EPIDEM BIOMAR, V5, P779; POTTER JD, 1995, JNCI-J NATL CANCER I, V87, P1039, DOI 10.1093/jnci/87.14.1039; POTTER JD, 1983, J NATL CANCER I, V71, P703; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RISCH HA, 1995, CANCER EPIDEM BIOMAR, V4, P21; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SICA V, 1984, CANCER RES, V44, P4670; SINGH S, 1994, ANTICANCER RES, V14, P1037; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; Troisi R, 1997, CANCER CAUSE CONTROL, V8, P130, DOI 10.1023/A:1018455810238; WEISS NS, 1981, J NATL CANCER I, V67, P57; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; WUWILLIAMS AH, 1991, CANCER RES, V51, P2307; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197	43	230	236	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					705	+		10.7326/0003-4819-128-9-199805010-00001	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556463				2023-01-03	WOS:000073363800001
J	Davies, CH; Ormerod, OJM				Davies, CH; Ormerod, OJM			Failed coronary thrombolysis	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; RANDOMIZED TRIAL; ARTERY PATENCY; INTRAVENOUS STREPTOKINASE; AORTIC COUNTERPULSATION; VASCULAR REOCCLUSION; RESCUE ANGIOPLASTY; STRONG PREDICTOR; EARLY FAILURE		Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Davies, CH (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.	Crispin.Davies@cardiov.ox.ac.uk						ABE S, 1994, J AM COLL CARDIOL, V23, P1382, DOI 10.1016/0735-1097(94)90381-6; Agnelli G, 1996, CARDIOVASC RES, V31, P232, DOI 10.1016/S0008-6363(96)00004-1; Anderson JL, 1996, AM J CARDIOL, V78, P1, DOI 10.1016/S0002-9149(96)00217-2; Apple FS, 1996, AM J CLIN PATHOL, V105, P6; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BELENKIE I, 1992, CAN J CARDIOL, V8, P357; Berger PB, 1997, CIRCULATION, V96, P122; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Boersma E, 1997, EUR HEART J, V18, P1703; BRUGEMANN J, 1990, BRIT HEART J, V64, P355; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; Christenson RH, 1997, CIRCULATION, V96, P1776, DOI 10.1161/01.CIR.96.6.1776; CLEMMENSEN P, 1990, AM J CARDIOL, V66, P1407, DOI 10.1016/0002-9149(90)90524-5; DEFRANCO AC, 1996, HANDBOOK; ElGaylani N, 1996, INT J CARDIOL, V57, P45, DOI 10.1016/S0167-5273(96)02780-5; ELLIS SG, 1994, CIRCULATION, V90, P2280, DOI 10.1161/01.CIR.90.5.2280; FEARS R, 1992, AM HEART J, V124, P305, DOI 10.1016/0002-8703(92)90591-I; GULBA DC, 1991, CIRCULATION, V83, P937, DOI 10.1161/01.CIR.83.3.937; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HO CH, 1990, THROMB RES, V58, P331, DOI 10.1016/0049-3848(90)90102-I; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; Iliceto S, 1996, EUR HEART J, V17, P344; Iliceto S, 1997, EUR HEART J, V18, P618; ISHIHARA M, 1995, AM J CARDIOL, V76, P73, DOI 10.1016/S0002-9149(99)80805-4; ISHII J, 1994, AM HEART J, V128, P641, DOI 10.1016/0002-8703(94)90259-3; Ishii J, 1997, CLIN CHIM ACTA, V262, P13, DOI 10.1016/S0009-8981(97)06547-9; Ito H, 1996, CIRCULATION, V93, P1993, DOI 10.1161/01.CIR.93.11.1993; JEREMY RW, 1990, J AM COLL CARDIOL, V16, P695, DOI 10.1016/0735-1097(90)90362-S; Julian DG, 1996, EUR HEART J, V17, P43; Kern MJ, 1996, CIRCULATION, V94, P1545, DOI 10.1161/01.CIR.94.7.1545; KIRCHER BJ, 1987, AM J CARDIOL, V59, P513, DOI 10.1016/0002-9149(87)91158-1; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; Klootwijk P, 1996, EUR HEART J, V17, P689; Kono T, 1996, J AM COLL CARDIOL, V28, P876, DOI 10.1016/S0735-1097(96)00240-9; KRUCOFF MW, 1997, J AM COLL CARDIOL, V29, P131; Kusniec J, 1997, EUR HEART J, V18, P420; LAPERCHE T, 1995, CIRCULATION, V92, P2079, DOI 10.1161/01.CIR.92.8.2079; LAPERCHE T, 1992, AM J CARDIOL, V70, P1129, DOI 10.1016/0002-9149(92)90042-W; LAVIN F, 1995, BRIT HEART J, V73, P422; LeBreton H, 1996, CARDIOVASC RES, V31, P235, DOI 10.1016/0008-6363(96)00005-3; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; MAES A, 1995, CIRCULATION, V92, P2072, DOI 10.1161/01.CIR.92.8.2072; MATTFELDT T, 1984, AM J CARDIOL, V54, P530, DOI 10.1016/0002-9149(84)90243-1; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; MAURI F, 1995, J AM COLL CARDIOL, V25, P805; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; MOLITERNO DJ, 1993, CIRCULATION, V88, P935, DOI 10.1161/01.CIR.88.3.935; MOUNSEY JP, 1995, BRIT HEART J, V74, P348; NEUHAUS KL, 1994, CIRCULATION, V90, P1638, DOI 10.1161/01.CIR.90.4.1638; NICOLAU JC, 1989, INT J CARDIOL, V25, P313, DOI 10.1016/0167-5273(89)90221-0; Ohman EM, 1997, CIRCULATION, V95, P846; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; ONODERA T, 1989, BRIT HEART J, V61, P385; OSTERMANN H, 1992, EUR HEART J, V13, P1225, DOI 10.1093/oxfordjournals.eurheartj.a060341; PARISE P, 1991, BLOOD COAGUL FIBRIN, V2, P749, DOI 10.1097/00001721-199112000-00009; Prendergast BD, 1997, INT J CARDIOL, V61, P39, DOI 10.1016/S0167-5273(97)00116-2; Purcell IF, 1997, HEART, V78, P465, DOI 10.1136/hrt.78.5.465; RICHARDSON SG, 1989, BRIT HEART J, V61, P390; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; SARAN RK, 1990, BRIT HEART J, V64, P113; Scharfstein JS, 1996, AM J CARDIOL, V78, P503, DOI 10.1016/S0002-9149(96)00353-0; SCHRODER R, 1995, J AM COLL CARDIOL, V26, P1657, DOI 10.1016/0735-1097(95)00372-X; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; SHAH PK, 1993, J AM COLL CARDIOL, V21, P55, DOI 10.1016/0735-1097(93)90716-E; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; Stauffer JC, 1997, CIRCULATION, V96, P1141; Steinhubl SR, 1997, LANCET, V350, P532, DOI 10.1016/S0140-6736(05)63135-2; Strasberg B, 1996, EUR HEART J, V17, P333; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; vandeWerf F, 1996, EUR HEART J, V17, P325; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; VELDKAMP RF, 1994, AM J CARDIOL, V73, P1069, DOI 10.1016/0002-9149(94)90285-2; WILLEMS JL, 1990, CIRCULATION, V82, P1147, DOI 10.1161/01.CIR.82.4.1147	76	43	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 18	1998	351	9110					1191	1196		10.1016/S0140-6736(97)11198-9	http://dx.doi.org/10.1016/S0140-6736(97)11198-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643708				2023-01-03	WOS:000073220200046
J	Capson, TL; Coley, PD; Kursar, TA				Capson, TL; Coley, PD; Kursar, TA			A new paradigm for drug discovery in tropical rainforests	NATURE BIOTECHNOLOGY			English	Editorial Material							BRINE SHRIMP; PLANTS		SMITHSONIAN TROP RES INST, BALBOA, PANAMA	Smithsonian Institution; Smithsonian Tropical Research Institute	Capson, TL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							Balick M. J., 1996, MED RESOURCES TROPIC; CLARK AM, 1993, ACS SYM SER, V534, P228; Coley P.D., 1991, PLANT ANIMAL INTERAC, P25; COLEY PD, 1996, IN PRESS ANN REV ECO, V27; Coley Phyllis D., 1996, P305; GENTRY AH, 1993, ACS SYM SER, V534, P13; LEVIN DA, 1976, AM NAT, V110, P261, DOI 10.1086/283063; MCLAUGHLIN JL, 1993, ACS SYM SER, V534, P112; Reid W.V., 1996, MED RESOURCES TROPIC, P142; SOLIS PN, 1993, PLANTA MED, V59, P250, DOI 10.1055/s-2006-959661	10	8	8	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1996	14	10					1200	+		10.1038/nbt1096-1200	http://dx.doi.org/10.1038/nbt1096-1200			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	VK618	9631071				2023-01-03	WOS:A1996VK61800002
J	Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR				Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR			Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-STREAM INFECTIONS; INSERTED CENTRAL CATHETERS; NOSOCOMIAL INFECTIONS; ACCESS DEVICES; VENOUS ACCESS; RECIPIENTS; POPULATION; PREVENTION; SYSTEM; CANCER	Background: Intravenous therapy in the outpatient and home settings is commonplace for many diseases and nutritional disorders. Few data are available on the rate of and risk factors for bloodstream infection among patients receiving such therapy. Objective: To determine rates of and risk factors for bloodstream infection among patients receiving home infusion therapy. Design: Prospective, observational cohort study. Setting: Cleveland, Ohio, and Toronto, Ontario, Canada. Patients: Patients receiving home infusion therapy through a central or midline catheter. Measurements: Primary laboratory-confirmed bloodstream infection. Results: Among 827 patients (988 catheters), the most common diagnoses were infections other than HIV (67%), cancer (24%), nutritional and digestive disease (17%), heart disease (14%), receipt of bone marrow or solid organ transplants (11%), and HIV infection (7%). Sixty-nine bloodstream infections occurred during 69 532 catheter-days (0.99 infections per 1000 days). In a Cox regression model with time-dependent covariates, independent risk factors for bloodstream infection were recent receipt of a bone marrow transplant (hazard ratio, 5.8 [95% CI, 3.0 to 11.3]), receipt of total parenteral nutrition (hazard ratio, 4.1 [CI, 2.3 to 7.2]), receipt of therapy outside the home (for example, in an outpatient clinic or physician's office) (hazard ratio, 3.6 [CI, 2.2 to 5.9]), use of a multilumen catheter (hazard ratio, 2.8 [CI, 1.7 to 4.7]), and previous bloodstream infection (hazard ratio, 2.5 [CI, 1.5 to 4.2]). Rates of bloodstream infection per 1000 catheter-days varied from 0.16 for patients with none of these 5 risk factors to 6.77 for patients with 3 or more risk factors. Centrally inserted venous catheters were associated with a higher risk than implanted ports were, but the difference was not statistically significant. Conclusion: Bloodstream infections seem to be infrequent among outpatients receiving infusions through central and midline catheters. However, the rate of infection increases with bone marrow transplantation, parenteral nutrition, infusion therapy in a hospital clinic or physician's office, and use of multilumen catheters. Compared with implanted ports or peripherally inserted catheters, centrally inserted venous catheters may confer greater risk for bloodstream infection.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Centers for Disease Control & Prevention - USA; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cleveland Clinic Foundation	Tokars, JI (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA.		mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				CAMPION E, 1998, NEW ENGL J MED, V333, P1213; Cookson ST, 1998, INFECT CONT HOSP EP, V19, P23; DANZIG LE, 1995, JAMA-J AM MED ASSOC, V273, P1862, DOI 10.1001/jama.273.23.1862; Do AN, 1999, J INFECT DIS, V179, P442, DOI 10.1086/314592; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Engelhard D, 1996, TRANSPLANTATION, V61, P430, DOI 10.1097/00007890-199602150-00020; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; HOWELL PB, 1995, CANCER, V75, P1367, DOI 10.1002/1097-0142(19950315)75:6<1367::AID-CNCR2820750620>3.0.CO;2-Z; Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477; Kellerman S, 1996, J PEDIATR-US, V129, P711, DOI 10.1016/S0022-3476(96)70154-3; LAM S, 1994, ARCH INTERN MED, V154, P1833, DOI 10.1001/archinte.154.16.1833; McDonald LC, 1998, INFECT CONT HOSP EP, V19, P772; Ng PK, 1997, MAYO CLIN PROC, V72, P225, DOI 10.4065/72.3.225; PARKER JW, 1995, J BONE JOINT SURG AM, V77A, P572, DOI 10.2106/00004623-199504000-00010; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pittet D, 1997, CLIN INFECT DIS, V24, P1068, DOI 10.1086/513640; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; RAVIGLIONE MC, 1989, AM J MED, V86, P780, DOI 10.1016/0002-9343(89)90473-7; *SAS I INC, 1992, P229 SAS I INC STAT, P434; Serody JS, 1997, INFECT DIS CLIN N AM, V11, P459, DOI 10.1016/S0891-5520(05)70365-2; Stroud L, 1997, INFECT CONT HOSP EP, V18, P479; VLADECK BC, 1994, JAMA-J AM MED ASSOC, V271, P1566	24	107	110	3	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					340	+		10.7326/0003-4819-131-5-199909070-00004	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475886				2023-01-03	WOS:000082458500003
J	Adam, S; Forrest, S				Adam, S; Forrest, S			ABC of intensive care - Other supportive care	BRITISH MEDICAL JOURNAL			English	Article									UCL Hosp, Intens Care Unit, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Adam, S (corresponding author), UCL Hosp, Intens Care Unit, London, England.								0	14	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					175	178		10.1136/bmj.319.7203.175	http://dx.doi.org/10.1136/bmj.319.7203.175			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406761	Green Published			2023-01-03	WOS:000081619300030
J	Bejjani, BP; Damier, P; Arnulf, I; Thivard, L; Bonnet, AM; Dormont, D; Cornu, P; Pidoux, B; Samson, Y; Agid, Y				Bejjani, BP; Damier, P; Arnulf, I; Thivard, L; Bonnet, AM; Dormont, D; Cornu, P; Pidoux, B; Samson, Y; Agid, Y			Transient acute depression induced by high-frequency deep-brain stimulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; MOOD DISORDERS; HUMAN AMYGDALA; STROKE		Grp Hosp Pitie Salpetriere, Ctr Invest Clin, Federat Neurol, F-75634 Paris, France; Grp Hosp Pitie Salpetriere, INSERM, U289, F-75634 Paris, France; Hop La Pitie Salpetriere, Serv Neurol, F-75651 Paris, France; Hop La Pitie Salpetriere, Serv Neurochirurg, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Serv Explorat Fonct Neurol, F-75651 Paris 13, France; CEA, Serv Hosp Frederic Joliot, F-91406 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Bejjani, BP (corresponding author), Hop La Pitie Salpetriere, Ctr Invest Clin, 47 Blvd Hop, F-75651 Paris 13, France.		Damier, Philippe/T-7829-2019; dormont, didier/B-2175-2012; samson, yves/C-5647-2013; Dormont, Didier/F-5492-2012	Arnulf, Isabelle/0000-0002-2240-2516; Holy Spirit University of Kaslik (USEK), FACULTY OF MEDICINE AND MEDICAL SCIENCESHoly Spirit University of Kaslik (USEK)/0000-0001-6734-4105; samson, yves/0000-0002-8080-1427				ADOLPHS R, 1995, J NEUROSCI, V15, P5879; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bejjani B, 1997, NEUROLOGY, V49, P1564, DOI 10.1212/WNL.49.6.1564; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Bevan MD, 1996, NEUROSCIENCE, V75, P5, DOI 10.1016/0306-4522(96)00377-6; DORMONT D, 1994, AM J NEURORADIOL, V15, P365; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; Fischer H, 1998, NEUROSCI LETT, V251, P137, DOI 10.1016/S0304-3940(98)00503-5; FOX PT, 1984, J CEREBR BLOOD F MET, V4, P329, DOI 10.1038/jcbfm.1984.49; Friston K.J., 1994, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; ILINSKY IA, 1985, J COMP NEUROL, V236, P315, DOI 10.1002/cne.902360304; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Mayberg H S, 1995, Adv Neurol, V65, P49; PARDO JV, 1993, AM J PSYCHIAT, V150, P713; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Schaltenbrand G, 1977, ATLAS STEREOTAXY HUM	24	463	476	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1476	1480		10.1056/NEJM199905133401905	http://dx.doi.org/10.1056/NEJM199905133401905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320386	Bronze			2023-01-03	WOS:000080198700005
J	Mallick, NP; Gokal, R				Mallick, NP; Gokal, R			Haemodialysis	LANCET			English	Article							CHRONIC-HEMODIALYSIS PATIENTS; BLOOD-PRESSURE CONTROL; CHRONIC-RENAL-FAILURE; DIALYSIS PATIENTS; MEMBRANE BIOCOMPATIBILITY; RISK-FACTORS; POPULATION; MORTALITY; DISEASE; PARAMETERS	This paper charts the development of haemodialysis, the cornerstone of renal replacement therapy (RRT). It has enabled patients with end-stage renal failure to survive for years, in many cases with a surprisingly good quality of life. Through technological advances, RRT can be offered to patients who are older and more frail. Many have intercurrent comorbid illness. Such patients can have good quality of life, but their survival is shorter since they are likely to succumb early to comorbid illnesses. The challenge to nephrologists is to provide treatment based on exacting standards for all those patients who can benefit, yet to maintain cost-effectiveness. There is increasing recognition that, however good the technology underpinning dialysis, what justifies the cost and commitment that dialysis entails is the provision for the patient of a satisfactory quality of life.	Manchester Royal Infirm, Dept Renal Med, Manchester M13 9WL, Lancs, England	University of Manchester	Mallick, NP (corresponding author), Manchester Royal Infirm, Dept Renal Med, Oxford Rd, Manchester M13 9WL, Lancs, England.							Bergstrom J, 1995, BLOOD PURIFICAT, V13, P361, DOI 10.1159/000170222; Bloembergen W E, 1996, Adv Ren Replace Ther, V3, P201; BROWN JH, 1994, NEPHROL DIAL TRANSPL, V9, P1136, DOI 10.1093/ndt/9.8.1136; Buoncristiani U, 1996, CONTRIB NEPHROL, V119, P152; CHARRA B, 1994, CONTRIB NEPHROL, V106, P179; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; CHAZOT C, 1995, NEPHROL DIAL TRANSPL, V10, P831; Cheung AK, 1997, SEMIN NEPHROL, V17, P196; DAVFIRDAS JT, 1997, KIDNEY INT, V52, P1345; *DISN APS, 1995, AUSTR NZ DIAL TRANSP, P135; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; Foley R N, 1997, Adv Ren Replace Ther, V4, P234; GOKAL R, 1995, J ROY COLL PHYS LOND, V29, P190; Hakim RM, 1996, J AM SOC NEPHROL, V7, P472; HIATT RA, 1982, AM J PUBLIC HEALTH, V72, P829, DOI 10.2105/AJPH.72.8.829; HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307; Khan A, 1996, HEALTH POLICY PLANN, V11, P30, DOI 10.1093/heapol/11.1.30; Kopple JD, 1997, ASAIO J, V43, P246; Locatelli F, 1996, NEPHROL DIAL TRANSPL, V11, P116; MALLICK NP, 1995, NEPHROL DIAL TRANSPL, V10, P2, DOI 10.1093/ndt/10.supp7.2; MCGEOWN MG, 1990, BRIT MED J, V301, P900, DOI 10.1136/bmj.301.6757.900; Owen WF, 1996, BLOOD PURIFICAT, V14, P278; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Parfrey PS, 1996, NEPHROL DIAL TRANSPL, V11, P1277; Parker TF, 1996, KIDNEY INT, V49, P551, DOI 10.1038/ki.1996.78; Pereira BJG, 1996, J AM SOC NEPHROL, V7, P861; Pierratos A, 1998, J AM SOC NEPHROL, V9, P859; Rocco MV, 1996, J AM SOC NEPHROL, V7, P889; RODERICK PJ, 1994, BRIT MED J, V309, P1111, DOI 10.1136/bmj.309.6962.1111; Tracy RE, 1996, SEMIN NEPHROL, V16, P126; Twardowski Z J, 1996, Adv Ren Replace Ther, V3, P124; *US DEP HHS, US REN DAT SYST 1993; *US NAT KIDN FDN, 1997, AM J KIDNEY DIS S2, V30; VALDERRABANO F, 1996, NEPHROL DIAL TRANSPL, V11, P125	34	51	56	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1999	353	9154					737	742		10.1016/S0140-6736(97)09411-7	http://dx.doi.org/10.1016/S0140-6736(97)09411-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073530				2023-01-03	WOS:000078966400044
J	Simoons, ML; Boersma, E; van der Zwaan, C; Deckers, JW				Simoons, ML; Boersma, E; van der Zwaan, C; Deckers, JW			The challenge of acute coronary syndromes	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; CHEST PAIN; TRIAL; REPERFUSION; ISCHEMIA; DISEASE; COST; CARE		Erasmus Univ, Acad Hosp Rotterdam Dijkzigt, Thoraxctr, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Simoons, ML (corresponding author), Erasmus Univ, Acad Hosp Rotterdam Dijkzigt, Thoraxctr, Bd 434, NL-3015 GD Rotterdam, Netherlands.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Armstrong PW, 1998, CIRCULATION, V98, P1860, DOI 10.1161/01.CIR.98.18.1860; Aufderheide T P, 1996, Prehosp Disaster Med, V11, P162; BLOOM BS, 1973, NEW ENGL J MED, V288, P72, DOI 10.1056/NEJM197301112880205; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Boersma E, 1998, DRUGS, V56, P31, DOI 10.2165/00003495-199856010-00004; BOERSMA H, 1998, CARDIOLOGIE, V5, P562; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BROWN KWG, 1963, LANCET, V2, P349; COBB LA, 1975, CIRCULATION, V52, P223; DARGIE HJ, 1993, EUR HEART J, V14, P969; DAY HW, 1963, DIS CHEST, V44, P423, DOI 10.1378/chest.44.4.423; DURRER D, 1979, P NETH AC SCI, P507; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; Geleijnse ML, 1998, J AM SOC ECHOCARDIOG, V11, P606, DOI 10.1016/S0894-7317(98)70036-7; GRIJSEELS EWM, 1995, EUR HEART J, V16, P325; Holmvang L, 1998, CIRCULATION, V98, P2004, DOI 10.1161/01.CIR.98.19.2004; Julian DG, 1996, EUR HEART J, V17, P43; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; LUBSEN J, 1986, BRIT HEART J, V56, P400; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670; Ronner E, 1998, EUR HEART J, V19, P1608, DOI 10.1053/euhj.1998.1222; SIMOONS ML, 1983, EUR HEART J, V4, P129, DOI 10.1093/eurheartj/4.suppl_D.129; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SIMOONS ML, 1985, LANCET, V2, P578; SIMOONS ML, IN PRESS EUR HEART J; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; VanderWerf F, 1997, EUR HEART J, V18, P1371; WACKERS FJT, 1975, BRIT HEART J, V37, P741; Wood D, 1998, EUR HEART J, V19, P1434	34	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1999	353			2			SII1	SII4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374758	Bronze			2023-01-03	WOS:000080812700001
J	Summerbell, CD; Watts, C; Higgins, JPT; Garrow, JS				Summerbell, CD; Watts, C; Higgins, JPT; Garrow, JS			Randomised controlled trial of novel, simple, and well supervised weight reducing diets in outpatients	BRITISH MEDICAL JOURNAL			English	Article							OBESITY	Objectives To investigate the contribution of novelty and simplicity to compliance with a low energy diet among obese outpatients. Design Three arm randomised trial for 16 weeks. Setting NHS hospital obesity clinic. Subjects 45 patients aged over 17 years with a body mass index > 27 who were not diabetic, pregnant, or lactating. Interventions Conventional 3.4 MJ diet (control), isoenergetic novel diet of milk only, or milk plus one designated food daily. Follow up visit every 4 weeks, Main outcome measure Weight loss. Results Mean weight loss (kg) after 16 weeks on control, milk only, and milk plus diets was 1.7 (95% confidence interval - 0.3 to 3.7), 9.4 (5.9 to 12.9), and 7.0 (2.7 to 11.3) respectively, Weight loss on the novel diets was significantly greater than on the control diet. Conclusions Dietary treatment can achieve as much weight loss in obese outpatients over 16 weeks as has been reported for the most successful drug treatment, but compliance with the prescribed diet is poor unless the diet is novel and simple.	Univ London St Bartholomews Hosp Med Coll, Rank Dept Human Nutr, London EC1M 6BQ, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; Queen Mary University London; University of London; University College London	Summerbell, CD (corresponding author), Univ Teesside, Sch Hlth, Middlesbrough TS1 3BA, Cleveland, England.		Summerbell, Carolyn/AAC-3159-2019; Higgins, Julian PT/H-4008-2011	Summerbell, Carolyn/0000-0003-1910-9383; Higgins, Julian PT/0000-0002-8323-2514				BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; BRAY GA, 1996, CIBA S, V201; Garrow J. S., 1988, OBESITY RELATED DIS; GARROW JS, 1989, INT J OBESITY, V13, P521; Glenny AM, 1997, INT J OBESITY, V21, P715, DOI 10.1038/sj.ijo.0800495; GUYGRAND B, 1989, LANCET, V2, P1142; James WPT, 1997, INT J OBESITY, V21, pS24; Lean MEJ, 1997, INT J OBESITY, V21, pS30; *SCOTT INT GUID NE, 1996, OB SCOTL; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WING RR, 1979, INT J OBESITY, V3, P261	12	62	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1998	317	7171					1487	1489		10.1136/bmj.317.7171.1487	http://dx.doi.org/10.1136/bmj.317.7171.1487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WJ	9831574	Green Published, Bronze			2023-01-03	WOS:000077338300023
J	Bove, G; Nilsson, N				Bove, G; Nilsson, N			Spinal manipulation in the treatment of episodic tension-type headache - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Episodic tension-type headache is common and is often treated using manual therapies. Few data exist for the efficacy of these interventions. Objective.-To determine the effects of spinal manipulation therapy on adults with episodic tension-type headache. Design.-Randomized controlled trial lasting 19 weeks. Setting.-Outpatient facility of a National Health Service-funded chiropractic research institution in Denmark. Participants.-Volunteer sample of 26 men and 49 women aged 20 to 59 years who met the diagnostic criteria for episodic tension-type headache as defined by the International Headache Society, Intervention.-Participants were randomized into 2 groups, 1 receiving soft tissue therapy and spinal manipulation (the manipulation group), and the other receiving soft tissue therapy and a placebo laser treatment (the control group). All participants received 8 treatments over 4 weeks; all treatments were performed by the same chiropractor, Main Outcome Measures.-Daily hours of headache, pain intensity per episode, and daily analgesic use, as recorded in diaries. Results.-Based on intent-to-treat analysis, no significant differences between the manipulation and control groups were observed in any of the 3 outcome measures, However, by week 7, each group experienced significant reductions in mean daily headache hours (manipulation group, reduction from 2.8 to 1.5 hours; control group, reduction from 3.4 to 1.9 hours) and mean number of analgesics per day (manipulation group, reduction from 0.66 to 0.38; control group, reduction from 0.82 to 0.59). These changes were maintained through the observation period. Headache pain intensity was unchanged for the duration of the trial. Conclusion.-As an isolated intervention, spinal manipulation does not seem to have a positive effect on episodic tension-type headache.	Odense Univ, Ctr Biomech, Dept Anat & Cell Biol, DK-5220 Odense M, Denmark	University of Southern Denmark	Nilsson, N (corresponding author), Odense Univ, Ctr Biomech, Dept Anat & Cell Biol, Campusvej 55, DK-5220 Odense M, Denmark.							Bergmann TF, 1993, CHIROPRACTIC TECHNIQ; BOGDUK N, 1987, PATIENT MANAGE, V11, P163; BOLINE PD, 1995, J MANIP PHYSIOL THER, V18, P148; GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5; HOYT WH, 1979, J AM OSTEOPATH ASSOC, V78, P322; LEWIT K, 1971, EUR NEUROL, V5, P365, DOI 10.1159/000114092; Nilsson N, 1997, J Manipulative Physiol Ther, V20, P326; NILSSON N, 1995, J MANIP PHYSIOL THER, V18, P435; NILSSON N, 1995, CERVICOGENIC HEADACH; OLESEN J, 1988, Cephalalgia, V8, P1; Pfaffenrath V, 1990, Funct Neurol, V5, P159; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; Turk Z, 1987, MANUAL MED, V3, P15; VERNON H, 1982, J MANIP PHYSIOL THER, V5, P109; [No title captured]; [No title captured]	17	94	94	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1576	1579		10.1001/jama.280.18.1576	http://dx.doi.org/10.1001/jama.280.18.1576			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820258	Bronze			2023-01-03	WOS:000076852000023
J	Qureshi, F; Pestian, J; Davis, P; Zaritsky, A				Qureshi, F; Pestian, J; Davis, P; Zaritsky, A			Effect of nebulized ipratropium on the hospitalization rates of children with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; BROMIDE; SALBUTAMOL; EFFICACY; ALBUTEROL; BRONCHOSPASM; INHALATION	Background Anticholinergic medications such as ipratropium improve the pulmonary function of patients with acute exacerbations of asthma, but their effect on hospitalization rates is uncertain. Methods We conducted a randomized, double-blind, placebo-controlled study of 434 children (2 to 18 years old) who had acute exacerbations of moderate or severe asthma treated in the emergency department. All the children received a nebulized solution of albuterol (2.5 or 5 mg per dose, depending on body weight) every 20 minutes for three doses and then as needed, A corticosteroid (2 mg of prednisone or prednisolone per kilogram of body weight) was given orally with the second dose of albuterol. Children in the treatment group received 500 mu g (2.5 mi) of ipratropium bromide with the second and third doses of albuterol; children in the control group received 2.5 mi of normal saline at these times. Results Overall, the rate of hospitalization was lower in the ipratropium group (59 of 215 children [27.4 percent]) than in the control group (80 of 219 [36.5 percent], P=0.05). For patients with moderate asthma (indicated by a peak expiratory flow rate of 50 to 70 percent of the predicted value or an asthma score of 8 to 11 on a 15-point scale), hospitalization rates were similar in the two groups (ipratropium: 8 of 79 children [10.1 percent]; control: 9 of 84 [10.7 percent]). For patients with severe asthma (defined as a peak expiratory flow rate of <50 percent of the predicted value or an asthma score of 12 to 15), the addition of ipratropium significantly reduced the need for hospitalization (51 of 136 children [37.5 percent], as compared with 71 of 135 [52.6 percent] in the control group; P=0.02). Conclusions Among children with a severe exacerbation of asthma, the addition of ipratropium bromide to albuterol and corticosteroid therapy significantly decreases the hospitalization rate. (N Engl J Med 1998;339:1030-5.) (C) 1998, Massachusetts Medical Society.	Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Div Pediat Emergency Med, Norfolk, VA 23507 USA; Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Dept Clin Outcomes, Norfolk, VA 23507 USA; Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Dept Pediat, Norfolk, VA 23507 USA	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School	Qureshi, F (corresponding author), Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Div Pediat Emergency Med, 601 Childrens Lane, Norfolk, VA 23507 USA.							BECK R, 1985, J PEDIATR-US, V107, P605, DOI 10.1016/S0022-3476(85)80033-0; BONER AL, 1987, ANN ALLERGY, V58, P54; DESTEFANO G, 1990, ANN ALLERGY, V65, P260; FitzGerald JM, 1997, CHEST, V111, P311, DOI 10.1378/chest.111.2.311; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Karpel JP, 1996, CHEST, V110, P611, DOI 10.1378/chest.110.3.611; *NAT HEART LUNG BL, 1991, NIH PUBL; *NAT HEART LUNG BL, 1997, NIH PUBL; ODRISCOLL BR, 1989, LANCET, V1, P1418; OSMOND MH, 1995, ACAD EMERG MED, V2, P651, DOI 10.1111/j.1553-2712.1995.tb03607.x; Qureshi F, 1997, ANN EMERG MED, V29, P205, DOI 10.1016/S0196-0644(97)70269-5; RAYNER RJ, 1987, ARCH DIS CHILD, V62, P840, DOI 10.1136/adc.62.8.840; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; SACKETT DL, 1997, EVIDENCE BASED MED P, P157; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; STORR J, 1986, ARCH DIS CHILD, V61, P602, DOI 10.1136/adc.61.6.602; Trapp RG., 1994, BASIC CLIN BIOSTATIS; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598; WATSON WTA, 1988, J ALLERGY CLIN IMMUN, V82, P1012, DOI 10.1016/0091-6749(88)90138-8	20	190	201	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1030	1035		10.1056/NEJM199810083391503	http://dx.doi.org/10.1056/NEJM199810083391503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761804				2023-01-03	WOS:000076294800003
J	Antonelli, M; Conti, G; Rocco, M; Bufi, M; De Blasi, RA; Vivino, G; Gasparetto, A; Meduri, GU				Antonelli, M; Conti, G; Rocco, M; Bufi, M; De Blasi, RA; Vivino, G; Gasparetto, A; Meduri, GU			A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOGENIC PULMONARY-EDEMA; FACE MASK; AIRWAY PRESSURE; PNEUMONIA; SUPPORT; TRIAL; DISEASE; THERAPY	Background and Methods The role of noninvasive positive-pressure ventilation delivered through a face mask in patients with acute respiratory failure is uncertain. We conducted a prospective, randomized trial of noninvasive positive-pressure ventilation as compared with endotracheal intubation with conventional mechanical ventilation in 64 patients with hypoxemic acute respiratory failure who required mechanical ventilation. Results Within the first hour of ventilation, 20 of 32 patients (62 percent) in the noninvasive-ventilation group and 15 of 32 (47 percent) in the conventional-ventilation group had an improved ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2:FiO(2)) (P=0.21). Ten patients in the noninvasive-ventilation group subsequently required endotracheal intubation. Seventeen patients in the conventional-ventilation group (53 percent) and 23 in the noninvasive-ventilation group (72 percent) survived their stay in the intensive care unit (odds ratio, 0.4; 95 percent confidence interval, 0.1 to 1.4; P = 0.19); 16 patients in the conventional-ventilation group and 22 patients in the noninvasive-ventilation group were discharged from the hospital. More patients in the conventional-ventilation group had serious complications (66 percent vs. 38 percent, P = 0.02) and had pneumonia or sinusitis related to the endotracheal tube (31 percent vs. 3 percent, P = 0.003). Among the survivors, patients in the noninvasive-ventilation group had shorter periods of ventilation (P = 0.006) and shorter stays in the intensive care unit (P = 0.002). Conclusions In patients with acute respiratory failure, noninvasive ventilation was as effective as conventional ventilation in improving gas exchange and was associated with fewer serious complications and shorter stays in the intensive care unit. (N Engl J Med 1998;339:429-35.) (C)1998, Massachusetts Medical Society.	Univ La Sapienza, Policlin Umberto I, Ist Anestesiol & Reanimaz, I-00161 Rome, Italy; Univ Tennessee, Dept Med, Lung Res Program, Div Pulm & Crit Care, Memphis, TN 38104 USA	Sapienza University Rome; University Hospital Sapienza Rome; University of Tennessee System; University of Tennessee Health Science Center	Antonelli, M (corresponding author), Univ La Sapienza, Policlin Umberto I, Ist Anestesiol & Reanimaz, Viale Policlin 155, I-00161 Rome, Italy.		Antonelli, Massimo/K-9915-2016; Rocco, Monica/B-8407-2013; De Blasi, Roberto A/B-6666-2013; Conti, Giorgio/AAB-9546-2022; Antonelli, Massimo/F-9848-2010	Antonelli, Massimo/0000-0003-3007-1670; Rocco, Monica/0000-0001-8380-3607; De Blasi, Roberto A/0000-0002-1069-2544; Conti, Giorgio/0000-0002-8566-9365; 				AHMED AH, 1992, THORAX, V47, P858; Antonelli M, 1996, CHEST, V110, P724, DOI 10.1378/chest.110.3.724; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Daskalopoulou E, 1993, CHEST, V103, p271S; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GREGORETTI C, 1992, American Review of Respiratory Disease, V145, pA75; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; MARTIN TJ, 1994, CRIT CARE MED, V23, pA129; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; Meduri GU, 1996, CLIN CHEST MED, V17, P513, DOI 10.1016/S0272-5231(05)70330-0; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; Snedecor G.W., 1967, STAT METHODS; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	26	619	652	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					429	435		10.1056/NEJM199808133390703	http://dx.doi.org/10.1056/NEJM199808133390703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700176				2023-01-03	WOS:000075342500003
J	Munro, AJ				Munro, AJ			What now for postoperative radiotherapy for lung cancer?	LANCET			English	Editorial Material									Ninewells Hosp, Dept Radiotherapy, Dundee DD1 9SY, Scotland	University of Dundee	Munro, AJ (corresponding author), Ninewells Hosp, Dept Radiotherapy, Dundee DD1 9SY, Scotland.							BARENDSEN GW, 1982, INT J RADIAT ONCOL, V8, P1981, DOI 10.1016/0360-3016(82)90459-X; PHILIPS P, 1993, INT J RADIAT ONCOL, V27, P525, DOI 10.1016/0360-3016(93)90375-6; Saunders M, 1997, LANCET, V350, P161, DOI 10.1016/S0140-6736(97)06305-8	3	53	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					250	251		10.1016/S0140-6736(98)22030-7	http://dx.doi.org/10.1016/S0140-6736(98)22030-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690399				2023-01-03	WOS:000074974500002
J	Smeenk, FWJM; van Haastregt, JCM; de Witte, LP; Crebolder, FJM				Smeenk, FWJM; van Haastregt, JCM; de Witte, LP; Crebolder, FJM			Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; TERMINAL CANCER; COST-EFFECTIVENESS; NATIONAL HOSPICE; ILL; STRATEGIES; CONTINUITY; SERVICE; DEATH	Objective: To investigate whether for patients with incurable cancer comprehensive home care programmes are more effective than standard care in maintaining the patients' quality of life and reducing their "readmission time" (percentage of days spent in hospital from start of care till death). Design: Systematic review. Methods: A computer aided search was conducted using the databases of Medline, Embase, CancerLit, and PsychLit The search for studies and the assessment of the methodological quality of the relevant studies were performed by two investigators, blinded from each other. Prospective, controlled studies investigating the effects of a home care intervention programme on patients' quality of life or on readmission time were included in the analyses. Results: Only 9 prospective controlled studies were found; eight were performed in the United States and 1 in the United Kingdom. Their methodological quality was judged to be moderate (median rating 62 on a 100 point scale). None of the studies showed a negative influence of home care interventions on quality of life: A significantly positive influence on the outcome measures was seen in 2 out of the 5 studies measuring patients' satisfaction with care, in 3/7 studies measuring physical dimensions of quality of life, in 1/6 studies measuring psychosocial dimensions, and in 2/5 studies measuring readmission time. The incorporation of team members' visits to patients at home or regular multidisciplinary team meetings into the intervention programme seemed to be related to positive results. Conclusions: The effectiveness of comprehensive home care programmes remains unclear. Given the enormity of the problems faced by society in caring for patients with terminal cancer, further research is urgently needed.	Catharina Hosp, Dept Multidisciplinary Oncol, NL-5602 ZA Eindhoven, Netherlands; Catharina Hosp, Dept Pulmonol, NL-5602 ZA Eindhoven, Netherlands; Inst Rehabil Res, Hlth Care Intervent & Serv Dept, NL-6430 AD Hoensbroek, Netherlands; Maastricht Univ, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands	Catharina Hospital; Catharina Hospital; Maastricht University	Smeenk, FWJM (corresponding author), Catharina Hosp, Dept Multidisciplinary Oncol, POB 1350, NL-5602 ZA Eindhoven, Netherlands.			de Witte, Luc/0000-0002-3013-2640				ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; AHMEDZAI S, 1991, EFFECT CANC QUALITY, P323; Beck-Friis Barbro, 1993, Palliative Medicine, V7, P93, DOI 10.1177/026921639300700202; CONKLING VK, 1989, CANCER, V64, P290, DOI 10.1002/1097-0142(19890701)64:1+<290::AID-CNCR2820641324>3.0.CO;2-K; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; DESSLOCH A, 1992, PSYCHOTHER PSYCH MED, V42, P424; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; FIELD D, 1993, FUTURE PALLIATIVE CA, P6; FRAUMENI JF, 1993, CANC PRINCIPLES PRAC, P196; Greenhalgh T, 1997, BRIT MED J, V315, P180, DOI 10.1136/bmj.315.7101.180; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; JONES RVH, 1993, BRIT MED J, V306, P249, DOI 10.1136/bmj.306.6872.249; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MACDONALD N, 1997, OXFORD TXB PALLIATIV, P11; MCCORKLE R, 1994, RES NURS HEALTH, V17, P243, DOI 10.1002/nur.4770170403; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; MEIER ML, 1995, SUPPORT CARE CANCER, V3, P389, DOI 10.1007/BF00364978; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOR V, 1985, HEALTH SERV RES, V20, P407; OHARE PA, 1993, CANCER INVEST, V11, P140, DOI 10.3109/07357909309024832; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PARKES CM, 1980, POSTGRAD MED J, V56, P685, DOI 10.1136/pgmj.56.660.685; SEALE C, 1991, SOC SCI MED, V32, P147, DOI 10.1016/0277-9536(91)90054-G; *STEER COMM FUT HL, 1988, CANC NETH SCEN CANC; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; TSAMANDOURAKI K, 1992, SCAND J SOC MED, V20, P51, DOI 10.1177/140349489202000110; VANDERAKKER PAM, 1994, LEVEN DOOD OVER TERM; VENTAFRIDDA V, 1989, TUMORI, V75, P619, DOI 10.1177/030089168907500622; VINCIGUERRA V, 1986, J CLIN ONCOL, V4, P1521, DOI 10.1200/JCO.1986.4.10.1521; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WILKES E, 1984, LANCET, V1, P950; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	36	92	92	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1939	1944		10.1136/bmj.316.7149.1939	http://dx.doi.org/10.1136/bmj.316.7149.1939			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY568	9641929	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000074636700024
J	Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB				Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB			Depressive symptoms and physical decline in community-dwelling older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; IMMUNE-SYSTEM; DISABILITY; PERFORMANCE; ANXIETY; FALLS; CARE	Context.-Significant symptoms of depression are common in the older community-dwelling population. Although depressive symptoms and disability may commonly occur in the same person, whether depressive symptoms contribute to subsequent functional decline has not been elucidated, Objective.-To determine whether depressive symptoms in older persons increase the risk of subsequent decline in physical function as measured by objective performance-based tests. Design.-A 4-year prospective cohort study. Setting.-The communities of Iowa and Washington counties, Iowa. Participants.-A total of 1286 persons aged 71 years and older who completed a short battery of physical performance tests in 1988 and again 4 years later. Main Outcome Measures.-Baseline depressive symptoms were assessed by the Center for Epidemiological Studies Depression Scale. Physical performance tests included an assessment of standing balance, a timed 2.4-m (8-ft) walk, and a timed test of 5 repetitions of rising from a chair and sitting down. Results.-After adjustment far baseline performance score, health status, and sociodemographic factors, increasing levels of depressive symptoms were predictive of greater decline in physical performance over 4 years (odds ratio for decline in those with depressed mood vs those without, 1.55; 95% confidence interval [CI], 1.02-2.34), Even among those at the high end of the functional spectrum, who reported no disability, the severity of depressive symptoms predicted subsequent decline in physical performance (odds ratio for decline, 1.03; 95% CI, 1.00-1.08). Conclusions.-This study provides evidence that older persons who report depressive symptoms are at higher risk of subsequent physical decline, These results suggest that prevention or reduction of depressed mood could play a role in reducing functional decline in older persons.	NIA, Epidemiol Demogr & Biometry Program, Bethesda, MD 20892 USA; INRCA Florence, Dept Geriatr, Florence, Italy; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Psychiat, Amsterdam, Netherlands; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Iowa	Guralnik, JM (corresponding author), NIA, Epidemiol Demogr & Biometry Program, Gateway Bldg,Suite 3C-309,7201 Wisconsin Ave, Bethesda, MD 20892 USA.	jg48s@nih.gov	Simonsick, Eleanor/W-6864-2019; Penninx, Brenda WJH/S-7627-2017	Penninx, Brenda WJH/0000-0001-7779-9672	NIA NIH HHS [N01-AG-02106, N01-AG-0215, N01-AG-02107] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000215, N01AG002107, N01AG002106] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; Beekman ATF, 1995, J AFFECT DISORDERS, V36, P65, DOI 10.1016/0165-0327(95)00061-5; Beekman ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; CRONBACH LJ, 1970, PSYCHOL BULL, V74, P68, DOI 10.1037/h0029382; Gallo JJ, 1997, J AM GERIATR SOC, V45, P570, DOI 10.1111/j.1532-5415.1997.tb03089.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, AGING-CLIN EXP RES, V6, P303, DOI 10.1007/BF03324256; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; HUISIANI BA, 1980, J COMMUNITY PSYCHOL, V8, P20; *HYP DET FOLL UP P, 1977, JAMA-J AM MED ASSOC, V237, P2385; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kohout FJ, 1993, J AGING HEALTH, V5, P79; KRONFOL Z, 1984, LANCET, V1, P1026; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; MILLER AH, 1993, ANN MED, V25, P481, DOI 10.3109/07853899309147316; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSOW I, 1966, J GERONTOL, V39, P686; SEEMAN TE, 1994, J GERONTOL, V49, pM97, DOI 10.1093/geronj/49.3.M97; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; *SPSS INC, 1993, SPSS ADV STAT REF GU; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TURNER RJ, 1988, J HEALTH SOC BEHAV, V29, P23, DOI 10.2307/2137178; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WINOGRAD CH, 1994, J AM GERIATR SOC, V42, P743, DOI 10.1111/j.1532-5415.1994.tb06535.x	42	580	589	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1720	1726		10.1001/jama.279.21.1720	http://dx.doi.org/10.1001/jama.279.21.1720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZQ544	9624025				2023-01-03	WOS:000073878700033
J	Coats, AJS				Coats, AJS			Teaching heart-failure patients how to breathe	LANCET			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; Royal Brompton Hosp, London SW3 6LY, England	Imperial College London; Royal Brompton Hospital	Coats, AJS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				CHUA TP, 1995, EUR HEART J, V16, P882, DOI 10.1093/oxfordjournals.eurheartj.a061019; Coats AJS, 1997, CARDIOVASC DRUG THER, V11, P265, DOI 10.1023/A:1007739830030; LIEBER C, 1992, YALE J BIOL MED, V65, P39; Mortara Andrea, 1996, Clinical Science (London), V91, P72; Ponikowski P, 1997, CIRCULATION, V96, P2586, DOI 10.1161/01.CIR.96.8.2586; STANESCU DC, 1981, J APPL PHYSIOL, V51, P1625, DOI 10.1152/jappl.1981.51.6.1625	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1299	1300		10.1016/S0140-6736(05)79050-4	http://dx.doi.org/10.1016/S0140-6736(05)79050-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643788				2023-01-03	WOS:000073439400003
J	Whelton, PK; Appel, LJ; Espeland, MA; Applegate, WB; Ettinger, WH; Kostis, JB; Kumanyika, S; Lacy, CR; Johnson, KC; Folmar, S; Cutler, JA				Whelton, PK; Appel, LJ; Espeland, MA; Applegate, WB; Ettinger, WH; Kostis, JB; Kumanyika, S; Lacy, CR; Johnson, KC; Folmar, S; Cutler, JA		TONE Collaborative Res Grp	Sodium reduction and weight loss in the treatment of hypertension in older persons - A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; MILD HYPERTENSION; RISK; THERAPY; WOMEN; MASS	Context.-Nonpharmacologic interventions are frequently recommended for treatment of hypertension in the elderly, but there is a paucity of evidence from randomized controlled trials in support of this recommendation. Objective.-To determine whether weight loss or reduced sodium intake is effective in the treatment of older persons with hypertension. Design.-Randomized controlled trial. Participants.-A total of 875 men and women aged 60 to 80 years with systolic blood pressure lower than 145 mm Hg and diastolic blood pressure lower than 85 mm Hg while receiving treatment with a single antihypertensive medication. Setting.-Four academic health centers. Intervention.-The 585 obese participants were randomized to reduced sodium intake, weight loss, both, or usual care, and the 390 nonobese participants were randomized to reduced sodium intake or usual care, Withdrawal of antihypertensive medication was attempted after 3 months of intervention. Main Outcome Measure.-Diagnosis of high blood pressure at 1 or more follow-up visits, or treatment with antihypertensive medication, or a cardiovascular event during follow-up (range, 15-36 months; median, 29 months). Results.-The combined outcome measure was less frequent among those assigned vs not assigned to reduced sodium intake (relative hazard ratio, 0.69; 95% confidence interval [CI], 0.59-0.81; P<.001) and, in obese participants, among those assigned vs not assigned to weight loss (relative hazard ratio, 0.70; 95% CI, 0.57-0.87; P<.001). Relative to usual care, hazard ratios among the obese participants were 0.60 (95% CI, 0.45-0.80; P<.001) for reduced sodium intake alone, 0.64 (95% CI, 0.49-0.85; P=.002) for weight loss alone, and 0.47 (95% CI, 0.35-0.64; P<.001) for reduced sodium intake and weight loss combined. The frequency of cardiovascular events during follow-up was similar in each of the 6 treatment groups. Conclusion.-Reduced sodium intake and weight loss constitute a feasible, effective, and safe nonpharmacologic therapy of hypertension in older persons.	Tulane Univ, Sch Publ Hlth & Trop Med, Off Dean, Dept Biostat & Epidemiol, New Orleans, LA 70112 USA; Johns Hopkins Univ, Sch Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27109 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Cardiovasc Dis & Hypertens, New Brunswick, NJ USA; Penn State Univ, Coll Med, Ctr Biostat & Epidemiol, Hershey, PA 17033 USA; NHLBI, Clin Applicat & Prevent Program, NIH, Bethesda, MD 20892 USA	Tulane University; Johns Hopkins University; Wake Forest University; Wake Forest University; University of Tennessee System; University of Tennessee Health Science Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Whelton, PK (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Off Dean, Dept Biostat & Epidemiol, 17th Floor,1501 Canal St, New Orleans, LA 70112 USA.	PWHELTON@TULANE.EDU	Appel, Larry/GLT-2608-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009771, R01AG009799] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-48642] Funding Source: Medline; NIA NIH HHS [R01 AG-09799, R01 AG-09771] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; *AM ASS CLIN CHEM, 1961, STAND METH CLIN CHEM, V3, P81; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; APPEL LA, 1997, J AM GERIATR SOC, V45, P185; Appel Lawrence J., 1995, Annals of Epidemiology, V5, P119, DOI 10.1016/1047-2797(94)00056-Y; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; BLACK HR, 1994, HYPERTENSION, V23, P275; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK NR, 1995, HYPERTENSION, V25, P1153, DOI 10.1161/01.HYP.25.6.1153; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; EWART CK, 1991, AM PSYCHOL, V46, P931, DOI 10.1037/0003-066X.46.9.931; FESKANICH D, 1989, COMPUT METH PROG BIO, V30, P47, DOI 10.1016/0169-2607(89)90122-3; HE J, 1994, AM J EPIDEMIOL, V139, P380, DOI 10.1093/oxfordjournals.aje.a117010; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; KLAG MJ, 1995, AM J EPIDEMIOL, V142, P295, DOI 10.1093/oxfordjournals.aje.a117635; Kumanyika S K, 1989, Clin Geriatr Med, V5, P769; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MACMAHON S, 1993, CLIN EXP HYPERTENS, V15, P967, DOI 10.3109/10641969309037085; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Puddey IB, 1995, J HYPERTENS, V13, P1229, DOI 10.1097/00004872-199511000-00002; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; STAMLER J, 1997, CAN J CARDIOL SB, V13, pB272; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; WRIGHT BM, 1970, LANCET, V1, P337	37	794	811	1	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					839	846		10.1001/jama.279.11.839	http://dx.doi.org/10.1001/jama.279.11.839			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515998	Bronze			2023-01-03	WOS:000072417600030
J	Evans, WE; Relling, MV; Rodman, JH; Crom, WR; Boyett, JM; Pui, CH				Evans, WE; Relling, MV; Rodman, JH; Crom, WR; Boyett, JM; Pui, CH			Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; HIGH-DOSE METHOTREXATE; CLINICAL PHARMACOKINETICS; SYSTEMIC EXPOSURE; ANTICANCER DRUGS; B-LINEAGE; IN-VIVO; PHARMACODYNAMICS; ACCUMULATION; TENIPOSIDE	Background The rate of clearance of antileukemic agents differs by a factor of 3 to 10 among children with acute lymphoblastic leukemia, We hypothesized that the outcome of treatment would be improved if doses were individualized to prevent low systemic exposure to the drugs in patients with fast drug clearance. Methods We stratified and randomly assigned 182 children with newly diagnosed acute lymphoblastic leukemia to postremission regimens that included high-dose methotrexate and teniposide plus cytarabine. The doses of these drugs were based on body-surface area (in the conventional-therapy group) or the rates of clearance of the three medications in each patient (in the individualized-treatment group). In the individualized-treatment group, doses were increased in patients with rapid clearance and decreased in patients with very slow clearance. Results Patients who received individualized doses had significantly fewer courses of treatment with systemic exposures below the target range than did patients who received conventional doses (P<0.001 for each medication). Among the patients with B-lineage leukemia, those who received individualized therapy had a significantly better outcome than those given conventional therapy (P=0.02); the mean (+/-SE) rates of continuous complete remission at five years were 76+/-6 percent and 66+/-7 percent, respectively. There was no significant difference between treatments for patients with T-lineage leukemia (P=0.54). In a proportional-hazards model, the time-dependent systemic exposure to methotrexate, but not to teniposide or cytarabine, was significantly related to the risk of early relapse in children with B-lineage leukemia. Conclusions; Adjusting the dose of methotrexate to account for the patient's ability to clear the drug can improve the outcome in children with B-lineage acute lymphoblastic leukemia. (C) 1998, Massachusetts Medical Society.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA020180, R01CA051001, R37CA036401, R29CA051001] Funding Source: NIH RePORTER; NCI NIH HHS [CA20180, R37 CA36401, CA51001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARREDO JC, 1994, BLOOD, V84, P564; BEHM FG, 1992, BLOOD, V79, P1011; DEVITA VT, 1986, J CLIN ONCOL, V4, P1157, DOI 10.1200/JCO.1986.4.8.1157; EVANS WE, 1991, SEMIN HEMATOL, V28, P15; EVANS WE, 1989, CLIN PHARMACOKINET, V16, P327, DOI 10.2165/00003088-198916060-00001; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; EVANS WE, 1992, J PHARMACOL EXP THER, V260, P71; Galpin AJ, 1997, MOL PHARMACOL, V52, P155, DOI 10.1124/mol.52.1.155; MAHONEY DH, 1995, CANCER, V75, P2623, DOI 10.1002/1097-0142(19950515)75:10<2623::AID-CNCR2820751033>3.0.CO;2-Y; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; NIEMEYER CM, 1991, BLOOD, V78, P2514, DOI 10.1182/blood.V78.10.2514.2514; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; PLUNKETT W, 1987, CANCER RES, V47, P3005; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; RELLING MV, 1994, J CLIN ONCOL, V12, P1667, DOI 10.1200/JCO.1994.12.8.1667; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RODMAN JH, 1987, J CLIN ONCOL, V5, P1007, DOI 10.1200/JCO.1987.5.7.1007; RODMAN JH, 1993, SEMIN ONCOL, V20, P18; RODMAN JH, 1993, J CLIN ONCOL, V11, P287, DOI 10.1200/JCO.1993.11.2.287; SIMONE JV, 1979, CANCER RES, V39, P43081; SINKULE JA, 1983, J CHROMATOGR, V274, P87, DOI 10.1016/S0378-4347(00)84411-4; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911; WILLIAMS DL, 1984, CANCER GENET CYTOGEN, V13, P239, DOI 10.1016/0165-4608(84)90046-3	25	381	388	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					499	505		10.1056/NEJM199802193380803	http://dx.doi.org/10.1056/NEJM199802193380803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468466				2023-01-03	WOS:000072061400003
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy in metastatic breast cancer	LANCET			English	Editorial Material							RESCUE		Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India; New York Hosp, Cornell Med Ctr, Stem Cell Transplantat & Clin Res Div Hematol Onc, New York, NY USA	Tata Memorial Centre (TMC); Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India.							BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BROUN ER, 1992, HIGH DOSE CANCER THE, P690; Dillman RO, 1996, BREAST CANCER RES TR, V37, P277, DOI 10.1007/BF01806509; GOLDSTONE AH, 1992, HIGH DOSE CANCER THE, P662; GULATI SC, 1993, PURGING BONE MARROW, P45; PETERS WP, 1995, P AN M AM SOC CLIN, V14, P317; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; ROWLINGS PA, 1997, P AM SOC CLIN ONCOL, V16, pA117; UNG O, 1995, J CLIN ONCOL, V13, P435, DOI 10.1200/JCO.1995.13.2.435	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					386	387		10.1016/S0140-6736(05)78349-5	http://dx.doi.org/10.1016/S0140-6736(05)78349-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482287				2023-01-03	WOS:000071982600005
J	Weg, JG; Anzueto, A; Balk, RA; Wiedemann, HP; Pattishall, EN; Schork, A; Wagner, LA				Weg, JG; Anzueto, A; Balk, RA; Wiedemann, HP; Pattishall, EN; Schork, A; Wagner, LA			The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							END-EXPIRATORY PRESSURE; EXTRACORPOREAL CO2 REMOVAL; INVERSE RATIO VENTILATION; ACUTE LUNG INJURY; MECHANICAL VENTILATION; PULMONARY BAROTRAUMA; MICROVASCULAR INJURY; SYNDROME ARDS; TIDAL VOLUME; FAILURE	Background In patients with the acute respiratory distress syndrome, pneumothorax and other air leaks - any extrusion of air outside the tracheobronchial tree - have been attributed to high ventilatory pressures or volumes and linked to increased mortality. Methods We analyzed data from a prospective trial of aerosolized synthetic surfactant in 725 patients with the acute respiratory distress syndrome induced by sepsis. We compared the ventilatory pressures and volumes in the patients without any air leaks (the highest values during the five-day study) with the pressures and volumes in those with pneumothorax or with any air leaks (the highest values during the 16- and 24-hour periods before the complication developed). Results Fifty patients (6.9 percent) had pneumothorax, and 77 (10.6 percent) had pneumothorax or other air leaks. There were no significant differences between patients with air leaks and those without air leaks in any pressure or volume examined. Overall mortality at 30 days was 40.0 percent (95 percent confidence interval, 36.4 to 43.6); among the patients with pneumothorax, it was 46.0 percent (95 percent confidence interval, 32.2 to 59.8), and among those without pneumothorax, it was 39.3 percent (95 percent confidence interval, 35.6 to 43.0; P=0.35). The mortality rate was 45.5 percent (95 percent confidence interval, 34.4 to 56.6) in the group with any air leaks and 39.0 percent (95 percent confidence interval, 35.3 to 42.8) in the group without air leaks (P=0.28). Conclusions In patients with sepsis-induced acute respiratory distress syndrome who were receiving mechanical ventilation with conventional pressures and volumes, there were no significant correlations between high ventilatory pressures or volumes and the development of pneumothorax or other air leaks. Pneumothorax or other air leaks were not associated with a significantly increased mortality rate. (C) 1998, Massachusetts Medical Society.	Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Cleveland Clin, Cleveland, OH 44106 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Rush University; Cleveland Clinic Foundation; GlaxoSmithKline; University of Michigan System; University of Michigan	Weg, JG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care, B1H245,Box 0024,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			Wiedemann, Herbert/0000-0002-4587-4401				AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; CALDWELL EJ, 1970, AM REV RESPIR DIS, V102, P516; CLEVENGER FW, 1990, ARCH SURG-CHICAGO, V125, P1542; DIRUSSO SM, 1995, CRIT CARE MED, V23, P1485, DOI 10.1097/00003246-199509000-00008; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1995, AM J RESP CRIT CARE, V151, P1568, DOI 10.1164/ajrccm.151.5.7735616; GAMMON RB, 1995, AM J RESP CRIT CARE, V152, P1235, DOI 10.1164/ajrccm.152.4.7551376; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; GATTINONI L, 1995, AM J RESP CRIT CARE, V151, P1807, DOI 10.1164/ajrccm.151.6.7767524; GREENFIELD LJ, 1964, ANESTHESIOLOGY, V25, P312, DOI 10.1097/00000542-196405000-00009; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HOLLANDER M, 1973, NONPARAMETRI STAT ME; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; Macklin CC, 1937, CAN MED ASSOC J, V36, P414; MATHIEUCOSTELLO OA, 1994, CHEST, V105, pS102, DOI 10.1378/chest.105.3_Supplement.102S; MAUNDER RJ, 1986, JAMA-J AM MED ASSOC, V255, P2463, DOI 10.1001/jama.255.18.2463; MEINERT CL, 1986, MONOGRAPHS EPIDEMIOL, V8; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; PEEVY KJ, 1990, CRIT CARE MED, V18, P634, DOI 10.1097/00003246-199006000-00012; PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; Pranikoff T, 1994, ASAIO J, V40, pM339, DOI 10.1097/00002480-199407000-00020; Remington RD, 1985, STAT APPL BIOL HLTH; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; SCHNAPP LM, 1995, CRIT CARE MED, V23, P272, DOI 10.1097/00003246-199502000-00012; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SLUTSKY AS, 1994, CHEST, V106, P656; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; TOMASHEFSKI JF, 1990, CLIN CHEST MED, V11, P593; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WRIGHT PE, 1994, CHEST, V106, P1517, DOI 10.1378/chest.106.5.1517; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	42	108	109	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					341	346		10.1056/NEJM199802053380601	http://dx.doi.org/10.1056/NEJM199802053380601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449726	Bronze			2023-01-03	WOS:000071822200001
J	Putney, SD; Burke, PA				Putney, SD; Burke, PA			Improving protein therapeutics with sustained-release formulations	NATURE BIOTECHNOLOGY			English	Review						drug delivery; controlled-release; protein stability; microencapsulation; PLGA	FIBROBLAST GROWTH-FACTOR; MOISTURE-INDUCED AGGREGATION; ENZYMATIC CATALYSIS; MOLECULAR-WEIGHT; ORGANIC-SOLVENTS; AQUEOUS-SOLUTION; SOLID-STATE; STABILIZATION; MICROSPHERES; STABILITY	Although numerous protein therapeutics have been approved or are in advanced clinical testing, the development of more sophisticated delivery systems for this rapidly expanding class of therapeutic agents has not kept pace. The short in vivo half-lives, the physical and chemical instability, and the low oral bioavailability of proteins currently necessitate their administration by frequent injections of protein solutions. This problem can be overcome by use of injectable depot formulations in which the protein is encapsulated in, and released slowly from, microspheres made of biodegradable polymers. Although the first report of sustained release of a microencapsulated protein was more than 20 years ago, the instability of proteins in these dosage forms has prevented their clinical use. Advances in protein stabilization, however, have allowed development of sustained-release forms of several therapeutic proteins, and clinical testing of a monthly formulation human growth hormone is currently in progress. The obvious advantage of this method of delivery is that the protein is administered less frequently, sometimes at lower overall doses, than when formulated as a solution. More importantly, it can justify commercial development of proteins that, for a variety of reasons, could not be marketed as solution formulations.	Alkermes Inc, Cambridge, MA 02139 USA; Amgen Corp, Thousand Oaks, CA 91320 USA	Alkermes; Amgen	Putney, SD (corresponding author), Alkermes Inc, 64 Sidney St, Cambridge, MA 02139 USA.	sputney@alkermes.com						AFFLECK R, 1992, P NATL ACAD SCI USA, V89, P1100, DOI 10.1073/pnas.89.3.1100; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; ARKY R, 1997, PHYSICIANS DESK REFE; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; Boury F, 1997, J CONTROL RELEASE, V45, P75, DOI 10.1016/S0168-3659(96)01547-7; BURKE PA, 1992, J BIOL CHEM, V267, P20057; Chang BS, 1996, BIOPHYS J, V71, P3399, DOI 10.1016/S0006-3495(96)79534-6; CHEN BL, 1994, PHARMACEUT RES, V11, P1581, DOI 10.1023/A:1018905720139; Chen L, 1997, J CONTROL RELEASE, V43, P261, DOI 10.1016/S0168-3659(96)01496-4; Cleland JL, 1997, PHARMACEUT RES, V14, P420, DOI 10.1023/A:1012031012367; CLELAND JL, 1997, P INT S CONTROL DEL, V24, P823; CLELAND JL, 1996, PHARMACEUT RES, V13, P1462; CLELAND JL, 1997, P INT S CONTROL DEL, V24, P85; COLEMAN JE, 1992, ANN REV BIOCH, V61; COSTANTINO HR, 1994, PHARMACEUT RES, V11, P21, DOI 10.1023/A:1018981208076; CREQUE HM, 1980, DIABETES, V29, P37, DOI 10.2337/diabetes.29.1.37; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DAUGHADAY WF, 1995, ENDOCRINOLOGY, V2, P303; DESAL UR, 1995, J AM CHEM SOC, V117, P940; DICKINSON E, 1993, LANGMUIR, V9, P242, DOI 10.1021/la00025a046; DICKINSON E, 1991, INT J BIOL MACROMOL, V13, P26, DOI 10.1016/0141-8130(91)90006-G; Dinbergs ID, 1996, J BIOL CHEM, V271, P29822, DOI 10.1074/jbc.271.47.29822; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; EPPSTEIN DA, 1990, Patent No. 4962091; EPPSTEIN DA, 1986, BIOL INTERFERON SYST, P401; Gombotz W. R., 1991, U.S. Patent, Patent No. [5,019,400, 5019400]; GOMBOTZ WR, 1993, J BIOMAT SCI-POLYM E, V5, P49; Griebenow K, 1996, J AM CHEM SOC, V118, P11695, DOI 10.1021/ja961869d; GU LC, 1991, PHARM RES-DORDR, V8, P485, DOI 10.1023/A:1015851228163; Hageman MJ, 1992, STABILITY PROTEIN PH, P273; HARRIS AG, 1995, J CLIN PHARMACOL, V35, P59, DOI 10.1002/j.1552-4604.1995.tb04746.x; HELLER J, 1990, BIODEGRADABLE POLYM, P121; HORA MS, 1990, BIO-TECHNOL, V8, P755, DOI 10.1038/nbt0890-755; HORBETT T, 1986, PROTEINS INTERFACES, P1; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; JOHNSON OL, 1997, PHARMACEUT RES, V14, P734; KLIBANOV AM, 1989, TRENDS BIOCHEM SCI, V14, P141, DOI 10.1016/0968-0004(89)90146-1; Krewson CE, 1996, J BIOMAT SCI-POLYM E, V8, P103; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LEE HJ, 1995, PEPTIDE BASED DRUG D, P69; LEONG KW, 1986, J BIOMED MATER RES, V20, P51, DOI 10.1002/jbm.820200106; LI SH, 1995, BIOCHEMISTRY-US, V34, P5762, DOI 10.1021/bi00017a008; LIU WR, 1991, BIOTECHNOL BIOENG, V37, P177, DOI 10.1002/bit.260370210; Lu W, 1995, PDA J Pharm Sci Technol, V49, P13; Maa YF, 1996, J CONTROL RELEASE, V38, P219, DOI 10.1016/0168-3659(95)00123-9; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; Mader K, 1997, POLYMER, V38, P4785, DOI 10.1016/S0032-3861(97)00003-7; MATHIOWITZ E, 1987, Journal of Controlled Release, V5, P13, DOI 10.1016/0168-3659(87)90033-2; MATHIOWITZ E, 1988, J APPL POLYM SCI, V35, P755, DOI 10.1002/app.1988.070350316; MENDEZ A, 1994, METH NEUROSCI, V21, P150; MITTAL S, 1994, NEUROREPORT, V5, P2577, DOI 10.1097/00001756-199412000-00043; Morlock M, 1997, EUR J PHARM BIOPHARM, V43, P29, DOI 10.1016/S0939-6411(96)00017-3; OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095; PETTIT DS, 1996, P INT S CONTROL DEL, V23, P857; PHILLIPS MC, 1977, CHEM IND-LONDON, P170; PIKAL MJ, 1994, FORMULATION DELIVERY, P120; PIKAL MJ, 1996, PEPTIDE PROTEIN DELI; PITT CG, 1990, INT J PHARMACEUT, V59, P173, DOI 10.1016/0378-5173(90)90108-G; SANDERS LM, 1986, J PHARM SCI, V75, P356, DOI 10.1002/jps.2600750407; SchroederTefft JA, 1997, J CONTROL RELEASE, V48, P29, DOI 10.1016/S0168-3659(97)00055-2; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SINGER SJ, 1962, ADV PROTEIN CHEM, V17, P1; STEINER DF, 1995, ENDOCRINOLOGY, V2, P1296; STRUCK MM, 1994, BIO-TECHNOL, V12, P674, DOI 10.1038/nbt0794-674; TABATA Y, 1993, J CONTROL RELEASE, V23, P55, DOI 10.1016/0168-3659(93)90070-L; TALMADGE JE, 1993, ADV DRUG DELIVER REV, V10, P247, DOI 10.1016/0169-409X(93)90049-A; TANIGUCHI E, 1991, Nippon Ganka Gakkai Zasshi, V95, P52; TARBEEK IC, 1996, BIOPHYS J, V70, P2396; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; TRACY MA, 1996, Patent No. 03116; TSAI PK, 1993, PHARMACEUT RES, V10, P649, DOI 10.1023/A:1018939228201; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; VRKLJAN M, 1994, PHARMACEUT RES, V11, P1004, DOI 10.1023/A:1018935420680; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; ZALE SE, 1996, Patent No. 5674534; Zignani M, 1997, J CONTROL RELEASE, V48, P115, DOI 10.1016/S0168-3659(97)00050-3; [No title captured]	77	399	478	3	108	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					153	157		10.1038/nbt0298-153	http://dx.doi.org/10.1038/nbt0298-153			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487521				2023-01-03	WOS:000071831300027
J	Sarasin, FP; Bounameaux, H				Sarasin, FP; Bounameaux, H			Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED PROTEIN-C; MOLECULAR-WEIGHT HEPARIN; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; OPTIMAL DURATION; THERAPY; RESISTANCE; MUTATION; RISK	Objective: To assess the risks and benefits of oral anticoagulant treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation. Such patients have over twice the risk of recurrence after the recommended treatment period, but more information is required before widespread genetic screening can be recommended. Design: A decision analysis Markov model (with data extracted form literature) representing the risks of developing symptomatic venous thromboembolism, the risks of major bleeding, and the efficacy of anticoagulant treatment. Subjects: A hypothetical cohort of 1000 carriers of factor V Leiden recovering from a first episode of deep vein thrombosis in the lower limbs. Main outcome measures: Risks and benefits of, firstly, stopping oral anticoagulation 3 months after first episode of thrombosis with reinitiation of treatment only after recurrent thrombosis and, secondly, extension of oral anticoagulation up to 1 to 5 years. Results: Despite consistent biases in favour of extended oral anticoagulation, analysis revealed that among factor V carriers the number of major haemorrhages induced by oral anticoagulants would exceed that of clinical pulmonary emboli prevented over the entire range of duration of anticoagulation (1 to 5 years). On the other hand, the number of recurrent deep vein thrombi prevented would exceed that of iatrogenic major bleedings. Conclusion: The lack of evidence of a net clinical benefit of prolonged oral anticoagulation, at least beyond 1 year, among patients recovering from acute deep vein thrombosis does not support the decision to promote widespread genetic screening programmes to detect the factor V mutation.	Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, CH-1211 Geneva 14, Switzerland; Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva	Sarasin, FP (corresponding author), Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, 24 Rue Micheli Crest, CH-1211 Geneva 14, Switzerland.	sarasin-francois@diogenes.hcuge.ch						BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BEYTH RJ, 1995, ARCH INTERN MED, V218, P279; Bounameaux H, 1996, BLOOD COAGUL FIBRIN, V7, P507, DOI 10.1097/00001721-199607000-00001; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; Koepke JA, 1996, AM J CLIN PATHOL, V106, P161; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; Manten B, 1996, THROMB HAEMOSTASIS, V76, P510; Marinelli I, 1997, THROMB HAEMOSTASIS, V77, P440; MONREAL M, 1992, CHEST, V102, P677, DOI 10.1378/chest.102.3.677; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SUDLOW MF, 1992, LANCET, V340, P873; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	31	43	43	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					95	99						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462312				2023-01-03	WOS:000071492300014
J	Dyer, C				Dyer, C			Doctors as gods	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					64	64		10.1136/bmj.319.7201.64	http://dx.doi.org/10.1136/bmj.319.7201.64			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390489	Green Published			2023-01-03	WOS:000081326500072
J	Hinds, CJ; Watson, D				Hinds, CJ; Watson, D			ABC of intensive care - Circulatory support	BRITISH MEDICAL JOURNAL			English	Article									Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med, London E1 4NS, England	University of London; Queen Mary University London	Hinds, CJ (corresponding author), Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med, Mile End Rd, London E1 4NS, England.								0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1749	1752		10.1136/bmj.318.7200.1749	http://dx.doi.org/10.1136/bmj.318.7200.1749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381715	Green Published			2023-01-03	WOS:000081216900037
J	White, NJ; Nosten, F; Looareesuwan, S; Watkins, WM; Marsh, K; Snow, RW; Kokwaro, G; Ouma, J; Hien, TT; Molyneux, ME; Taylor, TE; Newbold, CI; Ruebush, TK; Danis, M; Greenwood, BM; Anderson, RM; Olliaro, P				White, NJ; Nosten, F; Looareesuwan, S; Watkins, WM; Marsh, K; Snow, RW; Kokwaro, G; Ouma, J; Hien, TT; Molyneux, ME; Taylor, TE; Newbold, CI; Ruebush, TK; Danis, M; Greenwood, BM; Anderson, RM; Olliaro, P			Averting a malaria disaster	LANCET			English	Editorial Material							RESISTANT FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; DRUG-RESISTANCE; PYRIMETHAMINE; CHLOROQUINE; SULFADOXINE; ARTEMETHER; AFRICA		Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; Wellcome Mahidol Univ Oxford, Trop Med Res Programme, Bangkok, Thailand; KEMRI Wellcome Trust Collaborat Res Programme, Nairobi, Kenya; Minist Hlth, Natl Malaria Control Programme, Nairobi, Kenya; Cho Quan Hosp, Ctr Trop Dis, Ho Chi Minh City, Vietnam; Univ Malawi, Coll Med, Zomba, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Oxford, Inst Mol Med, Oxford, England; Ctr Dis Control & Prevent, Atlanta, GA USA; Grp Hosp Pitie Salpetriere, F-75634 Paris, France; London Sch Hyg & Trop Med, London WC1, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; WHO, CH-1211 Geneva, Switzerland	Mahidol University; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; University of Oxford; Centers for Disease Control & Prevention - USA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; London School of Hygiene & Tropical Medicine; University of Oxford; World Health Organization	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		Snow, Robert William/AFR-1436-2022; White, Nick/AAC-6527-2019; Nosten, Francois/AAC-5509-2019; White, Nicholas J/I-4629-2012	Snow, Robert William/0000-0003-3725-6088; White, Nick/0000-0002-1897-1978; Nosten, Francois/0000-0002-7951-0745; Newbold, Chris/0000-0002-9274-3789; Anderson, Roy/0000-0002-9528-3175				BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; BREWER TG, 1994, AM J TROP MED HYG, V51, P251, DOI 10.4269/ajtmh.1994.51.251; Brundtland G. H., 1998, 51 WORLD HLTH ASS GE; Handunnetti SM, 1996, T ROY SOC TROP MED H, V90, P563, DOI 10.1016/S0035-9203(96)90325-9; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; van Vugt M, 1998, ANTIMICROB AGENTS CH, V42, P135, DOI 10.1128/AAC.42.1.135; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2	13	440	451	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1965	1967		10.1016/S0140-6736(98)07367-X	http://dx.doi.org/10.1016/S0140-6736(98)07367-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371589				2023-01-03	WOS:000080668500047
J	Chiu, DT; Wilson, CF; Ryttsen, F; Stromberg, A; Farre, C; Karlsson, A; Nordholm, S; Gaggar, A; Modi, BP; Moscho, A; Garza-Lopez, RA; Orwar, O; Zare, RN				Chiu, DT; Wilson, CF; Ryttsen, F; Stromberg, A; Farre, C; Karlsson, A; Nordholm, S; Gaggar, A; Modi, BP; Moscho, A; Garza-Lopez, RA; Orwar, O; Zare, RN			Chemical transformations in individual ultrasmall biomimetic containers	SCIENCE			English	Article							ELECTRICAL BREAKDOWN; SINGLE MOLECULES; AQUEOUS CONTENTS; MEMBRANES; KINETICS; FUSION; CELL	Individual phospholipid vesicles, 1 to 5 micrometers in diameter, containing a single reagent or a complete reaction system, were immobilized with an infrared laser optical trap or by adhesion to modified borosilicate glass surfaces. Chemical transformations were initiated either by electroporation or by electrofusion, in each case through application of a short (10-microsecond), intense (20 to 50 kilovolts per centimeter) electric pulse delivered across ultramicroelectrodes. Product formation was monitored by far-field laser fluorescence microscopy. The ultrasmall characteristic of this reaction volume led to rapid diffusional mixing that permits the study of fast chemical kinetics. This technique is also well suited for the study of reaction dynamics of biological molecules within lipid-enclosed nanoenvironments that mimic cell membranes.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Univ Gothenburg, Dept Chem, S-41296 Gothenburg, Sweden; Pomona Coll, Dept Chem, Claremont, CA 91711 USA	Stanford University; University of Gothenburg; Claremont Colleges; Pomona College	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009; Nordholm, Sture/A-8506-2010	Zare, Richard/0000-0001-5266-4253	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09873] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CHANG DC, 1990, BIOPHYS J, V58, P1, DOI 10.1016/S0006-3495(90)82348-1; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V902, P360, DOI 10.1016/0005-2736(87)90204-5; Chiu DT, 1997, ANAL CHEM, V69, P1801, DOI 10.1021/ac961226g; Clark RA, 1997, ANAL CHEM, V69, P259, DOI 10.1021/ac960559a; Drott J, 1998, THIN SOLID FILMS, V330, P161, DOI 10.1016/S0040-6090(98)00543-4; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ERMAK DL, 1975, J CHEM PHYS, V62, P4189, DOI 10.1063/1.430300; FUNAKURA S, 1994, J PHYS CHEM-US, V98, P3073, DOI 10.1021/j100063a003; Jensen K, 1998, NATURE, V393, P735, DOI 10.1038/31590; Knight JB, 1998, PHYS REV LETT, V80, P3863, DOI 10.1103/PhysRevLett.80.3863; Kovacs GTA, 1996, ANAL CHEM, V68, pA407, DOI 10.1021/ac961977i; Kung CY, 1998, ANAL CHEM, V70, P658, DOI 10.1021/ac971107g; Masuhara H., 1994, MICROCHEMISTRY SPECT; Moscho A, 1996, P NATL ACAD SCI USA, V93, P11443, DOI 10.1073/pnas.93.21.11443; NEEDHAM D, 1993, METHOD ENZYMOL, V220, P111, DOI 10.1016/0076-6879(93)20078-H; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; STENGER DA, 1988, BIOPHYS J, V53, P833, DOI 10.1016/S0006-3495(88)83162-X; Tan WH, 1997, ANAL CHEM, V69, P4242, DOI 10.1021/ac970631k; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; TURQ P, 1977, J CHEM PHYS, V66, P3039, DOI 10.1063/1.434317; WILHELM C, 1993, BIOPHYS J, V64, P121, DOI 10.1016/S0006-3495(93)81346-8; You AJ, 1997, CHEM BIOL, V4, P969, DOI 10.1016/S1074-5521(97)90305-7; ZIMMERMANN U, 1982, BIOCHIM BIOPHYS ACTA, V694, P227, DOI 10.1016/0304-4157(82)90007-7	24	223	257	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1892	1895		10.1126/science.283.5409.1892	http://dx.doi.org/10.1126/science.283.5409.1892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10082457				2023-01-03	WOS:000079228600040
J	Liu, L; Li, PS; Asher, SA				Liu, L; Li, PS; Asher, SA			Entropic trapping of macromolecules by mesoscopic periodic voids in a polymer hydrogel	NATURE			English	Article							CRYSTALLINE COLLOIDAL ARRAYS; GEL-ELECTROPHORESIS; TRACER DIFFUSION; DNA; DIFFRACTION; POLYSTYRENE	The separation of macromolecules such as polymers and DNA by means of electrophoresis, gel permeation chromatography or filtration exploits size-dependent differences in the time it takes for the molecules to migrate through a random porous network. Transport through the gel matrices, which usually consist of full swollen crosslinked polymers(1-11), depends on the relative size of the macromolecule compared with the pore radius. Sufficiently small molecules are thought to adopt an approximately spherical conformation when diffusing through the gel matrix(1), whereas larger ones are forced to migrate in a snake-like fashion(3-5). Molecules of intermediate size, however, can get temporarily trapped in the largest pores of the matrix, where the molecule can extend and thus maximize its conformational entropy, This 'entropic trapping' is thought to increase the dependence of diffusion rate an molecular size(6-16). Here we report the direct experimental verification of this phenomenon. Bragg diffraction from a hydrogel containing a periodic array of monodisperse water voids confirms that polymers of different weights partition between the hydrogel matrix and the water voids according to the predictions of the entropic trapping theory. Our approach might also lead to the design of improved separation media based on entropic trapping.	Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Asher, SA (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.	asher+@pitt.edu						Asher S.A., 1986, Patent No. [US4632517A, 4632517]; ASHER SA, 1986, Patent No. 4627689; BAUMGARTNER A, 1987, J CHEM PHYS, V87, P3082, DOI 10.1063/1.453045; CASASSA EF, 1967, J POLYM SCI POL LETT, V5, P773, DOI 10.1002/pol.1967.110050907; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; de Gennes P. G., 1979, SCALING CONCEPTS POL; Flory P.J., 1953, PRINCIPLES POLYM CHE; GUILLOT G, 1985, MACROMOLECULES, V18, P2531, DOI 10.1021/ma00154a030; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HOAGLAND DA, 1992, MACROMOLECULES, V25, P6696, DOI 10.1021/ma00050a046; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; KESAVAMOORTHY R, 1992, J COLLOID INTERF SCI, V153, P188, DOI 10.1016/0021-9797(92)90310-I; KIM HD, 1986, MACROMOLECULES, V19, P2737, DOI 10.1021/ma00165a013; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; Liu L, 1997, J AM CHEM SOC, V119, P2729, DOI 10.1021/ja963885g; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MUTHUKUMAR M, 1989, MACROMOLECULES, V22, P1937, DOI 10.1021/ma00194a070; NEMOTO N, 1990, MACROMOLECULES, V23, P659, DOI 10.1021/ma00204a045; NOOLANDI J, 1987, PHYS REV LETT, V58, P2428, DOI 10.1103/PhysRevLett.58.2428; RIGHETTI PG, 1995, J CHROMATOGR A, V698, P3, DOI 10.1016/0021-9673(94)00068-K; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; ROTSTEIN NA, 1992, MACROMOLECULES, V25, P1316, DOI 10.1021/ma00030a018; Rousseau J, 1997, PHYS REV LETT, V79, P1945, DOI 10.1103/PhysRevLett.79.1945; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; SLATER GW, 1995, PHYS REV LETT, V75, P164, DOI 10.1103/PhysRevLett.75.164; SLATER GW, 1986, BIOPOLYMERS, V25, P431, DOI 10.1002/bip.360250305; SMISEK DL, 1990, SCIENCE, V248, P1221, DOI 10.1126/science.2349481; Teraoka I, 1996, MACROMOLECULES, V29, P2430, DOI 10.1021/ma951146z; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959	29	183	186	3	118	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1999	397	6715					141	144		10.1038/16426	http://dx.doi.org/10.1038/16426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157WQ	9923674				2023-01-03	WOS:000078085000039
J	Bensoussan, A; Talley, NJ; Hing, M; Menzies, R; Guo, A; Ngu, M				Bensoussan, A; Talley, NJ; Hing, M; Menzies, R; Guo, A; Ngu, M			Treatment of irritable bowel syndrome with Chinese herbal medicine - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYMPTOMS; CREDIBILITY; CRITIQUE	Context.-Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment. Objective.-To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS, Design.-Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997, Setting.-Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists, and received CHM in 3 Chinese herbal clinics. Patients.-A total of 116 patients who fulfilled the Rome criteria, an established standard for diagnosis of IBS. Intervention.-Patients were randomly allocated to 1 of 3 treatment groups: individualized Chinese herbal formulations (n = 38), a standard Chinese herbal formulation (n = 43), or placebo (n = 35). Patients received 5 capsules 3 times daily for 16 weeks and were evaluated regularly by a traditional Chinese herbalist and by a gastroenterologist. Patients, gastroenterologists, and herbalists were all blinded to treatment group. Main Outcome Measures.-Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the degree of interference in life caused by IBS symptoms assessed by patients. Results.-Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in bowel symptom scores as rated by patients (P = .03) and by gastroenterologists (P = .001), and significant global improvement as rated by patients (P = .007) and by gastroenterologists (P = .002), Patients reported that treatment significantly reduced the degree of interference with life caused by IBS symptoms (P = .03), Chinese herbal formulations individually tailored to the patient proved no more effective than standard CHM treatment. On follow-up 14 weeks after completion of treatment, only the individualized CHM treatment group maintained improvement. Conclusion.-Chinese herbal formulations appear to offer improvement in symptoms for some patients with IBS.	Univ Western Sydney Macarthur, Fac Hlth, Res Unit Complementary Med, Campbelltown, NSW 2560, Australia; Univ Sydney, Dept Behav Sci, Sydney, NSW 2006, Australia; Nepean Hosp, Dept Med, Sydney, NSW, Australia; Bondi Junct Endoscopy Ctr, Sydney, NSW, Australia; Balmain Chinese Herbal Ctr, Sydney, NSW, Australia; Concord Repatriat Gen Hosp, Gastroenterol Unit, Sydney, NSW, Australia	Western Sydney University; University of Sydney; Nepean Hospital; Concord Repatriation General Hospital	Bensoussan, A (corresponding author), Univ Western Sydney Macarthur, Fac Hlth, Res Unit Complementary Med, POB 555, Campbelltown, NSW 2560, Australia.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092; Bensoussan, Alan/0000-0002-7433-667X; Menzies, Ross/0000-0002-7589-960X				[Anonymous], 1992, GASTROENTEROL INT; ANTHONY HM, 1998, CLIN RES METHODOLOGY, P108; BENSOUSSAN A, 1993, AM J ACUPUNCT, V19, P357; Bensoussan A, 1996, SAFER CHOICE PRACTIC; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; CHEN DZ, 1995, NANJING MED U J, V15, P924; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; Hsu H-Y, 1986, 1986 ORIENTAL MATERI; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; LIU ZK, 1990, CHIN J INTEGRATED TR, V10, P615; PETRIE J, 1985, CLIN EXP RHEUMATOL, V3, P151; SHI ZQ, 1989, CHIN J INTEGRATED TR, V9, P241; Talley N, 1993, GASTROENTEROL INT, V6, P189; TALLEY NJ, 1995, AUST NZ J MED, V25, P302, DOI 10.1111/j.1445-5994.1995.tb01894.x; Talley NJ, 1996, AM J GASTROENTEROL, V91, P277; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; XU RL, 1995, SHANXI J TRADIT CHIN, V11, P10; YU ZX, 1991, CHIN J INTEGRATED TR, V11, P170	22	278	298	2	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1585	1589		10.1001/jama.280.18.1585	http://dx.doi.org/10.1001/jama.280.18.1585			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820260	Bronze			2023-01-03	WOS:000076852000025
J	Bavelier, D; Corina, DP; Neville, HJ				Bavelier, D; Corina, DP; Neville, HJ			Brain and language: A perspective frown sign language	NEURON			English	Review									Georgetown Univ, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Dept Psychol, Washington, DC 20007 USA; Univ Oregon, Dept Psychol, Eugene, OR 97403 USA	Georgetown University; Georgetown University; University of Oregon	Bavelier, D (corresponding author), Georgetown Univ, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA.			Bavelier, Daphne/0000-0002-5904-1240				Beeman M., 1998, RIGHT HEMISPHERE LAN; BRENTARI D, 1995, BRAIN LANG, V48, P69, DOI 10.1006/brln.1995.1003; Corina D, 1996, COGNITIVE NEUROPSYCH, V13, P321; Corina D, 1998, APHASIA IN ATYPICAL POPULATIONS, P261; Corina D., 1993, PHONOLOGY, V10, P165, DOI [10.1017/S0952675700000038, DOI 10.1017/S0952675700000038]; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; Heilman K.M., 1985, INT J CLIN NEUROPSYC, V2nd, P243; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; LIDDELL SK, 1998, IN PRESS LANGUAGE GE; Lillo-Martin Diane., 1991, UNIVERSAL GRAMMAR AM; McGuire PK, 1997, NEUROREPORT, V8, P695, DOI 10.1097/00001756-199702100-00023; Neville HJ, 1997, BRAIN LANG, V57, P285, DOI 10.1006/brln.1997.1739; Neville HJ, 1998, CURR OPIN NEUROBIOL, V8, P254, DOI 10.1016/S0959-4388(98)80148-7; Neville HJ, 1998, P NATL ACAD SCI USA, V95, P922, DOI 10.1073/pnas.95.3.922; Newport E., 1980, SIGNED SPOKEN LANGUA, P187; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Soderfeldt B, 1997, NEUROLOGY, V49, P82, DOI 10.1212/WNL.49.1.82; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x	18	22	23	3	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0896-6273			NEURON	Neuron	AUG	1998	21	2					275	278		10.1016/S0896-6273(00)80536-X	http://dx.doi.org/10.1016/S0896-6273(00)80536-X			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	114FK	9728908	Green Published, hybrid			2023-01-03	WOS:000075598300004
J	Adams, RJ; McKie, VC; Hsu, L; Files, B; Vichinsky, E; Pegelow, C; Abboud, M; Gallagher, D; Kutlar, A; Nichols, FT; Bonds, DR; Brambilla, D; Woods, G; Olivieri, N; Driscoll, C; Miller, S; Wang, W; Hurlett, A; Scher, C; Berman, B; Carl, E; Jones, AM; Roach, ES; Wright, E; Zimmerman, RA; Waclawiw, M; Pearson, H; Powars, D; Younkin, D; El-Gammal, T; Seibert, J; Moye, L; Espeland, M; Murray, R; McKinley, R; McKinley, S; Hagner, S; Weiner, S; Estow, S; Yelle, M; Brock, K; Carter, E; Chiarucci, K; Debarr, M; Feron, P; Harris, S; Hoey, L; Jacques, K; Kuisel, L; Lewis, N; Lindsey, R; Martin, B; McMeechan, C; Muracca, M; Rey, K; Roath, G; Hackney-Stephens, E; Sumter, L; Talbot, A; Taplin, G; Whittle, C; Woods, P; Harbin, J; Holley, L; Jackson, B; Kutlar, F; Miller, B; Odo, N; Sahm, M; Schweitzer, J; Winstead, A; Swift, T; Allen, F; Allen, K; Beasley, M; Ejantkar, A; Houston, E; Hunter, D; Luden, J; Ottenlips, J; Trocio, S; Hernandez, C; McKie, K; McMorrow-Touhy, AM; Perry, R; Bello, J; Luban, N; Moser, F; Caplan, L; DeWitt, D; Riela, A; Babyn, P; Cure, J; Davis, P; Fiqueroa, R; Gaensler, E; Hotson, W; Kodroff, M; Langston, J; Lewin, J; Rho, T; Seidel, G; Sutton, C; Vezina, G; Whitman, M; Al-Mateen, M; Barfield, J; Caragan, A; Curless, R; Facchini, S; Flemming, F; Holden, K; MacGregor, D; Murphy, J; Packer, R; Park, Y; Rose, A; Sutton, C; Wiznitzer, M				Adams, RJ; McKie, VC; Hsu, L; Files, B; Vichinsky, E; Pegelow, C; Abboud, M; Gallagher, D; Kutlar, A; Nichols, FT; Bonds, DR; Brambilla, D; Woods, G; Olivieri, N; Driscoll, C; Miller, S; Wang, W; Hurlett, A; Scher, C; Berman, B; Carl, E; Jones, AM; Roach, ES; Wright, E; Zimmerman, RA; Waclawiw, M; Pearson, H; Powars, D; Younkin, D; El-Gammal, T; Seibert, J; Moye, L; Espeland, M; Murray, R; McKinley, R; McKinley, S; Hagner, S; Weiner, S; Estow, S; Yelle, M; Brock, K; Carter, E; Chiarucci, K; Debarr, M; Feron, P; Harris, S; Hoey, L; Jacques, K; Kuisel, L; Lewis, N; Lindsey, R; Martin, B; McMeechan, C; Muracca, M; Rey, K; Roath, G; Hackney-Stephens, E; Sumter, L; Talbot, A; Taplin, G; Whittle, C; Woods, P; Harbin, J; Holley, L; Jackson, B; Kutlar, F; Miller, B; Odo, N; Sahm, M; Schweitzer, J; Winstead, A; Swift, T; Allen, F; Allen, K; Beasley, M; Ejantkar, A; Houston, E; Hunter, D; Luden, J; Ottenlips, J; Trocio, S; Hernandez, C; McKie, K; McMorrow-Touhy, AM; Perry, R; Bello, J; Luban, N; Moser, F; Caplan, L; DeWitt, D; Riela, A; Babyn, P; Cure, J; Davis, P; Fiqueroa, R; Gaensler, E; Hotson, W; Kodroff, M; Langston, J; Lewin, J; Rho, T; Seidel, G; Sutton, C; Vezina, G; Whitman, M; Al-Mateen, M; Barfield, J; Caragan, A; Curless, R; Facchini, S; Flemming, F; Holden, K; MacGregor, D; Murphy, J; Packer, R; Park, Y; Rose, A; Sutton, C; Wiznitzer, M			Prevention of a first stroke by transfusions in children with sickle, cell anemia and abnormal results on transcranial Doppler ultrasonography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; ANGIOGRAPHY; THERAPY	Background Blood transfusions prevent recurrent stroke in children with sickle cell anemia, but the value of transfusions in preventing a first stroke is unknown. We used transcranial Doppler ultrasonography to identify children with sickle cell anemia who were at high risk for stroke and then randomly assigned them to receive standard care or transfusions to prevent a first stroke. Methods To enter the study, children with sickle cell anemia and no history of stroke had to have undergone two transcranial Doppler studies that showed that the time-averaged mean blood-flow velocity in the internal carotid or middle cerebral artery was 200 cm per second or higher. The patients were randomly assigned to receive standard care or transfusions to reduce the hemoglobin S concentration to less than 30 percent of the total hemoglobin concentration. The incidence of stroke (cerebral infarction or intracranial hemorrhage) was compared between the two groups. Results A total of 130 children (mean [+/- SD] age, 8.3 +/- 3.3 years) were enrolled; 63 were randomly assigned to receive transfusions, and 67 to receive standard care. At base line, the transfusion group had a slightly lower mean hemoglobin concentration (7.2 vs. 7.6 g per deciliter, P = 0.001) and hematocrit (20.4 vs. 21.7 percent, P = 0.002). Ten patients dropped out of the transfusion group, and two patients crossed over from the standard-care group to the transfusion group. There were 10 cerebral infarctions and ? intracerebral hematoma in the standard-care group, as compared with 1 infarction in the transfusion group - a 92 percent difference in the risk of stroke (P<0.001). This result led to the early termination of the trial. Conclusions Transfusion greatly reduces the risk of a first stroke in children with sickle cell anemia who have abnormal results on transcranial Doppler ultrasonography. (N Engl J Med 1998;339:5-11.) (C) 1998. Massachusetts Medical Society.	Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat Hematol & Oncol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; Emory Univ, Sch Med, Sickle Cell Ctr, Atlanta, GA USA; E Carolina Univ, Sch Med, Dept Pediat Hematol & Oncol, Greenville, NC USA; Childrens Hosp Oakland, Dept Hematol & Oncol, Oakland, CA 94609 USA; Univ Miami, Sch Med, Sickle Cell Ctr, Miami, FL USA; Med Univ S Carolina, Pediat Sickle Cell Program, Charleston, SC 29425 USA; New England Res Inst, Watertown, MA 02172 USA; NHLBI, Bethesda, MD 20892 USA; Childrens Mercy Hosp, Dept Hematol & Oncol, Kansas City, MO 64108 USA; Hosp Sick Children, Dept Hematol & Oncol, Toronto, ON M5G 1X8, Canada; Childrens Natl Med Ctr, Dept Hematol & Oncol, Washington, DC 20010 USA; SUNY Hlth Sci Ctr, Pediat Sickle Cell Program, Brooklyn, NY 11203 USA; St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA; Columbia Presbyterian Med Ctr, Dept Pediat Hematol, New York, NY 10032 USA; Tulane Univ, Sch Med, Dept Pediat Hematol & Oncol, New Orleans, LA 70112 USA; Rainbow Babies & Childrens Hosp, Dept Pediat Hematol & Oncol, Cleveland, OH 44106 USA; Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; Univ Texas, SW Med Ctr, Dept Pediat Neurol, Dallas, TX USA; New England Res Inst, Watertown, MA 02172 USA; Childrens Hosp Philadelphia, Dept Neuroradiol, Philadelphia, PA 19104 USA; NHLBI, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Emory University; University of North Carolina; East Carolina University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Miami; Medical University of South Carolina; HealthCore, Inc; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Children's Mercy Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's National Health System; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; St Jude Children's Research Hospital; Columbia University; NewYork-Presbyterian Hospital; Tulane University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Georgia; Augusta University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; HealthCore, Inc; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adams, RJ (corresponding author), Med Coll Georgia, Dept Neurol, 1467 Harper St,HB-2060, Augusta, GA 30912 USA.		Olivieri, Nancy/AAI-2250-2020; Roach, Ewell/E-3958-2011; Hsu, Lewis L/H-8001-2019; Hsu, Lewis/A-3360-2008; Adams, Robert/GPW-8528-2022; Vichinsky, Elliott P/F-8541-2011	Hsu, Lewis L/0000-0002-3156-2378; Vichinsky, Elliott P/0000-0002-0500-9579; Brambilla, Donald/0000-0002-7276-4689	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL052193, U10HL052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL 52016, U10 HL 52193] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaslid R., 1992, TRANSCRANIAL DOPPLER, V1, P1; ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; ADAMS RJ, 1992, STROKE, V23, P1073, DOI 10.1161/01.STR.23.8.1073; Adams RJ, 1998, CONTROL CLIN TRIALS, V19, P110, DOI 10.1016/S0197-2456(97)00099-8; Adams RJ, 1993, TRANSCRANIAL DOPPLER, P160; Adams Robert J., 1994, P599; ALBERTS MJ, 1992, STROKE, V23, P663, DOI 10.1161/01.STR.23.5.663; BISSE E, 1988, J CHROMATOGR-BIOMED, V434, P95, DOI 10.1016/0378-4347(88)80065-3; BRASS LM, 1988, STROKE, V19, P1466, DOI 10.1161/01.STR.19.12.1466; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; COHEN AR, 1992, BLOOD, V79, P1657; MAEDA H, 1990, ULTRASOUND MED BIOL, V16, P9, DOI 10.1016/0301-5629(90)90080-V; MILLER ST, 1992, J PEDIATR-US, V120, P54, DOI 10.1016/S0022-3476(05)80597-9; Moser FG, 1996, AM J NEURORADIOL, V17, P965; Oakes, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438; Ohene-Frempong K, 1998, BLOOD, V91, P288; OHENEFREMPONG K, 1991, SEMIN HEMATOL, V28, P213; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; RANKIN J, 1957, Scott Med J, V2, P200; ROSSE WF, 1990, BLOOD, V76, P1431; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SEIBERT JJ, 1993, RADIOLOGY, V189, P457, DOI 10.1148/radiology.189.2.8105505; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; VERIHAC S, 1995, PEDIAT RADIOL S1, V25, pS14; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; WAYNE AS, 1993, BLOOD, V81, P1109	30	1094	1108	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					5	11		10.1056/NEJM199807023390102	http://dx.doi.org/10.1056/NEJM199807023390102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647873				2023-01-03	WOS:000074500000002
J	Nevitt, MC; Ettinger, B; Black, DM; Stone, K; Jamal, SA; Ensrud, K; Segal, M; Genant, HK; Cummings, SR				Nevitt, MC; Ettinger, B; Black, DM; Stone, K; Jamal, SA; Ensrud, K; Segal, M; Genant, HK; Cummings, SR			The association of radiographically detected vertebral fractures with back pain and function: A prospective study	ANNALS OF INTERNAL MEDICINE			English	Article						spinal fractures; back pain; osteoporosis, postmenopausal; activities of daily living	RESTRICTED ACTIVITY DAYS; BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; OLDER ADULTS; WOMEN; DISABILITY; DEFORMITIES; ALENDRONATE; PREDICTORS; MANAGEMENT	Background: Vertebral fractures are a hallmark of postmenopausal osteoporosis and an important end point in trials of osteoporosis treatment, but the clinical significance of these fractures remains uncertain. Objective: To determine the association of new vertebral fractures with back pain and back-related functional limitation in older women. Design: Prospective observational study. Setting: Multicenter Study of Osteoporotic Fractures. Participants: 7223 white women aged 65 years and older. Measurements: Lateral spine radiographs were obtained at baseline and at a follow-up examination an average of 3.7 years later. Prevalent and incident radiographic vertebral fractures were assessed by quantitative morphometry. Frequency and severity of back pain, disability in doing six activities involving the back, and days of bed rest and days of limited activity due to back pain were assessed annually by questionnaire during follow-up. Results: Among women without a vertebral fracture at baseline, those with at least one incident vertebral fracture were more likely to have increased back pain (odds ratio [OR], 2.4 [95% CI, 1.7 to 3.3]) and back disability (OR, 2.6 [CI, 1.9 to 3.7]) and at least 1 day of bed rest due to back pain (OR, 6.7 [CI, 4.4 to 10.2]) and 7 days of limited activity due to back pain per year (OR, 3.8 [CI, 2.7 to 5.0]). Among women with a fracture at baseline, those with an incident vertebral fracture also had a greater risk for increased back pain (OR, 2.0 [CI, 1.4 to 2.8]) and back disability (OR, 2.2 [CI, 1.5 to 3.1]) and at least 1 day of bed rest (OR, 7.9 [CI, 4.9 to 12.9]) and 7 days of limited activity per year (OR, 3.5 [CI, 2.4 to 5.0]). Women with incident fracture had about 10 additional limited-activity days and 1 to 2 days of bed rest per year. New vertebral fractures that did not come to medical attention were associated with increased back pain and functional limitation. Conclusion: New vertebral fractures, even those not recognized clinically, are associated with substantial increases in back pain and functional limitation due to back pain in older white women. Prevention of new vertebral fractures should reduce the burden of back pain and functional limitation in women with vertebral osteoporosis.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA; Kaiser Permanente Med Care Program, Oakland, CA USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; Vet Affairs Med Ctr, Minneapolis, MN USA	University of California System; University of California San Francisco; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Nevitt, MC (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.			Ensrud, Kristine/0000-0002-9069-3036	NIAMS NIH HHS [1-RO1-AR35582] Funding Source: Medline; NIA NIH HHS [5-RO1-AG05394, 1-RO1-AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005394, R01AG005407] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLACK DM, 1995, J BONE MINER RES, V10, P890; BLACK DM, 1991, J BONE MINER RES, V6, P883; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BURGER H, 1994, BRIT MED J, V309, P991, DOI 10.1136/bmj.309.6960.991; COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; ETTINGER B, 1992, J BONE MINER RES, V7, P449; ETTINGER B, 1988, MATURITAS, V10, P283, DOI 10.1016/0378-5122(88)90064-3; ETTINGER B, 1994, OSTEOPOROSIS INT, V4, P55, DOI 10.1007/BF02352262; FROST HM, 1981, ORTHOP CLIN N AM, V12, P671; Genant HK, 1996, J BONE MINER RES, V11, P984; GENANT HK, 1995, VERTEBRAL FRACTURE O; Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756-3282(95)00500-5; Hallal J C, 1991, Geriatr Nurs, V12, P285, DOI 10.1016/S0197-4572(05)80266-6; Huang C, 1996, J BONE MINER RES, V11, P1026; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LANE NE, 1993, J RHEUMATOL, V20, P1911; LEIDIG G, 1990, BONE MINER, V8, P217, DOI 10.1016/0169-6009(90)90107-Q; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LYLES KW, 1993, AM J MED, V94, P595, DOI 10.1016/0002-9343(93)90210-G; McCullagh P., 1989, GEN LINEAR MODELS; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NICHOLSON PHF, 1993, OSTEOPOROSIS INT, V3, P300, DOI 10.1007/BF01637315; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Ross P D, 1991, Osteoporos Int, V1, P134, DOI 10.1007/BF01625442; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; RYAN PJ, 1994, BONE, V15, P27, DOI 10.1016/8756-3282(94)90887-7; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; SPECTOR TD, 1993, J BONE MINER RES, V8, P817; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x; WIPF JE, 1995, MED CLIN N AM, V79, P231, DOI 10.1016/S0025-7125(16)30065-7; ZETTERBERG C, 1990, SPINE, V15, P783, DOI 10.1097/00007632-199008010-00009	38	604	615	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					793	+		10.7326/0003-4819-128-10-199805150-00001	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599190				2023-01-03	WOS:000073586500001
J	Langer, R				Langer, R			Drug delivery and targeting	NATURE			English	Review							CONTROLLED-RELEASE; BIOERODIBLE POLYANHYDRIDES; POLYMER; PROTEINS; MATRICES; INVIVO; ELECTROPORATION; CHEMOTHERAPY; MICROSPHERES; PERMEABILITY	When a pharmaceutical agent is encapsulated within, or attached to, a polymer or lipid, drug safety and efficacy can be greatly improved and new therapies are possible. This has provided the impetus for active study of the design of degradable materials, intelligent delivery systems and approaches for delivery through different portals in the body.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Langer, R (corresponding author), MIT, Dept Chem Engn, 45 Carlton St,Bldg E25, Cambridge, MA 02139 USA.			Iliescu, Florina Silvia/0000-0001-8808-8876; Zheng, Qiangqiang/0000-0001-5842-9318				Allcock HR, 1997, ANN NY ACAD SCI, V831, P13; ARTURSSON P, 1994, PHARMACEUT RES, V11, P1358, DOI 10.1023/A:1018967116988; Aspden TJ, 1997, J PHARM SCI, V86, P509, DOI 10.1021/js960182o; Bartus RT, 1996, EXP NEUROL, V142, P14, DOI 10.1006/exnr.1996.0175; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; Brocchini S, 1997, J AM CHEM SOC, V119, P4553, DOI 10.1021/ja970389z; BURNHAM NL, 1994, AM J HOSP PHARM, V51, P210, DOI 10.1093/ajhp/51.2.210; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; Chen HM, 1996, PHARMACEUT RES, V13, P1378, DOI 10.1023/A:1016030202104; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; COSTANTINO HR, 1994, J PHARM SCI-US, V83, P1662, DOI 10.1002/jps.2600831205; CRAMER MP, 1994, PHARMACOECONOMICS, V5, P482, DOI 10.2165/00019053-199405060-00005; CREMERS HFM, 1995, INT J PHARM, V120, P51, DOI 10.1016/0378-5173(94)00408-W; DANG WB, 1994, CANCER RES, V54, P1729; Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889; Duncan R, 1996, STP PHARMA SCI, V6, P237; DUNN R, 1996, J BIOACT COMPAT POLY, V11, P287; EDELMAN ER, 1987, J BIOMED MATER RES, V21, P339, DOI 10.1002/jbm.820210307; Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; FLORENCE AT, 1994, DRUG SAFETY, V10, P233, DOI 10.2165/00002018-199410030-00005; Florence AT, 1997, PHARM RES-DORDR, V14, P259, DOI 10.1023/A:1012029517394; FOLKMAN J, 1964, J Surg Res, V4, P139, DOI 10.1016/S0022-4804(64)80040-8; GOLDRAICH M, 1993, CLIN MATER, V13, P135, DOI 10.1016/0267-6605(93)90100-L; Goodson J M, 1996, Technol Health Care, V4, P269; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Gregoriadis G, 1997, FEBS LETT, V402, P107, DOI 10.1016/S0014-5793(96)01507-4; Gregoriadis G, 1995, TRENDS BIOTECHNOL, V13, P527, DOI 10.1016/S0167-7799(00)89017-4; Heller J., 1997, CONTROLLED DRUG DELI, P127; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; HillWest JL, 1995, J SURG RES, V59, P759, DOI 10.1006/jsre.1995.1236; Hoes CJT, 1996, J CONTROL RELEASE, V38, P245, DOI 10.1016/0168-3659(95)00126-3; James K, 1997, CONTROLLED DRUG DELI, P389; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; Kadiyala Sudha, 1995, P33; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; KOHN J, 1986, J IMMUNOL METHODS, V95, P31, DOI 10.1016/0022-1759(86)90314-5; Krewson CE, 1996, BRAIN RES, V727, P169; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; LANGER R, 1980, CHEM ENG COMMUN, V6, P15; LAURENCIN CT, 1993, J ORTHOPAED RES, V11, P256, DOI 10.1002/jor.1100110213; LAVON I, IN PRESS J CONTR REL; Lenaerts VM, 1990, BIOADHESIVE DRUG DEL; LeoneBay A, 1996, J MED CHEM, V39, P2571, DOI 10.1021/jm960038f; Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6; LEONG KW, 1985, J BIOMED MATER RES, V19, P941, DOI 10.1002/jbm.820190806; LEVY RJ, 1985, SCIENCE, V228, P1900; Li S, 1996, J CONTROL RELEASE, V39, P373, DOI 10.1016/0168-3659(95)00167-0; Lowman AM, 1997, MACROMOLECULES, V30, P4959, DOI 10.1021/ma970399k; MAEDA H, 1991, ADV DRUG DELIVER REV, V6, P181, DOI 10.1016/0169-409X(91)90040-J; Mathiowitz E, 1997, NATURE, V386, P410, DOI 10.1038/386410a0; MCKENNEY JM, 1976, AM J HOSP PHARM, V33, P792, DOI 10.1093/ajhp/33.8.792; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; Merino V, 1997, TRENDS BIOTECHNOL, V15, P288, DOI 10.1016/S0167-7799(97)01069-X; Milstein SJ, 1998, J CONTROL RELEASE, V53, P259, DOI 10.1016/S0168-3659(97)00259-9; MITRA A, 1993, OPHTHALMIC DRUG DELI, P223; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Murakami Y, 1997, DRUG DELIV, V4, P23, DOI 10.3109/10717549709033184; Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203; Narasimhan B, 1997, CONTROLLED DRUG DELI, P529; Ng SY, 1997, MACROMOLECULES, V30, P770, DOI 10.1021/ma9610626; NIVEN RW, 1995, CRIT REV THER DRUG, V12, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20; OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095; Pardridge WM, 1997, J CEREBR BLOOD F MET, V17, P713, DOI 10.1097/00004647-199707000-00001; Park J W, 1997, Adv Pharmacol, V40, P399, DOI 10.1016/S1054-3589(08)60146-5; Patton JS, 1996, ADV DRUG DELIVER REV, V19, P3, DOI 10.1016/0169-409X(95)00113-L; Peppas NA, 1996, BIOMATERIALS, V17, P1553, DOI 10.1016/0142-9612(95)00307-X; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; Peppas NA, 1997, CURR OPIN COLLOID IN, V2, P531, DOI 10.1016/S1359-0294(97)80103-3; Poiani GJ, 1997, AM J RESP CRIT CARE, V155, P1384, DOI 10.1164/ajrccm.155.4.9105083; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; PRAUSNITZ MR, 1995, BIO-TECHNOL, V13, P1205, DOI 10.1038/nbt1195-1205; PUTNAM D, 1995, ADV POLYM SCI, V122, P59; RODGERS C, 1992, J INTERV CARDIOL, V5, P195; Schuster J, 1997, PHARM RES-DORDR, V14, P354, DOI 10.1023/A:1012058323754; Service RF, 1997, SCIENCE, V277, P1199, DOI 10.1126/science.277.5330.1199; Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; Tabata Y, 1996, VACCINE, V14, P1677, DOI 10.1016/S0264-410X(96)00149-1; TAMADA JA, 1993, P NATL ACAD SCI USA, V90, P552, DOI 10.1073/pnas.90.2.552; Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454; Torchilin V P, 1994, Immunomethods, V4, P244, DOI 10.1006/immu.1994.1027; Valtonen S, 1997, NEUROSURGERY, V41, P44, DOI 10.1097/00006123-199707000-00011; Vandorpe J, 1997, BIOMATERIALS, V18, P1147, DOI 10.1016/S0142-9612(97)00052-5; YEH PY, 1995, J CONTROL RELEASE, V36, P109, DOI 10.1016/0168-3659(95)00057-F; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	91	1906	2048	11	862	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679		S			5	10						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK760	9579855				2023-01-03	WOS:000073360100003
J	Nabel, GJ				Nabel, GJ			From rhyme to reason	NATURE			English	Editorial Material							GENE-EXPRESSION INVIVO; ARTERIAL-WALL; DELIVERY; THERAPY		Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, 1150 W Med Ctr Dr,4520 MSRBI, Ann Arbor, MI 48109 USA.							ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BLAU HM, 1995, NEW ENGL J MED, V333, P1554, DOI 10.1056/NEJM199512073332308; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CHANG PL, 1995, SOMAT GENET HER; CHEN KS, 1995, J NEUROSCI, V15, P2819; Ellem KAO, 1997, CANCER IMMUNOL IMMUN, V44, P10, DOI 10.1007/s002620050349; EMERICH DP, 1997, NATURE, V27, P395; Grill R, 1997, J NEUROSCI, V17, P5560; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; KREMERS E, 1940, HIST PHARM, V3, P286; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; Magovern CJ, 1997, HUM GENE THER, V8, P215, DOI 10.1089/hum.1997.8.2-215; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; Nabel GJ, 1996, P NATL ACAD SCI USA, V93, P15388, DOI 10.1073/pnas.93.26.15388; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Petsko GA, 1996, NATURE, V384, P7; Simons JW, 1997, CANCER RES, V57, P1537; Stopeck AT, 1997, J CLIN ONCOL, V15, P341, DOI 10.1200/JCO.1997.15.1.341; Tsurumi Y, 1997, CIRCULATION, V96, P382; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0	26	8	9	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679		S			3	4						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK760	9579854				2023-01-03	WOS:000073360100002
J	Fisher, M; Bogousslavsky, J				Fisher, M; Bogousslavsky, J			Further evolution toward effective therapy for acute ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; MIDDLE CEREBRAL-ARTERY; THROMBOLYTIC THERAPY; RECANALIZATION; OCCLUSION; TIME; ANTAGONIST; CONSENSUS; RATS	The effective treatment of acute ischemic stroke remains an important goal of modern medicine and substantive advances are occurring. Recently, thrombolytic therapy with tissue-type plasminogen activator was approved for selected patients with acute ischemic stroke when therapy is started within 3 hours of onset. Streptokinase therapy for acute ischemic stroke has not been shown to be effective and is associated with an increased risk of hemorrhage, although it was not evaluated as early after stroke onset as tissue-type plasminogen activator. Various types of neuroprotective interventions are effective in animal models, but none has yet been proven effective in patients. In the future, combinations of thrombolytic and neuroprotective drugs may be used to attempt maximum rates of recovery after acute ischemic stroke. For combination therapy to achieve its maximum potential, patients with acute ischemic stroke will have to be carefully selected and treated.	Univ Massachusetts, Sch Med, Mem Hlth Care, Dept Neurol, Worcester, MA 01605 USA; Univ Lausanne, Dept Neurol, Lausanne, Switzerland	University of Massachusetts System; University of Massachusetts Worcester; University of Lausanne	Fisher, M (corresponding author), Univ Massachusetts, Sch Med, Mem Hlth Care, Dept Neurol, 119 Belmont St, Worcester, MA 01605 USA.	fisherm@memorialhc.org						*AC STROK TREATM I, 1998, STROKE, V29, P286; Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; Adams HP, 1996, NEUROLOGY, V47, P835; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Baird AE, 1997, ANN NEUROL, V41, P581, DOI 10.1002/ana.410410506; Barnard E A, 1988, Adv Exp Med Biol, V236, P31; BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; BergDammer E, 1996, CEREBROVASC DIS, V6, P222, DOI 10.1159/000108100; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; Bogousslavsky J, 1996, BRIT MED J, V313, P640; Boysen G, 1996, CEREBROVASC DIS, V6, P376, DOI 10.1159/000108060; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; BROTT T, 1997, ACUTE STROKE TREATME, P109; CANDELISE L, 1995, LANCET, V346, P1509; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; Clark WM, 1998, STROKE, V29, P287; Del Zoppo Gregory J., 1996, Stroke, V27, P164; Diener H. C., 1997, Stroke, V28, P271; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; DONNAN GA, 1995, LACUNAR OTHER SUBCOR; Edwards Keith, 1996, Neurology, V46, pA424; *ENL AC STROK TRIA, 1997, NEUROLOGY, V48, pA270; FAYAD PB, 1996, CURRENT REV CEREBROV, P81; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FISHER CM, 1979, ARCH NEUROL-CHICAGO, V36, P65, DOI 10.1001/archneur.1979.00500380035003; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FISHER M, 1995, JAMA-J AM MED ASSOC, V274, P908; FISHER M, 1993, JAMA-J AM MED ASSOC, V270, P360, DOI 10.1001/jama.270.3.360; Gillum RF, 1997, STROKE, V28, P1527, DOI 10.1161/01.STR.28.8.1527; Grotta J, 1997, STROKE, V28, P2338, DOI 10.1161/01.STR.28.12.2338; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; HOMMEL M, 1994, EXPERT OPIN INV DRUG, V3, P1011; HOROWITZ M, 1995, ANN NEUROL, V38, P56; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Jorgensen HS, 1997, NEUROLOGY, V49, P1335, DOI 10.1212/WNL.49.5.1335; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KOH JY, 1990, J NEUROSCI, V10, P693; Lyden PD, 1997, NEUROLOGY, V49, P14, DOI 10.1212/WNL.49.1.14; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MINEMATSU K, 1993, STROKE, V24, P2074, DOI 10.1161/01.STR.24.12.2074; Mitchell PJ, 1997, CEREBROVASC DIS, V7, P94, DOI 10.1159/000108174; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; PULSINELLI W, 1992, LANCET, V339, P533, DOI 10.1016/0140-6736(92)90347-6; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; Samuelsson M, 1996, STROKE, V27, P842, DOI 10.1161/01.STR.27.5.842; SANDERCOCK P, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92044-7; Scheller D., 1995, J CEREBR BLOOD F MET, V15, pS379; Scott P, 1996, STROKE, V27, P1453; Silver B, 1996, CLIN NEUROPHARMACOL, V19, P101, DOI 10.1097/00002826-199619020-00001; SILVER B, 1997, ACUTE STROKE TREATME, P150; Smith AG, 1997, NEUROLOGY, V48, P1613, DOI 10.1212/WNL.48.6.1613; Tietjen G. E., 1996, Neurology, V46, pA424; TOUZANI O, 1995, STROKE, V26, P2112, DOI 10.1161/01.STR.26.11.2112; VONKUMMER R, 1995, STROKE, V26, P581, DOI 10.1161/01.STR.26.4.581; WAHLGREN NG, 1997, CEREBROVASC DIS, V7, P19; WEISS GB, 1995, LIFE SCI, V56, P637, DOI 10.1016/0024-3205(94)00427-T; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; ZHANG AG, 1997, J CEREB BLOOD FLOW M, V16, P599	62	61	64	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1298	1303		10.1001/jama.279.16.1298	http://dx.doi.org/10.1001/jama.279.16.1298			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565012				2023-01-03	WOS:000073090300037
J	Kapur, N; House, A; Creed, F; Feldman, E; Friedman, T; Guthrie, E				Kapur, N; House, A; Creed, F; Feldman, E; Friedman, T; Guthrie, E			Management of deliberate self poisoning in adults in four teaching hospitals: descriptive study	BRITISH MEDICAL JOURNAL			English	Article									Manchester Royal Infirm, Dept Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England; Leicester Gen Hosp, Leicester LE5 4PW, Leics, England; Gen Infirm, Dept Liason Psychiat, Leeds LS1 3EX, W Yorkshire, England	University of Manchester; University of Oxford; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Leeds General Infirmary	Kapur, N (corresponding author), Manchester Royal Infirm, Dept Psychiat & Behav Sci, Oxford Rd, Manchester M13 9WL, Lancs, England.			House, Allan/0000-0001-8721-8026; Guthrie, Elspeth/0000-0002-5834-6616				*DEP HLTH SOC SEC, 1984, MAN DEL SELFHAR; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; Hawton K, 1995, Health Trends, V27, P18; HAWTON K, 1996, ATTEMPTED SUICIDE OX; HOUSE A, 1992, International Review of Psychiatry, V4, P15, DOI 10.3109/09540269209066298	5	106	107	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					831	832		10.1136/bmj.316.7134.831	http://dx.doi.org/10.1136/bmj.316.7134.831			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549454	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000072584300031
J	Lancaster, T; Swart, AM; Jick, H				Lancaster, T; Swart, AM; Jick, H			Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England; Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	University of Oxford; Boston University	Lancaster, T (corresponding author), Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England.			Jick, Hershel/0000-0003-4270-5992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; JICK H, 1995, PHARMACOTHERAPY, V15, P176; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Rayner SA, 1996, DRUG SAFETY, V14, P273, DOI 10.2165/00002018-199614050-00001	4	31	31	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					667	667		10.1136/bmj.316.7132.667	http://dx.doi.org/10.1136/bmj.316.7132.667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522792	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000072347900031
J	O'Brien, T; Welsh, J; Dunn, FG				O'Brien, T; Welsh, J; Dunn, FG			ABC of palliative care - Non-malignant conditions	BRITISH MEDICAL JOURNAL			English	Review									Marymount Hospice, Cork, Ireland; Cork Univ Hosp, Cork, Ireland; Univ Glasgow, Olav Kerr Chair Palliat Med, Glasgow G12 8QQ, Lanark, Scotland; Stobhill Gen Hosp, Glasgow G21 3UW, Lanark, Scotland	University College Cork; University of Glasgow	O'Brien, T (corresponding author), Marymount Hospice, Cork, Ireland.								0	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					286	289		10.1136/bmj.316.7127.286	http://dx.doi.org/10.1136/bmj.316.7127.286			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472516	Green Published			2023-01-03	WOS:000071702100032
J	LaCroix, AZ; Burke, W				LaCroix, AZ; Burke, W			Breast cancer and hormone replacement therapy	LANCET			English	Editorial Material							ESTROGEN		UNIV WASHINGTON,WOMENS HLTH CARE CTR,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	LaCroix, AZ (corresponding author), UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,GRP HLTH COOPERAT PUGET SOUND,DEPT EPIDEMIOL,SEATTLE,WA 98109, USA.							Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; CAULEY JA, 1996, JAMA-J AM MED ASSOC, V276, P611; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CUMMINGS SR, J BONE MINERAL RES S, pS139; KING RJB, 1991, J STEROID BIOCHEM, V39, P811, DOI 10.1016/0960-0760(91)90030-9; Kuller LH, 1997, ENVIRON HEALTH PERSP, V105, P593, DOI 10.2307/3433376; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; *WOM HLTH IN STUD, IN PRESS CONTROLLED; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903	11	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1042	1043		10.1016/S0140-6736(97)22041-6	http://dx.doi.org/10.1016/S0140-6736(97)22041-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213541				2023-01-03	WOS:A1997YA73400002
J	Littlewood, R; Douyon, C				Littlewood, R; Douyon, C			Clinical findings in three cases of zombification	LANCET			English	Article									UCL, DEPT PSYCHIAT, LONDON WC1E 6BT, ENGLAND; POLYCLIN MED, PORT AU PRINCE, HAITI	University of London; University College London	Littlewood, R (corresponding author), UCL, DEPT ANTHROPOL, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.							ARISTIDE JB, 1993, TOUT HOMME EST UN HO; Brodwin P, 1996, MED MORALITY HAITI C; Davis Wade, 1988, PASSAGE DARKNESS ETH; Decosse Sarah., 1996, THIRST JUSTICE DECAD; DIEDERICH B, 1972, PAPA DOC HAITI ITS D; DOUYON L, 1972, B CTR PSYCHIAT NEURO, V11, P5; DOUYON L, 1980, HAITI SANTE, V2, P19; FARMER Paul, 1992, AIDS ACCUSATION HAIT; HURSTON ZN, 1938, VODOO GODS; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; LAROSE S, 1977, SYMBOLS SENTIMENTS; LITTLEWOOD R, 1993, PATHOLOGY IDENTITY W; Mars LP, 1945, MAN, V45, P38, DOI 10.2307/2792947; METRAUX A, 1958, VAUDON HAITIEN; Nicholls David, 1979, DESSALINES DUVALIER; STJOHN S, 1884, HAYRI BLACK REPUBLIC; THOMSON I, 1992, BONJOUR BLANC; TORDA TA, 1973, MED J AUSTRALIA, V1, P599, DOI 10.5694/j.1326-5377.1973.tb110574.x; 1984, LANCET, V2, P1220	19	17	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1094	1096		10.1016/S0140-6736(97)04449-8	http://dx.doi.org/10.1016/S0140-6736(97)04449-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213568				2023-01-03	WOS:A1997YA73400043
J	Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF				Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF			In vivo protein transduction: Delivery of a biologically active protein into the mouse	SCIENCE			English	Article							CELLS; DRUGS; BRAIN	Delivery of therapeutic proteins into tissues and across the blood-brain barrier is severely limited by the size and biochemical properties of the proteins. Here it is shown that intraperitoneal injection of the 120-kilodalton beta-galactosidase protein, fused to the protein transduction domain from the human immunodeficiency virus TAT protein, results in-delivery of the biologically active fusion protein to all tissues in mice, including the brain. These results open new possibilities for direct delivery of proteins into patients in the context of protein therapy, as well as for epigenetic experimentation with model organisms.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.							Anderson WF, 1998, NATURE, V392, P25; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Elefanty AG, 1998, P NATL ACAD SCI USA, V95, P11897, DOI 10.1073/pnas.95.20.11897; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Gius DR, 1999, CANCER RES, V59, P2577; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HO AF, UNPUB, P42707; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KRALL WJ, 1992, NEW BIOL, V4, P581; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; RAPOPORT SI, 1972, SCIENCE, V170, P1243; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHELD WM, 1989, REV INFECT DIS S, V7, P1669; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHWARZE S, UNPUB; van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710	22	2084	2474	2	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1569	1572		10.1126/science.285.5433.1569	http://dx.doi.org/10.1126/science.285.5433.1569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477521				2023-01-03	WOS:000082359500066
J	Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V				Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V			Virginity examinations in turkey - Role of forensic physicians in controlling female sexuality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYMEN; GIRLS	Context Although the Turkish Medical Association has deemed "virginity examinations" a form of gender-based violence, women in Turkey are often subjected to such examinations by forensic physicians for both legal and social reasons. Little is known about these physicians' role and attitudes in this practice. Objectives To assess forensic physicians' experiences and attitudes regarding virginity examinations in Turkey and suggest potential solutions to the problems identified, Design Cross-sectional self-administered survey. Setting Surveys were completed during the Forensic Science Congress held in Kusadasi in April 1998 as well as in urban academic and medical practice settings between April and October 1998. Participants Of 158 physicians who practice, are formally trained in, or are in training for forensic medicine, 118 completed the survey (response rate, 74.7%). Main Outcome Measures Frequency and circumstances of conducting virginity examinations, opinions regarding beneficial and adverse consequences of these examinations, and recommendations for changing the practice, as measured by a 100-item questionnaire. Results Overall, survey respondents reported conducting 5901 examinations in the previous 12 months; 4045 were conducted because of alleged sexual assault and 1856 for social reasons, Although 68% of forensic physicians indicated that they believed virginity examinations are inappropriate in the absence of an allegation of sexual assault, 45% had conducted examinations for social reasons. The majority of the respondents (93%) agreed that the examinations are psychologically traumatic for the patient. In addition, more than half (58%) reported that at least 50% of patients undergo examinations against their will. Conclusions Nearly half of forensic physicians in Turkey conduct virginity examinations for social reasons despite beliefs that such examinations are inappropriate, traumatic to the patient, and often performed against the patient's will. Physicians' participation in such practices is inconsistent with principles of bioethics and international human rights.	Phys Human Rights, Boston, MA 02116 USA; Columbia Univ, Ctr Populat & Family Hlth, Joseph L Mailman Sch Publ Hlth, Program Forced Migrat & Hlth, New York, NY 10027 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Istanbul, Dept Forens Med, Istanbul, Turkey	Columbia University; University of California System; University of California San Francisco; Istanbul University	Iacopino, V (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.		Fincanci, Sebnem Korur/F-6684-2010; ARICAN, Nadir/G-2778-2012	Fincanci, Sebnem Korur/0000-0003-4484-4961; ARICAN, Nadir/0000-0002-9736-0277				Bandura A., 1990, ORIGINS TERRORISM PS, P161; BERENSON AB, 1992, PEDIATRICS, V89, P387; BERENSON AB, 1994, CURR OPIN OBSTET GYN, V6, P526; BUROSU E, 1992, CUMHURIYET      0509; Copelon Rhonda, 1998, WOMEN WAR READER, P63; Das V, 1996, DAEDALUS, V125, P67; FAHRI I, 1984, TOPLUMUMUZDA KADIN C, P152; Finkel MA, 1994, CHILD ABUSE MED DIAG, P185; GIARDINO AP, 1992, PRACTICAL GUIDE EVAL; GODDARD V, 1987, CULTURAL CONSTRUCTIO; Goodyear-Smith FA, 1998, FORENSIC SCI INT, V94, P147, DOI 10.1016/S0379-0738(98)00053-X; ISLAMI U, 1992, TURKIYE KAD N OLGUSU, P131; MATTHEWS CD, 1994, REPROD FERT DEVELOP, V6, P1; Onderoglu Selda, 1993, Okajimas Folia Anatomica Japonica, V70, P35; ORTNER SB, 1978, FEMINIST STUD, V4, P19; OZBAY F, 1992, TURKIYE KAD N OLGUSU, P151; OZUGURLU K, 1985, EVLILIK RAPORU ALTIN, P46; PETERSON VS, 1998, WOMEN WAR READER, P44; SCHEGEL A, 1991, AM ETHNOL, V18, P719; *SPSS INC, 1998, SPSS BAS 8 0 WIND; Staub E., 1990, PSYCHOL TORTURE, P49; XIAO Z, 1989, FEMINIST STUD, V15, P279; YUKSEL S, 1992, TURKIYE KAD N OLGUSU, P115; 1994, CUMHURIYET      0325; 1999, LOS ANGELES TIM 0106; [No title captured]	26	19	20	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					485	490		10.1001/jama.282.5.485	http://dx.doi.org/10.1001/jama.282.5.485			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442667				2023-01-03	WOS:000081784900029
J	Melville, M; Brown, N; Gray, D; Young, T; Hampton, J				Melville, M; Brown, N; Gray, D; Young, T; Hampton, J			Outcome and use of health services four years after admission for acute myocardial infarction: case record follow up study	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Univ Nottingham, Dept Math, British Heart Fdn, Cardiovasc Stat Unit, Nottingham NG7 2RH, England	University of Nottingham; University of Nottingham	Melville, M (corresponding author), Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England.		Young, Tracey A/A-4543-2010	Young, Tracey/0000-0001-8467-0471				*BRIT CARD SOC, 1998, STRAT PLANN CARD SER; DEBONO DP, 1994, J ROY COLL PHYS LOND, V28, P312; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GREENWOOD D, 1995, SOC SCI MED, V40, P639, DOI 10.1016/0277-9536(94)00147-L; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					230	231		10.1136/bmj.319.7204.230	http://dx.doi.org/10.1136/bmj.319.7204.230			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	221HB	10417086	Bronze, Green Published			2023-01-03	WOS:000081720300025
J	Onyebujoh, PC; Levin, JB; Fourie, FB; Garhiram, V; Tembe, LC; Phili, NP; Mthiyane, TCP; Moniwa, T; Bayer, G; Ramajoe, IM; Mncwabe, TAB; Mallisar, LGM; Saul, TNM; Levin, JB; Jackson, THFG; Suparsad, S; Fine, PEM; Pendlebury, DJS; Fine, E; Houghton, I; Clyde, J; Vos, HP; Padayatchi, N; Pala, A; Ramjee, A; Ramjee, M; Ramdeen, J; Masters, IH; Osbourne, G; Naidu, K; Bamba, S; Mazur, B; Czarnocki, R; Landers, K; Ndlovu, G; Maphumulo, N; Garhiram, V; Sturm, AW; Moodley, J; Pillay, C; Roux, L; Moodley, R; Sarawan, A; Jali, T; Manickam, F; Smith, A; Gopaul; Durosanmi, T; Moonsammy, R; Wyld, P; McCallum, J; Fulton, C; Bisset, K; Henderson, S; Stewart, D; Nticinka, O; Watson, D; Tuckwell, N; Kennard, D; Stanford, JL; Rook, GA; Grange, JM; Zumla, AA; Bateman, E; Hopwell, P; Darbyshire, J; Geiter, L; Nunn, A; Weyer, K				Onyebujoh, PC; Levin, JB; Fourie, FB; Garhiram, V; Tembe, LC; Phili, NP; Mthiyane, TCP; Moniwa, T; Bayer, G; Ramajoe, IM; Mncwabe, TAB; Mallisar, LGM; Saul, TNM; Levin, JB; Jackson, THFG; Suparsad, S; Fine, PEM; Pendlebury, DJS; Fine, E; Houghton, I; Clyde, J; Vos, HP; Padayatchi, N; Pala, A; Ramjee, A; Ramjee, M; Ramdeen, J; Masters, IH; Osbourne, G; Naidu, K; Bamba, S; Mazur, B; Czarnocki, R; Landers, K; Ndlovu, G; Maphumulo, N; Garhiram, V; Sturm, AW; Moodley, J; Pillay, C; Roux, L; Moodley, R; Sarawan, A; Jali, T; Manickam, F; Smith, A; Gopaul; Durosanmi, T; Moonsammy, R; Wyld, P; McCallum, J; Fulton, C; Bisset, K; Henderson, S; Stewart, D; Nticinka, O; Watson, D; Tuckwell, N; Kennard, D; Stanford, JL; Rook, GA; Grange, JM; Zumla, AA; Bateman, E; Hopwell, P; Darbyshire, J; Geiter, L; Nunn, A; Weyer, K		Durban Immunotherapy Trial Grp	Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial	LANCET			English	Article							CHEMOTHERAPY	Background Mycobacterium vaccae, an environmental saprophyte, has immunogenic properties that enhance the host immune response. Immunotherapy with M vaccae has been suggested to shorten short-course antituberculosis chemotherapy. We tested the hypothesis that the addition of M vaccae to standard short-course antituberculosis chemotherapy would decrease the time to achieve a negative sputum culture. Methods Patients with newly diagnosed tuberculosis were randomly assigned an injection of saline (placebo) or M vaccae on day 8. All patients received antituberculosis chemotherapy with rifampicin, isoniazid, pyrazinamide, and ethambutol. Sputum samples were checked by microscopy and culture every week for the first 8 weeks and monthly until the end of chemotherapy at 6 months. The primary outcome was the time to a negative sputum culture in the first 8 weeks. Intention-to-treat analysis was used and time to sputum clearance was assessed by log-rank test and Cox's proportional-hazards regression. Findings 172 patients received M vaccae and 175 patients received placebo. At 8 weeks, 70 patients in the M vaccae group and 65 patients in the placebo group had a negative culture; there was no difference between groups in the time to a negative culture (p=0.83). There was no interaction between HIV status and treatment. Interpretation M vaccae immunotherapy has no benefit when added to standard antituberculosis chemotherapy.	Reg Off, Durban, South Africa; London Sch Hyg & Trop Med, London WC1, England; King George V Mem Hosp, Durban, South Africa; Univ KwaZulu Natal, Sch Med, ZA-4001 Durban, South Africa; King Edward VIII Hosp, Durban, South Africa; Inveresk Clin Res, Edinburgh, Midlothian, Scotland; Stanford Rook Ltd, London, England; UCL, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Kwazulu Natal; University of London; University College London	Onyebujoh, PC (corresponding author), MRC, Natl TB Res Programme, Private Bag X385, ZA-0001 Pretoria, South Africa.		ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				[Anonymous], 1986, Am Rev Respir Dis, V134, P355; BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; BALASUBRAMANIAN R, 1990, TUBERCLE, V71, P253, DOI 10.1016/0041-3879(90)90037-9; Corlan E, 1997, RESP MED, V91, P13, DOI 10.1016/S0954-6111(97)90132-3; ETEMADI A, 1992, LANCET, V340, P1360, DOI 10.1016/0140-6736(92)92551-P; GRANGE JM, 1992, TUBERCLE LUNG DIS, V73, P249, DOI 10.1016/0962-8479(92)90128-7; KLEEBERG HH, 1985, B INT UNION TUBERC, V60, P147; KLEEBERG HH, 1980, LAB MANUAL TUBERCULO; MITCHISON DA, 1992, J ANTIMICROB CHEMOTH, V29, P477, DOI 10.1093/jac/29.5.477; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; ONYEBUJOH PC, 1995, RESP MED, V89, P199, DOI 10.1016/0954-6111(95)90248-1; POZIAK A, 1987, B IUALD, V62, P39; Ravioli, 1987, HLTH COOPERATION PAP, V7, P201; Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259; STANFORD JL, 1990, VACCINE, V8, P525, DOI 10.1016/0264-410X(90)90002-4; STANFORD JL, 1993, B IUTLD, V65, P27	16	70	71	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1999	354	9173					116	119						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408487				2023-01-03	WOS:000081377100014
J	Heaney, LG; McAllister, D; MacMahon, J				Heaney, LG; McAllister, D; MacMahon, J			Cost minimisation analysis of provision of oxygen at home: Are the Drug Tariff guidelines cost effective?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the level of oxygen cylinder use at which it becomes more cost effective to provide oxygen by concentrator at home in Northern Ireland, and to examine potential cost savings if cylinder use above this level had been replaced by concentrator in 1996. Design Cost minimisation analysis. Setting Area health boards in Northern Ireland. Main outcome measures Cost effective cut off point for switch to provision of oxygen from cylinder to concentrator. Potential maximum and minimum savings in Northern Ireland (sensitivity analysis) owing to switch to more cost effective strategy on the basis of provision of cylinders in 1996. Results In Northern Ireland it is currently cost effective to provide oxygen by concentrator when the patient is using three or more cylinders per month independent of the duration of the prescription. More widespread use of concentrators at this level of provision is likely to lead to a cost saving. Conclusions The Drug Tariff prescribing guidelines, advocating that provision of oxygen by concentrator becomes cheaper when 21 cylinders are being used per month-are currently inaccurate in Northern Ireland, Regional health authorities should review their current arrangements for provision of oxygen at home and perform a cost analysis to determine at what level it becomes more cost effective to provide oxygen by concentrator.	Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland; Univ Ulster, Sch Publ Policy & Law, Jordanstown, North Ireland	Belfast City Hospital; Ulster University	Heaney, LG (corresponding author), Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland.	LiamHeaney@ukgateway.net						[Anonymous], 1980, ANN INTERN MED, V93, P391; *DEP HLTH, 1996, DRUG TAR 10; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; FLENLEY DC, 1981, LANCET, V1, P681; Rees P. J., 1998, BMJ, V317, P935	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					19	23		10.1136/bmj.319.7201.19	http://dx.doi.org/10.1136/bmj.319.7201.19			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390453	Bronze, Green Published			2023-01-03	WOS:000081326500024
J	Short, A; Cumming, A				Short, A; Cumming, A			ABC of intensive care - Renal support	BRITISH MEDICAL JOURNAL			English	Article																			0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					41	44		10.1136/bmj.319.7201.41	http://dx.doi.org/10.1136/bmj.319.7201.41			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390462	Green Published			2023-01-03	WOS:000081326500035
J	Tergau, F; Naumann, U; Paulus, W; Steinhoff, BJ				Tergau, F; Naumann, U; Paulus, W; Steinhoff, BJ			Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy	LANCET			English	Article									Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany	University of Gottingen	Tergau, F (corresponding author), Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany.		Paulus, Walter/A-3544-2009	Paulus, Walter/0000-0001-5549-8377				Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; STEINHOFF BJ, 1992, NEUROLOGY, V42, P1429, DOI 10.1212/WNL.42.7.1429-b; WEISS SRB, 1995, NEUROREPORT, V6, P2171, DOI 10.1097/00001756-199511000-00018; Ziemann U, 1998, EPILEPSY RES, V30, P11, DOI 10.1016/S0920-1211(97)00079-X	5	240	270	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2209	2209		10.1016/S0140-6736(99)01301-X	http://dx.doi.org/10.1016/S0140-6736(99)01301-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392988				2023-01-03	WOS:000081091300016
J	Guyatt, GH; Sinclair, J; Cook, DJ; Glasziou, P				Guyatt, GH; Sinclair, J; Cook, DJ; Glasziou, P		Evidence-Based Med Working Grp; Cochrane Applicability Methods Working Grp	Users' guides to the medical literature - XVI. How to use a treatment recommendation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; CLINICAL-PRACTICE GUIDELINES; ATRIAL-FIBRILLATION; DIGESTIVE-TRACT; SELECTIVE DECONTAMINATION; MYOCARDIAL-INFARCTION; DECISION-ANALYSIS; HELP ME; WILL; PREFERENCES	Clinicians can often find treatment recommendations in traditional narrative reviews and the discussion sections of original articles and meta-analyses. Making a treatment recommendation involves framing a question, identifying management options and outcomes, collecting and summarizing evidence, and applying value judgments or preferences to arrive at an optimal course of action, Each step in this process can be conducted systematically (thus protecting against bias) or unsystematically (leaving the process open to bias). Clinicians faced with a plethora of recommendations may wish to attend to those that are less likely to be biased. Therefore, we propose a hierarchy of rigor of recommendations to guide clinicians when judging the usefulness of particular recommendations. Recommendations with the highest rigor consider all relevant options and outcomes, include a comprehensive collection of the methodologically highest quality data with an explicit strategy for summarizing the data (that is, a systematic review), and make an explicit statement of the values or preferences involved in moving from evidence to action, High rigor recommendations come from systematically developed, evidence-based practice guidelines or rigorously conducted decision analyses. Systematic reviews, which typically do not consider all relevant options and outcomes or make the preferences underlying recommendations explicit, offer intermediate rigor recommendations. Traditional approaches in which the collection and assessment of evidence remains unsystematic, all relevant options and outcomes may not be considered, and values remain implicit, provide recommendations of weak rigor. In an era in which clinicians are barraged by recommendations as to how to manage their patients, this hierarchy provides a potentially useful set of guides.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; Univ Queensland, Sch Med, Dept Social & Prevent Med, Herston, Qld, Australia	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; University of Queensland	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				AERDTS SJA, 1993, BRIT MED J, V307, P525; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; GROOTENDOORST P, IN PRESS MED CARE; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MCBRIDE R, 1994, LANCET, V343, P687; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; Robbins JM, 1998, ARCH PEDIAT ADOL MED, V152, P358; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	29	118	124	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1836	1843		10.1001/jama.281.19.1836	http://dx.doi.org/10.1001/jama.281.19.1836			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340372				2023-01-03	WOS:000080288800038
J	Hines, SC; Glover, JJ; Holley, JL; Babrow, AS; Badzek, LA; Moss, AH				Hines, SC; Glover, JJ; Holley, JL; Babrow, AS; Badzek, LA; Moss, AH			Dialysis patients' preferences for family-based advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; HEALTH-CARE; DIRECTIVES	Background: Most patients do not participate in advance care planning with physicians. Objective: To examine patients' preferences for involving their physicians and families in advance care planning. Design: Pace-to-face interviews with randomly selected patients. Setting: Community-based dialysis units in one rural and one urban region. Participants: 400 hemodialysis patients. Measurements: Questions about whom patients involve in advance care planning, whom patients would like to include in this planning, and patients' reactions to state legislation on surrogate decision makers in End-of-life care. Results: Patients more frequently discussed preferences for end-of-life care with family members than with physicians (50% compared with 6%; P < 0.001). More patients wanted to include family members in future discussions of advance care planning than wanted to include physicians (91% compared with 36%; P < 0.001). Patients were most comfortable with legislation that granted their family end-of-life decision-making authority in the event of their own incapacity (P < 0.001). Conclusion: Most patients want to include their families more than their physicians in advance care planning.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Morgantown, WV 26506 USA; Univ Rochester, Sch Med, Rochester, NY 14642 USA; Purdue Univ, W Lafayette, IN 47907 USA	West Virginia University; University of Rochester; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Moss, AH (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Box 9022, Morgantown, WV 26506 USA.	amoss@wvu.edu						*AM HLTH DEC, 1997, QUEST DIE DIGN AN AM, P5; *CHOIC DYING INC, 1997, STAT STAT GOV SURR D; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; Moss AH, 1996, CHEST, V110, P249, DOI 10.1378/chest.110.1.249; *NIH NAT I DIAB DI, 1997, US REN DAT SYST 1997; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; Sehgal AR, 1996, JAMA-J AM MED ASSOC, V276, P1652, DOI 10.1001/jama.276.20.1652; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; *VERM ETH NETW, 1997, VERM VOIC CAR DYING	20	76	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					825	828		10.7326/0003-4819-130-10-199905180-00016	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366372				2023-01-03	WOS:000080305000005
J	Karlawish, JHT; Quill, T; Meier, DE				Karlawish, JHT; Quill, T; Meier, DE		ACP ASIM End Life Care Consensus Panel	A consensus-based approach to providing palliative care to patients who lack decision-making capacity	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCE DIRECTIVES; PREFERENCES; NUTRITION; HYDRATION; FAMILY	Making palliative care decisions for a patient who lacks decision-making capacity presents several challenges. Other people, such as family and caregivers, must choose for the patient. The goals and values of these decision makers may conflict with those of each other and with those of the patient, who now lacks the capacity to participate in the decision. This paper presents a case study of a patient with severe Alzheimer disease who has two common clinical problems: neurogenic dysphagia and aspiration pneumonia. The case study describes a consensus-based decision-making strategy that keeps what is known about the patient's wishes and values in the foreground but also expects guidance from the physician and elicits input from family members and other people who care for and have knowledge about the patient. The steps of this process, including key clinical prompts and potential transition statements, are outlined and described. The overall goal of the case commentary is to demonstrate that physicians can guide a highly emotional and personal process in a structured manner that has meaning for the patient, family, physician, and other caregivers.	Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	Karlawish, JHT (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.				NATIONAL INSTITUTE ON AGING [K01AG000931] Funding Source: NIH RePORTER; NIA NIH HHS [1K01-AG00931-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; Brock DW, 1996, MILBANK Q, V74, P599, DOI 10.2307/3350394; Bruner J., 1990, ACTS MEANING; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Doyle D, 1998, OXFORD TXB PALLIATIV; Dresser R, 1995, HASTINGS CENT REP, V25, P32, DOI 10.2307/3527839; FINUCANE TE, 1995, J AM GERIATR SOC, V43, P447, DOI 10.1111/j.1532-5415.1995.tb05822.x; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; HENDERSON CT, 1992, J AM COLL NUTR, V11, P309; HURLEY AC, 1995, ADV NURS SCI, V18, P33, DOI 10.1097/00012272-199512000-00005; JANOFSKY JS, 1993, J GERIATR PSYCH NEUR, V6, P214, DOI 10.1177/089198879300600406; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kuczewski MG, 1996, HASTINGS CENT REP, V26, P30, DOI 10.2307/3528574; LO B, 1984, NEW ENGL J MED, V311, P402, DOI 10.1056/NEJM198408093110611; Meisel A, 1995, AM J LAW MED, V21, P335; MEISEL A, 1996, RIGHT DIE; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Volicer L, 1989, J Geriatr Psychiatry Neurol, V2, P188, DOI 10.1177/089198878900200404	26	76	76	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					835	840		10.7326/0003-4819-130-10-199905180-00018	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	196JJ	10366374				2023-01-03	WOS:000080305000007
J	Catherwood, E; Fitzpatrick, WD; Greenberg, ML; Holzberger, PT; Malenka, DJ; Gerling, BR; Birkmeyer, JD				Catherwood, E; Fitzpatrick, WD; Greenberg, ML; Holzberger, PT; Malenka, DJ; Gerling, BR; Birkmeyer, JD			Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Review						cost-benefit analysis; atrial fibrillation; electric countershock; amiodarone; aspirin	LOW-DOSE AMIODARONE; COMMUNITY STROKE PROJECT; CONGESTIVE-HEART-FAILURE; SINUS RHYTHM; RANDOMIZED TRIAL; DRUG-THERAPY; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; QUINIDINE THERAPY; ADVERSE REACTIONS	Background: Physicians managing patients with nonvalvular atrial fibrillation must consider the risks, benefits, and costs of treatments designed to restore and maintain sinus rhythm compared with those of rate control with antithrombotic prophylaxis. Objective: To compare the cost-effectiveness of cardioversion, with or without antiarrhythmic agents, with that of rate control plus warfarin or aspirin. Design: A Markov decision-analytic model was designed to simulate long-term health and economic outcomes. Data Sources: Published literature and hospital accounting information. Target Population: Hypothetical cohort of 70-year-old patients with different baseline risks for stroke. Time Horizon: 3 months. Perspective: Societal. Intervention: Therapeutic strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and rate control with antithrombotic treatment. Outcome Measures: Expected costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness. Results of Base-Case Analysis: Strategies involving cardioversion alone were more effective and less costly than those not involving this option. For patients at high risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was most cost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on relapse. This strategy was also preferred for the moderate-risk cohort (3.6% per year), but the benefit was more expensive ($18 900 per QALY). In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relapse was optimal. Results of Sensitivity Analysis: The choice of optimal strategy and incremental cost-effectiveness was substantially influenced by the baseline risk for stroke, rate of stroke in sinus rhythm, efficacy of warfarin, and costs and utilities for long-term warfarin and amiodarone therapy. Conclusions: Cardioversion alone should be the initial management strategy for persistent nonvalvular atrial fibrillation. On relapse of arrhythmia, repeated cardioversion plus low-dose amiodarone is cost-effective for patients at moderate to high risk for ischemic stroke.	Dartmouth Coll, Hitchcock Med Ctr, Div Cardiol, Lebanon, NH 03756 USA; Dartmouth Coll, Dartmouth Med Sch, Hanover, NH 03756 USA; Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, Dept Surg, White River Jct, VT USA	Dartmouth College; Dartmouth College	Catherwood, E (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Div Cardiol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.							ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; ANTMAN EM, 1990, J AM COLL CARDIOL, V15, P698, DOI 10.1016/0735-1097(90)90649-A; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Blackshear JL, 1996, MAYO CLIN PROC, V71, P150, DOI 10.4065/71.2.150; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Chan Kwan-Leung, 1998, Annals of Internal Medicine, V128, P639; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; CHUN SH, 1995, AM J CARDIOL, V76, P47, DOI 10.1016/S0002-9149(99)80799-1; COHEN IS, 1977, PROG CARDIOVASC DIS, V20, P151, DOI 10.1016/0033-0620(77)90004-4; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Cronenwett JL, 1997, J VASC SURG, V25, P298, DOI 10.1016/S0741-5214(97)70351-3; DEBELL LS, 1997, MOSBYS COMPLETE DRUG; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; DISCH DL, 1994, ANN INTERN MED, V120, P449, DOI 10.7326/0003-4819-120-6-199403150-00001; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECKMAN MH, 1995, CHEST, V108, pS457, DOI 10.1378/chest.108.4_Supplement.457S; Eckman MH, 1998, ARCH INTERN MED, V158, P1669, DOI 10.1001/archinte.158.15.1669; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESTES NAM, 1992, JAMA-J AM MED ASSOC, V267, P3332, DOI 10.1001/jama.267.24.3332; EWY GA, 1994, CLIN CARDIOL, V17, P79, DOI 10.1002/clc.4960170207; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FRAIRE AE, 1993, SOUTHERN MED J, V86, P67, DOI 10.1097/00007611-199301000-00014; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gentile F, 1998, J AM COLL CARDIOL, V31, p195A, DOI 10.1016/S0735-1097(97)84553-6; Gilligan DM, 1996, AM J MED, V101, P413, DOI 10.1016/S0002-9343(96)00194-5; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; Grace AA, 1998, NEW ENGL J MED, V338, P35, DOI 10.1056/NEJM199801013380107; HIRSH J, 1994, CIRCULATION, V89, P1469, DOI 10.1161/01.CIR.89.3.1469; HIRSH J, 1995, CHEST S, V108, pS2315; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Hohnloser SH, 1997, PACE, V20, P1989, DOI 10.1111/j.1540-8159.1997.tb03606.x; Holloway RG, 1996, NEUROLOGY, V46, P854; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LANDEFELD CS, 1989, AM J MED, V87, P144; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lee KL, 1997, CLIN CARDIOL, V20, P372, DOI 10.1002/clc.4960200414; Lee TT, 1997, ANN INTERN MED, V126, P337, DOI 10.7326/0003-4819-126-5-199703010-00001; LEVY S, 1994, CARDIOVASC DRUG THER, V8, P769, DOI 10.1007/BF00877125; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; Mackstaller LL, 1997, CLIN CARDIOL, V20, P640, DOI 10.1002/clc.4960200711; Maisel WH, 1997, ANN INTERN MED, V127, P281, DOI 10.7326/0003-4819-127-4-199708150-00004; Marrin CAS, 1997, ANN THORAC SURG, V64, P690, DOI 10.1016/S0003-4975(97)00526-2; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; McNamara RL, 1997, ANN INTERN MED, V127, P775, DOI 10.7326/0003-4819-127-9-199711010-00001; MIDDLEKAUFF HR, 1992, ANN INTERN MED, V116, P1017, DOI 10.7326/0003-4819-116-12-1017; MIDDLEKAUFF HR, 1993, AM J CARDIOL, V72, pF75, DOI 10.1016/0002-9149(93)90967-H; MORGANROTH J, 1985, AM HEART J, V110, P1176, DOI 10.1016/0002-8703(85)90008-0; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NATTEL S, 1995, AM HEART J, V130, P1094, DOI 10.1016/0002-8703(95)90214-7; NYGAARD TW, 1986, JAMA-J AM MED ASSOC, V256, P55, DOI 10.1001/jama.256.1.55; Olsson SB, 1996, J INTERN MED, V239, P3; Opolski G, 1997, CLIN CARDIOL, V20, P337, DOI 10.1002/clc.4960200407; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; PETERSEN P, 1989, LANCET, V1, P175; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; Prystowsky E N, 1996, Am J Cardiol, V78, P35, DOI 10.1016/S0002-9149(96)00564-4; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Prystowsky EN, 1997, ANN INTERN MED, V126, P244, DOI 10.7326/0003-4819-126-3-199702010-00012; REIMOLD SC, 1992, AM HEART J, V124, P924, DOI 10.1016/0002-8703(92)90974-Z; Roy D, 1997, AM J CARDIOL, V80, P464, DOI 10.1016/S0002-9149(97)00396-2; Seto TB, 1997, J AM COLL CARDIOL, V29, P122, DOI 10.1016/S0735-1097(96)00448-2; Simons GR, 1997, AM J CARDIOL, V80, P1551, DOI 10.1016/S0002-9149(97)00773-X; Singh BN, 1997, CLIN CARDIOL, V20, P608, DOI 10.1002/clc.4960200706; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Sopher SM, 1997, J AM COLL CARDIOL, V30, P799; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; Stollberger C, 1998, ANN INTERN MED, V128, P630, DOI 10.7326/0003-4819-128-8-199804150-00004; SUNG RJ, 1994, CARDIOVASC DRUG THER, V8, P773, DOI 10.1007/BF00877126; Tieleman RG, 1997, AM J CARDIOL, V79, P53, DOI 10.1016/S0002-9149(96)00675-3; *US NAT CTR HLTH S, 1991, VIT STAT US A, V2; VANGELDER I, 1995, PACE, V18, P797; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9; WEINBERG BA, 1993, AM HEART J, V125, P109, DOI 10.1016/0002-8703(93)90063-F; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 1997, AM J CARDIOL, V79, P1198; Yuan Z, 1998, AM J PUBLIC HEALTH, V88, P395, DOI 10.2105/AJPH.88.3.395; ZAREMBSKI DG, 1995, ARCH INTERN MED, V155, P1885, DOI 10.1001/archinte.155.17.1885	106	49	50	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					625	+		10.7326/0003-4819-130-8-199904200-00002	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00002			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215558				2023-01-03	WOS:000079786600001
J	Passalacqua, R; Campione, F; Caminiti, C; Salvagni, S; Barilli, A; Bella, M; Barni, S; Barsanti, G; Caffo, O; Carlini, P; Cinquemani, G; Di Costanzo, F; Giustini, L; Labianca, R; Mazzei, A; Olmeo, N; Paccagnella, A; Toscano, L; Cocconi, G				Passalacqua, R; Campione, F; Caminiti, C; Salvagni, S; Barilli, A; Bella, M; Barni, S; Barsanti, G; Caffo, O; Carlini, P; Cinquemani, G; Di Costanzo, F; Giustini, L; Labianca, R; Mazzei, A; Olmeo, N; Paccagnella, A; Toscano, L; Cocconi, G			Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy	LANCET			English	Article							COMPLEMENTARY; PREVALENCE; MEDICINE	Background An emotional campaign promoting the Di Bella cancer therapy was launched by the Italian media in 1997. Its effects on patients' hopes, feelings, and decisionmaking processes were largely unknown. We undertook an investigation of this issue. Methods Between Feb 25 and March 31, 1998,a ten-item. questionnaire was distributed to 1300 unselected adult patients attending 13 cancer-centres throughout Italy. Four expert psycho-oncologists reviewed the design and validity of the contents of the:questionnaire. Sociodemographic information was also collected. Findings 1120 (86%) questionnaires were-returned and analysed. The main sources of information were television/radio (62%) and newspapers (26%); only 5% cited doctors;,The campaign induced optimism in the patients about the efficacy of the method (ineffective 1%, effective 42%, uncertain 57%), and 53% said their hope of cure was increased. However, 48% felt more confused. 24% do not discuss new treatments with their oncologists, and 20% would like to but cannot. When choosing a treatment, the advice of a trusted doctor was judged more important than scientific progress (53% vs 32%) and 63% would try even unproven treatments in the hope of a cure. Replies to, many of the questions were influenced by patients' educational attainment and by the degree of communication with their oncologists. Interpretation Science cannot prevent the harm caused by such campaigns and their psychological consequences, particularly for less educated patients. When making decisions, patients are looking for hope from the treatment trust in their doctor, both of which depend on effective doctor-patient communications that therefore need to be improved.	Univ Hosp, Div Med Oncol, Parma, Italy; Univ Hosp, Epidemiol Unit, Parma, Italy; Univ Bologna, Dept Psychol, I-40126 Bologna, Italy; San Gerardo Hosp, Div Med Oncol, Monza, Italy; Campo Marte Hosp, Oncol Serv, Lucca, Italy; S Chiara Hosp, Div Med Oncol, Trent, Italy; Ist Regina Elena, Div Med Oncol 1, I-00161 Rome, Italy; NCI, Psychol Serv, Naples, Italy; S Maria Hosp, Div Med Oncol, Terni, Italy; Murri Hosp, Oncol Serv, Fermo, Italy; Osped Riuniti Bergamo, Med Oncol Unit, I-24100 Bergamo, Italy; NCI, Div Med Oncol, Bari, Italy; USL 1, Div Med Oncol, Sassari, Italy; USL 12, Div Med Oncol, Venice, Italy; S Luigi Hosp, Div Med Oncol, Catania, Italy	University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; University of Bologna; San Gerardo Hospital; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Fondazione Pascale; Ospedali Riuniti di Bergamo	Passalacqua, R (corresponding author), Azienda Osped, Div Oncol, Via Gramsci 14, I-43100 Parma, Italy.		Labianca, Roberto/N-1847-2016; Salvagni, Stefania/AAC-5798-2021; Caminiti, Caterina/AAE-3130-2022; Caffo, Orazio/AAE-5485-2020; Caminiti, Caterina/K-4532-2016	Labianca, Roberto/0000-0001-7149-822X; Caminiti, Caterina/0000-0002-3196-2435; Caffo, Orazio/0000-0001-7968-2531; Caminiti, Caterina/0000-0002-3196-2435				Abbott A, 1998, NATURE, V391, P217, DOI 10.1038/34503; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1026, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1026::AID-CNCR4>3.3.CO;2-#; Crocetti E, 1996, TUMORI, V82, P539, DOI 10.1177/030089169608200605; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fernandez CV, 1998, J CLIN ONCOL, V16, P1279, DOI 10.1200/JCO.1998.16.4.1279; Fleiss J. L., 1981, STAT METHODS RATES P, V2; *ISTAT NAT I STAT, 1996, INTR IT; Jacobs Joseph J., 1997, P2993; LEVY MHJ, 1988, AM SOC CLIN ONCOLOGY, P195; LOJACONO G, 1998, EPIDEMIOL PREVENT, V22, P3; Milano G, 1998, Epidemiol Prev, V22, P82; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; SIMINI B, 1998, LANCET, V351, P8941; Turone F, 1998, BRIT MED J, V316, P327, DOI 10.1136/bmj.316.7128.327a	15	23	23	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1310	1314		10.1016/S0140-6736(98)10253-2	http://dx.doi.org/10.1016/S0140-6736(98)10253-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218529				2023-01-03	WOS:000080278100011
J	Reagan, P				Reagan, P			Helen	LANCET			English	Article											Reagan, P (corresponding author), 2406 NE 19th Ave, Portland, OR 97212 USA.								0	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1265	1267		10.1016/S0140-6736(98)12219-5	http://dx.doi.org/10.1016/S0140-6736(98)12219-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217100				2023-01-03	WOS:000079744100042
J	Cobb, LA; Fahrenbruch, CE; Walsh, TR; Copass, MK; Olsufka, M; Breskin, M; Hallstrom, AP				Cobb, LA; Fahrenbruch, CE; Walsh, TR; Copass, MK; Olsufka, M; Breskin, M; Hallstrom, AP			Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-ARREST; COUNTERSHOCK; MANAGEMENT; SURVIVAL; IMPACT; DEATH	Context Use of automated external defibrillators (AEDs) by first arriving emergency medical technicians (EMTs) is advocated to improve the outcome for out-of-hospital ventricular fibrillation (VF). However, adding AEDs to the emergency medical system in Seattle, Wash, did not improve survival. Studies in animals have shown improved outcomes when cardiopulmonary resuscitation (CPR) was administered prior to an initial shock for VF of several minutes' duration. Objective To evaluate the effects of providing 90 seconds of CPR to persons with out-of-hospital VF prior to delivery of a shock by first-arriving EMTs. Design Observational, prospectively defined, population-based study with 42 months of preintervention analysis (July 1, 1990-December 31, 1993) and 36 months of postintervention analysis (January 1, 1994-December 31, 1996). Setting Seattle fire department-based, 2-tiered emergency medical system. Participants A total of 639 patients treated for out-of-hospital VF before the intervention and 478 after the intervention. Intervention Modification of the protocol for use of AEDs, emphasizing approximately 90 seconds of CPR prior to delivery of a shock. Main Outcome Measures Survival and neurologic status at hospital discharge determined by retrospective chart review as a function of early (<4 minutes) and later (greater than or equal to 4 minutes) response intervals. Results Survival improved from 24% (155/639) to 30% (142/478) (P = .04). That benefit was predominantly in patients for whom the initial response interval was 4 minutes or longer (survival, 17% [56/321] before vs 27% [60/220] after; P = .01). In a multivariate logistic model, adjusting for differences in patient and resuscitation factors between the periods, the protocol intervention was estimated to improve survival significantly (adds ratio, 1.42; 95% confidence interval, 1.07-1.90; P = .02). Overall, the proportion of victims who survived with favorable neurologic recovery increased from 17% (106/634) to 23% (109/474) (P = .01). Among survivors, the proportion having favorable neurologic function at hospital discharge increased from 71% (106/150) to 79% (109/138) (P<.11). Conclusion The routine provision of approximately 90 seconds of CPR prior to use of AED was associated with increased survival when response intervals were 4 minutes or longer.	Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Biostat, Seattle, WA 98104 USA; Seattle Fire Dept, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Cobb, LA (corresponding author), Univ Washington, Harborview Med Ctr, Dept Med, Box 359748, Seattle, WA 98104 USA.							Brown CG, 1996, ANN EMERG MED, V27, P184, DOI 10.1016/S0196-0644(96)70346-3; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; COBB LA, 1992, CIRCULATION, V85, P98; COBB LA, 1975, CIRCULATION, V52, P223; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; DITCHEY RV, 1992, CARDIOVASC RES, V26, P791, DOI 10.1093/cvr/26.8.791; DIXON WJ, 1990, BMDP STAT SOFTWARE M, P9; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; *EM CARD CAR COMM, 1991, AM J EMERG MED, V9, P91; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; Ferguson JJ, 1998, CIRCULATION, V97, P1217; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; Joyce S M, 1998, Prehosp Emerg Care, V2, P13, DOI 10.1080/10903129808958833; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; Martens P, 1993, Eur J Med, V2, P430; NIEMANN JT, 1992, CIRCULATION, V85, P281, DOI 10.1161/01.CIR.85.1.281; NOC M, 1994, J LAB CLIN MED, V124, P421; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; SCHNEIDER T, 1994, RESUSCITATION, V27, P197, DOI 10.1016/0300-9572(94)90033-7; Sweeney TA, 1998, ANN EMERG MED, V31, P234, DOI 10.1016/S0196-0644(98)70313-0; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEAVER WD, 1987, J AM COLL CARDIOL, V10, P1259, DOI 10.1016/S0735-1097(87)80128-6	27	519	546	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1182	1188		10.1001/jama.281.13.1182	http://dx.doi.org/10.1001/jama.281.13.1182			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181VW	10199427	Bronze			2023-01-03	WOS:000079464400032
J	Kruth, HS; Zhang, WY; Skarlatos, SI; Chao, FF				Kruth, HS; Zhang, WY; Skarlatos, SI; Chao, FF			Apolipoprotein B stimulates formation of monocyte-macrophage surface-connected compartments and mediates uptake of low density lipoprotein-derived liposomes into these compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; RECEPTOR-RELATED PROTEIN; RICH LIPID PARTICLES; HUMAN ATHEROSCLEROTIC LESIONS; UNESTERIFIED CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODIES; HYPERLIPIDEMIC RABBIT; BETA-VLDL; ACCUMULATION	Much of the cholesterol that accumulates in atherosclerotic plaques is found within monocyte-macrophages transforming these cells into "foam cells." Native low density lipoprotein (LDL) does not cause foam cell formation. Treatment of LDL with cholesterol esterase converts LDL into cholesterol-rich liposomes having >90% cholesterol in unesterified form. Similar cholesterol-rich liposomes are found in early developing atherosclerotic plaques surrounding foam cells. We now show that cholesterol-rich liposomes produced from cholesterol esterase-treated LDL can cause human monocyte-macrophage foam cell formation inducing a 3-5-fold increase in macrophage cholesterol content of which >60% is esterified. Although cytochalasin D inhibited LDL liposome-induced macrophage cholesteryl ester accumulation, LDL liposomes did not enter macrophages by phagocytosis. Rather, the LDL liposomes induced and entered surface-connected compartments within the macrophages, a unique endocytic pathway in these cells that we call patocytosis, LDL liposome apoB rather than LDL liposome lipid mediated LDL liposome uptake by macrophages, This was shown by the findings that: 1) protease treatment of the LDL liposomes prevented macrophage cholesterol accumulation; 2) liposomes prepared from LDL lipid extracts did not cause macrophage cholesterol accumulation; and 3) purified apoB induced and accumulated within macrophage surface-connected compartments. Although apoB mediated the macrophage uptake of LDL liposomes, this uptake did not occur through LDL, LDL receptor-related protein, or scavenger receptors, Also, LDL liposome uptake was not sensitive to treatment of macrophages with trypsin or heparinase, Cholesterol esterase-mediated transformation of LDL into cholesterol-rich liposomes is an LDL modification that: 1) stimulates uptake of LDL cholesterol by apoB-dependent endocytosis into surface-connected compartments, and 2) causes human monocyte-macrophage foam cell formation.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002832, ZIAHL002832] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; CAREW TE, 1978, BIOCHIM BIOPHYS ACTA, V529, P171, DOI 10.1016/0005-2760(78)90115-7; CHAO FF, 1988, AM J PATHOL, V131, P73; CHAO FF, 1992, J BIOL CHEM, V267, P4992; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAMBLE W, 1978, J LIPID RES, V19, P1068; GREVE H, 1988, J BIOL CHEM, V263, P12886; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1984, AM J PATHOL, V114, P201; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; LUNDBERG B, 1984, J LIPID RES, V25, P550; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; MORA R, 1990, J LIPID RES, V31, P1793; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; OBUNIKE JC, 1994, J BIOL CHEM, V269, P13129; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Seo T, 1997, J LIPID RES, V38, P765; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; SHECHTER I, 1981, J LIPID RES, V22, P63; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1994, J BIOL CHEM, V269, P22547; TERTOV VV, 1992, CIRC RES, V71, P218, DOI 10.1161/01.RES.71.1.218; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; WALSH MT, 1983, BIOCHEMISTRY-US, V22, P3170, DOI 10.1021/bi00282a021; WIKLUND O, 1985, J BIOL CHEM, V260, P956; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; XU XX, 1991, J BIOL CHEM, V266, P24849; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	46	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	1999	274	11					7495	7500		10.1074/jbc.274.11.7495	http://dx.doi.org/10.1074/jbc.274.11.7495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	175DV	10066816	hybrid			2023-01-03	WOS:000079078400088
J	Rawles, J; Sinclair, C; Jennings, K; Ritchie, L; Waugh, N				Rawles, J; Sinclair, C; Jennings, K; Ritchie, L; Waugh, N			Call to needle times after acute myocardial infarction in urban and rural areas in northeast Scotland: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES	Objective: To determine call to needle times and consider how best to provide timely thrombolytic treatment for patients with acute myocardial infarction. Design: Prospective observational study. Setting: City, suburban, and country practices referring patients to a single district general hospital in northeast Scotland. Subjects: 1046 patients with suspected acute myocardial infarction given thrombolytic treatment. Main outcome measures: Time from patients' calls for medical help until receipt of opiate or thrombolytic treatment, measured against a call to needle time of 90 minutes or less, as proposed by the British Heart Foundation. Results: General practitioners were the first medical contact in 97% (528/544) of calls by country patients and 68% (340/502) of city and suburban patients. When opiate was given by general practitioners, median call to opiate time was about 30 minutes (95% Within 90 minutes) in city, suburbs, and country; call to opiate delay was about 60 minutes in city and subul ban patients calling "999" for an ambulance. One third of country patients received thrombolytic treatment from their general practitioners with a median call to thrombolysis time of 45 minutes (93% within 90 minutes); this compares with 150 minutes (5% within 90 minutes) when this treatment was deferred until after hospital admission. In the city and suburbs, no thrombolytic treatment was given outside hospital, and only a minority of patients received it within 90 minutes of calling; median call to thrombolysis time was 95 (46% within 90 minutes) minutes. Conclusions: The first medical contact after acute myocardial infarction is most commonly with a general practitioner. This contact provides the optimum opportunity to give thrombolytic treatment within the British Heart Foundation's guideline.	Univ Aberdeen, Aberdeen Royal Infirm, Med Assessment Res Unit, Aberdeen AB25 2NZ, Scotland; Aberdeen Royal Infirm, Dept Cardiol, Aberdeen, Scotland; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB25 2NZ, Scotland; Grampian Hlth Board, Aberdeen AB15 6RE, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	Rawles, J (corresponding author), Univ Aberdeen, Aberdeen Royal Infirm, Med Assessment Res Unit, Aberdeen AB25 2NZ, Scotland.							Banerjee S, 1998, J ROY COLL PHYS LOND, V32, P36; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CAPEWELL S, 1997, HLTH B, V55, P399; COBBE SM, 1994, BMJ-BRIT MED J, V308, P216, DOI 10.1136/bmj.308.6923.216; LIDDELL R, 1996, 67 SCOTT OFF; RAWLES J, 1995, DRUGS, V50, P615, DOI 10.2165/00003495-199550040-00004; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; 1994, DRUG THERAPEUTICS B, V32, P65	9	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					576	578		10.1136/bmj.317.7158.576	http://dx.doi.org/10.1136/bmj.317.7158.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721115	Green Published, Bronze			2023-01-03	WOS:000075767800019
J	Robinson, SM; Mackenzie-Ross, S; Hewson, GLC; Egleston, C; Prevost, AT				Robinson, SM; Mackenzie-Ross, S; Hewson, GLC; Egleston, C; Prevost, AT			Psychological effect of witnessed resuscitation on bereaved relatives	LANCET			English	Article							PSYCHOMETRIC PROPERTIES; INVENTORY; ANXIETY; SCALE	Background Established practice is for the relatives of critically ill patients to be excluded from the clinical area during resuscitation. We aimed to discover whether relatives wanted to be present during the resuscitation of a family member and whether witnessing resuscitation had any adverse psychological effects on bereaved relatives. Methods In this pilot study, relatives of patients who required resuscitation were given the option to remain with the patient during resuscitation or were not given this choice and directed to the relatives' room (control group). The unit of randomisation was the patient who required resuscitation and not the relatives. One close relative was paired with each patient. All relatives were accompanied by a chaperone who gave emotional support and provided technical information on the resuscitation. Relatives were followed up 1 month after the resuscitation. We used a questionnaire to ask about the decision to be present, or absent during resuscitation, Bereaved relatives also completed five standardised psychological questionnaires to assess anxiety, depression, grief, intrusive imagery, and avoidance behaviour. Findings 25 patients underwent resuscitation (13 in witnessed resuscitation group, 12 in control group), Three patients in the witnessed group survived, all the control group patients died. Two relatives in each group were lost to follow-up. Thus, eight relatives who witnessed resuscitation and ten control-group relatives were followed up. There were no reported adverse psychological effects among the relatives who witnessed resuscitation, all of whom were satisfied with their decision to remain with the patient. The clinical team became convinced of the benefits to relatives of allowing them to witness resuscitation if they wished, so the trial was terminated. Interpretation In the context of the emergency department, routine exclusion of relatives from the resuscitation room may no longer be appropriate.	Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England; UCL, Subdept Clin Hlth Psychol, London, England; Univ Cambridge, Inst Publ Hlth, Dept Community Med, Ctr Appl Med Stat, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of London; University College London; University of Cambridge	Robinson, SM (corresponding author), Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England.			Robinson, Susan/0000-0002-1796-6739; Prevost, A. Toby/0000-0003-1723-0796				Back D, 1994, Nurs Times, V90, P34; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DOYLE CJ, 1987, ANN EMERG MED, V16, P107; Gregory C M, 1995, Accid Emerg Nurs, V3, P136, DOI 10.1016/S0965-2302(95)80006-9; Hanson C, 1992, J Emerg Nurs, V18, P104; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JUDKINS KC, 1994, BRIT MED J, V309, P406; OSUAGWN CC, 1991, J EMERG NURS, V17, P36; SCHILLING RJ, 1994, BRIT MED J, V309, P406, DOI 10.1136/bmj.309.6951.406; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZISOOK S, 1982, AM J PSYCHIAT, V139, P1590; ZOLTIE N, 1994, BRIT MED J, V309, P406	14	256	261	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					614	617		10.1016/S0140-6736(97)12179-1	http://dx.doi.org/10.1016/S0140-6736(97)12179-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113TE	9746023				2023-01-03	WOS:000075567400011
J	Sashidharan, SP; Smyth, M				Sashidharan, SP; Smyth, M			Care models for discharged psychiatric patients - Community based care is superior to conventional care	BRITISH MEDICAL JOURNAL			English	Letter									Univ Birmingham, Acad Unit, No Birmingham Mental Hlth Trust, Birmingham B23 7AL, W Midlands, England	University of Birmingham	Sashidharan, SP (corresponding author), Univ Birmingham, Acad Unit, No Birmingham Mental Hlth Trust, Birmingham B23 7AL, W Midlands, England.							MARSHALL M, 1997, COCHRANE LIB; Scott JE, 1995, SCHIZOPHRENIA BULL, V21, P657, DOI 10.1093/schbul/21.4.657; THOMPSON KS, 1990, HOSP COMMUNITY PSYCH, V41, P625; Tyrer P, 1998, BRIT MED J, V316, P106; Tyrer P, 1998, BRIT J PSYCHIAT, V172, P1, DOI 10.1192/bjp.172.1.1	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					283	283		10.1136/bmj.317.7153.283a	http://dx.doi.org/10.1136/bmj.317.7153.283a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677237	Green Published			2023-01-03	WOS:000075081900052
J	Harrington, C; Pollock, AM				Harrington, C; Pollock, AM			Decentralisation and privatisation of long-term care in UK and USA	LANCET			English	Editorial Material							STATE		Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA; St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of California System; University of California San Francisco; St Georges University London	Pollock, AM (corresponding author), Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA.			pollock, allyson/0000-0002-7388-3110				*AARP PUBL POL I, 1992, ACC FED PUBL BEN PRO; *AM HOSP ASS, 1996, HOSP STAT ANN STAT 1; Audit Commission, 1986, MAK REAL COMM CAR; BEDNEY B, 1996, 1995 STAT DAT BOOK L; *CA ADV NURS HOM R, 1995, IS YOU THINK YOU NEE; CROWN W, 1994, ANAL ASSET TESTING N; *DEP HLTH, 1995, LOC AUTH PERS SOC SE; *DEP HLTH, 1996, STAT B DEP HLTH; *DEP HLTH, 1996, LOC AUTH PERS SOC SE; *DEP HLTH COMM CAR, 1996, STAT B DEP HLTH COMM; HARRINGTON C, 1986, GERONTOLOGIST, V26, P437, DOI 10.1093/geront/26.4.437; Harrington C, 1996, J APPL GERONTOL, V15, P414, DOI 10.1177/073346489601500402; HARRINGTON C, 1996, NURSING FACILITIES S; HARRINGTON C, 1997, J APPL GERONTOL, V16, P53; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; *HCIA, 1995, 1995 GUID NURS HOM I; HENWOOD M, 1994, FITE CHANGE SNAPSHOT; *HLTH COMM HOUS CO, 1996, LONG TERM CAR FUT PR, V1; HOLAHAN J, 1987, MILBANK Q, V65, P112, DOI 10.2307/3350015; Leicester MC, 1996, PUBLIC HEALTH, V110, P109, DOI 10.1016/S0033-3506(96)80056-4; Levit KR, 1996, HEALTH CARE FINANC R, V18, P175; MANGAN T, 1994, RESIDENTIAL SERVICES; MECHANIC D, 1992, HEALTH AFFAIR, V11, P128, DOI 10.1377/hlthaff.11.1.128; *U CA, 1994, REP HLTH CAR FIN ADM; *US DEP COMM, 1996, STAT ABSTR US 1995; WALSH M, 1995, FORBES, V55, P180; WEINER JM, 1996, SPENDING DOWN MEDICA; 1996, LAINGS REV PRIVATE H; 1988, COMMUNITY CARE AGEND; 1989, CARING PEOPLE WHITE	30	17	17	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1805	1808		10.1016/S0140-6736(97)09039-9	http://dx.doi.org/10.1016/S0140-6736(97)09039-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZU444	9635970				2023-01-03	WOS:000074197600046
J	Redelmeier, DA; Tan, SH; Booth, GL				Redelmeier, DA; Tan, SH; Booth, GL			The treatment of unrelated disorders in patients with chronic medical diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONTARIO; HEALTH; RISK; CARE; BENEFIT; FRAUD	Background Patients can have several illnesses concurrently, yet some of these diseases may be neglected if one problem consumes attention. We conducted a population-based analysis in Ontario, Canada - where universal health insurance is provided - to determine whether unrelated disorders are less likely to be treated in patients with chronic diseases, Methods We studied the 1,344,145 residents of Ontario in 1995 who were 65 or older and eligible to receive prescription medications free of charge as part of the Ontario Drug Benefit program. Patients with diabetes mellitus were identified by prescriptions for insulin, pulmonary emphysema by prescriptions for ipratropium bromide, and psychotic syndromes by prescriptions for haloperidol. For each chronic disease, we selected an unrelated treatment: estrogen-replacement therapy for patients with diabetes mellitus, lipid-lowering medications for those with pulmonary emphysema, and medical treatment of arthritis for those with psychotic syndromes. Results The 30,669 patients with diabetes mellitus were less likely to receive estrogen-replacement therapy than the other subjects in the study (2.4 percent vs. 5.9 percent, P<0.001). The disease was associated with a 60 percent reduction in the odds of estrogen treatment (odds ratio, 0.40; 95 percent confidence interval, 0.37 to 0.43). Findings were similar for the 56,779 patients with pulmonary emphysema, who were less likely to receive lipid-lowering medications (odds ratio, 0.69; 95 percent confidence interval, 0.67 to 0.72; P<0.001), and the 17,336 patients with psychotic syndromes, who were less likely to receive medical treatments for arthritis (odds ratio, 0.59; 95 percent confidence interval, 0.57 to 0.62; P<0.001). Conclusions In patients 65 or older who have chronic medical diseases and who receive prescription medications free of charge, unrelated disorders are undertreated. Clinicians caring for patients with chronic diseases should remain alert to other disorders and minimize the number of missed opportunities for treating them. (C) 1998, Massachusetts Medical Society.	Sunnybrook Hlth Sci Ctr, Clin Epidemiol & Hlth Care Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Inst Clin Evaluat Sci Ontario, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Redelmeier, DA (corresponding author), Sunnybrook Hlth Sci Ctr, Clin Epidemiol & Hlth Care Res Program, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							ABRAMSON JH, 1982, J CHRON DIS, V35, P221, DOI 10.1016/0021-9681(82)90143-6; ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; BARHILLEL M, 1973, ORGAN BEHAV HUM PERF, V9, P396, DOI 10.1016/0030-5073(73)90061-5; BARTECCHI CE, 1994, NEW ENGL J MED, V330, P907, DOI 10.1056/NEJM199403313301307; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; ENRIGHT PL, 1995, CHEST, V107, P28, DOI 10.1378/chest.107.1.28; Estes W. K, 1964, CATEGORIES HUMAN LEA, P89; Fischhoff Baruch, 1982, JUDGMENT UNCERTAINTY, p[335, 341], DOI [10.1017/CBO9780511809477.024, DOI 10.1017/CB09780511809477.024]; FONG GT, 1986, COGNITIVE PSYCHOL, V18, P253, DOI 10.1016/0010-0285(86)90001-0; Fontana SA, 1997, AM J PUBLIC HEALTH, V87, P1190, DOI 10.2105/AJPH.87.7.1190; FRENCH O, 1995, CAN MED ASSOC J, V152, P569; GOEL V, 1996, PATTERNS HLTH CARE O, P27; Haffner SM, 1998, DIABETES CARE, V21, P160, DOI 10.2337/diacare.21.1.160; HARRIS MI, 1995, NIH PUBLICATION, P127; Hibbard JH, 1997, MILBANK Q, V75, P395, DOI 10.1111/1468-0009.00061; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; KARASU TB, 1980, HOSP COMMUNITY PSYCH, V31, P463; LINDMAN H, 1961, J EXP PSYCHOL, V62, P630, DOI 10.1037/h0046635; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MCISAAC W, 1994, CAN MED ASSOC J, V150, P473; McLaughlin TJ, 1997, J GEN INTERN MED, V12, P1, DOI 10.1046/j.1525-1497.1997.12105.x; MENDELSSOHN DC, 1995, ARCH INTERN MED, V155, P2473, DOI 10.1001/archinte.155.22.2473; Millman M, 1993, ACCESS HLTH CARE AM, P31; MYKKANEN L, 1993, DIABETOLOGIA, V36, P553, DOI 10.1007/BF02743273; QUINN K, 1992, CAN MED ASSOC J, V146, P2177; Shu A, 1996, CAN MED ASSOC J, V154, P1412; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; THALER RH, 1991, QUASIRATIONAL EC, P25; Thorburn WM., 1918, MIND 26, VI, P345, DOI DOI 10.1093/MIND/XXVII.3.345; Thurnheer R, 1997, CHEST, V112, P122, DOI 10.1378/chest.112.1.122; TVERSKY A, 1971, PSYCHOL BULL, V76, P105, DOI 10.1037/h0031322; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223	37	509	514	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1998	338	21					1516	1520		10.1056/NEJM199805213382106	http://dx.doi.org/10.1056/NEJM199805213382106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZN943	9593791				2023-01-03	WOS:000073699100006
J	Bonnema, J; van Wersch, AMEA; van Geel, AN; Pruyn, JFA; Schmitz, PIM; Paul, MA; Wiggers, T				Bonnema, J; van Wersch, AMEA; van Geel, AN; Pruyn, JFA; Schmitz, PIM; Paul, MA; Wiggers, T			Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							MODIFIED RADICAL-MASTECTOMY; AXILLARY DRAINAGE; NODE DISSECTION; COMPLICATIONS; ADJUSTMENT; SUPPORT; STRESS; STAY; TERM	Objective: To assess the medical and psychosocial effects of early hospital discharge after surgery for breast cancer on complication rate, patient satisfaction, and psychosocial outcomes. Design: Randomised trial comparing discharge from hospital 4 days after surgery (with drain in situ) with discharge after drain removal (mean 9 days in hospital). Psychosocial measurements performed before surgery and 1 and 4 months after. Setting: General hospital and cancer clinic in Rotterdam with a socioeconomically diverse population. Subjects: 125 women with operable breast cancer. Main outcome measures: Incidence of complications after surgery for breast cancer, patient satisfaction with treatment, and psychosocial effects of short stay or long stay in hospital. Results: Patient satisfaction with the short stay in hospital was high; only 4% (2/56 at 1 month after surgery and 2/52 at 4 months after surgery) of patients indicated that they would have preferred a longer stay. There were no significant differences in duration of drainage from the axilla between the short stay and long stay groups (median 8 v 9 days respectively, P = 0.45) or the incidence of wound complications (10 patients v 9 patients). The median number of seroma aspirations per patient was higher for the long stay group (1 v 3.5, P = 0.04). Leakage along the drain occurred more frequently in short stay patients (21 v 10 patients, P = 0.04). The two groups did not differ in scores for psychosocial problems (uncertainty anxiety, loneliness, disturbed sleep, loss of control, threat to self esteem), physical or psychological complaints, or in the coping strategies used. Before surgery; short stay patients scored higher on scales of depression (P = 0.03) and after surgery they were more likely to discuss their disease with their families (at 1 month P = 0.004, at 4 months P = 0.04). Conclusions: Early discharge from hospital after surgery for breast cancer is safe and is well received by patients. Early discharge seems to enhance the opportunity for social support within the family.	Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Zuider Hosp, Dept Surg Oncol, NL-3008 AE Rotterdam, Netherlands; Inst Hlth & Environm Issues, NL-4797 ZH Willemstad, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Bonnema, J (corresponding author), Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Zuider Hosp, Dept Surg Oncol, POB 5201, NL-3008 AE Rotterdam, Netherlands.							BLOOM JR, 1982, SOC SCI MED, V16, P1329, DOI 10.1016/0277-9536(82)90028-4; BOMAN L, 1993, EUR J SURG, V159, P67; Bonnema J, 1997, AM J SURG, V173, P76, DOI 10.1016/S0002-9610(96)00416-3; CLARK JA, 1992, AM SURGEON, V58, P239; Coveney E C, 1993, Eur J Surg Oncol, V19, P143; Cronbach L., 1960, ESSENTIALS PSYCHOL T; DEBOER MF, 1995, HEAD NECK-J SCI SPEC, V17, P503, DOI 10.1002/hed.2880170608; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOODMAN AA, 1993, ARCH SURG-CHICAGO, V128, P1149; Holcombe C, 1995, Eur J Surg Oncol, V21, P604, DOI 10.1016/S0748-7983(95)95133-4; INWANG R, 1991, ANN ROY COLL SURG, V73, P326; JEFFREY SS, 1995, ARCH SURG-CHICAGO, V130, P909; Kambouris A, 1996, AM SURGEON, V62, P123; Maddern GJ, 1996, BRIT J SURG, V83, P145, DOI 10.1046/j.1365-2168.1996.02185.x; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MCALEESE P, 1994, ANN SURG, V220, P740, DOI 10.1097/00000658-199412000-00006; McArdle JMC, 1996, BMJ-BRIT MED J, V312, P813; Mesters I, 1997, PSYCHOSOM MED, V59, P269, DOI 10.1097/00006842-199705000-00010; NELLES W B, 1991, Journal of Psychosocial Oncology, V9, P21, DOI 10.1300/J077v09n02_02; PEDERSEN SH, 1994, ANN SURG, V219, P374, DOI 10.1097/00000658-199404000-00008; PRUYN JFA, 1983, PATIENT EDUC COUNS, V5, P57, DOI 10.1016/0738-3991(83)90002-2; SOMERS RG, 1992, ANN SURG, V215, P146, DOI 10.1097/00000658-199202000-00009; SPIEGEL D, 1983, J PSYCHOSOC ONCOL, V1, P33, DOI DOI 10.1300/J077V01N01_04; Spielberger C., 1983, STAI MANUAL; TADYCH K, 1987, SURG GYNECOL OBSTET, V165, P483; VANDENBORNE HW, 1987, PATIENT EDUC COUNS, V9, P33, DOI 10.1016/0738-3991(87)90107-8; VANDENBORNE HW, 1985, LOTGENOTENCONTACT BI; vanWersch A, 1997, PATIENT EDUC COUNS, V30, P175, DOI 10.1016/S0738-3991(96)00950-0; VINTON AL, 1991, AM J SURG, V161, P584, DOI 10.1016/0002-9610(91)90905-S; WATSON M, 1990, PSYCHOL REP, V66, P39, DOI 10.2466/PR0.66.1.39-48; YLI M, 1995, ANN R COLL SURG ENGL, V77, P377	32	82	83	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1267	1271		10.1136/bmj.316.7140.1267	http://dx.doi.org/10.1136/bmj.316.7140.1267			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZK548	9554895	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000073335900019
J	Nightingale, SL				Nightingale, SL			Tobramycin inhalation product approved for use in cystic fibrosis therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2023-01-03	WOS:000072192800005
J	Koole, LH; Kruft, MAB; Aldenhoff, YBJ; van't Oost, NE; van Kroonenburgh, MJPG; van der Veen, FH				Koole, LH; Kruft, MAB; Aldenhoff, YBJ; van't Oost, NE; van Kroonenburgh, MJPG; van der Veen, FH			Sustained local drug delivery from a radiopaque implanted reservoir	NATURE BIOTECHNOLOGY			English	Article							POLYMERIC BIOMATERIALS; SOLID TUMORS; CHEMOTHERAPY; ACCESS	A new polymeric biomaterial that contains covalently bound iodine, and is therefore radiopaque, was used to construct a sustained local drug-delivery device. A polymeric wall was designed to be porous (i.e., passage of low-molecular-weight molecules across the wall is possible), self-healing, and biocompatible. Once implanted, the sphere cavity can be filled and refilled with a concentrated solution of a (cytostatic) drug, which is subsequently released by slow diffusion into the tissue region surrounding the sphere, This principle of sustained local drug delivery is shown by a series of in vitro experiments on the release of 5-fluorouracil, and in vivo animal experiments, using x-ray fluoroscopic and scintigraphic techniques.	Univ Limburg, Ctr Biomat Res, NL-6200 MD Maastricht, Netherlands; Acad Hosp Maastricht, Dept Nucl Med, NL-6202 AZ Maastricht, Netherlands; Acad Hosp Maastricht, Dept Cardiol, NL-6202 AZ Maastricht, Netherlands	Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Koole, LH (corresponding author), Univ Limburg, Ctr Biomat Res, POB 616, NL-6200 MD Maastricht, Netherlands.							Benzina A, 1996, J BIOMED MATER RES, V32, P459, DOI 10.1002/(SICI)1097-4636(199611)32:3<459::AID-JBM20>3.0.CO;2-A; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; BREM H, 1996, SCI MED, V12, P52; Chasin Mark, 1995, P1; CHIRILA TV, 1993, BIOMATERIALS, V14, P26, DOI 10.1016/0142-9612(93)90072-A; Davy KWM, 1997, POLYM INT, V43, P143, DOI 10.1002/(SICI)1097-0126(199706)43:2<143::AID-PI717>3.0.CO;2-M; Dionne KE, 1996, BIOMATERIALS, V17, P257, DOI 10.1016/0142-9612(96)85563-3; DRENTH W, 1982, KINETICS APPL ORGANI; EATCOCK MM, 1996, CANC CHEMOTHER PHARM, V38, P110; Giovanini MA, 1996, NEUROSURGERY, V39, P404, DOI 10.1097/00006123-199608000-00039; Haaz MC, 1996, CANCER CHEMOTH PHARM, V38, P52, DOI 10.1007/s002800050447; Jain RK, 1996, ANN BIOMED ENG, V24, P457, DOI 10.1007/BF02648108; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; Kruft MAB, 1997, BIOMATERIALS, V18, P31, DOI 10.1016/S0142-9612(96)00085-3; Kruft MAB, 1996, BIOMATERIALS, V17, P1803, DOI 10.1016/0142-9612(95)00339-8; Kruft MAB, 1996, MACROMOLECULES, V29, P5513, DOI 10.1021/ma951399s; KRUFT MAB, 1994, J BIOMED MATER RES, V28, P1259, DOI 10.1002/jbm.820281103; Laurencin Cato T., 1995, P59; Leroux JC, 1996, MICROENCAPSULATION M, P535; MOSZNER N, 1995, ANGEW MAKROMOL CHEM, V224, P115, DOI 10.1002/apmc.1995.052240112; OMMAYA AK, 1984, CANC DRUG DEL, V1, P169, DOI 10.1089/cdd.1984.1.169; TAMADA J, 1992, J BIOM SCI PE, V3, P305; TOGUCHI H, 1992, CLIN THER, V14, P121; WALTER KA, 1995, NEUROSURGERY, V37, P1129, DOI 10.1227/00006123-199512000-00013	25	12	12	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					172	176		10.1038/nbt0298-172	http://dx.doi.org/10.1038/nbt0298-172			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487525				2023-01-03	WOS:000071831300031
J	Madduri, K; Kennedy, J; Rivola, G; Inventi-Solari, A; Filippini, S; Zanuso, G; Colombo, AL; Gewain, KM; Occi, JL; MacNeil, DJ; Hutchinson, CR				Madduri, K; Kennedy, J; Rivola, G; Inventi-Solari, A; Filippini, S; Zanuso, G; Colombo, AL; Gewain, KM; Occi, JL; MacNeil, DJ; Hutchinson, CR			Production of the antitumor drug epirubicin (4 '-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius	NATURE BIOTECHNOLOGY			English	Article						metabolic engineering; antibiotics; fermentation	SACCHAROPOLYSPORA-ERYTHRAEA; DAUNORUBICIN BIOSYNTHESIS; POLYKETIDE SYNTHASE; GENE DISRUPTION; ANTIBIOTICS; CLONING; DOXORUBICIN; 3-O-ACYLTRANSFERASE; THERMOTOLERANS; MANIPULATION	A fermentation method that bypasses the low-yielding semisynthesis of epirubicin (4'-epidoxorubicin) and 4'-epidaunorubicin, important cancer chemotherapy drugs, has been developed for Streptomyces peucetius, This bacterium normally produces the anthracycline antibiotics, doxorubicin and daunorubicin; the 4'-epimeric anthracyclines are formed by introducing the heterologous Streptomyces avermitilis avrE or Saccharopolyspora eryBIV genes into an S. peucetius dnmV mutant blocked in the biosynthesis of daunosamine, the deoxysugar component of these antibiotics. Product yields were enhanced considerably by replacing the chromosomal copy of dnmV with avrE and by introducing further mutations that can increase daunorubicin and doxorubicin yields in the wild-type strain. This method demonstrates that valuable hybrid antibiotics can be made by combinatorial biosynthesis with bacterial deoxysugar biosynthesis genes.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Pharmacia & Upjohn Inc, Tech Operat, I-20014 Milan, Italy; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Mol Pharmacol & Biochem, Rahway, NJ 07065 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pfizer; Merck & Company	Hutchinson, CR (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.		Kennedy, Jonathan/G-5621-2010	MacNeil, Doug/0000-0001-7089-0668; Kennedy, Jonathan/0000-0002-9126-1198	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCAMONE F, 1975, J MED CHEM, V18, P703, DOI 10.1021/jm00241a013; ARISAWA A, 1994, APPL ENVIRON MICROB, V60, P2657, DOI 10.1128/AEM.60.7.2657-2660.1994; BIBB MJ, 1994, MOL MICROBIOL, V14, P533, DOI 10.1111/j.1365-2958.1994.tb02187.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGERDISSEN JJ, 1987, J ANTIBIOT, V40, P165, DOI 10.7164/antibiotics.40.165; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; EPP JK, 1989, GENE, V85, P293, DOI 10.1016/0378-1119(89)90421-6; Gallo MA, 1996, MICROBIOL-UK, V142, P269, DOI 10.1099/13500872-142-2-269; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; HARA O, 1992, J BACTERIOL, V174, P5141, DOI 10.1128/JB.174.15.5141-5144.1992; HILLEMANN D, 1991, NUCLEIC ACIDS RES, V19, P727, DOI 10.1093/nar/19.4.727; Hopwood D.A., 1985, GENETIC MANIPULATION; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; HUTCHINSON CR, 1997, BIOTECHNOLOGY ANTIBI, P683; INVENTISCOLARI A, 1996, Patent No. 27014; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KATZ L, 1995, GENETICS BIOCH ANTIB, P385; Khosla C, 1996, TRENDS BIOTECHNOL, V14, P335, DOI 10.1016/0167-7799(96)10046-9; Kurihara K, 1996, J ANTIBIOT, V49, P582, DOI 10.7164/antibiotics.49.582; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; LOMOVSKAYA N, 1997, PROCESS PREPARING DO; MACNEIL DJ, 1995, GENETICS BIOCH ANTIB, P421; MACPHERSON DF, 1994, MOL MICROBIOL, V11, P281, DOI 10.1111/j.1365-2958.1994.tb00308.x; MADDURI K, 1995, J BACTERIOL, V177, P1208, DOI 10.1128/jb.177.5.1208-1215.1995; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MEURER G, 1995, J BACTERIOL, V177, P477, DOI 10.1128/jb.177.2.477-481.1995; OCCI JL, 1991, ANN M SOC IND MICR P, P93; OTTEN SL, 1995, J BACTERIOL, V177, P6688, DOI 10.1128/jb.177.22.6688-6692.1995; OTTEN SL, 1997, J BACTERIOL, V179, P7316; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; Scotti C, 1996, J BACTERIOL, V178, P7316, DOI 10.1128/jb.178.24.7316-7321.1996; SERVICE RF, 1995, SCIENCE, V270, P724, DOI 10.1126/science.270.5237.724; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; SUARATO A, 1982, Patent No. 4345068; Summers RG, 1997, MICROBIOL-UK, V143, P3251, DOI 10.1099/00221287-143-10-3251; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; WEISS RB, 1992, SEMIN ONCOL, V19, P670; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	130	159	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1998	16	1					69	74		10.1038/nbt0198-69	http://dx.doi.org/10.1038/nbt0198-69			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YP708	9447597				2023-01-03	WOS:000071306000032
J	Reichman, LB				Reichman, LB			Whither Mycobacterium vaccae?	LANCET			English	Editorial Material									New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07107 USA.							[Anonymous], 1993, World Health Forum, V14, P438; AYVAZIAN LF, 1993, TUBERCULOSIS COMPREH, P1; GRANGE JM, 1994, J ROY SOC MED, V87, P272; Kimerling ME, 1999, INT J TUBERC LUNG D, V3, P451; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; 1948, BMJ, V2, P780	8	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					90	90		10.1016/S0140-6736(99)90049-1	http://dx.doi.org/10.1016/S0140-6736(99)90049-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408480				2023-01-03	WOS:000081377100006
J	Polo, O				Polo, O			Continuous positive airway pressure for treatment of sleep apnoea	LANCET			English	Editorial Material							DAYTIME FUNCTION; APNOEA/HYPOPNOEA SYNDROME; CPAP THERAPY		Univ Turku, Dept Physiol, Sleep Res Unit, FIN-20520 Turku, Finland; Univ Turku, Dept Pulm Dis & Clin Allergol, FIN-20520 Turku, Finland	University of Turku; University of Turku	Polo, O (corresponding author), Univ Turku, Dept Physiol, Sleep Res Unit, FIN-20520 Turku, Finland.							Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Engleman HM, 1998, THORAX, V53, P341, DOI 10.1136/thx.53.5.341; Martin SE, 1997, AM J RESP CRIT CARE, V155, P1596, DOI 10.1164/ajrccm.155.5.9154863; POLO O, 1992, ACTA PHYSL SCAN S606, V145, P1; Wright J, 1997, BRIT MED J, V314, P851	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2086	2087		10.1016/S0140-6736(99)99059-1	http://dx.doi.org/10.1016/S0140-6736(99)99059-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382686				2023-01-03	WOS:000080969300002
J	Maxwell, K; Streetly, A; Bevan, D				Maxwell, K; Streetly, A; Bevan, D			Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-SERVICES; CRISIS; PERCEPTIONS; MANAGEMENT; DEPENDENCE; BRITAIN; OPIATES; MODEL	Objective To investigate how sociocultural factors influence management of pain from sickle cell disease by comparing the experiences of those who usually manage their pain at home with those who are more frequently admitted to hospital for management of their pain. Design Qualitative analysis of semistructured individual interviews and focus group discussions. Participants 57 participants with genotype SS or S/beta-thal (44 subjects) or SC (9) (4 were unknown). 40 participants took part in focus groups, six took part in both focus groups and interviews, and nine were interviewed only. Participants were allocated to focus groups according to number of hospital admissions for painful crisis management during the precious year, ethnic origin, and sex. Results The relation between patients with sickle cell disease and hospital services is one of several major non-clinical dimensions shaping experiences of pain management and behaviour for seeking health care. Experiences of hospital care show a range of interrelated themes, which are common to most participants across variables of sex, ethnicity, and hospital attended: mistrust of patients with sickle cell disease; stigmatisation; excessive control (including both over- and undertreatment of pain); and neglect Individuals respond to the challenge of negotiating care with various strategies. Patients with sickle cell disease who are frequently admitted to hospital may try to develop long term relationships with their carers, may become passive or aggressive in their interactions with health professionals, or may regularly attend different hospitals. Those individuals who usually manage their pain at home express a strong sense of self responsibility for their management of pain and advocate self education, assertiveness, and resistance as strategies towards hospital services. Conclusions The current organisation and delivery of management of pain for sickle cell crisis discourage self reliance and encourage hospital dependence. Models of care should recognise the chronic nature of sickle cell disorders and prioritise patients' involvement in their care.	Univ London Kings Coll, Guys Sch Med Dent & Biomed Sci, Dept Publ Hlth Sci, London SE1 3QD, England; Univ London Kings Coll, Kings Sch Med Dent & Biomed Sci, London SE1 3QD, England; Univ London Kings Coll, St Thomass Sch Med Dent & Biomed Sci, London SE1 3QD, England; Univ London St Georges Hosp, Sch Med, Dept Haematol, London SW17 0QT, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; St Georges University London	Streetly, A (corresponding author), Univ London Kings Coll, Guys Sch Med Dent & Biomed Sci, Dept Publ Hlth Sci, London SE1 3QD, England.							ALLEYNE J, 1994, J ADV NURS, V19, P725, DOI 10.1111/j.1365-2648.1994.tb01144.x; Atkin K., 1998, HEALTH, V2, P305; BALLAS SK, 1998, SICKLE CELL PAIN; Black Janet, 1986, LIVING SICKLE CELL D; BROZOVIC M, 1987, BRIT MED J, V294, P1206, DOI 10.1136/bmj.294.6581.1206; *DEP HLTH, 1993, REP WORK PART STAND; DONOVAN JL, 1986, WE DONT BUY SICKNESS; Gignac MAM, 1998, SOC SCI MED, V47, P739, DOI 10.1016/S0277-9536(98)00149-X; Glaster B. G., 1967, THEORETICAL SENSITIV; GOOD MJD, 1992, PAIN HUMAN EXPERIENC, P169; HELMAN CG, 1994, CULTURE HLTH ILLNESS, P171; Konotey-Ahulu FID, 1998, LANCET, V351, P1438, DOI 10.1016/S0140-6736(05)79487-3; Layton DM, 1998, LANCET, V351, P1964, DOI 10.1016/S0140-6736(05)78656-6; LAYZELL S, 1992, AIDS CARE, V4, P203, DOI 10.1080/09540129208253091; Lorig K, 1996, AM BEHAV SCI, V39, P676, DOI 10.1177/0002764296039006005; MURRAY N, 1988, BRIT MED J, V297, P452, DOI 10.1136/bmj.297.6646.452; Olujohungbe A, 1998, BRIT MED J, V316, P1689, DOI 10.1136/bmj.316.7146.1689; ONeill B, 1997, BRIT MED J, V315, P801, DOI 10.1136/bmj.315.7111.801; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Serjeant G R, 1995, Curr Opin Hematol, V2, P103; SHAPIRO B, 1990, ADV PAIN RES THER, P313; Shapiro BS, 1997, J PAIN SYMPTOM MANAG, V14, P168, DOI 10.1016/S0885-3924(97)00019-5; STREETLY A, 1993, BRIT MED J, V306, P1491, DOI 10.1136/bmj.306.6891.1491; STREETLY A, 1997, SICKLE CELL DISORDER; WALDROP RD, 1995, AM J EMERG MED, V13, P529, DOI 10.1016/0735-6757(95)90163-9; Westerman MP, 1997, AM J HEMATOL, V54, P183, DOI 10.1002/(SICI)1096-8652(199703)54:3<183::AID-AJH2>3.0.CO;2-S	27	104	105	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1585	1590		10.1136/bmj.318.7198.1585	http://dx.doi.org/10.1136/bmj.318.7198.1585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207AL	10364116	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000080913100028
J	Smith, G; Nielsen, M				Smith, G; Nielsen, M			ABC of intensive care - Criteria for admission	BRITISH MEDICAL JOURNAL			English	Article									Queen Alexandra Hosp, Portsmouth, Hants, England; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Southampton	Smith, G (corresponding author), Queen Alexandra Hosp, Portsmouth, Hants, England.								0	57	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1544	1547		10.1136/bmj.318.7197.1544	http://dx.doi.org/10.1136/bmj.318.7197.1544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356016	Green Published			2023-01-03	WOS:000080757300034
J	Ashburn, MA; Staats, PS				Ashburn, MA; Staats, PS			Management of chronic pain	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHRONIC NONMALIGNANT PAIN; GABAPENTIN; NEUROPATHY; EFFICACY; PROGRAM	Chronic pain is a common condition for which patients seek care from various health-care providers. This type of pain causes much suffering and disability and is frequently mistreated or undertreated. Patients who present for evaluation for chronic pain should undergo a careful assessment before therapy. Patients with chronic pain commonly experience depression, sleep disturbance, fatigue, and decreased overall physical and mental functioning. They frequently require an interdisciplinary model of care to allow care givers to address the multiple components of the patient's pain experience. After a careful evaluation, therapy may include medication, nerve blocks, active physical therapy, behavioural interventions, and assistance with vocational evaluation and training. Less frequently therapy may include placement of implantable devices to alter the pain experience. these patients suffer from a chronic condition and often require long-term care, with frequent reassessment and adjustment of therapy. Although cure is possible, it is also infrequent. Therefore, therapy is provided with the aim of decreasing pain and suffering while improving physical and mental functioning.	Univ Utah, Hlth Sci Ctr, Dept Anesthesiol, Salt Lake City, UT 84132 USA; Johns Hopkins Univ, Pain Management Ctr, Dept Anesthesiol, Baltimore, MD USA	Utah System of Higher Education; University of Utah; Johns Hopkins University	Ashburn, MA (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Anesthesiol, Salt Lake City, UT 84132 USA.							ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; ASHBURN M, 1999, ACUTE PAIN CONTROL, V6, P10; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; BONICA JJ, 1991, ANIMAL PAIN, P1; Bove G, 1998, JAMA-J AM MED ASSOC, V280, P1576, DOI 10.1001/jama.280.18.1576; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; *FED STAT MED BOAR, 1998, FED STAT MED BOARDS; Feine JS, 1997, PAIN, V71, P5, DOI 10.1016/S0304-3959(96)03287-3; FORDYCE WE, 1973, ARCH PHYS MED REHAB, V54, P399; FRICTON JR, 1995, OROFASCIAL PAIN TEMP, P485; Garfinkel MS, 1998, JAMA-J AM MED ASSOC, V280, P1601, DOI 10.1001/jama.280.18.1601; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GUPTA MA, 1999, PRACTICAL MANAGEMENT; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Hill PA, 1996, PAIN CLINIC, V9, P181; Hubbard JE, 1996, CLIN J PAIN, V12, P330, DOI 10.1097/00002508-199612000-00013; Jacobson L, 1997, ANESTHESIOLOGY, V87, P1210, DOI 10.1097/00000542-199711000-00026; JANFAZA D, 1988, ANESTHESIOL ANALG, V87, P1242; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; LIPMAN A, 1998, MANAGEMENT PAIN, P99; Loeser J., 1990, MANAGEMENT PAIN, P2040; Long SP, 1998, MANAGEMENT PAIN, P299; OAKLEY J, 1999, PRACTICAL MANAGEMENT; ONGHENA P, 1992, PAIN, V49, P205, DOI 10.1016/0304-3959(92)90144-Z; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; STAATS P, 1997, PROGR ANESTHESIOL, V19, P367; Staats PS, 1996, PAIN FORUM, V5, P194; SWERDLOW M, 1984, CLIN NEUROPHARMACOL, V7, P51, DOI 10.1097/00002826-198403000-00003; TURK DC, 1996, ADULT SPINE PRINCIPL, P253; TURK DC, 1998, MANAGEMENT PAIN, P235; Winkelmuller M, 1996, J NEUROSURG, V85, P458, DOI 10.3171/jns.1996.85.3.0458; WOOLF CJ, IN PRESS LANCET	37	171	188	1	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1865	1869		10.1016/S0140-6736(99)04088-X	http://dx.doi.org/10.1016/S0140-6736(99)04088-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359427				2023-01-03	WOS:000080667800045
J	Lo, B; Quill, T; Tulsky, J				Lo, B; Quill, T; Tulsky, J		ACP ASIM End Life Care Consensus Panel	Discussing palliative care with patients	ANNALS OF INTERNAL MEDICINE			English	Article							TERMINALLY ILL; DEPRESSION; PHYSICIANS; AUTONOMY	Palliative care focuses on relief of suffering, psychosocial support, and closure near the end of life. Even experienced physicians often struggle when initiating complex, emotionally laden discussions about palliative care with seriously ill patients and their families. We use two hypothetical case scenarios to illustrate how physicians can initiate these discussions and to emphasize and illustrate several communication techniques. Physicians can elicit a patient's concerns, goals, and values by using open-ended questions and following up on the patient's response before discussing specific clinical decisions. Physicians can acknowledge patients' emotions, explore the meaning of these emotions, and encourage patients to say more about difficult topics. Physicians should also screen for unaddressed spiritual and existential concerns. Some patients may make statements or ask questions that are difficult for physicians to respond to. We provide examples of responses that align the physician with patients' wishes without reinforcing unrealistic plans. Exploring such difficult issues may lessen feelings of aloneness even when the physician cannot "fix" the problem, and it raises new opportunities for patients to find comfort. In addition to addressing physical suffering, physicians can extend their caring by acknowledging and exploring psychosocial, existential, or spiritual suffering. As patients struggle to find closure in their lives, active listening and empathy have therapeutic value in and of themselves.	Amer Soc Internal Med, Amer Coll Phys, Ctr Eth Professionalism, Philadelphia, PA 19106 USA	American College of Physicians	Lo, B (corresponding author), Amer Soc Internal Med, Amer Coll Phys, Ctr Eth Professionalism, 190 N Independence Mall W, Philadelphia, PA 19106 USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; BUCKMAN R, 1992, BREAK BAD NEWS, P98; Byock I, 1997, DYING WELL PROSPECT; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Doyle D, 1998, OXFORD TXB PALLIATIV; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 1998, OXFORD TXB PALLIATIV, P310; KATHOL RG, 1990, AM J PSYCHIAT, V147, P1021; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lipkin M, 1995, MED INTERVIEW; LO B, 1995, RESOLVING ETHICAL DI, P158; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MONROE B, 1998, OXFORD TXB PALLIATIV, P867; *N CUMM FDN FETZ I, 1997, SPIR BEL DYING PROC; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Speck P., 1998, OXFORD TXB PALLIATIV, P805; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003	26	198	201	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					744	749		10.7326/0003-4819-130-9-199905040-00015	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00015			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357694				2023-01-03	WOS:000080062300006
J	Nelson, JE				Nelson, JE			Saving lives and saving deaths	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									CUNY Mt Sinai Sch Med, Med Intens Care Unit, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nelson, JE (corresponding author), CUNY Mt Sinai Sch Med, Med Intens Care Unit, Box 1232,1 Gustave L Levy Pl, New York, NY 10029 USA.	jnelson@smtplink.mssm.edu							0	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					776	777		10.7326/0003-4819-130-9-199905040-00020	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357699				2023-01-03	WOS:000080062300011
J	Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP				Goodnough, LT; Brecher, ME; Kanter, MH; AuBuchon, JP			Medical progress - Transfusion medicine (First of two parts) - Blood transfusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; ACUTE LUNG INJURY; NON-B-HEPATITIS; UNITED-STATES; COLORECTAL-CANCER; TRANSMITTED VIRUSES; CELL TRANSFUSIONS; CONTROLLED TRIAL; OXYGEN DELIVERY		Washington Univ, Sch Med, Dept Med, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC USA; So Calif Permanente Med Grp, Dept Pathol, Woodland Hills, CA USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA	Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Dartmouth College	Goodnough, LT (corresponding author), Washington Univ, Sch Med, Dept Med, Div Lab Med, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.							AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1992, HEPATOLOGY, V15, P350, DOI 10.1002/hep.1840150228; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; AMMANN AJ, 1983, LANCET, V1, P956; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1983, TRANSFUSION, V23, P87; ATLAS SJ, 1994, TRANSFUSION, V34, P386, DOI 10.1046/j.1537-2995.1994.34594249048.x; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; AuBuchon JP, 1996, TRANSFUSION, V36, P222, DOI 10.1046/j.1537-2995.1996.36396182139.x; Audet AM, 1998, ORTHOPEDICS, V21, P851; Audet AM, 1996, INT J QUAL HEALTH C, V8, P41, DOI 10.1093/intqhc/8.1.41; BARNETTE RE, 1990, TRANSFUSION, V30, P253, DOI 10.1046/j.1537-2995.1990.30390194348.x; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BORDIN JO, 1994, BLOOD, V84, P1703; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1997, APPL MOL BIOL BLOOD, P123; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; Calder L, 1997, CAN MED ASSOC J, V156, pS1; *CAN COORD OFF HLT, 1998, LEUK TECHN US THEIR; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Carson JL, 1998, JAMA-J AM MED ASSOC, V279, P199, DOI 10.1001/jama.279.3.199; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P81; Centers for Disease Control (CDC), 1983, MMWR Morb Mortal Wkly Rep, V32, P101; Centers for Disease Control (CDC), 1989, MMWR-MORBID MORTAL W, V38, p[81, 93]; CHIU EKW, 1994, TRANSFUSION, V34, P950, DOI 10.1046/j.1537-2995.1994.341195065031.x; Churchill WH, 1998, TRANSFUSION, V38, P530, DOI 10.1046/j.1537-2995.1998.38698326332.x; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Cookson ST, 1996, 36 INT C ANT AG CHEM, P237; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DOMEN RE, 1995, TRANSFUS MED REV, V9, P53, DOI 10.1016/S0887-7963(05)80030-6; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; FRIEDMAN BA, 1980, TRANSFUSION, V20, P179, DOI 10.1046/j.1537-2995.1980.20280169958.x; Garratty G, 1997, TRANSFUSION, V37, P357, DOI 10.1046/j.1537-2995.1997.37497265334.x; GATENBY PA, 1993, AM J REPROD IMMUNOL, V29, P88, DOI 10.1111/j.1600-0897.1993.tb00571.x; GIMBLE JG, 1992, TRANSFUSION, V32, P446, DOI 10.1046/j.1537-2995.1992.32592327719.x; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; GOODNOUGH LT, 1993, AM J MED, V94, P509, DOI 10.1016/0002-9343(93)90086-5; GOODNOUGH LT, 1994, TRANSFUSION MED, V4, P35, DOI 10.1111/j.1365-3148.1994.tb00241.x; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; GOODNOUGH LT, 1995, ANN THORAC SURG, V60, P473, DOI 10.1016/0003-4975(95)98960-3; GOODNOUGH LT, 1992, TRANSFUSION, V32, P838; GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V274, P944; HEISS MM, 1994, J CLIN ONCOL, V12, P1859, DOI 10.1200/JCO.1994.12.9.1859; Hewlett IK, 1997, TRANSFUSION, V37, P346, DOI 10.1046/j.1537-2995.1997.37397240219.x; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; HJELLE B, 1993, BLOOD, V81, P1641; HOELTGE GA, 1989, CLEV CLIN J MED, V56, P267, DOI 10.3949/ccjm.56.3.267; Hogue CW, 1998, TRANSFUSION, V38, P924, DOI 10.1046/j.1537-2995.1998.381098440856.x; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; Jensen NJ, 1996, TRANSFUSION, V36, P216, DOI 10.1046/j.1537-2995.1996.36396182138.x; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kanno M, 1998, NEW ENGL J MED, V338, P333, DOI 10.1056/NEJM199801293380513; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIM DM, 1992, TRANSFUSION, V32, P221, DOI 10.1046/j.1537-2995.1992.32392213804.x; Klein HG, 1997, TRANSFUSION, V37, P95, DOI 10.1046/j.1537-2995.1997.37197176958.x; Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Lam HTC, 1996, ARCH PATHOL LAB MED, V120, P810; LENFANT C, 1992, TRANSFUSION, V32, P873, DOI 10.1046/j.1537-2995.1992.32993110764.x; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; Linden JV, 1997, TRANSFUSION, V37, P243, DOI 10.1046/j.1537-2995.1997.37297203534.x; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LUBAN NLC, 1994, TRANSFUSION, V34, P821, DOI 10.1046/j.1537-2995.1994.34994378286.x; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Opelz G, 1997, TRANSPLANTATION, V63, P964, DOI 10.1097/00007890-199704150-00010; Pau CP, 1996, TRANSFUSION, V36, P398, DOI 10.1046/j.1537-2995.1996.36596282582.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; PILIAVIN JA, 1990, TRANSFUSION, V30, P444, DOI 10.1046/j.1537-2995.1990.30590296381.x; PINDYCK J, 1987, JAMA-J AM MED ASSOC, V257, P1186, DOI 10.1001/jama.257.9.1186; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; *PROV PUBL HLTH SE, 1985, MMWR-MORBID MORTAL W, V34, P1; RAO TLK, 1985, ANESTHESIOLOGY REV, V12, P49; ROYSE D, 1995, TRANSFUSION, V35, P826, DOI 10.1046/j.1537-2995.1995.351096026363.x; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Schreiber GB, 1998, TRANSFUSION, V38, p114S; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SHULMAN IA, 1990, ARCH PATHOL LAB MED, V114, P412; Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x; SILVERGLEID AJ, 1989, TRANSFUSION, V29, P362, DOI 10.1046/j.1537-2995.1989.29489242806.x; SIMPSON MB, 1987, TRANSFUSION, V27, P192, DOI 10.1046/j.1537-2995.1987.27287150198.x; Spiess BD, 1998, J THORAC CARDIOV SUR, V116, P460, DOI 10.1016/S0022-5223(98)70012-1; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; Stramer SL, 1997, TRANSFUSION, V37, pS1; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1992, TRANSFUSION, V32, P876; Surgenor DM, 1998, TRANSFUSION, V38, P122, DOI 10.1046/j.1537-2995.1998.38298193094.x; SURGENOR DM, 1991, TRANSFUSION, V31, P531, DOI 10.1046/j.1537-2995.1991.31691306252.x; Theakston EP, 1997, AUST NZ J MED, V27, P62, DOI 10.1111/j.1445-5994.1997.tb00916.x; Thomson RA, 1998, TRANSFUSION, V38, P359, DOI 10.1046/j.1537-2995.1998.38498257374.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TOY PTCY, 1994, ARCH PATHOL LAB MED, V118, P435; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; Valeri CR, 1998, TRANSFUSION, V38, P602, DOI 10.1046/j.1537-2995.1998.38698326341.x; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; Vamvakas EC, 1996, TRANSFUS MED REV, V10, P44, DOI 10.1016/S0887-7963(96)80122-2; Vamvakas EC, 1996, TRANSFUSION, V36, P175, DOI 10.1046/j.1537-2995.1996.36296181932.x; van de Watering LMG, 1998, CIRCULATION, V97, P562; VRIELINK H, 1995, TRANSFUSION, V35, P601, DOI 10.1046/j.1537-2995.1995.35795357885.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; Warner DO, 1998, TRANSFUSION, V38, P738, DOI 10.1046/j.1537-2995.1998.38898375512.x; 1997, MMWR MORB MORTAL WKL, V46, P553; 1995, MMWR MORB MORTAL WKL, V44, P603; 1988, MMWR MORB MORTAL WKL, V37, P745; 1982, MMWR MORB WKLY REP, V31, P652; 1988, MMWR MORB MORTAL WKL, V37, P736	122	651	676	5	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					438	447		10.1056/NEJM199902113400606	http://dx.doi.org/10.1056/NEJM199902113400606			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971869				2023-01-03	WOS:000078571000006
J	Ezzo, J; Berman, BM; Vickers, AJ; Linde, K				Ezzo, J; Berman, BM; Vickers, AJ; Linde, K			Complementary medicine and the Cochrane Collaboration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYSTEMATIC REVIEWS; CONTROLLED TRIALS; CEREBRAL INSUFFICIENCY; ALTERNATIVE MEDICINE; GINKGO-BILOBA; METAANALYSES; PREVALENCE; ENGLISH; QUALITY; BIAS		Univ Maryland, Sch Med, Complementary Med Program, Baltimore, MD 21207 USA; Res Council Complementary Med, London, England; Tech Univ, Ctr Complementary Med Res, Munich, Germany	University System of Maryland; University of Maryland Baltimore; Technical University of Munich	Ezzo, J (corresponding author), Univ Maryland, Sch Med, Complementary Med Program, Kernan Hosp Mans,2200 Kernan Dr, Baltimore, MD 21207 USA.	jezzo@compmed.ummc.ab.umd.edu		Linde, Klaus/0000-0002-2902-970X				BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; *COMPL MED FIELD M, 1998, COCHR LIBR; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Dickersin K, 1998, CLIN OBSTET GYNECOL, V41, P315, DOI 10.1097/00003081-199806000-00012; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1997, SYSTEMATATIC REV, P17; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FISHBAIN DA, 1995, NIH TECHN ASS INT BE; FULDER SJ, 1985, LANCET, V2, P542; HOFMANS EA, 1990, LANCET, V336, P57, DOI 10.1016/0140-6736(90)91574-T; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; Kiley R, 1997, J ROY SOC MED, V90, P610, DOI 10.1177/014107689709001105; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KNIPSCHILD P, 1993, LANCET, V341, P1135, DOI 10.1016/0140-6736(93)93140-V; LEHMANN HP, 1995, MED DECIS MAKING, V15, P424; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MADDOCKS I, 1985, MED J AUSTRALIA, V142, P547, DOI 10.5694/j.1326-5377.1985.tb113490.x; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; WOOTTON JC, 1997, J ALTERN COMPLEM MED, V2, P261; 1998, COCHRANE LIBR	30	34	35	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1628	1630		10.1001/jama.280.18.1628	http://dx.doi.org/10.1001/jama.280.18.1628			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820271				2023-01-03	WOS:000076852000037
J	Potter, J; Langhorne, P; Roberts, M				Potter, J; Langhorne, P; Roberts, M			Routine protein energy supplementation in adults: Systematic review	BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CLINICAL-TRIAL; NUTRITIONAL SUPPORT; BODY-COMPOSITION; ELDERLY PATIENTS; DIETARY SUPPLEMENTATION; MUSCLE FUNCTION; MALNOURISHED PATIENTS; ENTERAL NUTRITION; IMMUNE FUNCTION		Victoria Infirm NHS Trust, Victoria Geriatr Unit, Glasgow G41 3DX, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm Trust, Dept Med, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Potter, J (corresponding author), Vicroria Infirm NHS Trust, Dept Med Elderly, Mansionhouse Unit, Glasgow G41 3DX, Lanark, Scotland.							Allison SP, 1995, HOSP UPDATE      FEB, P55; BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; Bracken Michael B., 1992, P13; BUNKER VW, 1994, BRIT J BIOMED SCI, V51, P128; BUNOUT D, 1989, EUR J CLIN NUTR, V43, P615; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; Chalmers I, 1995, SYSTEMATIC REV; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHANDRA RK, 1985, BRIT MED J, V291, P705, DOI 10.1136/bmj.291.6497.705; CHANDRA RK, 1990, AGE AGEING, V19, P25; CHIARELLI A, 1990, AM J CLIN NUTR, V51, P1035, DOI 10.1093/ajcn/51.6.1035; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EFTHIMIOU J, 1988, AM REV RESPIR DIS, V137, P1075, DOI 10.1164/ajrccm/137.5.1075; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ELKORT RJ, 1981, JPEN-PARENTER ENTER, V5, P385, DOI 10.1177/0148607181005005385; EVANS WK, 1987, J CLIN ONCOL, V5, P113, DOI 10.1200/JCO.1987.5.1.113; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1993, J GERONTOL, V48, P77, DOI 10.1093/geronj/48.Special_Issue.77; GALANOS AN, 1994, J AM GERIATR SOC, V42, P368, DOI 10.1111/j.1532-5415.1994.tb07483.x; Ganzoni A, 1994, Schweiz Rundsch Med Prax, V83, P13; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HANKEY CR, 1993, J HUM NUTR DIET, V6, P317, DOI 10.1111/j.1365-277X.1993.tb00377.x; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V36, P680, DOI 10.1093/ajcn/36.4.680; Hwang T L, 1991, J Formos Med Assoc, V90, P993; JEBB SA, 1993, AM J CLIN NUTR, V58, P455, DOI 10.1093/ajcn/58.4.455; KELLY SM, 1984, AM REV RESPIR DIS, V130, P33; KLIPSTEINGROBUSCH K, 1995, BRIT J NUTR, V73, P323, DOI 10.1079/BJN19950033; KNOWLES JB, 1988, CHEST, V93, P979; LARSSON J, 1990, CLIN NUTR, V9, P179, DOI 10.1016/0261-5614(90)90017-M; Lennard-Jones J E, 1992, POSITIVE APPROACH NU; LESOURD B, 1995, NUTR REV, V53, pS86; LEWIS MI, 1987, AM REV RESPIR DIS, V135, P1062; LOPES J, 1982, AM J CLIN NUTR, V36, P602, DOI 10.1093/ajcn/36.4.602; MARCIA E, 1991, NUTRITION, V7, P205; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; MEREDITH CN, 1992, J AM GERIATR SOC, V40, P155, DOI 10.1111/j.1532-5415.1992.tb01937.x; NAYAL H, 1992, NUTRITION, V8, P13; Olin AO, 1996, JPEN-PARENTER ENTER, V20, P93, DOI 10.1177/014860719602000293; OTTE KE, 1989, JPEN-PARENTER ENTER, V13, P152, DOI 10.1177/0148607189013002152; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POTTER J, 1995, AGE AGEING, V24, P131, DOI 10.1093/ageing/24.2.131; RANA SK, 1992, CLIN NUTR, V11, P337, DOI 10.1016/0261-5614(92)90084-4; REILLY JJ, 1994, BRIT J NUTR, V72, P33, DOI 10.1079/BJN19940007; ROEBOTHAN BV, 1994, AGE AGEING, V23, P49, DOI 10.1093/ageing/23.1.49; ROGERS RM, 1992, AM REV RESPIR DIS, V146, P1511, DOI 10.1164/ajrccm/146.6.1511; RUSSELL DM, 1983, AM J CLIN NUTR, V38, P229, DOI 10.1093/ajcn/38.2.229; SAGAR S, 1979, BMJ-BRIT MED J, V1, P293, DOI 10.1136/bmj.1.6159.293; SCHOLS AMWJ, 1995, AM J RESP CRIT CARE, V152, P1268, DOI 10.1164/ajrccm.152.4.7551381; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; SHULKA HS, 1984, INDIAN J MED RES, V80, P339; SHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408; SMITH RC, 1985, BRIT J SURG, V72, P458, DOI 10.1002/bjs.1800720619; Souba WW, 1996, BRIT MED J, V312, P864; SPIRTOS NM, 1988, AM J OBSTET GYNECOL, V158, P1285, DOI 10.1016/0002-9378(88)90358-4; VIR CS, 1980, GERONTOLOGY, V1, P3; VONMEYENFELDT MF, 1992, CLIN NUTR, V11, P180, DOI 10.1016/0261-5614(92)90026-M; WHITTAKER JS, 1990, AM REV RESPIR DIS, V142, P283, DOI 10.1164/ajrccm/142.2.283; WINDSOR JA, 1988, ANN SURG, V208, P209, DOI 10.1097/00000658-198808000-00013; WOO J, 1994, AGE AGEING, V23, P40, DOI 10.1093/ageing/23.1.40	61	134	135	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					495	501						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712593	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000075641400015
J	Pal, B				Pal, B			Following up outpatients by telephone: pilot study	BRITISH MEDICAL JOURNAL			English	Article									S Manchester Univ Hosp NHS Trust, Withington Hosp, Manchester M20 2LR, Lancs, England	Wythenshawe Hospital NHS Foundation Trust	Pal, B (corresponding author), S Manchester Univ Hosp NHS Trust, Withington Hosp, Manchester M20 2LR, Lancs, England.	bpal@fs1.with.man.ac.uk						HALLAM L, 1991, BRIT MED J, V302, P629, DOI 10.1136/bmj.302.6777.629; Lattimer V, 1997, BRIT MED J, V314, P198; PAL B, 1996, BR J RHEUMATOL S1, V35, pA250; RAO JN, 1994, BRIT MED J, V309, P1527, DOI 10.1136/bmj.309.6968.1527; Wootton R, 1996, BRIT MED J, V313, P1375, DOI 10.1136/bmj.313.7069.1375	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1647	1647		10.1136/bmj.316.7145.1647	http://dx.doi.org/10.1136/bmj.316.7145.1647			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603747	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000074022700024
J	O'Neill, J				O'Neill, J			A peaceful death	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					327	327		10.1136/bmj.319.7205.327	http://dx.doi.org/10.1136/bmj.319.7205.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426772	Green Published			2023-01-03	WOS:000081909100069
J	Maisonneuve, P; Agodoa, L; Gellert, R; Stewart, JH; Buccianti, G; Lowenfels, AB; Wolfe, RA; Jones, E; Disney, APS; Briggs, D; McCredie, M; Boyle, P				Maisonneuve, P; Agodoa, L; Gellert, R; Stewart, JH; Buccianti, G; Lowenfels, AB; Wolfe, RA; Jones, E; Disney, APS; Briggs, D; McCredie, M; Boyle, P			Cancer in patients on dialysis for end-stage renal disease: an international collaborative study	LANCET			English	Article							CELL CARCINOMA; TRANSPLANT RECIPIENTS; HEMODIALYSIS-PATIENTS; KIDNEY-DISEASE; INFECTION; RISK; REGISTRY	Background Previous studies have suggested that the frequency of cancer is higher in patients with end-stage renal disease (ESRD) than in the general population, but have not established whether this increase is confined to certain cancers or to certain categories of ESRD patients. The aim of this study was to examine the risk of cancer in a large cohort of patients treated by dialysis but not transplantation. Methods We assembled a cohort of 831 804 patients who received dialysis during the period 1980-94 for ESRD in the USA, Europe, Australia, or New Zealand. We compared the observed frequency ol: cancer among these patients during 2 045 035 person-years of follow-up with the frequency of cancer in the respective background populations. Findings During average follow-up of 2.5 years, 25 044 (3%) of 831 804 patients developed cancer compared with an expected number of 21 185 (standardised incidence ratio 1.18 [95% CI 1.17-1.20]). We observed a higher risk of cancer in patients younger than 35 years (3.68 [3.39-3.99]), and the risk gradually decreased with increasing age. High risks were observed for cancer of the kidney (3.60 [3.45-3.76]), bladder (1.50 [1.42-1.57]), and thyroid and other endocrine organs (2.28 [2.03-2.54]). Excess cancers appeared in several organs for which viruses have been suspected as causative agents, whereas cancers of the lung, colorectum, prostate. breast, and stomach were not consistently increased. Interpretation The overall risk of cancer is increased in patients with ESRD, and the distribution of tumour types resembles the pattern seen after transplantation (although we have no data to make the comparison with skin cancer). The excess risk can largely be ascribed to effects df underlying renal or urinary-tract disease, or of loss of renal function, on the kidney and bladder, and to increased susceptibility to viral carcinogenesis. The relative risk, which is especially high in younger patients, gradually diminishes with age.	European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy; NIDDKD, Div Kidney Urol & Hematol Dis, Bethesda, MD 20892 USA; CSK AM Banacha, Dept Internal Med & Nephrol, Warsaw, Poland; Univ Otago, Dept Med, Dunedin, New Zealand; Hosp E Bassini San Gerardo, Dept Nephrol & Dialysis, Monza, Italy; New York Med Coll, Valhalla, NY 10595 USA; Univ Michigan, USRDS Coordinating Ctr, Ann Arbor, MI 48109 USA; ERA EDTA Registry, London, England; ANZDATA Registry, Adelaide, SA, Australia; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Otago; New York Medical College; University of Michigan System; University of Michigan; University of Otago; Cancer Council New South Wales	Maisonneuve, P (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, Via Ripamonti 435, I-20141 Milan, Italy.	pmaison@ieo.it	Boyle, Peter/A-4380-2014; Maisonneuve, Patrick/U-9789-2018; Lowenfels, Albert/ABD-8388-2021; Gellert, Ryszard/F-4604-2010	Boyle, Peter/0000-0001-6251-0610; Maisonneuve, Patrick/0000-0002-5309-4704; Gellert, Ryszard/0000-0001-9382-0734				Adami HO, 1996, J NATL CANCER I, V88, P1472, DOI 10.1093/jnci/88.20.1472; Beutner Karl R., 1997, American Journal of Medicine, V102, P9; BRUNNER FP, 1995, NEPHROL DIAL TRANSPL, V10, P74, DOI 10.1093/ndt/10.supp1.74; Buccianti G, 1996, INT J CANCER, V66, P591, DOI 10.1002/(SICI)1097-0215(19960529)66:5<591::AID-IJC1>3.3.CO;2-W; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Cuckovic C, 1996, NEPHRON, V73, P710; DEVILLIERS EM, 1985, INT J CANCER, V36, P575, DOI 10.1002/ijc.2910360510; DISNEY APS, ANZDATA REGISTRY REP; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; Flattery M P, 1998, J Transpl Coord, V8, P105; INAMOTO H, 1991, NEPHRON, V59, P611, DOI 10.1159/000186652; ISEKI K, 1993, AM J KIDNEY DIS, V22, P308, DOI 10.1016/S0272-6386(12)70323-2; ISHIKAWA I, 1990, AM J KIDNEY DIS, V16, P452, DOI 10.1016/S0272-6386(12)80058-8; KANTOR AF, 1987, AM J EPIDEMIOL, V126, P370, DOI 10.1093/oxfordjournals.aje.a114668; KEITH DS, 1994, J AM SOC NEPHROL, V4, P1661; LEVINE E, 1992, UROL RADIOL, V13, P203; LORNOY W, 1986, LANCET, V1, P1271; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; MARPLE JT, 1994, J AM SOC NEPHROL, V4, P1951; *NCI, 1997, SURV EP END RES; NIU MT, 1993, AM J KIDNEY DIS, V22, P568, DOI 10.1016/S0272-6386(12)80930-9; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; PECQUEUX JC, 1990, UROL INT, V45, P290, DOI 10.1159/000281722; Penn I, 1994, Clin Transpl, P99; POPE JC, 1994, UROLOGY, V44, P497, DOI 10.1016/S0090-4295(94)80046-4; PORT FK, 1989, AM J KIDNEY DIS, V14, P119, DOI 10.1016/S0272-6386(89)80187-8; RAGHEB NE, 1991, SEMIN DIALYSIS, V4, P253, DOI 10.1111/j.1525-139X.1991.tb00104.x; SHEIL AGR, 1985, TRANSPLANT P, V17, P1685; *USRDS, 1997, NIH PUBL; Vamvakas S, 1998, AM J NEPHROL, V18, P89, DOI 10.1159/000013314; Winkelspecht B, 1997, NEPHROL DIAL TRANSPL, V12, P2099, DOI 10.1093/ndt/12.10.2099; YAMAMOTO T, 1995, NEPHRON, V70, P449, DOI 10.1159/000188644	32	625	647	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1999	354	9173					93	99		10.1016/S0140-6736(99)06154-1	http://dx.doi.org/10.1016/S0140-6736(99)06154-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408483				2023-01-03	WOS:000081377100010
J	Abe, O; Abe, R; Enomoto, K; Kikuchi, K; Koyama, H; Nomura, Y; Sakai, K; Sugimachi, K; Tominaga, T; Uchino, J; Yoshida, M; Benraadt, J; van de Velde, AO; van Dongen, JA; Vermorken, JB; Giokas, G; Lissaios, B; Harvey, VJ; Holdaway, TM; Kay, RG; Mason, BH; Coates, A; Forbes, JF; Focan, C; Lobelle, JP; Gates, GD; Powell, J; Durand, M; Mauriac, L; Bartholomeus, S; Piccart, MJ; Gelman, RS; Henderson, IC; Shapiro, CL; Hancock, AK; Masood, MB; Parker, D; Price, JJ; Jackson, S; Ragaz, J; Delozier, T; Mace-Lesec'h, J; Haybittle, JL; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Baum, M; Houghton, J; Riley, D; Dent, DM; Gudgeon, CA; Hacking, A; Gordon, NH; Davis, HL; Romestaing, P; Lehingue, Y; Owen, JR; Meier, P; Howell, A; Ribeiro, GC; Swindell, R; Albano, J; de Oliveira, CF; Gervasio, H; Gordilho, J; Carstensen, B; Palshof, T; Johansen, H; Korzeniowski, S; Skolyszewski, J; Portnoj, SM; Andersen, KW; Axelsson, CK; Blichert-Toft, M; Mouridsen, HT; Overgaard, M; Rose, C; Corcoran, N; Trampisch, HJ; Comis, RL; Davidson, NE; Gray, R; Robert, N; Tormey, DC; Wood, W; Chetty, U; Forrest, P; Jack, W; Rossbach, J; Sylvester, RJ; van de Velde, CJH; Cunningham, MP; Bonneterre, J; Fumoleau, P; Namer, M; Bastert, G; Rauschecker, H; Sauer, R; Sauerbrei, W; Schauer, A; Schumacher, M; de Schryver, A; Belfiglio, M; Mari, E; Nicolucci, A; Scorpiglione, N; Yosef, HMA; McArdle, CS; Smith, DC; Lara, PC; Boccardo, F; Rubagotti, A; Erazo, A; Medina, JY; Izuo, M; Morishita, Y; Bentley, A; Doran, Z; Fentiman, IS; Hayward, JL; Rubens, RD; Kaufmann, M; Jonat, W; Scheurlen, H; von Fournier, D; Fountzilas, G; Klafstrom, P; Blomqvist, C; Cuzick, J; Margreiter, R; Castiglione, M; Cavilli, F; Collins, J; Forbes, J; Gelber, RD; Goldhirsch, A; Lindtner, J; Price, KN; Rudenstam, CM; Senn, HJ; Bliss, JM; Chilvers, CED; Coombes, RC; Marty, M; Borovik, R; Brufman, G; Hayat, H; Robinson, E; Wigler, N; Pannuti, F; Takashima, S; Yasutomi, T; Sonoo, H; Yamashita, J; Ogawa, M; Welvaart, K; Hupperets, PSGJ; Bonte, J; Tengrup, I; Tennvall-Nittby, L; Martin, P; Romain, S; Ingle, JN; Suman, VJ; Buzdar, AU; Smith, T; Hakes, T; Wittes, R; de la Huerta, R; Sainz, MG; Bonadonna, G; del Vecchio, M; Valagussa, P; Veronesi, U; Dubois, JB; Bianco, AR; Lippman, ME; Pierce, LJ; Simon, R; Steinberg, SM; Myles, JD; Pater, JL; Pritchard, KI; Anderson, S; Brown, A; Bryant, J; Costantino, J; Dignam, J; Fisher, B; Redmond, C; Wieand, S; Wolmark, N; Jackson, IM; Palmer, MK; Bengtsson, NO; Larsson, LG; Lythgoe, JP; Kissin, M; Hannisdal, E; Varhaug, JE; Nissen-Meyer, R; Blamey, RW; Mitchell, AK; Robertson, JFR; Ueo, H; Mathe, G; Misset, JL; Abu-Zahra, HT; Clarke, EA; McLaughlin, JR; Clark, RM; Levine, M; Morimoto, K; Sawa, K; Takatsuka, Y; Gundersen, S; Hauer-Jensen, M; Host, H; Crossley, E; Harris, A; Beighton, A; Clarke, M; Collins, R; Davies, C; Evans, V; Godwin, J; Greaves, E; Harwood, C; Jackson, D; James, S; Lau, E; Mead, G; Naughten, A; Peto, R; Tooth, A; Rambert, P; Asselain, B; Salmon, RJ; Vilcoq, JR; Arriagada, R; Hill, C; Laplanche, A; Le, MG; Spielmann, M; Cocconi, G; di Blasio, B; Catalano, R; Creech, RH; Brockschmidt, J; Cooper, MR; Andrysek, O; Barkmanova, J; Falkson, CI; Abraham, M; Klijn, JGM; Treurniet-Donker, AD; van Putten, WLJ; Easton, D; Powles, TJ; Gazet, JC; Semiglazov, V; Deshpande, N; di Martino, L; Douglas, P; Lindtner, A; Notter, G; Bryant, AJS; Ewing, GH; Krushen-Kosloski, JL; George, WD; Gould, A; Stewart, HJ; Stroner, P; Moller, TR; Ryden, S; Carstensen, J; Hatschek, T; Soderberg, M; Carpenter, JT; Albain, K; Crowley, J; Green, S; Martino, S; Osborne, CK; Ravdin, PM; Rutqvist, LE; Wallgren, A; Holm, LE; Thurlimann, B; Brenner, H; Hercbergs, A; Yoshimoto, M; DeBoer, G; Paterson, AHG; Meakin, JW; Panzarella, T; Naja, A; Bahi, J; Reid, M; Spittle, M; Senanayake, F; Bergh, J; Holmberg, L; Sevelda, P; Zielinsky, CC; Gnant, M; Jakesz, R; Buchanan, RB; Cross, M; Dunn, JA; Gillespie, WM; Kelly, K; Morrison, JM; Litton, A; Chlebowski, RT; Bezwoda, WR; Caffier, H				Abe, O; Abe, R; Enomoto, K; Kikuchi, K; Koyama, H; Nomura, Y; Sakai, K; Sugimachi, K; Tominaga, T; Uchino, J; Yoshida, M; Benraadt, J; van de Velde, AO; van Dongen, JA; Vermorken, JB; Giokas, G; Lissaios, B; Harvey, VJ; Holdaway, TM; Kay, RG; Mason, BH; Coates, A; Forbes, JF; Focan, C; Lobelle, JP; Gates, GD; Powell, J; Durand, M; Mauriac, L; Bartholomeus, S; Piccart, MJ; Gelman, RS; Henderson, IC; Shapiro, CL; Hancock, AK; Masood, MB; Parker, D; Price, JJ; Jackson, S; Ragaz, J; Delozier, T; Mace-Lesec'h, J; Haybittle, JL; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Baum, M; Houghton, J; Riley, D; Dent, DM; Gudgeon, CA; Hacking, A; Gordon, NH; Davis, HL; Romestaing, P; Lehingue, Y; Owen, JR; Meier, P; Howell, A; Ribeiro, GC; Swindell, R; Albano, J; de Oliveira, CF; Gervasio, H; Gordilho, J; Carstensen, B; Palshof, T; Johansen, H; Korzeniowski, S; Skolyszewski, J; Portnoj, SM; Andersen, KW; Axelsson, CK; Blichert-Toft, M; Mouridsen, HT; Overgaard, M; Rose, C; Corcoran, N; Trampisch, HJ; Comis, RL; Davidson, NE; Gray, R; Robert, N; Tormey, DC; Wood, W; Chetty, U; Forrest, P; Jack, W; Rossbach, J; Sylvester, RJ; van de Velde, CJH; Cunningham, MP; Bonneterre, J; Fumoleau, P; Namer, M; Bastert, G; Rauschecker, H; Sauer, R; Sauerbrei, W; Schauer, A; Schumacher, M; de Schryver, A; Belfiglio, M; Mari, E; Nicolucci, A; Scorpiglione, N; Yosef, HMA; McArdle, CS; Smith, DC; Lara, PC; Boccardo, F; Rubagotti, A; Erazo, A; Medina, JY; Izuo, M; Morishita, Y; Bentley, A; Doran, Z; Fentiman, IS; Hayward, JL; Rubens, RD; Kaufmann, M; Jonat, W; Scheurlen, H; von Fournier, D; Fountzilas, G; Klafstrom, P; Blomqvist, C; Cuzick, J; Margreiter, R; Castiglione, M; Cavilli, F; Collins, J; Forbes, J; Gelber, RD; Goldhirsch, A; Lindtner, J; Price, KN; Rudenstam, CM; Senn, HJ; Bliss, JM; Chilvers, CED; Coombes, RC; Marty, M; Borovik, R; Brufman, G; Hayat, H; Robinson, E; Wigler, N; Pannuti, F; Takashima, S; Yasutomi, T; Sonoo, H; Yamashita, J; Ogawa, M; Welvaart, K; Hupperets, PSGJ; Bonte, J; Tengrup, I; Tennvall-Nittby, L; Martin, P; Romain, S; Ingle, JN; Suman, VJ; Buzdar, AU; Smith, T; Hakes, T; Wittes, R; de la Huerta, R; Sainz, MG; Bonadonna, G; del Vecchio, M; Valagussa, P; Veronesi, U; Dubois, JB; Bianco, AR; Lippman, ME; Pierce, LJ; Simon, R; Steinberg, SM; Myles, JD; Pater, JL; Pritchard, KI; Anderson, S; Brown, A; Bryant, J; Costantino, J; Dignam, J; Fisher, B; Redmond, C; Wieand, S; Wolmark, N; Jackson, IM; Palmer, MK; Bengtsson, NO; Larsson, LG; Lythgoe, JP; Kissin, M; Hannisdal, E; Varhaug, JE; Nissen-Meyer, R; Blamey, RW; Mitchell, AK; Robertson, JFR; Ueo, H; Mathe, G; Misset, JL; Abu-Zahra, HT; Clarke, EA; McLaughlin, JR; Clark, RM; Levine, M; Morimoto, K; Sawa, K; Takatsuka, Y; Gundersen, S; Hauer-Jensen, M; Host, H; Crossley, E; Harris, A; Beighton, A; Clarke, M; Collins, R; Davies, C; Evans, V; Godwin, J; Greaves, E; Harwood, C; Jackson, D; James, S; Lau, E; Mead, G; Naughten, A; Peto, R; Tooth, A; Rambert, P; Asselain, B; Salmon, RJ; Vilcoq, JR; Arriagada, R; Hill, C; Laplanche, A; Le, MG; Spielmann, M; Cocconi, G; di Blasio, B; Catalano, R; Creech, RH; Brockschmidt, J; Cooper, MR; Andrysek, O; Barkmanova, J; Falkson, CI; Abraham, M; Klijn, JGM; Treurniet-Donker, AD; van Putten, WLJ; Easton, D; Powles, TJ; Gazet, JC; Semiglazov, V; Deshpande, N; di Martino, L; Douglas, P; Lindtner, A; Notter, G; Bryant, AJS; Ewing, GH; Krushen-Kosloski, JL; George, WD; Gould, A; Stewart, HJ; Stroner, P; Moller, TR; Ryden, S; Carstensen, J; Hatschek, T; Soderberg, M; Carpenter, JT; Albain, K; Crowley, J; Green, S; Martino, S; Osborne, CK; Ravdin, PM; Rutqvist, LE; Wallgren, A; Holm, LE; Thurlimann, B; Brenner, H; Hercbergs, A; Yoshimoto, M; DeBoer, G; Paterson, AHG; Meakin, JW; Panzarella, T; Naja, A; Bahi, J; Reid, M; Spittle, M; Senanayake, F; Bergh, J; Holmberg, L; Sevelda, P; Zielinsky, CC; Gnant, M; Jakesz, R; Buchanan, RB; Cross, M; Dunn, JA; Gillespie, WM; Kelly, K; Morrison, JM; Litton, A; Chlebowski, RT; Bezwoda, WR; Caffier, H		Early Breast Canc Trialists Collaborative Gr	Polychemotherapy for early breast cancer: an overview of the randomised trials	LANCET			English	Article							REQUIRING PROLONGED OBSERVATION; ESTROGEN RECEPTORS; CHEMOTHERAPY; TAMOXIFEN; PATIENT; TUMORS; DESIGN; WOMEN	Background There have been many randomised trials of adjuvant prolonged polychemotherapy among women with early breast cancer, and an updated overview of their results is presented. Methods In 1995, information was sought on each woman in any randomised trial that began before 1990 and involved treatment groups that differed only with respect to the chemotherapy regimens that were being compared. Analyses involved about 18 000 women in 47 trials of prolonged polychemotherapy versus no chemotherapy, about 6000 in 11 trials of longer versus shorter polychemotherapy, and about 6000 in 11 trials of anthracycline-containing regimens versus CMF (cyclophosphamide, methotrexate, and fluorouracil). Findings For recurrence, polychemotherapy produced substantial and highly significant proportional reductions both among women aged under 50 at randomisation (35% [SD 4] reduction; 2p<0.00001) and among those aged 50-69 (20% [SD 3] reduction; 2p<0.00001); few women aged 70 or over had been studied. For mortality, the reductions were also significant both among women aged under 50 (27% [SD 5] reduction; 2p<0.00001) and among those aged 50-69 (11% [SD 3] reduction; 2p=0.0001). The recurrence reductions emerged chiefly during the first 5 years of follow-up, whereas the difference in survival grew throughout the first 10 years. After standardisation for age and time since randomisation, the proportional reductions in risk were similar for women with node-negative and node-positive disease. Applying the proportional mortality reduction observed in all women aged under 50 at randomisation would typically change a 10-year survival of 71% for those with node-negative disease to 78% (an absolute benefit of 7%), and of 42% for those with node-positive disease to 53% (an absolute benefit of 11%). The smaller proportional mortality reduction observed in all women aged 50-69 at randomisation would translate into smaller absolute benefits, changing a 10-year survival of 67% for those with node-negative disease to 69% (an absolute gain of 2%) and of 46% for those with node-positive disease to 49% (an absolute gain of 3%). The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given. In terms of other outcomes, there was a reduction of about one-fifth (2p=0.05) in contralateral breast cancer, which has already been included in the analyses of recurrence, and no apparent adverse effect on deaths from causes other than breast cancer (death rate ratio 0.89 [SD 0.09]). The directly randomised comparisons of longer versus shorter durations of polychemotherapy did not indicate any survival advantage with the use of more than about 3-6 months of polychemotherapy. By contrast, directly randomised comparisons did suggest that, compared with CMF alone, the anthracycline-containing regimens studied produced somewhat greater effects on recurrence (2p=0.006) and mortality (69% vs 72% 5-year survival; log-rank 2p=0.02). But this comparison is one of many that could have been selected for emphasis, the 99% CI reaches zero, and the results of several of the relevant trials are not yet available. Interpretation Some months of adjuvant polychemotherapy (eg, with CMF or an anthracycline-containing regimen) typically produces an absolute improvement of about 7-11% in 10-year survival for women aged under 50 at presentation with early breast cancer, and of about 2-3% for those aged 50-69 (unless their prognosis is likely to be extremely good even without such treatment). Treatment decisions involve consideration not only of improvements in cancer recurrence and survival but also of adverse side-effects of treatment, and this report makes no recommendations as to who should or should not be treated.	Radcliffe Infirm, Imperial Canc Res Fund, Nuffield Dept Clin Med, MRC,Clin Trial Serv Unit,EBCTCG Secretariat, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Abe, O (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Nuffield Dept Clin Med, MRC,Clin Trial Serv Unit,EBCTCG Secretariat, Oxford OX2 6HE, England.		Gnant, Michael/AAN-7054-2020; Nicolucci, Antonio/ABI-6234-2020; Brenner, Hermann/ABE-6383-2020; Fentiman, Ian S/I-7644-2019; Jonat, Walter/E-3024-2010; Gkiokas, Georgios/AAE-6312-2020; Brenner, Hermann/B-4627-2017; Boccardo, Francesco Mario/AAF-2654-2019; Barkmanova, Jaroslava/A-1411-2017; McLaughlin, John R/E-4577-2013; Fountzilas, George/ABF-2139-2020; Pritchard, Kathleen I/I-2184-2014; Fentiman, Ian/AAB-9886-2020	Gnant, Michael/0000-0003-1002-2118; Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Boccardo, Francesco Mario/0000-0002-5392-4077; Barkmanova, Jaroslava/0000-0003-1406-7292; Pritchard, Kathleen I/0000-0003-0758-9666; Bliss, Judith/0000-0001-7957-7424; Coombes, Raoul Charles/0000-0002-4811-1100; Gray, Richard/0000-0003-4440-574X; Bergh, Jonas/0000-0001-5526-1847; Arriagada, Rodrigo/0000-0002-3134-1735				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; ALBAIN K, 1997, P ASCO, V16, P450; [Anonymous], 1996, Lancet, V348, P1189; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1992, Lancet, V339, P1; Clahsen PC, 1997, J CLIN ONCOL, V15, P2526, DOI 10.1200/JCO.1997.15.7.2526; Clarke M, 1998, LANCET, V351, P1451; COLLINS R, 1996, OXFORD TXB MED, V1, P21; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; ELWOOD JM, 1980, BRIT J CANCER, V42, P635, DOI 10.1038/bjc.1980.296; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; GOLDHIRSCH A, 1985, J CLIN ONCOL, V3, P1059; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pritchard KI, 1997, J CLIN ONCOL, V15, P2302, DOI 10.1200/JCO.1997.15.6.2302; RAGAZ J, 1988, P AN M AM SOC CLIN, V7, P12	19	1668	1692	3	72	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					930	942						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752815				2023-01-03	WOS:000076002200008
J	Ciccone, A; Motto, C; Aritzu, E; Piana, A; Candelise, L				Ciccone, A; Motto, C; Aritzu, E; Piana, A; Candelise, L		MAST-I Collaborative Grp	Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis	LANCET			English	Article							ACUTE ISCHEMIC STROKE; THERAPY		Univ Milano, Ist Clin Neurol, IRCCS, Osped Maggiore Policlin, I-20162 Milano, Italy; Osped Niguarda Ca Granda, Div Neurol, I-20162 Milano, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Ospedale Niguarda Ca' Granda	Ciccone, A (corresponding author), Univ Milano, Ist Clin Neurol, IRCCS, Osped Maggiore Policlin, I-20162 Milano, Italy.	Alfonso.ciccone@pmp.it	Ciccone, Alfonso/AAB-6942-2022	Ciccone, Alfonso/0000-0002-4590-3575				Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CANDELISE L, 1995, LANCET, V346, P1509; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5	4	10	10	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					880	880		10.1016/S0140-6736(05)60007-4	http://dx.doi.org/10.1016/S0140-6736(05)60007-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742986				2023-01-03	WOS:000075857300016
J	Houdijk, APJ; Rijnsburger, ER; Jansen, J; Wesdorp, RIC; Weiss, JK; McCamish, MA; Teerlink, T; Meuwissen, SGM; Haarman, HJTM; Thijs, LG; van Leeuwen, PAM				Houdijk, APJ; Rijnsburger, ER; Jansen, J; Wesdorp, RIC; Weiss, JK; McCamish, MA; Teerlink, T; Meuwissen, SGM; Haarman, HJTM; Thijs, LG; van Leeuwen, PAM			Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; PARENTERAL-NUTRITION; SOLUBLE RECEPTORS; SEPTIC MORBIDITY; ABDOMINAL-TRAUMA; INJURY; GUT; SEVERITY; RELEASE; SEPSIS	Background Infections are an important cause of morbidity and mortality in patients with multiple trauma. Studies in both animals and human beings have suggested that glutamine-enriched nutrition decreases the number of infections. Methods Patients with multiple trauma with an expected survival of more than 48 h, and who had an Injury Severity Score of 20 or more, were randomly allocated glutamine-supplemented enteral nutrition or a balanced, isonitrogenous, isocaloric enteral-feeding regimen along with usual care. Each patient was assessed every 8 h for infection, the primary endpoint. Data were analysed both per protocol, which included enteral feeding for at least 5 days, and by intention to treat. Findings 72 patients were enrolled and 60 received enteral feeding (29 glutamine-supplemented) for at least 5 days. Five (17%) of 29 patients in the glutamine-supplemented group had pneumonia compared with 14 (45%) of 31 patients in the control group (p<0.02). Bacteraemia occurred in two (7%) patients in glutamine group and 13 (42%) in the control group (p<0.005). One patient in the glutamine group had sepsis compared with eight (26%) patients in the control group (p<0.02). Interpretation There was a low frequency of pneumonia, sepsis, and bacteraemia in patients with multiple trauma who received glutamine-supplemented enteral nutrition. Larger studies are needed to investigate whether glutamine-supplemented enteral nutrition reduces mortality.	Free Univ Amsterdam Hosp, Dept Surg, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Clin Chem, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Gastroenterol, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Acute Internal Med, NL-1081 HV Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Abbott Labs, Ross Prod Div, Columbus, OH USA; Ohio State Univ, Dept Med, Columbus, OH 43210 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Abbott Laboratories; University System of Ohio; Ohio State University	van Leeuwen, PAM (corresponding author), Free Univ Amsterdam Hosp, Dept Surg, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.		Xia, Xianfeng/F-9169-2011					BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEMELMAN FJ, 1994, NEPHROL DIAL TRANSPL, V9, P1786; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; CINAT ME, 1994, J AM COLL SURGEONS, V179, P529; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005; HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; HOUDIJK APJ, 1994, JPEN-PARENTER ENTER, V18, P422, DOI 10.1177/0148607194018005422; HUDIJK APJ, 1994, AM J PHYSIOL, V297, pG1035; KIRK SJ, 1990, J PARENTER ENTER NUT, V14, P226; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Long CL, 1996, J TRAUMA, V40, P97, DOI 10.1097/00005373-199601000-00018; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; ODWYER ST, 1989, JPEN-PARENTER ENTER, V13, P579, DOI 10.1177/0148607189013006579; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; RABINOVICI R, 1993, J TRAUMA, V35, P698, DOI 10.1097/00005373-199311000-00008; SOUBA WW, 1990, J SURG RES, V48, P1, DOI 10.1016/0022-4804(90)90136-P; SOUBA WW, 1990, J SURG RES, V48, P383, DOI 10.1016/0022-4804(90)90080-L; TAN LR, 1993, J TRAUMA, V34, P634, DOI 10.1097/00005373-199305000-00004; TEERLINK T, 1994, CLIN CHEM, V40, P245; TRAN DD, 1993, SURGERY, V114, P21; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	29	448	473	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					772	776		10.1016/S0140-6736(98)02007-8	http://dx.doi.org/10.1016/S0140-6736(98)02007-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737282				2023-01-03	WOS:000075762700011
J	Halm, EA; Fine, MJ; Marrie, TJ; Coley, CM; Kapoor, WN; Obrosky, DS; Singer, DE				Halm, EA; Fine, MJ; Marrie, TJ; Coley, CM; Kapoor, WN; Obrosky, DS; Singer, DE			Time to clinical stability in patients hospitalized with community-acquired pneumonia - Implications for practice guidelines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med			BACTEREMIC PNEUMOCOCCAL PNEUMONIA; ANTIMICROBIAL THERAPY; LENGTH; STAY; ADULTS; MULTICENTER; MANAGEMENT; SEVERITY; DISEASE; ILLNESS	Context.-Many groups have developed guidelines to shorten hospital length of stay in pneumonia in order to decrease costs, but the length of time until a patient hospitalized with pneumonia becomes clinically stable has not been established. Objective.-To describe the time to resolution of abnormalities in vital signs, ability to eat, and mental status in patients with community-acquired pneumonia and assess clinical outcomes after achieving stability. Design.-Prospective, multicenter, observational cohort study. Setting.-Three university and 1 community teaching hospital in Boston, Mass, Pittsburgh, Pa, and Halifax, Nova Scotia. Patients.-Six hundred eighty-six adults hospitalized with community-acquired pneumonia. Main Outcome Measures-Time to resolution of vital signs, ability to eat, mental status, hospital length of stay, and admission to an intensive care, coronary care, or telemetry unit. Results.-The median time to stability was 2 days for heart rate (less than or equal to 100 beats/min) and systolic blood pressure (greater than or equal to 90 mm Hg), and 3 days for respiratory rate (less than or equal to 24 breaths/min), oxygen saturation (greater than or equal to 90%), and temperature (less than or equal to 37.2 degrees C [99 degrees F]). The median time to overall clinical stability was 3 days for the most lenient definition of stability and 7 days for the most conservative definition. Patients with more severe cases of pneumonia at presentation took longer to reach stability. Once stability was achieved, clinical deterioration requiring intensive care, coronary care, or telemetry monitoring occurred in 1% of cases or fewer. Between 65% to 86% of patients stayed in the hospital more than 1 day after reaching stability, and fewer than 29% to 46% were converted to oral antibiotics within 1 day of stability, depending on the definition of stability. Conclusions.-Our estimates of time to stability in pneumonia and explicit criteria for defining stability can provide an evidence-based estimate of optimal length of stay, and outline a clinically sensible approach to improving the efficiency of inpatient management.	Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA; Dalhousie Univ, Halifax, NS B3H 3J5, Canada; Victoria Gen Hosp, Dept Med & Microbiol, Halifax, NS B3H 2Y9, Canada; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dalhousie University; Dalhousie University; University of Victoria; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Halm, EA (corresponding author), Mt Sinai Sch Med, Dept Hlth Policy, 1 Gustave L Levy Pl,POB 1077, New York, NY 10029 USA.				AHRQ HHS [R01 HS06468] Funding Source: Medline; BHP HRSA HHS [PE11001-08] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		Allison P.D., 2010, SURVIVAL ANAL USING; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005; BURNS L, 1991, MED CARE, V29, P225; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; Daifuku R, 1996, RESP MED, V90, P587, DOI 10.1016/S0954-6111(96)90016-5; DOUGLAS RM, 1973, MED J AUSTRALIA, V1, P42, DOI 10.5694/j.1326-5377.1973.tb119602.x; EHRENKRANZ NJ, 1992, INFECT CONT HOSP EP, V13, P21, DOI 10.2307/30146964; ESPOSITO AL, 1984, ARCH INTERN MED, V144, P945, DOI 10.1001/archinte.144.5.945; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FEIN AM, 1995, AM J RESP CRIT CARE, V152, P1149, DOI 10.1164/ajrccm.152.4.7551362; Fine MJ, 1997, ARCH INTERN MED, V157, P36, DOI 10.1001/archinte.157.1.36; Fine MJ, 1997, ARCH INTERN MED, V157, P47, DOI 10.1001/archinte.157.1.47; FINE MJ, 1993, MED CARE, V31, P371, DOI 10.1097/00005650-199304000-00008; FINE MJ, 1995, J GEN INTERN MED, V10, P359, DOI 10.1007/BF02599830; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FINKELSTEIN MS, 1983, J AM GERIATR SOC, V31, P19, DOI 10.1111/j.1532-5415.1983.tb06283.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLEHER C, 1993, HEALTH SERV RES, V27, P841; KHAN FA, 1989, CHEST, V96, P453; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Lieberman D, 1996, CHEST, V109, P1243, DOI 10.1378/chest.109.5.1243; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; MCCORMICK D, 1996, J GEN INTERN MED S, V11, P72; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; NORDSTROM K, 1983, SCAND J INFECT DIS, V15, P43, DOI 10.3109/inf.1983.15.issue-1.08; ORTQVIST A, 1988, SCAND J INFECT DIS, V20, P163, DOI 10.3109/00365548809032433; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; QUINTILIANI R, 1987, AM J MED, V82, P269; RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/archinte.155.12.1273; SANDERS WE, 1991, AM J MED, V91, P261, DOI 10.1016/0002-9343(91)90125-H; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; Siegel RE, 1996, CHEST, V110, P965, DOI 10.1378/chest.110.4.965; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; *VOL HOSP AM, 1993, EX PNEUM AN COST QUA; WEINGARTEN SR, 1994, CHEST, V105, P1109, DOI 10.1378/chest.105.4.1109; Weingarten SR, 1996, AM J RESP CRIT CARE, V153, P1110, DOI 10.1164/ajrccm.153.3.8630553; WEITZMAN S, 1983, ISRAEL J MED SCI, V19, P591; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; 1995, HLT CARE FINANCE SEP, P16	41	366	377	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1998	279	18					1452	1457		10.1001/jama.279.18.1452	http://dx.doi.org/10.1001/jama.279.18.1452			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL718	9600479	Bronze			2023-01-03	WOS:000073463500034
J	Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Pekurinen, M; Peramaki, E; Saarelainen, S; Svahn, T; Liljas, B				Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Pekurinen, M; Peramaki, E; Saarelainen, S; Svahn, T; Liljas, B			Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland	BRITISH MEDICAL JOURNAL			English	Article									Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland; Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Helsinki 00250, Finland; Cent Hosp No Karelia, Dept Pulm Dis, Kontioniemi 80780, Finland; Hlth Serv Res, Helsinki 00150, Finland; Suomen Astra Oy, Masala 02430, Finland; Astro Draco AB, S-22100 Lund, Sweden	Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital	Lahdensuo, A (corresponding author), Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland.		Herrala, Jaakko/L-9797-2013	Herrala, Jaakko/0000-0002-6524-1759				*BRIT THOR SOC, 1993, THORAX, V48, pS1; Lahdensuo A, 1996, BRIT MED J, V312, P748; *NAT HEART LUNG BL, 1992, NAT I HLTH PUBL; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	4	61	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1138	1139		10.1136/bmj.316.7138.1138	http://dx.doi.org/10.1136/bmj.316.7138.1138			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552954	Green Published			2023-01-03	WOS:000073067500033
J	Bolam, A; Manandhar, DS; Shrestha, P; Ellis, M; Costello, AMD				Bolam, A; Manandhar, DS; Shrestha, P; Ellis, M; Costello, AMD			The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES; SELF-EFFICACY; INTERVENTIONS	Objectives: To evaluate impact of postnatal health education for mothers on infant care and postnatal family planning practices in Nepal. Design: Randomised controlled trial with community follow up at 3 and 6 months post partum by interview Initial household survey of study areas to identify all pregnant women to facilitate follow up. Setting: Main maternity hospital in Kathmandu, Nepal. Follow up in urban Kathmandu and a periurban area southwest of the city. Subjects: 540 mothers randomly allocated to one of four groups: health education immediately after birth and three months later (group A), at birth only (group B), at three months only (group C), or none (group D). Interventions: Structured baseline household questionnaire; 20 minute, one to one health education at birth and three months later. Main outcome measures: Duration of exclusive breast feeding, appropriate immunisation of infant, knowledge of oral rehydration solution and need to continue breast feeding in diarrhoea, knowledge of infant signs suggesting pneumonia, uptake of postnatal family planning. Results: Mothers in groups A and B (received health education at birth) were slightly more likely to use contraception at six months after birth compared with mothers in groups C and D (no health education at birth) (odds ratio 1.62, 95% confidence interval 1.06 to 2.5). There were no other significant differences between groups with regards to infant feeding, infant care, or immunisation. Conclusions: Our findings suggest that the recommended practice of individual health education for postnatal mothers in poor communities has no impact on infant feeding, care, or immunisation, although uptake of family planning may be slightly enhanced.	Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England; Matern Hosp, Mother & Infant Res Act, Kathmandu, Nepal	University of London; University College London	Costello, AMD (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, 30 Guilford St, London WC1N 1EH, England.							Ad Hoc Group of the American Public Health Association, 1987, AM J PUBLIC HEALTH, V77, P89; ASHWORTH A, 1982, ARCH DIS CHILD, V57, P882, DOI 10.1136/adc.57.11.882; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BHARGAVA SK, 1990, NATL COLLABORATION S; BOLAM A, 1997, J NEPAL MED ASS, V35, P122; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS8; Hubley J. H., 1986, Health Education Research, V1, P233, DOI 10.1093/her/1.4.233; Kafatos A G, 1991, Hygie, V10, P32; KUNDI MZM, 1993, SOC SCI MED, V37, P649, DOI 10.1016/0277-9536(93)90104-C; LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V19, P788, DOI 10.1093/ije/19.4.788; MAIBACH E, 1995, HEALTH EDUC RES, V10, P37, DOI 10.1093/her/10.1.37; *NAT PLANN COMM, 1995, NEP MULT IND SURV PR; NEUPANE S, 1992, STUDY BREAST FEEDING; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; PARKIN JM, 1976, ARCH DIS CHILD, V51, P259, DOI 10.1136/adc.51.4.259; PRASAD B, 1995, BRIT MED J, V310, P621, DOI 10.1136/bmj.310.6980.621; TUPASI TE, 1989, ANN TROP PAEDIATR, V9, P82, DOI 10.1080/02724936.1989.11748603; *UN CHILDR FUND, 1993, STAT WORLDS CHILDR 1; UNITED NATIONS DEVELOPMENT PROGRAM, 1996, HUM DEV REP; *WHO, 1978, ABN AT DECL; World Bank, 1993, INV HLTH WORLD DEV R; World Bank, 1990, WORLD DEV REP 1990	22	103	105	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					805	811		10.1136/bmj.316.7134.805	http://dx.doi.org/10.1136/bmj.316.7134.805			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC488	9549449	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000072584300024
J	Ytterstad, B; Norton, R				Ytterstad, B; Norton, R			Does CPAP prevent injuries?	LANCET			English	Editorial Material									Injury Prevent Res Ctr, Auckland 1, New Zealand		Ytterstad, B (corresponding author), Injury Prevent Res Ctr, Private Bag 92019, Auckland 1, New Zealand.							Krieger J, 1997, CHEST, V112, P1561, DOI 10.1378/chest.112.6.1561; LANGLEY JD, 1988, ACCIDENT ANAL PREV, V20, P1, DOI 10.1016/0001-4575(88)90009-7; Lindqvist KS, 1996, ACCIDENT ANAL PREV, V28, P209, DOI 10.1016/0001-4575(95)00065-8; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Norton R, 1997, ACCIDENT ANAL PREV, V29, P699, DOI 10.1016/S0001-4575(97)00018-3; Wright J, 1997, BRIT MED J, V314, P851; YTTERSTAD B, 1995, ACCIDENT ANAL PREV, V27, P111, DOI 10.1016/0001-4575(94)00036-L	7	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					692	692		10.1016/S0140-6736(05)78491-9	http://dx.doi.org/10.1016/S0140-6736(05)78491-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB359	9504512				2023-01-03	WOS:000072463800005
J	Van de Werf, F; Adgey, J; Ardissino, D; Armstrong, PW; Aylward, P; Barbash, G; Betriu, A; Binbrek, AS; Califf, R; Diaz, R; Fanebust, R; Fox, K; Granger, C; Heikkila, J; Husted, S; Jansky, P; Langer, A; Lupi, E; Maseri, A; Meyer, J; Mlczoch, J; Mocceti, D; Myburgh, D; Oto, A; Paolasso, E; Pehrsson, K; Seabra-Gomes, R; Soares-Piegas, L; Sugrue, D; Tendera, M; Topol, E; Toutouzas, P; Vahanian, A; Verheugt, F; Wallentin, L; White, H; Berioli, S; Bluhmki, E; Brower, R; Danays, T; Fox, NL; Girault, C; Goetz, G; Houbracken, K; Jakob, H; Kaye, J; Sarelin, H; Clow, FW; Hacke, W; von Kummer, L; Lesaffre, E; Bluhmki, E; Bogaerts, K; Munster, K; Scheys, I; Truyen, M; Clow, FW; Fox, KAA; Brower, R; Hallstrom, A; Jones, D; Maggioni, A; Weaver, D				Van de Werf, F; Adgey, J; Ardissino, D; Armstrong, PW; Aylward, P; Barbash, G; Betriu, A; Binbrek, AS; Califf, R; Diaz, R; Fanebust, R; Fox, K; Granger, C; Heikkila, J; Husted, S; Jansky, P; Langer, A; Lupi, E; Maseri, A; Meyer, J; Mlczoch, J; Mocceti, D; Myburgh, D; Oto, A; Paolasso, E; Pehrsson, K; Seabra-Gomes, R; Soares-Piegas, L; Sugrue, D; Tendera, M; Topol, E; Toutouzas, P; Vahanian, A; Verheugt, F; Wallentin, L; White, H; Berioli, S; Bluhmki, E; Brower, R; Danays, T; Fox, NL; Girault, C; Goetz, G; Houbracken, K; Jakob, H; Kaye, J; Sarelin, H; Clow, FW; Hacke, W; von Kummer, L; Lesaffre, E; Bluhmki, E; Bogaerts, K; Munster, K; Scheys, I; Truyen, M; Clow, FW; Fox, KAA; Brower, R; Hallstrom, A; Jones, D; Maggioni, A; Weaver, D		ASSENT-2 Investigators	Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial	LANCET			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; EQUIVALENCE TRIALS; THROMBOLYSIS	Background Bolus fibrinolytic therapy facilitates early efficient institution of reperfusion therapy. Tenecteplase is a genetically engineered variant of alteplase with slower plasma clearance, better fibrin specificity, and high resistance to plasminogen-activator inhibitor-1. We did a double-blind, randomised, controlled trial to assess the efficacy and safety of tenecteplase compared with alteplase. Methods In 1021 hospitals, we randomly assigned 16 949 patients with acute myocardial infarction of less than 6 h duration rapid infusion of alteplase (less than or equal to 100 mg) or single-bolus injection of tenecteplase (30-50 mg according to bodyweight). All patients received aspirin and heparin (target activated partial thromboplastin time 50-75 s). The primary outcome was equivalence in all-cause mortality at 30 days. Findings Covariate-adjusted 30-day mortality rates were almost identical for the two groups-6.18% for tenecteplase and 6.15% for alteplase. The 95% one-sided upper boundaries of the absolute and relative differences in 30-day mortality were 0.61% and 10.00%, respectively, which met the prespecified criteria of equivalence (1% absolute or 14% relative difference in 30-day mortality, whichever difference proved smaller). Rates of intracranial haemorrhage were similar (0.93% for tenecteplase and 0.94% for alteplase), but fewer non-cerebral bleeding complications (26.43 vs 28.95%, p=0.0003) and less need for blood transfusion (4.25 vs 5.49%, p=0.0002) were seen with tenecteplase. The rate of death or non-fatal stroke at 30 days was 7.11% with tenecteplase and 7.04% with alteplase (relative risk 1.01 [95% CI 0.91-1.13]). Interpretation Tenecteplase and alteplase were equivalent for 30-day mortality. The ease of administration of tenecteplase may facilitate more rapid treatment in and out of hospital.	Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	Van de Werf, F (corresponding author), Univ Hosp Gasthuisberg, Dept Cardiol, Herestr 49, B-3000 Louvain, Belgium.	frans.vandewerf@uz.kuleuven.ac.be	Ardissino, Diego/AAC-4041-2022; Tendera, Michal/AAA-1875-2022; Fox, keith A A/I-3742-2013; Manolis, Antonis/F-5003-2014; Hacke, Werner/ABE-8661-2020	Manolis, Antonis/0000-0002-0336-4745; Piegas, Leopoldo/0000-0003-1021-817X; Bogaerts, Kris/0000-0003-0188-8665; solinas, emilia/0000-0003-3532-1317; Armstrong, Paul/0000-0002-0460-3445; Topol, Eric/0000-0002-1478-4729; Aylward, Philip/0000-0002-5358-8552				Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; Cannon CP, 1997, CIRCULATION, V95, P351; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; Koch GG, 1998, STAT MED, V17, P1863, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1863::AID-SIM989>3.3.CO;2-D; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; VANDEWERF F, 1990, LANCET, V336, P71; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632; White HD, 1998, J AM COLL CARDIOL, V31, P494	14	577	606	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					716	722		10.1016/S0140-6736(99)07403-6	http://dx.doi.org/10.1016/S0140-6736(99)07403-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475182				2023-01-03	WOS:000082233000010
J	Relling, MV; Rubnitz, JE; Rivera, GK; Boyett, JM; Hancock, ML; Felix, CA; Kun, LE; Walter, AW; Evans, WE; Pui, CH				Relling, MV; Rubnitz, JE; Rivera, GK; Boyett, JM; Hancock, ML; Felix, CA; Kun, LE; Walter, AW; Evans, WE; Pui, CH			High incidence of secondary brain tumours after radiotherapy and antimetabolites	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; 2ND MALIGNANT NEOPLASMS; HAMSTER OVARY CELLS; P53 GENE-MUTATIONS; CHEMOTHERAPEUTIC-AGENTS; CHILDHOOD; TUMORS; CANCER; CHILDREN; THERAPY	Background Brain tumours rarely occur in survivors of childhood acute lymphoblastic leukaemia after cranial radiotherapy. An unusually high frequency of brain tumours seen among children enrolled in one of our leukaemia treatment protocols, Total Therapy Study XII, prompted us to identify the potential causes of this complication. Methods We assessed clinical, biological, and pharmacokinetic features in all 52 children who received prophylactic cranial radiotherapy. We compared the cumulative incidence of brain tumours between subgroups, and with that of 421 children who received radiotherapy in previous studies. Findings The incidence of brain tumours among irradiated children (six of 52, 12.8% [SE 5.0]) was high compared with patients in the same study who did not receive radiotherapy (none of 101; p=0.0008) and with other protocols that included cranial radiotherapy (p<0.0001). Of the six children, four had erythrocyte concentrations of thioguanine nucleotide metabolites higher than the 70th percentile for the entire cohort, and three had a genetic defect in thiopurine catabolism, The 8-year cumulative incidence of brain tumour among children with defective versus wild-type thiopurine methyltransferase phenotype was 42.9% (SE 20.6) versus 8.3% (4.7; p=0.0077). This protocol differed from previous protocols, in that mow intensive systemic antimetabolite therapy was given before and during radiotherapy. Interpretation These data support the elimination of prophylactic radiotherapy for acute lymphoblastic leukaemia except in patients at high risk of central-nervous-system relapse. Underlying genetic characteristics and treatment variables may be associated with an increased risk of radiation-associated brain tumours.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Radiat Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA; Univ Tennessee, Coll Pharm, Memphis, TN USA; Univ Penn, Childrens Hosp, Sch Med, Philadelphia, PA 19104 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Relling, MV (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale, Memphis, TN 38105 USA.		Pui, Ching-Hon/N-8076-2018; Rubnitz, Jeffrey E/N-2619-2018; Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018	Pui, Ching-Hon/0000-0003-0303-5658; Rubnitz, Jeffrey E/0000-0001-9885-3527; Evans, William E./0000-0002-9333-5322; 	NATIONAL CANCER INSTITUTE [R29CA051001, R01CA051001, R37CA036401, R01CA036401, R01CA078224] Funding Source: NIH RePORTER; NCI NIH HHS [CA78224, CA36401, CA51001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUILINA G, 1990, CANCER RES, V50, P4248; BEHM FG, 1992, BLOOD, V79, P1011; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; Dalton VMK, 1998, J CLIN ONCOL, V16, P2848, DOI 10.1200/JCO.1998.16.8.2848; ELEXPURUCAMIRUAGA J, 1995, CANCER RES, V55, P4237; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FONTANA M, 1987, CANCER, V60, P1510, DOI 10.1002/1097-0142(19871001)60:7<1510::AID-CNCR2820600718>3.0.CO;2-V; GELBER RD, 1993, CANCER, V72, P261, DOI 10.1002/1097-0142(19930701)72:1<261::AID-CNCR2820720146>3.0.CO;2-O; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; HIESSE C, 1995, TRANSPLANT P, V27, P972; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAMES SJ, 1994, CANCER RES, V54, P5075; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P84; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; KUIJTEN RR, 1993, CANCER CAUSE CONTROL, V4, P455, DOI 10.1007/BF00050865; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MODAN B, 1974, LANCET, V1, P277; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUWELT EA, 1982, P NATL ACAD SCI-BIOL, V79, P4420, DOI 10.1073/pnas.79.14.4420; NYGAARD R, 1991, ACTA PAEDIATR SCAND, V80, P1220, DOI 10.1111/j.1651-2227.1991.tb11812.x; Qin DX, 1997, AM J CLIN ONCOL-CANC, V20, P263, DOI 10.1097/00000421-199706000-00011; ROSSO P, 1994, INT J CANCER, V59, P451, DOI 10.1002/ijc.2910590402; Rubnitz JE, 1997, LEUKEMIA, V11, P1201, DOI 10.1038/sj.leu.2400779; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Sharif M, 1998, INT J ONCOL, V12, P273; SWENBERG JA, 1977, NATL CANCER I MONOGR, P3; VOLONTE C, 1993, MOL BIOL CELL, V4, P71, DOI 10.1091/mbc.4.1.71; Walter AW, 1998, J CLIN ONCOL, V16, P3761, DOI 10.1200/JCO.1998.16.12.3761; WEISBURGER EK, 1977, CANCER, V40, P1935, DOI 10.1002/1097-0142(197710)40:4+<1935::AID-CNCR2820400827>3.0.CO;2-R	35	284	293	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					34	39		10.1016/S0140-6736(98)11079-6	http://dx.doi.org/10.1016/S0140-6736(98)11079-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406363				2023-01-03	WOS:000081243200012
J	Ochiya, T; Takahama, Y; Nagahara, S; Sumita, Y; Hisada, A; Itoh, H; Nagai, Y; Terada, M				Ochiya, T; Takahama, Y; Nagahara, S; Sumita, Y; Hisada, A; Itoh, H; Nagai, Y; Terada, M			New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet	NATURE MEDICINE			English	Article							DIRECT GENE-TRANSFER; SKELETAL-MUSCLE INVIVO; INTRAMUSCULAR INJECTION; MOUSE MUSCLE; EXPRESSION; MICE; VACCINATION; ADENOVIRUS; COLLAGEN; VECTOR		Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Mfg Technol Res Labs, Ibaraki, Osaka 567, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Discovery Res Labs 3, Ibaraki, Osaka 567, Japan; Koken Biosci Inst, Shinjuku Ku, Tokyo 169, Japan	National Cancer Center - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 104, Japan.		Ochiya, Takahiro/AAH-7585-2019					Anwer K, 1998, HUM GENE THER, V9, P659, DOI 10.1089/hum.1998.9.5-659; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; Jong YS, 1997, J CONTROL RELEASE, V47, P123, DOI 10.1016/S0168-3659(97)01637-4; Jorgensen L G, 1991, Eur J Vasc Surg, V5, P87, DOI 10.1016/S0950-821X(05)80933-8; KAMER FM, 1984, ARCH OTOLARYNGOL, V110, P93; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; Kumar V, 1996, NAT MED, V2, P857, DOI 10.1038/nm0896-857; Levy MY, 1996, GENE THER, V3, P201; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; Monahan PE, 1998, GENE THER, V5, P40, DOI 10.1038/sj.gt.3300548; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RUBIN AL, 1973, J CLIN PHARMACOL, V13, P309, DOI 10.1002/j.1552-4604.1973.tb00217.x; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sambrook J., 1989, MOL CLONING LAB MANU; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; THOMASON DB, 1990, AM J PHYSIOL, V258, pC578, DOI 10.1152/ajpcell.1990.258.3.C578; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Truong-Le VL, 1998, HUM GENE THER, V9, P1709, DOI 10.1089/hum.1998.9.12-1709; Vitiello L, 1996, GENE THER, V3, P396; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	30	198	216	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					707	710		10.1038/9560	http://dx.doi.org/10.1038/9560			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371512				2023-01-03	WOS:000080823300042
J	Recker, RR; Davies, KM; Dowd, RM; Heaney, RP				Recker, RR; Davies, KM; Dowd, RM; Heaney, RP			The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						estrogen replacement therapy; dose-response relationship, drug; osteoporosis, postmenopausal; calcium; vitamin D	POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; OOPHORECTOMIZED WOMEN; HORMONE REPLACEMENT; ENDOMETRIAL CANCER; HIP-FRACTURES; PREVENTION; OSTEOPOROSIS; RISK; MASS	Background: Hormone replacement therapy (HRT), the mainstay of osteoporosis prevention, is limited because of dose-related risks, side effects, and patient acceptance. The bone-sparing efficacy and tolerability of the lowest available doses of HRT have not been adequately studied in elderly women. Objective: To determine the bone-sparing effect of continuous low-dose HRT in elderly women. Design: Randomized, double-blind, placebo-controlled trial. Setting: University osteoporosis research and clinical center. Patients: 128 healthy white women (age > 65 years) with low bone mass recruited by word of mouth and by local advertisement. The principal eligibility criterion was spinal bone mineral density of 0.90 g/cm(2) or less. Intervention: Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogesterone, 2.5 mg/d, or matching placebo. Sufficient calcium supplementation was given to bring all calcium intakes above 1000 mg/d in both groups; supplemental oral 25-hydroxyvitamin D was given to maintain serum 25-hydroxyvitamin D levels of at least 75 nmol/L in both groups. Measurements: Bone mineral density of the spine, hip, total body, and forearm; serum total alkaline phosphatase and serum osteocalcin levels at 6-month intervals; and 24-hour urine creatinine and hydroxyproline excretion at baseline, 12 months, and 42 months. Results: During 3.5 years of observation, spinal bone mineral density increased by 3.5% (P < 0.001) in an intention-to-treat analysis and by 5.2% among patients with greater than 90% adherence to therapy. Significant increases were seen in total-body and forearm bone density (P < 0.01). Symptoms related to HRT (breast tenderness, spotting, pelvic discomfort, and mood changes) were mild and short-lived. Conclusions: Continuous low-dose HRT with conjugated equine estrogen and oral medroxyprogesterone combined with adequate calcium and vitamin D provides a bone-sparing effect that is similar or superior to that provided by other, higher-dose HRT regimens in elderly women. This combination is well tolerated by most patients.	Creighton Univ, Osteoporosis Res Ctr, Sch Med, Omaha, NE 68131 USA	Creighton University	Recker, RR (corresponding author), Creighton Univ, Osteoporosis Res Ctr, Sch Med, 601 N 30th St 5766, Omaha, NE 68131 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039221] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-39221] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLD J. S., 1966, CLIN ORTHOP RELATED RES, V49, P17; Barger-Lux MJ, 1998, OSTEOPOROSIS INT, V8, P222, DOI 10.1007/s001980050058; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BURING JE, 1986, AM J EPIDEMIOL, V124, P434, DOI 10.1093/oxfordjournals.aje.a114414; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CANN CE, 1980, JAMA-J AM MED ASSOC, V244, P2056; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cushing KL, 1998, OBSTET GYNECOL, V91, P35, DOI 10.1016/S0029-7844(97)00577-2; DAVIES KM, 1993, OSTEOPOROSIS INT, V3, P265, DOI 10.1007/BF01623831; DAVIES KM, 1989, J BONE MINER RES, V4, P341; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DawsonHughes B, 1997, AM J CLIN NUTR, V65, P67, DOI 10.1093/ajcn/65.1.67; ETTINGER B, 1993, CLIN THER, V15, P950; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; GALLAGHER JC, 1991, AM J MED, V90, P171; Gambrell RD, 1997, AM J OBSTET GYNECOL, V177, P1196, DOI 10.1016/S0002-9378(97)70040-1; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GLUER CC, 1995, OSTEOPOROSIS INT, V5, P262, DOI 10.1007/BF01774016; GRADY D, 1992, ANN INTERN MED, V117, P1038; HAHN RG, 1989, AM J OBSTET GYNECOL, V161, P1854, DOI 10.1016/S0002-9378(89)80006-7; HARRIS ST, 1991, ARCH INTERN MED, V151, P1980, DOI 10.1001/archinte.151.10.1980; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1993, AM J MED, V95, pS37, DOI 10.1016/0002-9343(93)90380-8; Littell R.C., 1996, SAS SYSTEMS MIXED MO; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; Notelovitz M, 1997, MENOPAUSE, V4, P80; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; Parfitt A. M., 1983, BONE HISTOMORPHOMETR, P86; Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; RECKER RR, 1993, J BONE MINER RES, V8, pS154; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Riggs BL, 1998, J BONE MINER RES, V13, P168, DOI 10.1359/jbmr.1998.13.2.168; SELBY PL, 1986, BRIT MED J, V293, P1337, DOI 10.1136/bmj.293.6558.1337; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201; WEBBER CE, 1994, MATURITAS, V19, P13, DOI 10.1016/0378-5122(94)90037-X; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Westerlind KC, 1998, J BONE MINER RES, V13, P1023, DOI 10.1359/jbmr.1998.13.6.1023; Zumoff B, 1998, P SOC EXP BIOL MED, V217, P30	56	178	186	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					897	+		10.7326/0003-4819-130-11-199906010-00005	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375338				2023-01-03	WOS:000080547900004
J	Wiktor, SZ; Sassan-Morokro, M; Grant, AD; Abouya, L; Karon, JM; Maurice, C; Djomand, G; Ackah, A; Domoua, K; Kadio, A; Yapi, A; Combe, P; Tossou, O; Roels, TH; Lackritz, EM; Coulibaly, D; De Cock, KM; Coulibaly, IM; Greenberg, AE				Wiktor, SZ; Sassan-Morokro, M; Grant, AD; Abouya, L; Karon, JM; Maurice, C; Djomand, G; Ackah, A; Domoua, K; Kadio, A; Yapi, A; Combe, P; Tossou, O; Roels, TH; Lackritz, EM; Coulibaly, D; De Cock, KM; Coulibaly, IM; Greenberg, AE			Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; IVORY-COAST; ANTIBIOTIC-RESISTANCE; AFRICAN PATIENTS; WEST-AFRICA; ADULTS; KENYA; CHEMOTHERAPY	Background There is a high incidence of opportunistic infection among HIV-1-infected patients with tuberculosis in Africa and, consequently, high mortality. We assessed the safety and efficacy of trimethoprim-sulphamethoxazole 800 mg/160 mg (co-trimoxazole) prophylaxis in prevention of such infections and in decrease of morbidity and mortality. Methods Between October, 1995, and April, 1998, we enrolled 771 HIV-1 seropositive and HIV-1 and HIV-2 dually seroreactive patients who had sputum-smear-positive pulmonary tuberculosis (median age 32 years [range 18-64], median CD4-cell count 317 cells/mu L) attending Abidjan's four largest outpatient tuberculosis treatment centres. Patients were randomly assigned one daily tablet of co-trimoxazole (n=386) or placebo (n=385) 1 month after the start of a standard 6-month tuberculosis regimen. We assessed adherence to study drug and tolerance monthly for 5 months and every 3 months thereafter, as well as rates of admission to hospital. Findings Rates of laboratory and clinical adverse events were similar in the two groups. 51 patients in the co-trimoxazole group (13.8/100 person-years) and 86 in the placebo group (25.4/100 person-years) died (decrease In risk 46% [95% CI 23-62], p<0.001). 29 patients on co-trimoxazole (8.2/100 person-years) and 47 on placebo (15.0/100 person-years) were admitted to hospital at least once after randomisation (decrease 43% [10-64]), p=0.02). There were significantly fewer admissions for septicaemia and enteritis in the co-trimoxazole group than in the placebo group. Interpretation In HIV-1-infected patients with tuberculosis, daily co-trimoxazole prophylaxis was well tolerated and significantly decreased mortality and hospital admission rates. Our findings may have important implications for improvement of clinical care for such patients in Africa.	Projet RETRO CI, Abidjan 01, Cote Ivoire; Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA; London Sch Hyg & Trop Med, London WC1, England; Ctr Diagnost & Rech SIDA, Abidjan, Cote Ivoire; CHU Treichville, Abidjan, Cote Ivoire; Minist Sante Publ, Programme Natl Lutte Contre SIDA, Malad Sexuellement Transmissibles & TB, Abidjan, Cote Ivoire	Centers for Disease Control & Prevention - USA; University of London; London School of Hygiene & Tropical Medicine	Wiktor, SZ (corresponding author), Projet RETRO CI, 01 BP 1712, Abidjan 01, Cote Ivoire.	szw0@cdc.gov		Lackritz, Eve/0000-0002-5397-7291; Roels, Thierry/0000-0002-0886-5645				Abouya L, 1998, AIDS, V12, P505, DOI 10.1097/00002030-199805000-00012; ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 1997, J CLIN MICROBIOL, V35, P1915, DOI 10.1128/JCM.35.7.1915-1915.1997; Aseffa A, 1997, E AFR MED J, V74, P708; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P535; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; Grant AD, 1998, INT J TUBERC LUNG D, V2, P926; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; Kariuki S, 1996, J ANTIMICROB CHEMOTH, V38, P425, DOI 10.1093/jac/38.3.425; KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; Mache A, 1997, E AFR MED J, V74, P183; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; *NAT I ALL INF DIS, 1998, SER ADV EXP REP MAN; Nkengasong JN, 1999, AIDS, V13, P109, DOI 10.1097/00002030-199901140-00015; Nkengasong JN, 1998, J CLIN MICROBIOL, V36, P123, DOI 10.1128/JCM.36.1.123-127.1998; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Satten GA, 1998, J AM STAT ASSOC, V93, P318, DOI 10.2307/2669628; VUGIA DJ, 1993, J INFECT DIS, V168, P564, DOI 10.1093/infdis/168.3.564; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625	32	355	359	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1469	1475		10.1016/S0140-6736(99)03465-0	http://dx.doi.org/10.1016/S0140-6736(99)03465-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232312				2023-01-03	WOS:000080278200009
J	van der Windt, DAWM; Koes, BW; Deville, W; Boeke, AJP; de Jong, BA; Bouter, LM				van der Windt, DAWM; Koes, BW; Deville, W; Boeke, AJP; de Jong, BA; Bouter, LM			Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CLINICAL-TRIALS; STEROID INJECTIONS; DISORDERS; MANAGEMENT; CAPSULITIS; PLACEMENT; ACCURACY	Objective to compare the effectiveness of corticosteroid injections with physiotherapy for the treatment of painful stiff shoulder. Design Randomised trial. Setting 40 general practices. Subjects 109 patients consulting general practitioners for shoulder pain were enrolled in the trial. Interventions Patients were randomly allocated to 6 weeks of treatment either with corticosteroid injections (53) or physiotherapy (56). Main outcome measures Outcome assessments were carried out 3, 7, 13, 26, and 52 weeks after randomisation; some of the assessments were done by an observer blind to treatment allocation. Primary outcome measures were the success of treatment as measured by scores on scales measuring improvement in the main complaint and pain, and improvement in scores on a scale measuring shoulder disability. Results At 7 weeks 40 (77%) out of 52 patients seared with injections were considered to be treatment successes compared with 26 (46%) out of 56 treated with physiotherapy (difference between groups 31%, 95% confidence interval 14% to 48%). The difference in improvement favoured those treated dth corticosteroids in nearly all outcome measures; these differences were statistically significant At 26 and 52 weeks differences between the groups were comparatively small. Adverse reactions wee generally mild However among women receiving treatment with corticosteroids adverse reactions were mure troublesome: facial flushing was reported by 9 women and irregular menstrual bleeding by 6, 2 of whom were postmenopausal. Conclusions The beneficial effects of corticosteroid injections administered by general practitioners for treatment of painful stiff shoulder are superior to those of physiotherapy. The differences between the intervention groups were mainly the result of the comparatively faster relief of symptoms that occurred in patients treated with injections. Adverse reactions were generally mild but doctors should be aware of the potential side effects of injections of triamcinolone, particularly in women.	Free Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Rehabil Med, NL-1105 AZ Amsterdam, Netherlands; Vrije Univ, Fac Med, Dept Gen Practice, Amsterdam, Netherlands; Vrije Univ, Fac Med, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van der Windt, DAWM (corresponding author), Free Univ Amsterdam, Fac Med, Inst Res Extramural Med, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Deville, Walter/B-5160-2013; Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482				Bakker JF, 1990, HUISARTS WETENSCHAP, V33, P196; BULGEN DY, 1984, ANN RHEUM DIS, V43, P353, DOI 10.1136/ard.43.3.353; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Croft P, 1996, BRIT MED J, V313, P601; CROFT P, 1993, EPIDEMIOLOGY RHEUMAT, P375; DACRE JE, 1989, ANN RHEUM DIS, V48, P322, DOI 10.1136/ard.48.4.322; DEWOLF AN, 1994, VADEMECUM, V12, P7; Eustace JA, 1997, ANN RHEUM DIS, V56, P59, DOI 10.1136/ard.56.1.59; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; HEEMSKERK MAM, 1997, NED TIJDSCHR FYSIOTH, V107, P146; JACOBS LGH, 1991, BRIT MED J, V302, P1498, DOI 10.1136/bmj.302.6791.1498; JONES A, 1993, BRIT MED J, V307, P1329, DOI 10.1136/bmj.307.6915.1329; LAMBERTS H, 1991, REASON ENCOUNTER E 1; LEE PN, 1974, ANN RHEUM DIS, V33, P116, DOI 10.1136/ard.33.2.116; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; NORUSIS MJ, 1992, SPSS PC PLUS ADV STA; Van der Heijden G.J.M.G., 1996, SHOULDER DISORDER TR, P79; van der Windt DAWM, 1998, ANN RHEUM DIS, V57, P82, DOI 10.1136/ard.57.2.82; vanderHeijden GJMG, 1997, BRIT MED J, V315, P25, DOI 10.1136/bmj.315.7099.25; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; White AET, 1996, J ORTHOP RHEUMATOL, V9, P37; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320	24	178	178	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1292	1296		10.1136/bmj.317.7168.1292	http://dx.doi.org/10.1136/bmj.317.7168.1292			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804720	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000076963800029
J	Limousin, P; Krack, P; Pollak, P; Benazzouz, A; Ardouin, C; Hoffmann, D; Benabid, AL				Limousin, P; Krack, P; Pollak, P; Benazzouz, A; Ardouin, C; Hoffmann, D; Benabid, AL			Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-FREQUENCY STIMULATION; GLOBUS-PALLIDUS; NEURONAL-ACTIVITY; GPI PALLIDOTOMY; MPTP MODEL; PRIMATE; REVERSAL; SYMPTOMS; MONKEYS	Background In many patients with idiopathic Parkinson's disease, treatment with levodopa is complicated by fluctuations between an "off" period (also referred to as "off medication"), when the medication is not working and the motor symptoms of parkinsonism are present, and an "on" period, when the medication is causing improved mobility (also referred to as "on medication"), often accompanied by debilitating dyskinesias. In animal models of Parkinson's disease, there is overactivity in the subthalamic nucleus, and electrical stimulation of the subthalamic nucleus improves parkinsonism. We therefore sought to determine the efficacy and safety of electrical stimulation of the subthalamic nucleus in patients with Parkinson's disease. Methods We studied 24 patients with idiopathic Parkinson's disease in whom electrodes were implanted bilaterally in the subthalamic nucleus under stereotactic guidance with imaging and electrophysiologic testing of the location. Twenty were followed for at least 12 months. Clinical evaluations included the Unified Parkinson's Disease Rating Scale, a dyskinesia scale, and timed tests conducted before and after surgery, when patients were off and on medications. Results After one year of electrical stimulation of the subthalamic nucleus, the patients' scores for activities of daily living and motor examination scores (Unified Parkinson's Disease Rating Scale parts II and III, respectively) off medication improved by 60 percent (P<0.001). The subscores improved for limb akinesia, rigidity, tremor, and gait. In the testing done on medication, the scores on part III improved by 10 percent (P<0.005). The mean dose of dopaminergic drugs was reduced by half. The cognitive-performance scores remained unchanged, but one patient had paralysis and aphasia after an intracerebral hematoma during the implantation procedure. Conclusions Electrical stimulation of the subthalamic nucleus is an effective treatment for advanced Parkinson's disease. The severity of symptoms off medication decreases, and the dose of levodopa can be reduced, with a consequent reduction in dyskinesias. (N Engl J Med 1998;339:1105-11.) (C) 1998, Massachusetts Medical Society.	Univ Grenoble 1, Dept Clin & Biol Neurosci, F-38043 Grenoble 9, France; MRC, Human Movement & Balance Unit, London, England; Univ Kiel, Dept Neurol, D-2300 Kiel, Germany	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Kiel	Pollak, P (corresponding author), Univ Grenoble 1, Dept Clin & Biol Neurosci, BP 217, F-38043 Grenoble 9, France.		Benabid, Alim L/Q-3506-2017; Benazzouz, Abdelhamid/E-5050-2016	Krack, Paul/0000-0002-3508-7295				AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1991, LANCET, V337, P401; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BROWN RG, 1990, TRENDS NEUROSCI, V13, P21, DOI 10.1016/0166-2236(90)90058-I; COOPER IS, 1958, PATHOGENESIS TREATME, P325; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALVEZJIMENEZ N, 1996, MOVEMENT DISORD, V11, P242; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Golbe LI, 1998, LANCET, V351, P998, DOI 10.1016/S0140-6736(98)22014-9; Gross C, 1997, J NEUROSURG, V87, P491, DOI 10.3171/jns.1997.87.4.0491; GUIOT G, 1953, REV NEUROL, V89, P578; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hassler R, 1954, NERVENARZT, V25, P441; Krack P, 1997, LANCET, V350, P1675, DOI 10.1016/S0140-6736(97)24049-3; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LANGSTON JW, 1984, BRAIN RES, V292, P390; LEPORE FE, 1985, NEUROLOGY, V35, P423, DOI 10.1212/WNL.35.3.423; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Limousin P, 1996, MOVEMENT DISORD, V11, P231, DOI 10.1002/mds.870110303; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; LOZANO AM, 1996, LANCET, V348, P1108; Mattis S., 1976, GERIATRIC PSYCHIAT, P77; Meyers R, 1942, N ST J MED, V42, P317; MILLER WC, 1987, ADV BEHAV BIOL, V32, P415; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Obeso JA, 1997, J NEUROL NEUROSUR PS, V62, P2, DOI 10.1136/jnnp.62.1.2; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Penney JB, 1996, ANN NEUROL, V39, P37; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; Tronnier VM, 1997, J NEUROSURG, V87, P700, DOI 10.3171/jns.1997.87.5.0700; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P521, DOI 10.1152/jn.1994.72.2.521	43	1363	1432	0	219	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1105	1111		10.1056/NEJM199810153391603	http://dx.doi.org/10.1056/NEJM199810153391603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770557				2023-01-03	WOS:000076448200003
J	Nachman, JB; Sather, HN; Sensel, MG; Trigg, ME; Cherlow, JM; Lukens, JN; Wolff, L; Uckun, FM; Gaynon, PS				Nachman, JB; Sather, HN; Sensel, MG; Trigg, ME; Cherlow, JM; Lukens, JN; Wolff, L; Uckun, FM; Gaynon, PS			Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CANCER STUDY-GROUP; PRESENTING FEATURES; PROGNOSTIC FACTORS; POOR-PROGNOSIS; MARROW RESPONSE; CHILDHOOD; METHOTREXATE; ADOLESCENTS; TRIAL	Background Children with high-risk acute lymphoblastic leukemia (ALL) who have a slow response to initial chemotherapy (more than 25 percent blasts in the bone marrow on day 7) have a poor outcome despite intensive therapy. We conducted a randomized trial in which such patients were treated with either an augmented intensive regimen of post-induction chemotherapy or a standard regimen of intensive post-induction chemotherapy. Methods Between January 1991 and June 1995, 311 children with newly diagnosed ALL who were either 1 to 9 years of age with white-cell counts of at least 50,000 per cubic millimeter or 10 years of age or older, had a slow response to initial therapy, and entered remission at the end of induction chemotherapy were randomly assigned to receive standard therapy (156 children) or augmented therapy (155). Those with lymphomatous features were excluded. Event-free survival and overall survival were assessed from the end of induction treatment. Results The outcome at five years was significantly better in the augmented-therapy group than in the standard-therapy group (Kaplan-Meier estimate of event-free survival [+/-SD]: 75.0+/-3.8 vs. 55.0+/-4.5 percent, P<0.001; overall survival: 78.4+/-3.7 vs. 66.7+/-4.2 percent, P=0.02). The difference between treatments was most pronounced among patients one to nine years of age, all of whom had white-cell counts of at least 50,000 per cubic millimeter (P<0.001). Risk factors for an adverse event in the entire cohort included a white-cell count of 200,000 per cubic millimeter or higher (P=0.004), race other than black or white (P<0.001), and the presence of a t(9;22) translocation (P=0.007). The toxic effects of augmented therapy were considerable but manageable. Conclusions Augmented post-induction chemotherapy results in an excellent outcome for most patients with high-risk ALL and a slow response to initial therapy. (C) 1998, Massachusetts Medical Society.	Childrens Canc Grp, Grp Operat Ctr, Arcadia, CA 91066 USA; Univ Chicago, Sect Pediat Hematol Oncol, Chicago, IL 60637 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ Iowa Hosp & Clin, Div Pediat Bone Marrow Transplantat, Iowa City, IA 52242 USA; Long Beach Mem Med Ctr, Dept Radiat Oncol, Long Beach, CA USA; Vanderbilt Univ, Dept Pediat Hematol Oncol, Nashville, TN USA; Oregon Hlth & Sci Univ, Dept Pediat Hematol Oncol, Portland, OR 97201 USA; Doernbecher Childrens Hosp, Portland, OR 97201 USA; Wayne Hughes Inst, St Paul, MN USA; Childrens Canc Grp, Acute Lymphoblast Leukemia Biol Reference Lab, St Paul, MN USA; Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA	University of Chicago; University of Southern California; University of Iowa; Vanderbilt University; Oregon Health & Science University; University of Wisconsin System; University of Wisconsin Madison	Nachman, JB (corresponding author), Childrens Canc Grp, Grp Operat Ctr, POB 60012, Arcadia, CA 91066 USA.			Uckun, Fatih M./0000-0001-9334-183X	NATIONAL CANCER INSTITUTE [U10CA017829, U10CA002971, U10CA013539] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17829, CA 13539, CA 02971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arico M., 1997, Blood, V90, p560A; BLOOMFIELD CD, 1986, BLOOD, V67, P415; Breslow N., 1984, CANCER CLIN TRIALS, P381; BRESLOW NE, 1975, INT STAT REV, V43, P45, DOI 10.2307/1402659; CAMITTA B, 1994, J CLIN ONCOL, V12, P1383, DOI 10.1200/JCO.1994.12.7.1383; Childhood A, 1996, LANCET, V347, P1783, DOI DOI 10.1016/S0140-6736(96)91615-3; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CRIST W, 1986, MED PEDIATR ONCOL, V14, P135, DOI 10.1002/mpo.2950140306; CRIST W, 1992, LEUKEMIA, V6, P162; CRIST WM, 1990, BLOOD, V76, P117; FLEMING T, 1958, CONTEMP CLIN TRIALS, V53, P457; GAJJAR A, 1995, BLOOD, V86, P1292, DOI 10.1182/blood.V86.4.1292.bloodjournal8641292; Garand R, 1993, Recent Results Cancer Res, V131, P283; GAYNON PS, 1988, AM J PEDIAT HEMATOL, V10, P42; GAYNON PS, 1990, MED PEDIATR ONCOL, V18, P273, DOI 10.1002/mpo.2950180403; HAMMOND D, 1986, MED PEDIATR ONCOL, V14, P124, DOI 10.1002/mpo.2950140305; HENZE G, 1981, KLIN PADIATR, V193, P145, DOI 10.1055/s-2008-1034450; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAND VJ, 1994, J CLIN ONCOL, V12, P1939, DOI 10.1200/JCO.1994.12.9.1939; Lange B., 1997, Blood, V90, p559A; LILLEYMAN JS, 1986, MED PEDIATR ONCOL, V14, P182, DOI 10.1002/mpo.2950140314; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; Nachman J, 1997, J CLIN ONCOL, V15, P2222, DOI 10.1200/JCO.1997.15.6.2222; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKERTON CR, 1986, MED PEDIATR ONCOL, V14, P69, DOI 10.1002/mpo.2950140202; PUI CH, 1994, J CLIN ONCOL, V12, P2601, DOI 10.1200/JCO.1994.12.12.2601; PUI CH, 1992, LEUKEMIA LYMPHOMA, V7, P173, DOI 10.3109/10428199209053620; PUI CH, 1991, BLOOD, V77, P440; PULLEN DJ, 1982, BLOOD, V60, P1159; RAIMONDI SC, 1993, BLOOD, V81, P2237; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; RIEHM H, 1987, KLIN PADIATR, V199, P151, DOI 10.1055/s-2008-1026781; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SANTANA VM, 1990, LEUKEMIA, V4, P87; Schrappe M, 1996, J CLIN ONCOL, V14, P2403, DOI 10.1200/JCO.1996.14.8.2403; SCHRAPPE M, 1994, KLIN PADIATR, V206, P208, DOI 10.1055/s-2008-1046607; SHIKANO T, 1986, CANCER, V58, P2239, DOI 10.1002/1097-0142(19861115)58:10<2239::AID-CNCR2820581013>3.0.CO;2-I; Steinherz PG, 1996, J CLIN ONCOL, V14, P389, DOI 10.1200/JCO.1996.14.2.389; STEINHERZ PG, 1991, CANCER-AM CANCER SOC, V68, P751, DOI 10.1002/1097-0142(19910815)68:4<751::AID-CNCR2820680416>3.0.CO;2-T; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P520, DOI 10.1200/JCO.1993.11.3.520; Uckun FM, 1996, LEUKEMIA LYMPHOMA, V24, P57, DOI 10.3109/10428199609045714	44	330	340	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1663	1671		10.1056/NEJM199806043382304	http://dx.doi.org/10.1056/NEJM199806043382304			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614257				2023-01-03	WOS:000073978000004
J	Nightingale, SL				Nightingale, SL			Teleconference on natural rubber/latex allergy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2023-01-03	WOS:000072192800007
J	Amato, MBP; Barbas, CSV; Medeiros, DM; Magaldi, RB; Schettino, GDP; Lorenzi, G; Kairalla, RA; Deheinzelin, D; Munoz, C; Oliveira, R; Takagaki, TY; Carvalho, CRR				Amato, MBP; Barbas, CSV; Medeiros, DM; Magaldi, RB; Schettino, GDP; Lorenzi, G; Kairalla, RA; Deheinzelin, D; Munoz, C; Oliveira, R; Takagaki, TY; Carvalho, CRR			Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1996 American-Lung-Association/American-Thoracic-Society International Conference	MAY 10-15, 1996	NEW ORLEANS, LOUISIANA	Amer Lung Assoc, Amer Thorac Soc			END-EXPIRATORY PRESSURE; RANDOMIZED CLINICAL-TRIALS; HYALINE-MEMBRANE FORMATION; MECHANICAL VENTILATION; LUNG INJURY; PERMISSIVE HYPERCAPNIA; PULMONARY CAPILLARIES; LIMITED VENTILATION; AIRWAY PRESSURES; STRESS FAILURE	Background In patients with the acute respiratory distress syndrome, massive alveolar collapse and cyclic lung reopening and overdistention during mechanical ventilation may perpetuate alveolar injury. We determined whether a ventilatory strategy designed to minimize such lung injuries could reduce not only pulmonary complications but also mortality at 28 days in patients with the acute respiratory distress syndrome. Methods We randomly assigned 53 patients with early acute respiratory distress syndrome (including 28 described previously), all of whom were receiving identical hemodynamic and general support, to conventional or protective mechanical ventilation. Conventional ventilation was based on the strategy of maintaining the lowest positive end-expiratory pressure (PEEP) for acceptable oxygenation, with a tidal volume of 12 ml per kilogram of bodyweight and normal arterial carbon dioxide levels (35 to 38 mm Hg). Protective ventilation involved end-expiratory pressures above the lower inflection point on the static pressure-volume curve, a tidal volume of less than 6 ml per kilogram, driving pressures of less than 20 cm of water above the PEEP value, permissive hypercapnia, and preferential use of pressure-limited ventilatory modes. Results After 28 days, 11 of 29 patients (38 percent) in the protective-ventilation group had died, as compared with 17 of 24 (71 percent) in the conventional-ventilation group (P<0.001). The rates of weaning from mechanical ventilation were 66 percent in the protective-ventilation group and 29 per cent in the conventional-ventilation group (P=0.005); the rates of clinical barotrauma were 7 percent and 42 percent, respectively (P=0.02), despite the use of higher PEEP and mean airway pressures in the protective-ventilation group. The difference in survival to hospital discharge was not significant; 13 of 29 patients (45 percent) in the protective-ventilation group died in the hospital, as compared with 17 of 24 in the conventional-ventilation group (71 percent, P=0.37). Conclusions As compared with conventional ventilation, the protective strategy was associated with improved survival at 28 days, a higher rate of weaning from mechanical ventilation, and a lower rate of barotrauma in patients with the acute respiratory distress syndrome. Protective ventilation was not associated with a higher rate of survival to hospital discharge. (C) 1998, Massachusetts Medical Society.	Univ Sao Paulo, Hosp Clin, Div Pulm, Resp Intens Care Unit, BR-05508 Sao Paulo, Brazil; Santa Casa Misericordia, Gen Intens Care Unit, Porto Alegre, RS, Brazil	Universidade de Sao Paulo	Amato, MBP (corresponding author), 135 Rue Dr Joel Lagos, BR-05344000 Sao Paulo, Brazil.		Barbas, Carmen Silvia Valente/H-1048-2013; Kairalla, Ronaldo/D-5736-2014; Lorenzi-Filho, Geraldo GLF/E-1062-2012; Carvalho, Carlos Roberto R/N-9827-2018; Gomes, Susimeire/L-8738-2013; amato, Marcelo Britto Passo/L-5001-2016; Carvalho, Carlos RR/H-2161-2011	Barbas, Carmen Silvia Valente/0000-0002-3922-6256; Kairalla, Ronaldo/0000-0001-7194-0479; Lorenzi-Filho, Geraldo GLF/0000-0002-7011-7373; Carvalho, Carlos Roberto R/0000-0002-1618-8509; amato, Marcelo Britto Passo/0000-0003-3525-8282; Takagaki, Teresa/0000-0003-2277-2100				ALBERT RK, 1985, CHEST, V87, P2, DOI 10.1378/chest.87.1.2; AMATO MBP, 1992, CHEST, V102, P1225, DOI 10.1378/chest.102.4.1225; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; AMATO MBP, 1995, AM J RESP CRIT CARE, V151, pA550; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; BSHOUTY Z, 1988, J APPL PHYSIOL, V64, P1900, DOI 10.1152/jappl.1988.64.5.1900; CARLTON DP, 1990, J APPL PHYSIOL, V69, P577, DOI 10.1152/jappl.1990.69.2.577; Carvalho CRR, 1997, AM J RESP CRIT CARE, V156, P1458, DOI 10.1164/ajrccm.156.5.9604081; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; EDMONDS HL, 1981, CRIT CARE MED, V9, P524, DOI 10.1097/00003246-198107000-00005; FU ZX, 1992, J APPL PHYSIOL, V73, P123, DOI 10.1152/jappl.1992.73.1.123; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Gattinoni L, 1991, MECHANICAL VENTILATI, P129; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; GREGORY GA, 1970, NEW ENGL J MED, V282, P1141, DOI 10.1056/NEJM197005142822007; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; JOHANSON WG, 1985, AM REV RESPIR DIS, V132, P358; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MARINI JJ, 1989, ANN INTERN MED, V110, P699, DOI 10.7326/0003-4819-110-9-699; MARINI JJ, 1994, ANESTHESIOLOGY, V80, P972, DOI 10.1097/00000542-199405000-00004; MATHIEUCOSTELLO O, 1995, J APPL PHYSIOL, V79, P908, DOI 10.1152/jappl.1995.79.3.908; MATHRU M, 1983, CRIT CARE MED, V11, P359, DOI 10.1097/00003246-198305000-00008; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; NAHUM A, 1996, AM J RESP CRIT CAR S, V153, pA531; PARKER JC, 1990, AM REV RESPIR DIS, V142, P321, DOI 10.1164/ajrccm/142.2.321; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETTY TL, 1988, AM REV RESPIR DIS, V138, P475, DOI 10.1164/ajrccm/138.2.475; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; SANDHAR BK, 1988, INTENS CARE MED, V14, P538, DOI 10.1007/BF00263527; SMITH PEM, 1986, INTENS CARE MED, V12, P86; SNYDER JV, 1987, OXYGEN TRANSPORT CRI, P358; SUGIURA M, 1994, J APPL PHYSIOL, V77, P1355, DOI 10.1152/jappl.1994.77.3.1355; TEBOUL JL, 1992, J CRIT CARE, V7, P22, DOI 10.1016/0883-9441(92)90005-R; TILSON MD, 1977, SURGERY, V82, P1833; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; WYSZOGRODSKI I, 1975, J APPL PHYSIOL, V38, P461, DOI 10.1152/jappl.1975.38.3.461; YEUNG HC, 1990, CRIT CARE MED, V18, P1347, DOI 10.1097/00003246-199012000-00007; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9	45	2287	2465	2	90	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					347	354		10.1056/NEJM199802053380602	http://dx.doi.org/10.1056/NEJM199802053380602			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449727				2023-01-03	WOS:000071822200002
J	O'Neill, B; Rodway, A				O'Neill, B; Rodway, A			ABC of palliative care - Care in the community	BRITISH MEDICAL JOURNAL			English	Review									British Med Assoc, London, England		O'Neill, B (corresponding author), British Med Assoc, BMA House, London, England.								0	7	7	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					373	377		10.1136/bmj.316.7128.373	http://dx.doi.org/10.1136/bmj.316.7128.373			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487177	Green Published			2023-01-03	WOS:000071863900035
J	Gershlick, AH; More, RS				Gershlick, AH; More, RS			Recent advances - Treatment of myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RECOMBINANT PLASMINOGEN-ACTIVATOR; PRIMARY ANGIOPLASTY REGISTRY; CHRONIC CANINE MODEL; CORONARY THROMBOLYSIS; ADJUNCTIVE THERAPY; TISSUE-TYPE; R-HIRUDIN; TRIAL; PREVENTION; STREPTOKINASE		Univ Leicester, Dept Med & Therapeut, Div Cardiol, Leicester LE3 9QP, Leics, England; St Marys Hosp, Portsmouth PO3 6AQ, Hants, England	University of Leicester	Gershlick, AH (corresponding author), Univ Leicester, Dept Med & Therapeut, Div Cardiol, Leicester LE3 9QP, Leics, England.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; Antman EM, 1996, EUR HEART J, V17, P971; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; CANNON CP, 1994, J AM COLL CARDIOL, V23, P993, DOI 10.1016/0735-1097(94)90581-9; COLLEN D, 1993, CIRCULATION, V87, P1850, DOI 10.1161/01.CIR.87.6.1850; COLLINS R, 1995, LANCET, V345, P669; *COR ART AC COR SY, 1997, NEW ENGL J MED, V336, P1621; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; GERSHLICK A, 1992, INT J CARDIOL, V36, P49, DOI 10.1016/0167-5273(92)90107-E; GOLD H, 1996, CIRCULATION, V94, P558; HAMPTON J, 1993, LANCET, V342, P759; HUNT D, 1992, LANCET, V339, P753; KAWAI C, 1992, CIRCULATION S, V86, P1; LEE CD, 1989, BLOOD, V73, P185; LEE LV, 1995, AM J CARDIOL, V75, P7, DOI 10.1016/S0002-9149(99)80517-7; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P387; MARTIN U, 1992, FIBRINOLYSIS, V6, P39, DOI 10.1016/0268-9499(92)90046-K; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MORE RS, 1993, BRIT HEART J, V69, P49; ONEILL WW, 1994, AM J CARDIOL, V73, P627, DOI 10.1016/0002-9149(94)90924-5; REMIMER KA, 1977, CIRCULATION, V56, P786; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROTE WE, 1994, J CARDIOVASC PHARM, V23, P194, DOI 10.1097/00005344-199402000-00004; ROTE WE, 1994, J CARDIOVASC PHARM, V23, P203, DOI 10.1097/00005344-199402000-00005; RUBSAMEN K, 1995, THROMB HAEMOSTASIS, V74, P1353; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; Stone GW, 1997, NEW ENGL J MED, V337, P1168; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1993, CORONARY ARTERY DIS, V4, P929; WILCOX RG, 1988, LANCET, V2, P525; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V	36	9	11	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	1998	316	7127					280	284		10.1136/bmj.316.7127.280	http://dx.doi.org/10.1136/bmj.316.7127.280			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472514	Green Published			2023-01-03	WOS:000071702100029
J	Davies, L; Angus, RM; Calverley, PMA				Davies, L; Angus, RM; Calverley, PMA			Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial	LANCET			English	Article							CHRONIC-BRONCHITIS; GLOBAL BURDEN; COPD; METHYLPREDNISOLONE; MORTALITY	Background The role of oral corticosteroids in treating patients with exacerbations of chronic obstructive pulmonary disease (COPD) remains contentious. We assessed in a prospective, randomised, double-blind, placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbations of COPD requiring hospital admission. Methods We recruited patients with non-acidotic exacerbations of COPD who were randomly assigned oral prednisolone 30 mg once daily (n=29) or identical placebo (n=27) for 14 days, in addition to standard treatment with nebulised bronchodilators, antibiotics, and oxygen. We did spirometry and recorded symptom scores daily in inpatients. Time to discharge and withdrawals were noted in each group. We recalled patients at 6 weeks to repeat spirometry and collect data on subsequent exacerbations and treatment. Hospital stay was analysed by intention to treat and forced expiratory volume in 1 s (FEV1) according to protocol. Findings FEV1 after bronchodilation increased more rapidly and to a greater extent in the corticosteroid-treated group: percentage predicted FEV1 after bronchodilation rose from 25.7% (95% CI 21.0-30.4) to 32.2% (27.3-27.1) in the placebo group (p<0.0001) compared with 28.2% (23.5-32.9) to 41.5% (35.8-47.2) in the corticosteroid-treated group (p<0.0001). Up to day 5 of hospital stay, FEV1 after bronchodilation increased by 90 mL daily (50.8-129.2) and by 30 mt daily (10.4-49.6) in the placebo group (p=0.039). Hospital stays were shorter in the corticosteroid-treated group. Groups did not differ at 6-week follow-up. Interpretation These data provide evidence to support the current practice of prescribing low-dose oral corticosteroids to all patients with non-acidotic exacerbations of COPD requiring hospital admission.	Univ Liverpool, Univ Hosp Aintree, Aintree Chest Ctr, Liverpool L9 7AL, Merseyside, England; Univ Liverpool, Univ Hosp Aintree, Dept Med, Liverpool L9 7AL, Merseyside, England	University of Liverpool; University of Liverpool	Calverley, PMA (corresponding author), Univ Liverpool, Univ Hosp Aintree, Clin Dept, Liverpool L9 7AL, Merseyside, England.							ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; Angus RM, 1995, THORAX, V50, P445; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bullard MJ, 1996, AM J EMERG MED, V14, P139, DOI 10.1016/S0735-6757(96)90120-5; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; Confalonieri M, 1998, THORAX, V53, P583, DOI 10.1136/thx.53.7.583; Decramer M, 1996, AM J RESP CRIT CARE, V153, P1958, DOI 10.1164/ajrccm.153.6.8665061; EMERMAN CL, 1989, CHEST, V95, P563, DOI 10.1378/chest.95.3.563; Gibson P G, 1998, J Qual Clin Pract, V18, P125; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; MOAYYEDI P, 1995, THORAX, V50, P834, DOI 10.1136/thx.50.8.834; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Osman LM, 1997, THORAX, V52, P67; Pearson MG, 1997, THORAX, V52, pS1; Poole PJ, 1997, NEW ZEAL MED J, V110, P272; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814	23	353	375	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					456	460		10.1016/S0140-6736(98)11326-0	http://dx.doi.org/10.1016/S0140-6736(98)11326-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465169				2023-01-03	WOS:000081896100009
J	Swinburn, JMA; Ali, SM; Banerjee, DJ; Khan, ZP				Swinburn, JMA; Ali, SM; Banerjee, DJ; Khan, ZP			To whom is our duty of care?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England		Khan, ZP (corresponding author), City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England.							[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; *C MED ROYAL COLL, 1995, J R COLL PHYSICIANS, V29, P381; PALLIS C, 1983, BRIT MED J, V286, P123, DOI 10.1136/bmj.286.6359.123; SPRUNG CL, 1995, CRIT CARE MED, V23, P618, DOI 10.1097/00003246-199504000-00004	5	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1753	1754						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381716				2023-01-03	WOS:000081216900038
J	Dunn, N; Thorogood, M; Faragher, B; de Caestecker, L; MacDonald, TM; McCollum, C; Thomas, S; Mann, R				Dunn, N; Thorogood, M; Faragher, B; de Caestecker, L; MacDonald, TM; McCollum, C; Thomas, S; Mann, R			Oral contraceptives and myocardial infarction: results of the MICA case-control study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; YOUNG-WOMEN; RISK; HEALTH	Objectives To determine the association between myocardial infarction and use of different types of oral contraception in young women. Design Community based case-control study. Data from interviews and general practice records. Setting England, Scotland, and Wales. Participants Cases (n = 448) were recruited from women aged between 16 and 44 who had suffered an incident myocardial infarction between 1 October 1993 and 16 October 1995. Controls (n = 1728) were women without a diagnosis of myocardial infarction matched for age and general practice. Main outcome measures Odds ratios for myocardial infarction in current users of all combined oral contraceptives stratified by their progestagen content compared with non-users; current users of third generation versus second generation oral contraceptives. Results The adjusted odds ratio for myocardial infarction was 1.40 (95% confidence interval 0.78 to 2.52) for all combined oral contraceptive users, 1.10 (0.52 to 2.30) for second generation users, and 1.96 (0.87 to 4.39) for third generation users. Subgroup analysis by progestagen content did not show any significant difference from 1, and there was no effect of duration of use. The adjusted odds ratio for third generation users versus second generation users was 1.78 (0.66 to 4.83). 87% of cases were not exposed to an oral contraceptive, and 88% had clinical cardiovascular risk factors or were smokers, or both. Smoking was strongly associated with myocardial infarction: adjusted odds ratio 12.5 (7.29 to 21.5) for smoking 20 or more cigarettes a day. Conclusions There was no significant association between the use of oral contraceptives and myocardial infarction. The modest and non-significant point estimates for this association have wide confidence intervals. There was no significant difference between second and third generation products.	Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; London Sch Hyg & Trop Med, London WC1 6FH, England; UMIST, Manchester Sch Management, Dept Org Psychol, Manchester M60 1QD, Lancs, England; Greater Glasgow Hlth Board, Dept Publ Hlth, Glasgow G3 8YU, Lanark, Scotland; Ninewells Hosp, Sch Med, Dept Clin Pharmacol & Therapeut, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England; Univ Newcastle Upon Tyne, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of London; London School of Hygiene & Tropical Medicine; University of Manchester; University of Dundee; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Newcastle University - UK	Dunn, N (corresponding author), Drug Safety Res Unit, Bursledon Hall, Southampton SO31 1AA, Hants, England.			MacDonald, Thomas/0000-0001-5189-6669				DebertRibeiro M, 1995, J CLIN EPIDEMIOL, V48, P1513; Dunn NR, 1997, PHARMACOEPIDEM DR S, V6, P283, DOI 10.1002/(SICI)1099-1557(199707)6:4<283::AID-PDS270>3.3.CO;2-6; Jick H, 1996, LANCET, V347, P627, DOI 10.1016/S0140-6736(96)91334-3; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; McAlpine R, 1998, PHARMACOEPIDEM DR S, V7, P311, DOI 10.1002/(SICI)1099-1557(199809/10)7:5<311::AID-PDS371>3.3.CO;2-F; OLIVER MF, 1986, MYOCARDIAL INFARCTIO, P215; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; SYDNEY S, 1996, OBSTET GYNECOL, V88, P939; TunstallPedoe H, 1997, BRIT MED J, V315, P722, DOI 10.1136/bmj.315.7110.722	12	130	132	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1579	1583		10.1136/bmj.318.7198.1579	http://dx.doi.org/10.1136/bmj.318.7198.1579			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364115	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000080913100019
J	Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL				Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL			Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin	ONCOGENE			English	Article						Etk; tyrosine kinase; PI3-kinase; photodynamic therapy; thapsigargin; apoptosis; prostate cancer	MOUSE LYMPHOMA-CELLS; PLECKSTRIN-HOMOLOGY DOMAIN; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; POLY(ADP-RIBOSE) POLYMERASE; ENDOPLASMIC-RETICULUM; ACTIVATION; AKT; PHOSPHORYLATION; RESISTANCE	Prostate carcinoma (PCA) is the most frequently diagnosed malignancy in American men. PCA at advanced stages can both proliferate abnormally and resist apoptosis, Among the many known signal transduction pathways, phosphatidylinositide-3'OH kinase (PI3-kinase) has been shown to play an important role in cell survival and resistance to apoptosis, In this study, we investigate the involvement of Etk/Bmx, a newly discovered tyrosine kinase that is a substrate of PI3-kinase, in protection of prostate cancer cells from apoptosis, Parental LNCaP cells and tno derivative cell lines, one overexpressing mild type Etk (Etkwt) and the other expressing a dominant negative Etk (EtkDN), were used to study the function of Etk. The cells mere treated with photodynamic therapy (PDT), a newly approved cancer treatment which employs a photosensitizer and visible light to produce an oxidative stress in cells, often leading to apoptosis. Our results indicate that PDT induces apoptosis in LNCaP cells, as measured by DNA fragmentation and by cleavage of poly(ADP-ribose) polymerase (PARP), and moreover, the extent of apoptosis was much reduced in Etkwt cells as compared to LNCaP or EtkDN cells. Assay of overall cell viability confirmed that Etkwt cells mere considerably less sensitive to PDT than were the parental LNCaP or EtkDN cells. Similar results were found in response to thapsigargin (TG). A specific inhibitor of PI3-kinase, LY294002, abolished Etk activity and markedly increased TG-induced PARP cleavage. The results suggest that Etk/Bmx is an efficient effector of PI3-kinase and that the newly described PI3-kinase/Etk pathway is involved in the protection of prostate carcinoma cells from apoptosis in response to PDT or TG.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, P01 CA48735, CA57179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA039207, R01CA057179, R37CA039207, P01CA048735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fisher AMR, 1997, PHOTOCHEM PHOTOBIOL, V66, P265, DOI 10.1111/j.1751-1097.1997.tb08653.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GOMER CJ, 1991, CANCER RES, V51, P6574; Hasan T., 1997, PHOTODYNAMIC THERAPY, P739; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; IWABUCHI H, 1995, CANCER RES, V55, P6172; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LI WWF, 1993, J BIOL CHEM, V268, P12003; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LIU H, 1997, J BIOL CHEM, V272, P21752; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; McConkey DJ, 1996, CANCER RES, V56, P5594; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tang DG, 1997, PROSTATE, V32, P284; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Tenniswood M, 1997, BRIT J UROL, V79, P27, DOI 10.1111/j.1464-410X.1997.tb16918.x; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Xue LY, 1997, PHOTOCHEM PHOTOBIOL, V66, P105, DOI 10.1111/j.1751-1097.1997.tb03145.x	48	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3391	3398		10.1038/sj.onc.1202687	http://dx.doi.org/10.1038/sj.onc.1202687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362360				2023-01-03	WOS:000080589300010
J	Manian, FA				Manian, FA			Whither continuity of care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	29	29	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1362	1363		10.1056/NEJM199904293401712	http://dx.doi.org/10.1056/NEJM199904293401712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219075				2023-01-03	WOS:000080001700012
J	Nenner, F				Nenner, F			A mother's voice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	1999	281	12					1065	1065		10.1001/jama.281.12.1065	http://dx.doi.org/10.1001/jama.281.12.1065			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	177EP	10188641				2023-01-03	WOS:000079197100001
J	Vroomen, PCAJ; de Krom, MCTFM; Wilmink, JT; Kester, ADM; Knottnerus, JA				Vroomen, PCAJ; de Krom, MCTFM; Wilmink, JT; Kester, ADM; Knottnerus, JA			Lack of effectiveness of bed rest for sciatica	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BACK-PAIN; MUSCULOSKELETAL; IMMOBILIZATION; COMPLICATIONS; TRIAL	Background and Methods Bed rest is widely advocated for sciatica, but its effectiveness has not been established. To study the effectiveness of bed rest in patients with a lumbosacral radicular syndrome of sufficient severity to justify treatment with bed rest for two weeks, we randomly assigned 183 subjects to either bed rest or watchful waiting for this period. The primary outcome measures were the investigator's and patient's global assessments of improvement after 2 and 12 weeks, and the secondary outcome measures were changes in functional status and in pain scores (after 2, 3, and 12 weeks), absenteeism from work, and the need for surgical intervention. Neither the investigators who assessed the outcomes nor those involved in data entry and analysis were aware of the patients' treatment assignments. Results After two weeks, 64 of the 92 patients in the bed-rest group (70 percent) reported improvement, as compared with 59 of the 91 patients in the control (watchful-waiting) group (65 percent) (adjusted odds ratio for improvement in the bed-rest group, 1.2; 95 percent confidence interval, 0.6 to 2.3). After 12 weeks, 87 percent of the patients in both groups reported improvement. The results of assessments of the intensity of pain, the bothersomeness of symptoms, and functional status revealed no significant differences between the two groups. The extent of absenteeism from work and rates of surgical intervention were similar in the two groups. Conclusions Among patients with symptoms and signs of a lumbosacral radicular syndrome, bed rest is not a more effective therapy than watchful waiting. (N Engl J Med 1999;340:418-23.) (C) 1999, Massachusetts Medical Society.	Maastricht Univ Hosp, Dept Neurol, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ Hosp, Dept Radiol, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ, Dept Methodol & Stat, Maastricht, Netherlands; Maastricht Univ, Dept Family Practice, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University	Vroomen, PCAJ (corresponding author), Maastricht Univ Hosp, Dept Neurol, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.	pvr@sncu.azm.nl	Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009; Vroomen, Patrick C.A.J./O-3664-2014	Vroomen, Patrick C.A.J./0000-0003-4806-417X				Altman DG, 1991, PRACTICAL STAT MED R; BEURSKENS AJ, 1995, SPINE, V20, P1017, DOI 10.1097/00007632-199505000-00008; BONDEPETERSEN F, 1994, ACTA PHYSIOL SCAND, V150, P65; Convertino VA, 1997, MED SCI SPORT EXER, V29, P187, DOI 10.1097/00005768-199702000-00004; COOMES EN, 1961, BMJ-BRIT MED J, V264, P20; COX DR, 1972, J R STAT SOC B, V34, P187; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DITTMER DK, 1993, CAN FAM PHYSICIAN, V39, P1428; Dittmer DK, 1993, CAN FAM PHYS, V39, P1435; FERRANDO AA, 1995, AVIAT SPACE ENVIR MD, V66, P976; FORDYCE WE, 1988, AM PSYCHOL, V43, P276, DOI 10.1037/0003-066X.43.4.276; HAERER AF, 1992, DEJONGS NEUROLOGICAL, P596; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; KLEINBAUM DG, 1994, LOGISTIC REGRESSION, P282; KOES BW, 1994, EUR J PHYS MED REHAB, V4, P86; Levine BD, 1997, CIRCULATION, V96, P517; LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Melzack R, 1994, TXB PAIN, P337; PEDERSEN BJ, 1995, BONE, V17, P91, DOI 10.1016/8756-3282(95)00149-8; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SUZUKI Y, 1994, ACTA PHYSIOL SCAND, V150, P5; TAKENAKA K, 1994, ACTA PHYSIOL SCAND, V150, P59; TEASELL R, 1993, CAN FAM PHYSICIAN, V39, P1440; VANLEEUWEN RB, 1986, MED CONTACT, V50, P1618; Waddell G, 1997, BRIT J GEN PRACT, V47, P647	30	122	131	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					418	423		10.1056/NEJM199902113400602	http://dx.doi.org/10.1056/NEJM199902113400602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971865				2023-01-03	WOS:000078571000002
J	Williams, CJ; Pieri, L; Sims, A				Williams, CJ; Pieri, L; Sims, A			We should strive to keep patients alive	BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA		St James Univ Hosp, Div Psychiat & Behav Sci Relat Med, Leeds LS9 7TF, W Yorkshire, England; Seacroft Hosp, Yorkshire Ctr Eating Disorder, Leeds LS14 6UH, W Yorkshire, England	Saint James's University Hospital	Williams, CJ (corresponding author), St James Univ Hosp, Div Psychiat & Behav Sci Relat Med, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							ECKERT ED, 1995, PSYCHOL MED, V25, P143, DOI 10.1017/S0033291700028166; Keyes A, 1950, BIOL HUMAN STARVATIO, V1; KEYES A, 1950, BIOL HUMAN STARVATIO, V2; LEE MA, 1992, J AM GERIATR SOC, V13, P21; OGILVIE AD, 1994, BRIT MED J, V309, P492, DOI 10.1136/bmj.309.6953.492; ONEILL J, 1994, AM J HOSPICE PAL NOV, P36; RATNASURIYA RH, 1991, BRIT J PSYCHIAT, V158, P495, DOI 10.1192/bjp.158.4.495; SLADE PD, 1973, PSYCHOL MED, V3, P188, DOI 10.1017/S0033291700048510; TILLER J, 1993, BRIT J PSYCHIAT, V162, P679, DOI 10.1192/bjp.162.5.679	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					195	196		10.1136/bmj.317.7152.195	http://dx.doi.org/10.1136/bmj.317.7152.195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	103FZ	9665907	Green Published			2023-01-03	WOS:000075047800033
J	Naude, JH; Le Roux, PJ				Naude, JH; Le Roux, PJ			Topical treatment of erectile dysfunction did not show results	BRITISH MEDICAL JOURNAL			English	Letter									Univ Cape Town, Dept Urol, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Dept Urol, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Cape Town	Naude, JH (corresponding author), Univ Cape Town, Dept Urol, ZA-7925 Cape Town, South Africa.							Gomaa A, 1996, BRIT MED J, V312, P1512, DOI 10.1136/bmj.312.7045.1512	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1318	1318		10.1136/bmj.316.7140.1318	http://dx.doi.org/10.1136/bmj.316.7140.1318			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554911	Green Published			2023-01-03	WOS:000073335900039
J	Griffiths, RD; Jones, C				Griffiths, RD; Jones, C			ABC of intensive care - Recovery from intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Whiston Hosp, Dept Med, Intens Care Res Grp, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Whiston Hospital	Griffiths, RD (corresponding author), Univ Liverpool, Whiston Hosp, Dept Med, Intens Care Res Grp, Liverpool L69 3BX, Merseyside, England.								0	88	92	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					427	429		10.1136/bmj.319.7207.427	http://dx.doi.org/10.1136/bmj.319.7207.427			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445926	Green Published			2023-01-03	WOS:000082098900021
J	Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS				Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS			Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model	BRITISH MEDICAL JOURNAL			English	Article									Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen NV, Denmark; Gentofte Hosp, Dept Neurol, DK-2900 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Jorgensen, HS (corresponding author), Bispebjerg Hosp, Dept Neurol, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.							Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; JORGENSEN HS, 1994, LANCET, V344, P156; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401	4	32	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					288	289		10.1136/bmj.319.7205.288	http://dx.doi.org/10.1136/bmj.319.7205.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426737	Bronze, Green Published			2023-01-03	WOS:000081909100021
J	Bisgaard, H; Moller, H				Bisgaard, H; Moller, H			Changes in risk of hospital readmission among asthmatic children in Denmark, 1978-93	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Bisgaard, H (corresponding author), Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark.	Bisgaard@RH.DK	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Moller, Henrik/0000-0001-8200-5929	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bisgaard H, 1997, PEDIATR PULM, P27; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Warner JO, 1998, PEDIATR PULM, V25, P1	4	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					229	230		10.1136/bmj.319.7204.229	http://dx.doi.org/10.1136/bmj.319.7204.229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417085	Bronze, Green Published			2023-01-03	WOS:000081720300024
J	Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF				Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF			Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue - An uncontrolled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lymphoma, mucosa-associated lymphoid tissue; Helicobacter pylori; Helicobacter infections; antibiotics; neoplasm staging	HELICOBACTER-PYLORI INFECTION; MANTLE CELL LYMPHOMA; MALT LYMPHOMA; MALIGNANT-LYMPHOMA; CLASSIFICATION; REGRESSION; ERADICATION; THERAPY; SYSTEM; CURE	Background: Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth. Objective: To determine the response of gastric MALT lymphoma to antibiotic treatment. Design: Prospective, uncontrolled treatment trial. Setting: University hospital referral center and three collaborating university and community hospitals. Patients: 34 patients with stage I or stage II N1 gastric MALT lymphoma. Intervention: Two of three oral antibiotic regimens-1) amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2) tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracycline, 500 mg four times daily, and metronidazole, 500 mg three times daily-were administered sequentially (usually in the order written) for 21 days at baseline and at 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate. Measurements: Complete remission was defined as the absence of histopathologic evidence of lymphoma on endoscopic biopsy. Partial remission was defined as a reduction in endoscopic tumor stage or 50% reduction in the size of large tumors. Results: 34 patients were followed for a mean (+/-SD) of 41 +/- 16 months (range, 18 to 70 months) after antibiotic treatment. Of 28 H. pylori-positive patients, 14 (50% [95% CI, 31% to 69%]) achieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of the 8), and 10 (36% [CI, 19% to 56%]) did not respond to treatment. Treatment failed in all 6 (100% [CI, 54% to 100%]) H. pylori-negative patients. Patients with endoscopic appearance of gastritis (stage I T1 disease) were most likely to achieve complete remission within 18 months. Tumors in the distal stomach were associated with more favorable response than tumors in the proximal stomach. Conclusions: A subset of H. pylori-positive gastric MALT lymphomas, including infiltrative tumors, may respond to antibiotics. The likelihood of: early complete remission seems to be greatest for superficial and distal tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Steinbach, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Box 78,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsteihb@aol.com	Graham, David/AAL-2165-2021	Shen, Yu/0000-0002-3899-7868; Steinbach, Gideon/0000-0001-7597-0544; Cabanillas, Fernando/0000-0001-9234-7893	NCI NIH HHS [CA-16672, R01 CA67540-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067540, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BLACKLEDGE G, 1979, CLIN ONCOL, V5, P209; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; CHAN JKC, 1990, AM J PATHOL, V136, P1153; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; GREINER A, 1994, LAB INVEST, V70, P572; HARRIS NL, 1994, BLOOD, V84, P1361; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; LUTHRA R, 1995, DIAGN MOL PATHOL, V4, P4, DOI 10.1097/00019606-199503000-00003; McLaughlin P, 1996, ANN ONCOL, V7, P211; MONTALBAN C, 1995, ANN ONCOL, V6, P355, DOI 10.1093/oxfordjournals.annonc.a059184; MOUTSOPOULOS HM, 1994, CLIN IMMUNOL IMMUNOP, V72, P162, DOI 10.1006/clin.1994.1123; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NAKAMURA S, 1995, CANCER, V76, P1313, DOI 10.1002/1097-0142(19951015)76:8<1313::AID-CNCR2820760804>3.0.CO;2-1; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; Neubauer A, 1997, JNCI-J NATL CANCER I, V89, P1350, DOI 10.1093/jnci/89.18.1350; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; Sackmann M, 1997, GASTROENTEROLOGY, V113, P1087, DOI 10.1053/gast.1997.v113.pm9322502; SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X; STEINBACH G, 1995, GASTROENTEROLOGY, V108, pA541; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	33	170	178	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					88	+		10.7326/0003-4819-131-2-199907200-00003	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419446				2023-01-03	WOS:000081509700002
J	Morgan, K; Prothero, D; Frankel, S				Morgan, K; Prothero, D; Frankel, S			The rise in emergency admissions - crisis or artefact? Temporal analysis of health services data	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Avon Hlth Author, Bristol BS2 8EE, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							Blatchford O, 1997, BRIT MED J, V315, P1322, DOI 10.1136/bmj.315.7119.1322; Capewell S, 1996, BRIT MED J, V312, P991; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; Kendrick S, 1996, Health Bull (Edinb), V54, P169	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					158	159		10.1136/bmj.319.7203.158	http://dx.doi.org/10.1136/bmj.319.7203.158			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406749	Green Published, Bronze			2023-01-03	WOS:000081619300020
J	Bates, DW; Leape, LL; Cullen, DJ; Laird, N; Petersen, LA; Teich, JM; Burdick, E; Hickey, M; Kleefield, S; Shea, B; Vander Vliet, M; Seger, DL				Bates, DW; Leape, LL; Cullen, DJ; Laird, N; Petersen, LA; Teich, JM; Burdick, E; Hickey, M; Kleefield, S; Shea, B; Vander Vliet, M; Seger, DL			Effect of computerized physician order entry and a team intervention on prevention of serious medication errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS; PREVENTABILITY; PHARMACISTS; MORTALITY; SYSTEMS; IMPACT	Context.-Adverse drug events (ADEs) are a significant and costly cause of injury during hospitalization. Objectives.-To evaluate the efficacy of 2 interventions for preventing nonintercepted serious medication errors, defined as those that either resulted in or had potential to result in an ADE and were not intercepted before reaching the patient. Design.-Before-after comparison between phase 1 (baseline) and phase 2 (after intervention was implemented) and, within phase 2, a randomized comparison between physican computer order entry (POE) and the combination of POE plus a team intervention. Setting.-Large tertiary care hospital. Participants.-For the comparison of phase 1 and 2, all patients admitted to a stratified random sample of 6 medical and surgical units in a tertiary care hospital over a 6-month period, and for the randomized comparison during phase 2, all patients admitted to the same units and 2 randomly selected additional units over a subsequent 9-month period. Interventions.-A physician computer order entry system (POE) for all units and a team-based intervention that included changing the role of pharmacists, implemented for half the units. Main Outcome Measure.-Nonintercepted serious medication errors. Results.-Comparing identical units between phases 1 and 2, nonintercepted serious medication errors decreased 55%, from 10.7 events per 1000 patient-days to 4.86 events per 1000 (P=.01). The decline occurred for all stages of the medication-use process. Preventable ADEs declined 17% from 4.69 to 3.88 (P=.37), while nonintercepted potential ADEs declined 84% from 5.99 to 0.98 per 1000 patient-days (P=.002). When POE-only was compared with the POE plus team intervention combined, the team intervention conferred no additonal benefit over POE. Conclusions.-Physician computer order entry decreased the rate of nonintercepted serious medication errors by more than half, although this decrease was larger for potential ADEs than for errors that actually resulted in an ADE.	Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Qual Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pharm, Boston, MA 02115 USA; Partners Healthcare Syst, Ctr Appl Med Informat Syst Res, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; St Elizabeths Med Ctr, Dept Anesthesiol, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brockton W Roxbury Vet Affairs Med Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; St. Elizabeth's Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, 75 Francis St, Boston, MA 02115 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROWN G, 1991, AM J HOSP PHARM, V48, P2644, DOI 10.1093/ajhp/48.12.2644; BROWN GC, 1979, HOSPITALS, V53, P61; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; FOLLI HL, 1987, PEDIATRICS, V79, P718; GLASER J, 1996, 1996 HEALTHC INF MAN, P1; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; KUPERMAN GJ, 1994, P ANN S COMPUT APPL, V18, P836; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MASSARO TA, 1993, ACAD MED, V68, P20, DOI 10.1097/00001888-199301000-00003; PATERNO M, 1996, P AMIA ANN FALL S, V20, P872; Perrow C, 1984, NORMAL ACCIDENTS; *SAS I INC, 1992, SAS VERS 6 11; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; TEICH JM, 1993, P ANN S COMPUT APPL, V17, P316; TEICH JM, 1992, P ANN S COMPUT APPL, V16, P99; TEICH JM, 1996, 2 NE DAV CPR REC S M, P3; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379	29	1383	1406	0	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1311	1316		10.1001/jama.280.15.1311	http://dx.doi.org/10.1001/jama.280.15.1311			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794308				2023-01-03	WOS:000076472500021
J	Holt, PR; Atillasoy, EO; Gilman, J; Guss, J; Moss, SF; Newmark, H; Fan, KH; Yang, K; Lipkin, M				Holt, PR; Atillasoy, EO; Gilman, J; Guss, J; Moss, SF; Newmark, H; Fan, KH; Yang, K; Lipkin, M			Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIETARY CALCIUM; FECAL WATER; CYTOLYTIC ACTIVITY; COLORECTAL-CANCER; LARGE-BOWEL; BILE-ACIDS; CARCINOGENESIS; MUCOSA; CHEMOPREVENTION; CYTOTOXICITY	Context.-Before the development of human colonic neoplasms, colonic epithelial cells showed altered growth and differentiation. These alterations characterized mucosa at risk for cancer formation and were termed intermediate biomarkers of risk. Modifications of the mucosa toward more normal features by nutrients or drugs are putative approaches to chemoprevention of colon cancer. Objective.-To determine whether increasing calcium intake via dairy products alters colonic biomarkers toward normal. Design.-Randomized, single-blind, controlled study. Setting.-Outpatient clinic. Participants.-Seventy subjects with a history of polypectomy for colonic adenomatous polyps. Intervention.-low-fat dairy products containing up to 1200 mg/d of calcium. Subjects were randomized to 4 strata by diet (control vs higher calcium) and age (<60 vs greater than or equal to 60 years). Main Outcome Measures.-Changes in total colonic epithelial cells and number and position of thymidine-labeled epithelial cells and changes in the ratio of sulfomucins (predominantly secreted by distal colorectal epithelial cells) to sialomucins and expression of cytokeratin AE1, 2 markers of colonic cell differentiation. Results.-During 6 and 12 months of treatment, reduction of colonic epithelial cell proliferative activity (P<.05), reduction in size of the proliferative compartment (P<.05), and restoration of acidic mucin (P<.02), cytokeratin AE1 distribution (P<.05), and nuclear size (P<.05) toward that of normal cells occurred. Control subjects showed no differences from baseline proliferative values at 6 and 12 months (P>.05). Conclusion.-Increasing the daily intake of calcium by up to 1200 mg via lowfat dairy food in subjects at risk for colonic neoplasia reduces proliferative activity of colonic epithelial cells and restores markers of normal cellular differentiation.	St Lukes Roosevelt Hosp, Dept Med, Gastrointestinal Div, New York, NY 10025 USA; Columbia Univ, New York, NY USA; Strang Canc Prevent Ctr, New York, NY USA; Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Cornell University; NewYork-Presbyterian Hospital	Holt, PR (corresponding author), St Lukes Roosevelt Hosp, Dept Med, Gastrointestinal Div, 1111 Amsterdam Ave, New York, NY 10025 USA.			holt, peter/0000-0002-8469-2766				ABDELALI H, 1995, MUTAT RES-FUND MOL M, V331, P133, DOI 10.1016/0027-5107(95)00059-R; AMBROS RA, 1990, ANAL QUANT CYTOL, V12, P172; [Anonymous], 1994, NIH Consens Statement, V12, P1; ARENDS JW, 1984, BIOCHIM BIOPHYS ACTA, V780, P1, DOI 10.1016/0304-419X(84)90005-2; Baron JA, 1998, GASTROENTEROLOGY, V114, pA563, DOI 10.1016/S0016-5085(98)82289-0; BOSTICK RM, 1995, JNCI-J NATL CANCER I, V87, P1307, DOI 10.1093/jnci/87.17.1307; COOPER D, 1985, LAB INVEST, V52, P243; DArgenio G, 1996, GASTROENTEROLOGY, V110, P1727, DOI 10.1053/gast.1996.v110.pm8964397; Duris I, 1996, HEPATO-GASTROENTEROL, V43, P152; FILIPE MI, 1974, CANCER-AM CANCER SOC, V34, P282, DOI 10.1002/1097-0142(197408)34:2<282::AID-CNCR2820340211>3.0.CO;2-W; FLEISS J, 1986, DESIGN ANAL CLIN EXP, P49; GARINCHESA P, 1986, AM J SURG PATHOL, V10, P829; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; Govers MJAP, 1996, CANCER RES, V56, P3270; HANSKI C, 1991, CANCER RES, V51, P5342; Holt PR, 1996, CANCER EPIDEM BIOMAR, V5, P937; LAPRE JA, 1993, CANCER RES, V53, P248; LAPRE JA, 1991, AM J PHYSIOL, V261, pG907, DOI 10.1152/ajpgi.1991.261.6.G907; Liew C, 1995, CARCINOGENESIS, V16, P3037, DOI 10.1093/carcin/16.12.3037; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; LIPKIN M, 1995, JNCI-J NATL CANCER I, V87, P1275, DOI 10.1093/jnci/87.17.1275; LIPKIN M, 1991, CALCIUM VITAMIN D CO; MELING GI, 1991, CANCER, V67, P1642, DOI 10.1002/1097-0142(19910315)67:6<1642::AID-CNCR2820670628>3.0.CO;2-R; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEWMARK HL, 1995, J CELL BIOCHEM, P247; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PENCE BC, 1988, CARCINOGENESIS, V9, P187, DOI 10.1093/carcin/9.1.187; Pence BC, 1996, NUTR CANCER, V25, P35, DOI 10.1080/01635589609514426; RICHTER F, 1995, CARCINOGENESIS, V16, P2685, DOI 10.1093/carcin/16.11.2685; SAMS JS, 1990, CANCER, V66, P502, DOI 10.1002/1097-0142(19900801)66:3&lt;502::AID-CNCR2820660317&gt;3.0.CO;2-N; Schmelz EM, 1996, CANCER RES, V56, P4936; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P504, DOI 10.1093/oxfordjournals.aje.a114998; SUN TT, 1994, CANC CELLS TRANSFORM; VERHEST A, 1990, CANCER, V65, P2047, DOI 10.1002/1097-0142(19900501)65:9<2047::AID-CNCR2820650926>3.0.CO;2-4; *VIT HLTH STAT CTR, 1994, 3 NAT HLTH NUT EX SU, P255; WEISBURGER J, 1991, AM CANC SOC TXB CLIN; WELBERG JWM, 1993, EUR J CLIN INVEST, V23, P63, DOI 10.1111/j.1365-2362.1993.tb00719.x; Yang K, 1996, CANCER RES, V56, P4644	39	111	114	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1074	1079		10.1001/jama.280.12.1074	http://dx.doi.org/10.1001/jama.280.12.1074			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757855				2023-01-03	WOS:000076002400036
J	Cook, DJ; Walter, SD; Cook, RJ; Griffith, LE; Guyatt, GH; Leasa, D; Jaeschke, RZ; Brun-Buisson, C				Cook, DJ; Walter, SD; Cook, RJ; Griffith, LE; Guyatt, GH; Leasa, D; Jaeschke, RZ; Brun-Buisson, C		Canadian Critical Care Trials Grp	Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients	ANNALS OF INTERNAL MEDICINE			English	Article						ventilators, mechanical; pneumonia; cross-infection; time factors	NOSOCOMIAL MAXILLARY SINUSITIS; INTENSIVE-CARE UNITS; RECEIVING MECHANICAL VENTILATION; PREVIOUS ANTIMICROBIAL THERAPY; INTUBATED PATIENTS; PSEUDOMONAS-AERUGINOSA; MULTIVARIATE-ANALYSIS; ENTERAL NUTRITION; MORTALITY; INFECTION	Background: Understanding the risk factors for ventilator-associated pneumonia can help to assess prognosis and devise and test preventive strategies. Objective: To examine the baseline and time-dependent risk factors for ventilator-associated pneumonia and to determine the conditional probability and cumulative risk over the duration of stay in the intensive care unit. Design: Prospective cohort study. Setting: 16 intensive care units in Canada. Patients: 1014 mechanically ventilated patients. Measurements: Demographic and time-dependent variables reflecting illness severity, ventilation, nutrition, and drug exposure. Pneumonia was classified by using five methods: adjudication committee, bedside clinician's diagnosis, Centers for Disease Control and Prevention definition, Clinical Pulmonary Infection score, and positive culture from bronchoalveolar lavage or protected specimen brush. Results: 177 of 1014 patients (17.5%) developed ventilator-associated pneumonia 9.0 +/- 5.9 days (median, 7 days [interquartile range, 5 to 10 days]) after admission to the intensive care unit. Although the cumulative risk increased over time, the daily hazard rate decreased after day 5 (3.3% at day 5, 2.3% at day 10, and 1.3% at day 15). independent predictors of ventilator-associated pneumonia in multivariable analysis were a primary admitting diagnosis of burns (risk ratio, 5.09 [95% CI, 1.52 to 17.03]), trauma (risk ratio, 5.00 [CI, 1.91 to 13.11]), central nervous system disease (risk ratio, 3.40 [CI, 1.31 to 8.81]), respiratory disease (risk ratio, 2.79 [CI, 1.04 to 7.51]), cardiac disease (risk ratio, 2.72 [CI, 1.05 to 7.01]), mechanical ventilation in the previous 24 hours (risk ratio, 2.28 [CI, 1.11 to 4.68]), witnessed aspiration (risk ratio, 3.25 [CI, 1.62 to 6.50]), and paralytic agents (risk ratio, 1.57 [CI, 1.03 to 2.39]). Exposure to antibiotics conferred protection (risk ratio, 0.37 [CI, 0.27 to 0.51]). Independent risk factors were the same regardless of the pneumonia definition used. Conclusions: The daily risk for pneumonia decreases with increasing duration of stay in the intensive care unit. Witnessed aspiration and exposure to paralytic agents are potentially modifiable independent risk factors. Exposure to antibiotics was associated with low rates of early ventilator-associated pneumonia, but this effect attenuates over time.	McMaster Univ, Med Ctr, Dept Clin Epidemiol, Hamilton, ON L8N 3Z5, Canada; Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada; Univ Paris 12, Hop Henri Mondor, Dept Med Intens Care, F-94010 Creteil, France; Univ Paris 12, Hop Henri Mondor, Infect Control Unit, F-94010 Creteil, France; Univ Western Ontario, London, ON, Canada	McMaster University; University of Waterloo; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Western University (University of Western Ontario)	Cook, DJ (corresponding author), St Josephs Hosp, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	debcook@fhs.csu.mcmaster.ca	Walter, Stephen/AAB-5548-2022	Walter, Stephen/0000-0003-4157-8928; Cook, Richard/0000-0002-1414-4908				Alvarez-lerma F, 1997, CLIN INTENSIVE CARE, V8, P164; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; ATHERTON ST, 1978, LANCET, V2, P968; Baraibar J, 1997, CHEST, V112, P1050, DOI 10.1378/chest.112.4.1050; Bonten MJM, 1997, CLIN INFECT DIS, V24, P309, DOI 10.1093/clinids/24.3.309; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; Brewer C, 1996, CHEST, V109, P1019; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; Cook, 1997, Crit Care, V1, P3, DOI 10.1186/cc1; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; COOK DJ, 1994, AM J RESP CRIT CARE, V149, pA640; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; Elatrous S, 1996, CLIN INTENSIVE CARE, V7, P276, DOI DOI 10.3109/TCIC.7.6.276.281; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; HOLZAPFEL L, 1993, CRIT CARE MED, V21, P1132, DOI 10.1097/00003246-199308000-00010; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1997, CHEST, V112, P765, DOI 10.1378/chest.112.3.765; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kropec A, 1996, INTENS CARE MED, V22, P1155, DOI 10.1007/BF01709329; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LIBERATI A, 1997, ACUTE RESP INFECT MO, V3, P1; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MICHELSON A, 1991, ANAESTHESIST, V40, P100; MONTECALVO MA, 1992, CRIT CARE MED, V20, P1377, DOI 10.1097/00003246-199210000-00004; MOSCONI P, 1991, EUR J EPIDEMIOL, V7, P320, DOI 10.1007/BF00144995; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; RELLO J, 1992, CHEST, V102, P1562, DOI 10.1378/chest.102.5.1562; RELLO J, 1994, INTENS CARE MED, V20, P193, DOI 10.1007/BF01704699; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Rello J, 1996, AM J RESP CRIT CARE, V154, P111, DOI 10.1164/ajrccm.154.1.8680665; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SALORD F, 1990, INTENS CARE MED, V16, P390, DOI 10.1007/BF01735177; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Timsit JF, 1996, AM J RESP CRIT CARE, V154, P116, DOI 10.1164/ajrccm.154.1.8680666; TIMSIT JF, 1995, CHEST, V108, P1036, DOI 10.1378/chest.108.4.1036; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	55	588	623	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					433	440		10.7326/0003-4819-129-6-199809150-00002	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735080				2023-01-03	WOS:000075892100001
J	Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM				Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM			Detection of a novel DNA virus (TTV) in blood donors and blood products	LANCET			English	Article							HEPATITIS-C VIRUS; NON-A; HEMOPHILIA; DETERGENT; OUTBREAK; GLOBULIN; SOLVENT	Background A newly discovered DNA virus, transfusion-transmitted virus (TTV), has been implicated as a cause of post-transfusion hepatitis. We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which TTV contaminates blood products such as factor VIII and IX clotting factors. We also investigated the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF). Methods We extracted DNA from plasma of blood donors and patients with FHF, and from blood products (factor VIII and IX clotting-factor concentrates, immunoglobulin preparations). We detected TTV by PCR using primers from a conserved region in the TTV genome. Findings TTV viraemia was detected in 19 (1.9%) of 1000 non-remunerated regular blood donors. Infection occurred more frequently in older donors (mean age 53 years), compared with the age prolife of donors infected with hepatitis C virus and other parenterally-transmitted viruses. TTV contamination was found in ten (56%) of 18 batches of factor VIII and IX concentrate manufactured from such nonremunerated donors, and in seven (44%) of 16 batches of commercially available products. Whereas solvent or detergent treatment had little effect on the detection of TTV in factor VIII and IX by PCR, this virucidal step seemed to inactivate TTV infectivity. TTV infection was detected in four (19%) of 21 patients with FHF; in three cases, infection was detected at the onset of disease and could thus not be excluded from its aetiology. Interpretation TTV viraemia is frequent in the blood-donor population, and transmission of TTV through transfusion of blood components may have occurred extensively. Clinical assessment of infected donors and recipients of blood and blood products, and assessment of TTV's aetiological role in hepatic and extra-hepatic disease, are urgently needed.	Univ Edinburgh, Dept Med Microbiol, Edinburgh EH3 9HB, Midlothian, Scotland; Edinburgh & SE Scotland Blood Transfus Serv, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Haematol, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Simmonds, P (corresponding author), Univ Edinburgh, Dept Med Microbiol, Teviot Pl, Edinburgh EH3 9HB, Midlothian, Scotland.			Simmonds, Peter/0000-0002-7964-4700				Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1016/0270-9139(91)91406-Q; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GARSON JA, 1990, LANCET, V335, P1473, DOI 10.1016/0140-6736(90)91510-H; Hanley JP, 1998, THROMB HAEMOSTASIS, V79, P291; Haydon GH, 1997, J VIRAL HEPATITIS, V4, P45, DOI 10.1046/j.1365-2893.1997.00122.x; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; KEDDA MA, 1995, HEPATOLOGY, V22, P1363, DOI 10.1002/hep.1840220504; KERNOFF PBA, 1985, BRIT J HAEMATOL, V60, P469, DOI 10.1111/j.1365-2141.1985.tb07444.x; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LAWLOR E, 1994, VOX SANG, V67, P18, DOI 10.1111/j.1423-0410.1994.tb00968.x; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; Yap PL, 1996, CLIN EXP IMMUNOL, V104, P35, DOI 10.1111/cei.1996.104.s1.35	21	349	371	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					191	195		10.1016/S0140-6736(98)03056-6	http://dx.doi.org/10.1016/S0140-6736(98)03056-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683208				2023-01-03	WOS:000074859800012
J	Quill, TE; Meier, DE; Block, SD; Billings, JA				Quill, TE; Meier, DE; Block, SD; Billings, JA			The debate over physician-assisted suicide: Empirical data and convergent views	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; CRITICALLY ILL PATIENTS; CANCER PAIN MANAGEMENT; MEDICAL ILLNESS; TERMINALLY ILL; HOPELESSLY ILL; WASHINGTON-STATE; EUTHANASIA; DEPRESSION; ATTITUDES	The debate over physician-assisted suicide is a small part of the process of improving care for all dying patients and their families. Available data, although limited, can help clarify this narrow debate and can provide a useful context for articulation of the common ground. This paper reviews these data, which suggest that unnecessary end-of-life suffering can be considerably reduced by improving access to and delivery of palliative care and improving recognition and treatment of pain and depression in terminally ill persons. It also sets forth possible areas of common ground between the two sides in the debate. Even with the best of care, a small number of dying patients will still have suffering that cannot be satisfactorily relieved, and some of these patients will request assistance in hastening death. Terminal sedation and the voluntary cessation of eating and drinking may be legally acceptable alternatives to physician-assisted suicide for the few patients whose suffering cannot be made tolerable with standard palliative interventions. Physicians should not violate their fundamental values when faced with such patients but should make patients aware of the full range of available alternatives to prolonged, intolerable distress. Physicians have the responsibility to give comprehensive palliative care to terminally ill patients and their families throughout the dying process and to make every effort to explore, understand, and address suffering that persists despite their best efforts.	Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Rochester, Sch Med & Dent, Rochester, NY USA; Mt Sinai Sch Med, New York, NY USA	Harvard University; Harvard Medical School; University of Rochester; Icahn School of Medicine at Mount Sinai	Quill, TE (corresponding author), Genesee Hosp, Dept Med, 224 Alexander St, Rochester, NY 14607 USA.		Van den Block, Lieve/D-1247-2011	Van den Block, Lieve/0000-0002-7770-348X				ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; *AM COLL PHYS ETH, 1992, ANN INTERN MED, V117, P946; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; American Thoracic Society, 1991, Ann Intern Med, V115, P478; Angell M, 1996, NEW ENGL J MED, V335, P1676, DOI 10.1056/NEJM199611283352209; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BALLE WF, 1993, CANCER, V72, P2786; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings J A, 1993, Hosp J, V9, P69, DOI 10.1300/J011v09n01_06; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BREITBART W, 1990, P 2 INT C CANC PAIN, V16; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BURNS MM, 1994, PSYCHOSOMATICS, V35, P80, DOI 10.1016/S0033-3182(94)71811-9; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; BYOCK I, 1997, DYING WELL PROSPECTS; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Cherny N I, 1994, J Palliat Care, V10, P31; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Coyle N, 1990, J Pain Symptom Manage, V5, P83; CUMMINGS NB, 1993, NEPHROLOGY UROLOGY A; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; Glantz L H, 1987, Law Med Health Care, V15, P231; Graber MA, 1996, J GEN INTERN MED, V11, P71, DOI 10.1007/BF02599581; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; HARRIS EC, 1994, MEDICINE, V73, P281, DOI 10.1097/00005792-199411000-00001; *HEML SOC, 1991, ROP POLL W COAST EUT; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; KASTING GA, 1993, PHYSICIAN ASSISTED D, P25; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LEE MA, 1992, J AM GERIATR SOC, V40, P983, DOI 10.1111/j.1532-5415.1992.tb04473.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; MASAND P, 1991, PSYCHOSOMATICS, V32, P203, DOI 10.1016/S0033-3182(91)72093-8; MASSIE MJ, 1994, J PAIN SYMPTOM MANAG, V9, P325, DOI 10.1016/0885-3924(94)90192-9; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; McGough P M, 1993, Camb Q Healthc Ethics, V2, P63; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; MEIER D, IN PRESS N ENGL J ME; MEIER DE, 1993, PHYSICIAN ASSISTED D; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; MORRISON RS, 1994, GENERATIONS      WIN, P48; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; *PRES COMM STUD ET, 1983, DEC FOR LIF TREATM R; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 1993, DEATH DIGNITY MAKING; RAPPAPORT W, 1993, SURGERY, V113, P163; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RIE MA, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3562997; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; Teno JM, 1997, J AM GERIATR SOC, V45, P939, DOI 10.1111/j.1532-5415.1997.tb02963.x; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIS OTHER MED; Ventafridda V, 1990, J Palliat Care, V6, P7; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; WOODS SW, 1986, J CLIN PSYCHIAT, V47, P12; 1992, JAMA, V276, P2229	97	50	50	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					552	558		10.7326/0003-4819-128-7-199804010-00006	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZE539	9518400				2023-01-03	WOS:000072803500006
J	Goldin-Meadow, S; Mylander, C				Goldin-Meadow, S; Mylander, C			Spontaneous sign systems created by deaf children in two cultures	NATURE			English	Article							GESTURAL COMMUNICATION; LANGUAGE-DEVELOPMENT; PARENTAL INPUT	Deaf children whose access to usable conventional linguistic input, signed or spoken, is severely limited nevertheless use gesture to communicate(1-3). These gestures resemble natural language in that they are structured at the level both of sentence(4) and of word(5). Although the inclination Ito use gesture maybe traceable to the fact that the deaf children's]tearing parents, like all speakers, gesture as they talk(6), the children themselves are responsible for introducing language-like structure into their gestures(7). We have explored the robustness of this phenomenon by observing deaf children of hearing parents in two cultures, an American and a Chinese culture, that differ in their child-rearing practices(8-12) and in the way gesture is used in relation to speech(13). The spontaneous sign systems developed in these cultures shared a number of structural similarities: patterned production and deletion of semantic elements ii the surface structure of a sentence; patterned ordering of those elements within the sentence; and concatenation of propositions within a sentence. These striking similarities offer critical empirical input towards resolving the ongoing debate about the 'innateness' of language in human infants(14-16).	Univ Chicago, Dept Psychol, Chicago, IL 60637 USA	University of Chicago	Goldin-Meadow, S (corresponding author), Univ Chicago, Dept Psychol, 5730 S Woodlawn Ave, Chicago, IL 60637 USA.		Galantucci, Bruno/E-5770-2010					CHEN CS, 1988, HUM DEV, V31, P351, DOI 10.1159/000276334; Chomsky N., 1965, ASPECTS THEORY SYNTA, DOI DOI 10.21236/AD0616323; Dixon R. M. W., 1994, ERGATIVITY; Fant L. J., 1972, AMESLAN; FEYEREISEN P, 1991, GESTURE SPEECH; GLEITMAN L, 1995, LANGUAGE INVITATION, V1, P1; Goldin-Meadow S., 1996, INT J PRIMATOL, V17, P145; GOLDINMEADOW S, 1994, COGNITIVE PSYCHOL, V27, P259, DOI 10.1006/cogp.1994.1018; GOLDINMEADOW S, 1995, COGNITION, V56, P195, DOI 10.1016/0010-0277(95)00662-I; GOLDINMEADOW S, 1983, SCIENCE, V221, P372, DOI 10.1126/science.6867713; GOLDINMEADOW S, 1984, MONOGR SOC RES CHILD, V49, P1, DOI 10.2307/1165838; GOLDINMEADOW S, 1977, SCIENCE, V197, P401, DOI 10.1126/science.877567; McNeill D., 1992, HAND MIND WHAT HANDS; MCNEILL D, UNPUB LANGUAGE GESTU; Miller PJ, 1997, CHILD DEV, V68, P557, DOI 10.2307/1131678; MOORES DF, 1974, LANGUAGE PERSPECTIVE, P377; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; Pinker S, 1995, LANGUAGE INSTINCT; Siegel S, 1956, NONPARAMETRIC STAT B; Silverstein M, 1976, GRAMMATICAL CATEGORI; Stevenson H W, 1990, Monogr Soc Res Child Dev, V55, P1; TERVOORT BT, 1961, AM ANN DEAF, V106, P436; Wang X.-L., 1996, RES FAMILY RESOURCES, P363; Wimsatt W.C., 1986, INTEGRATING SCI DISC, P185, DOI 10.1007/978-94-010-9435-1_11; YOUNG NF, 1972, AMERASIA J, V1, P31; Zar JH, 2010, BIOSTAT ANAL	26	175	176	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					279	281		10.1038/34646	http://dx.doi.org/10.1038/34646			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YR328	9440690				2023-01-03	WOS:000071484400049
J	Wolf, AR; Stoddart, P				Wolf, AR; Stoddart, P			Awake spinal anaesthesia in ex-premature infants	LANCET			English	Article									UNIV BRISTOL,UNIV DEPT ANAESTHESIA,BRISTOL BS2 8BJ,AVON,ENGLAND	University of Bristol	Wolf, AR (corresponding author), ROYAL HOSP SICK CHILDREN,BRISTOL BS2 8BJ,AVON,ENGLAND.							BRAWN WJ, 1995, ANN THORAC SURG, V59, P1441, DOI 10.1016/0003-4975(95)00147-D; COTE CJ, 1995, ANESTHESIOLOGY, V82, P809, DOI 10.1097/00000542-199504000-00002; HAOUARI N, 1995, BRIT MED J, V310, P1498, DOI 10.1136/bmj.310.6993.1498; KRANE EJ, 1995, ANESTH ANALG, V80, P7, DOI 10.1097/00000539-199501000-00003; OBERLANDER TF, 1995, ANESTH ANALG, V80, P20, DOI 10.1097/00000539-199501000-00005	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S13	S13		10.1016/0140-6736(95)90012-8	http://dx.doi.org/10.1016/0140-6736(95)90012-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454030	Bronze			2023-01-03	WOS:A1995TN12200013
J	Jenkinson, C; Davies, RJO; Mullins, R; Stradling, JR				Jenkinson, C; Davies, RJO; Mullins, R; Stradling, JR			Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial	LANCET			English	Article							DAYTIME SLEEPINESS; MEDICAL OUTCOMES; HEALTH-STATUS; APNEA; SF-36; SCALE	Background Nasal continuous positive airway pressure (NCPAP) is widely used as a treatment for obstructive sleep apnoea. However, to date there are no randomised controlled trials of this therapy against a well-matched control. We undertook a randomised prospective parallel trial of therapeutic NCPAP for obstructive sleep apnoea compared with a control group on subtherapeutic NCPAP. Methods Men with obstructive sleep apnoea, defined as an Epworth sleepiness score of 10 or more and ten or more dips per h of more than 4% SaO(2) caused by obstructive sleep apnoea on overnight sleep study, were randomly assigned therapeutic NCPAP or subtherapeutic NCPAP (about 1 cm H2O) for 1 month. Primary outcomes were subjective sleepiness (Epworth sleepiness score), objective sleepiness (maintenance of wakefulness test), and SF-36 questionnaire measurements of self-reported functioning and well-being. Findings 107 men entered the study: 53 received subtherapeutic NCPAP and 54 therapeutic NCPAP. Use of NCPAP by the two treatment groups was similar: 54 h (therapeutic) and 4.6 h (subtherapeutic) per night. Subtherapeutic NCPAP did not alter the overnight number of SaO(2) dips per h compared with baseline, and thus acted as a control. Therapeutic NCPAP was superior to subtherapeutic NCPAP in all primary outcome measures. The Epworth score was decreased from a median of 15.5 to 7.0 on therapeutic NCPAP, and from 15.0 to 13.0 on subtherapeutic NCPAP (between treatments, p<0.0001). Mean maintenance-of-wakefulness time increased from 22.5 to 32.9 min on therapeutic NCPAP and, not significantly, from 20.0 to 23.5 min on subtherapeutic NCPAP (between treatments p<0.005). Effect sizes for SF-36 measures of energy and vitality were 1.68 (therapeutic) and 0.97 (subtherapeutic) NCPAP (between treatments p<0.0001). For mental summary score, the corresponding values were 1.02 and 0.4 (between treatments p=0.002). Interpretation Therapeutic NCPAP reduces excessive daytime sleepiness and improves self-reported health status compared with a subtherapeutic control. Compared with controls, the effects of therapeutic NCPAP are large and confirm previous uncontrolled clinical observations and the results of controlled trials that used an oral placebo.	Oxford Radcliffe Trust, Osler Chest Unit, Oxford OX3 7LJ, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Care, Hlth Serv Res Unit, Oxford, England	University of Oxford	Stradling, JR (corresponding author), Oxford Radcliffe Trust, Osler Chest Unit, Churchill Campus, Oxford OX3 7LJ, England.							AUBERTTULKENS G, 1980, CLIN RES PROC, V16, P587; *AUSTR HLTH TECHN, 1996, EFF COST EFF NAS CON; Bennett LS, 1998, AM J RESP CRIT CARE, V158, P778, DOI 10.1164/ajrccm.158.3.9711033; Bennett LS, 1997, J SLEEP RES, V6, P142, DOI 10.1046/j.1365-2869.1997.00039.x; CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; COHEN J, 1977, STAT POWER BEHAV SCI; Doghramji K, 1997, ELECTROEN CLIN NEURO, V103, P554, DOI 10.1016/S0013-4694(97)00010-2; Douglas NJ, 1998, THORAX, V53, P414, DOI 10.1136/thx.53.5.414; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; FRASER AK, 1997, OBSTRUCTIVE SLEEP AP; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; JENKINSON C, 1995, AGE AGEING, V24, P505, DOI 10.1093/ageing/24.6.505; Jenkinson C, 1997, J SLEEP RES, V6, P199, DOI 10.1046/j.1365-2869.1997.00043.x; Jenkinson C, 1997, AGE AGEING, V26, P7, DOI 10.1093/ageing/26.1.7; Johns M, 1997, SLEEP, V20, P844, DOI 10.1093/sleep/20.10.844; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KRIEGER J, 1983, LANCET, V2, P1429; Mitler MM, 1998, ANN NEUROL, V43, P88; Stradling JR, 1999, AM J RESP CRIT CARE, V159, P130, DOI 10.1164/ajrccm.159.1.9805074; Stradling JR, 1997, THORAX, V52, P72, DOI 10.1136/thx.52.1.72; STRADLING JR, 1998, AM J RESP CRIT CARE, V157, pA344; SULLIVAN CE, 1981, LANCET, V1, P862; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; *WESS I HLTH RES D, 1994, CONT POS AIRW PRESS; Wright J, 1997, BRIT MED J, V314, P851; WRIGHT L, 1992, HLTH LIFESTYLES OXFO	30	567	571	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2100	2105		10.1016/S0140-6736(98)10532-9	http://dx.doi.org/10.1016/S0140-6736(98)10532-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382693				2023-01-03	WOS:000080969300009
J	Alm, JS; Swartz, J; Lilja, G; Scheynius, A; Pershagen, G				Alm, JS; Swartz, J; Lilja, G; Scheynius, A; Pershagen, G			Atopy in children of families with an anthroposophic lifestyle	LANCET			English	Article							BCG VACCINATION; ALLERGY; VIRUS; PREVALENCE; ANTIBODIES; RESPONSES; INFECTION; MEASLES; ASTHMA	Background Increased prevalence of atopic disorders in children may be associated with changes in types of childhood infections, vaccination programmes, and intestinal microflora. People who follow an anthroposophic way of life use antibiotics restrictively, have few vaccinations, and their diet usually contains live lactobacilli, which may affect the intestinal microflora. We aimed to study the prevalence of atopy in children from anthroposophic families and the influence of an anthroposophic lifestyle on atopy prevalence. have few live Methods In a cross-sectional study, 295 children aged 5-13 years at two anthroposophic (Steiner) schools near Stockholm, Sweden, were compared with 380 children of the same age at two neighbouring schools in terms of history;of atopic and infectious diseases, use of antibiotics and vaccinations, and social and environmental variables. Skin-prick tests were done for 13 common allergens, and we took blood samples from children and their parents for analysis of allergen-specific serum IgE-antibodies. Findings At the Steiner schools, 52% of the children had had antibiotics in the past, compared with 90% in the control schools. 18% and 93% of children, respectively, had had combined immunisation against measles, mumps, and rubella, and 61% of the children at the Steiner schools had had measles. Fermented vegetables, containing live lactobacilli, were consumed by 63% of the children at Steiner schools, compared with 4.5% at the control schools. Skin-prick tests and blood tests showed that-the children from Steiner schools had lower prevalence of atopy than controls (odds ratio 0.62 [95% CI 0.43-0.91]). There was an inverse relation between the number of characteristic features of an anthroposophic lifestyle and risk of atopy (p for trend=0.01). Interpretation Prevalence of atopy is lower in children from anthroposophic families than in children from other families. Lifestyle factors associated with anthroposophy may lessen the risk of atopy in childhood.	Karolinska Inst, Sachs Childrens Hosp, S-11895 Stockholm, Sweden; Karolinska Hosp & Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Environm Epidemiol, S-10401 Stockholm, Sweden; Vidar Clin, Jarna, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Alm, JS (corresponding author), Karolinska Inst, Sachs Childrens Hosp, Box 179 12, S-11895 Stockholm, Sweden.	Johan.Alm@sos.ki.se		Pershagen, Goran/0000-0002-9701-1130; Alm, Johan/0000-0002-9062-4479				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHILDS G., 1995, R STEINER HIS LIFE W; GOEBEL W, 1990, GUIDE CHILD HLTH; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1993, PEDIAT ALLERGY IMMUN, V4, P181; JOHANSSON ML, 1993, APPL ENVIRON MICROB, V59, P15, DOI 10.1128/AEM.59.1.15-20.1993; JORMALAINEN V, 1997, SMITTSKYDD, V6, P61; KONDO N, 1993, CLIN EXP ALLERGY, V23, P44, DOI 10.1111/j.1365-2222.1993.tb02483.x; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Pepys J., 1975, , Clinical aspects of immunology., P877; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; Rogers William., 1993, STATA TECHNICAL B, V13, P19; Schilthuis Willy, 1994, BIODYNAMIC AGR; SCHONECK A, 1998, CULTURED CABBAGE; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1995, PEDIATRICS, V95, P500; STADLER JF, 1993, DERMATOLOGY, V186, P23; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Vandenplas Y, 1997, ACTA PAEDIATR, V86, P1283, DOI 10.1111/j.1651-2227.1997.tb14898.x	30	385	390	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1485	1488		10.1016/S0140-6736(98)09344-1	http://dx.doi.org/10.1016/S0140-6736(98)09344-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232315	Green Submitted			2023-01-03	WOS:000080278200012
J	Walton, R; Dovey, S; Harvey, E; Freemantle, N				Walton, R; Dovey, S; Harvey, E; Freemantle, N			Computer support for determining drug dose: systematic review and meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; WARFARIN THERAPY; COST-BENEFIT; CARE; MANAGEMENT; INFUSION; DOCTORS	Objective To review the effectiveness of computer support for determining optimum drug dose. Design Systematic review of comparative studies where computers gave advice to clinicians on the most appropriate drug dose. Search methods used were standard for the Cochrane Collaboration on Effective Professional Practice. Subjects Comparative studies conducted worldwide and published between 1966 and 1996. Main outcome measures For qualitative review, relative percentage differences were calculated to compare effects of computer support in different settings. For quantitative data, effect sizes were calculated and combined in mete-analyses. Results Eighteen studies met the inclusion criteria The drugs studied were theophylline, warfarin, heparin, aminoglycosides, nitroprusside, lignocaine, oxytocin, fentanyl, and midazolam. The computer programs used individualised pharmacokinetic models to calculate the most appropriate dose. Meta-analysis of data from 671 patients showed higher blood concentrations of drug with computer support (effect size 0.69, 95% confidence interval 0.36 to 1.02) and reduced time to achieve therapeutic control (0.44, 0.17 to 0.71). The total dose of drug used was unchanged, and there were fewer unwanted effects of treatment Five of six studies measuring outcomes of care showed benefit from computer assistance. Conclusions This review suggests that using computers to determine the correct dose of certain drugs in acute hospital settings is beneficial. Computers may give doctors the confidence to use higher doses when necessary, adjusting the drug dose more accurately to individual patients. Further research is necessary to evaluate the benefits in general use.	Univ Oxford, Dept Publ Hlth & Primary Care, Imperial Canc Res Fund, Gen Practice Res Grp,Inst Hlth Sci, Oxford OX3 7LF, England; Alcuin Coll, Dept Hlth Sci & Clin Evaluat, York YO1 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of Oxford; University of York - UK; University of York - UK	Walton, R (corresponding author), Univ Oxford, Dept Publ Hlth & Primary Care, Imperial Canc Res Fund, Gen Practice Res Grp,Inst Hlth Sci, Oxford OX3 7LF, England.			Freemantle, Nick/0000-0001-5807-5740				ALVIS JM, 1985, ANESTHESIOLOGY, V63, P41, DOI 10.1097/00000542-198507000-00006; BALDWIN L, 1995, BRIT MED J, V310, P1154, DOI 10.1136/bmj.310.6988.1154; BERO LA, 1997, COCHRANE LIB; BURTON ME, 1991, CLIN PHARMACOL THER, V49, P685, DOI 10.1038/clpt.1991.86; CASNER PR, 1993, CLIN PHARMACOL THER, V53, P684, DOI 10.1038/clpt.1993.90; *COCHR COLL EFF PR, 1996, COCHR COLL EFF PROF; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESTACHE CJ, 1990, THER DRUG MONIT, V12, P427, DOI 10.1097/00007691-199009000-00004; Dickersin K, 1995, SYSTEMATIC REV, P17; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; Freemantle N, 1997, ANN INTERN MED, V126, P81, DOI 10.7326/0003-4819-126-1-199701010-00011; GONZALEZ ER, 1989, AM J EMERG MED, V7, P395, DOI 10.1016/0735-6757(89)90046-6; Hedges L.V., 2014, STAT METHODS META AN; HURLEY SF, 1986, AM REV RESPIR DIS, V134, P1219; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MUNGALL DR, 1994, CLIN PHARMACOL THER, V55, P591, DOI 10.1038/clpt.1994.73; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; RODMAN JH, 1984, ARCH INTERN MED, V144, P703, DOI 10.1001/archinte.144.4.703; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; ROSENTHAL R, 1986, PSYCHOL BULL, V99, P400, DOI 10.1037/0033-2909.99.3.400; Ruiz Ricardo, 1993, Biomedical Instrumentation and Technology, V27, P244; *SOC SURV GALL POL, 1993, COMP GP PRACT 199O S; Theil D R, 1993, J Cardiothorac Vasc Anesth, V7, P300, DOI 10.1016/1053-0770(93)90009-A; VANDENNIEUWENHUYZEN MCO, 1995, ANESTH ANALG, V81, P671, DOI 10.1097/00000539-199510000-00003; VERNER D, 1992, EUR J CLIN PHARMACOL, V43, P29, DOI 10.1007/BF02280750; WHITE KS, 1984, J AM COLL CARDIOL, V4, P571, DOI 10.1016/S0735-1097(84)80104-7; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; WHITE RH, 1991, THER DRUG MONIT, V13, P46, DOI 10.1097/00007691-199101000-00006; WILLCOURT RJ, 1994, AM J OBSTET GYNECOL, V170, P603, DOI 10.1016/S0002-9378(94)70236-5; Wolf Fredric, 1986, METAANALYSIS QUANTIT	31	77	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1999	318	7189					984	990		10.1136/bmj.318.7189.984	http://dx.doi.org/10.1136/bmj.318.7189.984			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186VU	10195972	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000079751500023
J	Akdis, CA; Blaser, K				Akdis, CA; Blaser, K			IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy	FASEB JOURNAL			English	Review						interleukin-10; T cell epitopes; microenvironments; bee venom	BEE VENOM PHOSPHOLIPASE-A2; MAST-CELLS; IN-VITRO; INTERLEUKIN-10 PRODUCTION; ALLERGEN IMMUNOTHERAPY; BLOOD EOSINOPHILS; MEDIATOR RELEASE; SENSITIZED MICE; HONEYBEE VENOM; GROWTH-FACTOR	Specific immunotherapy (SIT) is widely used for treatment of allergic diseases and could potentially be applied in other immunological disorders. Induction of specific unresponsiveness (anergy) in peripheral T cells and recovery by cytokines from the tissue microenvironment represent two key steps in SIT with whole allergen or antigenic T cell. peptides (PIT), The anergy is directed against the T cell epitopes of the respective antigen and characterized by suppressed proliferative and cytokine responses, It is initiated by autocrine action of IL-10, which is increasing-ly produced by the antigen-specific T cells. Later in therapy, B cells and monocytes also produce IL-10. The anergic T cells can be reactivated by different cytokines, Whereas IL-15 and IL-2 generate Th1 cytokine profile and an IgG4 antibody response, IL-4 reactivates a Th2 cytokine pattern and IgE antibodies. Increased IL-10 suppresses IgE and enhances IgG4 synthesis, resulting in a decreased antigen-specific IgE:IgG4 ratio, as observed normally in patients after SIT or PIT, The same state of anergy against the major bee venom allergen, phospholipase A(2), can be observed in subjects naturally anergized after multiple bee stings, Together, these data demonstrate the pivotal role of autocrine IL-10 in induction of specific T cell anergy and the important participation of the cytokine microenvironment in SIT, Furthermore, knowledge of the mechanisms explaining reasons for success or failure of SIT may enable possible predictive measures of the treatment.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				AALBERSE RC, 1983, J IMMUNOL, V130, P722; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 1997, STRATEGIES FOR IMMUNOINTERVENTIONS IN DERMATOLOGY, P131; Akdis CA, 1997, EUR J IMMUNOL, V27, P2351, DOI 10.1002/eji.1830270933; Akdis CA, 1997, J ALLERGY CLIN IMMUN, V99, P345, DOI 10.1016/S0091-6749(97)70052-6; Arock M, 1996, EUR J IMMUNOL, V26, P166, DOI 10.1002/eji.1830260126; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1992, IMMUNOTHERAPY IGE ME, P13; DADAGLIO G, 1994, J EXP MED, V179, P413, DOI 10.1084/jem.179.2.413; DE WMR, 1991, J EXP MED, V174, P1209; DELPRETE G, 1993, J IMMUNOL, V150, P353; DING L, 1992, J IMMUNOL, V148, P3133; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; ESSERY G, 1988, IMMUNOLOGY, V64, P413; Faith A, 1997, J IMMUNOL, V159, P53; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259, DOI 10.1016/S1081-1206(10)63012-8; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREENSTEIN JL, 1992, J ALLERGY CLIN IMMUN, V89, P322; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; IPPOLITI F, 1997, ALLERG IMMUNOL PARIS, V29, P123; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAGEYSABOTKA A, 1976, J ALLERGY CLIN IMMUN, V57, P29; KUNA P, 1993, J IMMUNOL, V150, P1932; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LUCAS AH, 1990, SPRINGER SEMIN IMMUN, V12, P385; Mahanty S, 1996, J INFECT DIS, V173, P769, DOI 10.1093/infdis/173.3.769; Marcotte GV, 1998, J ALLERGY CLIN IMMUN, V101, P506, DOI 10.1016/S0091-6749(98)70358-6; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; MULLER U, 1993, ALLERGY          S14, V48, P36; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TSAI LC, 1991, CLIN EXP ALLERGY, V21, P367, DOI 10.1111/j.1365-2222.1991.tb01670.x; Van Parijs L, 1998, SCIENCE, V280, P243; VARNEY VA, 1991, BRIT MED J, V302, P489; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WANG P, 1994, J IMMUNOL, V153, P811; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; WETTERWALD A, 1985, INT ARCH ALLER A IMM, V77, P195, DOI 10.1159/000233784; WYSS M, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb00690.x; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	72	186	198	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					603	609		10.1096/fasebj.13.6.603	http://dx.doi.org/10.1096/fasebj.13.6.603			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094921				2023-01-03	WOS:000079527200002
J	Naylor, MD; Brooten, D; Campbell, R; Jacobsen, BS; Mezey, MD; Pauly, MV; Schwartz, JS				Naylor, MD; Brooten, D; Campbell, R; Jacobsen, BS; Mezey, MD; Pauly, MV; Schwartz, JS			Comprehensive discharge planning and home follow-up of hospitalized elders - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE-HEART-FAILURE; MEDICARE PATIENTS; CARE; READMISSION; COMMUNITY; OUTCOMES; IMPACT; BIRTH	Context Comprehensive discharge planning by advanced practice nurses has demonstrated short-term reductions in readmissions of elderly patients, but the benefits of more intensive follow-up of hospitalized elders at risk for poor outcomes after discharge has not been studied. Objective To examine the effectiveness of an advanced practice nurse-centered discharge planning and home follow-up intervention for elders at risk for hospital readmissions. Design Randomized clinical trial with follow-up at 2, 6, 12, and 24 weeks after index hospital discharge. Setting Two urban, academically affiliated hospitals in Philadelphia, Pa. Participants Eligible patients were 65 years or older, hospitalized between August 1992 and March 1996, and had 1 of several medical and surgical reasons for admission. Intervention Intervention group patients received a comprehensive discharge planning and home follow-up protocol designed specifically for elders at risk for poor outcomes after discharge and implemented by advanced practice nurses. Main Outcome Measures Readmissions, time to first readmission, acute care visits after discharge, costs, functional status, depression, and patient satisfaction. Results A total of 363 patients (186 in the control group and 177 in the intervention group) were enrolled in the study; 70% of intervention and 74% of control subjects completed the trial. Mean age of sample was 75 years; 50% were men and 45% were black. By week 24 after the index hospital discharge, control group patients were more likely than intervention group patients to be readmitted at least once (37.1% vs 20.3%; P < .001). Fewer intervention group patients had multiple readmissions (6.2% vs 14.5%; P = .01) and the intervention group had fewer hospital days per patient (1.53 vs 4.09 days; P < .001). Time to first readmission was increased in the intervention group (P < .001). At 24 weeks after discharge, total Medicare reimbursements for health services were about $1.2 million in the control group vs about $0.6 million in the intervention group (P < .001). There were no significant group differences in postdischarge acute care visits, functional status, depression, or patient satisfaction. Conclusions An advanced practice nurse-centered discharge planning and home care intervention for at-risk hospitalized elders reduced readmissions, lengthened the time between discharge and readmission, and decreased the costs of providing health care. Thus, the intervention demonstrated great potential in promoting positive outcomes for hospitalized elders at high risk for rehospitalization while reducing costs.	Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Sch Nursing, Cleveland, OH 44106 USA; NYU, Div Nursing, New York, NY USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Case Western Reserve University; New York University	Naylor, MD (corresponding author), Univ Penn, Sch Nursing, 420 Guardian Dr, Philadelphia, PA 19104 USA.	naylor@pobox.upenn.edu			NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR002095] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; BROOTEN D, 1986, NEW ENGL J MED, V315, P934, DOI 10.1056/NEJM198610093151505; BROOTEN D, 1994, OBSTET GYNECOL, V84, P832; BROOTEN D, 1995, AM J MANAGE CARE, V1, P35; COX DR, 1972, J R STAT SOC, V66, P188; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; DEY AN, 1993, IN PRESS VITAL HLTH, V272; ELASHOFF JD, 1997, NQUERY ADVISOR VERSI; Experton B, 1997, AM J PUBLIC HEALTH, V87, P210, DOI 10.2105/AJPH.87.2.210; FEASLEY J, 1996, HLTH OUTC OLD PEOP; Fonarow GC, 1997, J AM COLL CARDIOL, V30, P725, DOI 10.1016/S0735-1097(97)00208-8; FRANKL SE, 1991, AM J MED, V90, P667; Graves E.J., 1995, VITAL HLTH STAT, V13, P1; *HLTH CAR FIN ADM, 1997, DAT DIV BUDG; *HLTH CAR INV AUTH, 1996, DRG HDB COMP CLIN FI; Kane RL, 1996, J AM GERIATR SOC, V44, P242, DOI 10.1111/j.1532-5415.1996.tb00909.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORNOWSKI R, 1995, AM HEART J, V129, P762, DOI 10.1016/0002-8703(95)90327-5; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; Lee E, 2013, STAT METHODS SURVIVA; MADDOX GL, 1964, J CHRON DIS, V17, P449, DOI 10.1016/0021-9681(64)90105-5; MAMON J, 1992, HEALTH SERV RES, V27, P155; MOINPOUR C, 1992, INSTRUMENTS CLIN NUR, P385; MORROWHOWELL N, 1994, MED CARE, V32, P486, DOI 10.1097/00005650-199405000-00007; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Smith LE, 1997, CLIN CARDIOL, V20, P949, DOI 10.1002/clc.4960201109; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Titler M G, 1995, J Cardiovasc Nurs, V9, P64; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5	37	1197	1213	5	101	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1999	281	7					613	620		10.1001/jama.281.7.613	http://dx.doi.org/10.1001/jama.281.7.613			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	165YA	10029122	Bronze			2023-01-03	WOS:000078548400031
J	Ruggenenti, P; Perna, A; Gherardi, G; Gaspari, F; Benini, R; Remuzzi, G				Ruggenenti, P; Perna, A; Gherardi, G; Gaspari, F; Benini, R; Remuzzi, G		GISEN	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial	LANCET			English	Article							CONVERTING-ENZYME-INHIBITOR; DIABETIC NEPHROPATHY; PROGRESSION; DISEASE	Background The Ramipril Efficacy In Nephropathy (REIN) study found that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, ramipril safely reduced the rate of decline of the glomerular filtration rate (GFR) and halved the combined risk of doubling of serum creatinine or end-stage renal failure (ESRF), as compared with placebo plus conventional antihypertensive drugs at the same level of blood pressure control. At the end of the core study patients continued on or shifted to ramipril and were formally enrolled into the REIN follow-up study. Methods 97 patients entered the follow-up study. Patients originally randomised to ramipril continued with the same daily dose (n=51), whereas those originally on placebo plus conventional antihypertensive drugs switched to ramipril after the first visit of the follow-up study (n=46). Ramipril (1.25 to 5.00 mg/day) and conventional antihypertensive therapy were targeted at achieving diastolic blood pressure under 90 mm Hg. The main efficacy variables were GFR decline and ESRF (need for dialysis). Analysis was by intention to treat. Findings During the follow-up study the mean rate of GFR decline per month decreased from 0.44 (SD 0.54) mL/min per 1.73 m(2) in the core study to 0.10 (0.50) mL/min per 1.73 m(2) in patients originally randomised to ramipril (p=0.017), and from 0.81 (1.12) to 0.14 (0.87) mL/min per 1.73 m(2) in those originally randomised to placebo plus conventional antihypertensive therapy (p=0.017). At the final visit, mean absolute GFR values were 12 mL/min per 1.73 m(2) higher (33% better) in patients randomised to ramipril than in those assigned placebo (n=26 and 17, respectively: 35.5 [19.0] vs 23.8 [9.4] mL/min per 1.73 m(2), p=0.01). 19 of the patients originally on ramipril versus 35 switched from placebo to ramipril progressed to ESRF (p=0.027) during the whole observation period; of these, six (8%) versus 14 (16%) reached that endpoint during the follow-up study; and the risk ratios were 1.86 (95% Cl 1.07-3.26) over the whole observation period and 2.95 (1.13-7.68) during follow-up. Beyond follow-up at month 36, the incidence of ESRF was zero in patients originally randomised to ramipril but 30% in patients on placebo plus conventional antihypertensive therapy. Interpretation In patients with chronic nephropathy and high risk of rapid progression to ESRF, ramipril reversed the tendency of GFR to decline with time. Moreover, a treatment period of sufficient duration (greater than or equal to 36 months) eliminated the need for dialysis. Even patients previously treated with antihypertensive drugs other than angiotensin-converting-enzyme inhibitors benefited shifting to ramipril.	Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24125 Bergamo, Italy; Osped Riuniti Bergamo, Div Nephrol, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Ruggenenti, P (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, Via Gavazzeni 11,Villa Camozzi, I-24125 Bergamo, Italy.		Perna, Annalisa/AAC-1323-2020; Remuzzi, Giuseppe/V-9766-2017	Perna, Annalisa/0000-0002-9257-0283; Manno, Carlo/0000-0002-7840-9426; Remuzzi, Giuseppe/0000-0002-6194-3446				GASPARI F, 1995, J AM SOC NEPHROL, V6, P1; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; *GRUPP IT STUD EP, 1991, J NEPHROL, V3, P193; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PERICO N, 1994, J AM SOC NEPHROL, V5, P1139; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, BRIT MED J, V316, P504, DOI 10.1136/bmj.316.7130.504; RUGGENENTI P, 1997, KIDNEY INT S63, V52, pS54; SHAPIRO SS, 1965, BIOMETRIKA, V52, P519	13	443	471	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1252	1256		10.1016/S0140-6736(98)04433-X	http://dx.doi.org/10.1016/S0140-6736(98)04433-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788454				2023-01-03	WOS:000076573800008
J	Kuroki, K; Masuda, A; Uehara, H; Kuroki, A				Kuroki, K; Masuda, A; Uehara, H; Kuroki, A			A new treatment for toxic megacolon	LANCET			English	Article									Kuroki Gastrointestinal Surg Hosp, Kagoshima 8900034, Japan; Kagoshima Univ, Dept Psychosomat Med, Kagoshima 890, Japan	Kagoshima University	Kuroki, K (corresponding author), Kuroki Gastrointestinal Surg Hosp, Kagoshima 8900034, Japan.							GREENSTEIN AJ, 1985, J CLIN GASTROENTEROL, V7, P137, DOI 10.1097/00004836-198504000-00007; JALAN KN, 1969, GASTROENTEROLOGY, V57, P68, DOI 10.1016/s0016-5085(19)33962-9; KWEICINSKI MG, 1987, J FOOT SURG, V26, P394; PURRMANN J, 1989, HEPATO-GASTROENTEROL, V36, P209; Sheth SG, 1998, LANCET, V351, P509, DOI 10.1016/S0140-6736(97)10475-5	5	21	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					782	782						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737284				2023-01-03	WOS:000075762700013
J	Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD				Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD			The changing pattern of prenatal care utilization in the United States, 1981-1995, using different prenatal care indices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; GESTATIONAL-AGE; PREGNANCY; MEDICAID; HEALTH; ADEQUACY; INDEXES; ULTRASOUND; LITIGATION; EXPANSION	Context.-Two measures traditionally used to examine adequacy of prenatal care indicate that prenatal care utilization remained unchanged through the 1980s and only began to rise slightly in the 1990s. In recent years, new measures have been developed that include a category for women who receive more than the recommended amount of care (intensive utilization). Objective.-To compare the older and newer indices in the monitoring of prenatal care trends in the United States from 1981 to 1995, for the overall population and for selected subpopulations. Second, to examine factors associated with receiving intensive utilization. Design.-Cross-sectional and trend analysis of national birth records. Setting.-The United States. Subjects.-All live births between 1981 and 1995 (N=54 million). Main Outcome Measures.-Trends in prenatal care utilization, according to 4 indices (the older indices: the Institute of Medicine Index and the trimester that care began, and the newer indices: the R-GINDEX and the Adequacy of Prenatal Care Utilization Index). Multiple logistic regression was used to assess the risk of intensive prenatal care use in 1981 and 1995. Results.-The newer indices showed a steadily increasing trend toward more prenatal care use throughout the study period (R-GINDEX, intensive or adequate use, 32.7% in 1981 to 47.1% in 1995; the Adequacy of Prenatal Care Utilization Index, intensive use, 18.4% in 1981 to 28.8% in 1995), especially for intensive utilization. Women having a multiple birth were much more likely to have had intensive utilization in 1995 compared with 1981 (R-GINDEX, 22.8% vs 8.5%). Teenagers were more likely to begin care later than adults, but similar proportions of teens and adults had intensive utilization. Intensive use among low-risk women also increased steadily each year. Factors associated with a greater likelihood of receiving intensive use in 1981 and 1995 were having a multiple birth, primiparity, being married, and maternal age of 35 years or older. Conclusions.-The proportion of women who began care early and received at least the recommended number of visits increased between 1981 and 1995. This change was undetected by more traditional prenatal care indices. These increases have cost and practice implications and suggest a paradox since previous studies have shown that rates of preterm delivery and low birth weight did not improve during this time.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Univ Alabama, Dept Maternal & Child Hlth, Birmingham, AL USA; Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Obstet, Boston, MA USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kogan, MD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd,Room 820, Hyattsville, MD 20782 USA.							Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1987, AM J PREV MED, V3, P243; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 1997, AM J PREV MED, V13, P290, DOI 10.1016/S0749-3797(18)30177-6; ALEXANDER GR, 1991, AM J PUBLIC HEALTH, V81, P1013, DOI 10.2105/AJPH.81.8.1013; *AM COLL OBST GYN, 1985, PROF LIAB INS ITS EF; *AM COLL OBST GYN, 1974, STAND OBST GYN SERV; [Anonymous], CAR OUR FUT CONT PRE; BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; BUESCHER PA, 1993, AM J PUBLIC HEALTH, V83, P1163, DOI 10.2105/AJPH.83.8.1163; DelgadoRodriguez M, 1996, EPIDEMIOLOGY, V7, P648, DOI 10.1097/00001648-199611000-00016; ENNIS M, 1991, LANCET, V338, P616, DOI 10.1016/0140-6736(91)90616-W; EWIGMAN B, 1993, BIRTH-ISS PERINAT C, V20, P212, DOI 10.1111/j.1523-536X.1993.tb00229.x; Farrow DC, 1997, MED CARE, V35, P297, DOI 10.1097/00005650-199703000-00010; FISCELLA K, 1995, OBSTET GYNECOL, V85, P468, DOI 10.1016/0029-7844(94)00408-6; Floyd L, 1981, J Med Assoc Ga, V70, P871; GORSKY RD, 1989, HLTH SERV RES, V24, P580; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; *I MED, 1993, ACC HLTH CAR AM; *I MED, 1985, PREV LOW BIRTH WEIGH; JEWELL SE, 1995, OBSTET GYNECOL, V85, P229, DOI 10.1016/0029-7844(94)00354-G; JOYCE T, 1988, MED CARE, V26, P348, DOI 10.1097/00005650-198804000-00004; KESSNER DM, 1973, CONTRASTS HLTH STATU, V1, P50; Kirby RS, 1997, PAEDIATR PERINAT EP, V11, P122, DOI 10.1046/j.1365-3016.1997.d01-6.x; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; Kotelchuck M, 1994, AM J PUBLIC HEALTH, V84, P1314; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; LEWIS CT, 1996, VITAL HLTH STAT, V21; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; MOR JM, 1995, AM J PREV MED, V11, P79, DOI 10.1016/S0749-3797(18)30481-1; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; *NAT CTR HLTH STAT, 1995, 1992 VIT STAT US, V1; *NAT CTR HLTH STAT, 1982, VIT HLTH STAT, V2; National Center for Health Statistics, 1987, HOSP PHYS HDB BIRTH; OREILLY MP, 1991, P 1991 PUBL HLTH C R, P57; Petersen D J, 1994, Minn Med, V77, P41; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; RICCIOTTI HA, 1995, FUTURE CHILD, V5, P71, DOI 10.2307/1602508; SAARIKEMPPAINEN A, 1995, ACTA OBSTET GYN SCAN, V74, P12, DOI 10.3109/00016349509009935; Schappert SM, 1997, VITAL HLTH STAT, V13; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; *US DEP HHS, 1996, TRENDS WELL BEING AM; *US GEN ACC OFF, 1993, PUBL GAO; VENTURA SJ, 1997, MON VITAL STAT RE S2, V11; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; Wells S, 1991, J Fla Med Assoc, V78, P31; Wilcox LS, 1996, FERTIL STERIL, V65, P361, DOI 10.1016/S0015-0282(16)58100-X	56	154	157	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1623	1628		10.1001/jama.279.20.1623	http://dx.doi.org/10.1001/jama.279.20.1623			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP489	9613911	Bronze			2023-01-03	WOS:000073758600031
J	Ouriel, K; Veith, FJ; Sasahara, AA				Ouriel, K; Veith, FJ; Sasahara, AA		Thrombolysis Peripheral Arterial Surg TOPAS In	A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOLYTIC THERAPY; PERIPHERAL ARTERIAL; ISCHEMIA; MANAGEMENT	Background Recent controlled trials suggest that thrombolytic therapy may be an effective initial treatment for acute arterial occlusion of the legs. A major potential benefit of initial thrombolytic therapy is that limb ischemia can be managed with less invasive interventions. Methods In this randomized, multicenter trial conducted at 113 North American and European sites, we compared vascular surgery (e.g., thrombectomy or bypass surgery) with thrombolysis by catheter-directed intraarterial recombinant urokinase; all patients (272 per group) had had acute arterial obstruction of the legs for 14 days or less. Infusions were limited to a period of 48 hours (mean [+/-SE], 24.4+/-0.86), after which lesions were corrected by surgery or angioplasty if needed. The primary end point was the amputation-free survival rate at six months. Results Final angiograms, which were available for 246 patients treated with urokinase, revealed recanalization in 196 (79.7 percent) and complete dissolution of thrombus in 167 (67.9 percent). Both treatment groups had similar significant improvements in mean ankle-brachial blood-pressure index. Amputation-free survival rates in the urokinase group were 71.8 percent at six months and 65.0 percent at one year, as compared with respective rates of 74.8 percent and 69.9 percent in the surgery group; the 95 percent confidence intervals for the differences were -10.5 to 4.5 percentage points at six months (P = 0.43) and -12.9 to 3.1 percentage points at one year (P = 0.23), At six months the surgery group had undergone 551 open operative procedures (excluding amputations), as compared with 315 in the thrombolysis group. Major hemorrhage occurred in 32 patients in the urokinase group (12.5 percent) as compared with 14 patients in the surgery group (5.5 percent) (P = 0.005). There were four episodes of intracranial hemorrhage in the urokinase group (1.6 percent), one of which was fatal. By contrast, there were no episodes of intracranial hemorrhage in the surgery group. Conclusions Despite its association with a higher frequency of hemorrhagic complications, intraarterial infusion of urokinase reduced the need for open surgical procedures, with no significantly increased risk of amputation or death. (C) 1998, Massachusetts Medical Society.	Univ Rochester, Sch Med & Dent, Dept Surg, Rochester, NY 14642 USA; Albert Einstein Sch Med, Dept Surg, Bronx, NY USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Rochester; Yeshiva University; Harvard University; Harvard Medical School	Ouriel, K (corresponding author), Univ Rochester, Sch Med & Dent, Dept Surg, 601 Elmwood Ave, Rochester, NY 14642 USA.							DORTER CT, 1974, RADIOLOGY, V111, P31; EARNSHAW JJ, 1991, BRIT J SURG, V78, P261, DOI 10.1002/bjs.1800780304; GRAOR RA, 1994, ANN SURG, V220, P251; GRAOR RA, 1985, J VASC SURG, V2, P406, DOI 10.1067/mva.1985.avs0020406; HESS H, 1982, NEW ENGL J MED, V307, P1627, DOI 10.1056/NEJM198212233072606; HILL SL, 1994, AM SURGEON, V60, P907; JIVEGARD L, 1988, J CARDIOVASC SURG, V29, P32; MARDER VJ, 1990, AM J HOSP PHARM, V47, pS15, DOI 10.1093/ajhp/47.9_Suppl_2.S15; MCNAMARA TO, 1985, AM J ROENTGENOL, V144, P769, DOI 10.2214/ajr.144.4.769; OURIEL K, 1994, J VASC SURG, V19, P1021, DOI 10.1016/S0741-5214(94)70214-4; Ouriel K, 1996, J VASC SURG, V23, P64, DOI 10.1016/S0741-5214(05)80036-9; RICOTTA J, 1991, CIRCULATION, V83, P120; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; SICARD GA, 1985, J VASC SURG, V2, P65, DOI 10.1067/mva.1985.avs0020065; YEAGER RA, 1992, J VASC SURG, V15, P385, DOI 10.1016/0741-5214(92)90260-F	15	475	504	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1105	1111		10.1056/NEJM199804163381603	http://dx.doi.org/10.1056/NEJM199804163381603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545358				2023-01-03	WOS:000073070100003
J	Papile, LA; Tyson, JE; Stoll, BJ; Wright, LL; Donovan, EF; Bauer, CR; Krause-Steinrauf, H; Verter, J; Korones, SB; Lemons, JA; Fanaroff, AA; Stevenson, DK				Papile, LA; Tyson, JE; Stoll, BJ; Wright, LL; Donovan, EF; Bauer, CR; Krause-Steinrauf, H; Verter, J; Korones, SB; Lemons, JA; Fanaroff, AA; Stevenson, DK			A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LUNG-DISEASE; EARLY POSTNATAL DEXAMETHASONE; RESPIRATORY-DISTRESS SYNDROME; BIRTH-WEIGHT INFANTS; BRONCHOPULMONARY DYSPLASIA; FOLLOW-UP; PRETERM INFANTS; CLINICAL-TRIALS; THERAPY	Background Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. Methods We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator-dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory-index scores (mean airway pressure x the fraction of inspired oxygen) of greater than or equal to 2.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of greater than or equal to 2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. Results The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P<0.001) in both groups. Conclusions Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age. (C) 1998, Massachusetts Medical Society.	Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Albuquerque, NM 87131 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Emory Univ, Atlanta, GA 30322 USA; NICHHD, Bethesda, MD 20892 USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Univ Miami, Miami, FL 33152 USA; George Washington Univ, Ctr Biostat, Rockville, MD USA; Univ Tennessee, Memphis, TN USA; Indiana Univ, Indianapolis, IN 46204 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Stanford Univ, Stanford, CA 94305 USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; Yale Univ, New Haven, CT USA; Wayne State Univ, Detroit, MI USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University System of Ohio; University of Cincinnati; University of Miami; George Washington University; University of Tennessee System; University of Tennessee Health Science Center; Indiana University System; Indiana University-Purdue University Indianapolis; Case Western Reserve University; Stanford University; Brown University; Women & Infants Hospital Rhode Island; Yale University; Wayne State University	Papile, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pediat, UNMH ACC 3 W, Albuquerque, NM 87131 USA.				NICHD NIH HHS [U10 HD21373, U10 HD27851, U10 HD27881] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027851, U10HD021373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD027881] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASSADI FK, 1996, INTENSIVE CARE FETUS, P1050; AVERY GB, 1985, PEDIATRICS, V75, P106; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; COTTERRELL M, 1972, J NEUROCHEM, V19, P2151, DOI 10.1111/j.1471-4159.1972.tb05124.x; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; DURAND M, 1995, PEDIATRICS, V95, P584; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FURMAN L, 1995, J PEDIATR-US, V126, P434, DOI 10.1016/S0022-3476(95)70464-7; GLADSTONE IM, 1989, PEDIATRICS, V84, P1072; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; JONES R, 1991, PEDIATRICS, V88, P421; JONES R, 1995, PEDIATRICS, V96, P897; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAZZI NJ, 1990, PEDIATRICS, V86, P722; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MAMMEL MC, 1987, DEV PHARMACOL THERAP, V10, P1; Marinelli KA, 1997, J PEDIATR-US, V130, P594, DOI 10.1016/S0022-3476(97)70244-0; NG PC, 1990, ARCH DIS CHILD-FETAL, V65, P54, DOI 10.1136/adc.65.1_Spec_No.54; OSHEA TM, 1993, AM J DIS CHILD, V147, P658, DOI 10.1001/archpedi.1993.02160300064024; OSHEA TM, 1997, PEDIATR RES, V41, pA207; PAPILE LA, 1994, PEDIATR RES, V35, pA246; Rastogi A, 1996, PEDIATRICS, V98, P204; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; Shinwell ES, 1996, ARCH DIS CHILD-FETAL, V74, pF33, DOI 10.1136/fn.74.1.F33; Stoll BJ, 1996, J PEDIATR-US, V129, P63, DOI 10.1016/S0022-3476(96)70191-9; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEICHSEL ME, 1977, ANN NEUROL, V2, P364, DOI 10.1002/ana.410020503; Yeh T. F., 1997, Pediatric Research, V41, p188A; YEH TF, 1990, J PEDIATR-US, V117, P273, DOI 10.1016/S0022-3476(05)80547-5; YEH TF, 1995, PEDIATR RES, V37, pA247	30	121	124	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1112	1118		10.1056/NEJM199804163381604	http://dx.doi.org/10.1056/NEJM199804163381604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545359	Bronze			2023-01-03	WOS:000073070100004
J	Hood, S; Birnie, D; Swan, L; Hillis, WS				Hood, S; Birnie, D; Swan, L; Hillis, WS			Questionnaire survey of thrombolytic treatment in accident and emergency departments in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Victoria Infirm, Dept Cardiol, Glasgow G42 9TY, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries DG1 4AL, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Hood, S (corresponding author), Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.		Hood, Sean David/H-5058-2014	Hood, Sean David/0000-0003-2852-7923				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; *CMA MED DAT, 1997, UK DIR EM SPEC CAR U; Hood S, 1996, Health Bull (Edinb), V54, P131	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					274	274		10.1136/bmj.316.7127.274	http://dx.doi.org/10.1136/bmj.316.7127.274			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472511	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000071702100025
J	Hayward, PE; DiazRossello, JL				Hayward, PE; DiazRossello, JL			New evidence for preventive perinatal care	LANCET			English	Article											Hayward, PE (corresponding author), WHO,PAN AMER HLTH ORG,LATIN AMER CTR HUMAN DEV,CASILLA CORREOS 627,MONTEVIDEO,URUGUAY.							CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; DIAZROSSELLO J, 1995, PEDIATR RES, V37, pA254; WRIGHT LL, 1995, AM J OBSTET GYNECOL, V173, P263, DOI 10.1016/0002-9378(95)90211-2; 1995, AM J OBSTET GYNECOL, V173, P246; 1995, LANCET, V345, P877	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S17	S17		10.1016/0140-6736(95)90016-0	http://dx.doi.org/10.1016/0140-6736(95)90016-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454034				2023-01-03	WOS:A1995TN12200017
J	Thurman, D; Guerrero, J				Thurman, D; Guerrero, J			Trends in hospitalization associated with traumatic brain injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE-PAYMENT SYSTEM; HEAD-INJURY; ACCURACY	Context Traumatic brain injury (TBI) is associated with more than 50 000 deaths in the United States each year, and recent observations suggest a substantial decline in TBI-related hospitalizations and deaths. Objective To analyze long-term trends in TBI-related hospitalization in the United States. Design, Setting, and Participants Analysis of existing data from 1980 through 1995 from the National Hospital Discharge Survey, an annual survey representing the US general population. The number of participating hospitals ranged from 400 to 494. Main Outcome Measures Annual rates of TBI-related hospitalization, stratified by age, sex, severity of injury, and outcome. Results The annual number of TBI cases identified from the sample during the study : period ranged from 1611 to 3129. Overall rates of hospitalization for TBI declined an estimated 51 %, from 199 to 98 per 100 000 per year. When analyzed by severity of injury, mild TBIs declined most during this period, from 130 to 51 hospitalizations per 100 000 per year (61 % decline; P<.001 compared with intermediate and severe TBI); The decline was greatest among those aged 5-14 years (-66%) and least among those. aged 65 years or older (-9%). The ratio of male to female rates showed little variation during the study period (ratio, 1.8; 95% confidence interval [CI], 1.6-2.0), as did the in-hospital mortality rate (mean, 5.3 per 100 000; 95% CI, 3.6-7.1). Conclusions Changes in hospital practices may be a major factor in the declining rates of TBI-related hospital admissions. These practices increasingly appear to exclude persons with less severe TBI from hospital admission and shift: their care to outpatient settings.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Thurman, D (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Mailstop F-41,4770 Buford Hwy NE, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062				ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Burt C W, 1998, Vital Health Stat 13, P1; *CDCP, 1997, DAT FIL DOC NAT HOSP; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; *CTR INJ RES POL J, 1997, ICDMAP90 SOTW; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; Graves E J, 1997, Vital Health Stat 13, P1; Gronwall D., 1989, MILD HEAD INJURY, P153; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; KISH L, 1965, SURVEY SAMPLING, P206; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; *NAT CTR HLTH STAT, 1997, DAT FIL DOC NAT HOSP; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Ruff R. M., 1989, MILD HEAD INJURY, P176; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THURMAN DJ, IN PRESS J HEAD TRAU; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DHHS, 1989, FED INT HEAD INJ TAS; *US DHHS, 1996, INT CLASS DIS	24	370	379	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					954	957		10.1001/jama.282.10.954	http://dx.doi.org/10.1001/jama.282.10.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485680				2023-01-03	WOS:000082335900033
J	Bartelink, H				Bartelink, H			Is neoadjuvant chemotherapy the answer for bladder cancer?	LANCET			English	Editorial Material							CISPLATIN; METHOTREXATE; VINBLASTINE; DOXORUBICIN		Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bartelink, H (corresponding author), Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands.							BOURHIS J, 1998, J CLIN ONCOL, V17, pA386; GHERSI D, 1995, BRIT J UROL, V75, P206; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; SCHER HI, 1988, J UROLOGY, V139, P470, DOI 10.1016/S0022-5347(17)42495-5; Shipley WU, 1997, INT J RADIAT ONCOL, V39, P937, DOI 10.1016/S0360-3016(97)00461-6; STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7; TANNOCK IF, 1990, SEMIN ONCOL, V17, P619; Thomas GM, 1999, NEW ENGL J MED, V340, P1198, DOI 10.1056/NEJM199904153401509	8	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					526	527		10.1016/S0140-6736(99)00210-X	http://dx.doi.org/10.1016/S0140-6736(99)00210-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470689				2023-01-03	WOS:000081991000002
J	Oral, H; Souza, JJ; Michaud, GF; Knight, BP; Goyal, R; Strickberger, SA; Morady, F				Oral, H; Souza, JJ; Michaud, GF; Knight, BP; Goyal, R; Strickberger, SA; Morady, F			Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENERGY INTRACARDIAC CARDIOVERSION; CONVENTIONAL EXTERNAL CARDIOVERSION; INTERNAL CARDIOVERSION; DEFIBRILLATION THRESHOLD; ANTIARRHYTHMIC DRUGS; CONVERSION EFFICACY; FLUTTER; AMIODARONE; SAFETY; PROCAINAMIDE	Background. Atrial fibrillation cannot always be converted to sinus rhythm by transthoracic electrical cardioversion. We examined the effect of ibutilide, a class iii antiarrhythmic agent, on the energy requirement for atrial defibrillation and assessed the value of this agent in facilitating cardioversion in patients with atrial fibrillation that is resistant to conventional transthoracic cardioversion. Methods. One hundred patients who had had atrial fibrillation for a mean (+/-SD) of 117 +/- 201 days were randomly assigned to undergo transthoracic cardioversion with or without pretreatment with 1 mg of ibutilide. We designed a step-up protocol in which shocks at 50, 100, 200, 300, and 360 J were used for transthoracic cardioversion. if transthoracic cardioversion was unsuccessful in a patient who had not received ibutilide pretreatment, ibutilide was administered and transthoracic cardioversion attempted again. Results. Conversion to sinus rhythm occurred in 36 of 50 patients who had not received ibutilide (72 percent) and in ail 50 patients who had received ibutilide (100 percent, P < 0.001). In all 14 patients in whom transthoracic cardioversion alone failed, sinus rhythm was restored when cardioversion was attempted again after the administration of ibutilide. Pretreatment with ibutilide was associated with a reduction in the mean energy required for defibrillation (166 +/- 80 J, as compared with 228 +/- 93 J without pretreatment; P < 0.001). Sustained polymorphic ventricular tachycardia occurred in 2 of the 64 patients who received ibutilide (3 percent), both of whom had an ejection fraction of 0.20 or less. The rates of freedom from atrial fibrillation after six months of follow-up were similar in the two randomized groups. Conclusions. The efficacy of transthoracic cardioversion for converting atrial fibrillation to sinus rhythm was enhanced by pretreatment with ibutilide. However, use of this drug should be avoided in patients with very low ejection fractions. (N Engl J Med 1999; 340:1849-54.) (C) 1999, Massachusetts Medical Society.	Univ Michigan, Med Ctr, Div Cardiol, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Morady, F (corresponding author), Univ Michigan, Med Ctr, Div Cardiol, Dept Internal Med, B1F245,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	fmorady@umich.edu						Alt E, 1997, EUR HEART J, V18, P1796; Alt E, 1997, AM J CARDIOL, V79, P621, DOI 10.1016/S0002-9149(96)00827-2; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENSER ME, 1997, CIRCULATION S1, V96, P383; CONNELL PN, 1973, J ELECTROCARDIOL, V6, P313, DOI 10.1016/S0022-0736(73)80053-6; Dahl C F, 1976, Med Instrum, V10, P151; Daoud EG, 1997, AM J CARDIOL, V79, P97, DOI 10.1016/S0002-9149(96)00689-3; Ellenbogen KA, 1996, J AM COLL CARDIOL, V28, P1082; EPSTEIN AE, 1992, CIRCULATION, V86, P1206, DOI 10.1161/01.CIR.86.4.1206; EWY GA, 1992, CIRCULATION, V86, P1645, DOI 10.1161/01.CIR.86.5.1645; EWY GA, 1980, CRIT CARE MED, V8, P164, DOI 10.1097/00003246-198003000-00015; EWY GA, 1977, HEART LUNG, V6, P847; FOGOROS RN, 1984, ANN INTERN MED, V100, P699, DOI 10.7326/0003-4819-100-5-699; GUARNIERI T, 1987, AM J CARDIOL, V60, P1061, DOI 10.1016/0002-9149(87)90352-3; GUARNIERI T, 1991, PACE, V14, P1007, DOI 10.1111/j.1540-8159.1991.tb04150.x; JUNG W, 1992, AM J CARDIOL, V70, P1023, DOI 10.1016/0002-9149(92)90354-2; Kerber R E, 1996, Am J Cardiol, V78, P22, DOI 10.1016/S0002-9149(96)00562-0; KERBER RE, 1981, CIRCULATION, V63, P676, DOI 10.1161/01.CIR.63.3.676; KERBER RE, 1984, J AM COLL CARDIOL, V3, P815, DOI 10.1016/S0735-1097(84)80258-2; KERBER RE, 1981, NEW ENGL J MED, V305, P658, DOI 10.1056/NEJM198109173051202; LABHASETWAR V, 1994, J CARDIOVASC PHARM, V24, P826, DOI 10.1097/00005344-199424050-00019; Lau CP, 1997, PACE, V20, P2442, DOI 10.1111/j.1540-8159.1997.tb06084.x; Lawton JS, 1996, AM J CARDIOL, V78, P647, DOI 10.1016/S0002-9149(96)00387-6; LEVY S, 1988, J AM COLL CARDIOL, V12, P514, DOI 10.1016/0735-1097(88)90428-7; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; LOWN B, 1967, BRIT HEART J, V29, P469; Luderitz B, 1996, AM J CARDIOL, V77, pA45, DOI 10.1016/S0002-9149(97)89117-5; Mansourati J, 1997, PACE, V20, P1919, DOI 10.1111/j.1540-8159.1997.tb03597.x; Murray KT, 1998, CIRCULATION, V97, P493; Neri R, 1997, PACE, V20, P2237, DOI 10.1111/j.1540-8159.1997.tb04242.x; RESNEKOV L, 1971, BRIT HEART J, V33, P339; Schmit C, 1996, J AM COLL CARDIOL, V28, P994, DOI 10.1016/S0735-1097(96)00274-4; Sopher SM, 1996, HEART, V75, P635, DOI 10.1136/hrt.75.6.635; Stambler BS, 1997, CIRCULATION, V96, P4298; Stambler BS, 1996, CIRCULATION, V94, P1613, DOI 10.1161/01.CIR.94.7.1613; VanGelder IC, 1997, PACE, V20, P2675; Volgman AS, 1998, J AM COLL CARDIOL, V31, P1414, DOI 10.1016/S0735-1097(98)00078-3; WESLEY RC, 1993, AM J PHYSIOL, V264, pH1269	38	241	247	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1849	1854		10.1056/NEJM199906173402401	http://dx.doi.org/10.1056/NEJM199906173402401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369847	Bronze			2023-01-03	WOS:000080863500001
J	Gokal, R; Mallick, NP				Gokal, R; Mallick, NP			Peritoneal dialysis	LANCET			English	Article							RENAL-TRANSPLANTATION; TECHNIQUE SURVIVAL; CAPD PATIENTS; HEMODIALYSIS; MULTICENTER; SELECTION; MORTALITY; ULTRAFILTRATION; CLEARANCE; REGISTRY	Peritoneal dialysis has now become an established form of renal replacement therapy; nearly half the patients on dialysis in the UK are treated in this way. Survival of patients is now equal to that with haemodialysis. However, long-term peritoneal dialysis (>8 years) is limited to a small percentage of patients because of dropout to haemodialysis for inherent complications of peritoneal dialysis-peritonitis, peritoneal access, inadequate dialysis, and patient-related factors. However, improvements in the understanding of the pathophysiological processes involving the peritoneal membrane have paved the way for advances in the delivery of adequate dialysis, more biocompatible dialysis fluids, and automated peritoneal dialysis. Other technical advances have led to a reduction in peritonitis. Peritoneal dialysis is an important dialysis modality and should be used as an integral part of RRT programmes.	Manchester Royal Infirm, Dept Renal Med, Manchester M13 9WL, Lancs, England	University of Manchester	Gokal, R (corresponding author), Manchester Royal Infirm, Dept Renal Med, Oxford Rd, Manchester M13 9WL, Lancs, England.							[Anonymous], 1997, Am J Kidney Dis, V30, pS67; Blake PG, 1996, PERITON DIALYSIS INT, V16, P248; BRUNORI G, 1997, PERITON DIAL INT S1, V17, pS28; Buoncristiani U., 1980, INT J NEPHROL UROL A, V1, P50; BURTON PR, 1987, LANCET, V1, P1115; CAVALLI PL, 1989, ADV PERIT D, V5, P52; CHARYTAN C, 1986, ARCH INTERN MED, V146, P1138, DOI 10.1001/archinte.146.6.1138; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Coles GA, 1998, KIDNEY INT, V54, P2234, DOI 10.1046/j.1523-1755.1998.00183.x; Davies S J, 1996, Perit Dial Int, V16 Suppl 1, pS158; Davies SJ, 1998, KIDNEY INT, V54, P2207, DOI 10.1046/j.1523-1755.1998.00180.x; Diaz-Buxo JA, 1994, TXB PERITONEAL DIALY, P399; DISNEY APS, 1995, AM J KIDNEY DIS, V25, P165; FALLER B, 1984, PERITON DIALYSIS B, V4, P10; Fenton SSA, 1997, AM J KIDNEY DIS, V30, P334, DOI 10.1016/S0272-6386(97)90276-6; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; GOKAL R, 1987, LANCET, V2, P1105; Gokal R, 1996, PERITON DIALYSIS INT, V16, P553; GOKAL R, 1995, J ROY COLL PHYS LOND, V29, P190; Gokal R, 1998, PERITON DIALYSIS INT, V18, P11; Gokal R, 1996, Curr Opin Nephrol Hypertens, V5, P521, DOI 10.1097/00041552-199611000-00012; GOKAL R, 1993, KIDNEY INT, V43, pS23; Gokal R, 1996, Perit Dial Int, V16 Suppl 1, pS13; GUDEX CM, 1995, QUAL LIFE RES, V4, P359, DOI 10.1007/BF01593889; HABACH G, 1995, J AM SOC NEPHROL, V5, P1940; Harty J, 1996, AM J KIDNEY DIS, V28, P553, DOI 10.1016/S0272-6386(96)90467-9; Harty J, 1996, Perit Dial Int, V16 Suppl 1, pS147; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; HUTCHISON AJ, 1992, KIDNEY INT, V42, pS153; Keane WF, 1996, PERITON DIALYSIS INT, V16, P557; KESHAVIAH PR, 1989, PERITON DIALYSIS INT, V9, P257; KHANNA R, 1993, ESSENTIALS PERITONEA; KOPPLE JD, 1995, KIDNEY INT, V47, P1148, DOI 10.1038/ki.1995.164; LAMB EJ, 1997, KIDNEY INT, V51, P182; LUPO A, 1994, AM J KIDNEY DIS, V24, P826, DOI 10.1016/S0272-6386(12)80678-0; Maiorca R, 1996, PERITON DIALYSIS INT, V16, P276; MAIORCA R, 1991, PERITON DIALYSIS INT, V11, P118; MAIORCA R, 1994, TXB PERITONEAL DIALY, P669; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; Mallick NP, 1999, LANCET, V353, P737, DOI 10.1016/S0140-6736(97)09411-7; MAXWELL MH, 1959, JAMA-J AM MED ASSOC, V170, P917, DOI 10.1001/jama.1959.03010080025004; MISTRY CD, 1987, LANCET, V2, P178; MISTRY CD, 1991, SEMIN DIALYSIS, V4, P9, DOI 10.1111/j.1525-139X.1991.tb00401.x; Nakayama M, 1997, KIDNEY INT, V51, P182, DOI 10.1038/ki.1997.22; Nissenson AR, 1997, ASAIO J, V43, P143; Nolph KD, 1996, PERITON DIALYSIS INT, V16, P15; PIRAINO B, 1995, PERITON DIALYSIS INT, V15, P303; POPOVICH RP, 1976, ABSTR AM SOC ART INT, V5, P64; SERKES KD, 1990, PERITON DIALYSIS INT, V10, P15; TEEHAN BP, 1990, ADV PERIT D, V6, P181; TEEHAN BP, 1985, PERITON DIALYSIS B, V5, P152; Tenckhoff H, 1973, Proc Eur Dial Transplant Assoc, V10, P363; TERAOKA S, 1995, AM J KIDNEY DIS, V25, P151, DOI 10.1016/0272-6386(95)90640-1; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS B, V7, P128; YOUNG GA, 1991, AM J KIDNEY DIS, V17, P462, DOI 10.1016/S0272-6386(12)80642-1	56	95	98	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					823	828		10.1016/S0140-6736(98)09410-0	http://dx.doi.org/10.1016/S0140-6736(98)09410-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459977				2023-01-03	WOS:000079089100045
J	Rao, VK; Iademarco, EP; Fraser, VJ; Kollef, MH				Rao, VK; Iademarco, EP; Fraser, VJ; Kollef, MH			Delays in the suspicion and treatment of tuberculosis among hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DIAGNOSIS; OUTBREAK; INFECTION; CARE; TRANSMISSION; MORTALITY; FAILURE; RISK	Background: Despite increased awareness of tuberculosis, delays in management are common. Objective: To investigate management delays among hospitalized patients with tuberculosis. Design: Retrospective cohort study. Setting: The Barnes-Jewish-Christian Health System, a network of eight community and tertiary-care facilities serving the St. Louis, Missouri, metropolitan area. Patients: All 203 patients with tuberculosis hospitalized in the Barnes-Jewish-Christian Health System from 1988 to 1996. Measurements: Time from admission to first consideration of the diagnosis (suspicion interval), first consideration and treatment initiation (treatment interval), and admission and treatment initiation (overall management interval) were determined. Delays were defined as intervals longer than 24 hours. Results: The overall management interval (median, 6 days [5th and 95th percentiles, 1 and 52 days]) exceeded 24 hours in 152 patients (74.9% [95% CI, 68.9% to 80.9%]). The suspicion interval (median, 1 day [5th and 95th percentiles, 0 and 16 days]) exceeded 24 hours in 54 patients (26.6% [CI, 20.5% to 32.7%]), and the treatment interval (median, 3 days [5th and 95th percentiles, 0 and 51 days]) was prolonged in 130 patients (64.0% [CI, 57.4% to 70.6%]). Overall management delays of more than 10 and 25 days occurred in 33.5% (CI, 27.0% to 40.0%) and 18.7% (CI, 13.3% to 24.1%) of patients, respectively. The 55 patients with smears that were positive for acid-fast bacilli had a median treatment interval of 3 days (5th and 95th percentiles, 0 and 33 days); in 58.2% of patients (CI, 45.2% to 71.2%), this interval exceeded 24 hours. Conclusions: Delays in initiation of treatment were more common than delays in the initial suspicion of tuberculosis. Both types of delays were common even in patients with disease that was confirmed by a positive smear. These data illustrate a need for improved education of physicians about the benefits of early initiation of therapy for tuberculosis.	Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA	Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Div Pulm & Crit Care, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@pulmonary.wustl.edu		Fraser, Victoria/0000-0001-6251-0733	PHS HHS [U50-CCU-710076-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Bock NN, 1996, AM J RESP CRIT CARE, V154, P1468, DOI 10.1164/ajrccm.154.5.8912766; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BYRD RB, 1977, ANN INTERN MED, V86, P799, DOI 10.7326/0003-4819-86-6-799; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; COUNSELL SR, 1989, ARCH INTERN MED, V149, P1274, DOI 10.1001/archinte.149.6.1274; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; ENARSON DA, 1978, CAN MED ASSOC J, V118, P1520; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GORDIN FM, 1989, AM REV RESPIR DIS, V139, P1090, DOI 10.1164/ajrccm/139.5.1090; HEFFNER JE, 1988, ARCH INTERN MED, V148, P1103, DOI 10.1001/archinte.148.5.1103; Kellerman S, 1997, INFECT CONT HOSP EP, V18, P542; LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193; Liam CK, 1997, INT J TUBERC LUNG D, V1, P326; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; MORAN GJ, 1995, ANN EMERG MED, V26, P290, DOI 10.1016/S0196-0644(95)70074-9; Murray P.R, 1995, MANUAL CLIN MICROBIO, V6th; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; *SAS I, 1990, SAS STAT US GUID, V2, P1071; Sumartojo EM, 1997, AM J PUBLIC HEALTH, V87, P2008, DOI 10.2105/AJPH.87.12.2008; Tacconelli E, 1997, INT J TUBERC LUNG D, V1, P582; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; *WHO, 1994, WHO PUBL, P170; 1996, AM J RESP CRIT CARE, V154, P251	36	65	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 2	1999	130	5					404	+		10.7326/0003-4819-130-5-199903020-00004	http://dx.doi.org/10.7326/0003-4819-130-5-199903020-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172AA	10068414				2023-01-03	WOS:000078898100003
J	McWhinney, IR				McWhinney, IR			Primary care: core values - Core values in a changing world	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; GENERAL-PRACTITIONERS; COMMUNITY		Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	McWhinney, IR (corresponding author), Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada.							Brown JB, 1997, CAN FAM PHYSICIAN, V43, P901; Carmichael LP, 1997, AM FAM PHYSICIAN, V56, P713; Dostoevsky Fyodor, 1958, BROTHERS KARAMAZOV; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HART JT, 1970, LANCET, V2, P223; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; *I MED, 1978, IOM PUBL, V7302; MacIntyre A., 1981, AFTER VIRTUE; MAY WF, 1983, PHYSICIANS COVENANT; MCCORMICK J, 1994, LANCET, V344, P390; Nutting P A, 1986, Am J Prev Med, V2, P140; NUTTING PA, 1986, AM J PUBLIC HEALTH, V76, P279, DOI 10.2105/AJPH.76.3.279; SALTMAN DC, 1995, MED J AUSTRALIA, V162, P3, DOI 10.5694/j.1326-5377.1995.tb138397.x; SMITH LFP, 1994, J MED ETHICS, V20, P175, DOI 10.1136/jme.20.3.175; Stewart M., 1995, PATIENT CTR MED PATIENT CTR MED; VEALE BM, 1996, THESIS AUSTR NATL U; WHITE KL, 1987, INT CLASSIFICATION P; Wilber K., 1995, SEX ECOLOGY SPIRITUA; World Health Organisation, 1978, ALM 1978 PRIM HLTH C; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544	21	89	89	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1807	1809		10.1136/bmj.316.7147.1807	http://dx.doi.org/10.1136/bmj.316.7147.1807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624075	Green Published			2023-01-03	WOS:000074286300032
J	Ebenbichler, GR; Resch, KL; Nicolakis, P; Wiesinger, GF; Uhl, F; Ghanem, AH; Fialka, V				Ebenbichler, GR; Resch, KL; Nicolakis, P; Wiesinger, GF; Uhl, F; Ghanem, AH; Fialka, V			Ultrasound treatment for treating the carpal tunnel syndrome: randomised "sham" controlled trial	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC ULTRASOUND; STEROID INJECTION	Objective: To assess the efficacy of ultrasound treatment for mild to moderate idiopathic carpal tunnel syndrome. Design: Randomised, double blind, "sham" controlled trial with assessments at baseline, after 2 weeks' and 7 weeks' treatment and at a follow up assessment 6 months later (8 months after baseline evaluation), Setting Outpatient clinic of a university department of physical medicine and rehabilitation in Vienna. Subjects: 45 patients with mild to moderate bilateral carpal tunnel syndrome as verified by electroneurography. Intervention: 20 sessions of ultrasound (active) treatment (1 MHz, 1.0 W/cm(2), pulsed mode 1:4, 15 minutes per session) applied to the area over the carpal tunnel of one wrist, and indistinguishable sham ultrasound treatment applied to the other. The first 10 treatments were performed daily (5 sessions/week); 10 further treatments were twice weekly for 5 weeks. Main outcome measures: Score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity). Results: Improvement was significantly more pronounced in actively treated than in sham treated mists for both subjective symptoms (P < 0.001, paired t test) and electroneurographic variables (motor distal latency P < 0.001, paired t test; sensory antidromic nerve conduction velocity P < 0.001, paired t test). Effects were sustained at 6 months' follow up. Conclusion: Results suggest there are satisfying short to medium term effects due to ultrasound treatment in patients with mild to moderate idiopathic carpal tunnel syndrome. Findings need to be confirmed, and ultrasound treatment will have to be compared with standard conservative and invasive treatment options.	Univ Vienna, Dept Phys Med & Rehabil, A-1090 Vienna, Austria; Univ Exeter, Dept Complementary Med, Exeter, Devon, England; Univ Vienna, Dept Neurol, A-1090 Vienna, Austria	University of Vienna; University of Exeter; University of Vienna	Ebenbichler, GR (corresponding author), Univ Vienna, Dept Phys Med & Rehabil, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							BARNETT SB, 1994, ULTRASOUND MED BIOL, V20, P205, DOI 10.1016/0301-5629(94)90060-4; BAYSAL AI, 1993, ACTA NEUROL SCAND, V88, P213; BINDER A, 1985, BRIT MED J, V290, P512, DOI 10.1136/bmj.290.6467.512; BURKE DT, 1994, ARCH PHYS MED REHAB, V75, P1241, DOI 10.1016/0003-9993(94)90012-4; BURTON RI, 1975, CURR PROBL SURG S7, V12, P17; BYL NN, 1992, ARCH PHYS MED REHAB, V73, P656; COTTON P, 1991, JAMA-J AM MED ASSOC, V265, P1921; CURRIER DP, 1978, ARCH PHYS MED REHAB, V59, P181; DAWSON DM, 1993, NEW ENGL J MED, V329, P2013, DOI 10.1056/NEJM199312303292707; DYSON M, 1987, PHYSIOTHERAPY, V73, P116; EDEL H, 1970, Archiv fuer Physikalische Therapie, V22, P255; ELHAG M, 1985, BRIT J ORAL MAX SURG, V23, P17, DOI 10.1016/0266-4356(85)90074-9; GELBERMAN RH, 1980, J BONE JOINT SURG AM, V62, P1181, DOI 10.2106/00004623-198062070-00020; GELBERMAN RH, 1981, J BONE JOINT SURG AM, V63, P380, DOI 10.2106/00004623-198163030-00009; GIANNINI F, 1991, ARCH PHYS MED REHAB, V72, P738; GIRLANDA P, 1993, J NEUROL, V240, P187, DOI 10.1007/BF00857526; HONG CZ, 1988, ARCH PHYS MED REHAB, V69, P410; KRAMER JF, 1989, AM J PHYS MED, V64, P1; Ludin HP, 1993, PRAKTISCHE ELEKTROMY; MAYR H, 1994, OSTERR Z PHYS MED, V4, P95; MCCONNELL JR, 1990, CLIN ORTHOP RELAT R, P181; OMALLEY MJ, 1992, J HAND SURG-AM, V17A, P638, DOI 10.1016/0363-5023(92)90307-B; STEVENS JC, 1987, MUSCLE NERVE, V10, P99, DOI 10.1002/mus.880100202; 1985, LANCET, V1, P854	24	148	150	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					731	735		10.1136/bmj.316.7133.731	http://dx.doi.org/10.1136/bmj.316.7133.731			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529407	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000072463700029
J	Auperin, A; Arriagada, R; Pignon, JP; Le Pechoux, C; Gregor, A; Stephens, RJ; Kristjansen, PEG; Johnson, BE; Ueoka, H; Wagner, H; Aisner, J				Auperin, A; Arriagada, R; Pignon, JP; Le Pechoux, C; Gregor, A; Stephens, RJ; Kristjansen, PEG; Johnson, BE; Ueoka, H; Wagner, H; Aisner, J		Prophylactic Cranial Irradiation Overview Colla	Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAIN IRRADIATION; FOLLOW-UP; COMPLETE RESPONSE; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; CARCINOMA; TRIAL; CYCLOPHOSPHAMIDE; RADIOTHERAPY; METASTASES	Background Prophylactic cranial irradiation reduces the incidence of brain metastasis in patients with small-cell lung cancer. Whether this treatment, when given to patients in complete remission, improves survival is not known. We performed a metaanalysis to determine whether prophylactic cranial irradiation prolongs survival. Methods We analyzed individual data on 987 patients with small-cell lung cancer in complete remission who took part in seven trials that compared prophylactic cranial irradiation with no prophylactic cranial irradiation. The main end point was survival. Results The relative risk of death in the treatment group as compared with the control group was 0.84 (95 percent confidence interval, 0.73 to 0.97; P = 0.01), which corresponds to a 5.4 percent increase in the rate of survival at three years (15.3 percent in the control group vs. 20.7 percent in the treatment group). Prophylactic cranial irradiation also increased the rate of disease-free survival (relative risk of recurrence or death, 0.75; 95 percent confidence interval, 0.65 to 0.86; P < 0.001) and decreased the cumulative incidence of brain metastasis (relative risk, 0.46; 95 percent confidence interval, 0.38 to 0.57; P < 0.001). Larger doses of radiation led to greater decreases in the risk of brain metastasis, according to an analysis of four total doses (8 Gy, 24 to 25 Gy, 30 Gy, and 36 to 40 Gy) (P for trend = 0.02), but the effect on survival did not differ significantly according to the dose. We also identified a trend (P = 0.01) toward a decrease in the risk of brain metastasis with earlier administration of cranial irradiation after the initiation of induction chemotherapy. Conclusions Prophylactic cranial irradiation improves both overall survival and disease-free survival among patients with small-cell lung cancer in complete remission, (N Engl J Med 1999;341:476-84.) (C) 1999. Massachusetts Medical Society.	Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Radiat Oncol, F-94805 Villejuif, France; Inst Radiomed, Santiago, Chile; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; MRC, Canc Trials Off, Cambridge, England; Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; Natl Naval Med Ctr, Bethesda, MD USA; Okayama Univ, Sch Med, Okayama 700, Japan; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Univ S Florida, Res Inst, Tampa, FL 33682 USA; Canc Inst New Jersey, New Brunswick, NJ USA	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; University of Edinburgh; University of Copenhagen; Walter Reed National Military Medical Center; Okayama University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Pignon, JP (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, Rue Camille Desmoulins, F-94805 Villejuif, France.	jppignon@igr.fr		Arriagada, Rodrigo/0000-0002-3134-1735; PIGNON, Jean-Pierre/0000-0003-2047-1582; Stewart, Lesley/0000-0003-0287-4724				Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954; ALBAIN KS, 1990, J CLIN ONCOL, V8, P1563, DOI 10.1200/JCO.1990.8.9.1563; ARONEY RS, 1983, CANCER TREAT REP, V67, P675; ARRIAGADA R, 1994, ANTICANCER RES, V14, P333; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; ARRIAGADA R, 1992, J CLIN ONCOL, V10, P447, DOI 10.1200/JCO.1992.10.3.447; BEILER DD, 1979, INT J RADIAT ONCOL, V5, P941, DOI 10.1016/0360-3016(79)90598-4; CATANE R, 1981, INT J RADIAT ONCOL, V7, P105, DOI 10.1016/0360-3016(81)90066-3; COX JD, 1978, CANCER-AM CANCER SOC, V42, P1135, DOI 10.1002/1097-0142(197809)42:3<1135::AID-CNCR2820420316>3.0.CO;2-N; EAGAN RT, 1981, CANCER CLIN TRIALS, V4, P261; *EARL BREAST CANC, 1990, TREAT EARL BREAST CA, V1; FRYTAK S, 1989, AM J CLIN ONCOL-CANC, V12, P27, DOI 10.1097/00000421-198902000-00007; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; HANSEN HH, 1973, CANCER CHEMOTH REP 3, V4, P239; HANSEN HH, 1980, CANCER, V46, P279, DOI 10.1002/1097-0142(19800715)46:2<279::AID-CNCR2820460210>3.0.CO;2-W; HIRSCH FR, 1982, CANCER, V50, P2433, DOI 10.1002/1097-0142(19821201)50:11<2433::AID-CNCR2820501131>3.0.CO;2-E; JACKSON DV, 1977, JAMA-J AM MED ASSOC, V237, P2730, DOI 10.1001/jama.237.25.2730; Johnson BE, 1996, J CLIN ONCOL, V14, P806, DOI 10.1200/JCO.1996.14.3.806; JOHNSON BE, 1990, J CLIN ONCOL, V8, P48, DOI 10.1200/JCO.1990.8.1.48; KATSENIS AT, 1982, LUNG CANC ETIOLOGY E, P277; KOMAKI R, 1985, Cancer Treatment Symposia, V2, P35; KRISTJANSEN PEG, 1993, CANCER TREAT REV, V19, P3, DOI 10.1016/0305-7372(93)90023-K; Laplanche A, 1998, LUNG CANCER-J IASLC, V21, P193, DOI 10.1016/S0169-5002(98)00056-7; LEE JS, 1986, INT J RADIAT ONCOL, V12, P313, DOI 10.1016/0360-3016(86)90344-5; LISHNER M, 1990, J CLIN ONCOL, V8, P215, DOI 10.1200/JCO.1990.8.2.215; MAURER LH, 1980, CANCER, V45, P30, DOI 10.1002/1097-0142(19800101)45:1<30::AID-CNCR2820450107>3.0.CO;2-6; MOUNTAIN CF, 1982, 3 WORLD C LUNG CANC, P153; MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336; NIIRANEN A, 1989, ACTA ONCOL, V28, P501, DOI 10.3109/02841868909092258; OHONOSHI T, 1993, LUNG CANCER-J IASLC, V10, P47, DOI 10.1016/0169-5002(93)90308-K; PEREZ CA, 1981, CANCER, V47, P2407, DOI 10.1002/1097-0142(19810515)47:10<2407::AID-CNCR2820471015>3.0.CO;2-R; ROSEN ST, 1983, AM J MED, V74, P615, DOI 10.1016/0002-9343(83)91019-7; ROSENMAN J, 1982, INT J RADIAT ONCOL, V8, P1041, DOI 10.1016/0360-3016(82)90174-2; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SEYDEL HG, 1985, AM J CLIN ONCOL-CANC, V8, P218, DOI 10.1097/00000421-198506000-00005; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Suwinski R, 1998, INT J RADIAT ONCOL, V40, P797, DOI 10.1016/S0360-3016(97)00856-0; Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403; Wagner H, 1996, P AN M AM SOC CLIN, V15, P376	39	1162	1231	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					476	484		10.1056/NEJM199908123410703	http://dx.doi.org/10.1056/NEJM199908123410703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441603				2023-01-03	WOS:000081962600003
J	Leape, LL; Cullen, DJ; Clapp, MD; Burdick, E; Demonaco, HJ; Erickson, JI; Bates, DW				Leape, LL; Cullen, DJ; Clapp, MD; Burdick, E; Demonaco, HJ; Erickson, JI; Bates, DW			Pharmacist participation on physician rounds and adverse drug events in the intensive care unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; PREVENTION; COSTS	Context Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs. However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied. Objective To measure the effect bf pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors. Design Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention. Setting A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital. Patients Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995. In addition, 50 patients were selected at random from the control unit during the baseline period. Intervention A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day. Main Outcome Measures Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist. Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases. Pharmacists recorded all recommendations, which were then analyzed by type and acceptance. Results The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5, P<.001) after the Intervention. In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days. The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians. Conclusions The presence of a. pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors. Nearly all the changes were readily accepted by physicians.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA; Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.							BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROYLES JE, 1991, DICP ANN PHARMAC, V25, P119, DOI 10.1177/106002809102500201; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; FOLLI HL, 1987, PEDIATRICS, V79, P718; Kilroy R A, 1993, Crit Care Nurs Clin North Am, V5, P221; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; MONTAZERI M, 1994, CRIT CARE MED, V22, P1044, DOI 10.1097/00003246-199406000-00027; SAS Institute Inc, 1988, SAS PROC GUID REL 6	13	953	995	0	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					267	270		10.1001/jama.282.3.267	http://dx.doi.org/10.1001/jama.282.3.267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422996	Bronze			2023-01-03	WOS:000081504400033
J	Levine, C				Levine, C			The loneliness of the long-term care giver	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									United Hosp Fund, New York, NY 10118 USA		Levine, C (corresponding author), United Hosp Fund, New York, NY 10118 USA.							Angell M, 1999, NEW ENGL J MED, V340, P48, DOI 10.1056/NEJM199901073400108; Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; BARUSCH AS, 1995, SOC WORK, V40, P315; Cassel CK, 1999, HEALTH AFFAIR, V18, P118, DOI 10.1377/hlthaff.18.1.118; GRAHAM J, 1999, CHICAGO TRIBUNE 0117; Levine C, 1999, ANN INTERN MED, V130, P148, DOI 10.7326/0003-4819-130-2-199901190-00010; LEVINE C, IN PRESS J HLTH AGIN; Levine C., 1998, ROUGH CROSSINGS FAMI; MINTZ S, 1999, COMMUNICATION   0106; SCHOFIELD H, 1998, FAMILY CAREGIVERS DI	10	69	72	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1587	1590		10.1056/NEJM199905203402013	http://dx.doi.org/10.1056/NEJM199905203402013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332025				2023-01-03	WOS:000080358900013
J	Zander, L; Chamberlain, G				Zander, L; Chamberlain, G			Place of birth	BRITISH MEDICAL JOURNAL			English	Review									Guys Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England; Kings Hosp, Sch Med, Dept Gen Practice, London, England; St Thomas Hosp, Sch Med, Dept Gen Practice, London, England	Guy's & St Thomas' NHS Foundation Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust	Zander, L (corresponding author), Guys Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England.							CAMPBELL R, 1994, WHERE BE BORN; CHAMBERLAIN G, 1995, HOME BIRTHS; *DEP HLTH, 1994, CHANG CHILDB; *GEN SERV MED COUN, 1997, GEN PRACT INTR CAR I; *MAT TASK GROUP RO, 1995, 72 MAT TASK GROUP RO; *NHS, 1997, STAT B NHS; *WELSH OFF, 1998, HLTH EV B MAT CHILD	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 13	1999	318	7185					721	723						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182JK	10074022				2023-01-03	WOS:000079495700031
J	Kollef, MH				Kollef, MH			Current concepts - The prevention of ventilator-associated pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HOSPITAL-ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; MECHANICAL VENTILATION; ATTRIBUTABLE MORTALITY; FEBRILE NEUTROPENIA; CONTROLLED TRIAL; RISK-FACTORS; COLONIZATION		Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care, St Louis, MO 63110 USA; Barnes Jewish Hosp, Med Intens Care Unit, St Louis, MO 63110 USA; Barnes Jewish Hosp, Dept Resp Care Serv, St Louis, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care, Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@pulmonary.wustl.edu			PHS HHS [UR8/CCU715087] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYCE JM, 1985, AM J INFECT CONTROL, V13, P228, DOI 10.1016/0196-6553(85)90063-X; Brewer C, 1996, CHEST, V109, P1019; COMETTA A, 1992, NEW ENGL J MED, V327, P234; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; CRAVEN DE, 1995, CHEST, V108, pS1, DOI 10.1378/chest.108.2_Supplement.1S; CRAVEN DE, 1984, AM REV RESPIR DIS, V129, P625; DELFAVERO A, 1991, ANN INTERN MED, V115, P7, DOI 10.7326/0003-4819-115-1-7; DeRiso A, 1996, CHEST, V109, P1556, DOI 10.1378/chest.109.6.1556; DJEDAINI K, 1995, AM J RESP CRIT CARE, V152, P1562, DOI 10.1164/ajrccm.152.5.7582295; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; GarrousteOrgeas M, 1997, AM J RESP CRIT CARE, V156, P1647, DOI 10.1164/ajrccm.156.5.96-04076; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Gaynes RP, 1996, JOINT COMM J QUAL IM, V22, P457, DOI 10.1016/S1070-3241(16)30248-6; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Hall JC, 1996, BRIT MED J, V312, P148; Herceg A, 1997, Commun Dis Intell, V21, P173; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Joiner G A, 1996, Am J Med Qual, V11, P100, DOI 10.1177/0885713X9601100208; KELLEGHAN SI, 1993, AM J INFECT CONTROL, V21, P322, DOI 10.1016/0196-6553(93)90390-P; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P466, DOI 10.1164/ajrccm.156.2.9612083; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; Kollef MH, 1998, CHEST, V113, P759, DOI 10.1378/chest.113.3.759; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378/chest.113.2.412; Kollef MH, 1998, CHEST, V113, P267, DOI 10.1378/chest.113.2.267; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378/chest.111.3.676; MAHER DW, 1994, ANN INTERN MED, V121, P492, DOI 10.7326/0003-4819-121-7-199410010-00004; Mitchell PLR, 1997, J CLIN ONCOL, V15, P1163, DOI 10.1200/JCO.1997.15.3.1163; NIEDERMAN MS, 1990, CHEST, V97, P170, DOI 10.1378/chest.97.1.170; NIEDERMAN MS, 1989, CHEST, V95, P155, DOI 10.1378/chest.95.1.155; Niederman MS, 1997, CLIN INFECT DIS, V24, P320, DOI 10.1093/clinids/24.3.320; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PIZZO PA, 1990, J HOSP INFECT, V15, P41, DOI 10.1016/0195-6701(90)90078-3; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Rello J, 1997, AM J RESP CRIT CARE, V156, P196, DOI 10.1164/ajrccm.156.1.9607030; Rello J, 1996, AM J RESP CRIT CARE, V154, P111, DOI 10.1164/ajrccm.154.1.8680665; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; RUMBAK MJ, 1995, CRIT CARE MED, V23, P1200, DOI 10.1097/00003246-199507000-00008; Russell AD, 1997, J APPL MICROBIOL, V83, P155, DOI 10.1046/j.1365-2672.1997.00198.x; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TABLAN OC, 1998, INFECT CONT HOSP EP, V19, P304; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004	54	284	307	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1999	340	8					627	634		10.1056/NEJM199902253400807	http://dx.doi.org/10.1056/NEJM199902253400807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169NP	10029648				2023-01-03	WOS:000078755700007
J	Lin, JL; Ho, HH; Yu, CC				Lin, JL; Ho, HH; Yu, CC			Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM CREATININE; EXPOSURE; NEPHROPATHY; DISEASE; IMPAIRMENT; EXCRETION; DIET; PLAY	Background: Nephropathy is known to occur in persons exposed to high levels of lead, but the question of whether long-term exposure to low levels of environmental lead is associated with impaired renal function remains controversial. Objective: To examine whether chelation therapy stows the progression of renal insufficiency in patients with mildly elevated body lead burden. Design: Randomized, controlled trial. Setting: Academic medical center in Taiwan. Patients: 32 patients with chronic renal insufficiency (serum creatinine level > 132.6 mu mol/L [1.5 mg/dL] and < 353.8 mu mol/L [4.0 mg/dL]), mildly elevated body lead burden (>0.72 mu mol [150 mu g] of lead per 72-hour urine collection and < 2.90 mu mol [600 mu g] of lead per 72-hour urine collection [EDTA mobilization tests]), and no history of heavy lead exposure. Intervention: The treatment group received 2 months of chelation therapy; the control group received no therapy. Measurements: The reciprocal of serum creatinine (1/Cr) was used as an index of progressive renal insufficiency. Results: Rates of progression of renal insufficiency were similar in the treatment group and the control group during a 12-month baseline observation period (1/Cr, 0.000054 L/mu mol per month compared with 0.000046 L/mu mol per month; P > 0.2). After the 2-month treatment period, improvement in renal function was greater in the treatment group than in the control group. In the 12 months after the treatment period, renal insufficiency progressed more slowly in the treatment group than in the control group (1/Cr, 0.000033 +/- 0.00038 L/mu mol per month compared with 0.000045 +/- 0.000038 L/mu mol per month; P = 0.0030). Conclusion: Chelation therapy seems to slow the progression of renal insufficiency in patients with mildly elevated body lead burden. This implies that long-term exposure to low levels of environmental lead may be associated with impaired renal function in patients with chronic renal disease.	Chang Gung Mem Hosp, Div Nephrol, Taipei, Taiwan; Chang Gung Mem Hosp, Poison Ctr, Taipei, Taiwan; Chang Gung Mem Hosp, Div Rheumatol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Lin, JL (corresponding author), Chang Gung Mem Hosp, Div Nephrol, 199 Tung Hwa N Rd, Taipei, Taiwan.							ALVESTRAND A, 1983, CLIN NEPHROL, V19, P67; BATUMAN V, 1981, NEW ENGL J MED, V304, P520, DOI 10.1056/NEJM198102263040905; BEHRINGER D, 1986, NEPHRON, V42, P323, DOI 10.1159/000183696; BRAZY PC, 1989, KIDNEY INT, V35, P670, DOI 10.1038/ki.1989.37; HENDERSON DA, 1958, MED J AUSTRALIA, V1, P377; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; KHALILMANESH F, 1992, ENVIRON RES, V58, P35, DOI 10.1016/S0013-9351(05)80203-8; Kim R, 1996, JAMA-J AM MED ASSOC, V275, P1177, DOI 10.1001/jama.275.15.1177; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.med.39.1.465; LIM VS, 1990, KIDNEY INT, V37, P131, DOI 10.1038/ki.1990.18; LIN JL, 1993, AM J NEPHROL, V13, P442, DOI 10.1159/000168661; LIN JL, 1992, AM J NEPHROL, V12, P457, DOI 10.1159/000168498; LIN JL, 1994, J HUM HYPERTENS, V8, P495; LIN JL, 1994, J RHEUMATOL, V21, P705; LIN JL, 1992, MINER ELECTROL METAB, V18, P1; MITCH WE, 1976, LANCET, V2, P1326; NUYTS GD, 1991, NEPHROL DIAL TRANSPL, V6, P307, DOI 10.1093/ndt/6.5.307; PAYTON M, 1994, AM J EPIDEMIOL, V140, P821, DOI 10.1093/oxfordjournals.aje.a117330; POLLOCK CA, 1988, INT J ARTIF ORGANS, V11, P75, DOI 10.1177/039139888801100204; RUTHERFORD WE, 1977, KIDNEY INT, V11, P62, DOI 10.1038/ki.1977.8; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; WEDEEN RP, 1979, ARCH INTERN MED, V139, P53, DOI 10.1001/archinte.139.1.53; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7	24	49	49	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 5	1999	130	1					7	13		10.7326/0003-4819-130-1-199901050-00003	http://dx.doi.org/10.7326/0003-4819-130-1-199901050-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151WW	9890856				2023-01-03	WOS:000077744500002
J	Schneider, T; Stallmach, A; von Herbay, A; Marth, T; Strober, W; Zeitz, M				Schneider, T; Stallmach, A; von Herbay, A; Marth, T; Strober, W; Zeitz, M			Treatment of refractory Whipple disease with interferon-gamma	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Saarland, D-66421 Homburg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; NIAID, Mucosal Immun Sect, NIH, Bethesda, MD 20892 USA	Saarland University; Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zeitz, M (corresponding author), Univ Saarland, D-66421 Homburg, Germany.							BJERKNES R, 1988, SCAND J GASTROENTERO, V23, P611, DOI 10.3109/00365528809093921; ECTOERS N, 1992, GASTROENTEROLOGY, V106, pA676; FELDMAN M, 1980, ANN INTERN MED, V93, P709, DOI 10.7326/0003-4819-93-5-709; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; GALLIN JI, 1995, ANN INTERN MED, V123, P216, DOI 10.7326/0003-4819-123-3-199508010-00009; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; KEINATH RD, 1985, GASTROENTEROLOGY, V88, P1867, DOI 10.1016/0016-5085(85)90012-5; MAIZEL H, 1970, MEDICINE, V49, P175, DOI 10.1097/00005792-197005000-00001; MARTH T, 1994, CLIN IMMUNOL IMMUNOP, V72, P217, DOI 10.1006/clin.1994.1134; Marth T, 1997, GASTROENTEROLOGY, V113, P442, DOI 10.1053/gast.1997.v113.pm9247462; MARTIN FF, 1972, GASTROENTEROLOGY, V63, P6; PAULLEY JW, 1952, GASTROENTEROLOGY, V22, P128; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; vonHerbay A, 1997, GASTROENTEROLOGY, V113, P434, DOI 10.1053/gast.1997.v113.pm9247461; vonHerbay A, 1996, GASTROENTEROLOGY, V110, P1735, DOI 10.1053/gast.1996.v110.pm8964398	17	59	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1998	129	11					875	877		10.7326/0003-4819-129-11_Part_1-199812010-00006	http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143DF	9867729				2023-01-03	WOS:000077239200005
J	Straus, WL; Qazi, SA; Kundi, Z; Nomani, NK; Schwartz, B				Straus, WL; Qazi, SA; Kundi, Z; Nomani, NK; Schwartz, B		Pakistan Co-Trimoxazole Study Grp	Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; COMMUNITY; PENICILLIN	Background Cotrimoxazole is widely used in treatment of paediatric pneumonia in developing countries, but drug resistance may decrease its effectiveness. We studied the effectiveness of co-trimoxazole compared with that of amoxycillin in pneumonia therapy, and assessed the clinical impact of co-trimoxazole resistance. Methods We recruited 595 children, aged 2-59 months, with non-severe or severe pneumonia (WHO criteria) diagnosed in the outpatient wards of two urban Pakistan hospitals. Patients were randomly assigned on a 2:1 basis co-trimoxazole (n=398) or amoxycillin (n=197) in standard WHO doses and dosing schedules, and were monitored in study wards. The primary outcome was inpatient therapy failure (clinical criteria) or clinical evidence of pneumonia at outpatient follow-up examination. Findings There were 92 (23%) therapy failures in the cotrimoxazole group and 30 (15%) in the amoxycillin group (p=0.03)-26 (13%) versus 12 (12%) among children with non-severe pneumonia (p=0.856) and 66 (33%) versus 18 (18%) among those with severe pneumonia (p=0.009). For patients with severe pneumonia, age under 1 year (p=0.056) and positive chest radiographs (p=0.005) also predicted therapy failure. There was no significant association between antimicrobial minimum inhibitory concentration and outcome among bacteraemic children treated with co-trimoxazole. Interpretation Co-trimoxazole provided effective therapy in non-severe pneumonia. For severe, life-threatening pneumonia, however, co-trimoxazole is less likely than amoxycillin to be effective.	Ctr Dis Control & Prevent, US PHS, US Dept HHS, Atlanta, GA USA; Childrens Hosp, Pakistan Inst Med Sci, Islamabad, Pakistan; Rawalpindi Gen Hosp, Rawalpindi, Pakistan; Natl Inst Hlth, Islamabad, Pakistan	Centers for Disease Control & Prevention - USA; United States Public Health Service; Pakistan Institute of Medical Sciences; Rawalpindi Medical College	Straus, WL (corresponding author), Merck & Co Inc, Outcomes Res & Management, POB 4,WP39-160, W Point, PA 19486 USA.							ALARIO AJ, 1987, J PEDIATR-US, V111, P187, DOI 10.1016/S0022-3476(87)80065-3; Bushby SR, 1973, J INFECT DIS S, V128, P442; CAMPBELL H, 1988, LANCET, V2, P1182; GAHFOOR A, 1990, REV INFECT DIS    S8, V12, pS907; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; ISAACS D, 1989, PEDIATR INFECT DIS J, V8, P143; JERNIGAN D, 1996, P INT C ANT AG CHEM; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KHAN MA, 1993, ANN TROP PAEDIATR, V13, P73, DOI 10.1080/02724936.1993.11747627; MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101; *NAT COMM CLIN LAB, 1985, M7A NAT COMM CLIN LA; National Committee for Clinical Laboratory Standards, 1997, PERF STAND ANT DISK; ODEMPSEY TJ, 1993, ARCH DIS CHILD, V68, P429; Ostroff SM, 1996, CLIN INFECT DIS, V23, P1069, DOI 10.1093/clinids/23.5.1069; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; SIMPSON W, 1974, PEDIATR RADIOL, V2, P155, DOI 10.1007/BF00972727; SIMPSON W, 1974, PEDIATR RADIOL, V2, P97, DOI 10.1007/BF01314938; TANWANI AK, 1995, QUALITY CONTROL CLIN, P108; WHO, 1990, AC RESP INF CHILDR C; *WHO, 1991, WHOARI9120; 1997, MORB MORTAL WKLY REP, V46, P62	24	98	102	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					270	274		10.1016/S0140-6736(97)10294-X	http://dx.doi.org/10.1016/S0140-6736(97)10294-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690406				2023-01-03	WOS:000074974500009
J	Meyer, O; Kirpotin, D; Hong, KL; Sternberg, B; Park, JW; Woodle, MC; Papahadjopoulos, D				Meyer, O; Kirpotin, D; Hong, KL; Sternberg, B; Park, JW; Woodle, MC; Papahadjopoulos, D			Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STERICALLY STABILIZED LIPOSOMES; TRANSFECTION; LIPIDS; CELLS	Modification of liposome surface with polyethylene glycol was used to improve oligodeoxyribonucleotide (ODN) loading, stability of the resulting complexes, and specificity of cellular delivery of ODN by cationic liposomes. Liposomes composed of a cationic lipid (DOTAP, DOGS, DDAB), a neutral lipid (DOPE), and a phospholipid derivative of polyethylene glycol (PEG-PE) formed a complex with 18-mer phosphorothioate up to ODN/lipid molar ratio of 0.25, The complexes showed intact vesicular structures similar to original liposomes and their size (100-130 nm) was unchanged after several weeks of storage, whereas complexes lacking PEG-PE showed progressive aggregation and/or precipitation. After exposure to human plasma, PEG-modified cationic liposomes retained over 60% of the originally bound ODN, PEG-coated complexes resulted in 4-13-fold enhancement of the ODN uptake by human breast cancer cells in serum-supplemented growth medium, relative to free ODN, Complexes containing conjugated anti-HER2 F(ab') fragments at the distal termini of PEG chains efficiently delivered ODN primarily irate che cytoplasm and nuclei of HERS overexpressing cancer cells and greatly enhanced the biological activity of antisense ODN. The development of PEG-modified cationic liposomes may lead to improved ODN potency in vivo.	Calif Pacific Med Ctr, Res Inst, Liposome Res Lab, San Francisco, CA 94115 USA; Genet Therapy Inc, Gaithersburg, MD 20878 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Novartis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Papahadjopoulos, D (corresponding author), Calif Pacific Med Ctr, Res Inst, Liposome Res Lab, 2200 Webster St, San Francisco, CA 94115 USA.	papah@cooper.cpmc.org	Hong, Kunlun/E-9787-2015	Hong, Kunlun/0000-0002-2852-5111; Kirpotin, Dmitri/0000-0002-1726-4040	NATIONAL CANCER INSTITUTE [P50CA058207] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA58207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H; BAGG A, 1993, ONCOGENES TUMOR SUPP, P141; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HALDAR S, 1994, CANCER RES, V54, P2095; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; HUNSTON DL, 1975, ANAL BIOCHEM, V63, P99, DOI 10.1016/0003-2697(75)90193-1; JAASKELAINEN I, 1994, BBA-BIOMEMBRANES, V1195, P115, DOI 10.1016/0005-2736(94)90017-5; KENWORTHY AK, 1995, BIOPHYS J, V68, P1903, DOI 10.1016/S0006-3495(95)80368-1; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MORRISON WR, 1964, ANAL BIOCHEM, V7, P281; NAGEL KM, 1993, PHARMACOTHERAPY, V13, P177; OLON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P19; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PAPAHADJOPOULOS D, 1995, LIPOSOMES TOOLS BASI, P177; PARK JW, 1995, P NATL ACAD SCI USA, V92, P1327, DOI 10.1073/pnas.92.5.1327; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Sternberg B., 1992, LIPOSOME TECHNOLOGY, P363; THIERRY AR, 1995, DELIVERY STRATEGIES, P199; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; WOODLE MC, 1992, BIOPHYS J, V61, P902, DOI 10.1016/S0006-3495(92)81897-0; Woodle MC, 1997, NUCLEOS NUCLEOT NUCL, V16, P1731, DOI 10.1080/07328319708006265; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C; YUAN F, 1995, CANCER RES, V55, P3752; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195	29	195	217	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15621	15627		10.1074/jbc.273.25.15621	http://dx.doi.org/10.1074/jbc.273.25.15621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624154	hybrid, Green Published			2023-01-03	WOS:000074284200048
J	Berthold, HK; Sudhop, T; von Bergmann, K				Berthold, HK; Sudhop, T; von Bergmann, K			Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METAANALYSIS; LIPIDS; BIOSYNTHESIS; HEPATOCYTES; EXCRETION; POWDER; PLASMA; HUMANS	Context.-Garlic-containing drugs have been used in the treatment of hypercholesterolemia even though their efficacy is not generally established. Little is known about the mechanisms of action of the possible effects on cholesterol in humans. Objective.-To estimate the hypocholesterolemic effect of garlic oil and to investigate the possible mechanism of action. Design-Double-blind, randomized, placebo-controlled trial. Setting.-Outpatient lipid clinic. Patients.-We investigated 25 patients (mean age, 58 years) with moderate hypercholesterolemia. Intervention.-Steam-distilled garlic oil preparation (5 mg twice a day) vs placebo each for 12 weeks with wash-out periods of 4 weeks. Main Outcome Measures.-Serum lipoprotein concentrations, cholesterol absorption, and cholesterol synthesis. Results.-Baseline lipoprotein profiles were (mean [SD]):total cholesterol, 7.53 (0.75) mmol/L (291 [29] mg/dL); low-density lipoprotein cholesterol (LDL-C), 5.35 (0.78) mmol/L (207 [30] mg/dL); high-density lipoprotein cholesterol (HDL-C), 1.50 (0.41) mmol/L (58 [16] mg/dL); and triglycerides, 1.45 (0.73) mmol/L (127 [64] mg/dL). Lipoprotein levels were virtually unchanged at the end of both treatment periods (mean difference [95% confidence interval]): total cholesterol, 0.085 (-0.201 to 0.372) mmol/L (3.3 [-7.8 to 14.4] mg/dL), P=.54; LDL-C, 0.001 (-0.242 to 0.245) mmol/L (0.04 [-9.4 to 9.5] mg/dL), P=.99; HDL-C, 0.050 (-0.028 to 0.128) mmol/L (1.9 [-1.1 to 4.9] mg/dL), P=.20; triclycerides, 0.047 (-0.229 to 0.135) mmol/L (4.2 [-20.3 to 12.0]) mg/dL, P=.60. Cholesterol absorption (37.5% [10.5%] vs 38.3% [10.7%], P=.58), cholesterol synthesis (12.7 [6.5] vs 13.4 [6.6] mg/kg of body weight per day, P=.64), mevalonic acid excretion (192 [66] vs 187 [66] mu g/d, P=.78), and changes in the ratio of lathosterol to cholesterol in serum (4.4% [24.3%] vs 10.6% [21.1%], P=.62) were not different in garlic and placebo treatment. Conclusions.-The commercial garlic oil preparation investigated had no influence on serum lipoproteins, cholesterol absorption, or cholesterol synthesis. Garlic therapy for treatment of hypercholesterolemia cannot be recommended on the basis of this study.	Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany	University of Bonn	Berthold, HK (corresponding author), Univ Bonn, Dept Clin Pharmacol, Sigmund Freud St 25, D-53105 Bonn, Germany.		Berthold, Heiner K./E-6017-2011	Berthold, Heiner K./0000-0002-1457-2216				Adler AJ, 1997, AM J CLIN NUTR, V65, P445, DOI 10.1093/ajcn/65.2.445; BEAGLEHOLE R, 1996, LANCET, V348, P186; BJORKHEM I, 1987, J LIPID RES, V28, P1137; CZUBAYKO F, 1991, J LIPID RES, V32, P1861; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEBHARDT R, 1994, BBA-LIPID LIPID MET, V1213, P57, DOI 10.1016/0005-2760(94)90222-4; GEBHARDT R, 1993, LIPIDS, V28, P613, DOI 10.1007/BF02536055; HARENBERG J, 1988, ATHEROSCLEROSIS, V74, P247, DOI 10.1016/0021-9150(88)90244-4; JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C; Jones PJH, 1997, AM J CLIN NUTR, V66, P438, DOI 10.1093/ajcn/66.2.438; LELORIE J, 1997, NEW ENGL J MED, V337, P736; Lindenthal B, 1996, J LIPID RES, V37, P2193; LUTJOHANN D, 1993, J LIPID RES, V34, P1039; MADER FH, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1111; Neil Andrew, 1994, Current Opinion in Lipidology, V5, P6, DOI 10.1097/00041433-199402000-00002; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; REUTER HD, 1991, Z PHYTOTHER, V12, P83; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P329; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; Steiner M, 1996, AM J CLIN NUTR, V64, P866, DOI 10.1093/ajcn/64.6.866; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009; WINKLER G, 1992, DTSCH APOTH ZTG, V132, P2312	24	136	146	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1900	1902		10.1001/jama.279.23.1900	http://dx.doi.org/10.1001/jama.279.23.1900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634262				2023-01-03	WOS:000074109700038
J	Pellegrino, ED				Pellegrino, ED			Emerging ethical issues in palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA	Georgetown University	Pellegrino, ED (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, 4000 Reservior Rd NW,Room D-238, Washington, DC 20007 USA.							ASHLEY BM, 1989, HLTH CARE ETHICS, P184; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Canadian Palliative Care Association, 1995, PALL CAR CONS STAND; CLARK D, 1993, FUTURE PALLIATIVE CA; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FOLEY KM, 1993, OPIOIDS, V2, P697; Glick SM, 1997, NEW ENGL J MED, V336, P954, DOI 10.1056/NEJM199703273361312; GREGORY J, 1772, DUTIES OFFICES PHYSI; HIGGINSON I, 1993, J PUBLIC HEALTH MED, V15, P3, DOI 10.1093/oxfordjournals.pubmed.a042817; HIPPOCRATES, 1972, JOINTS 8, V2, P299; Hippocrates, 1923, ART HIPPOCRATES, V2, P193; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Lynn J, 1997, New Horiz, V5, P56; Nash A, 1989, Prof Nurse, V4, P443; OBrien C.P., 1996, GOODMAN GILMANS PHAR, Vninth, P557; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; PELLEGRINO ED, 1981, PHILOS BASIS MED PRA, P223; PIUS XII, 1957, ALLOCUTIO ACTA APOST, V49, P129; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; RANDALL F, 1996, PALLIATIVE CARE ETHI; Sulmasy DP, 1996, CLIN PULM MED, V3, P86; SURBONE A, 1997, COMMUNICATION CANC P; WOODRUFF R, 1993, PALLIATIVE MED SYMPT	23	34	36	2	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1521	1522		10.1001/jama.279.19.1521	http://dx.doi.org/10.1001/jama.279.19.1521			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605885				2023-01-03	WOS:000073608100013
J	Nava, S; Ambrosino, N; Clini, E; Prato, M; Orlando, G; Vitacca, M; Brigada, P; Fracchia, C; Rubini, F				Nava, S; Ambrosino, N; Clini, E; Prato, M; Orlando, G; Vitacca, M; Brigada, P; Fracchia, C; Rubini, F			Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lung diseases, obstructive; respiration, artificial; ventilator weaning; respiratory insufficiency	POSITIVE-PRESSURE VENTILATION; ACUTE EXACERBATIONS; FACE MASK; NOSOCOMIAL PNEUMONIA; NASAL VENTILATION; PREDICTION; RISK; COMPLICATIONS; SURVIVAL; SUPPORT	Background: In patients with acute exacerbations of chronic obstructive pulmonary disease, mechanical ventilation is often needed. The rate of weaning failure is high in these patients, and prolonged mechanical ventilation increases intubation-associated complications. Objective: To determine whether noninvasive ventilation improves the outcome of weaning from invasive mechanical ventilation. Design: Multicenter, randomized trial. Setting: Three respiratory intensive care units. Patients: Intubated patients with chronic obstructive pulmonary disease and acute hypercapnic respiratory failure. Intervention: A T-piece weaning trial was attempted 48 hours after intubation. If this failed, two methods of weaning were compared: 1) extubation and application of: noninvasive pressure support ventilation by face mask and 2) invasive pressure support ventilation by an endotracheal tube. Measurements: Arterial blood gases, duration of mechanical ventilation, time in the intensive care unit, occurrence of nosocomial pneumonia, and survival at 60 days. Results: At admission, all patients had severe hypercapnic respiratory failure (mean pH, 7.18 +/- 0.06; mean PaCo2, 94.2 +/- 24.2 mm Hg), sensory impairment, and similar clinical characteristics. At 60 days, 22 of 25 patients (88%) who were ventilated noninvasively were successfully weaned compared with 17 of 25 patients (68%) who were ventilated invasively. The mean duration of mechanical ventilation was 16.6 +/- 11.8 days for the invasive ventilation group and 10.2 +/- 6.8 days for the noninvasive ventilation group (P = 0.021). Among patients who received noninvasive ventilation, the probability of survival and weaning during ventilation was higher (P = 0.002) and time in the intensive care unit was shorter (15.1 +/- 5.4 days compared with 24.0 +/- 13.7 days for patients who received invasive ventilation; P = 0.005). Survival rates at 60 days differed (92% for patients who received noninvasive ventilation and 72% for patients who received invasive ventilation; P = 0.009). None of the patients weaned noninvasively developed nosocomial pneumonia, whereas 7 patients weaned invasively did. Conclusions: Noninvasive pressure support ventilation during weaning reduces weaning time, shortens the time in the intensive care unit, decreases the incidence of nosocomial pneumonia, and improves 60-day survival rates.	Ctr Med Riabilitaz Montescano, Div Pneumol, I-27040 Montescano, PV, Italy; Ctr Med Riabilitaz Gussago, Div Pneumol, I-25064 Gussago, Italy; Osped S Giacomo, Serv Anestesia & Rianmaz, I-15060 Novi Ligure, Italy; Fdn S Maugeri, Ist Ricovero & Cura Carattere Sci, Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS	Nava, S (corresponding author), Ctr Med Riabilitaz Montescano, Div Pneumol, I-27040 Montescano, PV, Italy.		Ambrosino, Nicolino/AAC-2005-2020; VITACCA, MICHELE/AAB-8883-2020; Clini, Enrico/ABE-6642-2020; Clini, Enrico/A-4496-2017	Ambrosino, Nicolino/0000-0002-5331-1393; VITACCA, MICHELE/0000-0002-9389-7915; Clini, Enrico/0000-0002-1515-5094; Clini, Enrico/0000-0002-1515-5094				BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; CONTI G, 1992, CRIT CARE MED, V20, P366, DOI 10.1097/00003246-199203000-00013; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; GOLDSTONE J, 1991, THORAX, V46, P56, DOI 10.1136/thx.46.1.56; GOODENBERGER DM, 1992, CHEST, V102, P1277, DOI 10.1378/chest.102.4.1277; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LEMAIRE F, 1993, INTENS CARE MED S, V19, pS6973; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; NAVA S, 1994, EUR RESPIR J, V7, P1645, DOI 10.1183/09031936.94.07091645; Nava S, 1997, CHEST, V111, P1631, DOI 10.1378/chest.111.6.1631; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RESTRICK LJ, 1993, RESP MED, V87, P199, DOI 10.1016/0954-6111(93)90092-E; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Seneff MG, 1996, CHEST, V110, P469, DOI 10.1378/chest.110.2.469; SPORN PHS, 1988, CLIN CHEST MED, V9, P113; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; UDWADIA ZF, 1992, THORAX, V47, P715, DOI 10.1136/thx.47.9.715; VITACCA M, 1993, INTENS CARE MED, V19, P450, DOI 10.1007/BF01711086	30	420	473	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					721	+		10.7326/0003-4819-128-9-199805010-00004	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556465				2023-01-03	WOS:000073363800003
J	Manian, FA				Manian, FA			Should we accept mediocrity?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1067	1069		10.1056/NEJM199804093381513	http://dx.doi.org/10.1056/NEJM199804093381513			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535676				2023-01-03	WOS:000072969500013
J	Fanselow, MS				Fanselow, MS			Pavlovian conditioning, negative feedback, and blocking: Mechanisms that regulate association formation	NEURON			English	Review							FEAR; NALOXONE; PAIN		Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Fanselow, MS (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.							BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; FANSELOW MS, 1979, B PSYCHONOMIC SOC, V14, P88; FANSELOW MS, 1981, LEARN MOTIV, V12, P398, DOI 10.1016/0023-9690(81)90002-3; FANSELOW MS, 1984, TRENDS NEUROSCI, V7, P460; HELMSTETTER FJ, 1993, BRAIN RES, V612, P253, DOI 10.1016/0006-8993(93)91669-J; Kamin L. J., 1968, MIAMI S PREDICTION B, P9; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; Kim JJ, 1998, SCIENCE, V279, P570, DOI 10.1126/science.279.5350.570; MAUK MD, 1997, LEARN MEMORY, V3, P130; Rescorla R.A., 1972, CLASSICAL CONDITION, P65; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; YOUNG SL, 1992, J EXP PSYCHOL ANIM B, V18, P400, DOI 10.1037/0097-7403.18.4.400; Zener K, 1937, AM J PSYCHOL, V50, P384, DOI 10.2307/1416644	14	109	109	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0896-6273			NEURON	Neuron	APR	1998	20	4					625	627		10.1016/S0896-6273(00)81002-8	http://dx.doi.org/10.1016/S0896-6273(00)81002-8			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	ZK649	9581755	Bronze			2023-01-03	WOS:000073346500002
J	Arras, M; Mollnau, H; Strasser, R; Wenz, R; Ito, WD; Schaper, J; Schaper, W				Arras, M; Mollnau, H; Strasser, R; Wenz, R; Ito, WD; Schaper, J; Schaper, W			The delivery of angiogenic factors to the heart by microsphere therapy	NATURE BIOTECHNOLOGY			English	Article						drug delivery; targeting; heart disease	FIBROBLAST GROWTH-FACTOR; MEDIATED GENE-TRANSFER; ISCHEMIC MYOCARDIUM; INJECTION; ARTERIES	Microspheres offer the possibility of local noninvasive delivery of drugs over an extended period of time. We adsorbed fibroblast growth factor (FGF) to microspheres of precapillary size that were injected via a coronary catheter. We showed that FGF was released from these microspheres and taken up by endothelial cells, which proliferated following translocation of FGF to the nucleus. This method for application of growth factors allows the precise delivery of angiogenic substances to any selected part of the heart or other organs without causing inflammation or ischemia.	Max Planck Inst Physiol & Clin Res, Dept Expt Cardiol, D-61231 Bad Nauheim, Germany; Merck KGAA, Merck Biomat, Darmstadt, Germany	Max Planck Society; Merck KGaA	Ito, WD (corresponding author), Max Planck Inst Physiol & Clin Res, Dept Expt Cardiol, Benekestr 2, D-61231 Bad Nauheim, Germany.	wito@kerckhoff.mpg.de		Arras, Margarete/0000-0003-3864-9879				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76; BATTLER A, 1993, J AM COLL CARDIOL, V22, P2001, DOI 10.1016/0735-1097(93)90790-8; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; DENEFLE P, 1995, EXP OPIN INVESTIGATI, V4, P1129; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; LANDAU C, 1995, AM HEART J, V129, P1051, DOI 10.1016/0002-8703(95)90383-6; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553; LI JJ, 1995, CARDIOVASC RES, V30, P97, DOI 10.1016/S0008-6363(95)00005-4; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; SCHAPER W, 1988, PROG CARDIOVASC DIS, V31, P57, DOI 10.1016/0033-0620(88)90011-4; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588	18	51	69	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					159	162		10.1038/nbt0298-159	http://dx.doi.org/10.1038/nbt0298-159			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487522				2023-01-03	WOS:000071831300028
J	Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA				Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA			Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme	BRITISH MEDICAL JOURNAL			English	Article									Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England	University of Nottingham	Mayne, S (corresponding author), Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England.							[Anonymous], 1991, PRESCRIBERS J, V1, P137; HUCHET J, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P101; LETSKY EA, 1994, BRIT MED J, V309, P213, DOI 10.1136/bmj.309.6949.213; RAAFAT A, 1996, TRANSFUSION MED S2, V6, P26; TOVEY LAD, 1983, LANCET, V2, P244	5	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1588	1588		10.1136/bmj.315.7122.1588	http://dx.doi.org/10.1136/bmj.315.7122.1588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437277	Green Published			2023-01-03	WOS:000071021900024
J	Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH				Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH			Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; RISK		Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark; Aarhus Univ Hosp, Dept Med 5, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danish Cancer Society; Aarhus University; Aarhus University	Mellemkjaer, L (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Olsen, Jorgen Helge/0000-0001-9633-5662				JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; POULTER NR, 1995, LANCET, V346, P1575; Spitzer WO, 1996, BRIT MED J, V312, P83; Thomas SHL, 1996, LANCET, V348, P402, DOI 10.1016/S0140-6736(05)65016-7; Vandenbroucke JP, 1996, LANCET, V348, P401, DOI 10.1016/S0140-6736(96)24032-2	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					820	821		10.1136/bmj.319.7213.820	http://dx.doi.org/10.1136/bmj.319.7213.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496825	Bronze, Green Published			2023-01-03	WOS:000082865200023
J	Alam, NH; Majumder, RN; Fuchs, GJ				Alam, NH; Majumder, RN; Fuchs, GJ		CHOICE Study Grp	Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double blind clinical trial	LANCET			English	Article							DIARRHEA; GLUCOSE	Background The effects of oral rehydration solution (ORS) with reduced osmolarity on children with acute watery diarrhoea are known, but little is known about the effects of such ORS on adults with cholera. We aimed to compare the efficacy and safety of an ORS with reduced osmolarity with that of standard WHO ORS in adults with cholera. Methods We undertook a double-blind, controlled clinical trial In adults with severe cholera at the International Centre for Diarrhoeal Disease Research, Bangladesh. Our primary outcomes were mean stool output in the 24 h after randomisation. proportion of patients who needed unscheduled intravenous therapy, and proportion of patients with biochemical hyponatraemia 24 h randomisation, unscheduled randomisation. Findings 147 patients received ORS with reduced osmolarity and 153 received standard WHO ORS. There was no significant difference between the two groups in terms of main outcome variables: mean initial 24 h and total stool output (reduced osmolarity vs standard WHO ORS 212 [SE 8] vs 207 [8] and 284 [13] vs 273 [13] g/kg respectively), duration of diarrhoea (46 [1.5] vs 43 [1.5]). The proportion of patients vomiting during the first 24 h and the proportion who received unscheduled intravenous infusion during the first 24 h was similar between groups. More patients on reduced osmolarity ORS than on standard WHO ORS developed hyponatraemia during the first 24 h, defined as serum sodium concentration below 130 mmol/L (29 of 142 vs 16 of 150; odds ratio 2.1[95% CI 1.1-4.1]). However, all hyponatraemic patients in both groups were symptom-free and the proportion of patients with serum sodium concentration below 125 mmol/L was similar between groups. Interpretation There was no difference in clinical outcome between cholera patients treated with reduced osmolarity ORS solution and those treated with standard WHO ORS. The risk of increased incidence of symptom-free hyponatraemia in patients with cholera treated with an ORS with reduced osmolarity should be further assessed by meta-analysis. The risk should be taken Into account when choice of ORS is made in areas in which cholera is endemic.	Int Ctr Diarrhoeal Dis Res, Bangladesh ICDDR B, Dhaka, Bangladesh; Louisiana State Univ, Sch Med, New Orleans, LA USA	International Centre for Diarrhoeal Disease Research (ICDDR); Louisiana State University System	Alam, NH (corresponding author), Int Ctr Diarrhoeal Dis Res, Bangladesh ICDDR B, GPO Box 128, Dhaka, Bangladesh.		Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				ALAM NH, 1992, GUT, V33, P560, DOI 10.1136/gut.33.4.560; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; International Study Group on Reduced-Osmolality ORS Solutions, 1995, LANCET, V346, P282; MAHALANABIS D, 1995, ACTA PAEDIATR, V84, P289, DOI 10.1111/j.1651-2227.1995.tb13630.x; Rabbani G.H., 1990, TXB SECRETORY DIARRH, P233; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; SARKER SA, 1995, ACTA PAEDIATR, V84, P775, DOI 10.1111/j.1651-2227.1995.tb13755.x; *WHO DIV DIARRH AC, 1994, JOINT WHO ICDDR B CO	10	46	47	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					296	299		10.1016/S0140-6736(98)09332-5	http://dx.doi.org/10.1016/S0140-6736(98)09332-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440307				2023-01-03	WOS:000081646000013
J	Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD				Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD			Are we really dying for a tan?	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; VITAMIN-D; EXPOSURE; SUNLIGHT; POPULATION; MORTALITY; MELANOMA		Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England	University of Bristol	Ness, AR (corresponding author), Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England.		Ness, Andy R/M-7612-2013; Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Ness, Andy R/0000-0003-3548-9523; Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ARTHEY S, 1995, SOC SCI MED, V40, P265, DOI 10.1016/0277-9536(94)E0063-X; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; Bridgwood A, 1996, HLTH ENGLAND 1995 WH; CARTER S, 1997, TOURISM HLTH; CHEW KSY, 1995, SOC SCI MED, V40, P223, DOI 10.1016/0277-9536(94)E0070-9; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; Finkel E, 1998, LANCET, V351, P1866, DOI 10.1016/S0140-6736(05)78819-X; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Freedman DM, 1997, BRIT MED J, V314, P1451, DOI 10.1136/bmj.314.7092.1451; Grimes DS, 1996, QJM-INT J MED, V89, P579; Haines A, 1997, BRIT MED J, V315, P870, DOI 10.1136/bmj.315.7112.870; HUTTON D, 1998, VOGUE            MAY, P114; KHAW KT, 1995, LANCET, V345, P337, DOI 10.1016/S0140-6736(95)90336-4; LUND B, 1978, HORM METAB RES, V10, P553, DOI 10.1055/s-0028-1093390; MARKS R, 1995, ARCH DERMATOL, V131, P415, DOI 10.1001/archderm.131.4.415; McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005; MELIA J, 1995, HLTH HYG, V16, P153; *OFF NAT STAT, 1997, MORT STAT CAUS ENGL; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; *SECR STAT HLTH, 1992, HLTH NAT; Utiger RD, 1998, NEW ENGL J MED, V338, P828, DOI 10.1056/NEJM199803193381209; VIK T, 1979, BMJ-BRIT MED J, V2, P176, DOI 10.1136/bmj.2.6183.176; WEHR TA, 1989, AM J PSYCHIAT, V146, P829; West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714	25	42	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					114	116		10.1136/bmj.319.7202.114	http://dx.doi.org/10.1136/bmj.319.7202.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398641	Green Published			2023-01-03	WOS:000081438200040
J	Trieman, N; Leff, J; Glover, G				Trieman, N; Leff, J; Glover, G			Outcome of long stay psychiatric patients resettled in the community: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TAPS PROJECT; FOLLOW-UP; POPULATIONS; HOSPITALS; DIFFICULT; CLOSURE	Objective To examine the outcome of a population of long stay psychiatric patients resettled in the community. Design Prospective study with 5 year follow up. Setting Over 140 residential settings in north London. Subjects 670 long stay patients from two London hospitals (Friern and Claybury) discharged to the community from 1985 to 1993. Main outcome measures Continuity and quality of residential care, readmission to hospital, mortality, crime, and vagrancy. Results Of the 523 patients who survived the 5 year follow up period, 469 (89.6%) were living in the community by the end of follow up, 310 (59.2%) in their original community placement A third (210) of all patients were readmitted at least once. Crime and homelessness presented few problems. Standardised mortality ratios for the group were comparable with those reported for similar populations. Conclusions When carefully planned and adequately resourced, community care for long star psychiatric patients is beneficial to most individuals and has minimal detrimental effects on society.	UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Inst Psychiat, Sect Community Psychiat, London SE5 8AF, England	University of London; University College London; UCL Medical School; University of London; King's College London	Trieman, N (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England.	n.trieman@fleet69.demon.co.uk						CLIFFORD P, 1991, BRIT J PSYCHIAT, V158, P190, DOI 10.1192/bjp.158.2.190; Gooch C, 1996, PSYCHOL MED, V26, P511, DOI 10.1017/S0033291700035595; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; HAUGLAND G, 1983, AM J PSYCHIAT, V140, P848; HAZEL M, 1998, BRIT J PSYCHIAT, V172, P35; JONES D, 1993, BRIT J PSYCHIAT, V162, P36, DOI 10.1192/S0007125000292234; *KINGS FUND, 1997, LOND MENT HLTH; LAMB HR, 1993, BRIT J PSYCHIAT, V162, P587, DOI 10.1192/bjp.162.5.587; Leff J, 1996, AM J PSYCHIAT, V153, P1318; LEFF J, 1994, BRIT J PSYCHIAT, V165, P13, DOI 10.1192/S000712500029315X; MODESTIN J, 1995, BRIT J PSYCHIAT, V166, P667, DOI 10.1192/bjp.166.5.667; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P30, DOI 10.1192/S0007125000292222; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P18, DOI 10.1192/S0007125000292209; Timms P W, 1989, Health Trends, V21, P70; Trieman N, 1998, ACTA PSYCHIAT SCAND, V98, P354, DOI 10.1111/j.1600-0447.1998.tb10098.x; Trieman N, 1996, BRIT J PSYCHIAT, V169, P289, DOI 10.1192/bjp.169.3.289; Trieman N, 1996, PSYCHOL MED, V26, P765, DOI 10.1017/S0033291700037788; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0	18	39	45	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					13	16		10.1136/bmj.319.7201.13	http://dx.doi.org/10.1136/bmj.319.7201.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214KE	10390451	Bronze, Green Published			2023-01-03	WOS:000081326500022
J	Ebenbichler, GR; Erdogmus, CB; Resch, KL; Funovics, MA; Kainberger, F; Barisani, G; Aringer, M; Nicolakis, P; Wiesinger, GF; Baghestanian, M; Preisinger, E; Fialka-Moser, V				Ebenbichler, GR; Erdogmus, CB; Resch, KL; Funovics, MA; Kainberger, F; Barisani, G; Aringer, M; Nicolakis, P; Wiesinger, GF; Baghestanian, M; Preisinger, E; Fialka-Moser, V			Ultrasound therapy for calcific tendinitis of the shoulder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATION	Background and Methods Although ultrasound therapy is used to treat calcific tendinitis of the shoulder, its efficacy has not been rigorously evaluated. We conducted a randomized, double-blind comparison of ultrasonography and sham insonation in patients with symptomatic calcific tendinitis verified by radiography. Patients were assigned to receive 24 15-minute sessions of either pulsed ultrasound (frequency, 0.89 MHz; intensity, 2.5 W per square centimeter; pulsed mode, 1:4) or an indistinguishable sham treatment to the area over the calcification. The first 15 treatments were given daily (five times per week), and the remainder were given three times a week for three weeks. Randomization was conducted according to shoulders rather than patients, so a patient with bilateral tendinitis might receive either or both therapies. Results We enrolled 63 consecutive patients (70 shoulders). Fifty-four patients (61 shoulders) completed the study. There were 32 shoulders in the ultrasound-treatment group and 29 in the sham-treatment group. After six weeks of treatment, calcium deposits had resolved in six shoulders (19 percent) in the ultrasound-treatment group and decreased by at least 50 percent in nine shoulders (28 percent), as compared with respective values of zero and three (10 percent) in the sham-treatment group (P=0.003). At the nine-month follow-up visit, calcium deposits had resolved in 13 shoulders (42 percent) in the ultrasound-treatment group and improved in 7 shoulders (23 percent), as compared with respective values of 2 (8 percent) and 3 (12 percent) in the sham-treatment group (P=0.002). At the end of treatment, patients who had received ultrasound treatment had greater decreases in pain and greater improvements in the quality of life than those who had received sham treatment; at nine months, the differences between the groups were no longer significant. Conclusions In patients with symptomatic calcific tendinitis of the shoulder, ultrasound treatment helps resolve calcifications and is associated with shortterm clinical improvement. (N Engl J Med 1999;340:1533-8.) (C)1999, Massachusetts Medical Society.	Univ Hosp Vienna, Dept Phys Med & Rehabil, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Osteoradiol, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Traumat Surg, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Rheumatol, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Angiol, A-1090 Vienna, Austria; Forschungsinst Balneol & Kurortwissensch, Bad Elster, Germany	University Hospital Vienna; University Hospital Vienna; University Hospital Vienna; University Hospital Vienna; University Hospital Vienna	Ebenbichler, GR (corresponding author), Univ Hosp Vienna, Dept Phys Med & Rehabil, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Aringer, Martin/AAJ-7641-2020	Aringer, Martin/0000-0003-4471-8375				ALDES J H, 1954, West J Surg Obstet Gynecol, V62, P369; ARK JW, 1992, ARTHROSCOPY, V8, P183, DOI 10.1016/0749-8063(92)90034-9; BINDER A, 1984, LANCET, V1, P695; BOOTH RE, 1975, ORTHOP CLIN N AM, V6, P353; Bosworth BM, 1941, J AMER MED ASSOC, V116, P2477, DOI 10.1001/jama.1941.02820220019004; CHARD MD, 1994, ANN RHEUM DIS, V53, P30, DOI 10.1136/ard.53.1.30; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; DYSON M, 1968, CLIN SCI, V35, P273; Dyson M, 1978, Physiotherapy, V64, P105; Ebenbichler GR, 1997, J RHEUMATOL, V24, P235; FLAX H J, 1964, Am J Phys Med, V43, P117; GAM AN, 1995, PAIN, V63, P85, DOI 10.1016/0304-3959(95)00018-N; GARTNER J, 1995, ORTHOPADE, V24, P284; GARTNER J, 1993, Z ORTHOP GRENZGEB, V131, P461, DOI 10.1055/s-2008-1040055; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; HARMON PH, 1958, AM J SURG, V95, P527, DOI 10.1016/0002-9610(58)90436-7; KENDALL M, 1979, ADV THEORY STAT, V2, P580; KLEIN W, 1992, ARTHOSKOPIE, V5, P247; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Loew M, 1995, J Shoulder Elbow Surg, V4, P101, DOI 10.1016/S1058-2746(05)80062-X; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCKENDRY RJR, 1982, J RHEUMATOL, V9, P75; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; NACCACHE PH, 1991, ARTHRITIS RHEUM, V34, P333, DOI 10.1002/art.1780340311; Perron M, 1997, ARCH PHYS MED REHAB, V78, P379, DOI 10.1016/S0003-9993(97)90229-X; Proost P, 1996, INT J CLIN LAB RES, V26, P211, DOI 10.1007/BF02602952; Rathbun J B, 1970, J Bone Joint Surg Br, V52, P540; ROMPE JD, 1995, CLIN ORTHOP RELAT R, P196; SAS Institute, 1990, SAS STAT US GUID VER; Smith RE, 1997, J LEUKOCYTE BIOL, V62, P612, DOI 10.1002/jlb.62.5.612; TERHAAR G, 1987, ULTRASOUND MED BIOL, V13, P659, DOI 10.1016/0301-5629(87)90064-0; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; UHTHOFF HK, 1976, CLIN ORTHOP RELAT R, P164; Uhthoff HK, 1996, ANN CHIR GYNAECOL FE, V85, P111	34	174	179	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1533	1538		10.1056/NEJM199905203402002	http://dx.doi.org/10.1056/NEJM199905203402002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332014				2023-01-03	WOS:000080358900002
J	Sequeira, W				Sequeira, W			Yoga in treatment of carpal-tunnel syndrome	LANCET			English	Editorial Material									Cook Cty Hosp, Rush Med Coll, Div Rheumatol, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; Rush University	Sequeira, W (corresponding author), Cook Cty Hosp, Rush Med Coll, Div Rheumatol, Chicago, IL 60612 USA.							GARFINKEL MS, 1994, J RHEUMATOL, V21, P2341; Garfinkel MS, 1998, JAMA-J AM MED ASSOC, V280, P1601, DOI 10.1001/jama.280.18.1601; HASLOCK I, 1994, BRIT J RHEUMATOL, V33, P787; MEHTA S, 1990, YOGA INVENGAR WAY; MEYERS E, 1996, YOUGA YOU, P9; Vedanthan PK, 1998, ALLERGY ASTHMA PROC, V19, P3, DOI 10.2500/108854198778557971; vonSchroeder HP, 1996, HAND CLIN, V12, P643	7	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 27	1999	353	9154					689	690		10.1016/S0140-6736(98)00393-6	http://dx.doi.org/10.1016/S0140-6736(98)00393-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DR	10073507				2023-01-03	WOS:000078966400005
J	Fielden, JM; Bradbury, NS				Fielden, JM; Bradbury, NS			Observational study of defibrillation in theatre	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England		Fielden, JM (corresponding author), Royal Berkshire Hosp, Reading RG1 5AN, Berks, England.	jonathan@jfielden.demon.cu.uk						ALDERSON K, 1996, TIMES           0302, P3; BELL JH, 1995, ANAESTHESIA, V50, P692, DOI 10.1111/j.1365-2044.1995.tb06095.x; CHAMBERLAIN D, 1992, RESUSCITATION, V24, P111, DOI 10.1016/0300-9572(92)90016-6; *RES COUNC UK, 1994, ADV LIF SUPP HDB; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a	5	11	11	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 23	1999	318	7178					232	233						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161MG	9915731				2023-01-03	WOS:000078292300024
J	Parmar, MKB; Torri, V; Bonaventura, A; Bonazzi, C; Colombo, N; Delaloye, JF; Marsoni, S; Mangioni, C; Sandercock, J; Sessa, C; Williams, C; Tinazzi, A; Flann, M; Geiser, K; Scorpiglione, N; Stewart, JF; Chaves, J; Palmeiro, E; Curtain, A; McCormack, T; Gennatas, C; Marras, F; Oppo, TG; Balestrino, M; Malzoni, C; Malzoni, M; Belli, M; Geminiani, ML; Crestani, G; Monaco, A; Vavala, V; Piatto, E; Barattini, G; Fornara, PG; Chetri, MC; Santeufemia, G; Artioli, F; Carone, D; Fanizza, G; Trentadue, R; Priolo, D; Scollo, P; Nigro, SC; Petrina, M; Mastrantonio, P; Spanna, GD; Zagni, R; Belloni, C; Colleoni, R; Redaelli, L; Cavagnini, A; Di Costanzo, G; Perroni, D; Arienti, S; Orfanotti, G; Cantoni, FM; Secli, R; Bianchi, A; Martinello, R; Mollica, G; Maizzi, D; Picchiarelli, ME; Fiorini, G; Borsani, M; Colombo, E; Garsia, S; Melgrati, L; Paggi, G; Brunenghi, GM; Casini, M; Isa, L; Algeri, R; Prozio, G; Belfiore, G; Angelini, F; D'Aprile, M; Moreschi, M; Mauri, ML; Natale, N; Senzani, FM; Pavanato, G; Poggi, G; Garuti, G; Luerti, M; Cruciani, G; Pagano, F; Baccolo, M; Poddi, ER; Bocciolone, L; Sabelli, MA; Maggi, R; Restelli, C; D'Antona, A; Locatelli, MC; Pessi, A; Raina, A; Chiari, S; Gabriele, A; Pittelli, MR; Iacobelli, P; Dogliotti, L; Gorzegno, G; Musso, P; Vegna, G; Coco, G; Alletti, DG; Picciotto, F; Lucchese, V; Epis, A; di Palumbo, VS; Drudi, G; Ravaioli, A; Zampella, D; Morandi, MG; Gorga, G; Zucchelli, C; Cariello, S; Galletto, L; Sussio, M; Massacesi, L; Massacesi, M; Carli, A; Tucci, E; Tajani, E; Corrado, G; Bumma, S; Durando, A; Massobrio, M; Sberveglieri, M; Biasio, M; Guercio, E; Jura, R; Danese, S; Wierdis, T; Farnelli, C; Tarantino, G; Grassi, R; Repetti, F; Rocchi, B; Grampa, M; Ercoli, A; Griso, C; Signori, E; Zanini, L; Presti, M; Klimek, M; Urbanski, K; Biswas, A; Viegas, O; Kochli, O; Dreher, E; Fey, M; Beck, G; Ludin, J; Bonnefoi, H; Krauer, F; Bauer, J; Delmore, G; Furrer, C; Lorenz, U; Thurlimann, B; Lorenz, U; Bronz, L; Sanna, P; Wyss, D; Goldhirsch, A; Gyr, T; Leidi, L; Pastorelli, G; Pagani, O; Rey, P; Hailer, U; Benz, J; Kaye, SB; Reed, NS; Symonds, RP; Atkinson, RJ; Axford, AT; Rustin, G; Seckl, MJ; Green, JA; Scott, IV; Guthrie, D; Harper, PG; Calman, F; Dobbs, HJ; Weir, P; Cassoni, A; Lederman, JA; Souhami, RL; Bozzino, J; Adab, F; Redman, CWE; Scoble, JE; Paterson, M; Daniel, F; Cowley, N; Williams, CJ; Spooner, D; Hong, A; McIllmurray, M; Hendy-Ibbs, P; Hall, V; Iveson, TJ; Whitehouse, JMA; Garry, R; Lamont, A; Robinson, A; Trask, CW; Clubb, AW; Murrell, D; Newman, G; Wilkins, M; Goldthorp, WO; Roberts, JK; Radstone, DJ; Whipp, MJ; Ledermann, JA; Pater, J; Buyse, M; Omura, G				Parmar, MKB; Torri, V; Bonaventura, A; Bonazzi, C; Colombo, N; Delaloye, JF; Marsoni, S; Mangioni, C; Sandercock, J; Sessa, C; Williams, C; Tinazzi, A; Flann, M; Geiser, K; Scorpiglione, N; Stewart, JF; Chaves, J; Palmeiro, E; Curtain, A; McCormack, T; Gennatas, C; Marras, F; Oppo, TG; Balestrino, M; Malzoni, C; Malzoni, M; Belli, M; Geminiani, ML; Crestani, G; Monaco, A; Vavala, V; Piatto, E; Barattini, G; Fornara, PG; Chetri, MC; Santeufemia, G; Artioli, F; Carone, D; Fanizza, G; Trentadue, R; Priolo, D; Scollo, P; Nigro, SC; Petrina, M; Mastrantonio, P; Spanna, GD; Zagni, R; Belloni, C; Colleoni, R; Redaelli, L; Cavagnini, A; Di Costanzo, G; Perroni, D; Arienti, S; Orfanotti, G; Cantoni, FM; Secli, R; Bianchi, A; Martinello, R; Mollica, G; Maizzi, D; Picchiarelli, ME; Fiorini, G; Borsani, M; Colombo, E; Garsia, S; Melgrati, L; Paggi, G; Brunenghi, GM; Casini, M; Isa, L; Algeri, R; Prozio, G; Belfiore, G; Angelini, F; D'Aprile, M; Moreschi, M; Mauri, ML; Natale, N; Senzani, FM; Pavanato, G; Poggi, G; Garuti, G; Luerti, M; Cruciani, G; Pagano, F; Baccolo, M; Poddi, ER; Bocciolone, L; Sabelli, MA; Maggi, R; Restelli, C; D'Antona, A; Locatelli, MC; Pessi, A; Raina, A; Chiari, S; Gabriele, A; Pittelli, MR; Iacobelli, P; Dogliotti, L; Gorzegno, G; Musso, P; Vegna, G; Coco, G; Alletti, DG; Picciotto, F; Lucchese, V; Epis, A; di Palumbo, VS; Drudi, G; Ravaioli, A; Zampella, D; Morandi, MG; Gorga, G; Zucchelli, C; Cariello, S; Galletto, L; Sussio, M; Massacesi, L; Massacesi, M; Carli, A; Tucci, E; Tajani, E; Corrado, G; Bumma, S; Durando, A; Massobrio, M; Sberveglieri, M; Biasio, M; Guercio, E; Jura, R; Danese, S; Wierdis, T; Farnelli, C; Tarantino, G; Grassi, R; Repetti, F; Rocchi, B; Grampa, M; Ercoli, A; Griso, C; Signori, E; Zanini, L; Presti, M; Klimek, M; Urbanski, K; Biswas, A; Viegas, O; Kochli, O; Dreher, E; Fey, M; Beck, G; Ludin, J; Bonnefoi, H; Krauer, F; Bauer, J; Delmore, G; Furrer, C; Lorenz, U; Thurlimann, B; Lorenz, U; Bronz, L; Sanna, P; Wyss, D; Goldhirsch, A; Gyr, T; Leidi, L; Pastorelli, G; Pagani, O; Rey, P; Hailer, U; Benz, J; Kaye, SB; Reed, NS; Symonds, RP; Atkinson, RJ; Axford, AT; Rustin, G; Seckl, MJ; Green, JA; Scott, IV; Guthrie, D; Harper, PG; Calman, F; Dobbs, HJ; Weir, P; Cassoni, A; Lederman, JA; Souhami, RL; Bozzino, J; Adab, F; Redman, CWE; Scoble, JE; Paterson, M; Daniel, F; Cowley, N; Williams, CJ; Spooner, D; Hong, A; McIllmurray, M; Hendy-Ibbs, P; Hall, V; Iveson, TJ; Whitehouse, JMA; Garry, R; Lamont, A; Robinson, A; Trask, CW; Clubb, AW; Murrell, D; Newman, G; Wilkins, M; Goldthorp, WO; Roberts, JK; Radstone, DJ; Whipp, MJ; Ledermann, JA; Pater, J; Buyse, M; Omura, G		ICON Collaborators	ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer	LANCET			English	Article							SURVIVAL; STAGE	Background A series of meta-analyses of randomised controlled trials raised the question of whether the three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) was more or less effective than optimal-dose single-agent carboplatin for women with advanced ovarian cancer. Methods We carried out an international, multicentre, randomised trial to compare CAP with single-agent carboplatin in women with ovarian cancer requiring chemotherapy. 1526 patients were entered from 132 centres in nine countries. Analyses were by intention to treat. Findings 728 patients have died (368/766 allocated CAP vs 360/760 allocated carboplatin) and the survival curves show no evidence of a difference between CAP and carboplatin (hazard ratio 1.00 [95% CI 0.86-1.16]; p = 0.98). The results indicate a median survival of 33 months and a 2-year survival of 60% for both groups. We found no evidence that CAP or carboplatin were more or less effective in different subgroups defined by age, stage, residual disease, differentiation, histology, and coordinating centre. CAP was substantially more toxic than carboplatin, causing more alopecia, leucopenia, and nausea. More thrombocytopenia occurred with carboplatin. Interpretation Single-agent carboplatin, with the dose calculated by the area-under-the-curve method, is a safe, effective, and appropriate standard of treatment for women with advanced ovarian cancer.	Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Parmar, MKB (corresponding author), Ist Ric Farmacol Mario Negri, Via Eritrea 62, I-20157 Milan, Italy.		Pagani, Olivia/ABF-3164-2020; Scollo, Paolo/AAU-5274-2021; Rustin, Gordon J. S./J-9763-2019; Torri, Valter/H-7550-2015; Colombo, Nicoletta/AAB-8319-2019; Danese, Silvio/ABH-9571-2020	Torri, Valter/0000-0001-9541-9354; Danese, Silvio/0000-0001-7341-1351; Buyse, Marc/0000-0002-4559-0994; Marsoni, Silvia/0000-0002-5361-7122; Sandercock, Josie/0000-0001-7337-8635				AHERN RP, 1995, J CLIN ONCOL, V13, P726, DOI 10.1200/JCO.1995.13.3.726; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BUYSE M, 1991, J CLIN ONCOL, V9, P1668; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; CALVERT AH, 1991, SEMIN ONCOL, V18, P28; GHERSI D, 1992, EUR J CANCER, V28A, P1297, DOI 10.1016/0959-8049(92)90497-P; HAND R, 1993, JAMA-J AM MED ASSOC, V269, P1119, DOI 10.1001/jama.269.9.1119; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MUGGIA FM, 1997, P AN M AM SOC CLIN, V16, pA352; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PETTERSSON F, 1995, ANN REPORT RESULTS T, V22; QAZI F, 1995, CA-CANCER J CLIN, V45, P88, DOI 10.3322/canjclin.45.2.88; Skarlos DV, 1996, EUR J CANCER, V32A, P421, DOI 10.1016/0959-8049(95)00537-4; STEWART LA, 1991, BRIT MED J, V303, P884; STUART G, 1998, P AN M AM SOC CLIN, V17, pA361; YANCIK R, 1993, CANCER, V71, P517	16	129	132	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1571	1576						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843101				2023-01-03	WOS:000076998900008
J	Cardini, F; Huang, WX				Cardini, F; Huang, WX			Moxibustion for correction of breech presentation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERTEX-PRESENTATION; CEPHALIC VERSION; GESTATIONAL-AGE; HUMAN-FETUS; PREGNANCY; POSITION; BIRTH	Context.-Traditional Chinese medicine uses moxibustion (burning herbs to stimulate acupuncture points) of acupoint BL 67 (Zhiyin, located beside the outer corner of the fifth toenail), to promote version of fetuses in breech presentation. Its effect may be through increasing fetal activity. However, no randomized controlled trial has evaluated the efficacy of this therapy. Objective.-To evaluate the efficacy and safety of moxibustion on acupoint BL 67 to increase fetal activity and correct breech presentation. Design.-Randomized, controlled, open clinical trial. Setting.-Outpatient departments of the Women's Hospital of Jiangxi Province, Nanchang, and Jiujiang Women's and Children's Hospital in the People's Republic of China. Patients.-Primigravidas in the 33rd week of gestation with normal pregnancy and an ultrasound diagnosis of breech presentation. Interventions.-The 130 subjects randomized to the intervention group received stimulation of acupoint BL 67 by moxa (Japanese term for Artemisia vulgaris) rolls for 7 days, with treatment for an additional 7 days if the fetus persisted in the breech presentation. The 130 subjects randomized to the control group received routine care but no interventions for breech presentation. Subjects with persistent breech presentation after 2 weeks of treatment could undergo external cephalic version anytime between 35 weeks' gestation and delivery. Main Outcome Measures.-Fetal movements counted by the mother during 1 hour each day for 1 week; number of cephalic presentations during the 35th week and at delivery. Results.-The intervention group experienced a mean of 48.45 fetal movements vs 35.35 in the control group (P < .001; 95% confidence interval [CI] for difference, 10.56-15.60). During the 35th week of gestation, 98 (75.4%) of 130 fetuses in the intervention group were cephalic vs 62 (47.7%) of 130 fetuses in the control group (P < .001; relative risk [RR], 1.58; 95% CI, 1.29-1.94). Despite the fact that 24 subjects in the control group and 1 subject in the intervention group underwent external cephalic version, 98 (75.4%) of the 130 fetuses in the intervention group were cephalic at birth vs 81 (62.3%) of the 130 fetuses in the control group (P = .02; RR, 1.21; 95% CI, 1.02-1.43). Conclusion.-Among primigravidas with breech presentation during the 33rd week of gestation, moxibustion for 1 to 2 weeks increased fetal activity during the treatment period and cephalic presentation after the treatment period and at delivery.	Jiangxi Womens Hosp, Nanchang, Peoples R China		Cardini, F (corresponding author), Via Risorgimento 15, I-37126 Verona, Italy.							BABKIN PS, 1994, ZH NEVROPATOL PSIKH, V94, P19; Bartlett D, 1997, EARLY HUM DEV, V48, P261, DOI 10.1016/S0378-3782(97)01865-3; BARTLETT D, 1994, DEV MED CHILD NEUROL, V36, P833; BOOS R, 1987, GEBURTSH FRAUENHEILK, V47, P341, DOI 10.1055/s-2008-1035833; CARDINI F, 1993, AM J CHINESE MED, V21, P133, DOI 10.1142/S0192415X93000169; CARDINI F, 1991, AM J CHINESE MED, V19, P105, DOI 10.1142/S0192415X9100017X; *COOP RES GROUP MO, 1984, 2 NAT S AC MOX AC AN; ENGEL K, 1992, GEBURTSH FRAUENHEILK, V52, P241, DOI 10.1055/s-2007-1026138; GOTTLICHER S, 1985, GEBURTSH FRAUENHEILK, V45, P534, DOI 10.1055/s-2008-1036364; GOTTLICHER S, 1989, GEBURTSH FRAUENHEILK, V49, P363, DOI 10.1055/s-2008-1026601; HICKOK DE, 1992, AM J OBSTET GYNECOL, V166, P851, DOI 10.1016/0002-9378(92)91347-D; HILL LM, 1990, AM J PERINAT, V7, P92, DOI 10.1055/s-2007-999455; HOFMEYR GJ, 1998, COCHRANE LIBRARY PRE; HUGHEY MJ, 1985, AM J OBSTET GYNECOL, V153, P885, DOI 10.1016/S0002-9378(85)80276-3; Rayl J, 1996, AM J OBSTET GYNECOL, V174, P28, DOI 10.1016/S0002-9378(96)70368-X; SCHEER K, 1976, AM J OBSTET GYNECOL, V125, P269, DOI 10.1016/0002-9378(76)90609-8; SIVAL DA, 1993, EARLY HUM DEV, V34, P13, DOI 10.1016/0378-3782(93)90036-T; THORP JM, 1991, OBSTET GYNECOL, V78, P394; WENG J, 1984, 2 NAT S AC MOX AC AN; WESTGREN M, 1985, BRIT J OBSTET GYNAEC, V92, P19, DOI 10.1111/j.1471-0528.1985.tb01043.x; *WHO REG OFF W PAC, 1995, WHO W PAC SER, V15; XIANGTONG Z, 1980, RES ACUPUNCTURE MOXI, P810	22	125	134	3	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1580	1584		10.1001/jama.280.18.1580	http://dx.doi.org/10.1001/jama.280.18.1580			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820259				2023-01-03	WOS:000076852000024
J	Stilling, B; Mehlsen, J; Hamberg, O; Larsen, JJ; Gram, NC; Madsbad, S				Stilling, B; Mehlsen, J; Hamberg, O; Larsen, JJ; Gram, NC; Madsbad, S			Effect of starch-free bread on metabolic control in type 2 diabetes	LANCET			English	Article							FATTY-ACIDS; LIPOPROTEINS		Rigshosp, Nutr Unit, DK-1263 Copenhagen K, Denmark; Frederiksberg Hosp, Dept Clin Physiol, Frederiksberg, Denmark; Amtssygehuset, Dept Med F, Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark; Hvidovre Hosp, Dept Endocrinol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Stilling, B (corresponding author), Rigshosp, Nutr Unit, 2111, DK-1263 Copenhagen K, Denmark.		Mehlsen, Jesper/AAA-5848-2022	Madsbad, Sten/0000-0002-5017-1815				[Anonymous], 1987, Diabetes Care, V10, P639; GARG A, 1988, NEW ENGL J MED, V319, P829, DOI 10.1056/NEJM198809293191304; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; Toeller M, 1997, DIABETOLOGIA, V40, P1219, DOI 10.1007/s001250050810	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					369	370		10.1016/S0140-6736(05)60468-0	http://dx.doi.org/10.1016/S0140-6736(05)60468-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717929				2023-01-03	WOS:000075110500017
J	Russon, L; Alison, D				Russon, L; Alison, D			Palliative care does not mean giving up	BRITISH MEDICAL JOURNAL			English	Article									St James Univ Hosp, Palliat Care Team, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Russon, L (corresponding author), St James Univ Hosp, Palliat Care Team, Ashley Wing, Leeds LS9 7TF, W Yorkshire, England.							ONEILL J, 1994, AM J HOSPICE PAL NOV, P36; *STAND MED ADV COM, 1992, PRINC PROV PALL CAR; World Health Organization, 1990, CANC PAIN REL PALL C	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					196	197						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9705638				2023-01-03	WOS:000075047800035
J	Miller, TP; Dahlberg, S; Cassady, JR; Adelstein, DJ; Spier, CM; Grogan, TM; LeBlanc, M; Carlin, S; Chase, E; Fisher, RI				Miller, TP; Dahlberg, S; Cassady, JR; Adelstein, DJ; Spier, CM; Grogan, TM; LeBlanc, M; Carlin, S; Chase, E; Fisher, RI			Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFUSE HISTIOCYTIC LYMPHOMA; FIELD RADIATION-THERAPY; STAGE-I; FOLLOW-UP; INITIAL CHEMOTHERAPY; LIMITED-STAGE; DISEASE; SURVIVAL	Background Patients with clinically localized, intermediate- or high-grade non-Hodgkin's lymphoma usually receive initial treatment with a doxorubicin-containing regimen such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Pilot studies suggest that eight cycles of CHOP alone or three cycles of CHOP followed by involved-field radiotherapy are effective in such patients. Methods We compared these two approaches in a prospective, randomized, multi-institutional study. The end points were progression-free survival, overall survival, and life-threatening or fatal toxic effects. Two hundred eligible patients were randomly assigned to receive CHOP plus radiotherapy, and 201 received CHOP alone. Results Patients treated with three cycles of CHOP plus radiotherapy had significantly better progression-free survival (P=0.03) and overall survival (P=0.02) than patients treated with CHOP alone. The five-year estimates of progression-free survival for patients receiving CHOP plus radiotherapy and for patients receiving CHOP alone were 77 percent and 64 percent, respectively. The five-year estimates of overall survival for patients receiving CHOP plus radiotherapy and for patients receiving CHOP alone were 82 percent and 72 percent, respectively. The adverse effects included one death in each treatment group. Life-threatening toxic effects of any type were seen in 61 of 200 patients treated with CHOP plus radiotherapy and in 80 of 201 patients treated with CHOP alone (P=0.06). The left ventricular function was decreased in seven patients who received CHOP alone, whereas no cardiac events were recorded in the group receiving CHOP plus radiotherapy (P=0.02). Conclusions Three cycles of CHOP followed by involved-field radiotherapy are superior to eight cycles of CHOP alone for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma. (N Engl J Med 1998;339:21-6.) (C) 1998, Massachusetts Medical Society.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; SW Oncol Grp, Ctr Stat, Seattle, WA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Arizona Center Cancer Care; University of Arizona; Southwest Oncology Group; Cleveland Clinic Foundation; Loyola University Chicago	Miller, TP (corresponding author), SW Oncol Grp, Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.				NATIONAL CANCER INSTITUTE [U10CA013612, U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [CA387926, CA32102, CA13612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSEN JF, 1993, J CLIN ONCOL, V11, P255, DOI 10.1200/JCO.1993.11.2.255; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BONADONNA G, 1984, ADJUVANT THERAPY CAN, V4, P661; CABANILLAS F, 1980, CANCER, V46, P2356, DOI 10.1002/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X; CARBONE PP, 1971, CANCER RES, V31, P1860; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GLICK JH, 1995, P AN M AM SOC CLIN, V14, P391; JONES SE, 1989, J CLIN ONCOL, V7, P1186, DOI 10.1200/JCO.1989.7.9.1186; KAMINSKI MS, 1986, ANN INTERN MED, V104, P747, DOI 10.7326/0003-4819-104-6-747; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LANDBERG TG, 1979, CANCER, V44, P831, DOI 10.1002/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S; LEVITT SH, 1980, CANCER TREAT REP, V64, P175; LONGO DL, 1989, J CLIN ONCOL, V7, P1295, DOI 10.1200/JCO.1989.7.9.1295; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER TP, 1983, BLOOD, V62, P413; MILLER TP, 1980, CANCER CHEMOTH PHARM, V4, P67; MILLER TP, 1979, LANCET, V1, P358; NISSEN NI, 1983, CANCER, V52, P1, DOI 10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M; ROSENBERG SA, 1982, CANCER, V49, P2112; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SWEET DL, 1981, BLOOD, V58, P1218; TRAVIS LB, 1993, JNCI-J NATL CANCER I, V85, P1932, DOI 10.1093/jnci/85.23.1932; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312	25	693	735	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					21	26		10.1056/NEJM199807023390104	http://dx.doi.org/10.1056/NEJM199807023390104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647875				2023-01-03	WOS:000074500000004
J	Rosa, L; Rosa, E; Sarner, L; Barrett, S				Rosa, L; Rosa, E; Sarner, L; Barrett, S			A close look at therapeutic touch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								Context.-Therapeutic Touch (TT) is a widely used nursing practice rooted in mysticism but alleged to have a scientific basis. Practitioners of TT claim to treat many medical conditions by using their hands to manipulate a "human energy field" perceptible above the patient's skin. Objective.-To investigate whether TT practitioners can actually perceive a "human energy field." Design.-Twenty-one practitioners with TT experience for from 1 to 27 years were tested under blinded conditions to determine whether they could correctly identify which of their hands was closest to the investigator's hand. Placement of the investigator's hand was determined by flipping a coin. Fourteen practitioners were tested 10 times each, and 7 practitioners were tested 20 times each. Main Outcome Measure.-Practitioners of TT were asked to state whether the investigator's unseen hand hovered above their right hand or their left hand. To show the validity of TT theory, the practitioners should have been able to locate the investigator's hand 100% of the time. A score of 50% would be expected through chance alone. Results.-Practitioners of TT identified the correct hand in only 123 (44%) of 280 trials, which is close to what would be expected for random chance. There was no significant correlation between the practitioner's score and length of experience (r=0.23). The statistical power of this experiment was sufficient to conclude that if TT practitioners could reliably detect a human energy field, the study would have demonstrated this. Conclusions.-Twenty-one experienced TT practitioners were unable to detect the investigator's "energy field." Their failure to substantiate TT's most fundamental claim is unrefuted evidence that the claims of TT are groundless and that further professional use is unjustified.	Natl Therapeut Touch Study Grp, Loveland, CO 80537 USA; Natl Council Against Hlth Fraud Inc, Questionable Nurse Practices Task Force, Loveland, CO USA; Quackwatch Inc, Allentown, PA USA		Sarner, L (corresponding author), Natl Therapeut Touch Study Grp, 711 W 9th St, Loveland, CO 80537 USA.	nttsg@ezlink.com; sbinfo@quackwatch.com						BANDMAN EL, 1995, CRITICAL THINKING NU; BARRETT EAM, 1990, VISIONS ROGERS SCI B, P15; Bogulawski M, 1980, Top Clin Nurs, V2, P27; Boguslawski M, 1979, J Contin Educ Nurs, V10, P9; BOWERS DP, 1992, THESIS SAN JOSE STAT; BRIERTON TD, 1992, LABOR LAW J, V43, P411; BROWN CC, 1977, J ALTER ST CONSCIOUS, V3, P169; BROWN PR, 1981, THESIS U NEVADA RENO; BRUNJES CAF, 1983, TOP CLIN NURS, V5, P72; BULLOUGH VL, 1993, SKEPTICAL INQUIRER, V17, P169; BUSH AM, 1992, PSYCHOL REP, V70, P891, DOI 10.2466/PR0.70.3.891-896; BUTGEREIT B, 1994, BIRMINGHAM NEWS 1117, pA1; CABICO LL, 1992, THESIS DYOUVILLE COL; CALVERT R, 1994, MASSAGE MAGAZINES, V47, P56; CARPENITO LJ, 1995, NURISNG DIAGNOSIS AP, P355; CHIAPPONE J, 1989, LIGHT TOUCH EASY GUI, P14; Claman HN, 1994, REPORT CHANCELLORS C; CLARK AJ, 1992, 3 ANN W AL C CLIN NU; CLARK PE, 1984, NURS RES, V33, P37; *COL STAT BOARD NU, 1992, SUBC INV AW CONT ED; COWENS C, 1996, GIFT HEALING YOU CAN; DOLLAR CE, 1993, THESIS U MISSISSIPPI; EDGE H, 1979, 22 ANN CONV PAR ASS; EMERY CE, 1994, PROVIDENCE SUN  1127, pA1; FEDORUK RB, 1984, THESIS U MARYLAND BA; FIELY D, 1995, COLUMBUS DISPAT 0820, pB1; Fish S, 1993, J Christ Nurs, V10, P6; France N E, 1993, J Holist Nurs, V11, P319, DOI 10.1177/089801019301100402; Gagne D, 1994, Arch Psychiatr Nurs, V8, P184, DOI 10.1016/0883-9417(94)90052-3; GLAZER S, 1995, WASHINGTON POST 1219, P19; GUERRERO MA, 1985, THESIS U TEXAS GALVE; Haddad A, 1994, RN, V57, P21; HADDAD A, 1994, RN, V57, P24; HALE EH, 1986, THESIS TEXAS WOMENS; HAMILTONWYATT GK, 1988, THESIS MICHIGAN STAT; HEIDT P, 1981, NURS RES, V30, P32, DOI 10.1097/00006199-198101000-00014; Heidt P R, 1990, Image J Nurs Sch, V22, P180; HINZE ML, 1988, THESIS U TEXAS AUSTI; Hogg P, 1985, THESIS CALIFORNIA SC; Hover D, 1992, Beginnings, V12, P3; HUGHES PP, 1994, THESIS U NEW MEXICO; JACKSON MEM, 1981, THERPAEUTIC TOUCH BO, P72; JARBOUX D, 1994, BOULDER SUNDARY 0102, pE3; JOEL LA, 1995, AM J NURS, V95, P7; Karagulla S., 1989, CHAKRAS HUMAN ENERGY; KAUFFOLD MP, 1995, CHICAGO TRIBUNE 1119, P1; Keegan L, 1996, RN, V59, P59; Keegan L, 1989, J Post Anesth Nurs, V4, P17; KELLER E, 1986, NURS RES, V35, P101; KNASTER M, 1989, E W, V19, P54; KNASTER M, 1989, E W, V19, P59; KNASTER M, 1989, E W, V19, P79; Kramer N A, 1990, Pediatr Nurs, V16, P483; Krieger D, 1975, J N Y State Nurses Assoc, V6, P6; Krieger D, 1990, Imprint, V37, P86; Krieger D, 1975, Am J Nurs, V75, P784; KRIEGER D, 1979, AM J NURS, V79, P660, DOI 10.2307/3462338; KRIEGER D, 1975, J HOLISTIC HLTH, V1, P23; KRIEGER D, 1990, IMPRINT, V37, P86; KRIEGER D, 1997, THERAPEUTIC TOUCH IN, P162; KRIEGER D, 1972, HUMAN DIMENSIONS AUT, P12; Krieger D., 1987, LIVING THERAPEUTIC T; KRIEGER D, 1976, INT J PSYCHOENERGY S, V1, P121; KRIEGER D, 1987, LIVING THERAPEUTIC T, P157; KRIEGER D, 1973, P 9 ANA NURS RES C N, P39; Krieger D. K., 1993, ACCEPTING YOUR POWER; Leduc E, 1987, Neonatal Netw, V5, P46; Ledwith S P, 1995, RN, V58, P51; LEVINE ME, 1979, AM J NURS, V79, P1379, DOI 10.1097/00000446-197908000-00011; LIKONBERGER HJ, 1985, INTERPRETIVE STUDY N; LIONBERGER HJ, 1986, NURSING RES METHODOL, P169; MACKEY RB, 1995, AM J NURS, V95, P27; MACRAE J, 1979, AM J NURS, V79, P664; MAXWELL J, 1996, CHRISTIANITY TODAY, V40, P96; MEEHAN MTC, 1990, NATL LEAGUE NURISNG, P67; MEEHAN MTC, 1992, NURSING INTERVETIONS, P201; MEEHAN MTC, 1990, VISIONS ROGERS SCI B, P197; MEEHAN MTC, 1985, EFFECT THERAPEUTIC T; Meehan T C, 1993, Nurs Sci Q, V6, P69, DOI 10.1177/089431849300600206; MEEHAN TC, 1995, RES NURS HEALTH, V18, P471, DOI 10.1002/nur.4770180512; MEEHAN TC, 1995, AM J NURS, V95, P17; Mersmann C.A., 1993, THESIS NEW YORK U NE; MESENGER TC, 1994, J GERONTOL NURS, V20, P17; MISRA MM, 1993, THESIS CALIFORNIA ST; MOCCIA P, 1986, NEW APPROACHES THEOR, P15; MOCCIA P, 1994, TIME, V144, P18; Mulloney S S, 1996, J Cardiovasc Nurs, V10, P27; NODINE JL, 1987, THESIS U ARIZONA TUC; OLSON T, 1995, N&HC PERSPECT COMMUN, V16, P97; PARKES BS, 1985, THESIS U TEXAS AUSTI; PETERS PJ, 1992, THESIS WALDEN U MINN; POLK SH, 1995, THESIS ARIZONA STATE; POST NW, 1990, THESIS SAN JOSE STAT; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P550; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P47; QUINN J, 1982, INVESTIGATION EFFECT; Quinn J F, 1992, Holist Nurs Pract, V6, P26; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Quinn J F, 1989, Nurs Sci Q, V2, P79, DOI 10.1177/089431848900200207; Quinn J F, 1992, Holist Nurs Pract, V7, P32; QUINN JF, 1993, ADV NURS SCI, V15, P13, DOI 10.1097/00012272-199306000-00003; QUINN JF, 1979, AM J NURS, V79, P662; QUINN JF, 1994, THERAPEUTIC TOUCH HE; Randolph G, 1979, Top Clin Nurs, V1, P31; RANDOLPH GL, 1984, NURS RES, V33, P33; RAUCHEISEN ML, 1984, RN MAG, V47, P49; Rogers M.E., 1970, INTRO THEORETICAL BA; ROSA LA, 1906, SUREY THERAPEUTIC TO; ROSA LA, 1993, ROCKY MOUNTAIN SKEPT, V10, P10; SAMAREL N, 1992, J ADV NURS, V17, P651, DOI 10.1111/j.1365-2648.1992.tb01960.x; Sandroff R, 1980, RN, V43, P24; SANDROFF R, 1980, RN, V43, P82; SATIR F, 1994, OLYMPIAN        0719; SCHLOTFELDT RM, 1973, P 9 ANA NURS RES C N, P59; Schmidt C M, 1995, RN, V58, P54; SCHMIDT CM, 1995, RN, V58, P52; SCHMIDT CM, 1995, RN, V58, P54; SCHWEITZER SF, 1980, THESIS U NEVADA RENO; SHUZMAN E, 1993, THESIS NEW YORK U NE; SIES MM, 1993, THESIS MICHIGAN STAT; Simington J A, 1993, Clin Nurs Res, V2, P438, DOI 10.1177/105477389300200406; Snyder M, 1995, J Gerontol Nurs, V21, P34; SNYDER M, 1995, J GERONTOL NURS, V21, P54; SODERGREN KA, 1993, THESIS U MINNESOTA M; STRANEVA JAE, 1992, THESIS INDIANA U BLO; Swackhamer A H, 1995, RN, V58, P49; THARNSTROM CAL, 1993, THESIS SAN JOSE STAT; Thayer M B, 1990, Pediatr Nurs, V16, P70; THOMASBECKETT JG, 1991, THESIS MICHIGAN STAT; TURNER JG, 1996, EFFECT THERAPEUTIC T; TURNER JG, 1994, TRISERVICE NURSING R; WALIKE BC, 1975, AM J NURS, V75, P1278; WALIKE BC, 1975, AM J NURS, V75, P1275; WALKE BC, 1975, AM J NURS, V75, P1292; Wirth DP, 1993, COMPLEMENTARY THERAP, V1, P127; Wirth DP, 1990, SUBTLE ENERGIES, V1, P1; WOODS DL, 1993, THESIS SEATTLE U WAS; 1989, U COLORADO SCH N MAY, P1	138	135	137	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1005	1010		10.1001/jama.279.13.1005	http://dx.doi.org/10.1001/jama.279.13.1005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533499	Bronze, Green Published			2023-01-03	WOS:000072669700028
J	Ramirez, A; Addington-Hall, J; Richards, M				Ramirez, A; Addington-Hall, J; Richards, M			ABC of palliative care - The carers	BRITISH MEDICAL JOURNAL			English	Review							CANCER		United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England; Lambeth Healthcare NHS Trust, London, England; Univ London Kings Coll, Sch Med & Dent, London, England; St Christophers Hospice, London, England	University of London; King's College London; University of London; King's College London	Ramirez, A (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England.							ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Faulkner Ann, 1994, TALKING CANC PATIENT; Graham J, 1996, PALLIATIVE MED, V10, P185, DOI 10.1177/026921639601000302; SEALE C, 1991, Palliative Medicine, V5, P12, DOI 10.1177/026921639100500104	5	81	84	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					208	211						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468691				2023-01-03	WOS:000071616400035
J	Neven, P; DeMuylder, X				Neven, P; DeMuylder, X			Hormonal interventions and cancer risk	LANCET			English	Article											Neven, P (corresponding author), ALGEMERE KLIN ST JAN,DEPT OBSTET & GYNAECOL,BROEKST 114,B-1000 BRUSSELS,BELGIUM.							ASSIKIS VJ, 1995, INT J GYNECOL OBSTET, V49, P241, DOI 10.1016/0020-7292(95)02387-R; BERAL V, 1995, J CLIN EPIDEMIOL, V48, P165, DOI 10.1016/0895-4356(94)00114-6; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; SILVA ID, 1995, BRIT J CANCER, V72, P485, DOI 10.1038/bjc.1995.360; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346			S			S8	S8		10.1016/0140-6736(95)90007-1	http://dx.doi.org/10.1016/0140-6736(95)90007-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN122	9454051	Bronze			2023-01-03	WOS:A1995TN12200008
J	Ali, SA; Joao, HC; Hammerschmid, F; Eder, J; Steinkasserer, A				Ali, SA; Joao, HC; Hammerschmid, F; Eder, J; Steinkasserer, A			Transferrin Trojan horses as a rational approach for the biological delivery of therapeutic peptide domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN-SERUM TRANSFERRIN; PROTEASE CLEAVAGE SITE; HUMAN-TUMOR CELLS; DIFERRIC TRANSFERRIN; FUSION MECHANISM; INHIBITION; TOXIN; REPLICATION	One novel approach for the biological delivery of peptide drugs is to incorporate the sequence of the peptide into the structure of a natural transport protein, such as human serum transferrin. To examine whether this is feasible, a peptide sequence cleavable by the human immunodeficiency virus type 1 protease (VSQNYPIVL) was inserted into various regions of human serum transferrin, and the resultant proteins were tested for function. Experimentally, molecular modeling was used to identify five candidate insertion sites in surface exposed loops of human serum transferrin that were distant from biologically active domains. These insertions were cloned using polymerase chain reaction mutagenesis, and the proteins were expressed using a baculovirus expression vector system. Analysis of the mutant proteins provided a number of important findings: (a) they retained native human serum transferrin function, (b) the inserted peptide sequence was surface exposed, and most importantly, (c) two of these mutants could be cleaved by human immunodeficiency virus-1 protease. In conclusion, this investigation has validated the use of human serum transferrin as a carrier protein for functional peptide domains introduced into its structure using protein engineering. These findings will be useful for developing a novel class of therapeutic agents for a broad spectrum of diseases.	Novartis Res Inst, A-1230 Vienna, Austria	Novartis	Steinkasserer, A (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Hartmannstr 14, D-91052 Erlangen, Germany.		Ali, Stuart/D-4445-2013; Ali, Stuart/P-5514-2019	Ali, Stuart/0000-0002-4124-2896; Ali, Stuart/0000-0002-4124-2896				Ali SA, 1996, BIOCHEM J, V319, P191, DOI 10.1042/bj3190191; ALI SA, 1995, BIOTECHNIQUES, V18, P746; Ali SA, 1996, ANAL BIOCHEM, V238, P93, DOI 10.1006/abio.1996.0256; Ali SA, 1997, BIOTECHNIQUES, V22, P1060, DOI 10.2144/97226bm10; ALI SA, 1997, GENE CLONING ANAL CU, P133; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BERGAMASCHI G, 1993, BRIT J HAEMATOL, V68, P379; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Choudhury I, 1998, J ACQ IMMUN DEF SYND, V17, P104, DOI 10.1097/00042560-199802010-00002; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Dibbern DA, 1997, J CLIN INVEST, V99, P2837, DOI 10.1172/JCI119476; FAULK W P, 1990, Molecular Biotherapy, V2, P57; FAULK WP, 1980, LANCET, V2, P390; Finkelstein AV, 1997, CURR OPIN STRUC BIOL, V7, P60, DOI 10.1016/S0959-440X(97)80008-5; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; HALL WA, 1994, NEUROSURGERY, V34, P649, DOI 10.1227/00006123-199404000-00012; HATANO T, 1993, TUMOR BIOL, V14, P288, DOI 10.1159/000217841; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUEBERS H, 1985, P SOC EXP BIOL MED, V179, P222; HUEBERS H, 1981, P NATL ACAD SCI-BIOL, V78, P621, DOI 10.1073/pnas.78.1.621; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; ISHIGURO K, 1992, SOMAT CELL MOLEC GEN, V18, P45, DOI 10.1007/BF01233448; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kashanchi F, 1997, VIROLOGY, V227, P431, DOI 10.1006/viro.1996.8346; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; LASKE DW, 1994, J NEUROSURG, V80, P520, DOI 10.3171/jns.1994.80.3.0520; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; PACUSZKA T, 1992, BIOCHEMISTRY-US, V31, P4773, DOI 10.1021/bi00135a005; PANACCIO M, 1987, IMMUNOL CELL BIOL, V65, P461, DOI 10.1038/icb.1987.55; RASO V, 1984, J BIOL CHEM, V259, P1143; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; SEYMOUR GJ, 1987, UROL RES, V15, P341; SIZENSKY JA, 1992, AM J REPROD IMMUNOL, V27, P163, DOI 10.1111/j.1600-0897.1992.tb00744.x; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; YEH CJG, 1984, CLIN IMMUNOL IMMUNOP, V32, P1, DOI 10.1016/0090-1229(84)90037-0; YEH CJG, 1984, VOX SANG, V46, P217, DOI 10.1111/j.1423-0410.1984.tb00078.x; ZOLOTUKHIN AS, 1994, NUCLEIC ACIDS RES, V22, P4725, DOI 10.1093/nar/22.22.4725	51	20	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	1999	274	34					24066	24073		10.1074/jbc.274.34.24066	http://dx.doi.org/10.1074/jbc.274.34.24066			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	227ZV	10446177	hybrid			2023-01-03	WOS:000082110900056
J	Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA				Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA			Older persons' preferences for site of terminal care	ANNALS OF INTERNAL MEDICINE			English	Article							PALLIATIVE CARE; DEATH; PLACE; HOME; TEAM; LIFE; END	Background: Little is known about patients' preferences for site of terminal care, Objective: To describe older persons' preferences for home or hospital as the site of terminal care and to explore potential reasons for their preferences. Design: Cross-sectional quantitative and qualitative interviews. Setting: Participants' homes. Patients: Community-dwelling persons 65 years of age or older who were recently hospitalized with congestive heart failure, chronic obstructive pulmonary disease, or pneumonia and were not selected according to life expectancy; 246 patients participated in quantitative interviews and 29 participated in qualitative interviews. Measurements: Preference for site of terminal care and the reasons for that preference. Results: In quantitative interviews, 118 patients (48%) preferred terminal care in the hospital, 106 (43%) preferred home, and 22 (9%) did not know. One third changed their preference when asked about their preference in the event of a nonterminal illness. Reasons for preference identified during qualitative interviews included the desire to be with family members and concerns about burden to family members and their ability to provide necessary care. Concern about long-term care needs resulted in preference for a nursing home when choice was not constrained to home and hospital. Conclusions: Preference for home as the site of care for terminal illness exceeds existing practice. However, the current debate about home versus hospital as the ideal site for end-of-life care may ignore an important issue to older persons-namely, the care of disabilities that precede death.	Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, West Haven, CT 06516 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale Univ, Program Aging, New Haven, CT 06511 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University	Fried, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu						Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gilbar O, 1996, Hosp J, V11, P31, DOI 10.1300/J011v11n01_03; Glaster B. G., 1967, THEORETICAL SENSITIV; GROTHJUNCKER A, 1983, J AM GERIATR SOC, V31, P457, DOI 10.1111/j.1532-5415.1983.tb05116.x; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; MCWHINNEY IR, 1995, CAN MED ASSOC J, V152, P361; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; *NAT CTR HLTH STAT, 1990, VIT STAT US  A, V2; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415	13	108	110	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					109	112		10.7326/0003-4819-131-2-199907200-00006	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419426				2023-01-03	WOS:000081509700005
J	Colleoni, M; Price, KN; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A				Colleoni, M; Price, KN; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A		Int Breast Canc Study Grp	Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil	LANCET			English	Article								Combined chemotherapy for early breast cancer with cyclophosphamide, methotrexate, and fluorouracil has low associated mortality, but related deaths were seen among women aged 65 years or older in International Breast Cancer Study Group trials.	European Inst Oncol, Div Med Oncol, I-20141 Milan, Italy; IBCSG Stat Ctr, Boston, MA USA; Frontier Sci & Technol Res Fdn, Boston, MA USA; IBCSG Coordinating Ctr, Bern, Switzerland; Australian New Zealand Breast Canc Trials Grp, Sydney, NSW, Australia; Australian Canc Soc, Sydney, NSW, Australia; Osped Civico, Lugano, Switzerland	IRCCS European Institute of Oncology (IEO); Frontier Science Foundation	Colleoni, M (corresponding author), European Inst Oncol, Div Med Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Colleoni, Marco/AAN-8647-2020	Colleoni, Marco/0000-0002-5743-3013				Abe O, 1998, LANCET, V352, P930; GOLDHIRSCH A, 1994, CANCER, V74, P1139, DOI 10.1002/1097-0142(19940801)74:3+<1139::AID-CNCR2820741524>3.0.CO;2-K; Goldhirsch A, 1998, ANN ONCOL, V9, P489, DOI 10.1023/A:1008236502420; Hurny C, 1996, LANCET, V347, P1279; OSBORNE CK, 1996, DIS BREAST, P548	5	31	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					130	131		10.1016/S0140-6736(99)02015-2	http://dx.doi.org/10.1016/S0140-6736(99)02015-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408495				2023-01-03	WOS:000081377100022
J	Reid, FDA; Cook, DG; Majeed, A				Reid, FDA; Cook, DG; Majeed, A			Explaining variation in hospital admission rates between general practices: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY ADMISSIONS; REFERRAL RATES; EAST LONDON; PRACTITIONERS; DEPRIVATION; PATIENT; ASTHMA	Objectives To quantify the extent of the variation in hospital admission rates between general practices, and to investigate whether this variation can be explained by factors relating to the patient, the hospital, and the general practice. Design Cross sectional analysis of routine data. Setting Merton, Sutton, and Wandsworth Health Authority, which includes areas of inner and outer London. Subjects 209 136 hospital admissions in 1995-6 in patients registered with 120 general practices in the study area. Main outcome measures Hospital admission rate for general practices for overall, emergency, and elective admissions. Results Crude admission rates for general practices displayed a twofold difference between the 10th and the 90th centile for all, emergency, and elective admissions. This difference was only minimally reduced by standardising for age and sex. Sociodemographic patient factors derived from census data accounted for 42% of the variation in overall admission rates; 45% in emergency admission rates; and 25% in elective admission rates. There was a strong positive correlation between factors related to deprivation and emergency, but not elective, admission rates, raising questions about equity of provision of health care. The percentage of each practice's admissions to different local hospitals added significantly to the explanation of variation, while the general practice characteristics considered added very little. Conclusions Hospital admission rates varied greatly between general practices; this was largely explained by differences in patient populations. The lack of significant factors related to general practice is of little help for the direct management of admission rates, although the effect of sociological rather than organisational practice variables should routinely be standardised for differences in patient populations and hospitals used.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England	St Georges University London; St Georges University London	Reid, FDA (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.			Majeed, Azeem/0000-0002-2357-9858; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1993, SPSS WINDOWS BASE SY; ARMITAGE P, 1987, STATISTICAL METHODS, P403; Capewell S, 1996, BRIT MED J, V312, P991; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Crombie D L, 1988, Health Trends, V20, P53; DEMARCO P, 1993, BRIT MED J, V307, P1465, DOI 10.1136/bmj.307.6917.1465; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HippisleyCox J, 1997, BRIT MED J, V314, P1458, DOI 10.1136/bmj.314.7092.1458; MAJEED A, 1996, HLTH TRENDS, V28, P52; Majeed A, 1998, CLIN MANAGE, V7, P160; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; NOONE A, 1989, J ROY COLL GEN PRACT, V39, P404; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; THAKKER Y, 1994, ARCH DIS CHILD, V70, P488, DOI 10.1136/adc.70.6.488; Whynes DK, 1996, FAM PRACT, V13, P174, DOI 10.1093/fampra/13.2.174; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160	24	82	82	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					98	103		10.1136/bmj.319.7202.98	http://dx.doi.org/10.1136/bmj.319.7202.98			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398636	Green Published, Bronze			2023-01-03	WOS:000081438200035
J	Chamberlain, G; Steer, PL				Chamberlain, G; Steer, PL			ABC of labour care - Obstetric emergencies	BRITISH MEDICAL JOURNAL			English	Review									Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; Chelsea & Westminster Hosp, Imperial Coll, Sch Med, London, England	Singleton Hospital; Imperial College London	Chamberlain, G (corresponding author), Singleton Hosp, Swansea SA2 8QA, W Glam, Wales.							*DEP HLTH, 1994, CONF ENQ MAT DEATH 1, P43; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; JAMES D, 1999, HIGH RISK OBSTET; Love CDB, 1996, BRIT J OBSTET GYNAEC, V103, P864, DOI 10.1111/j.1471-0528.1996.tb09903.x; *SANDS, 1991, GUID PROF	5	11	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1342	1345		10.1136/bmj.318.7194.1342	http://dx.doi.org/10.1136/bmj.318.7194.1342			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323825	Green Published			2023-01-03	WOS:000080418400041
J	Discher, BM; Won, YY; Ege, DS; Lee, JCM; Bates, FS; Discher, DE; Hammer, DA				Discher, BM; Won, YY; Ege, DS; Lee, JCM; Bates, FS; Discher, DE; Hammer, DA			Polymersomes: Tough vesicles made from diblock copolymers	SCIENCE			English	Article							COMPLEX PHASE-BEHAVIOR; FLUID MEMBRANES; CURVATURE ELASTICITY; PHYSICAL-PROPERTIES; BILAYER-MEMBRANES; BLOCK-COPOLYMERS; SURFACTANT; COHESION	Vesicles were made from amphiphilic diblock copolymers and characterized by micromanipulation. The average molecular weight of the specific polymer studied, polyethyleneoxide-polyethylethylene (EO40-EE37), is several times greater than that of typical phospholipids in natural membranes. Both the membrane bending and area expansion moduli of electroformed polymersomes (polymer-based Liposomes) fell within the range of Lipid membrane measurements, but the giant polymersomes proved to be almost an order of magnitude tougher and sustained far greater areal strain before rupture. The polymersome membrane was also at Least 10 times Less permeable to water than common phospholipid bilayers. The results suggest a new class of synthetic thin-shelled capsules based on block copolymer chemistry.	Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Minnesota System; University of Minnesota Twin Cities	Discher, DE (corresponding author), Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA.			discher, dennis/0000-0001-6163-2229; Lee, James/0000-0002-7173-4875	NHLBI NIH HHS [P01-HL18208, R01-HL62352-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062352, P01HL018208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; BENSHAUL A, 1995, HDB PHYSICS BIOL SYS, V1, pCH7; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; Cevc G., 1995, HDB BIOL PHYSICS, V1; Chaieb S, 1998, PHYS REV E, V58, P7733, DOI 10.1103/PhysRevE.58.7733; Cornelissen JJLM, 1998, SCIENCE, V280, P1427, DOI 10.1126/science.280.5368.1427; DEULING HJ, 1976, J PHYS-PARIS, V37, P1335, DOI 10.1051/jphys:0197600370110133500; Dobereiner HG, 1997, PHYS REV E, V55, P4458, DOI 10.1103/PhysRevE.55.4458; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Hajduk DA, 1998, J PHYS CHEM B, V102, P4269, DOI 10.1021/jp973323z; Harasym TO, 1997, CANCER CHEMOTH PHARM, V40, P309, DOI 10.1007/s002800050662; Harris J. M., 1997, POLYETHYLENE GLYCOL; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lasic D., 1995, HDB BIOL PHYS, V1; LIN Z, 1993, J PHYS CHEM-US, V97, P3571, DOI 10.1021/j100116a022; LONGO MI, 1994, SCIENCE, V266, P1032; Longo ML, 1997, BIOPHYS J, V73, P1430, DOI 10.1016/S0006-3495(97)78175-X; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; Needham D., 1996, VESICLES; Netz RR, 1996, PHYS REV E, V53, P3875, DOI 10.1103/PhysRevE.53.3875; PETROV AG, 1984, PROG SURF SCI, V16, P389, DOI 10.1016/0079-6816(84)90016-9; SACKMANN E, 1995, HDB BIOL PHYSICS A, V1; Seifert U., 1995, P403; SEIFERT U, 1991, PHYS REV A, V44, P1182, DOI 10.1103/PhysRevA.44.1182; SVETINA S, 1989, EUR BIOPHYS J BIOPHY, V17, P101, DOI 10.1007/BF00257107; SZLEIFER I, 1988, PHYS REV LETT, V60, P1966, DOI 10.1103/PhysRevLett.60.1966; WALTER A, 1991, BIOPHYS J, V60, P1315, DOI 10.1016/S0006-3495(91)82169-5; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; Yu K, 1998, MACROMOLECULES, V31, P3509, DOI 10.1021/ma971419l	34	2103	2183	17	963	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1143	1146		10.1126/science.284.5417.1143	http://dx.doi.org/10.1126/science.284.5417.1143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325219				2023-01-03	WOS:000080359100029
J	Anglaret, X; Chene, G; Attia, A; Toure, S; Lafont, S; Combe, P; Manlan, K; N'Dri-Yoman, T; Salamon, R				Anglaret, X; Chene, G; Attia, A; Toure, S; Lafont, S; Combe, P; Manlan, K; N'Dri-Yoman, T; Salamon, R		Cotrimo Cl Study Grp	Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WEST-AFRICAN CITY; DEVELOPING-WORLD; IVORY-COAST; HIV; INFECTION; KENYA; SULFAMETHOXAZOLE; COTRIMOXAZOLE; PROPHYLAXIS	Background In sub-Saharan Africa, various bacterial diseases occur before pneumocystosis or toxoplasmosis in the course of HIV-1 infection, and are major causes of morbidity and mortality. We did a randomised, double blind, placebo-controlled clinical trial at community-health centres in Abidjan, Cote d'Ivoire, to assess the efficacy of trimethoprim-sulphamethoxazole (co-trimoxazole) chemoprophylaxis at early stages of HIV-1 infection. Method 843 HIV-infected patients were screened and 545 enrolled in the study. Eligible adults (with HIV-1 or HIV-1 and HIV-2 dual seropositivity at stages 2 or 3 of the WHO staging system) received co-trimoxazole chemoprophylaxis (trimethoprim 160 mg, sulphamethoxazole 800 mg) daily or a matching placebo. The primary outcome was the occurrence of severe clinical events, defined as death or hospital admission irrespective of the cause. Analyses were by intention to treat. Findings Four of the randomised patients were excluded (positive for HIV-2 only). 120 severe events occurred among 271 patients in the co-trimoxazole group and 198 among 270 in the placebo group. Significantly fewer patients in the co-trimoxazole group than in the placebo group had at least one severe event (84 vs 124); the probability of remaining free of severe events was 63.7% versus 45.8% (hazard ratio 0.57 [95% CI 0.43-0.75], p=0.0001) and the benefit was apparent in all subgroups of initial CD4-cell count. Survival did not differ between the groups (41 vs 46 deaths, p=0.51). Cotrimoxazole was generally well tolerated though moderate neutropenia occurred in 62 patients ( vs 26 in the placebo group). Interpretation Patients who might benefit from cotrimoxazole trimoxazole could be recruited on clinical criteria in community clinics without knowing the patients CD4-cell count. This affordable measure will enable quick public-health intervention, while monitoring bacterial susceptibility and haematological tolerance.	CHU Treichville, Ctr Diagnost & Rech SIDA, Abidjan 01, Cote Ivoire; Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France; CHU Yopougon, Med Serv, Abidjan, Cote Ivoire	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Anglaret, X (corresponding author), CHU Treichville, Ctr Diagnost & Rech SIDA, 01 BP 1839, Abidjan 01, Cote Ivoire.		Anglaret, Xavier/F-7333-2013; chene, genevieve/H-8665-2014; Anglaret, Xavier/T-2757-2019; Lafont, Sylviane/AAD-4464-2019	chene, genevieve/0000-0002-8368-6460; Ouassa, Timothee Dieudonne/0000-0002-5456-3103; Anglaret, Xavier/0000-0003-3319-8423; Lafont, Sylviane/0000-0003-0483-6238				Anglaret X, 1997, J CLIN MICROBIOL, V35, P1915, DOI 10.1128/JCM.35.7.1915-1915.1997; Anglaret X, 1998, INT J STD AIDS, V9, P432; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; CAHN P, 1993, AIDS, V7, P711; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CLERINX J, 1995, CLIN INFECT DIS, V21, P1282, DOI 10.1093/clinids/21.5.1282; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358; Edge MD, 1996, AIDS, V10, P1635, DOI 10.1097/00002030-199612000-00007; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; GILKS CF, 1993, J ANTIMICROB CHEMOTH, V31, P119, DOI 10.1093/jac/31.suppl_B.119; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Kaplan JE, 1996, AM J TROP MED HYG, V55, P1; Kariuki S, 1996, J ANTIMICROB CHEMOTH, V38, P425, DOI 10.1093/jac/38.3.425; KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84, DOI 10.1093/clinids/15.1.84; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MAYER HB, 1993, AIDS, V7, P1687, DOI 10.1097/00002030-199312000-00029; Tumbarello M, 1997, AIDS, V11, P1070; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 1997, Weekly Epidemiological Record, V72, P357	26	317	325	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1463	1468		10.1016/S0140-6736(98)07399-1	http://dx.doi.org/10.1016/S0140-6736(98)07399-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232311				2023-01-03	WOS:000080278200008
J	Stiell, IG; Wells, GA; Field, BJ; Spaite, DW; De Maio, VJ; Ward, R; Munkley, DP; Lyver, MB; Luinstra, LG; Campeau, T; Maloney, J; Dagnone, E				Stiell, IG; Wells, GA; Field, BJ; Spaite, DW; De Maio, VJ; Ward, R; Munkley, DP; Lyver, MB; Luinstra, LG; Campeau, T; Maloney, J; Dagnone, E		OPALS Study Grp	Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program - OPALS study phase II	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 17-19, 1998	CHICAGO, IL	Soc Acad Emergency Med			EMERGENCY MEDICAL-SERVICES; AUTOMATIC EXTERNAL DEFIBRILLATOR; AMERICAN-HEART-ASSOCIATION; PREHOSPITAL DEFIBRILLATION; HEALTH-PROFESSIONALS; RESUSCITATION; METAANALYSIS; TECHNICIANS; MANAGEMENT; EXPERIENCE	Context Survival rates for out-of-hospital cardiac arrest are low; published survival rates in Ontario are only 2.5%. This study represents phase II of the Ontario Prehospital Advanced Life Support (OPALS) study, which is designed to systematically evaluate the effectiveness and efficiency of various prehospital interventions for patients with cardiac arrest, trauma, and critical illnesses. Objective To assess the impact on out-of-hospital cardiac arrest survival of the implementation of a rapid defibrillation program in a large multicenter emergency medical services (EMS) system with existing basic life support and defibrillation (BLS-D) level of care. Design Controlled clinical trial comparing survival for 36 months before (phase I) and 12 months after (phase II) system optimization. Setting Nineteen urban and suburban Ontario communities (populations ranging from 16 000 to 750 000 [total, 2.7 million]). Patients All patients who had out-of-hospital cardiac arrest in the study communities for whom resuscitation was attempted by emergency responders. Interventions Study communities optimized their EMS systems to achieve the target response interval from when a call was received until a vehicle stopped with a defibrillator of 8 minutes or less for 90% of cardiac arrest cases. Working both locally and provincially, communities implemented multiple measures, including defibrillation by firefighters, base paging, tiered response agreements with fire departments, continuous quality improvement for response intervals, and province-wide revision and implementation of standard dispatch policies. All response times were obtained from a central dispatch system. Main Outcome Measure Survival to hospital discharge. Results The 4690 cardiac arrest patients studied in phase I and the 1641 in phase II were similar for all clinical and demographic characteristics, including age, sex, witnessed status, rhythm, and receipt of bystander cardiopulmonary resuscitation. The proportion of cases meeting the 8-minute response criterion improved (76.7 % vs 92.5 %; P<.001) as did most median response intervals. Overall survival to hospital discharge for all rhythm groups combined improved from 3.9% to 5.2% (P = .03). The 33% relative increase in survival represents an additional 21 lives saved each year in the study communities (approximately 1 life per 120 000 residents). The charges were estimated to be US $46 900 per life saved for establishing the rapid defibrillation program and US $2400 per life saved annually for maintaining the program. Conclusion An inexpensive, multifaceted system optimization approach to rapid defibrillation can lead to significant improvements in survival after cardiac arrest in a large BLS-D EMS system.	Univ Ottawa, Div Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Civic Hosp, Leob Hlth Res Inst, Ottawa, ON, Canada; Sunnybrook Base Hosp Program, Toronto, ON, Canada; Univ Arizona, Arizona Emergency Med Res Ctr, Tucson, AZ USA; Niagara Reg Base Hosp Program, Niagara Falls, ON, Canada; Joseph Brant Mem Hosp, Dept Emergency Med, Burlington, ON, Canada; Ontario Minist Hlth, Toronto, ON M5W 1R5, Canada; Queens Univ, Div Emergency Med, Kingston, ON, Canada; Med Res Council Canada, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Arizona; Queens University - Canada	Stiell, IG (corresponding author), Ottawa Hosp, Loeb Hlth Res Inst, Clin Epidemiol Unit, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.			Stiell, Ian/0000-0002-2583-6408; Spaite, Daniel/0000-0003-2601-6476				*AM HEART ASS, 1990, TXB ADV CARD LIF SUP; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BRISON RJ, 1992, CAN MED ASSOC J, V147, P191; CARVETH SW, 1974, ARCH SURG-CHICAGO, V108, P528; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2171; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Nichol G, 1996, ANN EMERG MED, V27, P700, DOI 10.1016/S0196-0644(96)70187-7; NICHOL G, 1994, JAMA-J AM MED ASSOC, V271, P504; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PANTRIDG.JF, 1967, LANCET, V2, P271; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SHUSTER M, 1993, ANN EMERG MED, V22, P721, DOI 10.1016/S0196-0644(05)81856-6; SPAITE DW, 1995, ANN EMERG MED, V25, P697; Stapczynski JS, 1997, ACAD EMERG MED, V4, P552, DOI 10.1111/j.1553-2712.1997.tb03577.x; Stiell IG, 1998, ANN EMERG MED, V32, P180, DOI 10.1016/S0196-0644(98)70135-0; Stiell IG, 1999, ANN EMERG MED, V33, P44, DOI 10.1016/S0196-0644(99)70415-4; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; TORRANCE GW, 1993, HLTH STAT HLTH POLIC; VALENZUELA TD, 1990, ANN EMERG MED, V19, P1407, DOI 10.1016/S0196-0644(05)82609-5; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003	33	264	271	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1999	281	13					1175	1181		10.1001/jama.281.13.1175	http://dx.doi.org/10.1001/jama.281.13.1175			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	181VW	10199426	Bronze			2023-01-03	WOS:000079464400031
J	Inouye, SK; Bogardus, ST; Charpentier, PA; Leo-Summers, L; Acampora, D; Holford, TR; Cooney, LW				Inouye, SK; Bogardus, ST; Charpentier, PA; Leo-Summers, L; Acampora, D; Holford, TR; Cooney, LW			A multicomponent intervention to prevent delirium in hospitalized older patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIAL; ACUTE CONFUSIONAL STATES; ELDERLY MEDICAL PATIENTS; MINI-MENTAL STATE; PREDICTIVE MODEL; PROGNOSIS; SELECTION; FRACTURES; RECOVERY; PROGRAM	Background Since in hospitalized older patients delirium is associated with poor outcomes, we evaluated the effectiveness of a multicomponent strategy for the prevention of delirium. Methods We studied 852 patients 70 years of age or older who had been admitted to the general-medicine service at a teaching hospital. Patients from one intervention unit and two usual-care units were enrolled by means of a prospective matching strategy. The intervention consisted of standardized protocols for the management of six risk factors for delirium: cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration. Delirium, the primary outcome, was assessed daily until discharge. Results Delirium developed in 9.9 percent of the intervention group, as compared with 15.0 percent of the usual-care group (matched odds ratio, 0.60; 95 percent confidence interval, 0.39 to 0.92). The total number of days with delirium (105 vs. 161, P=0.02) and the total number of episodes (62 vs. 90, P=0.03) were significantly lower in the intervention group. However, the severity of delirium and recurrence rates were not significantly different. The overall rate of adherence to the intervention was 87 percent, and the total number of targeted risk factors per patient was significantly reduced. Intervention was associated with significant improvement in the degree of cognitive impairment among patients with cognitive impairment at admission and with a significant reduction in the rate of use of sleep medications among all patients. Among the other risk factors, there were trends toward improvement in immobility, visual impairment, and hearing impairment. Conclusions The risk-factor intervention strategy that we studied resulted in significant reductions in the number and duration of episodes of delirium in hospitalized older patients. The intervention had no significant effect on the severity of delirium or on recurrence rates; this finding suggests that primary prevention of delirium is probably the most effective treatment strategy. (N Engl J Med 1999;340:669-76.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06504 USA	Yale University; Yale University	Inouye, SK (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 20 York St,Tompkins 15, New Haven, CT 06504 USA.		Inouye, Sharon/R-7216-2019		NATIONAL INSTITUTE ON AGING [R01AG012551] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG12551] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ADM AG, 1995, PROF OLD AM; Beresin E V, 1988, J Geriatr Psychiatry Neurol, V1, P127, DOI 10.1177/089198878800100302; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUDD S, 1974, NURS RES, V23, P341; CHARPENTIER PA, 1995, GERONTOLOGIST, V35, P181; CHATHAM MA, 1978, HEART LUNG, V7, P995; COLE MG, 1994, CAN MED ASSOC J, V151, P965; COLE MG, 1993, CAN MED ASSOC J, V149, P41; COLE MG, 1991, J AM GERIATR SOC, V39, P1183, DOI 10.1111/j.1532-5415.1991.tb03572.x; CUMMINGS JL, 1985, CLIN NEUROPSYCHIATRY, P9; Elie M, 1998, J GEN INTERN MED, V13, P204, DOI 10.1046/j.1525-1497.1998.00047.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GREENLAND S, 1989, AM J EPIDEMIOL, V130, P1066, DOI 10.1093/oxfordjournals.aje.a115409; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; HALL JP, 1988, MED J AUSTRALIA, V148, P271; HOBBS FB, 1996, CURRENT POPULATI P23, V190; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HOLFORD TR, 1989, AM J EPIDEMIOL, V130, P1247, DOI 10.1093/oxfordjournals.aje.a115453; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAYNE OL, 1971, NEW ENGL J MED, V284, P518, DOI 10.1056/NEJM197103112841003; LYNN HS, 1992, BIOMETRICS, V48, P397, DOI 10.2307/2532299; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; Makuch RW, 1998, STAT MED, V17, P1517, DOI 10.1002/(SICI)1097-0258(19980715)17:13<1517::AID-SIM859>3.0.CO;2-0; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Nagley S J, 1986, J Gerontol Nurs, V12, P27; OWENS JF, 1982, NURS RES, V31, P60; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; Rizzo JA, 1996, MED CARE, V34, P954, DOI 10.1097/00005650-199609000-00007; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; RUMMANS TA, 1995, MAYO CLIN PROC, V70, P989, DOI 10.4065/70.10.989; SCHINDLER BA, 1989, GEN HOSP PSYCHIAT, V11, P358, DOI 10.1016/0163-8343(89)90124-2; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; *US BUR CENS, 1996, STAT ABSTR US 1996, P116; Wanich C K, 1992, Image J Nurs Sch, V24, P201; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P329, DOI 10.1002/nur.4770080405; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	45	1705	1754	3	98	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1999	340	9					669	676		10.1056/NEJM199903043400901	http://dx.doi.org/10.1056/NEJM199903043400901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	172ZB	10053175	Green Published			2023-01-03	WOS:000078955200001
J	Shah, S				Shah, S			Why leeches influence my physical examination	LANCET			English	Article											Shah, S (corresponding author), 420 E 70th St,6J, New York, NY 10021 USA.							EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406	1	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					2014	2015		10.1016/S0140-6736(98)09291-5	http://dx.doi.org/10.1016/S0140-6736(98)09291-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872267				2023-01-03	WOS:000077663000048
J	Ghooi, RB; Ghooi, SR				Ghooi, RB; Ghooi, SR			A mother in pain	LANCET			English	Editorial Material											Ghooi, RB (corresponding author), 697 Pocket A,Sarita Vihar,Mathura Rd, New Delhi 110044, India.								0	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1998	352	9140					1625	1625		10.1016/S0140-6736(98)07150-5	http://dx.doi.org/10.1016/S0140-6736(98)07150-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843124				2023-01-03	WOS:000076998900048
J	Garfinkel, MS; Singhal, A; Katz, WA; Allan, DA; Reshetar, R; Schumacher, HR				Garfinkel, MS; Singhal, A; Katz, WA; Allan, DA; Reshetar, R; Schumacher, HR			Yoga-based intervention for carpal tunnel syndrome - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Carpal tunnel syndrome is a common complication of repetitive activities and causes significant morbidity, Objective.-To determine the effectiveness of a yoga-based regimen for relieving symptoms of carpal tunnel syndrome. Design.-Randomized, single-blind, controlled trial. Setting.-A geriatric center and an industrial site in 1994-1995. Patients.-Forty-two employed or retired individuals with carpal tunnel syndrome (median age, 52 years; range, 24-77 years). Intervention.-Subjects assigned to the yoga group received a yoga-based intervention consisting of 11 yoga postures designed for strengthening, stretching, and balancing each joint in the upper body along with relaxation given twice weekly for 8 weeks. Patients in the control group were offered a wrist splint to supplement their current treatment. Main Outcome Measures.-Changes from baseline to 8 weeks in grip strength, pain intensity, sleep disturbance, Phalen sign, and Tinel sign, and in median nerve motor and sensory conduction time. Results.-Subjects in the yoga groups had significant improvement in grip strength (increased from 162 to 187 mm Hg; P = .009) and pain reduction (decreased from 5.0 to 2.9 mm; P = .02), but changes in grip strength and pain were not significant for control subjects. The yoga group had significantly more improvement in Phalen sign (12 improved vs 2 in control group; P = .008), but no significant differences were found in sleep disturbance, Tinel sign, and median nerve motor and sensory conduction time. Conclusion.-In this preliminary study, a yoga-based regimen was more effective than wrist splinting or no treatment in relieving some symptoms and signs of carpal tunnel syndrome.	Univ Penn, Sch Med, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Arthrit Immunol Ctr, Philadelphia, PA USA; Univ Penn, Presbyterian Med Ctr, Philadelphia, PA 19104 USA; Amer Board Internal Med, Philadelphia, PA USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Pennsylvania Presbyterian Medical Center; American Board of Internal Medicine	Garfinkel, MS (corresponding author), 2301 Cherry St,16F, Philadelphia, PA 19103 USA.							Atroshi I, 1996, J HAND SURG-AM, V21A, P651, DOI 10.1016/S0363-5023(96)80020-7; GARFINKEL MS, 1994, J RHEUMATOL, V21, P2341; GARFINKEL MS, 1992, EFFECT YOGA RELAXATI; HUSKISSON EC, 1982, J RHEUMATOL, V9, P768; IYENGAR BKS, 1966, LIGHT YOGA, P544; MOSSMAN SS, 1987, BRIT MED J, V294, P680, DOI 10.1136/bmj.294.6573.680; PASCARELLI E, 1994, REPETITIVE STRAIN IN, P55; PHALEN GS, 1966, J BONE JOINT SURG AM, VA 48, P211, DOI 10.2106/00004623-196648020-00001; STEINBERG DR, 1992, J HAND SURG-AM, V17A, P77, DOI 10.1016/0363-5023(92)90117-8; THOMPSON R, 1992, NATIONS BUS, V80, P1	10	172	172	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1601	1603		10.1001/jama.280.18.1601	http://dx.doi.org/10.1001/jama.280.18.1601			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820263	Bronze			2023-01-03	WOS:000076852000028
J	Ifudu, O				Ifudu, O			Care of patients undergoing hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STAGE RENAL-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; IMPROVED SEXUAL FUNCTION; MAINTENANCE HEMODIALYSIS; DIALYSIS PATIENTS; VASCULAR ACCESS; LIPID PROFILE; SHORT-TERM; FAILURE; THERAPY		SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, 450 Clarkson Ave,Box 52, Brooklyn, NY 11203 USA.							ALAKAILA K, 1987, SCAND J GASTROENTERO, V22, P372, DOI 10.3109/00365528709078607; AlHomrany M, 1997, AM J NEPHROL, V17, P32, DOI 10.1159/000169068; Barth R. H., 1996, Journal of the American Society of Nephrology, V7, P1439; BAZZI C, 1991, CLIN NEPHROL, V35, P176; BEAMISH MR, 1971, BRIT J HAEMATOL, V21, P617, DOI 10.1111/j.1365-2141.1971.tb02724.x; BLANKESTIJN PJ, 1995, J AM SOC NEPHROL, V5, P1703; BODDY K, 1972, BMJ-BRIT MED J, V1, P771, DOI 10.1136/bmj.1.5803.771; BOMMER J, 1979, LANCET, V2, P496; BORAH MF, 1978, KIDNEY INT, V14, P491, DOI 10.1038/ki.1978.154; CHARRA B, 1983, NEPHRON, V33, P96, DOI 10.1159/000182920; CHEIGH JS, 1992, AM J KIDNEY DIS, V19, P453, DOI 10.1016/S0272-6386(12)80954-1; CLAUSEN T, 1989, KIDNEY INT, V35, P1, DOI 10.1038/ki.1989.1; deLemos JA, 1996, J AM SOC NEPHROL, V7, P2044; DELMEZ JA, 1991, J CLIN ENDOCR METAB, V72, P735, DOI 10.1210/jcem-72-4-735; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FAIRBANKS VF, 1995, WILLIAMS HEMATOLOGY, P490; FARIAS MAG, 1994, AM J KIDNEY DIS, V23, P382; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; FENVES AZ, 1986, AM J KIDNEY DIS, V7, P130, DOI 10.1016/S0272-6386(86)80133-0; Fishbane S, 1997, AM J KIDNEY DIS, V29, P319, DOI 10.1016/S0272-6386(97)90192-X; GARCIALEONI ME, 1990, EUR J CLIN MICROBIOL, V9, P283, DOI 10.1007/BF01968062; GEERLINGS W, 1993, NEPHROL DIAL TRANSPL, V8, P585; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HOU SH, 1994, AM J KIDNEY DIS, V23, P60, DOI 10.1016/S0272-6386(12)80813-4; HOY WE, 1978, NEPHRON, V20, P182, DOI 10.1159/000181220; Ifudu O, 1996, AM J NEPHROL, V16, P118, DOI 10.1159/000168982; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; Ifudu O, 1996, INT J ARTIF ORGANS, V19, P384, DOI 10.1177/039139889601900702; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; Ifudu O, 1997, J Assoc Acad Minor Phys, V8, P49; Ifudu O, 1997, AM J KIDNEY DIS, V29, P549, DOI 10.1016/S0272-6386(97)90336-X; IFUDU O, 1995, DIALYSIS TRANSPLANT, V24, P292; ISHIKAWA I, 1991, NEPHRON, V58, P257, DOI 10.1159/000186434; KAHN JK, 1990, AM HEART J, V119, P484, DOI 10.1016/S0002-8703(05)80268-6; KANG JY, 1988, DIGEST DIS SCI, V33, P774, DOI 10.1007/BF01550962; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; LINAS SL, 1991, KIDNEY INT, V39, P771, DOI 10.1038/ki.1991.95; LIVIO M, 1986, NEW ENGL J MED, V315, P731, DOI 10.1056/NEJM198609183151204; Lundin AP., 1990, SEMIN DIALYSIS, V3, P5, DOI DOI 10.1111/J.1525-139X.1990.TB00003.X; Madore F, 1997, J AM SOC NEPHROL, V8, P1921; MALLUCHE HH, 1992, KIDNEY INT, V42, pS62; MANNUCCI PM, 1983, NEW ENGL J MED, V308, P8, DOI 10.1056/NEJM198301063080102; MCMAHON LP, 1990, AM J NEPHROL, V10, P404, DOI 10.1159/000168156; OH MS, 1975, NEPHRON, V14, P421, DOI 10.1159/000180476; OWEN CH, 1994, ANN THORAC SURG, V58, P1729, DOI 10.1016/0003-4975(94)91671-3; Pastan S, 1998, NEW ENGL J MED, V338, P1428, DOI 10.1056/NEJM199805143382006; POLLOCK CA, 1994, KIDNEY INT, V45, P897, DOI 10.1038/ki.1994.118; PORT FK, 1989, AM J KIDNEY DIS, V14, P119, DOI 10.1016/S0272-6386(89)80187-8; RAO TKS, 1987, NEW ENGL J MED, V316, P1062, DOI 10.1056/NEJM198704233161705; REMUZZI G, 1978, NEPHRON, V22, P347, DOI 10.1159/000181474; RUIZ P, 1990, NEW ENGL J MED, V322, P717, DOI 10.1056/NEJM199003153221102; SANDLE GI, 1987, CLIN SCI, V73, P247, DOI 10.1042/cs0730247; SCHAEFER RM, 1989, CLIN NEPHROL, V31, P1; SCHLESSINGER SD, 1994, AM J KIDNEY DIS, V23, P655, DOI 10.1016/S0272-6386(12)70275-5; The USRDS Dialysis Morbidity and Mortality Study (Wave 1), 1996, REN DAT SYST USRDS 1, P45; TISHER CC, 1994, ANN INTERN MED, V121, P62; Tzamaloukas A H, 1988, J Diabet Complications, V2, P75, DOI 10.1016/0891-6632(88)90007-4; VALJI K, 1991, RADIOLOGY, V178, P243, DOI 10.1148/radiology.178.1.1824582; VANGEELEN JA, 1987, NEPHRON, V45, P216, DOI 10.1159/000184120; WEIZMAN R, 1983, PSYCHOSOM MED, V45, P259, DOI 10.1097/00006842-198306000-00008	62	55	57	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1054	1062		10.1056/NEJM199810083391507	http://dx.doi.org/10.1056/NEJM199810083391507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761808				2023-01-03	WOS:000076294800007
J	Hulley, S; Grady, D; Bush, T; Furberg, C; Herrington, D; Riggs, B; Vittinghoff, E				Hulley, S; Grady, D; Bush, T; Furberg, C; Herrington, D; Riggs, B; Vittinghoff, E		HERS	Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; ACUTE MYOCARDIAL-INFARCTION; VENOUS THROMBOEMBOLISM; RISK; USERS; MORTALITY; HYPERCHOLESTEROLEMIA; CHOLESTEROL; ASSOCIATION; PRAVASTATIN	Context. - Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials. Objective. - To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease. Design. - Randomized, blinded, placebo-controlled secondary prevention trial. Setting. - Outpatient and community settings at 20 US clinical centers. Participants. - A total of 2763 women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus, Mean age was 66.7 years. Intervention. - Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in I tablet daily (n = 1380) or a placebo of identical appearance (n = 1383), Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years. Main Outcome Measures. - The primary outcome was the occurrence of nonfatal myocardial infarction (MI) or CHD death. Secondary cardiovascular outcomes included coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke or transient ischemic attack, and peripheral arterial disease. All-cause mortality was also considered. Results. - Overall, there were no significant differences between groups in the primary outcome or in any of the secondary cardiovascular outcomes: 172 women in the hormone group and 176 women in the placebo group had MI or CHD death (relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22), The lack of an overall effect occurred despite a net 11% lower low-density lipoprotein cholesterol level and 10% higher high-density lipoprotein cholesterol level in the hormone group compared with the placebo group (each P < .001). Within the overall null effect, there was a statistically significant time trend, with more CHD events in the hormone group than in the placebo group in year 1 and fewer in years 4 and 5, More women in the hormone group than in the placebo group experienced venous thromboembolic events (34 vs 12; RH, 2.89; 95% CI, 1.50-5.58) and gallbladder disease (84 vs 62; RH, 1.38; 95% CI, 1.00-1.92), There were no significant differences in several other end points for which power was limited, including fracture, cancer, and total mortality (131 vs 123 deaths; RH, 1.08; 95% CI, 0.84-1.38). Conclusions. - During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events and gallbladder disease. Based on the finding of no overall cardiovascular benefit and a pattern of early increase in risk of CHD events, we do not recommend starting this treatment for the purpose of secondary prevention of CHD. However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Johns Hopkins Univ, Baltimore, MD USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Wyeth Ayerst Res, Radnor, PA USA	University of California System; University of California San Francisco; Johns Hopkins University; Wake Forest University; Pfizer	Hulley, S (corresponding author), Univ Calif San Francisco, Box 0886, San Francisco, CA 94143 USA.							Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; [Anonymous], 1970, JAMA, V214, P1303; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Guetta V, 1996, CIRCULATION, V93, P1928, DOI 10.1161/01.CIR.93.10.1928; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Herrington DM, 1998, AM HEART J, V136, P115, DOI 10.1016/S0002-8703(98)70191-7; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; LAN KKG, 1984, COMMUN STAT-THEOR M, V13, P2339, DOI 10.1080/03610928408828830; MANN RD, 1994, J CLIN EPIDEMIOL, V47, P307, DOI 10.1016/0895-4356(94)90014-0; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McCrohon JA, 1996, CLIN ENDOCRINOL, V45, P435, DOI 10.1046/j.1365-2265.1996.8070816.x; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Newton KM, 1997, AM J EPIDEMIOL, V145, P269; OBrien JE, 1996, J AM COLL CARDIOL, V28, P1111, DOI 10.1016/S0735-1097(96)00306-3; OKeefe JH, 1997, J AM COLL CARDIOL, V29, P1; PEPI Trial, 1995, JAMA-J AM MED ASSOC, V274, P1676; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; RAUTAHARJU PM, 1992, J ELECTROCARDIOL, V24, P179; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Rossouw JE, 1996, CIRCULATION, V94, P2982, DOI 10.1161/01.CIR.94.11.2982; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAMAAN SA, 1995, J AM COLL CARDIOL, V26, P1403, DOI 10.1016/0735-1097(95)00360-6; SARREL PM, 1995, MENOPAUSE, V2, P187, DOI 10.1097/00042192-199502040-00001; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; Sullivan JM, 1997, AM J CARDIOL, V79, P847, DOI 10.1016/S0002-9149(97)00001-5; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8	56	4679	4834	1	213	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					605	613		10.1001/jama.280.7.605	http://dx.doi.org/10.1001/jama.280.7.605			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718051	Bronze			2023-01-03	WOS:000075384300028
J	Schnitzer, JE				Schnitzer, JE			Vascular targeting as a strategy for cancer therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOLID TUMORS		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Schnitzer, JE (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; SCHNITZER JE, 1997, VASCULAR ENDOTHELIUM, V3, P77	7	72	78	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					472	474		10.1056/NEJM199808133390711	http://dx.doi.org/10.1056/NEJM199808133390711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700184				2023-01-03	WOS:000075342500011
J	Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V				Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V		SAGE Study Grp	Management of pain in elderly patients with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME; GERIATRIC PAIN; PREVALENCE; RELIEF; ETHNICITY; RESIDENTS; PROGRAM; HOSPICE; SAMPLE; CARE	Context.-Cancer pain can be relieved with pharmacological agents as indicated by the World Health Organization (WHO). All too frequently pain management is reported to be poor. Objective.-To evaluate the adequacy of pain management in elderly and minority cancer patients admitted to nursing homes. Design.-Retrospective, cross-sectional study. Setting.-A total of 1492 Medicare-certified and/or Medicaid-certified nursing homes in 5 states participating in the Health Care Financing Administration's demonstration project, which evaluated the implementation of the Resident Assessment Instrument and its Minimum Data Set. Study Population.-A group of 13 625 cancer patients aged 65 years and older discharged from the hospital to any of the facilities from 1992 to 1995, Data were from the multilinked Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Main Outcome Measure.-Prevalence and predictors of daily pain and of analgesic treatment. Pain assessment was based on patients' report and was completed by a multidisciplinary team of nursing home personnel that observed, over a 7-day period, whether each resident complained or showed evidence of pain daily. Results.-A total of 4003 patients (24%, 29%, and 38% of those aged greater than or equal to 85 years, 75 to 84 years, and 65 to 74 years, respectively) reported daily pain. Age, gender, race, marital status, physical function, depression, and cognitive status were all independently associated with the presence of pain. Of patients with daily pain, 16% received a WHO level 1 drug, 32% a WHO level 2 drug, and only 26% received morphine. Patients aged 85 years and older were less likely to receive either weak opiates or morphine than those aged 65 to 74 years (13% vs 38%, respectively). More than a quarter of patients (26%) in daily pain did not receive any analgesic agent. Patients older than 85 years in daily pain were also more likely to receive no analgesia (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.13-1.73), Other independent predictors of failing to receive any analgesic agent were minority race (OR, 1.63; 95% CI, 1.18-2.26 for African Americans), low cognitive performance (OR, 1.23; 95% CI, 1.05-1.44), and the number of other medications received (Oc, 0.65; 95% CI, 0.5-0.84 for 11 or more medications). Conclusions.-Daily pain is prevalent among nursing home residents with cancer and is often untreated, particularly among older and minority patients.	Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA; Univ Cattolica Sacro Cuore, Ist Med Interna & Geriatria, Rome, Italy; St Christophers Hospice, London, England; Harvard Univ, Sch Med, Hebrew Rehabil Ctr Aged, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Hackensack, NJ USA; Hackensack Univ Med Ctr, Homecare Inst, Hackensack, NJ USA	Brown University; Brown University; Brown University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Harvard University; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Hackensack University Medical Center	Gambassi, G (corresponding author), Brown Univ, Ctr Gerontol & Hlth Care Res, Box G-B213, Providence, RI 02912 USA.	Giovanni_Gambassi@brown.edu	Bernabei, Roberto/AAB-2704-2019	Bernabei, Roberto/0000-0002-9197-004X	PHS HHS [17C90428] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ball JK, 1996, MED CARE, V34, P970, DOI 10.1097/00005650-199609000-00008; Bernabei R, 1998, J AM GERIATR SOC, V46, P251, DOI 10.1111/j.1532-5415.1998.tb02553.x; BERNABEI R, IN PRESS J GERONTOL; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COHENMANSFIELD J, 1993, J GERONTOL, V48, pP96, DOI 10.1093/geronj/48.2.P96; CORRAN TM, 1994, PROG PAIN RES MANAG, V2, P895; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Elliott TE, 1997, J PAIN SYMPTOM MANAG, V13, P191, DOI 10.1016/S0885-3924(96)00275-8; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; Fisher-Morris M, 1997, AGE AGEING, V26, P497, DOI 10.1093/ageing/26.6.497; FOLEY KM, 1995, J CLIN ONCOL, V13, P2149, DOI 10.1200/JCO.1995.13.9.2149; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; GOLDBERG RJ, 1986, J CHRON DIS, V39, P37, DOI 10.1016/0021-9681(86)90105-0; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; HIGGINSON I, 1994, SOC SCI MED, V38, P553, DOI 10.1016/0277-9536(94)90251-8; *I MED, 1997, APPR DEATH IMPR CAR, P51; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KWENTUS JA, 1985, GERIATRICS, V40, P48; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lindesay J, 1997, INT J GERIATR PSYCH, V12, P344, DOI 10.1002/(SICI)1099-1166(199703)12:3<344::AID-GPS504>3.0.CO;2-I; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; MELDING PS, 1991, PAIN, V46, P119, DOI 10.1016/0304-3959(91)90064-5; Mogil JS, 1997, PAIN, V70, P267, DOI 10.1016/S0304-3959(97)03333-2; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; PORTENOY RK, 1994, CANCER-AM CANCER SOC, V74, P907, DOI 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-#; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; PORTENOY RK, 1992, ONCOLOGY, V2, P86; Porter FL, 1996, PAIN, V68, P413, DOI 10.1016/S0304-3959(96)03210-1; Repetto L, 1998, CANCER, V82, P760, DOI 10.1002/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.0.CO;2-V; Rischer JB, 1996, JOINT COMM J QUAL IM, V22, P683, DOI 10.1016/S1070-3241(16)30275-9; SAS, 2003, US GUID STAT; SCHECHTERN L, 1989, PEDIATR CLIN N AM, V36, P631; Scherder EJA, 1997, ALZ DIS ASSOC DIS, V11, P171, DOI 10.1097/00002093-199709000-00010; Schroll M, 1997, LANCET, V350, P604, DOI 10.1016/S0140-6736(05)63321-1; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41, P541, DOI 10.1111/j.1532-5415.1993.tb01892.x; SHAUGHNESSY PW, 1990, NEW ENGL J MED, V322, P21, DOI 10.1056/NEJM199001043220105; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; STEIN WM, 1993, J PAIN SYMPTOM MANAG, V8, P474, DOI 10.1016/0885-3924(93)90190-7; STJERNSWARD J, 1988, CANCER SURV, V7, P195; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Vallerand A H, 1997, Semin Oncol Nurs, V13, P16, DOI 10.1016/S0749-2081(97)80045-9; Yeager K A, 1997, Cancer Pract, V5, P39; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 1991, MINIMUM DATA SET PLU	57	759	776	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1877	1882		10.1001/jama.279.23.1877	http://dx.doi.org/10.1001/jama.279.23.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634258	Bronze			2023-01-03	WOS:000074109700034
J	Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S				Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S			Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies	BRITISH MEDICAL JOURNAL			English	Article									Huddinge Univ Hosp, Karolinska Inst, Dept Clin Pharmacol, Med Pharmacoepidemiol Unit, S-14186 Huddinge, Sweden; Boston Univ, Sch Med, Slone Epidemiol Unit, Brookline, MA 02146 USA; Mahidol Univ, Bangkok 10700, Thailand; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	Karolinska Institutet; Boston University; Mahidol University; Hebrew University of Jerusalem	Wiholm, BE (corresponding author), Med Prod Agcy, POB 26, S-75103 Uppsala, Sweden.			Issaragrisil, Surapol/0000-0002-8924-0646; Kaufman, David/0000-0002-2150-5070	NHLBI NIH HHS [R01-HL35068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035068] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; Issaragrisil S, 1997, BLOOD, V89, P4034; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643	4	28	29	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					666	666		10.1136/bmj.316.7132.666	http://dx.doi.org/10.1136/bmj.316.7132.666			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522791	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000072347900030
J	Kern, WV; Cometta, A; de Rock, R; Langenaeken, J; Paesmans, M; Gaya, H				Kern, WV; Cometta, A; de Rock, R; Langenaeken, J; Paesmans, M; Gaya, H		European Org Res Treatment Canc	Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEBRILE NEUTROPENIC PATIENTS; CEFTAZIDIME PLUS AMIKACIN; EARLY HOSPITAL DISCHARGE; 400 MG IV; LOW-RISK; ANTIBIOTIC-THERAPY; CLINICAL-TRIALS; COMPARATIVE PHARMACOKINETICS; ESCHERICHIA-COLI; RANDOMIZED TRIAL	Background Intravenously administered antimicrobial agents have been the standard choice for the empirical management of fever in patients with cancer and granulocytopenia. If orally administered empirical therapy is as effective as intravenous therapy, it would offer advantages such as improved quality of life and lower cost. Methods In a prospective, open-label, multicenter trial, we randomly assigned febrile patients with cancer who had granulocytopenia that was expected to resolve within 10 days to receive empirical therapy with either oral ciprofloxacin (750 mg twice daily) plus amoxicillin-clavulanate (625 mg three times daily) or standard daily doses of intravenous ceftriaxone plus amikacin. All patients were hospitalized until their fever resolved. The primary objective of the study was to determine whether there was equivalence between the regimens, defined as an absolute difference in the rates of success of 10 percent or less. Results Equivalence was demonstrated at the second interim analysis, and the trial was terminated after the enrollment of 353 patients. In the analysis of the 312 patients who were treated according to the protocol and who could be evaluated, treatment was successful in 86 percent of the patients in the oral-therapy group (95 percent confidence interval, 80 to 91 percent) and 84 percent of those in the intravenous-therapy group (95 percent confidence interval, 78 to 90 percent; P=0.02). The results were similar in the intention-to-treat analysis (80 percent and 77 percent, respectively; P=0.03), as were the duration of fever, the time to a change in the regimen, the reasons for such a change, the duration of therapy, and survival. The types of adverse events differed slightly between the groups but were similar in frequency. Conclusions In low-risk patients with cancer who have fever and granulocytopenia, oral therapy with ciprofloxacin plus amoxicillin-clavulanate is as effective as intravenous therapy. (N Engl J Med 1999; 341:312-8.) (C) 1999, Massachusetts Medical Society.	Univ Ulm, Med Klin & Poliklin, Sekt Infect & Klin Immunol, D-89070 Ulm, Germany; CHU Vaudois, CH-1011 Lausanne, Switzerland; Allgemeen Ziekenhuis Middleheim, Antwerp, Belgium; Inst Jules Bordet, B-1000 Brussels, Belgium; Royal Brompton Hosp, London SW3 6LY, England; Patras Univ Hosp, Patras, Greece; Brown Univ, Providence, RI 02912 USA; Natl Inst Canc Res, Genoa, Italy; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; Kingston Reg Canc Ctr, Kingston, ON, Canada	Ulm University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Institut Jules Bordet; Royal Brompton Hospital; University of Patras; Brown University; University of Genoa; IRCCS AOU San Martino IST; Hebrew University of Jerusalem	Kern, WV (corresponding author), Univ Ulm, Med Klin & Poliklin, Sekt Infect & Klin Immunol, D-89070 Ulm, Germany.	winfried.kern@medizin.uni-ulm.de	Calandra, Thierry/D-9017-2015; Sanz, Miguel/F-7485-2018	Calandra, Thierry/0000-0003-3051-1285; Sanz, Miguel/0000-0003-1489-1177				Ball P, 1997, J CHEMOTHERAPY, V9, P167, DOI 10.1179/joc.1997.9.3.167; BASH RO, 1994, CANCER, V74, P189, DOI 10.1002/1097-0142(19940701)74:1<189::AID-CNCR2820740130>3.0.CO;2-7; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRUNIER H, 1993, PEST 3 PLANNING EVAL; CALANDRA T, 1993, ANN INTERN MED, V119, P584, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00006; CATCHPOLE C, 1994, J ANTIMICROB CHEMOTH, V33, P103, DOI 10.1093/jac/33.1.103; COMETTA A, 1994, NEW ENGL J MED, V330, P1240, DOI 10.1056/NEJM199404283301717; COMETTA A, 1995, ANTIMICROB AGENTS CH, V39, P445, DOI 10.1128/AAC.39.2.445; Cometta AF, 1996, ANTIMICROB AGENTS CH, V40, P1108, DOI 10.1128/AAC.40.5.1108; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; Elting LS, 1997, CLIN INFECT DIS, V25, P247, DOI 10.1086/514550; GARDEMBASPAIN M, 1991, ANN ONCOL, V2, P485, DOI 10.1093/oxfordjournals.annonc.a057996; Hann I, 1997, BRIT J HAEMATOL, V99, P580, DOI 10.1046/j.1365-2141.1997.4453255.x; Hidalgo M, 1999, CANCER, V85, P213, DOI 10.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.3.CO;2-4; Horowitz HW, 1996, LEUKEMIA LYMPHOMA, V23, P159, DOI 10.3109/10428199609054816; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; HUGHES WT, 1990, J INFECT DIS, V161, P1316; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P681, DOI 10.1128/AAC.38.4.681; LAN KKG, 1989, BIOMETRICS, V45, P1017, DOI 10.2307/2531701; LAN KKG, 1993, STAT MED, V12, P753, DOI 10.1002/sim.4780120804; LIM SH, 1990, BRIT J HAEMATOL, V76, P41, DOI 10.1111/j.1365-2141.1990.tb07935.x; Lucas KG, 1996, CANCER, V77, P791, DOI 10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.3.CO;2-B; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MALIK IA, 1992, LANCET, V339, P1092, DOI 10.1016/0140-6736(92)90674-R; MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2; MEROPOL NJ, 1994, EUR J CANCER, V30A, P1595, DOI 10.1016/0959-8049(94)90069-8; MEUNIER F, 1991, ANTIMICROB AGENTS CH, V35, P873, DOI 10.1128/AAC.35.5.873; MULLEN CA, 1990, J CLIN ONCOL, V8, P1998, DOI 10.1200/JCO.1990.8.12.1998; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P142; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; ROSSINI F, 1994, SUPPORT CARE CANCER, V2, P259, DOI 10.1007/BF00365733; RUBENSTEIN EB, 1993, CANCER-AM CANCER SOC, V71, P3640, DOI 10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H; RUBIN M, 1988, CANCER INVEST, V6, P167, DOI 10.3109/07357908809077045; SHAH A, 1994, J ANTIMICROB CHEMOTH, V33, P795, DOI 10.1093/jac/33.4.795; TALCOTT JA, 1994, J CLIN ONCOL, V12, P107, DOI 10.1200/JCO.1994.12.1.107; TALCOTT JA, 1992, J CLIN ONCOL, V10, P316, DOI 10.1200/JCO.1992.10.2.316; VELASCO E, 1995, AM J CLIN ONCOL-CANC, V18, P429, DOI 10.1097/00000421-199510000-00014	39	251	260	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					312	318		10.1056/NEJM199907293410502	http://dx.doi.org/10.1056/NEJM199907293410502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423465	Bronze			2023-01-03	WOS:000081666900002
J	Bendor, R				Bendor, R			Arthritis and I	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					150	152		10.7326/0003-4819-131-2-199907200-00015	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419434				2023-01-03	WOS:000081509700013
J	Grant, IS; Andrews, PJD				Grant, IS; Andrews, PJD			ABC of intensive care - Neurological support	BRITISH MEDICAL JOURNAL			English	Article									Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Grant, IS (corresponding author), Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.								0	6	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					110	113		10.1136/bmj.319.7202.110	http://dx.doi.org/10.1136/bmj.319.7202.110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398640	Green Published			2023-01-03	WOS:000081438200039
J	Remuzzi, G; Schieppati, A				Remuzzi, G; Schieppati, A			Lessons from the Di Bella affair	LANCET			English	Editorial Material									Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Ballmaier M, 1998, NAT MED, V4, P258, DOI 10.1038/nm0398-258b; Raschetti R, 1999, BRIT MED J, V318, P224; Simini B, 1998, LANCET, V351, P428, DOI 10.1016/S0140-6736(05)78379-3; 1998, SCRIP, V2329, P6; 1998, NATURE, V392, P421	5	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1289	1290		10.1016/S0140-6736(99)90044-2	http://dx.doi.org/10.1016/S0140-6736(99)90044-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218523				2023-01-03	WOS:000080278100005
J	O'Donnell, CA; McConnachie, A; Moffat, K; Drummond, N; Wilson, P; Ross, S				O'Donnell, CA; McConnachie, A; Moffat, K; Drummond, N; Wilson, P; Ross, S			Cross sectional study of social variation in use of an out of hours patient transport service	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland; Univ Glasgow, Publ Hlth Res Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow	O'Donnell, CA (corresponding author), Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland.			O'Donnell, Kate/0000-0002-5368-3779				Carlisle R, 1998, BRIT MED J, V316, P520, DOI 10.1136/bmj.316.7130.520; Carstairs V., 1991, DEPRIVATION HLTH SCO; Hallam L, 1997, BMJ-BRIT MED J, V314, P157, DOI 10.1136/bmj.314.7075.157; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; [No title captured]	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					566	567		10.1136/bmj.318.7183.566	http://dx.doi.org/10.1136/bmj.318.7183.566			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037631	Green Published			2023-01-03	WOS:000078966300026
J	Schneider, MME; Borleffs, JCC; Stolk, RP; Jaspers, CAJJ; Hoepelman, AIM				Schneider, MME; Borleffs, JCC; Stolk, RP; Jaspers, CAJJ; Hoepelman, AIM			Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE; INFECTION; AIDS	Background Prophylactic drugs for Pneumocystis carinii pneumonia (PCP) are strongly recommended for HIV-1-infected patients with CD4 cell counts of less than 200 cells/mu L. Because of the highly active antiretroviral therapy (HAART) currently available, we speculated that prophylaxis can be discontinued in patients with CD4 cell counts of more than 200 cells/mu L. Methods In this prospective observational study, PCP prophylaxis (primary or secondary) was discontinued in HIV-1-infected patients whose CD4 cell count had increased above 200 cells/mu L (documented twice with an interval of at least 1 month) as a result of HAART. Patients and their CD4 cell counts were monitored every 3 months. The primary endpoint of the study was the occurrence or reoccurrence of PCP. Findings 78 patients were enrolled: 62 patients were receiving prophylaxis for primary prevention of PCP and 16 patients for secondary prevention of PCP. At the time of discontinuation of prophylaxis, the mean CD4 cell count was 347 cells/mu L, and HIV-1-RNA was not detectable in 61 patients. The lowest mean CD4 cell count during prophylaxis was 79 cells/mu L. Patients stopped prophylaxis 9.8 (SD 6.4) months after they started HAART, The mean follow-up after discontinuation of prophylaxis was 12.7 (SD 7.6) months, and none of the patients developed PCP (97.5% one-sided CI 0-4.4%). Interpretation The preliminary results of this study indicate that PCP prophylaxis can be stopped safely in HIV-1-infected patients whose CD4 cell counts have increased above 200 cells/mu L after treatment with HAART.	Univ Utrecht Hosp, Dept Internal Med, Div Infect Dis & AIDS, NL-3508 GA Utrecht, Netherlands; Univ Utrecht Hosp, Eijkman Winkler Inst, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	Schneider, MME (corresponding author), Univ Utrecht Hosp, Dept Internal Med, Div Infect Dis & AIDS, POB 85500, NL-3508 GA Utrecht, Netherlands.		Stolk, Ronald P/B-2341-2013	Stolk, Ronald P/0000-0002-0518-1205				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MOORE RD, 1998, 5 C RETR OPP INF CHI, P184; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; ROWE PM, 1998, LANCET, V350, P720; SCHNEIDER MME, 1995, J INFECT DIS, V171, P1632, DOI 10.1093/infdis/171.6.1632; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; *USPHS IDSA PREV O, 1997, MMWR-MORBID MORTAL W, V46, P1; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519	19	136	140	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 16	1999	353	9148					201	203		10.1016/S0140-6736(98)07204-3	http://dx.doi.org/10.1016/S0140-6736(98)07204-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159LW	9923876				2023-01-03	WOS:000078175600013
J	Chang, CCY; Lee, CYG; Chang, ET; Cruz, JC; Levesque, MC; Chang, TY				Chang, CCY; Lee, CYG; Chang, ET; Cruz, JC; Levesque, MC; Chang, TY			Recombinant acyl-CoA : cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-KINASE-C; BILIARY LIPID SYSTEMS; COENZYME-A; RADIATION INACTIVATION; MOLECULAR-CLONING; APOLIPOPROTEIN-B; RECONSTITUTION; LIPOSOMES; ENZYMES	Acyl-coenzyme A:cholesterol acyltransferase (ACAT) is an integral membrane protein located in the endoplasmic reticulum. It catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty acyl coenzyme A. The first gene encoding the enzyme, designated as ACAT-I, was identified in 1993 through an expression cloning approach, We isolated a Chinese hamster ovary cell line that stably expresses the recombinant human ACAT-1 protein bearing an N-terminal hexahistidine tag. We purified this enzyme approximately 7000-fold from crude cell extracts by first solubilizing the cell membranes with the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, then proceeding with an ACAT-1 monoclonal antibody affinity column and an immobilized metal affinity column. The final preparation is enzymologically active and migrates as a single band at 54 kDa on SDS-polyacrylamide gel electrophoresis. Pure ACAT-1 dispersed in mixed micelles containing sodium taurocholate, phosphatidylcholine, and cholesterol remains catalytically active. The cholesterol substrate saturation curves of the enzyme assayed either in mixed micelles or in reconstituted vesicles are both highly sigmoidal. The oleoyl-coenzyme A substrate saturation curves of the enzyme assayed under the same conditions are both hyperbolic. These results support the hypothesis that ACAT is an allosteric enzyme regulated by cholesterol.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ British Columbia, Dept Obstet & Gynecol, Androl Lab, Vancouver, BC V6T 2B5, Canada	Dartmouth College; University of British Columbia	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.		Chang, Ellen/E-3168-2010; Chang, Ellen/G-5700-2010	Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306, R01HL036709, R37HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60306, HL 36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; CABRAL DJ, 1989, HDB PHYSL 6, V3, P621; CADIGAN KM, 1988, J LIPID RES, V29, P1683; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CAREY MC, 1978, J CLIN INVEST, V61, P998, DOI 10.1172/JCI109025; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARR TP, 1995, J LIPID RES, V36, P25; CASES S, 1997, CIRCULATION S1, V96, P230; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHANG TY, 1983, ENZYMES, V16, P523; DAVIS JM, 1982, J IMMUNOL METHODS, V50, P161, DOI 10.1016/0022-1759(82)90222-8; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; ERICKSON SK, 1994, J LIPID RES, V35, P763; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HASAN MT, 1991, SOMAT CELL MOLEC GEN, V17, P513, DOI 10.1007/BF01233175; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; Lee O, 1998, J LIPID RES, V39, P1722; MATHUR SN, 1983, BIOCHIM BIOPHYS ACTA, V751, P401, DOI 10.1016/0005-2760(83)90299-0; MAZER NA, 1983, BIOCHEMISTRY-US, V22, P426, DOI 10.1021/bi00271a029; MAZER NA, 1980, BIOCHEMISTRY-US, V19, P601, DOI 10.1021/bi00545a001; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Meiner VL, 1998, J BIOL CHEM, V273, P1064, DOI 10.1074/jbc.273.2.1064; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; MUKHERJEE S, 1958, J BIOL CHEM, V230, P91; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SHI SP, 1989, BIOCHIM BIOPHYS ACTA, V982, P187, DOI 10.1016/0005-2736(89)90054-0; STANGE EF, 1985, CHOLESTEROL ABSORPTI, P121; STURLEY SL, 1997, CIRCULATION S1, V96, P411; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TANAKA M, 1993, J BIOL CHEM, V268, P12713; VENTIMIGLIA JB, 1986, ANAL BIOCHEM, V157, P323, DOI 10.1016/0003-2697(86)90633-0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON MD, 1994, J LIPID RES, V35, P943; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	47	103	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					35132	35141		10.1074/jbc.273.52.35132	http://dx.doi.org/10.1074/jbc.273.52.35132			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857049	hybrid			2023-01-03	WOS:000077719700067
J	Heyland, DK; MacDonald, S; Keefe, L; Drover, JW				Heyland, DK; MacDonald, S; Keefe, L; Drover, JW			Total parenteral nutrition in the critically ill patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE RANDOMIZED TRIAL; THERMALLY INJURED PATIENTS; CLINICAL-TRIALS; POSTOPERATIVE PERIOD; ABDOMINAL-SURGERY; SEPTIC MORBIDITY; MAJOR SURGERY; AMINO-ACIDS; SUPPORT; CARCINOMA	Context.-Nutritional support has become a standard of care for hospitalized patients, but whether total parenteral nutrition (TPN) affects morbidity and mortality is unclear. Objective.-To examine the relationship between TPN and complication and mortality rates in critically ill patients. Data Sources.-Computerized search of published research on MEDLINE from 1980 to 1998, personal files, and review of relevant reference lists. Study Selection.-We reviewed 210 titles, abstracts, and papers. Primary studies were included if they were randomized clinical trials of critically ill or surgical patients that evaluated the effect of TPN (compared with standard care) on complication and mortality rates. We excluded studies comparing TPN with enteral nutrition. Data Extraction.-Relevant data were abstracted on the methodology and outcomes of primary studies. Data were abstracted in duplicate, independently. Data Synthesis.-There were 26 randomized trials of 2211 patients comparing the use of TPN with standard care (usual oral diet plus intravenous dextrose) in surgical and critically ill patients. When the results of these trials were aggregated, TPN had no effect on mortality (risk ratio [RR], 1.03; 95% confidence interval [CI], 0.81-1.31). Patients who received TPN tended to have a lower complication rate, but this result was not statistically significant (RR, 0.84; 95% CI, 0.64-1.09), We examined several a priori hypotheses and found that studies including only malnourished patients were associated with lower complication rates but no difference in mortality when compared with studies of nonmalnourished patients, Studies published since 1989 and studies with a higher methods score showed no treatment effect, while studies published in 1988 or before and studies with a lower methods score demonstrated a significant treatment effect. Complication rates were lower in studies that did not use lipids; however, there was no difference in mortality rates between studies that did not use lipids and those studies that did, Studies limited to critically ill patients demonstrated a significant increase in complication and mortality rates compared with studies of surgical patients. Conclusions.-Total parenteral nutrition does not influence the overall mortality rate of surgical or critically ill patients. It may reduce the complication rate, especially in malnourished patients, but study results are influenced by patient population, use of lipids, methodological quality, and year of publication.	Kingston Gen Hosp, Nutr Serv, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Surg, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Heyland, DK (corresponding author), Kingston Gen Hosp, Nutr Serv, 76 Stuart St,Angada 3, Kingston, ON K7L 2V7, Canada.	dkh@post.queensu.ca						ABEL RM, 1976, ARCH SURG-CHICAGO, V111, P45; ASKANAZI J, 1986, ANN SURG, V203, P236, DOI 10.1097/00000658-198603000-00002; *ASPEN BOARD DIR, 1993, JPEN J PARENTER EN S, V17; BASTTISTELLA ED, 1997, J TRAUMA, V43, P52; BEALE RJ, 1997, INTENSIVE CARE ME S1, V23, P5128; BELLANTONE R, 1988, ACTA CHIR SCAND, V154, P249; BELLANTONE R, 1988, JPEN-PARENTER ENTER, V12, P195, DOI 10.1177/0148607188012002195; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BONAU RA, 1984, JPEN-PARENTER ENTER, V8, P622, DOI 10.1177/0148607184008006622; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; BOWER RH, 1986, ANN SURG, V203, P13, DOI 10.1097/00000658-198601000-00003; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; BROWN RO, 1990, CRIT CARE MED, V18, P1096, DOI 10.1097/00003246-199010000-00009; BUCHMAN AL, 1995, JPEN-PARENTER ENTER, V19, P453, DOI 10.1177/0148607195019006453; Cerra FB, 1997, CHEST, V111, P769, DOI 10.1378/chest.111.3.769; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; Chiarelli A G, 1996, Minerva Anestesiol, V62, P1; COLLINS JP, 1978, LANCET, V1, P788; CULEBRASFERNANDEZ JM, 1987, INFUS KLIN ERN, V14, P202; DEITCH EA, 1987, ANN SURG, V205, P681, DOI 10.1097/00000658-198706000-00010; DEMPSEY DT, 1988, AM J CLIN NUTR, V47, P352, DOI 10.1093/ajcn/47.2.352; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; Doglietto GB, 1996, ANN SURG, V223, P357, DOI 10.1097/00000658-199604000-00003; FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303; FAN ST, 1989, CLIN NUTR, V8, P23, DOI 10.1016/0261-5614(89)90021-6; FIGUERAS J, 1988, ACTA CHIR SCAND, V154, P435; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; FORD WDA, 1984, SURGERY, V96, P527; FREEMAN J, 1990, NEW ENGL J MED, V323, P301, DOI 10.1056/NEJM199008023230504; FREUND H, 1979, ANN SURG, V190, P18, DOI 10.1097/00000658-197907000-00004; GARDEN OJ, 1983, BRIT J SURG, V70, P79, DOI 10.1002/bjs.1800700208; GYS T, 1990, ACTA CHIR BELG, P234; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; HANSELL DT, 1989, JPEN-PARENTER ENTER, V13, P349, DOI 10.1177/0148607189013004349; HEATLEY RV, 1979, POSTGRAD MED J, V55, P541, DOI 10.1136/pgmj.55.646.541; HENSLE TW, 1978, J UROLOGY, V119, P355, DOI 10.1016/S0022-5347(17)57489-3; Herndon D N, 1989, J Burn Care Rehabil, V10, P309, DOI 10.1097/00004630-198907000-00004; HERNDON DN, 1987, J TRAUMA, V27, P195, DOI 10.1097/00005373-198702000-00018; HEYLAND DK, 1993, INTENS CARE MED, V19, P435, DOI 10.1007/BF01711083; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; HOGBIN BM, 1984, JPEN-PARENTER ENTER, V8, P511, DOI 10.1177/0148607184008005511; HOLTER AR, 1977, J SURG RES, V23, P31, DOI 10.1016/0022-4804(77)90186-X; HUGHES CA, 1980, CLIN SCI, V59, P317, DOI 10.1042/cs0590317; HWANG TL, 1993, JPEN-PARENTER ENTER, V17, P254, DOI 10.1177/0148607193017003254; JENSEN S, 1985, MED ONCOL TUMOR PHAR, V2, P225; JIMENEZ FJJ, 1995, CLIN NUTR, V14, P88, DOI 10.1016/S0261-5614(95)80028-X; KORETZ RL, 1995, AM J RESP CRIT CARE, V151, P570, DOI 10.1164/ajrccm.151.2.7842222; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; LEVINE GM, 1974, GASTROENTEROLOGY, V67, P975; LO CW, 1989, NUTR REV, V47, P193, DOI 10.1111/j.1753-4887.1989.tb02837.x; MEGUID MM, 1988, BRIT J CLIN PRACT, V42, P53; MEZEY E, 1991, HEPATOLOGY, V14, P1090, DOI 10.1002/hep.1840140624; MOGHISSI K, 1977, BRIT J SURG, V64, P125, DOI 10.1002/bjs.1800640211; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MULLER JM, 1986, WORLD J SURG, V10, P53; MULLER JM, 1982, LANCET, V1, P68; NAYLOR AF, 1967, BIOMETRICS, V23, P349, DOI 10.2307/2528167; NEUVONEN P, 1986, JPEN-PARENTER ENTER, V10, P160, DOI 10.1177/0148607186010002160; NORDENSTROM J, 1979, AM J CLIN NUTR, V32, P2416, DOI 10.1093/ajcn/32.12.2416; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PRESHAW RM, 1979, CAN J SURG, V22, P437; REILLY J, 1990, JPEN-PARENTER ENTER, V14, P386, DOI 10.1177/0148607190014004386; ROTHMAN JR, 1986, MODERN EPIDEMIOLOGY, P177; ROTHMAN KJ, 1979, EPIDEMIOLOGICAL ANAL; SACKS HS, 1983, NEW ENGL J MED, V309, P1353; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; SCHROEDER D, 1981, JPEN J PARENTER ENTE, V15, P376; SEIDNER DL, 1989, JPEN-PARENTER ENTER, V13, P614, DOI 10.1177/0148607189013006614; SIMMS JM, 1980, JPEN, V4, P422; SMITH RC, 1988, JPEN-PARENTER ENTER, V12, P587, DOI 10.1177/0148607188012006587; THOMPSON BR, 1981, J SURG RES, V30, P497, DOI 10.1016/0022-4804(81)90096-2; VENTE JP, 1991, WORLD J SURG, V15, P128, DOI 10.1007/BF01658984; VONMEYENFELDT MF, 1992, CLIN NUTR, V11, P180, DOI 10.1016/0261-5614(92)90026-M; WARNOLD I, 1984, ANN SURG, V199, P299, DOI 10.1097/00000658-198403000-00009; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; WOOLFSON AMJ, 1989, CLIN NUTR, V8, P15, DOI 10.1016/0261-5614(89)90020-4; YAMADA N, 1983, BRIT J SURG, V70, P267, DOI 10.1002/bjs.1800700508	81	365	376	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1998	280	23					2013	2019		10.1001/jama.280.23.2013	http://dx.doi.org/10.1001/jama.280.23.2013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146YW	9863853				2023-01-03	WOS:000077462300032
J	Hinkovska-Galcheva, VT; Boxer, LA; Mansfield, PJ; Harsh, D; Blackwood, A; Shayman, JA				Hinkovska-Galcheva, VT; Boxer, LA; Mansfield, PJ; Harsh, D; Blackwood, A; Shayman, JA			The formation of ceramide-1-phosphate during neutrophil phagocytosis and its role in liposome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IGG-DEPENDENT PHAGOCYTOSIS; LEUKEMIA HL-60 CELLS; MEMBRANE-FUSION; PHOSPHOLIPASE-D; DIACYLGLYCEROL KINASE; CYCLE ARREST; CERAMIDE; SPHINGOSINE; AGGREGATION	Ceramide, a product of agonist-stimulated sphingomyelinase activation, is known to be generated during the phagocytosis of antibody-coated erythrocytes by polymorphonuclear leukocytes. Agonist-stimulated formation of ceramide-1-phosphate is now shown to occur in (PO4)-P-32-labeled neutrophils. Ceramide-1-phosphate is formed by a calcium-dependent ceramide kinase, found predominately in the neutrophil plasma membrane. The neutrophil kinase is specific for ceramide because, in contrast to the bacterial diglyceride kinase, ceramide is not phosphorylated under conditions specific for diglyceride phosphorylation, Conversely, 1,2-diacylglycerol does not serve as substrate for the neutrophil ceramide kinase, Ceramide kinase activation occurs in a time-dependent fashion, reaching peak activity 10 min after formyl peptide stimulation and challenge with antibody coated erythrocytes. The lipid kinase activity is optimal at pH 6.8. Because the formation of the phagolysosome is a critical event in phagocytosis, the effect of ceramide-1-phosphate in promoting the fusion of liposomes was determined. Both the addition of increasing concentrations of sphingomyelinase D and ceramide phosphate promoted liposomal fusion, In summary, ceramide-1-phosphate is formed during phagocytosis through activation of ceramide kinase. Ceramide-1-phosphate may promote phagolysosome formation.	Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, 1560 MSRBII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jshayman@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487, P50DK039255] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20065] Funding Source: Medline; NIDDK NIH HHS [DK39255, DK41487] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BOXER GJ, 1985, HOSP PRACT, V40, P69; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DUZGUNES N, 1987, BIOCHEMISTRY-US, V26, P8435, DOI 10.1021/bi00399a061; DUZGUNES N, 1981, BIOCHIM BIOPHYS ACTA, V642, P182, DOI 10.1016/0005-2736(81)90148-6; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FOREHAND JR, 1993, J IMMUNOL, V151, P4918; FRANCIS JW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P1, DOI 10.1016/0005-2736(90)90183-O; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HINKOVSKAGALCHE.V, 1998, BLOOD, V91, P1; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JOLLES J, 1981, BIOCHEM J, V194, P283, DOI 10.1042/bj1940283; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KANOH H, 1983, J BIOL CHEM, V258, P1767; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1994, CURR TOP MEMBR, V40, P361, DOI 10.1016/S0070-2161(08)60988-0; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; POMMIER CG, 1983, J EXP MED, V157, P1844, DOI 10.1084/jem.157.6.1844; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; Suchard SJ, 1997, J IMMUNOL, V158, P4961; SYNDERMAN R, 1988, INFLAMMATION BASIC P, P309; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; WOODIN AM, 1966, BIOCHEM J, V99, P493, DOI 10.1042/bj0990493	40	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33203	33209		10.1074/jbc.273.50.33203	http://dx.doi.org/10.1074/jbc.273.50.33203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837889	hybrid			2023-01-03	WOS:000077462500019
J	Partonen, T; Lonnqvist, J				Partonen, T; Lonnqvist, J			Seasonal affective disorder	LANCET			English	Article							NONSEASONAL MOOD DISORDERS; REST-ACTIVITY DISTURBANCES; EVENING LIGHT TREATMENT; CEREBRAL BLOOD-FLOW; WINTER DEPRESSION; FOLLOW-UP; BRIGHT-LIGHT; CIRCADIAN PHASE; MELATONIN SUPPRESSION; PERSONALITY-DISORDERS	Seasonal affective disorder (SAD) is a form of recurrent depressive or bipolar disorder, with episodes that vary in severity. Seasonal patterns of depressive episodes are common, but SAD seems to be less common than such patterns suggest. SAD was at first believed to be related to abnormal melatonin metabolism, but later findings did not support this hypothesis. Studies of brain serotonin function support the hypothesis of disturbed activity. The short-allele polymorphism for serotonin transporter is more common in patients with SAD than in healthy people. Atypical depressive symptoms commonly precede impaired functioning, and somatic symptoms are frequently the presenting complaint at visits to family physicians, The best treatment regimens include 2500 Ix of artificial light exposure in the morning. When patients seem to have no response or to prefer another treatment, antidepressants should be considered.	Univ Helsinki, Dept Psychiat, FIN-00300 Helsinki, Finland; Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, FIN-00300 Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare	Partonen, T (corresponding author), Univ Helsinki, Dept Psychiat, FIN-00300 Helsinki, Finland.	timo.partonen@ktl.fi	Partonen, Timo/G-1105-2012	Partonen, Timo/0000-0003-1951-2455				ALLEN JM, 1993, AM J PSYCHIAT, V150, P443; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSON JL, 1994, J PSYCHOSOM RES, V38, P323, DOI 10.1016/0022-3999(94)90037-X; Arbisi PA, 1996, PSYCHIAT RES, V59, P171, DOI 10.1016/0165-1781(95)02816-1; Avery DH, 1997, BIOL PSYCHIAT, V41, P1109, DOI 10.1016/S0006-3223(96)00210-7; BERMAN K, 1993, J AFFECT DISORDERS, V29, P219, DOI 10.1016/0165-0327(93)90011-8; Blacker CVR, 1997, J AFFECT DISORDERS, V43, P41, DOI 10.1016/S0165-0327(96)00102-4; Blazer DG, 1998, BRIT J PSYCHIAT, V172, P164, DOI 10.1192/bjp.172.2.164; BOOKER JM, 1992, AM J PSYCHIAT, V149, P1176; BOUHUYS AL, 1994, J AFFECT DISORDERS, V31, P39, DOI 10.1016/0165-0327(94)90125-2; Brunner DP, 1996, BIOL PSYCHIAT, V40, P485, DOI 10.1016/0006-3223(95)00656-7; CHECKLEY SA, 1993, BRIT J PSYCHIAT, V163, P332, DOI 10.1192/bjp.163.3.332; COHEN RM, 1992, ARCH GEN PSYCHIAT, V49, P545; COIRO V, 1993, PSYCHONEUROENDOCRINO, V18, P551, DOI 10.1016/0306-4530(93)90032-G; Eagles JM, 1998, J AFFECT DISORDERS, V49, P1, DOI 10.1016/S0165-0327(97)00177-8; Eagles JM, 1997, BRIT J PSYCHIAT, V171, P53, DOI 10.1192/bjp.171.1.53; FAEDDA GL, 1993, ARCH GEN PSYCHIAT, V50, P17; GALLIN PF, 1995, AM J OPHTHALMOL, V119, P202, DOI 10.1016/S0002-9394(14)73874-7; GLAST PA, 1990, BIOL PSYCHIAT, V28, P989; Glod CA, 1997, J AM ACAD CHILD PSY, V36, P188, DOI 10.1097/00004583-199702000-00009; Graw P, 1998, J AFFECT DISORDERS, V48, P69, DOI 10.1016/S0165-0327(97)00142-0; Graw P, 1997, PSYCHOPATHOLOGY, V30, P208, DOI 10.1159/000285049; JACOBSEN FM, 1987, ARCH GEN PSYCHIAT, V44, P1086; Jang KL, 1997, PSYCHIAT RES, V70, P145, DOI 10.1016/S0165-1781(97)00030-9; JOSEPHVANDERPOOL JR, 1991, J CLIN ENDOCR METAB, V72, P1382, DOI 10.1210/jcem-72-6-1382; JOSEPHVANDERPOOL JR, 1993, BIOL PSYCHIAT, V33, P496, DOI 10.1016/0006-3223(93)90003-V; KASPER S, 1989, ARCH GEN PSYCHIAT, V46, P823; Kogan AO, 1998, AM J PSYCHIAT, V155, P293; KRAUCHI K, 1993, PSYCHIAT RES, V46, P107, DOI 10.1016/0165-1781(93)90013-7; Krauchi K, 1997, COMPR PSYCHIAT, V38, P80, DOI 10.1016/S0010-440X(97)90085-7; LABBATE LA, 1994, J CLIN PSYCHIAT, V55, P189; LAM RW, 1995, AM J PSYCHIAT, V152, P1765; LAM RW, 1991, COMPR PSYCHIAT, V32, P552, DOI 10.1016/0010-440X(91)90034-A; LEONHARDT G, 1994, COMPR PSYCHIAT, V35, P457, DOI 10.1016/0010-440X(94)90229-1; Levitan RD, 1998, AM J PSYCHIAT, V155, P428, DOI 10.1176/ajp.155.3.428; Levitan RD, 1998, ARCH GEN PSYCHIAT, V55, P244, DOI 10.1001/archpsyc.55.3.244; LEVITT AJ, 1993, J AFFECT DISORDERS, V28, P51, DOI 10.1016/0165-0327(93)90076-V; LEWY AJ, 1987, SCIENCE, V235, P352, DOI 10.1126/science.3798117; LINGJAERDE O, 1993, ACTA PSYCHIAT SCAND, V88, P372, DOI 10.1111/j.1600-0447.1993.tb03476.x; Madden PAF, 1996, ARCH GEN PSYCHIAT, V53, P47; MAGNUSSON A, 1993, ARCH GEN PSYCHIAT, V50, P947; MEESTERS Y, 1993, J AFFECT DISORDERS, V28, P165, DOI 10.1016/0165-0327(93)90102-P; Michalon M, 1997, J PSYCHIATR NEUROSCI, V22, P19; Molin J, 1996, J AFFECT DISORDERS, V37, P151, DOI 10.1016/0165-0327(95)00090-9; MURASE S, 1995, ACTA PSYCHIAT SCAND, V92, P51, DOI 10.1111/j.1600-0447.1995.tb09542.x; MURPHY DGM, 1993, BRIT J PSYCHIAT, V163, P327, DOI 10.1192/bjp.163.3.327; Nayyar K, 1996, BRIT J PSYCHIAT, V168, P627, DOI 10.1192/bjp.168.5.627; Neumeister A, 1998, ARCH GEN PSYCHIAT, V55, P524, DOI 10.1001/archpsyc.55.6.524; Neumeister A, 1997, AM J PSYCHIAT, V154, P1153; Neumeister A, 1998, PSYCHOL MED, V28, P257, DOI 10.1017/S0033291797006375; OBRIEN JT, 1993, BRIT J PSYCHIAT, V163, P338, DOI 10.1192/bjp.163.3.338; OREN DA, 1994, AM J PSYCHIAT, V151, P591; Oren DA, 1993, DEPRESSION, V1, P29; Ozaki N, 1996, BIOL PSYCHIAT, V40, P1267, DOI 10.1016/0006-3223(95)00649-4; Ozaki N, 1995, PSYCHIAT RES, V59, P151, DOI 10.1016/0165-1781(95)02788-2; Partonen T, 1997, BIOL PSYCHIAT, V42, P509, DOI 10.1016/S0006-3223(96)00376-9; Partonen T, 1996, PSYCHOL MED, V26, P1075, DOI 10.1017/S003329170003539X; Partonen T, 1996, J AFFECT DISORDERS, V41, P93, DOI 10.1016/S0165-0327(96)00073-0; Raheja SK, 1996, J AFFECT DISORDERS, V41, P193, DOI 10.1016/S0165-0327(96)00087-0; ReichbornKjennerud T, 1996, J AFFECT DISORDERS, V41, P101, DOI 10.1016/S0165-0327(96)00076-6; REICHBORNKJENNERUD T, 1994, ACTA PSYCHIAT SCAND, V90, P413, DOI 10.1111/j.1600-0447.1994.tb01616.x; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; Rosenthal NE, 1998, MOL PSYCHIATR, V3, P175, DOI 10.1038/sj.mp.4000360; ROSENTHAL NE, 1989, BIOL PSYCHIAT, V25, P1029, DOI 10.1016/0006-3223(89)90291-6; SACK RL, 1990, ARCH GEN PSYCHIAT, V47, P343; SAKAMOTO K, 1993, ACTA PSYCHIAT SCAND, V87, P258, DOI 10.1111/j.1600-0447.1993.tb03368.x; SAKAMOTO K, 1995, AM J PSYCHIAT, V152, P862; Schwartz PJ, 1996, AM J PSYCHIAT, V153, P1028; Schwartz PJ, 1997, ARCH GEN PSYCHIAT, V54, P375; Schwartz PJ, 1997, BIOL PSYCHIAT, V42, P122, DOI 10.1016/S0006-3223(96)00332-0; SWEDO SE, 1995, AM J PSYCHIAT, V152, P1016; Swedo SE, 1997, J AM ACAD CHILD PSY, V36, P816, DOI 10.1097/00004583-199706000-00019; Tam EM, 1997, J AFFECT DISORDERS, V44, P39, DOI 10.1016/S0165-0327(97)01447-X; Teicher MH, 1997, ARCH GEN PSYCHIAT, V54, P124; Terman M, 1996, AM J PSYCHIAT, V153, P1423; TERMAN M, 1989, NEUROPSYCHOPHARMACOL, V2, P1, DOI 10.1016/0893-133X(89)90002-X; THALEN BE, 1995, ACTA PSYCHIAT SCAND, V92, P274, DOI 10.1111/j.1600-0447.1995.tb09583.x; THALEN BE, 1995, ACTA PSYCHIAT SCAND, V91, P352, DOI 10.1111/j.1600-0447.1995.tb09794.x; Thalen BE, 1997, ACTA PSYCHIAT SCAND, V96, P385, DOI 10.1111/j.1600-0447.1997.tb09934.x; THOMPSON C, 1995, BRIT J PSYCHIAT, V167, P380, DOI 10.1192/bjp.167.3.380; THOMPSON C, 1990, LANCET, V336, P703, DOI 10.1016/0140-6736(90)92202-S; Thompson C, 1997, BRIT J PSYCHIAT, V170, P431, DOI 10.1192/bjp.170.5.431; Vasile RG, 1997, BIOL PSYCHIAT, V42, P1000, DOI 10.1016/S0006-3223(97)00155-8; WEHR TA, 1986, ARCH GEN PSYCHIAT, V43, P870; WHO, 1993, ICD 10 CLASS MENT BE; WICKI W, 1992, EUR ARCH PSY CLIN N, V241, P301, DOI 10.1007/BF02195980; WINTON F, 1989, PSYCHOL MED, V19, P585, DOI 10.1017/S0033291700024181; WIRZJUSTICE A, 1993, ARCH GEN PSYCHIAT, V50, P929; Yatham LN, 1997, BIOL PSYCHIAT, V42, P24, DOI 10.1016/S0006-3223(96)00243-0; YOUNG MA, 1991, J AFFECT DISORDERS, V22, P191, DOI 10.1016/0165-0327(91)90065-Z	90	134	137	3	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1998	352	9137					1369	1374		10.1016/S0140-6736(98)01015-0	http://dx.doi.org/10.1016/S0140-6736(98)01015-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	133NB	9802288				2023-01-03	WOS:000076691700047
J	DiPaola, RS; Zhang, HY; Lambert, GH; Meeker, R; Licitra, E; Rafi, MM; Zhu, BT; Spaulding, H; Goodin, S; Toledano, MB; Hait, WN; Gallo, MA				DiPaola, RS; Zhang, HY; Lambert, GH; Meeker, R; Licitra, E; Rafi, MM; Zhu, BT; Spaulding, H; Goodin, S; Toledano, MB; Hait, WN; Gallo, MA			Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIETHYLSTILBESTROL; CELLS; MICE; EXPRESSION; APOPTOSIS; ESTRADIOL; EXTRACTS; GINSENG	Background Herbal mixtures are popular alternatives to demonstrated therapies. PC-SPES, a commercially available combination of eight herbs, is used as a nonestrogenic treatment for cancer of the prostate. Since other herbal medicines have estrogenic effects in vitro, we tested the estrogenic activity of PC-SPES in yeast and mice and in men with prostate cancer. Methods We measured the estrogenic activity of PC-SPES with transcriptional-activation assays in yeast and a biologic assay in mice. We assessed the clinical activity of PC-SPES in eight patients with hormone-sensitive prostate cancer by measuring serum prostate-specific antigen and testosterone concentrations during and after treatment. Results In complementary yeast assays, a 1:200 dilution of an ethanol extract of PC-SPES had estrogenic activity similar to that of 1 nM estradiol, and in ovariectomized CD-1 mice, the herbal mixture increased uterine weights substantially. In six of six men with prostate cancer, PC-SPES decreased serum testosterone concentrations (P<0.05), and in eight of eight patients it decreased serum concentrations of prostate-specific antigen. All eight patients had breast tenderness and loss of libido, and one had venous thrombosis. High-performance liquid chromatography, gas chromatography, and mass spectrometry showed that PC-SPES contains estrogenic organic compounds that are distinct from diethylstilbestrol, estrone, and estradiol. Conclusions PC-SPES has potent estrogenic activity. The use of this unregulated mixture of herbs may confound the results of standard or experimental therapies and may produce clinically significant adverse effects. (N Eng[ J Med 1998;339:785-91.) (C) 1998, Massachusetts Medical Society.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ 08901 USA; Canc Inst New Jersey, New Brunswick, NJ USA; Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	DiPaola, RS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, 195 Little Albany St, New Brunswick, NJ 08901 USA.				NATIONAL CANCER INSTITUTE [P20CA057142, P30CA072720, R03CA077133] Funding Source: NIH RePORTER; NCI NIH HHS [CA57142, CA72720, R03-CA77133] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRIKIAN AG, 1994, BRIT J UROL, V74, P630, DOI 10.1111/j.1464-410X.1994.tb09196.x; Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; CITRIN DL, 1985, CANCER, V56, P457, DOI 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7; Cott JM, 1997, PHARMACOPSYCHIATRY, V30, P108, DOI 10.1055/s-2007-979529; Delos S, 1995, J STEROID BIOCHEM, V55, P375, DOI 10.1016/0960-0760(95)00184-0; DROZ JP, 1908, PROSTATE, V24, P62; Duda RB, 1996, ANN SURG ONCOL, V3, P515, DOI 10.1007/BF02306082; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FAN S, 1995, Patent No. 5417979; Fielden MR, 1997, ENVIRON HEALTH PERSP, V105, P1238, DOI 10.1289/ehp.971051238; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; Halicka HD, 1997, INT J ONCOL, V11, P437; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; Robertson CN, 1996, J NATL CANCER I, V88, P908, DOI 10.1093/jnci/88.13.908; See DM, 1997, IMMUNOPHARMACOLOGY, V35, P229, DOI 10.1016/S0162-3109(96)00125-7; SUCHAR LA, 1995, J PHARMACOL EXP THER, V272, P197; Volz HP, 1997, PHARMACOPSYCHIATRY, V30, P72, DOI 10.1055/s-2007-979522; WALKER BE, 1983, TERATOLOGY, V27, P73, DOI 10.1002/tera.1420270111; WALKER BE, 1983, J NATL CANCER I, V70, P477; Zava DT, 1997, ENVIRON HEALTH PERSP, V105, P637, DOI 10.2307/3433383; Zhu BT, 1997, CANCER RES, V57, P2419	24	257	274	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					785	791		10.1056/NEJM199809173391201	http://dx.doi.org/10.1056/NEJM199809173391201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738085	Bronze			2023-01-03	WOS:000075909200001
J	Marshall, SJ				Marshall, SJ			On being a ginseng connoisseur	LANCET			English	Editorial Material																			0	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1898	1898		10.1016/S0140-6736(05)78859-0	http://dx.doi.org/10.1016/S0140-6736(05)78859-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652710				2023-01-03	WOS:000074347100072
J	Lambert, CM; Hurst, NP; Forbes, JF; Lochhead, A; Macleod, M; Nuki, G				Lambert, CM; Hurst, NP; Forbes, JF; Lochhead, A; Macleod, M; Nuki, G			Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; TRIAL	Objective: To test the clinical equivalence and resource consequences of day care with inpatient care for active rheumatoid arthritis. Design: Randomised controlled clinical trial with integrated cost minimisation economic evaluation. Setting: Rheumatic diseases unit at a teaching hospital between 1994 and 1996. Subjects: 118 consecutive patients with active rheumatoid arthritis randomised to receive either day care or inpatient care. Main outcome measures: Clinical assessments recorded on admission, discharge, and follow up at 12 months comprised: the health assessment questionnaire, Ritchie articular index, erythrocyte sedimentation rate, hospital anxiety and depression scale, and Steinbrocker functional class. Resource estimates were of the direct and indirect costs relating to treatment for rheumatoid arthritis. Secondary outcome measures (health utility) were ascertained by time trade off and with the quality of well being scale. Results: Both groups had improvement in scores on the health assessment questionnaire and Ritchie index and erythrocyte sedimentation rate after hospital treatment (P < 0.0001) but clinical outcome did not differ significantly between the groups either at discharge or follow up. The mean hospital cost per patient for day care, pound 798 (95% confidence interval pound 705 to pound 888), was lower than for inpatient care, pound 1253 (pound 1155 to pound 1370), but this difference was offset by higher community travel, and readmission costs. The difference in total cost per patient between day care and inpatient care was small (pound 1789 (pound 1539 to pound 2027) v pound 2021 (pound 1834 to pound 2230)). Quantile regression analysis showed a cost difference in favour of day care up to the 50th centile (pound 374; pound 639 to pound 109). Conclusions: Day care and inpatient care for patients with uncomplicated active rheumatoid arthritis have equivalent clinical outcome with a small difference in overall resource cost in favour of day care. The choice of management strategy may depend increasingly on convenience, satisfaction, or more comprehensive health measures reflecting the preferences of patients, providers, and service commissioners.	Univ Edinburgh, Western Gen Hosp, Dept Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Lambert, CM (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.		Forbes, John F/L-2558-2013	Forbes, John F/0000-0002-8255-3762				ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; ANAND KB, 1982, J ROY COLL PHYS LOND, V16, P53; ANDERSON RB, 1988, J RHEUMATOL, V15, P556; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; CAPELL HM, 1992, J ROY COLL PHYS LOND, V26, P76; Chaudhary MA, 1996, STAT MED, V15, P1447; Efron B., 1993, INTRO BOOTSTRAP; Gould W, 1992, STATA TECHNICAL B RE, V2, P137; HART LE, 1995, ARTHRITIS RHEUM S, V38, P382; HELEWA A, 1989, ARTHRITIS RHEUM, V32, P1505, DOI 10.1002/anr.1780321203; JOHANNESSON M, 1993, J HEALTH ECON, V12, P459, DOI 10.1016/0167-6296(93)90005-Y; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; Kwoh CK, 1996, ARTHRITIS RHEUM-US, V39, P713; LAMBERT CM, 1994, BRIT J RHEUMATOL, V33, P383; LAMBERT CM, 1995, BRIT J RHEUMATOL, V34, P774; LEE P, 1974, Q J MED, V43, P205; MOR V, 1988, J CLIN EPIDEMIOL, V41, P771, DOI 10.1016/0895-4356(88)90164-3; RITCHIE DM, 1968, Q J MED, V37, P393; ROBINSON R, 1993, BRIT MED J, V307, P726, DOI 10.1136/bmj.307.6906.726; ROSENBERG K, 1990, BAILLIERE CLIN OB GY, V4, P89, DOI 10.1016/S0950-3552(05)80214-7; *STAT, 1997, STAT STAT SOFTW REL; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; Torrance G W, 1972, Health Serv Res, V7, P118; VLIELAND TPM, 1997, BR J RHEUMATOL, V37, P82; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; ZELIN M, 1979, NEW ENGL J MED, V300, P1242; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	55	56	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					965	969		10.1136/bmj.316.7136.965	http://dx.doi.org/10.1136/bmj.316.7136.965			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550954	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000072856100018
J	Walker, MF; Gladman, JRF; Lincoln, NB; Siemonsma, P; Whiteley, T				Walker, MF; Gladman, JRF; Lincoln, NB; Siemonsma, P; Whiteley, T			Occupational therapy for stroke patients not admitted to hospital: a randomised controlled trial	LANCET			English	Article							REHABILITATION; SCALE	Background Patients who have a stroke are not always admitted to hospital, and 22-60% remain in the community, frequently without coordinated rehabilitation. We aimed to assess the efficacy of an occupational therapy intervention for patients with stroke who were not admitted to hospital. Methods In this single-blind randomised controlled trial, consecutive stroke patients on a UK community register in Nottingham and Derbyshire were allocated randomly to up to 5 months of occupational therapy at home or to no intervention (control group) 1 month after their stroke. The aim of the occupational therapy was to encourage independence in personal and instrumental activities of daily living. Patients were assessed on outcome measures at baseline (before randomisation) and at 6 months. The primary outcome measure was the score on the extended activities of daily living (EADL) scale at 6 months. Other outcome measures included the Barthel index, the general health questionnaire 28, the carer strain index, and the London handicap scale. All assessments were done by an independent assessor who was unaware of treatment allocation. The analysis included only data from completed questionnaires. Findings 185 patients were included: 94 in the occupational therapy group and 91 in the control group. 22 patients were not assessed at 6 months. At follow-up, patients who had occupational therapy had significantly higher median scores than the controls on: the EADL scale (16 vs 12, p<0.01, estimated difference 3 [95% CI 1 to 41); the Barthel index (20 vs 18, p<0.01, difference 1, [0-1]); the carer strain index (1 vs 3, p<0.05, difference 1[0 to 2]); and the London handicap scale (76 vs 65, p<0.05, difference 7, [0 3 to 13.5]). There were no significant differences on the general health questionnaire between the patient or carer. Interpretation Occupational therapy significantly reduced disability and handicap in patients with stroke who were not admitted to hospital.	City Hosp NHS Trust, Div Stroke Med, Nottingham NG5 1PB, England; Univ Nottingham, Dept Psychol, Nottingham NG7 2RD, England; Univ Nottingham, Div Rehabil & Ageing, Nottingham NG7 2RD, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham	Walker, MF (corresponding author), City Hosp NHS Trust, Div Stroke Med, Nottingham NG5 1PB, England.		Lincoln, Nadina B/B-9149-2009; Gladman, John/M-7429-2015	Gladman, John/0000-0002-8506-7786; Walker, Marion/0000-0002-3534-591X				BAMFORD J, 1986, BRIT MED J, V292, P1329; BROCKLEHURST J C, 1978, Age and Ageing, V7, P100, DOI 10.1093/ageing/7.2.100; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; GLADMAN JRF, 1993, AGE AGEING, V22, P419, DOI 10.1093/ageing/22.6.419; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HARWOOD RH, 1994, J NEUROL NEUROSUR PS, V57, P825, DOI 10.1136/jnnp.57.7.825; HEWER RL, 1976, P 9 PFIZ INT S ED CH; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lincoln NB, 1998, DISABIL REHABIL, V20, P457, DOI 10.3109/09638289809166110; LINCOLN NB, 1976, PHYSIOTHERAPY, V65, P48; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; MAHONEY F I, 1965, Md State Med J, V14, P61; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; Noad R, 1998, BR J THER REHABIL, V5, P578; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Siemonsma PC, 1997, CLIN REHABIL, V11, P273, DOI 10.1177/026921559701100402; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969; WALKER MF, 1996, CLIN REHABIL, V10, P23, DOI DOI 10.1177/026921559601000105; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P144, DOI 10.1136/jech.47.2.144	22	111	112	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					278	280		10.1016/S0140-6736(98)11128-5	http://dx.doi.org/10.1016/S0140-6736(98)11128-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440303				2023-01-03	WOS:000081646000009
J	Giuffrida, A; Gravelle, H; Roland, M				Giuffrida, A; Gravelle, H; Roland, M			Measuring quality of care with routine data: avoiding confusion between performance indicators and health outcomes	BRITISH MEDICAL JOURNAL			English	Article							PREVENTABLE HOSPITALIZATIONS; ACCESS; RATES; POPULATION; ADMISSIONS; CHILDREN	Objective To investigate the impact of factors outside the control of primary care on performance indicators proposed as measures of the quality of primary care. Design Multiple regression analysis relating admission rates standardised for age and sex for asthma, diabetes, and epilepsy to socioeconomic population characteristics and to the supply of secondary care resources. Setting 90 family health services authorities in England, 1989-90 to 1994-5. Results At health authority level socioeconomic characteristics, health status, and secondary care supply factors explained 45% of the variation in admission rates for asthma, 33% for diabetes, and 55% for epilepsy. When health authorities were ranked, only four of the 10 with the highest age-sex standardised admission rates for asthma in 1994-5 remained in the top 10 when allowance was made for socioeconomic characteristics, health status, and secondary care supply factors. There was also substantial year to year variation in the rates. Conclusion Health outcomes should relate to crude rates of adverse events in the population. These give the best indication of the size of a health problem. Performance indicators, however, should relate to those aspects of care which can be altered by the staff whose performance is being measured.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO10 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.			Gravelle, Hugh/0000-0002-7753-4233				ARNOLD J, 1989, USING HLTH OUTCOMES; Aveyard P, 1997, J Eval Clin Pract, V3, P275, DOI 10.1046/j.1365-2753.1997.t01-1-00004.x; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BEGLEY CE, 1994, J COMMUN HEALTH, V19, P377, DOI 10.1007/BF02260406; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; Billings J, 1989, USE SMALL AREA ANAL; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; DUROJAIYE LIA, 1989, PUBLIC HEALTH, V103, P181, DOI 10.1016/S0033-3506(89)80073-3; FARMER A, 1990, BRIT J GEN PRACT, V40, P56; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Lambrew JM, 1996, MED CARE, V34, P138, DOI 10.1097/00005650-199602000-00006; *MA DIV HLTH CAR F, 1995, IMPR PRIM CAR US PRE; MACKINNON JG, 1983, J ECONOMETRICS, V21, P53, DOI 10.1016/0304-4076(83)90119-7; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; *NHS EX, 1998, NEW NHS NAT FRAM ASS; *NHS EX, 1994, HLTH SERV IND HDB 19; *SECR STAT HLTH, 1997, CM3807; Smith P., 1994, FORMULA DISTRIBUTING; WATTS JP, 1996, EUR RESPIR J, V9, P2087; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITE H, 1978, ECONOMETRICA, V46, P817	24	118	121	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					94	98		10.1136/bmj.319.7202.94	http://dx.doi.org/10.1136/bmj.319.7202.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	216JD	10398635	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000081438200034
J	Saigal, S; Stoskopf, BL; Feeny, D; Furlong, W; Burrows, E; Rosenbaum, PL; Hoult, L				Saigal, S; Stoskopf, BL; Feeny, D; Furlong, W; Burrows, E; Rosenbaum, PL; Hoult, L			Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the European-Society-for-Pediatric-Research	SEP 01-05, 1996	LYON, FRANCE	European Soc Pediat Res			BIRTH-WEIGHT INFANTS; LIFE-SUSTAINING TREATMENT; QUALITY-OF-LIFE; AGE 8 YEARS; INTENSIVE-CARE; CHILDREN; DECISIONS; ATTITUDES; UTILITIES; CANCER	Context In neonatal intensive care, parents make important clinical management decisions in conjunction with health care professionals. Yet little information is available on whether preferences of health care professionals and parents for the resulting health outcomes differ. Objective To measure and compare preferences for selected health states from the perspectives of health care professionals (ie, neonatologists and neonatal nurses), parents of extremely low-birth-weight (ELBW) or normal birth-weight infants, and adolescents who were either ELBW or normal birth-weight infants. Design Cross-sectional cohort study. Setting and Participants A total of 742 participants were recruited and interviewed between 1993 and 1995, including 100 neonatologists from hospitals throughout Canada; 103 neonatal nurses from 3 regional neonatal intensive care units; 264 adolescents (aged 12-16 years), including 140 who were ELBW infants and 124 sociodemographically matched term controls; and 275 parents of the recruited adolescents. Main Outcome Measure Preferences (utilities) for 4 to 5 hypothetical health states of children were obtained by direct interviews using the standard gamble method. Results Overall, neonatologists and nurses had similar preferences for the 5 health states, and a similar proportion rated some health states as worse than death (59% of neonatologists and 68% of nurses; P=.20). Health care professionals rated the health states lower than did parents of ELBW and term infants (P<.001). Overall, 64% of health care professionals and 45% of parents rated 1 or more health states to be worse than death (P<.001), Differences in mean utility scores between health care professionals and parents and adolescent respondents were most pronounced for the 2 most severely disabled health states (P<.001). Conclusions When asked to rate the health-related quality of life for the hypothetical conditions of children, health care professionals tend to provide lower utility scores than do adolescents and their parents. These findings have implications for decision making in the neonatal intensive care unit.	McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada; Hamilton Hlth Sci Corp, Childrens Hosp, Hamilton, ON, Canada; Hlth Util Inc, Dundas, ON, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Saigal, S (corresponding author), McMaster Univ, Dept Pediat, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	saigal@fhs.mcmaster.ca	Rosenbaum, Peter/AAW-7913-2021; Furlong, William J/A-1077-2008	Rosenbaum, Peter/0000-0001-6751-5613; 	AHRQ HHS [HS-08385] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CADMAN D, 1984, DEV BEHAV PEDIAT, V5, P60; CADMAN D, 1986, 64800633 DM ONT MIN; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; Doron MW, 1998, PEDIATRICS, V102, P574, DOI 10.1542/peds.102.3.574; DOYAL L, 1994, ARCH DIS CHILD-FETAL, V70, pF66, DOI 10.1136/fn.70.1.F66; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; Feeny D. H., 1996, QUALITY LIFE PHARMAC, V2, P239; FURLOG W, 1990, MCMASTER U WORKING P, V909; HARRISON H, 1993, PEDIATRICS, V92, P643; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LANTOS JD, 1994, ARCH DIS CHILD-FETAL, V71, pF218, DOI 10.1136/fn.71.3.F218; LEE SK, 1991, PEDIATRICS, V88, P110; OH W, 1995, PEDIATRICS, V96, P974; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; SAIGAL S, 1994, J PEDIATR-US, V125, P411, DOI 10.1016/S0022-3476(05)83288-3; SAIGAL S, 1994, J PEDIATR-US, V125, P418, DOI 10.1016/S0022-3476(05)83289-5; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; SAIGAL S, 1995, PEDIATR RES, V38, P453; Saigal S, 1998, MEASURING HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS, P151; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SILVERMAN WA, 1992, PEDIATRICS, V90, P971; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; STAHLMAN MT, 1990, J PEDIATR-US, V116, P167, DOI 10.1016/S0022-3476(05)82869-0; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Tyson JE, 1996, JAMA-J AM MED ASSOC, V276, P492, DOI 10.1001/jama.276.6.492; van der Heide A, 1998, PEDIATRICS, V101, P413, DOI 10.1542/peds.101.3.413; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64	34	247	250	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					1991	1997		10.1001/jama.281.21.1991	http://dx.doi.org/10.1001/jama.281.21.1991			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	200NN	10359387	Bronze			2023-01-03	WOS:000080546700028
J	Morris, M; Eifel, PJ; Lu, JD; Grigsby, PW; Levenback, C; Stevens, RE; Rotman, M; Gershenson, DM; Mutch, DG				Morris, M; Eifel, PJ; Lu, JD; Grigsby, PW; Levenback, C; Stevens, RE; Rotman, M; Gershenson, DM; Mutch, DG			Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; PARAAORTIC LYMPH-NODES; UTERINE CERVIX; PHASE-II; STAGE-IB; IRRADIATION; THERAPY; TRIAL; PROGNOSIS	Background and Methods We compared the effect of radiotherapy to a pelvic and para-aortic field with that of pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin in women with advanced cervical cancer. Between 1990 and 1997, 403 women with advanced cervical cancer confined to the pelvis (stages IIB through IVA or stage IB or IIA with a tumor diameter of at least 5 cm or involvement of pelvic lymph nodes) were randomly assigned to receive either 45 Gy of radiation to the pelvis and para-aortic lymph nodes or 45 Gy of radiation to the pelvis alone plus two cycles of fluorouracil and cisplatin (days 1 through 5 and days 22 through 26 of radiation). Patients were then to receive one or two applications of low-dose-rate intracavitary radiation, with a third cycle of chemotherapy planned for the second intracavitary procedure in the combined-therapy group. Results Of the 403 eligible patients, 193 in each group could be evaluated. The median duration of follow-up was 43 months. Estimated cumulative rates of survival at five years were 73 percent among patients treated with radiotherapy and chemotherapy and 58 percent among patients treated with radiotherapy alone (P=0.004). Cumulative rates of disease free survival at five years were 67 percent among patients in the combined-therapy group and 40 percent among patients in the radiotherapy group (P<0.001). The rates of both distant metastases (P<0.001) and locoregional recurrences (P<0.001) were significantly higher among patients treated with radiotherapy alone. The seriousness of side effects was similar in the two groups, with a higher rate of reversible hematologic effects in the combined-therapy group. Conclusions The addition of chemotherapy with fluorouracil and cisplatin to treatment with external-beam and intracavitary radiation significantly improved survival among women with locally advanced cervical cancer. (N Engl J Med 1999;340:1137-43.) (C)1999, Massachusetts Medical Society.	Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Radiat Therapy Oncol Grp, Stat Unit, Philadelphia, PA USA; Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA; Washington Univ, Sch Med, Div Gynecol Oncol, St Louis, MO USA; NYU, Dept Radiat Oncol, New York, NY USA; SUNY Hlth Sci Ctr, Dept Radiat Oncol, Brooklyn, NY 11203 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Radiation Therapy Oncology Group (RTOG); Washington University (WUSTL); Washington University (WUSTL); New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Morris, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, 1515 Holcombe Blvd,Box 34, Houston, TX 77030 USA.	morris@mdanderson.org			NCI NIH HHS [U10CA32115, U10CA21661] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA032115, U10CA021661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ RD, 1989, GYNECOL ONCOL, V35, P130, DOI 10.1016/0090-8258(89)90029-2; BAUER M, 1986, INT J RADIAT ONCOL, V12, P1101, DOI 10.1016/0360-3016(86)90235-X; Chen MD, 1997, GYNECOL ONCOL, V67, P131, DOI 10.1006/gyno.1997.4851; Corn BW, 1998, AM J CLIN ONCOL-CANC, V21, P31, DOI 10.1097/00000421-199802000-00007; COX DR, 1972, J R STAT SOC B, V34, P187; DELGADO G, 1989, GYNECOL ONCOL, V35, P314, DOI 10.1016/0090-8258(89)90070-X; EIFEL PJ, 1990, CANCER, V65, P2507, DOI 10.1002/1097-0142(19900601)65:11<2507::AID-CNCR2820651120>3.0.CO;2-9; EIFEL PJ, 1994, INT J RADIAT ONCOL, V29, P9, DOI 10.1016/0360-3016(94)90220-8; Fields AL, 1996, GYNECOL ONCOL, V61, P416, DOI 10.1006/gyno.1996.0166; FYLES A, 1992, RADIOTHER ONCOL, V25, P273, DOI 10.1016/0167-8140(92)90247-R; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Grigsby FW, 1996, AM J CLIN ONCOL-CANC, V19, P1; Grigsby PW, 1998, INT J RADIAT ONCOL, V41, P817, DOI 10.1016/S0360-3016(98)00132-1; HRESHCHYSHYN MM, 1979, INT J RADIAT ONCOL, V5, P317, DOI 10.1016/0360-3016(79)91209-4; John M, 1996, GYNECOL ONCOL, V61, P221, DOI 10.1006/gyno.1996.0129; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P167; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; KIM K, 1990, BIOMETRICS, V46, P81, DOI 10.2307/2531632; LANCIANO RM, 1991, INT J RADIAT ONCOL, V20, P667, DOI 10.1016/0360-3016(91)90007-Q; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; MALFETANO J, 1993, CANCER, V71, P3703, DOI 10.1002/1097-0142(19930601)71:11<3703::AID-CNCR2820711138>3.0.CO;2-8; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; ROTMAN M, 1995, JAMA-J AM MED ASSOC, V274, P387, DOI 10.1001/jama.274.5.387; SHEPHERD JH, 1995, INT J GYNECOL CANCER, V5, P319; STEHMAN FB, 1993, J CLIN ONCOL, V11, P1523, DOI 10.1200/JCO.1993.11.8.1523; STEHMAN FB, 1991, CANCER, V67, P2776, DOI 10.1002/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L; THOMAS G, 1990, GYNECOL ONCOL, V38, P446, DOI 10.1016/0090-8258(90)90089-4; THOMAS G, 1984, INT J RADIAT ONCOL, V10, P1785, DOI 10.1016/0360-3016(84)90550-9	32	1665	1760	0	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1999	340	15					1137	1143		10.1056/NEJM199904153401501	http://dx.doi.org/10.1056/NEJM199904153401501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185TZ	10202164	Bronze			2023-01-03	WOS:000079687700001
J	Johansen, KL; Mulligan, K; Schambelan, M				Johansen, KL; Mulligan, K; Schambelan, M			Anabolic effects of nandrolone decanoate in patients receiving dialysis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN GROWTH-HORMONE; CHRONIC-RENAL-FAILURE; DEPENDENT DIABETES-MELLITUS; HEMODIALYSIS-PATIENTS; MAINTENANCE HEMODIALYSIS; CARDIOVASCULAR-DISEASE; SERUM-LIPOPROTEIN; BODY-COMPOSITION; CAPD PATIENTS; RISK FACTOR	Context Patients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and strength in healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated. Objective To assess the effects of an anabolic steroid, nandrolone decanoate, on lean body mass (LBM), functional status, and quality of life in dialysis patients. Design Randomized, double-blind, placebo-controlled trial conducted between April 1996 and July 1997. Setting Hospital-based outpatient dialysis unit. Patients Twenty-nine patients undergoing dialysis for at least 3 months. Intervention Nandrolone decanoate, 100 mg (n = 14), or placebo (n = 15) by intramuscular injection once a week for 6 months. Main Outcome Measures Weight, LBM, fatigue, grip strength, walking and stair-climbing times, and treadmill performance after 3 and 6 months of treatment. Results Lean body mass increased significantly in patients given nandrolone compared with patients given placebo (mean change [SD], +4.5 [2.3] kg; P<.001 compared with baseline). This effect was significantly greater than the change in LBM in the placebo group (mean change [SD], +1.9 [1.6] kg; P = .003 compared with baseline; P = .005 compared with nandrolone group). Serum creatinine levels increased in the nandrolone group (+168 [203] mmol/L [1.9 {2.3} mg/dL]; P = .02) but not in the placebo group (-4.0 [177] mmol/L [0.04 {2.0} mg/dL]; P = .95), suggesting an increase in muscle mass. Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the nandrolone group, while those in the placebo group increased from 38.7 to 42.1 seconds (P = .05). Peak oxygen consumption increased in the individuals in the nandrolone group who performed treadmill tests, but not to a statistically significant degree. Grip strength did not change in either group. Conclusions Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Nephrol, San Francisco, CA USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Endocrinol, San Francisco, CA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Johansen, KL (corresponding author), San Francisco Vet Affairs Med Ctr, Nephrol Sect, Box 111J,4150 Clement St, San Francisco, CA 94121 USA.	johanse@itsa.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00083] Funding Source: Medline; NIDDK NIH HHS [DK-45833] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1971, EITS MANUAL PROFILE; [Anonymous], 1991, GUID EX TEST PRESCR; Avram MM, 1996, ADV PERIT D, V12, P266; Bartens W, 1996, PERITON DIALYSIS INT, V16, P27; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; BOTERO D, 1993, J PEDIATR-US, V123, P590, DOI 10.1016/S0022-3476(05)80959-X; BRADLEY JR, 1990, CLIN SCI, V79, P239, DOI 10.1042/cs0790239; Campbell A., 1976, QUALITY AM LIFE PERC, DOI DOI 10.7758/9781610441032; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; COLES GA, 1972, Q J MED, V41, P25; CRESSMAN MD, 1992, CIRCULATION, V86, P475, DOI 10.1161/01.CIR.86.2.475; GLAZER G, 1994, METABOLISM, V43, P204, DOI 10.1016/0026-0495(94)90246-1; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HAKIM RM, 1993, AM J KIDNEY DIS, V21, P125, DOI 10.1016/S0272-6386(12)81083-3; HENDLER ED, 1974, NEW ENGL J MED, V291, P1046, DOI 10.1056/NEJM197411142912002; HURLEY BF, 1984, JAMA-J AM MED ASSOC, V252, P507, DOI 10.1001/jama.252.4.507; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; IKIZLER TA, 1994, KIDNEY INT, V46, P1178, DOI 10.1038/ki.1994.382; KOLLIND M, 1987, HORM METAB RES, V19, P156, DOI 10.1055/s-2007-1011766; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P1002, DOI 10.1016/S0272-6386(12)81075-4; Kronenberg F, 1996, AM J KIDNEY DIS, V27, P1, DOI 10.1016/S0272-6386(96)90026-8; LAZARUS JM, 1993, AM J KIDNEY DIS, V21, P99, DOI 10.1016/S0272-6386(12)80731-1; LINDHOLM DD, 1973, T AM SOC ART INT ORG, V19, P475; Lippi G, 1997, SCAND J CLIN LAB INV, V57, P507, DOI 10.3109/00365519709084601; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MANSON JM, 1986, SURGERY, V100, P188; MOORE GE, 1993, MED SCI SPORT EXER, V25, P18, DOI 10.1249/00005768-199301000-00004; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; PAINTER P, 1986, NEPHRON, V42, P47, DOI 10.1159/000183632; PAINTER P, 1984, PERIT DIAL B S, V4, pS94; POLLOCK CA, 1990, AM J KIDNEY DIS, V16, P38, DOI 10.1016/S0272-6386(12)80783-9; SARGENT JA, 1983, KIDNEY INT S13, V23, pS19; SCHULMAN G, 1993, AM J KIDNEY DIS, V21, P527, DOI 10.1016/S0272-6386(12)80399-4; TAYEK JA, 1992, CLIN RES, V40, pA95; Teruel JL, 1997, AM J KIDNEY DIS, V29, P569, DOI 10.1016/S0272-6386(97)90340-1; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; United States Renal Data System, 1994, USRDS 1994 ANN DAT R; Woodrow G, 1996, NEPHROL DIAL TRANSPL, V11, P1613, DOI 10.1093/oxfordjournals.ndt.a027623; ZIEGLER TR, 1991, J AM SOC NEPHROL, V2, P1130	40	173	177	2	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1275	1281		10.1001/jama.281.14.1275	http://dx.doi.org/10.1001/jama.281.14.1275			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208142	Bronze			2023-01-03	WOS:000079628700031
J	Keating, NL; Cleary, PD; Rossi, AS; Zaslavsky, AM; Ayanian, JZ				Keating, NL; Cleary, PD; Rossi, AS; Zaslavsky, AM; Ayanian, JZ			Use of hormone replacement therapy by postmenopausal women in the United States	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med		estrogen replacement therapy; demography; socioeconomic factors; educational status; hysterectomy	NUTRITION EXAMINATION SURVEY; CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; CARDIOVASCULAR-DISEASE; RANCHO-BERNARDO; NATIONAL-HEALTH; RISK; OSTEOPOROSIS; PROGESTIN; DETERMINANTS	Background: The benefits and risks of hormone replacement therapy (HRT) in postmenopausal women are not fully defined, and individual characteristics and preferences may influence decisions to use this therapy. Previous studies of postmenopausal women who use HRT have been conducted in local or highly selected cohorts or have not focused on current use. Objective: To examine sociodemographic, clinical, and psychological factors associated with current use of HRT in a national population-based cohort. Design: Random-digit telephone survey. Setting: Probability sample of U.S. households with a telephone. Participants: 495 postmenopausal women 50 to 74 years of age in 1995. Measurements: Current use of HRT. Results: Current use of HRT was reported by 37.6% of women (58.7% of those who underwent hysterectomy and 19.6% of those who did not undergo hysterectomy; P = 0.001). In multivariable analyses, use of HRT was more common among women in the South (adjusted odds ratio, 2.67 [95% CI, 1.08 to 6.59]) and West (odds ratio, 2.76 [CI, 1.01 to 7.53]) than the Northeast. Use was more common among college graduates (odds ratio, 3.72 [CI, 1.29 to 10.71]) and less common among women with diabetes mellitus (odds ratio, 0.17 [CI, 0.05 to 0.51]). Other cardiac risk factors and most psychological characteristics were not associated with HRT use. Conclusions: Sociodemographic factors, such as region and education, may be more strongly associated with use of HRT than clinical factors, such as risk for cardiovascular disease. Future efforts should focus on understanding sociodemographic variations, defining which women are most likely to benefit, and targeting therapy to them.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Massachusetts, Amherst, MA 01003 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Massachusetts System; University of Massachusetts Amherst	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.		Cleary, Paul/AAF-7048-2019; Keating, Nancy L/I-9968-2019	Keating, Nancy L/0000-0002-8274-4681				[Anonymous], 1987, BRIT MED J, V295, P914; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Bem S. L., 1981, BEM SEX ROLE INVENTO; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; Brinton LA, 1997, NEW ENGL J MED, V336, P1821, DOI 10.1056/NEJM199706193362509; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Col N. F., 1997, JGIM, V12, P60; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Connelly M. T., 1997, JGIM, V12, P126; DERBY CA, 1993, AM J EPIDEMIOL, V137, P1125, DOI 10.1093/oxfordjournals.aje.a116616; Dunn LB, 1997, ARCH DERMATOL, V133, P339, DOI 10.1001/archderm.133.3.339; EGELAND GM, 1991, PREV MED, V20, P343, DOI 10.1016/0091-7435(91)90033-Z; EGELAND GM, 1988, PREV MED, V17, P403, DOI 10.1016/0091-7435(88)90039-4; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; Ford ES, 1998, J CLIN EPIDEMIOL, V51, P55, DOI 10.1016/S0895-4356(97)00225-4; FOWLER FJ, 1993, SURVEY RES METHODS, P40; FRANE J, 1989, SUDAAN PROFESSIONAL; Goldberg L. R., 1992, PSYCHOL ASSESSMENT, V4, P26, DOI [10.1037/1040-3590.4.1.26, DOI 10.1037/1040-3590.4.1.26]; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Handa VL, 1996, J AM GERIATR SOC, V44, P1; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; Heitjan DF, 1997, AM J PUBLIC HEALTH, V87, P548, DOI 10.2105/AJPH.87.4.548; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; John O. P., 1990, HDB PERSONALITY THEO; KJERULFF K, 1993, AM J PUBLIC HEALTH, V83, P106, DOI 10.2105/AJPH.83.1.106; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.pu.13.050192.002051; Levy P., 1991, SAMPLING POPULATIONS; MANTEL N, 1959, J NATL CANCER I, V22, P719; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Matthews KA, 1996, AM J EPIDEMIOL, V143, P983; McNagny SE, 1997, ANN INTERN MED, V127, P1093, DOI 10.7326/0003-4819-127-12-199712150-00007; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459; Persson I, 1997, J CLIN EPIDEMIOL, V50, P611, DOI 10.1016/S0895-4356(97)00004-8; POKRAS R, 1988, AM J PUBLIC HEALTH, V78, P852, DOI 10.2105/AJPH.78.7.852; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rose G, 1982, CARDIOVASCULAR SURVE; Rossouw J E, 1995, J Am Med Womens Assoc (1972), V50, P50; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Rubin Donald B., 1978, P SURV RES METH SECT, P20, DOI DOI 10.1631/JZUS.C10B0359; SCALLEY EK, 1993, J WOMENS HEALTH, V2, P289; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; SCHWARTZ M, 1985, CLIN ORTHOP RELAT R, P180; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SOLOMON CG, 1996, CIRCULATION S1, V94, P339; Stafford RS, 1997, AM J OBSTET GYNECOL, V177, P381, DOI 10.1016/S0002-9378(97)70202-3; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANDEVEN M, 1986, AM J EPIDEMIOL, V124, P268, DOI 10.1093/oxfordjournals.aje.a114385; THORNBERRY TO, 1988, TELEPHONE SURVEY MET, P25; TRAPNELL PD, 1990, J PERS SOC PSYCHOL, V59, P781, DOI 10.1037/0022-3514.59.4.781; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; *WHO, 1996, COMP INT DIAGN INT 2; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	69	266	277	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	1999	130	7					545	553		10.7326/0003-4819-130-7-199904060-00002	http://dx.doi.org/10.7326/0003-4819-130-7-199904060-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	183BG	10189323				2023-01-03	WOS:000079533300001
J	Heymsfield, SB; Allison, DB; Vasselli, JR; Pietrobelli, A; Greenfield, D; Nunez, C				Heymsfield, SB; Allison, DB; Vasselli, JR; Pietrobelli, A; Greenfield, D; Nunez, C			Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Hydroxycitric acid, the active ingredient in the herbal compound Garcinia cambogia, competitively inhibits the extramitochondrial enzyme adenosine triphosphate-citrate (pro-3S)-lyase. As a citrate cleavage enzyme that may play an essential role in de novo lipogenesis inhibition, G cambogia is claimed to lower body weight and reduce fat mass in humans. Objective.-To evaluate the efficacy of G cambogia for body weight and fat mass loss in overweight human subjects. Design.-Twelve-week randomized, double-blind, placebo-controlled trial. Setting.-Outpatient weight control research unit. Participants.-Overweight men and women subjects (mean body mass index [weight in kilograms divided by the square of height in meters], approximately 32 kg/m(2)). Intervention.-Subjects were randomized to receive either active herbal compound (1500 mg of hydroxycitric acid per day) or placebo, and both groups were prescribed a high-fiber, low-energy diet. The treatment period was 12 weeks. Body weight was evaluated every other week and fat mass was measured at weeks 0 and 12. Main Outcome Measures.-Body weight change and fat mass change. Results.-A total of 135 subjects were randomized to either active hydroxycitric acid (n = 66) or placebo (n = 69); 42 (64%) in the active hydroxycitric acid group and 42 (61%) in the placebo group completed 12 weeks of treatment (P = .74). Patients in both groups lost a significant amount of weight during the 12-week treatment period (P < .001); however, between-group weight loss differences were not statistically significant (mean [SD], 3.2 [3.3] kg vs 4.1 [3.9] kg; P = .14). There were no significant differences in estimated percentage of body fat mass loss between treatment groups, and the fraction of subject weight loss as fat was not influenced by treatment group. Conclusions.-Garcinia cambogia failed to produce significant weight loss and fat mass loss beyond that observed with placebo.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr,Dept Med, New York, NY 10025 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Heymsfield, SB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr,Dept Med, 1090 Amsterdam Ave,14th Floor, New York, NY 10025 USA.	sbh2@columbia.edu	Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425; Allison, David/0000-0003-3566-9399	NCRR NIH HHS [RR00645] Funding Source: Medline; NIDDK NIH HHS [P30DK26687] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badmaev V., 1995, NUTR 1995 NUTR DIET; BRAY GA, 1993, ANN INTERN MED, V119, P707, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00016; Burstein L., 1989, MULTILEVEL INVESTIGA; *COMM PROP MED PRO, 1997, NOT GUID CLIN INV DR; Conte A.A., 1993, AM J BARIATR MED SUM, P17; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DRAO RN, 1988, NUTR RES, V8, P209; GIROLA M, 1996, ACTA TOXICOL THER, V17, P25; Graham J W, 1994, NIDA Res Monogr, V142, P13; Heymsfield S. B., 1996, HUMAN BODY COMPOSITI, P129; Heymsfield SB, 1996, AM J CLIN NUTR, V64, P478, DOI 10.1093/ajcn/64.3.478S; Heymsfield SB., 1992, MODERN NUTR HLTH DIS, V8, P812; HOBBS LS, 1994, NEW DIET PILLS, P161; Lewis Y. S., 1965, PHYTOCHEMISTRY, V4, P610; LOWENSTEIN JM, 1971, J BIOL CHEM, V246, P629; Martius C., 1941, Z PHYSL CHEM, V269, P33; *NIH, 1992, AM J CLIN NUTR, V55, pS487; Niklson IA, 1997, PSYCHOPHARMACOL BULL, V33, P41; Pietrobelli A, 1997, INT J OBESITY, V21, P110, DOI 10.1038/sj.ijo.0800374; Pietrobelli A, 1996, AM J PHYSIOL-ENDOC M, V271, pE941, DOI 10.1152/ajpendo.1996.271.6.E941; RUSSELLAULET M, 1991, J BONE MINER RES, V6, P411; SULLIVAN AC, 1974, LIPIDS, V9, P129, DOI 10.1007/BF02532137; SULLIVAN AC, 1972, ARCH BIOCHEM BIOPHYS, V150, P183, DOI 10.1016/0003-9861(72)90025-2; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; SULLIVAN AC, 1974, FED PROC, V33, P656; Thom E, 1996, INT J OBES S4, V20, P48; Vasselli JR, 1998, FASEB J, V12, pA505; VONLIPPMANN EO, 1983, BER DTSCH CHEM GES, V16, P1078; WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3; WEBSTER JD, 1984, HUM NUTR-CLIN NUTR, V38C, P299; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907	31	222	237	2	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1596	1600		10.1001/jama.280.18.1596	http://dx.doi.org/10.1001/jama.280.18.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820262	Bronze			2023-01-03	WOS:000076852000027
J	Bundred, N; Maguire, P; Reynolds, J; Grimshaw, J; Morris, J; Thomson, L; Barr, L; Baildam, A				Bundred, N; Maguire, P; Reynolds, J; Grimshaw, J; Morris, J; Thomson, L; Barr, L; Baildam, A			Randomised controlled trial of effects of early discharge after surgery for breast cancer	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the effect of early discharge from hospital after surgery for breast cancer on physical and psychological illness. Design Randomised controlled trial comparing discharge two days after surgery (before removal of drain) with standard management (discharge after removal of drain). Setting Regional breast unit. Subjects 100 women with early breast cancer undergoing mastectomy and axillary node clearance (20) or breast conservation surgery (80). Main outcome measures Physical illness (infection seroma formation, shoulder movement) and psychological illness (checklist of concerns, Rotterdam symptom questionnaire, hospital anxiety and depression scale) preoperatively and at one month and three months postoperatively. Results Women discharged early had greater shoulder movement (odds ratio 0.28 (95% confidence interval 0.08 to 0.95); P = 0.042) and less wound pain (odds ratio 0.28 (0.10 to 0.79); P = 0.016) three months after surgery compared with women given standard management. One month after surgery scores were significantly lower on the Rotterdam symptom questionnaire in patients who were discharged early (ratio of geometric mean scores 0.73 (0.55 to 0.98); P = 0.035), but rates of psychological illness generally did not differ between groups. Conclusions Increased rates of physical or psychological illness did not result from early discharge after surgery for breast cancer. This policy can be recommended for patients with support at home.	Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England; Univ S Manchester Hosp, Dept Med Stat, Manchester M20 8LR, Lancs, England; Christie Hosp NHS Trust, Canc Res Campaign, Psychol Med Grp, Manchester M20 4BX, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Christie NHS Foundation Trust; Christie Hospital	Bundred, N (corresponding author), Univ S Manchester Hosp, Dept Surg, Nell Lane, Manchester M20 8LR, Lancs, England.	bundredn@fs1.with.man.ac.uk		Barr, Lester/0000-0003-4030-8192; Grimshaw, Jeremy/0000-0001-8015-8243				BALL ABS, 1992, ANN ROY COLL SURG, V74, P126; Bonnema J, 1998, BRIT MED J, V316, P1267, DOI 10.1136/bmj.316.7140.1267; COHEN AM, 1986, AM J SURG, V151, P465, DOI 10.1016/0002-9610(86)90104-2; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; Devlen JL., 1984, THESIS U MANCHESTER; EDWARDS MJ, 1988, ANN SURG, V208, P330, DOI 10.1097/00000658-198809000-00010; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; Funnel IC, 1992, ANN R COLL SURG ENGL, V4, P178; Holcombe C, 1995, Eur J Surg Oncol, V21, P604, DOI 10.1016/S0748-7983(95)95133-4; IBBOTSON T, 1994, EUR J CANCER, V30A, P37, DOI 10.1016/S0959-8049(05)80015-2; Pannuti F, 1992, J Palliat Care, V8, P11; [No title captured]	12	87	88	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1998	317	7168					1275	1279		10.1136/bmj.317.7168.1275	http://dx.doi.org/10.1136/bmj.317.7168.1275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GP	9804712	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000076963800021
J	Gordon, PN; Williamson, S; Lawler, PG				Gordon, PN; Williamson, S; Lawler, PG			As seen on TV: observational study of cardiopulmonary resuscitation in British television medical dramas	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENTS PREFERENCES; ELDERLY PATIENTS; SURVIVAL; RELATIVES; DECISION; VIEWS	Objective: To determine the frequency and accuracy with which cardiopulmonary resuscitation is portrayed in British television medical dramas. design: Observational study. Subjects: 64 episodes of three major British television medical dramas: Casualty, Cardiac Arrest, and Medics. Main outcome measures: Frequency of cardiopulmonary resuscitation shown on television; age, sex, and diagnosis of the patients undergoing resuscitation; rate of survival through resuscitation. Results: Overall 52 patients had a cardiorespiratory arrest on screen and 3 had a respiratory arrest alone, all the arrests occurring in 40 of the 64 episodes. Of the 52 patients having cardiorespiratory arrest, 32 (62%) underwent an attempt at cardiopulmonary resuscitation; 8 attempts were successful. Al 3 of the patients having respiratory arrests alone received ventilatory support and survived. On 48% of occasions, victims of cardiac arrest seemed to be less than 35 years old. Conclusions: Cardiorespiratory resuscitation is often depicted in British television medical dramas. Patients portrayed receiving resuscitation are likely to be in a younger age group than in real life. Though the reasons for resuscitation are more varied and more often associated with trauma than in reality, the overall success rate is nevertheless realistic. Widespread overoptimism of patients for survival after resuscitation cannot necessarily be blamed on British television medical dramas.	S Cleveland Hosp, Dept Obstet & Gynaecol, Middlesbrough TS4 3BW, Cleveland, England		Gordon, PN (corresponding author), S Cleveland Hosp, Dept Obstet & Gynaecol, Middlesbrough TS4 3BW, Cleveland, England.	patrickg@globalnet.co.uk						Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Diem SJ, 1996, NEW ENGL J MED, V334, P1578, DOI 10.1056/NEJM199606133342406; EKSTROM L, 1994, RESUSCITATION, V27, P181, DOI 10.1016/0300-9572(94)90031-0; FLORIN D, 1993, J ROY COLL PHYS LOND, V27, P135; HEAP MJ, 1993, ANAESTHESIA, V48, P1027; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; JUDE JR, 1961, JAMA-J AM MED ASSOC, V178, P1063, DOI 10.1001/jama.1961.03040500005002; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LIDDLE J, 1994, J ROY COLL PHYS LOND, V28, P228; Markert RJ, 1996, NEW ENGL J MED, V335, P1605; MEAD GE, 1995, J MED ETHICS, V21, P39, DOI 10.1136/jme.21.1.39; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; Turow J, 1996, LANCET, V347, P1240, DOI 10.1016/S0140-6736(96)90747-3; Valentin A, 1995, RESUSCITATION, V30, P217, DOI 10.1016/0300-9572(95)00898-5; WAGG A, 1995, J ROY COLL PHYS LOND, V29, P20	21	40	42	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1998	317	7161					780	783		10.1136/bmj.317.7161.780	http://dx.doi.org/10.1136/bmj.317.7161.780			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740563	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000076084200023
J	Herzog, CA; Ma, JZ; Collins, AJ				Herzog, CA; Ma, JZ; Collins, AJ			Poor long-term survival after acute myocardial infarction among patients on long-term dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINNESOTA HEART SURVEY; DIABETES-MELLITUS; TRENDS; HEMODIALYSIS; MORBIDITY; MORTALITY	Background Cardiovascular disease is common in patients on long-term dialysis, and it accounts for 44 percent of overall mortality in this group. We undertook a study to assess long-term survival after acute myocardial infarction among patients in the United States who were receiving long-term dialysis, Methods Patients on dialysis who were hospitalized during the period from 1977 to 1995 for a first myocardial infarction after the initiation of renal-replacement therapy were retrospectively identified from the U.S. Renal Data System data base. Overall mortality and mortality from cardiac causes (including all in-hospital deaths) were estimated by the life-table method. The effect of independent predictors on survival was examined in a Cox regression model with adjustment for existing illnesses. Results The overall mortality (+/-SE) after acute myocardial infarction among 34,189 patients on long term dialysis was 59.3+/-0.3 percent at one year, 73.0+/-0.3 percent at two years, and 89.9+/-0.2 percent at five years. The mortality from cardiac causes was 40.8+/-0.3 percent at one year, 51.8+/-0.3 percent at two years, and 70.2+/-0.4 percent at five years. Patients who were older or had diabetes had higher mortality than patients without these characteristics. Adverse outcomes occurred even in patients who had acute myocardial infarction in 1990 through 1995. Also, the mortality rate after myocardial infarction was considerably higher for patients on long-term dialysis than for renal-transplant recipients. Conclusions Patients on dialysis who have acute myocardial infarction have high mortality from cardiac causes and poor long-term survival. (N Engl J Med 1998;339:799-805.) (C) 1998, Massachusetts Medical Society.	Hennepin Cty Med Ctr, Dept Internal Med, Minneapolis, MN 55415 USA; Univ Minnesota, Minneapolis, MN USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Herzog, CA (corresponding author), Hennepin Cty Med Ctr, Dept Internal Med, 701 Pk Ave, Minneapolis, MN 55415 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049540] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 RO1 DK 49540] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; COLLINS AJ, 1990, AM J KIDNEY DIS, V15, P422, DOI 10.1016/S0272-6386(12)70360-8; COX DR, 1972, J R STAT SOC B, V34, P187; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HELD P J, 1991, Journal of the American Society of Nephrology, V2, P328; HERZOG CA, 1997, CIRCULATION S1, V96, P202; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEANE WF, 1994, AM J KIDNEY DIS, V24, P1010, DOI 10.1016/S0272-6386(12)81076-6; KONG TQ, 1993, CIRCULATION, V88, P49; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V3; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V2; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V1; Rubin Timothy A., 1996, Journal of the American College of Cardiology, V27, p67A; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; SPRAFKA JM, 1991, DIABETES CARE, V14, P537, DOI 10.2337/diacare.14.7.537; *USRDS, 1992, USRDS NIH PUBL, P61; *USRDS, 1997, USRDS NIH PUBL, pD1; *USRDS, 1997, USRDS NIH PUBL, P35; *USRDS, 1997, USRDS NIH PUBL, P21; *USRDS, 1997, USRDS NIH PUBL, pC1; *USRDS, 1997, USRDS NIH PUBL, P69; *USRDS, 1997, USRDS NIH PUBL, P91	28	715	749	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					799	805		10.1056/NEJM199809173391203	http://dx.doi.org/10.1056/NEJM199809173391203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738087	Bronze			2023-01-03	WOS:000075909200003
J	Grimes, D; von Hertzen, H; Piaggio, G; Van Look, PFA; Peregoudov, S; Vucurevic, M; Roberts, HE; Wu, SC; Bagshaw, SN; Otubu, JA; Ogedengbe, OK; Pretnar-Darovec, A; Kirkman, RJ; Ding, JH; Mittal, S; Leavesley, G; Austin, KL; Creinin, M; Adetoro, OO; Guilbert, E; Chen, JK; Bygdeman, M; Bartfai, G; Khomassuridze, A; Cheng, WY; Oyunbileg, A; Sparrow, M				Grimes, D; von Hertzen, H; Piaggio, G; Van Look, PFA; Peregoudov, S; Vucurevic, M; Roberts, HE; Wu, SC; Bagshaw, SN; Otubu, JA; Ogedengbe, OK; Pretnar-Darovec, A; Kirkman, RJ; Ding, JH; Mittal, S; Leavesley, G; Austin, KL; Creinin, M; Adetoro, OO; Guilbert, E; Chen, JK; Bygdeman, M; Bartfai, G; Khomassuridze, A; Cheng, WY; Oyunbileg, A; Sparrow, M		Task Force Postovulatory Methods Fertility Reg	Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception	LANCET			English	Article							POST-COITAL CONTRACEPTION; POSTCOITAL CONTRACEPTION; LONG	Background A previous randomised study suggested that the progestagen, levonorgestrel, given alone in two separate doses each of 0.75 mg caused nausea and vomiting in fewer women and might be more effective than the Yuzpe regimen of combined oral contraceptives for emergency contraception, although the difference was not significant. We compared these two regimens when started within 72 h of unprotected coitus. Methods We enrolled in the double-blind, randomised trial 1998 women at 21 centres worldwide. Women with regular menses, not using hormonal contraception, and requesting emergency contraception after one unprotected coitus, received levonorgestrel (0.75 mg, repeated 12 h later) or the Yuzpe regimen (ethinyloestradiol 100 mu g plus levonorgestrel 0.5 mg, repeated 12 h later). Findings Outcome was unknown for 43 women (25 assigned levonorgestrel, 18 assigned Yuzpe regimen). Among the remaining 1955 women, the crude pregnancy rate was 1.1% (11/976) in the levonorgestrel group compared with 3.2% (31/979) in the Yuzpe regimen group. The crude relative risk of pregnancy for levonorgestrel compared with the Yuzpe regimen was 0.36 (95% CI 0.18-0.70). The proportion of pregnancies prevented (compared with the expected number without treatment) was 85% (74-93) with the levonorgestrel regimen and 57% (39-71) with the Yuzpe regimen. Nausea (23.1 vs 50.5%) and vomiting (5.6 vs 18.8%) were significantly less frequent with the levonorgestrel regimen than with the Yuzpe regimen (p<0.01). The efficacy of both treatments declined with increasing time since unprotected coitus (p=0.01). Interpretation The levonorgestrel regimen was better tolerated and more effective than the current standard in hormonal emergency contraception. With either regimen, the earlier the treatment is given, the more effective it seems to be.	New Zealand Family Planning Assoc, Auckland, New Zealand; Natl Res Inst Family Planning, Beijing, Peoples R China; New Zealand Family Planning Assoc, Christchurch, New Zealand; Univ Jos, Jos, Nigeria; Univ Lagos, Lagos, Nigeria; Univ Ljubljana, Dept Obstet & Gynaecol, Ljubljana, Slovenia; Univ Manchester, Manchester M13 9PL, Lancs, England; Jiangsu Family Planning Inst, Nanjing, Peoples R China; All India Inst Med Sci, New Delhi, India; Family Planning Assoc Western Australia, Northbridge, Australia; Ctr Res Human Reprod, Panama City, Panama; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; Ogun State Univ Teaching Hosp, Shagamu, Nigeria; Univ Laval, Le Ctr Hosp, Ste Foy, PQ G1K 7P4, Canada; Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China; Karolinska Hosp, Stockholm, Sweden; Albert Szent Gyorgyi Med Univ, H-6701 Szeged, Hungary; Zhordania Inst Human Reprod, Tbilisi, Georgia; Tianjin Municipal Res Inst Family Planning, Tianjin, Peoples R China; State Res Ctr MCH Human Reprod, Ulaanbaatar, Mongolia; New Zealand Family Planning Assoc, Wellington, New Zealand	National Research Institute for Family Planning - China; University of Jos; University of Lagos; University of Ljubljana; University of Manchester; All India Institute of Medical Sciences (AIIMS) New Delhi; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Karolinska Institutet; Karolinska University Hospital; Szeged University	von Hertzen, H (corresponding author), WHO, Special Programme Res Dev & Res Training Huma, CH-1211 Geneva 27, Switzerland.		Creinin, Mitchell/AAH-3488-2020	Creinin, Mitchell/0000-0001-5967-8180				FASOLI M, 1989, CONTRACEPTION, V39, P459, DOI 10.1016/0010-7824(89)90123-6; FASOLI M, 1989, CONTRACEPTION, V39, P699; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; GROU F, 1994, AM J OBSTET GYNECOL, V171, P1529, DOI 10.1016/0002-9378(94)90396-4; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; KANE LA, 1989, NEW ZEAL MED J, V102, P151; Machin D, 1997, SAMPLE SIZE TABLES C; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; Trussell J, 1998, CONTRACEPTION, V57, P363, DOI 10.1016/S0010-7824(98)00042-0; Trussell J, 1996, FAM PLANN PERSPECT, V28, P58, DOI 10.2307/2136125; Trussell J, 1996, OBSTET GYNECOL, V88, P150, DOI 10.1016/0029-7844(96)00036-1; WEBB AMC, 1992, BMJ-BRIT MED J, V305, P927, DOI 10.1136/bmj.305.6859.927; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301; YUZPE AA, 1982, FERTIL STERIL, V37, P508	14	547	562	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1998	352	9126					428	433						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708750				2023-01-03	WOS:000075252000009
J	Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK				Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK			A multidisciplinary approach to therapy for unresectable malignant thymoma	ANNALS OF INTERNAL MEDICINE			English	Article							INVASIVE THYMOMA; NEOADJUVANT CHEMOTHERAPY; CLINICAL STAGES; CISPLATIN; SURVIVAL; CYCLOPHOSPHAMIDE; INTERGROUP; RESECTION; PHASE	Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor. Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma. Design: Prospective cohort study. Setting: Tertiary care cancer center. Participants: All eligible patients had newly diagnosed, histologically proven, unresectable malignant thymoma. Intervention: The treatment regimen consisted of induction chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone), surgical resection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone). Tissue samples were taken at the time of surgical resection for assessment of tumor necrosis and Ki-67 expression. Measurements: Tumor response and resectability (both overall and after induction chemotherapy) and disease-free survival rate in patients who received multimodal therapy. Results: 13 patients were consecutively enrolled from February 1990 to December 1996, and 12 evaluable patients were assessed for response. Disease responded to induction chemotherapy completely in 3 patients (25%) and partially in 8 patients (67%); 1 patient had a minor response (8%). Eleven patients had surgical resection; 1 refused surgery. Tumors were removed completely in 9 (82%) and incompletely in 2 (18%) of 11 patients who had been receiving radiation therapy and consolidation chemotherapy. All 12 patients are alive (100% at 7 years), with a median follow-up of 43 months, and 10 patients are disease free (73 % disease-free survival at 7 years). A high correlation was seen between tumor necrosis after induction chemotherapy and Ki-67 expression (r = -0.88). Conclusions: Aggressive multimodal treatment is highly effective and may cure locally advanced, unresectable malignant thymoma.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Shin, DM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Shin, Dong Moon/G-9649-2013; Ray, Dana M/C-3470-2013	Shin, Dong Moon/0000-0002-8245-4174; Putnam, Joe/0000-0002-7504-2104				BERRUTI A, 1993, ANN ONCOL, V4, P429, DOI 10.1093/oxfordjournals.annonc.a058527; BLUMBERG D, 1995, ANN THORAC SURG, V60, P908, DOI 10.1016/0003-4975(95)00669-C; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COWEN D, 1995, RADIOTHER ONCOL, V34, P9, DOI 10.1016/0167-8140(94)01493-M; Giaccone G, 1996, J CLIN ONCOL, V14, P814, DOI 10.1200/JCO.1996.14.3.814; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOMAKI R, 1994, MOSS RAD ONCOLOGY RA, P320; LOEHRER PJ, 1990, ANN INTERN MED, V113, P520, DOI 10.7326/0003-4819-113-7-520; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164, DOI 10.1200/JCO.1994.12.6.1164; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093, DOI 10.1200/JCO.1997.15.9.3093; MACCHIARINI P, 1991, CANCER, V68, P706, DOI 10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H; MAGGI G, 1986, CANCER-AM CANCER SOC, V58, P765, DOI 10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO;2-S; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; MCCART JA, 1993, J SURG ONCOL, V54, P233, DOI 10.1002/jso.2930540409; PARK HS, 1994, CANCER-AM CANCER SOC, V73, P2491, DOI 10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6; REA F, 1993, J THORAC CARDIOV SUR, V106, P543; THOMAS C R JR, 1990, Current Opinion in Oncology, V2, P359; Uematsu M, 1996, INT J RADIAT ONCOL, V35, P357, DOI 10.1016/0360-3016(96)00086-7; VERLEY JM, 1985, CANCER, V55, P1074, DOI 10.1002/1097-0142(19850301)55:5<1074::AID-CNCR2820550524>3.0.CO;2-T; Yang WI, 1996, HUM PATHOL, V27, P70, DOI 10.1016/S0046-8177(96)90140-9	20	92	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					100	104		10.7326/0003-4819-129-2-199807150-00006	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669967				2023-01-03	WOS:000074852000004
J	Morrell, CJ; Walters, SJ; Dixon, S; Collins, KA; Brereton, LML; Peters, J; Brooker, CGD				Morrell, CJ; Walters, SJ; Dixon, S; Collins, KA; Brereton, LML; Peters, J; Brooker, CGD			Cost effectiveness of community leg ulcer clinics: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENOUS ULCERS; COMPRESSION; INDEX; CARE	Objectives: To establish the relative cost effectiveness of community leg ulcer clinics that use four layer compression bandaging versus usual care provided by district nurses. Design: Randomised controlled trial with 1 year of follow up. Setting: Eight community based research clinics in four trusts in Trent Subjects: 233 patients with venous leg ulcers allocated at random to intervention (120) or control (113) group. Interventions: Weekly treatment with four layer bandaging in a leg ulcer clinic (clinic group) or usual care at home by the district nursing service (control group). Main outcome measures: Time to complete ulcer healing, patient health status, and recurrence of ulcers. Satisfaction with care, use of services, and personal costs were also monitored. Results: The ulcers of patients in the clinic group tended to heal sooner than those in the control group over the whole 12 month follow up (log rank P = 0.03). At 12 weeks, 34% of patients in the clinic group were healed compared with 24% in the control. The crude initial healing rate of ulcers in intervention compared with control patients was 1.45 (95% confidence interval 1.04 to 2.03), No significant differences were found between the groups in health status. Mean total NHS costs were pound 878.06 per year for the clinic group and pound 859.34 for the control (P = 0.89). Conclusions: Community based leg ulcer clinics with trained nurses using four layer bandaging is more effective than traditional home based treatment. This benefit is achieved at a small additional cost and could be delivered at reduced cost if certain service configurations were used.	Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; No Gen Hosp, Sch Nursing & Midwifery, Sheffield S5 7NA, S Yorkshire, England; Univ Manchester, Sch Nursing, Manchester M13 9PL, Lancs, England	University of Sheffield; Northern General Hospital; University of Manchester	Morrell, CJ (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	j.morrell1@sheffield.ac.uk		Brooker, Charlie/0000-0003-1005-526X; Dixon, Simon/0000-0001-7394-7009				ANDERSON MH, 1995, QUAL LIFE RES, V4, P388; [Anonymous], 1997, BRIT J COMMUNITY HLT, V2, P427; [Anonymous], 1995, COMP HLTH STAT; BLAIR SD, 1988, BRIT MED J, V297, P1159, DOI 10.1136/bmj.297.6657.1159; BLAIR SD, 1988, PHLEBOLOGY, V31, P129; Bosanquet N, 1993, Health Trends, V25, P146; BOSANQUET N, 1992, PHLEBOLOGY, V7, P44; Brereton, 1998, BRIT J COMMUNITY NUR, V3, P6; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; Collett D., 1994, MODELLING SURVIVAL D; CULLUM N, 1994, NURSING MANAGEMENT L; Efron B., 1993, INTRO BOOTSTRAP; Fletcher A, 1995, J Wound Care, V4, P471; FRANKS PJ, 1995, AGE AGEING, V24, P490, DOI 10.1093/ageing/24.6.490; Hamer C, 1994, J Wound Care, V3, P99; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Hyland M E, 1994, J Wound Care, V3, P294; LAING W, 1992, CHRONIC VENOUS DIS L; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; MOFFATT CJ, 1992, BRIT MED J, V305, P1389, DOI 10.1136/bmj.305.6866.1389; Morrell L., 1997, BRIT J COMMUNITY HLT, V2, P156; NETTEN A, 1996, UNIT COSTS HLTH SOCI; NORUSIS NJ, 1993, SPSS WINDOWS ADV STA; Price P, 1993, J Wound Care, V2, P304; Simon DA, 1996, BRIT MED J, V312, P1648, DOI 10.1136/bmj.312.7047.1648; SKENE AI, 1992, BRIT MED J, V305, P1119, DOI 10.1136/bmj.305.6862.1119; Thompson B, 1996, J WOUND CARE, V5, P212; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson E., 1989, HLTH THENDS, V21, P97	33	104	106	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1998	316	7143					1487	1491		10.1136/bmj.316.7143.1487	http://dx.doi.org/10.1136/bmj.316.7143.1487			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582132	Green Accepted, Green Published, Bronze, Green Submitted			2023-01-03	WOS:000073707700020
J	Tang, JL; Armitage, JM; Lancaster, T; Silagy, CA; Fowler, GH; Neil, HAW				Tang, JL; Armitage, JM; Lancaster, T; Silagy, CA; Fowler, GH; Neil, HAW			Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-FAT DIET; SERUM-CHOLESTEROL; WEIGHT-REDUCTION; GENERAL-PRACTICE; CLINICAL-TRIALS; HEART-DISEASE; RISK-FACTORS; LIPOPROTEINS; METAANALYSIS; LIPIDS	Objectives: To estimate the efficacy of dietary advice to lower blood total cholesterol concentration in free-living subjects and to investigate the efficacy of different dietary recommendations. Design: Systematic overview of 19 randomised controlled trials including 28 comparisons. Subjects: Free-living subjects. Interventions: Individualised dietary advice to modify fat intake. Main outcome measure: Percentage difference in blood total cholesterol concentration between the intervention and control groups. Results: The percentage reduction in blood total cholesterol attributable to dietary advice after at least six months of intervention was 5.3% (95% confidence interval 4.7% to 5.9%). Including both short and long duration studies, the effect was 8.5% at 3 months and 5.5% at 12 months. Diets equivalent to the step 2 diet of the American Heart Association were of similar efficacy to diets that aimed to lower total fat intake or to raise the polyunsaturated to saturated fatty acid ratio. These diets were moderately more effective than the step 1 diet of the American Heart Association (6.1% v 3.0% reduction in blood total cholesterol concentration; P < 0.0001). On the basis of reported food intake, the targets for dietary change were seldom achieved. The observed reductions in blood total cholesterol concentrations in the individual trials were consistent with those predicted from dietary intake on the basis of the Keys equation. Conclusions: Individualised dietary advice for reducing cholesterol concentration is modestly effective in free-living subjects. More intensive diets achieve a greater reduction in serum cholesterol concentration. Failure to comply fully with dietary recommendations is the likely explanation for this limited efficacy.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford, England; Univ Oxford, Radcliffe Infirm, Div Publ Hlth & Primary Care, Oxford OX2 6HE, England; Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Flinders University South Australia	Armitage, JM (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Harkness Bldg, Oxford, England.	Jane.armitage@ctsu.ox.ac.uk	Tang, JL/G-1759-2013; Tang, Jin-Ling/AAJ-4090-2021					ANDERSON JW, 1992, AM J CLIN NUTR, V56, P887, DOI 10.1093/ajcn/56.5.887; [Anonymous], 1995, JAMA, V273, P1429; [Anonymous], 1965, LANCET, V2, P501; BARON JA, 1990, BRIT J GEN PRACT, V40, P137; BLOEMBERG BPM, 1991, AM J EPIDEMIOL, V134, P39, DOI 10.1093/oxfordjournals.aje.a115991; BOYD NF, 1988, JNCI-J NATL CANCER I, V80, P1244, DOI 10.1093/jnci/80.15.1244; Bracken Michael B., 1992, P13; BURR ML, 1989, LANCET, V2, P757; BUZZARD IM, 1990, J AM DIET ASSOC, V90, P42; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CURZIO JL, 1989, J HYPERTENS, V7, pS254, DOI 10.1097/00004872-198900076-00123; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DELORGERIL, 1995, LANCET, V345, P738; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DEMARKWAHNEFRIED W, 1990, J AM DIET ASSOC, V90, P223; DENKE MA, 1995, ARCH INTERN MED, V155, P17, DOI 10.1001/archinte.155.1.17; DREON DM, 1990, JAMA-J AM MED ASSOC, V263, P2462, DOI 10.1001/jama.263.18.2462; DUFFIELD RGM, 1983, LANCET, V2, P639; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Gregory J, 1990, DIETARY NUTR SURVEY; HARRIS WS, 1989, J LIPID RES, V30, P785; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; INSULL W, 1990, ARCH INTERN MED, V150, P421, DOI 10.1001/archinte.150.2.421; JALKANEN L, 1991, SCAND J SOC MED, V19, P66, DOI 10.1177/140349489101900112; JOHNSTON HJ, 1995, MED J AUSTRALIA, V162, P524, DOI 10.5694/j.1326-5377.1995.tb138510.x; KEYS A, 1957, LANCET, V2, P959; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P368; KORMHOUT D, 1986, BIBL NUTR DIET, V37, P119; KUUSI T, 1985, J LIPID RES, V26, P360; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEREN P, 1968, B NEW YORK ACAD MED, V44, P1012; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; MACMAHON S, 1987, NEPHRON, V47, P8, DOI 10.1159/000184544; MARNIEMI J, 1990, INT J OBESITY, V14, P113; MARTIN MJ, 1986, LANCET, V2, P933; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; REID CM, 1994, J HYPERTENS, V12, P291; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; RIVELLESE AA, 1994, BRIT MED J, V308, P227, DOI 10.1136/bmj.308.6923.227; SARKKINEN ES, 1994, ATHEROSCLEROSIS, V105, P9, DOI 10.1016/0021-9150(94)90003-5; SCIARRONE SEG, 1992, J HYPERTENS, V10, P287, DOI 10.1097/00004872-199203000-00013; *SECR STAT HLTH, 1992, CMNDCMND; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SINGH RB, 1991, NUTRITION, V7, P210; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1968, CIRCULATION, V37, P428	56	183	188	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	1998	316	7139					1213	1219		10.1136/bmj.316.7139.1213	http://dx.doi.org/10.1136/bmj.316.7139.1213			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552999	Green Published			2023-01-03	WOS:000073224100025
J	Ballard, RA; Ballard, PL; Cnaan, A; Pinto-Martin, J; Davis, DJ; Padbury, JF; Phibbs, RH; Parer, JT; Hart, MC; Mannino, FL; Sawai, SK				Ballard, RA; Ballard, PL; Cnaan, A; Pinto-Martin, J; Davis, DJ; Padbury, JF; Phibbs, RH; Parer, JT; Hart, MC; Mannino, FL; Sawai, SK		N Am Thyrotropin-Releas Horm Study Grp	Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; THYROID-HORMONES; FETAL SHEEP; PRENATAL TREATMENT; PREMATURE-INFANTS; CONTROLLED TRIAL; SURFACTANT; MATURATION; THERAPY; GLUCOCORTICOIDS	Background Pulmonary disease is common in preterm infants, de!despite antenatal glucocorticoid therapy. The addition of antenatal thyrotropin-releasing hormone therapy has been reported to decrease pulmonary morbidity in these infants. Methods We enrolled 996 women at 13 North American centers who were in preterm labor at <30 weeks' gestation in a double-blind, placebo-controlled, randomized trial of antenatal thyrotropin-releasing hormone, given intravenously in four doses of 400 mu g each at eight-hour intervals. The primary outcome was chronic lung disease or death of the infant on or before the 28th day after delivery, and secondary outcomes were respiratory distress syndrome and chronic lung disease or death at 36 weeks' postmen strual age, Complete data were available for 981 women and their 1134 live-born infants. The 769 infants born at less than or equal to:32 weeks' gestation were defined as the group at risk.:. Results There were no significant differences between the at-risk treatment and placebo groups in mean (+/-SD) birth weight (1109+/-354 vs. 1097+/-355 g), gestational age (27.9+/-2.1 vs. 27.9+/-2.1 weeks), sex, or race. The frequencies of respiratory distress syndrome (66 percent vs, 65 percent), death at 28 days (11 percent vs. 11 percent), chronic lung disease or death at 28 days (45 percent vs. 42 percent) and at 36 weeks (32 percent vs. 34 percent), and other neonatal complications as well as the severity of; lung disease were not significantly different in the at-risk treatment and placebo groups, Similarly, there were no differences in outcome between the treatment and placebo groups for the infants born at >32 weeks' gestation. Conclusions in preterm infants at risk for lung disease, antenatal administration of thyrotropin-releasing hormone and glucocorticoid is no more beneficial than glucocorticoid alone, (C) 1998, Massachusetts Medical Society.	Univ Penn, Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; St Josephs Hosp, Phoenix, AZ USA; Univ Calif San Diego, San Diego, CA 92103 USA; Good Samaritan Hosp, Phoenix, AZ USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Ottawa; Children's Hospital of Eastern Ontario; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California San Francisco; St. Joseph's Hospital and Medical Center; University of California System; University of California San Diego	Ballard, RA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Div Neonatol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029201] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040, M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00040, MO1-RR000425] Funding Source: Medline; NICHD NIH HHS [R01-HD29201] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTHABE F, 1991, PEDIATR RES, V29, pA200; BALLARD PL, 1995, AM J OBSTET GYNECOL, V173, P254, DOI 10.1016/0002-9378(95)90210-4; BALLARD PL, 1992, PEDIATR RES, V32, P673, DOI 10.1203/00006450-199212000-00009; BALLARD PL, 1984, J CLIN INVEST, V74, P898, DOI 10.1172/JCI111507; BALLARD PL, 1986, MONOGR ENDOCRINOL, V28, P197; BALLARD RA, 1992, LANCET, V339, P510, DOI 10.1016/0140-6736(92)90337-3; BOSHIER DP, 1989, J DEV PHYSIOL, V12, P49; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; Crowther CA, 1997, PEDIATRICS, V99, P311, DOI 10.1542/peds.99.3.311; CROWTHER CA, 1995, LANCET, V345, P877; CROWTHER CA, 1994, PREGNANCY CHILDBIRTH; DEZEGHER F, 1992, ARCH DIS CHILD-FETAL, V67, P450, DOI 10.1136/adc.67.4_Spec_No.450; GILSTRAP LC, 1995, JAMA-J AM MED ASSOC, V273, P413, DOI 10.1001/jama.1995.03520290065031; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P678, DOI 10.1210/jcem-62-4-678; GROSS I, 1984, PEDIATR RES, V18, P191; IKEGAMI M, 1991, J APPL PHYSIOL, V70, P2268, DOI 10.1152/jappl.1991.70.5.2268; IKEGAMI M, 1987, AM REV RESPIR DIS, V136, P892, DOI 10.1164/ajrccm/136.4.892; KARI MA, 1994, PEDIATRICS, V93, P730; KNIGHT DB, 1994, AM J OBSTET GYNECOL, V171, P11, DOI 10.1016/S0002-9378(94)70070-2; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIGGINS GC, 1988, J APPL PHYSIOL, V65, P1880, DOI 10.1152/jappl.1988.65.4.1880; MAYA F, 1991, J PEDIATR-US, V119, P966, DOI 10.1016/S0022-3476(05)83057-4; McCormick MC, 1997, PEDIATRICS, V99, P476, DOI 10.1542/peds.99.3.476; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; MOYA F, 1986, PEDIATR RES, V20, P982, DOI 10.1203/00006450-198610000-00018; MOYA FR, 1993, SEMIN PERINATOL, V17, P267; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SCHELLENBERG JC, 1988, J APPL PHYSIOL, V65, P94, DOI 10.1152/jappl.1988.65.1.94; Torres J, 1998, AM J OBSTET GYNECOL, V178, P33; WARBURTON D, 1988, PEDIATR RES, V24, P166, DOI 10.1203/00006450-198808000-00005; Zimmerman J J, 1994, Curr Probl Pediatr, V24, P159, DOI 10.1016/0045-9380(94)90033-7	31	49	49	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	1998	338	8					493	498		10.1056/NEJM199802193380802	http://dx.doi.org/10.1056/NEJM199802193380802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX639	9468465	Bronze			2023-01-03	WOS:000072061400002
J	Newstead, CG				Newstead, CG			Cancer risk in patients on dialysis	LANCET			English	Editorial Material							STAGE RENAL-DISEASE; TRANSPLANTATION; CARCINOMA		St James Univ Hosp, Renal Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Newstead, CG (corresponding author), St James Univ Hosp, Renal Unit, Beckett St, Leeds LS9 7TF, W Yorkshire, England.							Bukvic D, 1996, Srp Arh Celok Lek, V124 Suppl 1, P181; CHANTREL, 1999, NEPHROL DIAL TRANSPL, V14, P129; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Curtis J J, 1998, J Am Soc Nephrol, V9, pS137; Kliem V, 1996, TRANSPLANT INT, V9, P231, DOI 10.1111/j.1432-2277.1996.tb00885.x; Levine E, 1996, RADIOL CLIN N AM, V34, P947; Newstead CG, 1998, LANCET, V351, P610, DOI 10.1016/S0140-6736(98)22009-5; RAINE AEG, 1992, NEPHROL DIAL TRANSPL, V7, P7; SMITH PK, 1989, DRUGS KIDNEY, P1; Swindle P, 1998, BRIT J UROL, V81, P229; TAYLOR JS, 1972, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1972.tb106534.x; Vamvakas S, 1997, SCHWEIZ MED WSCHR, V127, P597	12	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					90	91		10.1016/S0140-6736(99)00207-X	http://dx.doi.org/10.1016/S0140-6736(99)00207-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408481				2023-01-03	WOS:000081377100007
J	Pandey, AV; Tekwani, BL; Singh, RL; Chauhan, VS				Pandey, AV; Tekwani, BL; Singh, RL; Chauhan, VS			Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THALASSEMIC ERYTHROCYTES; PLASMODIUM-FALCIPARUM; RODENT MALARIA; QUINOLINE ANTIMALARIALS; DRUG ACCUMULATION; IN-VITRO; CHLOROQUINE; HEMATIN; MECHANISM; POLYMERIZATION	Endoperoxide antimalarials based on the ancient Chinese drug Qinghaosu (artemisinin) are currently our major hope in the fight against drug-resistant malaria. Rational drug design based on artemisinin and its analogues is slow as the mechanism of action of these antimalarials is not clear. Here we report that these drugs, at least in part, exert their effect by interfering with the plasmodial hemoglobin catabolic pathway and inhibition of heme polymerization. In an in vitro experiment we observed inhibition of digestive vacuole proteolytic activity of malarial parasite by artemisinin, These observations were further confirmed by ex vivo experiments showing accumulation of hemoglobin in the parasites treated with artemisinin, suggesting inhibition of hemoglobin degradation. We found artemisinin to be a potent inhibitor of heme polymerization activity mediated by Plasmodium yoelii lysates as well as Plasmodium falciparum histidine-rich protein II. Interaction of artemisinin with the purified malarial hemozoin in vitro resulted in the concentration-dependent breakdown of the malaria pigment. Our results presented here may explain the selective and rapid toxicity of these drugs on mature, hemozoin-containing, stages of malarial parasite. Since artemisinin and its analogues appear to have similar molecular targets as chloroquine despite having different structures, they can potentially bypass the quinoline resistance machinery of the malarial parasite, which causes sublethal accumulation of these drugs in resistant strains.	Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, New Delhi 110067, India; Cent Drug Res Inst, Div Biochem, Lucknow 226001, Uttar Pradesh, India; RML Avadh Univ, Dept Biochem, Faizabad 224001, Uttar Pradesh, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Chauhan, VS (corresponding author), Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, Aruna Asaf Ali Marg,POB 10504, New Delhi 110067, India.	virender@icgeb.res.in	Chauhan, Virander S./K-5276-2019; Pandey, Amit V/A-7223-2008; Pandey, Amit V/AAO-6442-2020	Pandey, Amit V/0000-0001-8331-5902; Pandey, Amit V/0000-0001-8331-5902				Adams PA, 1996, BIOCHEM J, V318, P25, DOI 10.1042/bj3180025; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Bohle DS, 1997, J BIOL CHEM, V272, P713, DOI 10.1074/jbc.272.2.713; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; CAILLARD V, 1992, EXP PARASITOL, V75, P449, DOI 10.1016/0014-4894(92)90258-C; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1987, J BIOL CHEM, V262, P15552; Fitch CD, 1996, MOL BIOCHEM PARASIT, V82, P261, DOI 10.1016/0166-6851(96)02744-2; Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GEARY TG, 1989, AM J TROP MED HYG, V40, P240, DOI 10.4269/ajtmh.1989.40.240; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Grigorov M, 1997, J CHEM INF COMP SCI, V37, P124, DOI 10.1021/ci9601168; HIEN TT, 1993, LANCET, V341, P603; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; Ignatushchenko MV, 1997, FEBS LETT, V409, P67, DOI 10.1016/S0014-5793(97)00405-5; Jefford CW, 1996, HELV CHIM ACTA, V79, P1475, DOI 10.1002/hlca.19960790520; KAMCHONWONGPAISAN S, 1994, J CLIN INVEST, V93, P467, DOI 10.1172/JCI116994; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P238, DOI 10.4269/ajtmh.1999.60.238; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B; Mohapatra PK, 1996, INDIAN J MED RES, V104, P284; Newton P, 1999, ANNU REV MED, V50, P179, DOI 10.1146/annurev.med.50.1.179; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Paitayatat S, 1997, J MED CHEM, V40, P633, DOI 10.1021/jm960767v; PANDEY AV, 1995, BIOMED RES-TOKYO, V16, P115, DOI 10.2220/biomedres.16.115; Pandey AV, 1999, ANAL BIOCHEM, V268, P159, DOI 10.1006/abio.1998.2997; Pandey AV, 1997, FEBS LETT, V402, P236, DOI 10.1016/S0014-5793(96)01536-0; Pandey AV, 1998, CURR SCI INDIA, V75, P911; Pandey AV, 1997, MOL BIOCHEM PARASIT, V90, P281, DOI 10.1016/S0166-6851(97)00161-8; Pandey AV, 1999, J PHARMACEUT BIOMED, V20, P203, DOI 10.1016/S0731-7085(99)00021-7; Pandey AV, 1996, FEBS LETT, V393, P189, DOI 10.1016/0014-5793(96)00881-2; PETERS W, 1986, ANN TROP MED PARASIT, V80, P483, DOI 10.1080/00034983.1986.11812054; Platel DFN, 1999, MOL BIOCHEM PARASIT, V98, P215, DOI 10.1016/S0166-6851(98)00170-4; Ridley RG, 1997, ANN TROP MED PARASIT, V91, P559, DOI 10.1080/00034989760932; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SHERR L, 1995, AIDS CARE, V7, P85; SHUKLA KL, 1995, J MOL GRAPHICS, V13, P215, DOI 10.1016/0263-7855(94)00001-9; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Sullivan DJ, 1998, J BIOL CHEM, V273, P31103, DOI 10.1074/jbc.273.47.31103; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1992, BIOCHIM BIOPHYS ACTA, V1122, P256, DOI 10.1016/0167-4838(92)90401-X; Vattanaviboon P, 1998, MOL PHARMACOL, V53, P492, DOI 10.1124/mol.53.3.492; WELLEMS TE, 1992, NATURE, V355, P108, DOI 10.1038/355108a0; YANG YZ, 1993, BIOCHEM PHARMACOL, V46, P336, DOI 10.1016/0006-2952(93)90425-V	59	200	207	2	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19383	19388		10.1074/jbc.274.27.19383	http://dx.doi.org/10.1074/jbc.274.27.19383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383451	hybrid			2023-01-03	WOS:000081196300074
J	Steer, P; Flint, C				Steer, P; Flint, C			ABC of labour care - Physiology and management of normal labour	BRITISH MEDICAL JOURNAL			English	Review									Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England; Thames Valley Univ, London, England	Imperial College London; University of West London	Steer, P (corresponding author), Chelsea & Westminster Hosp, Imperial Coll Sch Med, London, England.							BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; DAVIES R, 1995, TURNBULLS OBSTET; LIU DTY, 1991, LABOUR WARD MANUAL; PHILPOTT RH, 1972, BRIT MED J, V4, P163, DOI 10.1136/bmj.4.5833.163; Rogers J, 1998, LANCET, V351, P693, DOI 10.1016/S0140-6736(97)09409-9; WHITTLE M, 1995, TURNBULLS OBSTET	6	11	11	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1999	318	7186					793	796		10.1136/bmj.318.7186.793	http://dx.doi.org/10.1136/bmj.318.7186.793			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BX	10082709	Green Published, Green Submitted			2023-01-03	WOS:000079421700033
J	Holmich, P; Uhrskou, P; Ulnits, L; Kanstrup, IL; Nielsen, MB; Bjerg, AM; Krogsgaard, K				Holmich, P; Uhrskou, P; Ulnits, L; Kanstrup, IL; Nielsen, MB; Bjerg, AM; Krogsgaard, K			Effectiveness of active physical training as treatment for long-standing adductor-related groin pain in athletes: randomised trial	LANCET			English	Article							INJURIES; TENDON; SOCCER	Background Groin pain is common among athletes. A major cause of long-standing problems is adductor-related groin pain. The purpose of this randomised clinical trial was to compare an active training programme (AT) with physiotherapy treatment without active training (PT) in the treatment of adductor-related groin pain in athletes. Methods 68 athletes with long-standing (median 40 weeks) adductor-related groin pain-after examination according to a standardised protocol-were randomly assigned to AT or PT. The treatment period was 8-12 weeks. 4 months after the end of treatment a standardised examination was done. The examining physician was unaware of the treatment allocation. The ultimate outcome measure was full return to sports at the same level without groin pain. Analyses were by intention to treat. Findings 23 patients in the AT group and four in the PT group returned to sports without groin pain (odds ratio, multiple-logistic-regression analysis, 12.7 [95% CI 3.4-47.2]). The subjective global assessments of the effect of the treatments showed a significant (p = 0.006) linear trend towards a better effect in the AT group. A per-protocol analysis did not show appreciably different results. Interpretation AT with a programme aimed at improving strength and coordination of the muscles acting on the pelvis, in particular the adductor muscles, is very effective in the treatment of athletes with long-standing adductor-related groin pain, The potential preventive value of a short programme based upon the principles of AT should be assessed in future, randomised, clinical trials.	Amager Univ Hosp, Dept Orthopaed Surg, Clin Sports Med, DK-2300 Copenhagen S, Denmark; Herlev Univ Hosp, Dept Rheumatol, Herlev, Denmark; Herlev Univ Hosp, Dept Clin Physiol, Herlev, Denmark; Glostrup Univ Hosp, Dept Radiol, Glostrup, Denmark; Univ Copenhagen, Inst Prevent Med, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen	Holmich, P (corresponding author), Amager Univ Hosp, Dept Orthopaed Surg, Clin Sports Med, DK-2300 Copenhagen S, Denmark.		Nielsen, Michael Bachmann/U-2749-2018	Nielsen, Michael Bachmann/0000-0002-9380-1688; Krogsgaard, Kim/0000-0002-7153-9287; Holmich, Per/0000-0003-2098-0272				AKERMARK C, 1992, AM J SPORT MED, V20, P640, DOI 10.1177/036354659202000604; BALDUINI FC, 1988, CLIN SPORT MED, V7, P349; Bradshaw C, 1997, AM J SPORT MED, V25, P402, DOI 10.1177/036354659702500322; EKSTRAND J, 1983, MED SCI SPORT EXER, V15, P267, DOI 10.1249/00005768-198315030-00014; EKSTRAND J, 1982, THESIS U LINKOPING S; ENGSTROM B, 1990, AM J SPORT MED, V18, P101, DOI 10.1177/036354659001800118; GARRETT WE, 1987, AM J SPORT MED, V15, P448, DOI 10.1177/036354658701500504; Hackney R G, 1993, Br J Sports Med, V27, P58; HASSELMAN CT, 1995, PHYSICIAN SPORTSMED, V23, P53, DOI 10.1080/00913847.1995.11947813; Holmich P, 1997, SPORTS MED ARTHROSC, V5, P285; HOLMICH P, 1998, SCAND J MED SCI SPOR, V8, P331; HOLMICH P, 1998, SCAND J MED SCI SPOR, V8, P332; HOLT MA, 1995, AM J SPORT MED, V23, P601, DOI 10.1177/036354659502300515; KALEBO P, 1992, AM J SPORT MED, V20, P634, DOI 10.1177/036354659202000603; KARLSSON J, 1994, SPORTS MED, V17, P141, DOI 10.2165/00007256-199417020-00006; Lovell G, 1995, Aust J Sci Med Sport, V27, P76; MALYCHA P, 1992, AUST NZ J SURG, V62, P123; MANNICHE C, 1988, LANCET, V2, P1473; MARTENS MA, 1987, AM J SPORT MED, V15, P353, DOI 10.1177/036354658701500410; MOLLER MHL, 1985, INT J SPORTS MED, V6, P50, DOI 10.1055/s-2008-1025813; Morrenhof JW, 1989, STABILISATION HUMAN; NIELSEN AB, 1989, AM J SPORT MED, V17, P803, DOI 10.1177/036354658901700614; Renstrom P, 1980, Br J Sports Med, V14, P30; RENSTROM PAF, 1994, CLIN PRACTICE SPORTS, P97; SWAIN R, 1995, PHYSICIAN SPORTSMED, V23, P55; TAYLOR DC, 1991, AM J SPORT MED, V19, P239, DOI 10.1177/036354659101900306; TAYLOR DC, 1990, AM J SPORT MED, V18, P300, DOI 10.1177/036354659001800314; TROPP H, 1985, THESIS U SWEDEN LINK; WIKTORSSONMOLLER M, 1983, AM J SPORT MED, V11, P249, DOI 10.1177/036354658301100412	29	275	277	0	121	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1999	353	9151					439	443		10.1016/S0140-6736(98)03340-6	http://dx.doi.org/10.1016/S0140-6736(98)03340-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166JQ	9989713				2023-01-03	WOS:000078572800009
J	Sourander, L; Rajala, T; Raiha, I; Makinen, J; Erkkola, R; Helenius, H				Sourander, L; Rajala, T; Raiha, I; Makinen, J; Erkkola, R; Helenius, H			Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)	LANCET			English	Article							CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BREAST-CANCER; RISK; HEALTH	Background Advantages and disadvantages of postmenopausal oestrogen replacement therapy (ERT) are still not clear. We aimed to analyse the relation between postmenopausal oestrogen replacement therapy (ERT), cardiovascular disease, and cancer. Methods We examined 7944 women born between 1923 and 1930, who participated in a mammography screening for breast cancer, and who were followed up from 1987 to 1995, The follow-up consisted of 53 305 person-years. 988 women were current users and 757 were former users of ERT. Information about hormone use and health events was obtained through biennial questionnaires and recording and linking information from the hospital discharge registers of the region, the national cancer register, the social insurance reimbursement register, and the national death register. We used proportional-hazards models to calculate risk ratios and 95% CIs, adjusted for eight confounding variables. Findings Current ERT was associated with decreased cardiovascular mortality and a decrease in sudden cardiac death. Adjusted risk ratio (RR) for cardiovascular mortality in current users was 0.21 (95% CI 0.08-0.59) and in former users 0.75 (0.41-1.37). Absolute risk per 1000 person-years for deaths from acute myocardial infarction (AMI) was 1.1 in never users, 1.2 in former users, and 0.45 in current users (p=0.197). Corresponding absolute risk for other coronary-artery-disease (CAD) deaths was 1.0, 0.81, and 0 (p=0.009), and for deaths from stroke 1.2, 1.0, and 0.15 (p=0.012), Absolute risk for sudden cardiac death was 1.6 in never users, 1.0 in former users, and 0 in current users (p<0.001). Cardiovascular morbidity was not decreased by ERT: the RR for current use was 1.07 (0.86-1.32) and for former use 1.11 (0.89-1.39). Incidence of cardiovascular disease per 1000 person-years was 24.9 in never users, 23.4 in former users, and 20.9 in current users (p=0.153). Breast-cancer morbidity did not increase with current ERT--the RR was 0.57 (0.27-1.20). Incidence of breast cancer was 1.8, 1.6, and 1.0 in never, former, and current users (p=0.242). Endometrial cancer increased with current ERT-the RR was 5.06 (2.47-10.41). Incidence of endometrial cancer was 0.52 in never users, 0.51 in former users, and 2.1 in current users (p<0.001). Interpretation Current ERT reduced primarily sudden cardiac death and predicted reduced cardiovascular mortality, but did not reduce morbidity. ERT did not increase the risk of breast cancer, but associated with increased risk of endometrial cancer.	Univ Turku, Dept Geriatr, Turku 20700, Finland; Univ Turku, Dept Obstet & Gynaecol, Turku 20700, Finland; Univ Turku, Dept Biostat, Turku 20700, Finland	University of Turku; University of Turku; University of Turku	Sourander, L (corresponding author), Univ Turku, Dept Geriatr, Kunnallissairaalantie 20, Turku 20700, Finland.							AKHTAR M, 1994, SUDDEN CARDIAC DEATH; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; *CENTR STAT OFF FI, 1974, OFF STAT FINL, V9; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Collett D., 1994, MODELING SURVIVAL DA; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Huikuri HV, 1996, CIRCULATION, V94, P122, DOI 10.1161/01.CIR.94.2.122; KATSOUYANNI K, 1997, J CLIN ENDOCR METAB, V82, P1549; LOBO RA, 1992, AM J OBSTET GYNECOL, V166, P1997, DOI 10.1016/0002-9378(92)91401-U; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Matthews KA, 1996, AM J EPIDEMIOL, V143, P983; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; PUKKALA E, 1995, CONTRIBUTION EPIDEMI, V7; SISMOND P, 1996, EUR MENOPAUSE J, V3, P227; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; *STAT FINL, 1996, CAUS DATH; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702	25	147	148	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 26	1998	352	9145					1965	1969		10.1016/S0140-6736(98)05066-1	http://dx.doi.org/10.1016/S0140-6736(98)05066-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150KA	9872245				2023-01-03	WOS:000077663000009
J	Kaptchuk, TJ; Eisenberg, DM				Kaptchuk, TJ; Eisenberg, DM			The persuasive appeal of alternative medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PREVALENCE; DISEASE	Alternative medicine has a major presence and persuasive attraction in the industrialized western world. The extent to which these practices have clinical efficacy according to biomedical criteria is a matter of ongoing research and debate. It may be that independent of any such efficacy, the attraction of alternative medicine is related to the power of its underlying shared beliefs and cultural assumptions. The fundamental premises are an advocacy of nature, vitalism, "science," and spirituality. These themes offer patients a participatory experience of empowerment, authenticity, and enlarged self-identity when illness threatens their sense of intactness and connection to the world. A discussion of these themes may enable conventionally trained clinicians to better understand their patients' attraction to and acceptance of alternative medical therapies.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res, 330 Brookline Ave,LW-600, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER; NIAMS NIH HHS [U24 AR43441] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1982, CRUSADERS FITNESS HI; APPLE RD, 1996, VITAMIA VITAMINS AM; Barbour Ian G., 1966, ISSUES SCI RELIG; BLUMHAGEN DW, 1979, ANN INTERN MED, V91, P111, DOI 10.7326/0003-4819-91-1-111; BRADER CS, 1973, SPIRITS REBELLION RI; BRODY H, 1994, LIT MED, V13, P79; BROWN PS, 1985, MED HIST, V29, P71, DOI 10.1017/S0025727300043751; Bynum W.F, 1987, MED FRINGE MED ORTHO; CAMPBELL A, 1984, 2 FACES HOMEOPATHY; Campbell B.F., 1980, ANCIENT WISDOM REVIV; Cooper RA, 1996, HEALTH AFFAIR, V15, P226, DOI 10.1377/hlthaff.15.3.226; Cooter Roger, 1988, STUDIES HIST ALTERNA; CSORDAS T J, 1988, Medical Anthropology Quarterly, V2, P121, DOI 10.1525/maq.1988.2.2.02a00030; CSORDAS TJ, 1983, CULT MED PSYCHIAT, V7, P333, DOI 10.1007/BF00052238; DUBISCH J, 1981, AM DIMENSION CULTURA; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Felker M. E, 1983, ANTHR MED CULTURE ME; Filliozat Jean, 1964, CLASSICAL DOCTRINE I; Frank J.D., 1961, PERSUASION HEALING C; Fuller R., 1989, ALTERNATIVE MED AM R; Fuller R.C., 1982, MESMERISM AM CURE SO; GEVITZ N, 1995, MT SINAI J MED, V62, P127; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; GLIK DC, 1988, SOC SCI MED, V27, P1197, DOI 10.1016/0277-9536(88)90349-8; GOLDSTEIN MS, 1988, SOC SCI MED, V26, P853, DOI 10.1016/0277-9536(88)90178-5; GORDON DR, 1988, BIOMEDICINE EXAMINED; GRIM P, 1982, PHILOS SCI OCCULT; HAHNEMANN S, 1980, ORGANON MED; Haigh E, 1975, Bull Hist Med, V49, P72; Haller Jr John S., 1994, MED PROTESTANTS ECLE; HUXTABLE RJ, 1992, ANN INTERN MED, V117, P165, DOI 10.7326/0003-4819-117-2-165; Ingelfinger F J, 1977, N Engl J Med, V296, P1167, DOI 10.1056/NEJM197705192962013; KANDEL RF, 1980, NUTR ANTHR CONT APPR; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 1998, B HIST MED, V72, P389, DOI 10.1353/bhm.1998.0159; Kaptchuk TJ, 1998, NUTRITION, V14, P471; KAPTCHUK TJ, 1996, FUNDAMENTALS COMPLEM; KAPTCHUK TJ, 1996, COMPLEMENTARY MED EF; KIRMAYER LJ, 1993, CULT MED PSYCHIAT, V17, P161, DOI 10.1007/BF01379325; KLEINMAN AM, 1973, INQUIRY, V16, P206, DOI 10.1080/00201747308601685; KNIPSCHILD P, 1989, BRIT MED J, V299, P491, DOI 10.1136/bmj.299.6697.491; KOPELMAN L, 1981, J MED PHILOS, V6, P209, DOI 10.1093/jmp/6.2.209; LEDERMANN EK, 1986, PHILOS MED; LILIENFELD AM, 1982, B HIST MED, V56, P1; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Luhrmann T.M., 1989, PERSUASIONS WITCHS C; Lyng Stephen, 1990, HOLISTIC HLTH BIOMED; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; MARTIN SC, 1994, ISIS, V85, P207, DOI 10.1086/356807; MARTIN SC, 1993, TECHNOL CULT, V34, P808, DOI 10.2307/3106416; Marwick C, 1997, JAMA-J AM MED ASSOC, V278, P1725, DOI 10.1001/jama.1997.03550210021013; MAUSKOPF S, 1979, RECEPTION UNCONVENTI; Mauskopf SH, 1980, ELUSIVE SCI ORIGINS; MCCLENON J, 1984, DEVIANT SCI CASE PAR; MCGUIRE MB, 1983, CULT MED PSYCHIAT, V7, P221, DOI 10.1007/BF00049311; Meyer Donald, 1965, POSITIVE THINKERS ST; NEUBURGER M, 1933, DOCTRIN HEALING POWE; Nissenbaum Stephen, 1980, SEX DIET DEBILITY JA; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oppenheim J., 1985, OTHER WORLD SPIRITUA; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PALMER DD, 1910, CHIROPRACTIC; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; ROTHSTEIN W, 1972, AM PHYSICIANS 19 CEN; SCHAFER R, 1975, J AM DIET ASSOC, V66, P129; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Shumaker, 1972, OCCULT SCI RENAISSAN; SIMON A, 1979, JAMA-J AM MED ASSOC, V242, P1385, DOI 10.1001/jama.242.13.1385; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; SULLIVAN M, 1986, CULT MED PSYCHIAT, V10, P331, DOI 10.1007/BF00049269; SULLIVAN MD, 1993, J MED PHILOS, V18, P213, DOI 10.1093/jmp/18.2.213; Tambiah S.J., 1990, MAGIC SCI RELIG SCOP; TURNER BS, 1982, BRIT J SOCIOL, V33, P254, DOI 10.2307/589935; TWIGG J, 1979, RELIGION, V9, P13, DOI 10.1016/0048-721X(79)90051-4; TYLER VE, 1987, PLANTA MED, P1; Unschuld Paul O., 1985, MED CHINA HIST IDEAS; WALLIS R, 1979, MARGINS SCI SOCIAL C; Warner J. H, 1978, PERSPECTIVES AM HIST, V11, P291; WHEELER R, 1939, VITALISM; Whorton J C, 1977, J Hist Med Allied Sci, V32, P115; WILLIAM J, 1961, VARIETIES RELIG EXPE	84	171	173	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1998	129	12					1061	1065		10.7326/0003-4819-129-12-199812150-00011	http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	147DC	9867762				2023-01-03	WOS:000077471900010
J	Diamond, HS; Goldberg, E; Janosky, JE				Diamond, HS; Goldberg, E; Janosky, JE			The effect of full-time faculty hospitalists on the efficiency of care at a community teaching hospital	ANNALS OF INTERNAL MEDICINE			English	Article						hospitalists; quality of health care; cost-benefit analysis; patient readmission; length of stay	UNIT	Background: Hospitalists are increasingly being used for inpatient care. Objective: To investigate whether the use of hospitalists is beneficial. Design: Retrospective cohort study. Setting: Inpatient medical service of a 500-bed community teaching hospital. Participants: 1620 patients in the study group, seen during the hospitalist year; 1679 patients from the same outpatient practice as the study group, seen during the previous year (prehospitalist year); an unselected comparison group of 3413 patients seen during the prehospitalist year and 3223 patients seen during the hospitalist year; and a subset of the unselected comparison group, cared for by outpatient practices, who had a prehospitalist length of stay similar to that of the study group (743 patients in the prehospitalist year and 786 in the hospitalist year). Interventions: Full-time faculty hospitalists cared for the study group, were in the hospital during normal working hours, and made decisions throughout the day. In the prehospitalist year and in the comparison groups, primary care physicians managed their own hospitalized patients. Measurements: Length of stay; cost of care; costs of hematology and chemistry evaluation, pharmacy, and radiology; and readmissions were determined for the prehospitalist and hospitalist years. Results: In the study group, median length of stay decreased from 6.01 to 5.01 days (P < 0.001). Median cost of care decreased from $4139 to $3552 (P < 0.001), and the 14-day readmission rate decreased from 9.9 to 4.64 readmissions per 100 admissions (P < 0.001). In the comparison groups, length of stay decreased but both cost of care and readmission rates increased. Conclusion: Hospitalists may improve the efficiency of inpatient care. Further study in various settings is needed to verify these findings.	Western Penn Hosp, Dept Med, Pittsburgh, PA 15224 USA; Univ Pittsburgh, Sch Med, Div Biostat, Dept Med & Clin Epidemiol, Pittsburgh, PA 15261 USA	West Penn Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Diamond, HS (corresponding author), Western Penn Hosp, Dept Med, 4800 Friendship Ave, Pittsburgh, PA 15224 USA.							BRANDNER J, 1995, MANAGED CARE     JUL, P19; BROOK RH, 1987, HLTH CARE FINANCE RE, P39; CAMERON JM, 1985, NEW ENGL J MED, V312, P1233, DOI 10.1056/NEJM198505093121906; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; DIAMOND HS, 1993, J GEN INTERN MED, V8, P614, DOI 10.1007/BF02599717; GIPE B, 1996, COST QUALITY, V2, P6; HORN SD, 1983, AM J PUBLIC HEALTH, V73, P25, DOI 10.2105/AJPH.73.1.25; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Moore J D Jr, 1997, Mod Healthc, V27, P54; Moore J D Jr, 1997, Mod Healthc, V27, P58; NELSON JR, 1997, HOSPITALIST, V1, P1; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	16	135	135	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					197	+		10.7326/0003-4819-129-3-199808010-00006	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104UA	9696727				2023-01-03	WOS:000075032700004
J	Tarnow-Mordi, WO				Tarnow-Mordi, WO			Room air or oxygen for asphyxiated babies?	LANCET			English	Editorial Material							RANDOMIZATION; TRIALS		Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Int Neonatal Network, Dundee DD1 9SY, Scotland	University of Dundee	Tarnow-Mordi, WO (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Int Neonatal Network, Dundee DD1 9SY, Scotland.							ALEXANDER F, 1989, J EPIDEMIOL COMMUN H, V43, P29, DOI 10.1136/jech.43.1.29; American Heart Association Emergency Cardiac Care Committee and Subcommittees, 1992, J AMER MED ASSOC, V268, P2276, DOI [10.1001/jama.268.16.2276, DOI 10.1001/JAMA.268.16.2276]; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; GRANT A, 1989, LANCET, V2, P345; RAMJI S, 1993, PEDIATR RES, V34, P809, DOI 10.1203/00006450-199312000-00023; SAUGSTAD OD, 1990, ACTA PAEDIATR SCAND, V79, P881, DOI 10.1111/j.1651-2227.1990.tb11348.x; SAUGSTAD OD, 1975, PEDIATR RES, V9, P158, DOI 10.1203/00006450-197504000-00002; SAUGSTAD OD, 1996, PRENAT NEONAT MED, V1, P26; SAUGSTAD OD, 1998, PEDIATRICS, V102; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; TarnowMordi W, 1997, BRIT J OBSTET GYNAEC, V104, P763, DOI 10.1111/j.1471-0528.1997.tb12015.x	11	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					341	342		10.1016/S0140-6736(05)60464-3	http://dx.doi.org/10.1016/S0140-6736(05)60464-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717918				2023-01-03	WOS:000075110500006
J	Emanuel, EJ; Battin, MP				Emanuel, EJ; Battin, MP			What are the potential cost savings from legalizing physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERMINAL CANCER-PATIENTS; ACTIVE EUTHANASIA; MEDICAL DECISIONS; MANAGED DEATH; DATA SHOW; LAST YEAR; CARE; LIFE; END; ATTITUDES		Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA; Univ Utah, Dept Philosophy, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Internal Med, Div Med Eth, Salt Lake City, UT USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, 44 Binney St, Boston, MA 02115 USA.							Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DORONZIO JC, 1993, NY TIMES        0608, pA25; Emanuel EJ, 1998, MINN LAW REV, V82, P983; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRYE A, 1994, WASHINGTON POST 0102, pC3; Ginzberg E, 1980, Inquiry, V17, P293; GODEC MS, 1993, WASHINGTON POST 0502, pC3; KASS LR, 1989, PUBLIC INTEREST, V94, P25; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LAPUMA J, 1995, ARCH INTERN MED, V155, P1553, DOI 10.1001/archinte.1995.00430140133014; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LONG SH, 1984, INQUIRY-J HEALTH CAR, V21, P315; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; *NAT HOSP ORG, 1995, AN COST SAV MED HOSP; PETERSON PG, 1996, AM GROW UP IT GROWS, P176; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; Riley G F, 1989, Health Care Financ Rev, V11, P1; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; SULMASY DP, 1995, ARCH INTERN MED, V155, P133, DOI 10.1001/archinte.155.2.133; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Maas PJ, 1992, HEALTH POLICY, V22, P1	42	53	53	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					167	172		10.1056/NEJM199807163390306	http://dx.doi.org/10.1056/NEJM199807163390306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ922	9664094				2023-01-03	WOS:000074782900006
J	Stefanick, ML; Mackey, S; Sheehan, M; Ellsworth, N; Haskell, WL; Wood, PD				Stefanick, ML; Mackey, S; Sheehan, M; Ellsworth, N; Haskell, WL; Wood, PD			Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; WEIGHT-LOSS; OVERWEIGHT MEN; PLASMA-LIPIDS; RISK-FACTORS; EFFICACY; TRIAL	Background Guidelines established by the National Cholesterol Education Program (NCEP) promote exercise and weight loss for the treatment of abnormal lipoprotein levels. Little is known, however, about the effects of exercise or the NCEP diet, which is moderately low in fat and cholesterol, in persons with lipoprotein levels that place them at high risk for coronary heart disease. Methods We studied plasma lipoprotein levels in 180 postmenopausal women, 45 through 64 years of age, and 197 men, 30 through 64 years of age, who had low high-density lipoprotein (HDL) cholesterol levels (less than or equal to 59 mg per deciliter in women and less than or equal to 44 mg per deciliter in men) and moderately elevated levels of low-density lipoprotein (LDL) cholesterol (>125 mg per deciliter but <210 mg per deciliter in women and >125 mg per deciliter but <190 mg per deciliter in men). The subjects were randomly assigned to aerobic exercise, the NCEP Step 2 diet, or diet plus exercise, or to a control group, which received no intervention. Results Dietary intake of fat and cholesterol decreased during the one-year study (P<0.001), as did body weight, in women and men in either the diet group or the diet-plus-exercise group, as compared with the controls (P<0.001) and the exercise group (P<0.05), in which dietary intake and body weight were unchanged. Changes in HDL cholesterol and triglyceride levels and the ratio of total to HDL cholesterol did not differ significantly among the treatment groups, for subjects of either sex. The serum level of LDL cholesterol was significantly reduced among women (a decrease of 14.5 +/- 22.2 mg per deciliter) and men (a decrease of 20.0 +/- 17.3 mg per deciliter) in the diet-plus-exercise group, as compared with the control group (women had a decrease of 2.5 +/- 16.6 mg per deciliter, P<0.05; men had a decrease of 4.6 +/- 21.1 mg per deciliter, P<0.001). The reduction in LDL cholesterol in men in the diet-plus-exercise group was also significant as compared with that among the men in the exercise group (3.6 +/- 18.8 mg per deciliter, P<0.001). In contrast, changes in LDL cholesterol levels were not significant among the women (a decrease of 7.3 +/- 18.9 mg per deciliter) or the men (10.8 +/- 18.8 mg per deciliter) in the diet group, as compared with the controls. Conclusions The NCEP Step 2 diet failed to lower LDL cholesterol levels in men or women with highrisk lipoprotein levels who did not engage in aerobic exercise. This finding highlights the importance of physical activity in the treatment of elevated LDL cholesterol levels. (N Engl J Med 1998;339:12-20.) (C) 1998, Massachusetts Medical Society.	Stanford Univ, Sch Med, Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Stefanick, ML (corresponding author), 730 Welch Rd,Suite B, Palo Alto, CA 94304 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045733] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45733] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; [Anonymous], 1996, JAMA, V276, P241; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Connor WE, 1997, NEW ENGL J MED, V337, P562; Connor WE, 1997, NEW ENGL J MED, V337, P566; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.1093/biomet/58.3.403; FORTMANN SP, 1988, AM J CARDIOL, V62, P89, DOI 10.1016/0002-9149(88)91370-7; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAINLINE A, 1982, DHEW PUBLICATION; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; Katan MB, 1997, NEW ENGL J MED, V337, P563; Katan MB, 1997, NEW ENGL J MED, V337, P567; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; Knopp RH, 1997, JAMA-J AM MED ASSOC, V278, P1509, DOI 10.1001/jama.278.18.1509; KRISETHERTON PM, 1988, J AM DIET ASSOC, V88, P1373; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; *OFF MED APPL RES, 1992, NIH CONS STAT, V10; PEDERSEN TR, 1994, LANCET, V344, P1383; POSNER BM, 1982, AM J CLIN NUTR, V36, P546, DOI 10.1093/ajcn/36.3.546; REAVEN GM, 1986, J NUTR, V116, P1143, DOI 10.1093/jn/116.7.1143; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1979, CIRCULATION, V60, P427; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SAVIN WM, 1980, CIRCULATION, V62, P55, DOI 10.1161/01.CIR.62.1.55; SCHAEFER EJ, 1995, ARTERIOSCL THROM VAS, V15, P1079, DOI 10.1161/01.ATV.15.8.1079; SCHAKEL SF, 1988, J AM DIET ASSOC, V88, P1268; Stefanick M L, 1993, Exerc Sport Sci Rev, V21, P363; Stefanovic-Racic M., 1994, P417; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS PT, 1983, ATHEROSCLEROSIS, V47, P173, DOI 10.1016/0021-9150(83)90153-3; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703	36	384	400	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					12	20		10.1056/NEJM199807023390103	http://dx.doi.org/10.1056/NEJM199807023390103			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647874	Bronze			2023-01-03	WOS:000074500000003
J	Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ				Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ			Effect of electrical cardioversion on myocardial cells in patients in intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, A-6020 Innsbruck, Austria	University of Innsbruck	Neumayr, G (corresponding author), Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.		Wiedermann, Christian J./ABG-9521-2020					DOHERTY PW, 1979, AM J CARDIOL, V43, P225, DOI 10.1016/S0002-9149(79)80008-9; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; METCALFE MJ, 1988, BRIT MED J, V296, P1364, DOI 10.1136/bmj.296.6633.1364	5	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1207	1207		10.1136/bmj.316.7139.1207	http://dx.doi.org/10.1136/bmj.316.7139.1207			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552995	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000073224100023
J	Schiff, GD; Rucker, TD				Schiff, GD; Rucker, TD			Computerized prescribing - Building the electronic infrastructure for better medication usage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHYSICIAN ORDER ENTRY; PRACTICE GUIDELINES; DECISION-SUPPORT; HEALTH-CARE; PATIENT; INFORMATION; SYSTEM; ERRORS; DRUGS; PREVENTION	Computerized prescribing in the practice of medicine is a change that is overdue. Virtually all prescriptions in the United States are still handwritten. instead, medications should be ordered on a computer interacting with 3 databases: patient drug history, scientific drug information and guideline reference, and patient-specific (weight, laboratory) data. Current problems with prescribing on which computerized prescribing could have a positive impact include (1) drug selection; (2) patient role in pharmacotherapy risk-benefit decision making; (3) screening for interactions (drug-drug, drug-laboratory, drug-disease); (4) linkages between laboratory and pharmacy; (5) dosing calculations and scheduling; (6) coordination between team members, particularly concerning patient education; (7) monitoring and documenting adverse effects; and (8) postmarketing surveillance of therapy outcomes, Computerized prescribing is an important component of clinician order entry. Development of this tool has been impeded by a number of conceptual, implementation, and policy barriers. Overcoming these constraints will require clinically and professionally guided vision and leadership.	Cook Cty Hosp, Dept Med, Collaborat Res Unit, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Chicago, IL USA	John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schiff, GD (corresponding author), Cook Cty Hosp, Dept Med, Collaborat Res Unit, 1825 W Harrison St,Room 220,Adm Bldg, Chicago, IL 60612 USA.	gdschiff@aol.com						*AG HLTH CAR POL R, 1995, AHCPR PUBL; Amatayakul M, 1997, Health Data Manag, V5, P56; Andrade Susan E., 1996, Pharmacoepidemiology and Drug Safety, V5, P113; [Anonymous], 1997, LANCET, V349, P369; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P400, DOI 10.1093/ajhp/52.4.400; Bates D W, 1994, Qual Manag Health Care, V2, P18; Bates DW, 1996, DRUG SAFETY, V15, P303, DOI 10.2165/00002018-199615050-00001; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1996, AM J HEALTH-SYST PH, V53, P747; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLOBEL B, 1997, ELECT PATIENT REC, V5, P3; Bradley CP, 1997, BRIT MED J, V314, P744, DOI 10.1136/bmj.314.7082.744; Cannon B, 1996, J Am Pharm Assoc (Wash), VNS36, P668; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Chewning B, 1996, SOC SCI MED, V42, P389, DOI 10.1016/0277-9536(95)00156-5; Chin T L, 1997, Health Data Manag, V5, P78; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Cohen MR, 1996, AM J HEALTH-SYST PH, V53, P737, DOI 10.1093/ajhp/53.7.737; *COUNC COMP, 1998, HIGHW HLTH TRANSF US; CROSS MA, 1996, HLTH DATA MANAGE, V4, P70; DAVIS P, 1996, CONTESTED GROUND PUB; DOYLE E, 1995, AM COLL PHYS OBSERVE, V15, P7; ELLINOY BJ, 1989, AM J HOSP PHARM, V46, P1549, DOI 10.1093/ajhp/46.8.1549a; Elson RB, 1997, J AM MED INFORM ASSN, V4, P266, DOI 10.1136/jamia.1997.0040266; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; Faich Gerald A., 1996, Pharmacoepidemiology and Drug Safety, V5, P393, DOI 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.3.CO;2-8; Felkey BG, 1997, AM J HEALTH-SYST PH, V54, P274, DOI 10.1093/ajhp/54.3.274; Gabrieli E R, 1991, Top Health Rec Manage, V11, P27; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GIBBS S, 1990, J ROY SOC MED, V83, P292, DOI 10.1177/014107689008300505; GLABMAN M, 1996, AM COLL PHYS OBS OCT, V16, P8; GRAY BH, 1997, HLTH AFF MILLWOOD, V16, P106; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Hampton C. E., 1997, Journal of Investigative Medicine, V45, p311A; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; HEADDEN S, 1996, US NEWS WORLD R 0826, P47; *I MED COMM IMPR M, 1991, COMP BAS PAT REC ESS; *INT SOC PHARM, 1997, DAT PRIV MED REC CON; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEGLER JD, 1990, M D COMPUT, V7, P155; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; LIPTON HL, 1995, INT J TECHNOL ASSESS, V11, P485, DOI 10.1017/S0266462300008692; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LORTIE FM, 1986, CAN MED ASSOC J, V135, P27; Lyons RF, 1996, J CLIN PHARM THER, V21, P221, DOI 10.1111/j.1365-2710.1996.tb01142.x; Marsa L., 1997, PRESCRIPTION PROFIT; MARTIN J, 1995, GRET TRANSITION USIN; Martin R, 1996, BRIT MED J, V312, P1418; MARUYAMA H, 1989, ANN INTERN MED, V110, P333; McCarthy R, 1997, Bus Health, V15, P39; MCCARTHY R, 1997, DRUG BENEFIT TRENDS, V9, P36; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; MILES P, 1995, JOINT COMM J QUAL IM, V21, P32; Miller RA, 1997, J AM MED INFORM ASSN, V4, P442, DOI 10.1136/jamia.1997.0040442; Morris LA, 1997, MED CARE, V35, P996, DOI 10.1097/00005650-199710000-00002; MUIRHEAD G, 1996, DRUG TOPICS, V140, P61; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; *NAT COUNC PAT INF, 1995, PRESCR MED COMPL REV; NIGHTINGALE SL, 1995, INT J TECHNOL ASSESS, V11, P399, DOI 10.1017/S026646230000862X; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Poikonen J, 1997, AM J HEALTH-SYST PH, V54, P281, DOI 10.1093/ajhp/54.3.281; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; RASON JT, 1990, HUMAN ERROR; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RELMAN AS, 1982, NEW ENGL J MED, V306, P669, DOI 10.1056/NEJM198203183061109; Rovelli F, 1996, LANCET, V348, P169; RUCKER TD, 1990, MED CARE, V28, P928, DOI 10.1097/00005650-199010000-00007; RUCKER TD, 1974, JAMA-J AM MED ASSOC, V230, P889; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SCHIFF GD, 1995, JOINT COMM J QUAL IM, V21, P549, DOI 10.1016/S1070-3241(16)30181-X; SCHIFF GD, 1996, EX ERR HLTH CAR DEV; SCHIFF GD, 1993, U S P OP C PAT ED RO, P13; SCHNEIDER R, 1995, AM J HEALTH-SYST PH, V52, P2184, DOI 10.1093/ajhp/52.20.2184; SCHOENENBERGER RA, 1995, JAMA-J AM MED ASSOC, V274, P1622, DOI 10.1001/jama.274.20.1622; Schriger DL, 1997, JAMA-J AM MED ASSOC, V278, P1585, DOI 10.1001/jama.278.19.1585; Schulman KA, 1996, ANN INTERN MED, V124, P906, DOI 10.7326/0003-4819-124-10-199605150-00008; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Siwicki B, 1997, Health Data Manag, V5, P54; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; *SOW UN PRIM CAR I, 1996, PROD PUBL, V24; SZOLOVITS P, 1996, ELECT PATIENT RECORD, V4, P8; Thompson CA, 1996, AM J HEALTH-SYST PH, V53, P712, DOI 10.1093/ajhp/53.7.712; TOGNONI G, 1986, LANCET, V2, P1028; Tuttle MS, 1997, J AM MED INFORM ASSN, V4, P322, DOI 10.1136/jamia.1997.0040322; United States Department of Health and Human Services, 1996, HLTH PEOPL 2000 REV HLTH PEOPL 2000 REV; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Walton RT, 1997, BRIT MED J, V315, P791; Weed LL, 1997, BRIT MED J, V315, P231, DOI 10.1136/bmj.315.7102.231; Weingarten S, 1997, JAMA-J AM MED ASSOC, V277, P1977, DOI 10.1001/jama.277.24.1977; WIJNANDS MJH, 1992, BRIT J RHEUMATOL, V31, P253, DOI 10.1093/rheumatology/31.4.253; Wolinsky H, 1997, ANN INTERN MED, V127, P953, DOI 10.7326/0003-4819-127-10-199711150-00026; WYATT J, 1995, BRIT MED J, V311, P1181, DOI 10.1136/bmj.311.7014.1181; 1996, LANCET, V347, P1127; 1995, FED REG, V60, P44182; 1994, DRUG THER B, V32, P32	108	174	180	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1024	1029		10.1001/jama.279.13.1024	http://dx.doi.org/10.1001/jama.279.13.1024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533503				2023-01-03	WOS:000072669700032
J	Faulkner, A				Faulkner, A			ABC of palliative care - Communication with patients, families, and other professionals	BRITISH MEDICAL JOURNAL			English	Review									Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England; The Mount, Sheffield, S Yorkshire, England	University of Sheffield	Faulkner, A (corresponding author), Univ Sheffield, Sch Med, Sheffield, S Yorkshire, England.							FAULKNER A, 1997, EFFECTIVE INTERACTIO; Faulkner Ann, 1994, TALKING CANC PATIENT; Meredith C, 1996, BMJ-BRIT MED J, V313, P724	3	53	53	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					130	132						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462321				2023-01-03	WOS:000071492300028
J	Evans, TW; Smithies, M				Evans, TW; Smithies, M			ABC of intensive care - Organ dysfunction	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London, England; Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales	Imperial College London; Royal Brompton Hospital; Cardiff University	Evans, TW (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London, England.								0	21	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1606	1609		10.1136/bmj.318.7198.1606	http://dx.doi.org/10.1136/bmj.318.7198.1606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364125	Green Published			2023-01-03	WOS:000080913100034
J	Gapstur, SM; Morrow, M; Sellers, TA				Gapstur, SM; Morrow, M; Sellers, TA			Hormone replacement therapy and risk of breast cancer with a favorable histology - Results of the Iowa Women's Health Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; FAMILY HISTORY; UNITED-STATES; ESTROGEN; MORTALITY; QUESTIONNAIRE; CARCINOMA; SURVIVAL; DISEASE	Context. Long-term, postmenopausal use of hormone replacement therapy (HRT) appears to increase breast cancer risk. Whether the effect of HRT use on risk of breast cancer varies among histological types of invasive carcinoma is unknown. Objective. To determine associations between HRT use and risk of ductal carcinoma in situ (DCIS), invasive carcinoma with favorable histology, and invasive ductal or lobular carcinoma. Design. Prospective cohort study whose participants were followed up continuously for 11 years from January 1986 to December 1996. Setting and Participants. Iowa Women's Health Study, a population-based random sample of postmenopausal women aged 55 to 69 years in 1986. A total of 1520 incident breast cancer cases occurred in the at-risk cohort of 37105 women. Main outcome Measures. Multivariate-adjusted relative risk (RR) of tumor-specific breast cancers associated with duration of ever, current, or past HRT use. Results. Duration of ever HRT use was associated with risk of invasive carcinoma with a favorable histology, with an RR of 1.81 (95% confidence interval [Cl], 1.07-3.07) for those who used HRT 5 or fewer years vs an RR of 2.65 (95% CI, 1.34-5.23) for those who used HRT for more than 5 years (P for trend = .005) after adjustment for age and other breast cancer risk factors. There was no association between ever HRT use and the incidence of DCIS or invasive ductal or lobular carcinoma. Among current hormone users, after adjusting for age and other breast cancer risk factors, the RRs (95% Cls) of invasive carcinoma with a favorable histology were 4.42 (2.00-9.76) and 2.63 (1.18-5.89) for 5 or fewer years of use and for more than 5 years of use, respectively. Risk of invasive ductal or lobular carcinoma was associated with current use (less than or equal to 5 years) of HRT with an RR of 1.38 (95% Cl, 1.03-1.85). Conclusions. Exposure to HRT was associated most strongly with an increased risk of invasive breast cancer with a favorable prognosis. These data add important clinical information for assessing the risks and benefits of HRT use.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lynn Sage Comprehens Breast Ctr, Chicago, IL 60611 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	Northwestern University; Northwestern University; Northwestern University; Mayo Clinic	Gapstur, SM (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CLAUS EB, 1993, CANCER, V71, P147, DOI 10.1002/1097-0142(19930101)71:1<147::AID-CNCR2820710124>3.0.CO;2-V; DUBIN N, 1986, AM J EPIDEMIOL, V123, P1101, DOI 10.1093/oxfordjournals.aje.a114338; EWERTZ M, 1991, INT J CANCER, V49, P526, DOI 10.1002/ijc.2910490409; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; JORDAN VC, 1998, P AM SOC CLIN ONCOL, V17, P46; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; Longnecker MP, 1996, CANCER EPIDEM BIOMAR, V5, P961; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PEREZMESA CM, 1988, CANC BREAST, P206; Ries L, 1998, SEER CANC STAT REV 1; ROSEN PP, 1979, ANN CLIN LAB SCI, V9, P144; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491; SQUITIERI R, 1994, J AM COLL SURGEONS, V178, P167; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STRICKLAND DM, 1992, OBSTET GYNECOL, V80, P400; WEISS NS, 1978, ANN INTERN MED, V88, P410, DOI 10.7326/0003-4819-88-3-410; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	34	174	177	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2091	2097		10.1001/jama.281.22.2091	http://dx.doi.org/10.1001/jama.281.22.2091			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367819				2023-01-03	WOS:000080668000031
J	Burstein, HJ; Gelber, S; Guadagnoli, E; Weeks, JC				Burstein, HJ; Gelber, S; Guadagnoli, E; Weeks, JC			Use of alternative medicine by women with early-stage breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; UNITED-STATES; COMPLEMENTARY THERAPIES; CONVENTIONAL TREATMENT; CONSERVING SURGERY; RISK; PREVALENCE; DISTRESS	Background We analyzed the use of alternative medicine by women who had received standard therapy for early-stage breast cancer diagnosed between September 1993 and September 1995. Methods A cohort of 480 patients with newly diagnosed early-stage breast cancer was recruited from a Massachusetts statewide cohort of women participating in a study of how women choose treatment for cancer. Alternative medical treatments, conventional therapies, and health-related quality of life were examined. Results New use of alternative medicine after surgery for breast cancer was common (reported by 28.1 percent of the women); such use was not associated with choices about standard medical therapies after we controlled for clinical and sociodemographic variables. A total of 10.6 percent of the women had used alternative medicine before they were given a diagnosis of breast cancer. Women who initiated the use of alternative medicine after surgery reported a worse quality of life than women who never used alternative medicine. Mental health scores were similar at base line among women who decided to use alternative medicine and those who did not, but three months after surgery the use of alternative medicine was independently associated with depression, fear of recurrence of cancer, lower scores for mental health and sexual satisfaction, and more physical symptoms as well as symptoms of greater intensity. All groups of women reported improving quality of life one year after surgery. Conclusions Among women with newly diagnosed early-stage breast cancer who had been treated with standard therapies, new use of alternative medicine was a marker of greater psychosocial distress and worse quality of life. (N Engl J Med 1999; 340:1733-9.) (C) 1999, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA059408] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN J, 1998, BOSTON GLOBE    0412, pE1; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1026, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1026::AID-CNCR4>3.3.CO;2-#; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; Crocetti E, 1998, EUR J CANCER, V34, P324, DOI 10.1016/S0959-8049(97)10043-0; DANIELSON KJ, 1988, CAN MED ASSOC J, V138, P1005; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ganz PA, 1998, J CLIN ONCOL, V16, P501, DOI 10.1200/JCO.1998.16.2.501; GANZ PA, 1993, MED CARE, V31, P419, DOI 10.1097/00005650-199305000-00004; GANZ PA, 1995, JNCI-J NATL CANCER I, V87, P1372, DOI 10.1093/jnci/87.18.1372; Gevitz N, 1988, OTHER HEALERS UNORTH, P1; Guadagnoli E, 1998, J CLIN ONCOL, V16, P101, DOI 10.1200/JCO.1998.16.1.101; HARRIS L, 1987, HLTH INFORMATION USE; LASRY JCM, 1992, CANCER, V69, P2111, DOI 10.1002/1097-0142(19920415)69:8<2111::AID-CNCR2820690817>3.0.CO;2-T; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; LERNER IJ, 1992, CA-CANCER J CLIN, V42, P181, DOI 10.3322/canjclin.42.3.181; MAUNSELL E, 1992, CANCER-AM CANCER SOC, V70, P120, DOI 10.1002/1097-0142(19920701)70:1<120::AID-CNCR2820700120>3.0.CO;2-U; MEYEROWITZ BE, 1979, CANCER, V43, P1613, DOI 10.1002/1097-0142(197905)43:5<1613::AID-CNCR2820430508>3.0.CO;2-8; Mor V, 1994, J Natl Cancer Inst Monogr, P191; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; ROWLAND JH, 1996, DIS BREAST, P919; S.A.S. Institute, 1990, SAS STAT US GUID; SCHAG CAC, 1993, J CLIN ONCOL, V11, P783, DOI 10.1200/JCO.1993.11.4.783; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P194; SIEGEL A, 1998, P AM SOC CLIN ONCOL, V17, P667; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; VandeCreek L, 1999, ALTERN THER HEALTH M, V5, P71; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	33	458	465	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1733	1739		10.1056/NEJM199906033402206	http://dx.doi.org/10.1056/NEJM199906033402206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352166				2023-01-03	WOS:000080620200006
J	Weiderpass, E; Baron, JA; Adami, HO; Magnusson, C; Lindgren, A; Bergstrom, R; Correia, N; Persson, I				Weiderpass, E; Baron, JA; Adami, HO; Magnusson, C; Lindgren, A; Bergstrom, R; Correia, N; Persson, I			Low-potency oestrogen and risk of endometrial cancer: a case-control study	LANCET			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; HEART-DISEASE; ESTROGEN; ESTRIOL; PREVENTION; ESTRADIOL; MORTALITY	Background. Urogenital symptoms are common among postmenopausal women. Such symptoms may be alleviated by low-potency oestrogen formulations administered orally or vaginally. Although low-potency oestrogen formulations are assumed to have few, if any, adverse effects on the endometrium, risk of endometrial neoplasia has not been quantified. Methods. In a nationwide population-based case-control study in Sweden of endometrial cancer among postmenopausal women, we obtained detailed information on hormone replacement from 789 cases of endometrial cancer and 3368 population controls. In a histopathological review, 80 cases were reclassified as having endometrial atypical hyperplasia. Odds ratios and 95% Cl were calculated with unconditional logistic regression. Findings. After multivariate adjustment, oral use of oestriol 1-2 mg daily increased the relative risk of endometrial cancer and endometrial atypical hyperplasia: the odds ratios for at least 5 years of use compared with never use were 3.0 (95% Cl 2.0-4.4) and 8.3 (4.0-17.4), respectively. The association was stronger for well-differentiated cancers and those with limited invasion. The excess relative risk was lost rapidly after cessation of treatment. Only weak associations were observed between vaginal application of low-potency oestrogen formulations and relative risk of endometrial neoplasia. Interpretation. Oral, but not vaginal, treatment with low-potency oestrogen formulations increases the relative risk of endometrial neoplasia. Thus close surveillance of patients is needed, and addition of a progestagen should be considered.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; Falun Hosp, Dept Pathol, Falun, Sweden; Harvard Univ, Sch Publ Hlth, Harvard Ctr Canc Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; Dartmouth College; Falun Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Weiderpass, E (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.		Weiderpass, Elisabete/AAP-2747-2021; Weiderpass, Elisabete/M-4029-2016	Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128; Correia, Nestor/0000-0003-4852-9985; Magnusson, Cecilia/0000-0002-8567-6725	NATIONAL CANCER INSTITUTE [R01CA058427] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; BORGLIN N E, 1959, Acta Obstet Gynecol Scand, V38, P157; BOTELLA J, 1995, J STEROID BIOCHEM, V55, P77, DOI 10.1016/0960-0760(95)00156-T; Bygdeman M, 1996, MATURITAS, V23, P259, DOI 10.1016/0378-5122(95)00955-8; Cardozo L, 1998, BRIT J OBSTET GYNAEC, V105, P403, DOI 10.1111/j.1471-0528.1998.tb10124.x; CLARK JH, 1977, ENDOCRINOLOGY, V100, P91, DOI 10.1210/endo-100-1-91; ENGLUND DE, 1980, ACTA OBSTET GYN SCAN, V59, P449, DOI 10.3109/00016348009155427; ESPOSITO G, 1991, GYNECOL ENDOCRINOL, V5, P131, DOI 10.3109/09513599109028436; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GRADY D, 1996, CANC EPIDEMIOLOGY PR, P1058; Granberg S, 1997, MATURITAS, V27, P35, DOI 10.1016/S0378-5122(97)01107-9; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEIMER G, 1984, ACTA OBSTET GYN SCAN, V63, P563, DOI 10.3109/00016348409156720; Heimer G, 1996, Acta Obstet Gynecol Scand Suppl, V163, P1; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KORACH K, 1980, ENDOCRINOLOGY, V106, P1900, DOI 10.1210/endo-106-6-1900; LAURITZEN C, 1961, ACTA ENDOCRINOL-COP, V38, P73, DOI 10.1530/acta.0.0380073; Minaguchi H, 1996, J Obstet Gynaecol Res, V22, P259; NILSSON K, 1992, MATURITAS, V15, P121, DOI 10.1016/0378-5122(92)90246-Z; PERSSON I, 1986, ACTA PATH MICRO IM A, V94, P187; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Salmi T, 1980, Acta Endocrinol Suppl (Copenh), V233, P37; Schairer C, 1997, EPIDEMIOLOGY, V8, P59, DOI 10.1097/00001648-199701000-00010; SCHIFF I, 1980, AM J OBSTET GYNECOL, V138, P1137, DOI 10.1016/S0002-9378(16)32780-6; Speroff L., 1994, CLIN GYNECOLOGIC END, P583; ToozsHobson P, 1996, BMJ-BRIT MED J, V313, P350, DOI 10.1136/bmj.313.7053.350; VERMEULEN A, 1968, STEROIDS, V11, P609, DOI 10.1016/S0039-128X(68)80009-1	28	129	132	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1824	1828		10.1016/S0140-6736(98)10233-7	http://dx.doi.org/10.1016/S0140-6736(98)10233-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359406				2023-01-03	WOS:000080667800010
J	Ghoname, ESA; Craig, WF; White, PF; Ahmed, HE; Hamza, MA; Henderson, BN; Gajraj, NM; Huber, PJ; Gatchel, RJ				Ghoname, ESA; Craig, WF; White, PF; Ahmed, HE; Hamza, MA; Henderson, BN; Gajraj, NM; Huber, PJ; Gatchel, RJ			Percutaneous electrical nerve stimulation for low back pain - A randomized crossover study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPINAL MANIPULATION; CONTROLLED TRIAL; EXERCISE; TENS; ELECTROACUPUNCTURE; REHABILITATION; MEDICINE; PROGRAM; MODEL	Context Low back pain (LBP) contributes to considerable disability and lost wages in the United States. Commonly used opioid and nonopioid analgesic drugs produce adverse effects and are of limited long-term benefit in the management of this patient population. Objective To compare the effectiveness of a novel nonpharmacologic pain therapy, percutaneous electrical nerve stimulation (PENS), with transcutaneous electrical nerve stimulation (TENS) and flexion-extension exercise therapies in patients with long-term LBP. Design A randomized, single-blinded, sham-controlled, crossover study from March 1997 to December 1997. Setting An ambulatory pain management center at a university medical center. Patients Twenty-nine men and 31 women with LBP secondary to degenerative disk disease. Interventions Four therapeutic modalities (sham-PENS, PENS, TENS, and exercise therapies) were each administered for a period of 30 minutes 3 times a week for 3 weeks. Main Outcome Measures Pretreatment and posttreatment visual analog scale (VAS) scores for pain, physical activity, and quality of sleep; daily analgesic medication usage; a global patient assessment questionnaire; and Health Status Survey Short Form (SF-36). Results PENS was significantly more effective in decreasing VAS pain scores after each treatment than sham-PENS, TENS, and exercise therapies (after-treatment mean +/- SD VAS for pain, 3.4 +/- 1.4 cm, 5.5 +/- 1.9 cm, 5.6 +/- 1.9 cm, and 6.4 +/- 1.9 cm, respectively). The average +/- SD daily oral intake of nonopioid analgesics (2.6 +/- 1.4 pills per day) was decreased to 1.3 +/- 1.0 pills per day with PENS (P < .008) compared with 2.5 +/- 1.1, 2.2 +/- 1.0, and 2.6 +/- 1.2 pills per day with sham-PENS, TENS, and exercise, respectively. Compared with the other 3 modalities, 91 % of the patients reported that PENS was the most effective in decreasing their LBP. The PENS therapy was also significantly more effective in improving physical activity, quality of sleep, and sense of well-being (P < .05 for each). The SF-36 survey confirmed that PENS improved posttreatment function more than sham-PENS, TENS, and exercise. Conclusions In this sham-controlled study, PENS was more effective than TENS or exercise therapy in providing short-term pain relief and improved physical function in patients with long-term LBP.	Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	White, PF (corresponding author), Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Eugene McDermott Ctr Pain Management, 5161 Harry Hines Blvd,Suite CS 2-202, Dallas, TX 75235 USA.	pwhite@mednet.swmed.edu						Ahmed HE, 1998, ANESTH ANALG, V87, P911, DOI 10.1097/00000539-199810000-00031; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Faas A, 1996, SPINE, V21, P2874, DOI 10.1097/00007632-199612150-00016; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Hadler NM, 1997, NEW ENGL J MED, V337, P341, DOI 10.1056/NEJM199707313370511; HERMAN E, 1994, SPINE, V19, P561, DOI 10.1097/00007632-199403000-00012; KRAUS H, 1983, AM FAM PHYSICIAN, V28, P153; LAITINEN J, 1976, American Journal of Chinese Medicine, V4, P169, DOI 10.1142/S0192415X76000214; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; LIAO SJ, 1992, ACUPUNCTURE ELECTRO, V17, P249, DOI 10.3727/036012992816357666; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MANNICHE C, 1995, DAN MED BULL, V42, P301; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; MELZACK R, 1983, PHYS THER, V63, P489, DOI 10.1093/ptj/63.4.489; Moore SR, 1997, ARCH PHYS MED REHAB, V78, P55, DOI 10.1016/S0003-9993(97)90010-1; Romita VV, 1997, BRAIN RES BULL, V42, P289, DOI 10.1016/S0361-9230(96)00264-X; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; Sun R, 1997, ANESTH ANALG, V84, pS339; THOMPSON A, 1973, THOMPSONS MANEUVER N; TWOMEY L, 1995, SPINE, V20, P615, DOI 10.1097/00007632-199503010-00021; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WALSH DM, 1995, PAIN, V61, P39, DOI 10.1016/0304-3959(94)00147-7; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021; [No title captured]	28	130	147	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1999	281	9					818	823		10.1001/jama.281.9.818	http://dx.doi.org/10.1001/jama.281.9.818			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KF	10071003				2023-01-03	WOS:000078804300032
J	Matroule, JY; Bonizzi, G; Morliere, P; Paillous, N; Santus, R; Bours, V; Piette, J				Matroule, JY; Bonizzi, G; Morliere, P; Paillous, N; Santus, R; Bours, V; Piette, J			Pyropheophorbide-a methyl ester-mediated photosensitization activates transcription factor NF-kappa B through the interleukin-1 receptor-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTODYNAMIC THERAPY; SINGLET OXYGEN; CERAMIDE GENERATION; INDUCED EXPRESSION; IN-VIVO; CELLS; TUMOR; PROTEINS; KINASE; ALPHA	Pyropheophorbide-a methyl ester (PPME) is a second generation of photosensitizers used in photodynamic therapy. We demonstrated that PPME photosensitization activated NF-kappa B transcription Factor in colon cancer cells. Unexpectedly, this activation occurred in two separate waves, i.e. a rapid and transient one and a second slower but sustained phase. The former was due to photosensitization by PPME localized in the cytoplasmic membrane which triggered interleukin-l receptor internalization and the transduction pathways controlled by the interleukin-l type I receptor. Indeed, TRAF6 dominant negative mutant abolished NF-kappa B activation by PPME photosensitization, and TRAF2 dominant negative mutant was without any effect, and overexpression of I kappa B kinases increased gene transcription controlled by NF-kappa B, Oxidative stress was not likely involved in the activation. On the other hand, the slower and sustained wave could be the product of the release of ceramide through activation of the acidic sphingomyelinase, PPME localization within the lysosomal membrane could explain why ceramide acted as second messenger in NF-kappa B activation by PPME photosensitization. These data will allow a better understanding of the molecular basis of tumor eradication by photodynamic therapy, in particular the importance of the host cell response in the treatment.	Univ Liege, Inst Pathol B23, Virol Lab, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Med Chem Lab, B-4000 Liege, Belgium; Museum Natl Hist Nat, F-75231 Paris 05, France; Univ Toulouse, IMRCP Lab, CNRS URA 470, F-31062 Toulouse, France	University of Liege; University of Liege; Museum National d'Histoire Naturelle (MNHN); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Virol Lab, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Bonizzi, Giuseppina/AAD-9042-2022					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATHAR M, 1988, J INVEST DERMATOL, V90, P652, DOI 10.1111/1523-1747.ep12560814; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bonizzi G, 1997, J IMMUNOL, V159, P5264; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Daziano JP, 1996, PHOTOCHEM PHOTOBIOL, V64, P712, DOI 10.1111/j.1751-1097.1996.tb03129.x; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY TJ, 1993, PHOTOCHEM PHOTOBIOL, V58, P895, DOI 10.1111/j.1751-1097.1993.tb04990.x; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FISHER AMR, 1995, LASER SURG MED, V17, P2, DOI 10.1002/lsm.1900170103; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAULLIER JM, 1995, PHOTOCHEM PHOTOBIOL, V62, P114, DOI 10.1111/j.1751-1097.1995.tb05247.x; GEZE M, 1993, J PHOTOCH PHOTOBIO B, V20, P23, DOI 10.1016/1011-1344(93)80128-V; GLINSKI JA, 1995, PHOTOCHEM PHOTOBIOL, V62, P144, DOI 10.1111/j.1751-1097.1995.tb05250.x; Gollnick SO, 1997, CANCER RES, V57, P3904; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Henderson BW, 1997, CANCER RES, V57, P4000; ITO T, 1978, PHOTOCHEM PHOTOBIOL, V28, P493, DOI 10.1111/j.1751-1097.1978.tb06957.x; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KESSEL D, 1984, BIOCHEM PHARMACOL, V33, P1389, DOI 10.1016/0006-2952(84)90403-9; KIK G, 1996, BRIT J CANCER, V74, P30; Kim MJ, 1998, BLOOD, V91, P4106, DOI 10.1182/blood.V91.11.4106.411k40_4106_4117; Korbelik M, 1997, BRIT J CANCER, V75, P202, DOI 10.1038/bjc.1997.34; KRUTMANN J, 1989, J BIOL CHEM, V264, P11407; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Morliere P, 1998, CANCER RES, V58, P3571; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pandey RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P194, DOI 10.1111/j.1751-1097.1996.tb02442.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; PIETTE J, 1986, PHOTOCHEM PHOTOBIOL, V44, P793, DOI 10.1111/j.1751-1097.1986.tb05539.x; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIEMAN DJ, 1992, ONCOL RES, V4, P193; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Separovic D, 1997, CANCER RES, V57, P1717; SERET A, 1990, PHOTOCHEM PHOTOBIOL, V52, P601, DOI 10.1111/j.1751-1097.1990.tb01805.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLARI R, 1994, BIOCHEM PHARMACOL, V47, P93, DOI 10.1016/0006-2952(94)90441-3; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sousa C, 1996, PHOTOCHEM PHOTOBIOL, V63, P601, DOI 10.1111/j.1751-1097.1996.tb05662.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; VILE GF, 1995, FREE RADICAL BIO MED, V18, P721, DOI 10.1016/0891-5849(94)00192-M; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	71	75	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2988	3000		10.1074/jbc.274.5.2988	http://dx.doi.org/10.1074/jbc.274.5.2988			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915837	hybrid			2023-01-03	WOS:000078319500055
J	Rose, SPR				Rose, SPR			Neurogenetic determinism and the new euphenics	BRITISH MEDICAL JOURNAL			English	Review							BEHAVIOR		Open Univ, Brain & Behav Res Grp, Milton Keynes MK7 6AA, Bucks, England	Open University - UK	Rose, SPR (corresponding author), Open Univ, Brain & Behav Res Grp, Milton Keynes MK7 6AA, Bucks, England.							[Anonymous], 1997, LIFELINES BIOL FREED; Breggin PR, 1998, TALKING BACK RITALIN; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; ROSE S, 1995, NATURE, V373, P380, DOI 10.1038/373380a0	5	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1707	1708		10.1136/bmj.317.7174.1707	http://dx.doi.org/10.1136/bmj.317.7174.1707			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857135	Green Published			2023-01-03	WOS:000077742300023
J	O'Brien, E; Bouchier-Hayes, D; Fitzgerald, D; Atkins, N				O'Brien, E; Bouchier-Hayes, D; Fitzgerald, D; Atkins, N			The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic	LANCET			English	Editorial Material									Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland		O'Brien, E (corresponding author), Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland.			Atkins, Neil/0000-0002-9575-4686				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Atkins N, 1998, J HYPERTENS, V16, pS198; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Fagerberg B, 1998, AM J HYPERTENS, V11, P14, DOI 10.1016/S0895-7061(97)00363-4; Gensini GF, 1998, EUR HEART J, V19, pA53; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hasnain S, 1998, J HUM HYPERTENS, V12, P469, DOI 10.1038/sj.jhh.1000648; MOHER M, 1997, BMJ-BRIT MED J, V515, P69; Ramsay LE, 1998, AM J HYPERTENS, V11, p79S, DOI 10.1016/S0895-7061(98)00063-6; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Simon A, 1997, AM J HYPERTENS, V10, P813, DOI 10.1016/S0895-7061(97)00118-0; Stephens N, 1997, LANCET, V349, P1710, DOI 10.1016/S0140-6736(97)22024-6; Webster MWI, 1997, LANCET, V350, pSI23	13	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1998	352	9141					1700	1702		10.1016/S0140-6736(97)09026-0	http://dx.doi.org/10.1016/S0140-6736(97)09026-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853458				2023-01-03	WOS:000077110300045
J	Heffner, JE; Barbieri, C				Heffner, JE; Barbieri, C			Compliance with do-not-resuscitate orders for hospitalized patients transported to radiology departments	ANNALS OF INTERNAL MEDICINE			English	Article							DNR ORDERS	Background: Little is known about the effectiveness of do-not-resuscitate (DNR) orders during transport of hospitalized patients away from their rooms. Objective: To determine compliance with DNR orders in radiology departments. Design: Observational study. Setting: 248 hospital-based radiology departments. Participants: 248 radiology department representatives. Measurements: 10-item questionnaire examining the response of radiology personnel to patients with DNR orders who experience cardiopulmonary arrest. Results: Written DNR protocols and structured procedures for communicating DNR status were used by 18.5% (CI, 13.7% to 23.4%) and 18.1% (CI, 13.3% to 23.0%) of departments, respectively. Medical chart review was the only source of information on DNR status for 41.5% (CI, 35.4% to 47.7%) of departments. It was found that 20.2% of respondents (CI, 15.2% to 25.2%) would resuscitate patients with DNR orders and that 38.3% (CI, 32.3% to 44.4%) had resuscitated patients with DNR orders in the past. Conclusions: Most radiology departments do not have formal procedures to prevent patients from undergoing unwanted or inappropriate resuscitative interventions, and DNR orders are frequently overruled.	St Josephs Hosp, Mercy Hlth Serv Res Grp, Phoenix, AZ 85001 USA	St. Joseph's Hospital and Medical Center	Heffner, JE (corresponding author), Med Univ S Carolina, Dept Med, Room 812 CSB,171 Ashley Ave, Charleston, SC 29425 USA.							*AM COLL SURG, 1994, AM COLL SURG B, V79, P29; *AM HOSP ASS, 1996, AM HOSP ASS GUID HLT; *AM MED ASS, 1997, GRAD MED ED DIR 1997; *AM SOC AN, 1994, ETH GUID AN CAR PAT, P746; Casarett D, 1997, NEW ENGL J MED, V336, P1908, DOI 10.1056/NEJM199706263362611; CLEMENCY MV, 1993, ANESTH ANALG, V76, P394; *DHEW, 1995, DHEW PUBL; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; Heffner JE, 1996, ARCH INTERN MED, V156, P793, DOI 10.1001/archinte.156.7.793; Heffner JE, 1998, ARCH INTERN MED, V158, P1090, DOI 10.1001/archinte.158.10.1090; Heffner JE, 1997, ARCH INTERN MED, V157, P685, DOI 10.1001/archinte.157.6.685; Jacobson JA, 1996, RADIOLOGY, V198, P21, DOI 10.1148/radiology.198.1.8539381; LAPUMA J, 1988, ARCH INTERN MED, V148, P2193, DOI 10.1001/archinte.148.10.2193; MCDERMOTT VGM, 1993, BRIT J RADIOL, V66, P667, DOI 10.1259/0007-1285-66-788-667; MITTELBERGER JA, 1993, ARCH INTERN MED, V153, P228, DOI 10.1001/archinte.153.2.228; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; Terry PB, 1996, RADIOLOGY, V198, P17, DOI 10.1148/radiology.198.1.8539372; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; WALL SD, 1991, AM J ROENTGENOL, V157, P911, DOI 10.2214/ajr.157.5.1927808; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056	20	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					801	805		10.7326/0003-4819-129-10-199811150-00010	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841586				2023-01-03	WOS:000076984800006
J	Delbanco, T				Delbanco, T			Leeches, spiders, and astrology: Predilections and predictions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEPRESSION; PLACEBO											Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; BROWN WA, 1994, NEUROPSYCHOPHARMACOL, V10, P265, DOI 10.1038/npp.1994.53; DELBANCO TL, 1994, ANN INTERN MED, V121, P803, DOI 10.7326/0003-4819-121-10-199411150-00011; DELBANCO TL, 1994, NEUROPSYCHOPHARMACOL, V10, P279, DOI 10.1038/npp.1994.57; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; Hart Julian Tudor, 1998, Health Expect, V1, P3, DOI 10.1046/j.1369-6513.1998.00001.x; TYLE L, 1998, FATHER SPIN E BERNAY	8	12	12	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1560	1562		10.1001/jama.280.18.1560	http://dx.doi.org/10.1001/jama.280.18.1560			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	136GX	9820247				2023-01-03	WOS:000076852000011
J	Eisenberg, DM; Davis, RB; Ettner, SL; Appel, S; Wilkey, S; van Rompay, M; Kessler, RC				Eisenberg, DM; Davis, RB; Ettner, SL; Appel, S; Wilkey, S; van Rompay, M; Kessler, RC			Trends in alternative medicine use in the United States, 1990-1997 - Results of a follow-up national survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; ADVERSE REACTIONS; HERBAL MEDICINES; PREVALENCE; THERAPIES; COST	Context.-A prior national survey documented the high prevalence and costs of alternative medicine use in the United States in 1990. Objective.-To document trends in alternative medicine use in the United States between 1990 and 1997, Design.-Nationally representative random household telephone surveys using comparable key questions were conducted in 1991 and 1997 measuring utilization in 1990 and 1997, respectively. Participants.-A total of 1539 adults in 1991 and 2055 in 1997. Main Outcomes Measures.-Prevalence, estimated costs, and disclosure of alternative therapies to physicians. Results.-Use of at least 1 of 16 alternative therapies during the previous year increased from 33.8% in 1990 to 42.1% in 1997 (P less than or equal to.001). The therapies increasing the most included herbal medicine, massage, megavitamins, self-help groups, folk remedies, energy healing, and homeopathy. The probability of users visiting an alternative medicine practitioner increased from 36.3% to 46.3% (P = .002), In both surveys alternative therapies were used most frequently for chronic conditions, including back problems, anxiety, depression, and headaches. There was no significant change in disclosure rates between the 2 survey years; 39.8% of alternative therapies were disclosed to physicians in 1990 vs 38.5% in 1997, The percentage of users paying entirely out-of-pocket for services provided by alternative medicine practitioners did not change significantly between 1990 (64.0%) and 1997 (58.3%) (P = .36). Extrapolations to the US population suggest a 47.3% increase in total visits to alternative medicine practitioners, from 427 million in 1990 to 629 million in 1997, thereby exceeding total visits to all US primary care physicians. An estimated 15 million adults in 1997 took prescription medications concurrently with herbal remedies and/or high-dose vitamins (18.4% of all prescription users). Estimated expenditures for alternative medicine professional services increased 45.2% between 1990 and 1997 and were conservatively estimated at $21.2 billion in 1997, with at least $12.2 billion paid out-of-pocket. This exceeds the 1997 out-of-pocket expenditures for all US hospitalizations. Total 1997 out-of-pocket expenditures relating to alternative therapies were conservatively estimated at $27.0 billion, which is comparable with the projected 1997 out-of-pocket expenditures for all US physician services. Conclusions.-Alternative medicine use and expenditures increased substantially between 1990 and 1997, attributable primarily to an increase in the proportion of the population seeking alternative therapies, rather than increased visits per patient.	Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Eisenberg, DM (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res & Educ, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Van Rompay, Maria/G-9452-2012		NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bouchayer F., 1990, COMPLEMENT MED RES, V4, P4; DARCY PF, 1991, ADVERSE DRUG REACT T, V10, P189; DARCY PF, 1993, ADVERSE DRUG REACT T, V12, P147; De Smet P., 1996, MECH DRUG INTERACTIO, P327, DOI [10.1007/978-3-642-61015-8_12, DOI 10.1007/978-3-642-61015-8_12]; DESMET PAGM, 1995, DRUG SAFETY, V13, P81, DOI 10.2165/00002018-199513020-00003; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; GoldbeckWood S, 1996, BRIT MED J, V313, P131, DOI 10.1136/bmj.313.7050.131a; GROVES RM, 1998, NONRESPONSE HOUSEHOL, P159; *HLTH CAR FIN ADM, NAT HLTH CAR EXP PRO; *LANDM HEALTHC, 1998, LANDM REP PUBL PERC; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; *MED INC, CUST REP MED BILL CO; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; PIEL E, 1991, THERAPEUTIKON, V5, P549; RASMUSSEN NK, 1990, COMPLEMENT MED RES, V4, P16; *RES TRIANGL I, 1997, SUDAAN PROF SOFTW SU; SCHAPPERT SM, 1992, ADV DATA VITAL HLTH, V2213, P1; SERMEUS G, 1990, COMPLEMENTARY MED RE, V4, P9; Shekelle PG, 1996, MED CARE, V34, P863, DOI 10.1097/00005650-199609000-00001; *US BUR CENS, 1990, US POP EST AG SEX RA; *US BUR LAB STAT D, 1998, CONS PRIC IND ALL UR; VASKILAMPI T, 1993, CLIN RES METHODOLOGY, P204; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; Woodwell D A, 1997, Adv Data, P1	29	4682	4792	9	271	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1998	280	18					1569	1575		10.1001/jama.280.18.1569	http://dx.doi.org/10.1001/jama.280.18.1569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	136GX	9820257	Bronze			2023-01-03	WOS:000076852000022
J	Raschke, RA; Gollihare, B; Wunderlich, TA; Guidry, JR; Leibowitz, AI; Peirce, JC; Lemelson, L; Heisler, MA; Susong, C				Raschke, RA; Gollihare, B; Wunderlich, TA; Guidry, JR; Leibowitz, AI; Peirce, JC; Lemelson, L; Heisler, MA; Susong, C			A computer alert system to prevent injury from adverse drug events - Development and evaluation in a community teaching hospital	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREATININE CLEARANCE; INFORMATION-SYSTEM; MEDICAL INPATIENTS; SURVEILLANCE; ERRORS; COSTS	Context.-Adverse drug events (ADEs) are the most common type of iatrogenic injury occurring in hospitalized patients. Errors leading to ADEs are often due to restricted availability of information at the time of physician order writing. Objectives.-To develop, implement, and evaluate a computer alert system designed to correct errors that might lead to ADEs and to detect ADEs before maximum injury occurs. Design.-Prospective case series. Setting.-A 650-bed community teaching hospital in Phoenix, Ariz. Patients.-Consecutive sample of 9306 nonobstetrical adult patients admitted during the last 6 months of 1997. Interventions.-Thirty-seven drug-specific ADEs were targeted. Our hospital information system was programmed to generate alerts in clinical situations with increased risk for ADE-related injury. A clinical system was developed to ensure physician notification of alerts. Main Outcome Measures.-A true-positive alert was defined as one in which the physician wrote orders consistent with the alert recommendation after alert notification. Results.-During the 6-month study period, the alert system fired 1116 times and 596 were true-positive alerts (positive predictive value of 53%). The alerts identified opportunities to prevent patient injury secondary to ADEs at a rate of 64 per 1000 admissions. A total of 265 (44%) of the 596 true-positive alerts were unrecognized by the physician prior to alert notification. Conclusions.-Clinicians can use hospital information systems to detect opportunities to prevent patient injury secondary to a broad range of ADEs.	Good Samaritan Reg Med Ctr, Phoenix, AZ 85006 USA; Samaritan Hlth Syst, Phoenix, AZ USA; Desert Samaritan Med Ctr, Phoenix, AZ USA		Raschke, RA (corresponding author), Good Samaritan Reg Med Ctr, 1111 E McDowell Rd, Phoenix, AZ 85006 USA.	robert@samaritan.edu	Tao, Youyou/D-2367-2014	Raschke, Robert/0000-0003-3495-7065				BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BENNETT WM, 1994, DRUG PRESCRIBING REN, P19; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Dalton-Bunnow M F, 1993, Hosp Pharm, V28, P746; EDLAVITCH SA, 1988, ARCH INTERN MED, V148, P1499, DOI 10.1001/archinte.148.7.1499; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; LARSON EB, 1987, ANN INTERN MED, V107, P169, DOI 10.7326/0003-4819-107-2-169; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; OCONNELL MB, 1992, ANN PHARMACOTHER, V26, P627, DOI 10.1177/106002809202600503; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; SCHROEDER CG, 1986, AM J HOSP PHARM, V43, P355, DOI 10.1093/ajhp/43.2.355; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; WHIPPLE JK, 1994, ANN PHARMACOTHER, V28, P655, DOI 10.1177/106002809402800517; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292	33	249	253	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1317	1320		10.1001/jama.280.15.1317	http://dx.doi.org/10.1001/jama.280.15.1317			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794309				2023-01-03	WOS:000076472500022
J	Campbell, H; Hotchkiss, R; Bradshaw, N; Porteous, M				Campbell, H; Hotchkiss, R; Bradshaw, N; Porteous, M			Integrated care pathways	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NURSING CASE-MANAGEMENT; PRACTICE GUIDELINES; QUALITY; STAY; LENGTH; COSTS		Western Gen Hosp, Edinburgh EH8 9AG, Midlothian, Scotland; Western Infirm & Associated Hosp, Glasgow G11 6NT, Lanark, Scotland	University of Edinburgh	Campbell, H (corresponding author), Western Gen Hosp, Edinburgh EH8 9AG, Midlothian, Scotland.		Campbell, Harry/E-2959-2010	Campbell, Harry/0000-0002-6169-6262				Baker J, 1996, Nurs Stand, V10, P39; BOWEN J, 1994, NEUROLOGY, V44, P1961, DOI 10.1212/WNL.44.10.1961; Bultema JK, 1996, J NURS ADMIN, V26, P31, DOI 10.1097/00005110-199601000-00007; CATHERWOOD E, 1994, PROG CARDIOVASC DIS, V37, P121, DOI 10.1016/S0033-0620(05)80039-8; Coffey R J, 1992, Qual Manag Health Care, V1, P45; COHEN EL, 1991, J NURS ADMIN, V21, P20; Crombie I K, 1993, Qual Health Care, V2, P47, DOI 10.1136/qshc.2.1.47; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; Ethridge P, 1989, Nurs Manage, V20, P30; Gabbay J, 1992, Qual Health Care, V1, P43, DOI 10.1136/qshc.1.1.43; Goodyear H M, 1995, Qual Health Care, V4, P190, DOI 10.1136/qshc.4.3.190; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Heymann T, 1994, Int J Health Care Qual Assur, V7, P14, DOI 10.1108/09526869410074702; Hofmann P A, 1993, Jt Comm J Qual Improv, V19, P235; HOYLE RM, 1994, J VASC SURG, V20, P396, DOI 10.1016/0741-5214(94)90138-4; Kitchiner D, 1996, ARCH DIS CHILD, V75, P166, DOI 10.1136/adc.75.2.166; Koch MO, 1996, J UROLOGY, V155, P1681, DOI 10.1016/S0022-5347(01)66164-0; LUMSDON K, 1993, HOSP HLTH NETWO 1020, P34; Mansfield C D, 1995, Qual Health Care, V4, P250, DOI 10.1136/qshc.4.4.250; McNicol M, 1993, Qual Health Care, V2, P215, DOI 10.1136/qshc.2.4.215; MOSHER C, 1992, AM J NURS, V92, P41, DOI 10.2307/3426626; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Pearson SD, 1996, AM J MED, V100, P283, DOI 10.1016/S0002-9343(97)89486-7; ROSSITER D, 1995, DISABIL REHABIL, V17, P443, DOI 10.3109/09638289509166659; SCHRIEFER J, 1994, JOINT COMM J QUAL IM, V20, P485, DOI 10.1016/S1070-3241(16)30095-5; *SIGN, 1995, CLIN GUID CRIT APPR; STEAD L, 1995, HLTH CARE RISK R NOV, P13; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; TRUBO R, 1993, MED ECON, V69, P69; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3; *VAL MON UN, 1996, CLIN PATHW LIT REV; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; Wentworth DA, 1996, STROKE, V27, P1040, DOI 10.1161/01.STR.27.6.1040; Williams J G, 1993, Qual Health Care, V2, P73, DOI 10.1136/qshc.2.2.73; ZANDER K, 1988, J NURS ADMIN, V18, P23	37	534	544	1	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					133	137						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR408	9462322				2023-01-03	WOS:000071492300029
J	Nakajima, T; Nashimoto, A; Kitamura, M; Kito, T; Iwanaga, T; Okabayashi, K; Goto, M				Nakajima, T; Nashimoto, A; Kitamura, M; Kito, T; Iwanaga, T; Okabayashi, K; Goto, M		Gastric Canc Surg Study Grp	Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial	LANCET			English	Article							CYTOSINE-ARABINOSIDE; CURATIVE RESECTION; CHEMOTHERAPY; 5-FLUOROURACIL; THERAPY; DOXORUBICIN; CARCINOMA; COMBINATION; 5-FU	Background To study the survival benefit of adjuvant chemotherapy in gastric cancer, seven cancer centres in Japan carried out a phase III clinical trial of adjuvant chemotherapy after curative gastrectomy for macroscopically serosa-negative gastric cancer. Methods 579 patients were enrolled in the study, stratified by disease stage (T1, n=188; T2, n=323), and allocated randomly adjuvant chemotherapy or no further treatment, 285 of 288 cases in the treatment group and 288 of 291 in the control group were eligible, Six cases were excluded because they did not fulfil the entry criteria. The treatment group had intravenous mitomycin (1.4 mg/m(2)) and fluorouracil (166.7 mg/m(2)) twice weekly for 3 weeks after surgery, and oral UFT (uracil plus tegafur, 300 mg daily) for 18 months. Analyses were by intention to treat. Findings No serious toxic effects were observed in the treatment group. At median follow-up of 72 months, 59 patients in the control group and 47 in the treatment group had died. There was no significant difference in survival between the groups (5-year survival 82.9% control vs 85.8% treated; hazard ratio 0.738 [95% CI 0.498-1.093]). 5-year survival of patients with T1 (mucosal or submucosal) cancer in the control and treatment groups was 94.9% versus 92.0%, and that of patients with T2 (muscularis propria or subserosa) cancer was 76.9% versus 83.0%. However, a test for heterogeneity and interaction over T1 and T2 subgroups revealed no significant difference in terms of drug response. Interpretation There was no survival benefit with this adjuvant therapy regimen for patients with macroscopically serosa-negative gastric cancer (T1 and T2) after curative gastrectomy. Patients with T1 cancer can be excluded from future trials, because curative surgery alone yielded a very good survival rate and there seemed no need for adjuvant therapy.	Canc Inst Hosp, Dept Surg, Toshima Ku, Tokyo 170, Japan; Niigata Canc Ctr, Dept Surg, Niigata, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo, Japan; Aichi Canc Ctr, Dept Surg, Nagoya, Aichi 464, Japan; Ctr Adult Dis, Dept Surg, Osaka 537, Japan; Natl Canc Ctr, Dept Surg, Tokyo 104, Japan; Hokkaido Canc Ctr, Dept Surg, Sapporo, Hokkaido, Japan; Osaka Univ, Dept Informat & Math Sci, Osaka, Japan	Japanese Foundation for Cancer Research; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Aichi Cancer Center; National Cancer Center - Japan; Osaka University	Nakajima, T (corresponding author), Canc Inst Hosp, Dept Surg, Toshima Ku, 1-37-1 Kamilkebukuro, Tokyo 170, Japan.							AJANI JA, 1990, J CLIN ONCOL, V8, P1231, DOI 10.1200/JCO.1990.8.7.1231; ALLUM WH, 1989, BRIT J CANCER, V60, P739, DOI 10.1038/bjc.1989.350; BLAKE JRS, 1981, CLIN ONCOL, V7, P13; BLOKHINA NG, 1972, NEOPLASMA, V19, P351; COCCONI G, 1982, CANCER TREAT REP, V66, P1263; COOMBES RC, 1990, J CLIN ONCOL, V8, P1362, DOI 10.1200/JCO.1990.8.8.1362; COPPIN CML, 1987, SEMIN ONCOL, V14, P34; DIXON WJ, 1971, ANN SURG, V173, P26, DOI 10.1097/00000658-197101000-00004; DOUGLASS H, 1981, P AN M AM SOC CLIN, V17, P430; ENGSTROM PF, 1985, CANCER-AM CANCER SOC, V55, P1868, DOI 10.1002/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B; ENGSTROM PF, 1984, ADJUVANT THERAPY CAN, V4, P449; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; HIGGINS GA, 1983, CANCER, V52, P1105, DOI 10.1002/1097-0142(19830915)52:6<1105::AID-CNCR2820520629>3.0.CO;2-Z; HUGIER PF, 1980, AM J SURG, V139, P197; KAJITANI T, 1981, JPN J SURG, V11, P127; Kelsen D, 1996, J CLIN ONCOL, V14, P1818, DOI 10.1200/JCO.1996.14.6.1818; KLEIN H O, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P84; KROOK JE, 1991, CANCER, V67, P2454, DOI 10.1002/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2; LISE M, 1995, J CLIN ONCOL, V13, P2757, DOI 10.1200/JCO.1995.13.11.2757; NAKAJIMA T, 1995, WORLD J SURG, V19, P570, DOI 10.1007/BF00294725; NAKAJIMA T, 1984, J CLIN ONCOL, V2, P1366, DOI 10.1200/JCO.1984.2.12.1366; Nakajima T, 1997, ANN SURG ONCOL, V4, P203, DOI 10.1007/BF02306611; NAKAJIMA T, 1980, JPN J CLIN ONCOL, V10, P187; NAKAJIMA T, 1989, ONCOLOGIA, V22, P100; NAKAJIMA T, 1988, GASTRIC CANC, P125; NAKAJIMA T, 1994, JPN J CANC CHEMOTHER, V21, P1813; Nakajima Toshifusa, 1994, Journal of Japan Society for Cancer Therapy, V29, P654; OTA K, 1972, CANCER CHEMOTH REP 1, V56, P373; SCHREML W, 1984, ADJUVANT THERAPY CAN, V4, P441; SERLIN O, 1977, CANCER, V40, P1318, DOI 10.1002/1097-0142(197709)40:3<1318::AID-CNCR2820400349>3.0.CO;2-9; WILKE H, 1990, SEMIN ONCOL, V17, P61; WILS JA, 1991, J CLIN ONCOL, V9, P827, DOI 10.1200/JCO.1991.9.5.827	32	132	143	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					273	277		10.1016/S0140-6736(99)01048-X	http://dx.doi.org/10.1016/S0140-6736(99)01048-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440302				2023-01-03	WOS:000081646000008
J	Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG				Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG			Lesson of the week - Managing patients with deliberate self harm who refuse treatment in the accident and emergency department	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England		Hassan, TB (corresponding author), Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England.							*BRIT ASS ACC EM M, 1996, DIR 1996; *BRIT MED ASS, 1993, RIGHTS RESP DOCT; British Medical Association, 1995, ASS MENT CAP GUID DO; HAWTON K, 1996, ATTEMPTED SUICIDE OX; *MED DEF UN, 1996, CONS TREATM; *MEN PROT SOC, 1998, CONS	6	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					107	109		10.1136/bmj.319.7202.107	http://dx.doi.org/10.1136/bmj.319.7202.107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398639	Green Published			2023-01-03	WOS:000081438200038
J	Swinburn, JMA; Banerjee, DJ; Khan, ZP				Swinburn, JMA; Banerjee, DJ; Khan, ZP			Ethical dilemma - Discontinuation of ventilation after brain stem death	BRITISH MEDICAL JOURNAL			English	Editorial Material									City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England		Swinburn, JMA (corresponding author), City Hosp NHS Trust, Dept Anaesthet & Intens Care, Birmingham B18 7QH, W Midlands, England.								0	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1753	1753						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381716				2023-01-03	WOS:000081216900039
J	Altschuler, EL; Wisdom, SB; Stone, L; Foster, C; Galasko, D; Llewellyn, DME; Ramachandran, VS				Altschuler, EL; Wisdom, SB; Stone, L; Foster, C; Galasko, D; Llewellyn, DME; Ramachandran, VS			Rehabilitation of hemiparesis after stroke with a mirror	LANCET			English	Article									Univ Calif San Diego, Brain & Percept Lab, La Jolla, CA 92093 USA; USN, Med Ctr, Dept Neurosci, San Diego, CA 92134 USA	University of California System; University of California San Diego; United States Department of Defense; United States Navy	Altschuler, EL (corresponding author), Univ Calif San Diego, Brain & Percept Lab, 9500 Gilman Dr,0190, La Jolla, CA 92093 USA.							Altschuler E. L., 1998, Society for Neuroscience Abstracts, V24, P1408; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; RAMACHANDRAN VS, 1995, NATURE, V377, P489, DOI 10.1038/377489a0; Seitz RJ, 1998, ARCH NEUROL-CHICAGO, V55, P1081, DOI 10.1001/archneur.55.8.1081; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152	5	356	407	4	69	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2035	2036		10.1016/S0140-6736(99)00920-4	http://dx.doi.org/10.1016/S0140-6736(99)00920-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376620				2023-01-03	WOS:000080812200015
J	Portenoy, RK; Lesage, P				Portenoy, RK; Lesage, P			Management of cancer pain	LANCET			English	Article							QUALITY-OF-LIFE; THERAPY; MORPHINE	Patients with cancer have diverse symptoms, impairments In physical and psychological functioning, and other difficulties that can undermine their quality of life. If inadequately controlled, pain can have a profoundly adverse impact on the patient and his or her family. The critical importance of pain management as part of routine cancer care has been forcefully advanced by WHO, international and national professional organisations, and governmental agencies. The prevalence of chronic pain is about 30-50% among patients with cancer who are undergoing active treatment for a solid tumour and 70-90% among those with advanced disease. Prospective surveys indicate that as many as 90% of patients could attain adequate relief with simple drug therapies, but this success rate is not achieved in routine practice. Inadequate management of pain is the result of various issues that include: undertreatment by clinicians with insufficient knowledge of pain assessment and therapy; inappropriate concerns about opioid side-effects and addiction; a tendency to give lower priority to symptom control than to disease management; patients under-reporting of pain and non-compliance with therapy; and impediments to optimum analgesic therapy in the healthcare system. To improve the management of cancer pain, every practitioner involved in the care of these patients must ensure that his or her medical information is current and that patients receive appropriate education.	Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center	Portenoy, RK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA.	Rportenoy@bethisraelny.org						Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *AM PAIN SOC, 1992, PRINC AN US TREATM A; Bloomfield DJ, 1998, J CLIN ONCOL, V16, P1218, DOI 10.1200/JCO.1998.16.3.1218; BRUERA E, 1990, ADV PAIN RES THER, V16, P203; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CELLA DF, 1994, J PAIN SYMPTOM MANAG, V9, P186, DOI 10.1016/0885-3924(94)90129-5; Cherny N I, 1994, J Palliat Care, V10, P57; CHERNY NI, IN PRESS TXB PAIN; Curtis E B, 1991, J Palliat Care, V7, P25; Derby S, 1998, CNS DRUGS, V9, P99, DOI 10.2165/00023210-199809020-00003; DERBY S, 1997, T PALLIAT CARE, V1, P95; DOYLE E, 1998, OXFORD TXB PALLIATIV; Ingham JM, 1993, CURR OPIN ANAESTH, V6, P838; Jacox A, 1994, AHCPR PUBLICATION; Portenoy R. K., 1994, Annals Academy of Medicine Singapore, V23, P160; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; PORTENOY RK, 1992, LANCET, V339, P1026, DOI 10.1016/0140-6736(92)90545-E; PORTENOY RK, 1998, CONT DIAGNOSIS MANAG, P40; PORTENOY RK, 1998, OXFORD TXB PALLIATIV, P361; RIPAMONTI C, 1994, J PAIN SYMPTOM MANAG, V9, P193, DOI 10.1016/0885-3924(94)90130-9; Saunders C, 1984, MANAGEMENT TERMINAL, P232; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VENTAFRIDDA V, 1990, ANN ONCOL, V1, P415, DOI 10.1093/oxfordjournals.annonc.a057794; Waldman Steven D., 1993, P285; World Health Organization, 1996, CANC PAIN REL PALL C	29	452	478	3	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1695	1700		10.1016/S0140-6736(99)01310-0	http://dx.doi.org/10.1016/S0140-6736(99)01310-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335806				2023-01-03	WOS:000080408000047
J	Ellis, H; Moran, BJ; Thompson, JN; Parker, MC; Wilson, MS; Menzies, D; McGuire, A; Lower, AM; Hawthorn, RJS; O'Brien, F; Buchan, S; Crowe, AM				Ellis, H; Moran, BJ; Thompson, JN; Parker, MC; Wilson, MS; Menzies, D; McGuire, A; Lower, AM; Hawthorn, RJS; O'Brien, F; Buchan, S; Crowe, AM			Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study	LANCET			English	Article							INTESTINAL-OBSTRUCTION	Background Adhesions after abdominal and pelvic surgery are important complications, although their basic epidemiology is unclear. We investigated the frequency of such complications in the general population to provide a basis for the targeting and assessment of new adhesion-prevention measures. Methods We used validated data from the Scottish National Health Service medical record linkage database to identify patients undergoing open abdominal or pelvic surgery in 1986, who had no record of such surgery in the preceding 5 years; Patients were followed up for 10 years and subsequent readmissions were:reviewed and outcomes classified by the degree of adhesion. We also assessed the rate of adhesion-related admissions in 1994 for the population of 5 million people. Findings 1209 (5.7%) of all readmissions (21 347) were classified as being directly related to adhesions, with 1169 (3.8%) managed operatively. Overall, 34.6% of the 29 790 patients who underwent open abdominal or pelvic surgery in 1986 were readmitted a mean of 2.1 times over 10 years for a disorder directly or possibly related to adhesions, or for abdominal or pelvic surgery that could be potentially complicated by adhesions. 22.1% of all outcome readmissions occurred in the first year after initial:surgery, but readmissions continued steadily throughout the 10-year period. In 1994, 4199 admissions were directly related to adhesions. Interpretation Postoperative adhesions have important consequences to patients, surgeons, and the health system. Surgical procedures with a high risk of adhesion-related complications need to be identified and adhesion prevention carefully assessed.	Guys Kings Coll & St Thomass, Sch Biomed Sci, Div Anat Cell & Human Biol, London SE1 9RT, England; N Hampshire Hosp, Dept Surg, Basingstoke, Hants, England; Chelsea & Westminster Hosp, Dept Surg, London, England; Joyce Green Hosp, Dept Surg, Dartford, England; Macclesfield Hosp, Dept Surg, Macclesfield, Cheshire, England; Stepping Hill Hosp, Stockport, England; Colchester Dist Gen Hosp, Dept Surg, Colchester, Essex, England; City Univ London, Sch Social Sci, London EC1V 0HB, England; Univ Oxford, Inst Hlth Sci, Oxford Hlth Econ Grp, Oxford, England; St Bartholomews Hosp, Fertil Ctr, London, England; So Gen Hosp NHS Trust, Dept Gynecol, Glasgow, Lanark, Scotland; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh, Midlothian, Scotland; Strategan Dis & Therapy Management, Basingstoke, Hants, England	University of London; King's College London; Imperial College London; City University London; University of Greenwich; University of Oxford; University of London; Queen Mary University London; NHS National Services Scotland	Ellis, H (corresponding author), Guys Kings Coll & St Thomass, Sch Biomed Sci, Div Anat Cell & Human Biol, Guys Campus, London SE1 9RT, England.							*CENTR STAT OFF, 1995, SOC TRENDS, V25; Ellis H, 1997, EUR J SURG, V163, P5; Ellis H, 1998, ANN CHIR GYNAECOL FE, V87, P9; FAZIO VW, 1995, ANN SURG, V222, P120, DOI 10.1097/00000658-199508000-00003; Harley K, 1996, Health Bull (Edinb), V54, P410; HERSHLAG A, 1991, CLIN OBSTET GYNECOL, V34, P395, DOI 10.1097/00003081-199106000-00023; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KROOK S, 1947, ACTA CHIR SCAND    S, V95, P1; MENZIES D, 1993, ANN ROY COLL SURG, V75, P147; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; *NAT HLTH SERV SCO, 1996, SCOTT HLTH STAT 1996, V38, P50; Ray NF, 1998, J AM COLL SURGEONS, V186, P1, DOI 10.1016/S1072-7515(97)00127-0	12	661	691	4	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1476	1480		10.1016/S0140-6736(98)09337-4	http://dx.doi.org/10.1016/S0140-6736(98)09337-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232313				2023-01-03	WOS:000080278200010
J	Hebert, PC; Wells, G; Blajchman, MA; Marshall, J; Martin, C; Pagliarello, G; Tweeddale, M; Schweitzer, I; Yetisir, E				Hebert, PC; Wells, G; Blajchman, MA; Marshall, J; Martin, C; Pagliarello, G; Tweeddale, M; Schweitzer, I; Yetisir, E		Canadian Critical Care Trials Grp	A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OXYGEN DELIVERY; ILL PATIENTS; MORTALITY; DISEASE; MANAGEMENT; SYSTEM; RBC	Background To determine whether a restrictive strategy of red-cell transfusion and a liberal strategy produced equivalent results in critically ill patients, we compared the rates of death from all causes at 30 days and the severity of organ dysfunction. Methods We enrolled 838 critically ill patients with euvolemia after initial treatment who had hemoglobin concentrations of less than 9.0 g per deciliter within 72 hours after admission to the intensive care unit and randomly assigned 418 patients to a restrictive strategy of transfusion, in which red cells were transfused if the hemoglobin concentration dropped below 7.0 g per deciliter and hemoglobin concentrations were maintained at 7.0 to 9.0 g per deciliter, and 420 patients to a liberal strategy, in which transfusions were given when the hemoglobin concentration fell below 10.0 g per deciliter and hemoglobin concentrations were maintained at 10.0 to 12.0 g per deciliter. Results Overall, 30-day mortality was similar in the two groups (18.7 percent vs. 23.3 percent, P = 0.11). However, the rates were significantly lower with the restrictive transfusion strategy among patients who were less acutely ill - those with an Acute Physiology and Chronic Health Evaluation II score of less than or equal to 20 (8.7 percent in the restrictive-strategy group and 16.1 percent in the liberal-strategy group, P = 0.03) - and among patients who were less than 55 years of age (5.7 percent and 13.0 percent, respectively; P = 0.02), but not among patients with clinically significant cardiac disease (20.5 percent and 22.9 percent, respectively; P = 0.69). The mortality rate during hospitalization was significantly lower in the restrictive-strategy group (22.2 percent vs. 28.1 percent, P = 0.05). Conclusions A restrictive strategy of red-cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients, with the possible exception of patients with acute myocardial infarction and unstable angina. (N Engl J Med 1999;340:409-17) (C) 1999. Massachusetts Medical Society.	Univ Ottawa, Crit Care Program, Ottawa, ON, Canada; Univ Ottawa, Clin Epidemiol Unit, Ottawa, ON, Canada; McMaster Univ, Dept Pathol, Hamilton, ON, Canada; Univ Toronto, Crit Care Program, Toronto, ON, Canada; Univ Western Ontario, Crit Care Program, London, ON, Canada; Univ British Columbia, Crit Care Program, Vancouver, BC V5Z 1M9, Canada	University of Ottawa; University of Ottawa; McMaster University; University of Toronto; Western University (University of Western Ontario); University of British Columbia	Hebert, PC (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd,Box 205, Ottawa, ON K1H 8L6, Canada.		Wells, George A/M-4549-2017; Martin, Claudio/G-3327-2011	Wells, George A/0000-0002-2289-9139; 				BAKER CH, 1986, CIRC SHOCK, V20, P127; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BORDIN JO, 1994, BLOOD, V84, P1703; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; *CAN RED CROSS SOC, 1993, CLIN GUID TRANSF PRO; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Hebert PC, 1997, CAN MED ASSOC J, V156, pS9; Hebert PC, 1998, CRIT CARE MED, V26, P482, DOI 10.1097/00003246-199803000-00019; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V274, P944; Heyland DK, 1996, CRIT CARE MED, V24, P517, DOI 10.1097/00003246-199603000-00025; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGENFELD JE, 1991, SURGERY, V110, P398; MARSHALL JC, 1992, CRIT CARE MED, V20, pS80; RUSSELL JA, 1994, AM J RESP CRIT CARE, V149, P533, DOI 10.1164/ajrccm.149.2.8306058; van de Watering LMG, 1998, CIRCULATION, V97, P562; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; WEISEL RD, 1984, J THORAC CARDIOV SUR, V88, P26	25	3348	3468	2	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1999	340	6					409	417		10.1056/NEJM199902113400601	http://dx.doi.org/10.1056/NEJM199902113400601			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166HW	9971864	Bronze			2023-01-03	WOS:000078571000001
J	Sawicki, PT				Sawicki, PT		Work Grp Study Patient Self-Management Oral	A structured teaching and self-management program for patients receiving oral anticoagulation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTHROMBIN TIME MONITOR; WARFARIN THERAPY	Context Control of oral anticoagulation therapy has been reported to often be inadequate. Previous retrospective investigations suggest that patients' self-adjustment of oral anticoagulants may lead to improved control. Objective To investigate the effects of patients' self-management of oral anticoagulation therapy on accuracy of control and measures of treatment-related quality of life. Design Randomized, single-blind, multicenter trial. Setting and Participants A total of 179 patients receiving long-term oral anticoagulation treatment were enrolled at 5 referral centers in Germany. Intervention Patients were randomized to an oral anticoagulation selfmanagement group based on a structured treatment and teaching program and international normalized ratio (INR) self-monitoring. The control group received conventional care as provided by family physicians, including referral to specialists if necessary. Main Outcome Measures Deviation of INR values from the individual INR target range (squared) and the 5 categories of treatment-related quality of life. Results Deviation of INR value from the mean of the INR target range was significantly lower in the intervention group at 3-month (squared INR deviation, 0.59 vs 0.95; P < .001) and 6-month follow-up (0.65 vs 0.83; P = .03) compared with the control group. Also, the intervention group had INR values within the target range more often (repeated measurement analysis for categorical data, P = .006). The results were mainly due to less frequent suboptimal INR values in the intervention group (32.8% vs 50.0% [P = .03] at 3-month, and 33.7% vs 48.2% [P = .08] at 6-month follow-up). Treatment-related quality-of-life measures, especially treatment satisfaction scores, were significantly higher in the intervention group compared with controls. Conclusions An anticoagulation education program that includes selfmanagement of anticoagulation therapy results in improved accuracy of anticoagulation control and in treatment-related quality-of-life measures. Further studies are needed to describe whether the program will reduce risk of bleeding or thromboembolism.	Univ Dusseldorf, Dept Metab Dis & Nutr, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Sawicki, PT (corresponding author), Univ Dusseldorf, Dept Metab Dis & Nutr, POB 101007, D-40001 Dusseldorf, Germany.	Sawicki@med.uni-duesseldorf.de						*AD HOC COMM WORK, 1993, J HEART VALVE DIS, V2, P398; ANDERSON DR, 1993, ARCH INTERN MED, V153, P1441, DOI 10.1001/archinte.153.12.1441; ANSELL J, 1989, ARCH INTERN MED, V149, P2509, DOI 10.1001/archinte.149.11.2509; ANSELL JE, 1995, ARCH INTERN MED, V155, P2185, DOI 10.1001/archinte.155.20.2185; BERNARDO A, 1992, THROMBOSIS EMBOLISM, P325; DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; HARRIES AD, 1981, LANCET, V1, P1320; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; KITCHEN S, 1994, THROMB HAEMOSTASIS, V72, P426; KOCH GG, 1977, BIOMETRICS, V33, P133, DOI 10.2307/2529309; KUMAR S, 1989, THROMB HAEMOSTASIS, V62, P729; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P155; MASSICOTTE P, 1995, J PEDIATR-US, V127, P389, DOI 10.1016/S0022-3476(95)70069-2; MUHLHAUSER I, 1993, J INTERN MED, V233, P321; PATERSON CE, 1986, ARCH INTERN MED, V146, P581; Rosendaal FR, 1996, NEW ENGL J MED, V335, P587, DOI 10.1056/NEJM199608223350810; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; *SAS I INC, 1987, SAS STAT VERS 6 GUID; SAWICKI PT, 1995, J HYPERTENS, V13, P933, DOI 10.1097/00004872-199508000-00015; SCHULMAN S, 1994, J INTERN MED, V236, P143, DOI 10.1111/j.1365-2796.1994.tb01276.x; *STAND ADV COMM HA, 1982, BMJ-BRIT MED J, V285, P274; TODD C, 1994, HDB PSYCHOL DIABETES, P15; vandenBesselaar AMHP, 1995, BLOOD COAGUL FIBRIN, V6, P726, DOI 10.1097/00001721-199512000-00005; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730	26	287	290	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1999	281	2					145	150		10.1001/jama.281.2.145	http://dx.doi.org/10.1001/jama.281.2.145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155VJ	9917117				2023-01-03	WOS:000077966800034
J	Levinson, W; Altkorn, D				Levinson, W; Altkorn, D			Primary prevention of postmenopausal osteoporosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HORMONE REPLACEMENT THERAPY; BONE-MINERAL DENSITY; BREAST-CANCER; WOMEN; ESTROGEN; RISK; MORTALITY; DISEASE; OLDER		Univ Chicago, Gen Internal Med Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Gen Internal Med Sect, Dept Med, 5841 S Maryland Ave,MC 6098, Chicago, IL 60637 USA.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P509; 1998, SCI AM MED, V15, pR11; 1998, OSTEOPOROSIS INT S4, V8, pS1	17	17	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1821	1822		10.1001/jama.280.21.1821	http://dx.doi.org/10.1001/jama.280.21.1821			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846765				2023-01-03	WOS:000077176600010
J	Herman, ST; Pedley, TA				Herman, ST; Pedley, TA			New options for the treatment of epilepsy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NEWLY-DIAGNOSED EPILEPSY; PHARMACOKINETICS; CARBAMAZEPINE; LAMOTRIGINE; VIGABATRIN; SAFETY		Columbia Presbyterian Med Ctr, Inst Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University	Pedley, TA (corresponding author), Columbia Presbyterian Med Ctr, Inst Neurol, 710 W 168th St, New York, NY 10032 USA.			Herman, Susan/0000-0002-6556-083X				Bergey GK, 1997, NEUROLOGY, V49, P739, DOI 10.1212/WNL.49.3.739; Biton V, 1997, EPILEPSIA, V38, pS42, DOI 10.1111/j.1528-1157.1997.tb04518.x; Blum D E, 1998, Adv Neurol, V76, P57; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Chadwick DW, 1997, EPILEPSIA, V38, pS59, DOI 10.1111/j.1528-1157.1997.tb04522.x; DEVINSKY O, 1995, ANN NEUROL, V38, P670, DOI 10.1002/ana.410380418; Dooley J, 1996, NEUROLOGY, V46, P240, DOI 10.1212/WNL.46.1.240; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; FEUCHT M, 1994, EPILEPSIA, V35, P993, DOI 10.1111/j.1528-1157.1994.tb02544.x; KALVIAINEN R, 1995, ARCH NEUROL-CHICAGO, V52, P989, DOI 10.1001/archneur.1995.00540340081016; Krauss GL, 1998, NEUROLOGY, V50, P614, DOI 10.1212/WNL.50.3.614; LEPPIK IE, 1990, NEUROLOGY, V40, P456, DOI 10.1212/WNL.40.3_Part_1.456; Macdonald RL, 1997, CURR OPIN NEUROL, V10, P121, DOI 10.1097/00019052-199704000-00009; MOTTE J, 1997, NEW ENGL J MED, V337, P1801; Pellock JM, 1997, EPILEPSIA, V38, P1261, DOI 10.1111/j.1528-1157.1997.tb00061.x; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; Sachdeo RC, 1997, EPILEPSIA, V38, P294, DOI 10.1111/j.1528-1157.1997.tb01120.x; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Shorvon S, 1997, EPILEPSIA, V38, pS45, DOI 10.1111/j.1528-1157.1997.tb04519.x; Vigevano F, 1997, EPILEPSIA, V38, P1270; WALKER MC, 1995, PHARMACOL THERAPEUT, V67, P351, DOI 10.1016/0163-7258(95)00021-6	21	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					693	694		10.1001/jama.280.8.693	http://dx.doi.org/10.1001/jama.280.8.693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728627				2023-01-03	WOS:000075446900013
J	Nazerali, H; Hogerzeil, HV				Nazerali, H; Hogerzeil, HV			The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study	BRITISH MEDICAL JOURNAL			English	Article									WHO, Act Programme Essential Drugs, CH-1211 Geneva, Switzerland; Zimbabwe Essential Drugs Act Programme, Harare, Zimbabwe	World Health Organization	Hogerzeil, HV (corresponding author), WHO, Act Programme Essential Drugs, CH-1211 Geneva, Switzerland.							HOGERZEIL HV, 1992, BRIT MED J, V304, P210, DOI 10.1136/bmj.304.6821.210; Hogerzeil HV, 1996, EUR J OBSTET GYN R B, V69, P25, DOI 10.1016/0301-2115(95)02530-8; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; NAZERALI H, 1996, WHODAP9416; WALKER GJA, 1988, LANCET, V2, P393	5	32	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					512	513						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712597				2023-01-03	WOS:000075641400020
J	Fraenkel, L; Zhang, YQ; Chaisson, CE; Evans, SR; Wilson, PWF; Felson, DT				Fraenkel, L; Zhang, YQ; Chaisson, CE; Evans, SR; Wilson, PWF; Felson, DT			The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal Women	ANNALS OF INTERNAL MEDICINE			English	Article							MENSTRUAL-CYCLE; HEALTHY WOMEN; DIAGNOSIS; PROGESTERONE; POPULATION; ESTRADIOL	Background: Hormonal factors may play an important role in the pathophysiology of the Raynaud phenomenon. Experimental studies have shown an increased vasoconstrictor response to estrogen, a response that can be prevented by the addition of progesterone. Objective: To measure the association between estrogen replacement therapy (alone and with progesterone) and the Raynaud phenomenon. Design: Cross-sectional study. Setting: Framingham Offspring Study. Participants: 497 postmenopausal women. Measurements: Prevalence of the Raynaud phenomenon according to hormone use. Covariates measured included age, body mass index, smoking, alcohol consumption, and p-blocker use. Results: Forty-nine women were classified as having the Raynaud phenomenon (9.9%). The prevalence of this phenomenon was 8.4% among women who did not receive estrogen, 19.1% among women receiving estrogen alone, and 9.8% among women receiving estrogen plus progesterone. The adjusted odds ratio for the Raynaud phenomenon was 2.5 (95% CI, 1.2 to 5.3) for unopposed estrogen and 0.9 (CI, 0.3 to 2.6) for estrogen plus progesterone, with nonusers as the reference group. Conclusions: Unopposed estrogen therapy was associated with the Raynaud phenomenon in postmenopausal women. This association was not present in women who were receiving combined hormone therapy.	Boston Univ, Ctr Arthritis, Boston, MA 02118 USA; Boston Univ, Med Ctr, Boston, MA USA; NHLBI, Bethesda, MD USA	Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Fraenkel, L (corresponding author), Boston Univ, Ctr Arthritis, A203,715 Albany St, Boston, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Zhang, Yuqing/0000-0001-7954-1149; Felson, David/0000-0002-2668-2447; Chaisson, Christine/0000-0002-3207-9257	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIAMS NIH HHS [AR20613] Funding Source: Medline; NIA NIH HHS [AG09300] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTURA BM, 1975, J PHARMACOL EXP THER, V193, P403; BARTELINK ML, 1994, EUR J CLIN PHARMACOL, V46, P557, DOI 10.1007/BF00196115; BRENNAN P, 1993, BRIT J RHEUMATOL, V32, P357; COFFMAN JD, 1990, J VASC MED BIOL, V2; EASTCOTT HH, 1976, BRIT MED J, V2, P477, DOI 10.1136/bmj.2.6033.477-c; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; FELSON DT, 1995, AM J EPIDEMIOL, V142, P485, DOI 10.1093/oxfordjournals.aje.a117664; Greenstein D, 1996, ANGIOLOGY, V47, P427, DOI 10.1177/000331979604700501; HAMLET MA, 1980, AM J PHYSIOL, V239, pH450, DOI 10.1152/ajpheart.1980.239.4.H450; KEIL JE, 1991, INT J EPIDEMIOL, V20, P221, DOI 10.1093/ije/20.1.221; LEPPERT J, 1987, ANGIOLOGY, V38, P871, DOI 10.1177/000331978703801201; LEVINE JD, 1989, BRAIN RES, V487, P143, DOI 10.1016/0006-8993(89)90949-9; MARICQ HR, 1988, J RHEUMATOL, V15, P454; OKEEFFE ST, 1992, J RHEUMATOL, V19, P1415; ROBERTS JM, 1977, NATURE, V270, P624, DOI 10.1038/270624a0; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; SOLERTE SB, 1988, BRIT J OBSTET GYNAEC, V95, P1305, DOI 10.1111/j.1471-0528.1988.tb06822.x; TERREGINO CA, 1985, ANGIOLOGY, V36, P88, DOI 10.1177/000331978503600204; Valter I, 1998, J RHEUMATOL, V25, P697; WILLIAMS LT, 1977, J CLIN INVEST, V60, P815, DOI 10.1172/JCI108835	20	43	45	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					208	211		10.7326/0003-4819-129-3-199808010-00009	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696729				2023-01-03	WOS:000075032700006
J	Burdett, S; Parmar, MKB; Stewart, LA; Souhami, RL; Arriagada, R; Girling, DJ; Pignon, JP; Torri, V; Brichet, AH; Lafitte, JJ; Dautzenberg, B; Debevec, M; Kovac, V; Stephens, RJ; Gregor, A; Piantadosi, S; Rocmans, P; Van Houtte, P; Wang, M				Burdett, S; Parmar, MKB; Stewart, LA; Souhami, RL; Arriagada, R; Girling, DJ; Pignon, JP; Torri, V; Brichet, AH; Lafitte, JJ; Dautzenberg, B; Debevec, M; Kovac, V; Stephens, RJ; Gregor, A; Piantadosi, S; Rocmans, P; Van Houtte, P; Wang, M		PORT Meta-Anal Trialists Grp	Postoperative radiotherapy in nonsmall-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials	LANCET			English	Article							RADIATION	Background The role of postoperative radiotherapy in treatment of patients with completely resected non-small-cell lung cancer (NSCLC) remains unclear. We undertook a systematic review and meta-analysis of the available evidence from randomised trials. Methods Updated data were obtained on individual patients from all available randomised trials of postoperative radiotherapy versus surgery alone. Data on 2128 patients from nine randomised trials (published and unpublished) were analysed by intention to treat. There were 707 deaths among 1056 patients assigned postoperative radiotherapy and 661 among 1072 assigned surgery alone. Median follow-up was 3.9 years (2.3-9.8 for individual trials) for surviving patients. Findings The results show a significant adverse effect of postoperative radiotherapy on survival (hazard ratio 1.21 [95% CI 1.08-1.34]). This 21% relative increase in the risk of death is equivalent to an absolute detriment of 7% (3-11) at 2 years, reducing overall survival from 55% to 48%. Subgroup analyses suggest that this adverse effect was greatest for patients with stage I/II, N0-N1 disease, whereas for those with stage III, N2 disease there was no clear evidence of an adverse effect. Interpretation Postoperative radiotherapy is detrimental to patients with early-stage completely resected NSCLC and should not be used routinely for such patients. The role of postoperative radiotherapy in the treatment of N2 tumours is not clear and may warrant further research.	MRC, Canc Trials Off, Cambridge CB2 2BW, England; UCL, Sch Med, London, England; Inst Radiomed, Santiago, Chile; Inst Gustave Roussy, Villejuif, France; Ist Ric Farmacol Mario Negri, Milan, Italy; CHRU, Hop Calmette, Lille, France; Inst Oncol, Ljubljana, Slovenia; European Org Res Treatment Canc, Brussels, Belgium; Hop St Pierre & Erasme, Brussels, Belgium; Inst Jules Bordet, B-1000 Brussels, Belgium; Chinese Acad Med Sci, Beijing 100037, Peoples R China	University of London; University College London; UCL Medical School; UNICANCER; Gustave Roussy; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universite de Lille - ISITE; CHU Lille; Institute of Oncology - Slovenia; European Organisation for Research & Treatment of Cancer; Universite Libre de Bruxelles; Institut Jules Bordet; Chinese Academy of Medical Sciences - Peking Union Medical College	Stewart, LA (corresponding author), MRC, Canc Trials Off, 5 Shaftesbury Rd, Cambridge CB2 2BW, England.	ls@cto.mrc.ac.uk	Torri, Valter/H-7550-2015	Torri, Valter/0000-0001-9541-9354; PIGNON, Jean-Pierre/0000-0003-2047-1582; Stewart, Lesley/0000-0003-0287-4724				ALBERTI W, 1995, BRIT MED J, V311, P899; BANGMA PJ, 1972, CARCINOMA BRONCHUS M, P163; BASSORICCI S, 1991, LUNG CANCER, V7, P99; Debevec M, 1996, LUNG CANCER, V14, P99, DOI 10.1016/0169-5002(95)00515-3; Dickersin K, 1995, SYSTEMATIC REV, P17; *EAR BREAST CANC T, 1990, TRATM EARL BREAST CA; ISRAEL L, 1979, LUNG CANC PROGR THER, P443; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lafitte JJ, 1996, ANN THORAC SURG, V62, P830, DOI 10.1016/S0003-4975(96)00507-3; Parkin DM, 1993, LUNG CANCER, V9, P1; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PATERSON R, 1962, Clin Radiol, V13, P141, DOI 10.1016/S0009-9260(62)80036-1; Rankin EM, 1986, RANDOMISED TRIALS CA, P447; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SmolleJuettner FM, 1996, EUR J CARDIO-THORAC, V10, P947, DOI 10.1016/S1010-7940(96)80395-2; Stephens RJ, 1996, BRIT J CANCER, V74, P632, DOI 10.1038/bjc.1996.413; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; VANHOUTTE P, 1980, INT J RADIAT ONCOL, V6, P983, DOI 10.1016/0360-3016(80)90105-4; WANG M, 1994, CHIN J RAD ONCOL, V3, P39; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	644	654	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					257	263						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690404				2023-01-03	WOS:000074974500007
J	Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S				Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S		Swedish Hip Fracture Study Grp	Hormone replacement therapy and risk of hip fracture: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; BONE-DENSITY; ESTROGEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREVENTION; AGE	Objective: To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. Design: Population based case-control study. Setting: Six counties in Sweden. Subjects: 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. Main outcome measure: Use of hormone replacement therapy. Results: Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01), For every year of therapy the overall risk decreased by 6% (3% to 9%): 4%, (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously with a duration of use more than five years, was associated with all odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (-7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with skin patches gave similar risk estimates as oral regimens. Conclusions: Recent use of hormone replacement therapy is required for optimum fracture protection, but therapy can bt started several years after the menopause. The protective effect increases with duration of use, and an oestrogen-sparing effect is achieved when progestins are included in the regimen.	Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Stockholm Cty Council, Dept Epidemiol, S-17176 Stockholm, Sweden; Malmo Gen Hosp, Dept Orthopaed, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Dartmouth College; Dartmouth College; Karolinska Institutet; Stockholm County Council; Uppsala University; Uppsala University Hospital	Michaelsson, K (corresponding author), Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden.	Karl.Michaelsson@ortopedi.uu.se	Michaelsson, Karl/AAM-9094-2021	Magnusson, Cecilia/0000-0002-8567-6725; Michaelsson, Karl/0000-0003-2815-1217	NINR NIH HHS [NR 1 RO 1 CA58427] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1985, LANCET, V2, P800; Christiansen C, 1990, Osteoporos Int, V1, P7; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; HEANEY RP, 1992, J INTERN MED, V231, P169, DOI 10.1111/j.1365-2796.1992.tb00520.x; HILLARD TC, 1991, CALCIFIED TISSUE INT, V49, pS55, DOI 10.1007/BF02555090; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; MELTON LJ, 1987, BONE MINER, V2, P321; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P412, DOI 10.1016/S0002-9378(97)70207-2; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140-6736(97)90007-6; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	28	201	206	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1858	1863						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632404				2023-01-03	WOS:000074686500016
J	Astin, JA				Astin, JA			Why patients use alternative medicine - Results of a national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; UNITED-STATES; CARE; PRACTITIONERS; SOMATIZATION; PREVALENCE; THERAPIES; ATTITUDES; BEHAVIORS; DOCTORS	Context.-Research both in the United States and abroad suggests that significant numbers of people are involved with various forms of alternative medicine. However, the reasons for such use are, at present, poorly understood. Objective.-To investigate possible predictors of alternative health care use. Methods.-Three primary hypotheses were tested. People seek out these alternatives because (1) they are dissatisfied in some way with conventional treatment; (2) they see alternative treatments as offering more personal autonomy and control over health care decisions; and (3) the alternatives are seen as more compatible with the patients' values, worldview, or beliefs regarding the nature and meaning of health and illness. Additional predictor variables explored included demographics and health status. Design.-A written survey examining use of alternative health care, health status, values, and attitudes toward conventional medicine. Multiple logistic regression analyses were used in an effort to identify predictors of alternative health care use. Setting and Participants.-A total of 1035 individuals randomly selected from a panel who had agreed to participate in mail surveys and who live throughout the United States. Main Outcome Measure.-Use of alternative medicine within the previous year. Results.-The response rate was 69%. The following variables emerged as predictors of alternative health care use: more education (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.1-1.3); poorer health status (OR, 1.3, 95% CI, 1.1-1.5); a holistic orientation to health (OR, 1.4; 95% CI, 1.1-1.9); having had a transformational experience that changed the person's worldview (OR, 1.8; 95% CI, 1.3-2.5); any of the following health problems: anxiety (OR, 3.1; 95% CI, 1.6-6.0); back problems (OR, 2.3; 95% CI, 1.7-3.2); chronic pain (OR, 2.0; 95% CI, 1.1-3.5); urinary tract problems (OR, 2.2; 95% CI, 1.3-3.5); and classification in a cultural group identifiable by their commitment to environmentalism, commitment to feminism, and interest in spirituality and personal growth psychology (OR, 2.0; 95% CI, 1.4-2.7). Dissatisfaction with conventional medicine did not predict use of alternative medicine. Only 4.4% of those surveyed reported relying primarily on alternative therapies. Conclusion.-Along with being more educated and reporting poorer health status, the majority of alternative medicine users appear to be doing so not so much as a result of being dissatisfied with conventional medicine but largely because they find these health care alternatives to be more congruent with their own values, beliefs, and philosophical orientations toward health and life.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Astin, JA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 730 Welch Rd, Palo Alto, CA 94304 USA.							AVINA RL, 1978, WESTERN J MED, V128, P366; BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; Bernstein JH, 1997, SOC SCI MED, V44, P1341, DOI 10.1016/S0277-9536(97)84076-2; BORKAN J, 1994, J FAM PRACTICE, V39, P545; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHARLTON BG, 1993, J ROY SOC MED, V86, P125; DEAN K, 1981, SOC SCI MED-MED SOC, V15, P673, DOI 10.1016/0271-7123(81)90091-2; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Duggan R M, 1995, Altern Ther Health Med, V1, P28; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fuller R., 1989, ALTERNATIVE MED AM R; FURNHAM A, 1988, SOC SCI MED, V26, P685, DOI 10.1016/0277-9536(88)90060-3; FURNHAM A, 1993, BRIT J CLIN PSYCHOL, V32, P237, DOI 10.1111/j.2044-8260.1993.tb01051.x; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; JENSEN P, 1990, ACTA DERM-VENEREOL, V70, P425; KLEINMAN A, 1984, ALTERNATIVE MED POPU; Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LEVIN JS, 1986, SOC SCI MED, V23, P889, DOI 10.1016/0277-9536(86)90217-0; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McGuire Meredith, 1988, RITUAL HEALING SUBUR; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Ostrow MJ, 1997, J ACQ IMMUN DEF SYND, V15, P115, DOI 10.1097/00042560-199706010-00003; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; PERKIN MR, 1994, J ROY SOC MED, V87, P523; RAY PH, 1997, AM DEMOGRAPHICS  FEB; RAY PH, IN PRESS CULTURAL CR; RIESMANN F, 1994, SOC POLICY       SPR, P53; SALMON JW, 1984, ALTERNATIVE MED POPU; SUTHERLAND LR, 1994, J CLIN GASTROENTEROL, V19, P194, DOI 10.1097/00004836-199410000-00004; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x	34	1904	1948	8	230	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1548	1553		10.1001/jama.279.19.1548	http://dx.doi.org/10.1001/jama.279.19.1548			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZN087	9605899	Bronze			2023-01-03	WOS:000073608100033
J	Schierhout, G; Roberts, I				Schierhout, G; Roberts, I			Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN	Objective: To determine the effect on mortality of resuscitation with colloid solutions compared with resuscitation with crystalloids. Design: Systematic review of randomised controlled trials of resuscitation with colloids compared with crystalloids for volume replacement of critically ill patients; analysis stratified according to patient type and quality of allocation concealment Subjects: 37 randomised controlled trials were eligible, of which 26 unconfounded trials compared colloids with crystalloids (n = 1622). (The 10 trials that compared colloid in hypertonic crystalloid with isotonic crystalloid (n = 1422) and one trial that compared colloid in isotonic crystalloid with hypertonic crystalloid (n = 38) are described in the longer version on our website www.bmj.com). Main outcome measures: Mortality from all causes at end of follow up for each trial. Results: Resuscitation with colloids was associated with an increased absolute risk of mortality of 4% (95% confidence interval 0% to 8%), or four extra deaths for every 100 patients resuscitated. The summary effect measure shifted towards increased mortality with colloids when only trials with adequate concealment of allocation were included. There was no evidence for differences in effect among patients with different types of injury that required fluid resuscitation. Conclusions: This systematic review does not support the continued use of colloids for volume replacement in critically ill patients.	UCL, Sch Med, Inst Child Hlth,Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	Schierhout, G (corresponding author), UCL, Sch Med, Inst Child Hlth,Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England.			Schierhout, Gill/0000-0002-6399-7624				Armstrong RF, 1994, CRITICAL CARE ALGORI; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BISONNI RS, 1991, J FAM PRACTICE, V32, P387; EGGER M, IN PRESS BMJ; Fakhry S. M., 1995, Journal of Burn Care and Rehabilitation, V16, P86; MCGRATH K, 1991, MED J AUSTRALIA, V154, P657, DOI 10.5694/j.1326-5377.1991.tb121251.x; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; SCHNEIDER M, IN PRESS J EVAL CLIN; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; VELANOVICH V, 1989, SURGERY, V105, P65; VERMEULEN LC, 1995, ARCH INTERN MED, V155, P373, DOI 10.1001/archinte.155.4.373; YIM JM, 1995, ARCH INTERN MED, V155, P2450, DOI 10.1001/archinte.155.22.2450	12	361	390	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	1998	316	7136					961	964		10.1136/bmj.316.7136.961	http://dx.doi.org/10.1136/bmj.316.7136.961			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550953	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000072856100017
J	Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER				Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER			Over-the-counter analgesics and risk of ovarian cancer	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLORECTAL-CANCER; COLON-CANCER; ASPIRIN USE	Background Evidence that aspirin and other non-steroidal anti-inflammatory drugs reduce risk for colorectal cancer has prompted interest in their ability to prevent other cancers. We aimed to find out what effect over-the-counter analgesics have on risk of ovarian cancer. Methods In a case-control study we compared use of over-the-counter analgesics by 563 women from eastern Massachusetts and New Hampshire, USA, who had epithelial ovarian cancer with 523 women from the general population. We calculated exposure odds ratios to estimate the effect of over-the-counter analgesics on ovarian cancer risk. Use of over-the-counter analgesics was assessed through interviews and defined as use al least once a week continuously for at least 6 months. Findings The odds ratio for risk of ovarian cancer for aspirin use was 0.75 (95% CI 0.52-1.10), that for ibuprofen was 1.03 (0.64-1.64), and that for paracetamol was 0.52 (0.31-0.86), after adjusting for age, study centre, education, religion, parity, oral contraceptive use, and menstrual, arthritic, or headache pain. Relative to no use, the lower risk of ovarian cancer associated with paracetamol was more apparent for use on a daily basis, 0.39 (0.21-0.74), for more than 10 years of use, 0.40 (0.19-0.88), or for more than 20 tablet years defined as (tablets per dayXyears of use), 0.45 (0.20-0.99). Interpretation In our data, there was a statistically significant inverse association between paracetamol use and ovarian cancer risk. There was a modest but nonsignificant inverse association with aspirin use and ovarian cancer and no association with ibuprofen use. Experimental studies in rodents demonstrating uterine and ovarian atrophy at high doses of paracetamol and decreased ovarian-cyst formation at lower doses suggest a biological basis for our observations.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Dartmouth College; Norris Cotton Cancer Center	Cramer, DW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA 02115 USA.			Harlow, Bernard/0000-0002-6735-8862	NCI NIH HHS [R01 CA 54419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berkel HJ, 1996, EPIDEMIOL REV, V18, P205, DOI 10.1093/oxfordjournals.epirev.a017926; GOODWIN JS, 1981, MED CLIN N AM, V65, P829, DOI 10.1016/S0025-7125(16)31500-0; GREENBERG ER, 1996, IARC SCI PUBL, V139, P91; *INT AG RES CANC W, 1990, IARC MONOGRAPHS; ISENHOWER WD, 1986, BIOL RES PREG PERIN, V7, P6; LOGAN RF, 1993, BRIT MED J, V309, P285; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; *NAT TOX PROGR, 1993, NIH PUBL; PASHA KV, 1989, BRAIN RES BULL, V22, P617, DOI 10.1016/0361-9230(89)90079-8; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; SANTACOLOMA TA, 1991, BIOCHEM BIOPH RES CO, V176, P1256, DOI 10.1016/0006-291X(91)90421-3; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301	15	190	192	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					104	107		10.1016/S0140-6736(97)08064-1	http://dx.doi.org/10.1016/S0140-6736(97)08064-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439495				2023-01-03	WOS:000071591900012
J	Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF				Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF			Admission trends in a rural south African hospital during the early years of the HIV epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESOURCE UTILIZATION; DRUG-USERS; TUBERCULOSIS; INFECTION; RISK; IMPACT; DISTRICT; NAIROBI; COHORT; WOMEN	Context Few studies have attempted to quantify the effect of the epidemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for health care in developing countries. More data are required to improve understanding of its impact and to guide development of appropriate response strategies. Objective To assess the HIV/AIDS epidemic's impact on demand for inpatient hospital care in a rural area of South Africa. Design Retrospective analysis of data from general hospital and individual ward admission registers, a tuberculosis program database, and patient case notes. Setting and Patients Patients admitted between 1991 and 1998 to a 450-bed hospital that serves Hlabisa District, South Africa (population approximate to 200 000), where HIV seroprevalence among antenatal clinic attendees increased from 4% in 1992 to 29% in 1998, Main Outcome Measures Number of admissions to 9 hospital wards, number of clinical AIDS and general medical admissions (both excluding tuberculosis), and number of tuberculosis admissions to adult medical wards during the study period. Results Total hospital admissions increased by 81%, from 6562 in 1991 to 11 872 in 1998, Adult tuberculosis ward admissions increased by 360%, from 303 to 1393, In 1998, tuberculosis patients accounted for 47% and 30% of adult male and female medical ward admissions, respectively, and for 11% of total hospital admissions. Nontuberculosis clinical AIDS cases increased 43-fold, accounting for 4% of adult medical admissions in 1997 vs 0.2% in 1991. Tuberculosis and nontuberculosis clinical AIDS cases were the only types of admission to show a clear and consistent upward trend over the period studied. Patterns in other types of admissions varied more and changes were smaller. Conclusions The HIV/AIDS epidemic has had an important impact on demand for adult tuberculosis and general medical care in a rural South African district hospital. If this impact is shown to extend to other rural South African areas, response strategies are urgently needed.	Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England; Hlabisa Hosp, Hlabisa, South Africa; MRC, Ctr Epidemiol Res S Africa, Mtubatuba, South Africa	Liverpool School of Tropical Medicine; University of Liverpool	Floyd, K (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.	kfloyd@liverpool.ac.uk	Gilks, Charles/B-4184-2012; Wilkinson, David/A-6207-2008	Gilks, Charles/0000-0002-8953-3123; Wilkinson, David/0000-0002-7265-9846				ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1997, HUM DEV REP 1997; ARTHUR G, 1998, 12 WORLD AIDS C JUN; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BUVE AMA, 1992, 8 INT C AIDS JUL 19, V2; Coleman RL, 1997, J ACQ IMMUN DEF SYND, V16, P50, DOI 10.1097/00042560-199709010-00008; DUNN DT, 1992, LANCET, V87, P456; FOSTER SD, 1993, COST BURDEN AIDS ZAM; GILKS CF, 1992, Q J MED, V82, P25; Harries A, 1996, TB HIV CLIN MANUAL; Harries AD, 1997, ANN TROP MED PARASIT, V91, P771, DOI 10.1080/00034989760527; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KARSTAEDT AS, 1996, S AFR MED J, V86, P1490; KING R, 1994, T ROY SOC TROP MED H, V88, P295, DOI 10.1016/0035-9203(94)90083-3; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NUNN P, 1993, TUBERCLE LUNG DIS, V74, P273, DOI 10.1016/0962-8479(93)90054-2; OKELLO DO, 1994, E AFR MED J, V71, P816; *REP S AFR DEP HLT, 1996, EPIDEMIOLOGICAL COMM, V23, P4; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMITH PG, 1994, TUBERCULOSIS PATHOGE, pCH4; *STAT CORP, 1999, STAT STAT SOFTW COMP; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; *UNAIDS, UNAIDS9810; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P420, DOI 10.1016/S0035-9203(97)90263-7; Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016; Wilkinson D, 1997, S AFR MED J, V87, P447; YEUNG S, IN PRESS J TROP PAED	30	45	45	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1087	1091		10.1001/jama.282.11.1087	http://dx.doi.org/10.1001/jama.282.11.1087			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493210				2023-01-03	WOS:000082512300036
J	Chatal, JF; Hoefnagel, CA				Chatal, JF; Hoefnagel, CA			Radionuclide therapy	LANCET			English	Article							THYROID-CARCINOMA; METASTASES; TUMORS; PAIN; RADIOIMMUNOTHERAPY; RADIOTHERAPY; PALLIATION; ANTIBODY; LYMPHOMA; TRIAL	Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment. In cancer treatment, it often combines the advantage of target selectivity (like brachytherapy or external beam radiotherapy) with that of being systemic, as with chemotherapy, and it may be used as part of a therapeutic strategy with curative intent or for disease control and palliation. Toxicity is generally limited to the haematopoietic tissue and few side-effects are observed. When cure is feasible, the long-term consequences of radionuclide therapy (eg, fertility disorders and leukaemia or other secondary cancers) do compare favourably with the risks associated with and accepted for chemotherapy and radiotherapy.	Ctr Rene Gauducheau, Dept Nucl Med, F-44000 Nantes, France; Netherlands Canc Inst, Dept Nucl Med, Amsterdam, Netherlands	UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Netherlands Cancer Institute	Chatal, JF (corresponding author), Ctr Rene Gauducheau, Dept Nucl Med, F-44000 Nantes, France.							Chatal J. F., 1998, NUCL MED CLIN DIAGNO, P1101; DEKRAKER J, 1995, EUR J CANCER, V31A, P600, DOI 10.1016/0959-8049(95)00063-O; Hnatowich DJ, 1999, J NUCL MED, V40, P693; Hoefnagel CA, 1999, EUR J NUCL MED, V26, P277, DOI 10.1007/s002590050389; HUMM JL, 1990, J NUCL MED, V31, P75; LUI SY, 1998, J CLIN ONCOL, V16, P3270; Maloney DG, 1997, BLOOD, V90, P2188; McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306; Otte A, 1998, LANCET, V351, P417, DOI 10.1016/S0140-6736(05)78355-0; Quirijnen JMSP, 1996, J NUCL MED, V37, P1511; RAOUL JL, 1994, J NUCL MED, V35, P1782; Reubi J C, 1997, Q J Nucl Med, V41, P63; ROBINSON RG, 1995, JAMA-J AM MED ASSOC, V274, P420, DOI 10.1001/jama.274.5.420; Schlumberger M, 1996, J NUCL MED, V37, P598; SCHLUMBERGER M, 1988, J NUCL MED, V29, P1790; Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574; Stolz B, 1998, EUR J NUCL MED, V25, P668, DOI 10.1007/s002590050268; Taal BG, 1996, J CLIN ONCOL, V14, P1829, DOI 10.1200/JCO.1996.14.6.1829; Troncone L, 1991, J NUCL BIOL MED, V35, P177; Wahl RL, 1998, J NUCL MED, V39, p21S; WHELDON TE, 1991, RADIOTHER ONCOL, V21, P91, DOI 10.1016/0167-8140(91)90080-Z	21	71	75	2	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					931	935		10.1016/S0140-6736(99)06002-X	http://dx.doi.org/10.1016/S0140-6736(99)06002-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489968				2023-01-03	WOS:000082511800041
J	Persidis, A				Persidis, A			Cardiovascular disease drug discovery	NATURE BIOTECHNOLOGY			English	Article									Argonex Inc, Business Dev, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 706 Forest St, Charlottesville, VA 22903 USA.							Fox KAA, 1999, CARDIOVASC DRUG THER, V13, P211, DOI 10.1023/A:1007792024993; Hwang DM, 1997, CIRCULATION, V96, P4146; Li A, 1999, AM J MED GENET, V86, P57, DOI 10.1002/(SICI)1096-8628(19990903)86:1<57::AID-AJMG11>3.0.CO;2-R; Meyer BJ, 1996, EUR HEART J, V17, P1318; Persidis A, 1998, NAT BIOTECHNOL, V16, P209, DOI 10.1038/nbt0298-209; Plebani M, 1999, INT J CLIN LAB RES, V29, P56, DOI 10.1007/s005990050064; *WHO, 1995, WORLD HLTH STAT Q, V48; *WHO, 1993, WORLD HLTH STAT Q, V46	8	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					930	931		10.1038/12935	http://dx.doi.org/10.1038/12935			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471943				2023-01-03	WOS:000082365800039
J	Wallace, PGM; Ridley, SA				Wallace, PGM; Ridley, SA			ABC of intensive care - Transport of critically ill patients	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England	University of Glasgow; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Wallace, PGM (corresponding author), Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland.								0	44	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					368	371		10.1136/bmj.319.7206.368	http://dx.doi.org/10.1136/bmj.319.7206.368			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435964	Green Published			2023-01-03	WOS:000082001700025
J	Wear, A				Wear, A			The early modern debate about foreign drugs: localism versus universalism in medicine	LANCET			English	Review									Wellcome Inst Hist Med Sci, London NW1 2BE, England	University of London; University College London	Wear, A (corresponding author), Wellcome Inst Hist Med Sci, 183 Euston Rd, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bright Timothy, 1580, TREATISE WHEREIN IS; BRUSH SB, 1993, AM ANTHROPOL, V95, P653, DOI 10.1525/aa.1993.95.3.02a00060; BRUSH SB, 1996, VALUING LOCAL KNOWLE; COLES W, 1656, ART SIMPLING, P95; DELAPRIMAUDAYE P, 1618, FRENCH ACAD, P787; DERENOU J, 1657, MED DISPENSATORY; dOrta Garcia, 1563, COLOQUIOS SIMPLES DR; ESTES JW, 1995, PHARM HIST, V37, P2; Frampton John, 1577, IOYFULL NEWES OUT NE; FUCHS L, 1539, MEDENDIS SINGULARUM; GOODMAN J, 1993, TOBACCO HIST CULTURE, P39; HARRISON W, DESCRIPTION ENGLAND, P265; Jutte Robert, 1994, POVERTY DEVIANCE EAR; LANNING JT, 1985, ROYAL PROTOMEDICATO, P58; MONARDES N, 1574, LIBROS UNO QUE TRATA; MORAN BT, 1993, PHARM HIST, V35, P104; MUN T, 1621, DISCOURSE TRADE ENGL, P8; PAGEL W, 1958, PARACELSUS; Primrose J., 1651, POPULAR ERROURS ERRO; QUETEL C, 1990, HIST SYPHILIS; ROBERTS RS, 1965, EVOLUTION PHARM BRIT, P168; Shiva Vandana, 1997, BIOPIRACY PLUNDER NA; Slack Paul., 1988, POVERTY POLICY TUDOR, P162; Wake ChristopherH.H., 1979, J EUR ECON HIST, V8, P361; 1585, DISCOURSE MED CALLED	25	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					149	151		10.1016/S0140-6736(98)08290-7	http://dx.doi.org/10.1016/S0140-6736(98)08290-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408503				2023-01-03	WOS:000081377100045
J	Guan, L; Ehrmann, M; Yoneyama, H; Nakae, T				Guan, L; Ehrmann, M; Yoneyama, H; Nakae, T			Membrane topology of the xenobiotic-exporting subunit, MexB, of the MexA,B-OprM extrusion pump in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE FUSIONS; MULTIDRUG EFFLUX SYSTEM; GRAM-NEGATIVE BACTERIA; PHOA-GENE FUSIONS; ESCHERICHIA-COLI; INNER MEMBRANE; RESISTANCE GENE; DRUG EXTRUSION; ACTIVE EFFLUX; PROTEIN	The MexA,B-OprM efflux pump assembly of Pseudomonas aeruginosa consists of two inner membrane proteins and one outer membrane protein. The cytoplasmic membrane protein, MexB, appears to function as the xenobiotic-exporting subunit, whereas the MexA and OprM proteins are supposed to function as the membrane fusion protein and the outer membrane channel protein, respectively. Computer-aided hydropathy analyses of MexB predicted the presence of up to 17 potential transmembrane segments. To verify the prediction, we analyzed the membrane topology of MexB using the alkaline phosphatase gene fusion method. We obtained the following unique characteristics. MexB bears 12 membrane spanning segments leaving both the amino and carboxyl termini in the cytoplasmic side of the inner membrane. Both the first and fourth periplasmic loops had very long hydrophilic domains containing 311 and 314 amino acid residues, respectively. This fact suggests that these loops may interact with other pump subunits, such as the membrane fusion protein MexA and the outer membrane protein OprM, Alignment of the amino- and the carboxyl-terminal halves of MexB showed a 30% homology and transmembrane segments 1, 2, 3, 4, 5, and 6 could be overlaid with the segments 7, 8, 9, 10, 11, and 12, respectively. This result suggested that the MexB has a a-fold repeat that strengthen the experimentally determined topology model. This paper reports the structure of the pump subunit, MexB, of the MexA,B-OprM efflux pump assembly. This is the first time to verify the topology of the resistant-nodulation-division efflux pump protein.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Tokai University; University of Konstanz	Nakae, T (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan.	nakae@is.icc.u-tokai.ac.jp	Ehrmann, Michael/A-7307-2012; Guan, Lan/B-5288-2010	Ehrmann, Michael/0000-0002-1927-260X; 				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BROWN MRW, 1975, RESISTANCE PSEUDOMON, P71; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DONG QH, 1994, MOL MICROBIOL, V14, P185, DOI 10.1111/j.1365-2958.1994.tb01278.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Enomoto H, 1998, BBA-BIOMEMBRANES, V1370, P77, DOI 10.1016/S0005-2736(97)00245-9; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; FUKUDA H, 1990, ANTIMICROB AGENTS CH, V34, P1757, DOI 10.1128/AAC.34.9.1757; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gotoh N, 1998, FEMS MICROBIOL LETT, V165, P21, DOI 10.1016/S0378-1097(98)00250-X; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HIRAI K, 1987, ANTIMICROB AGENTS CH, V31, P582, DOI 10.1128/AAC.31.4.582; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI Y, 1991, BIOCHEM BIOPH RES CO, V178, P1043, DOI 10.1016/0006-291X(91)90997-L; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Nakae Taiji, 1997, J Infect Chemother, V3, P173, DOI 10.1007/BF02490031; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ocaktan A, 1997, J BIOL CHEM, V272, P21964, DOI 10.1074/jbc.272.35.21964; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Srikumar R, 1997, J BACTERIOL, V179, P7875, DOI 10.1128/jb.179.24.7875-7881.1997; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351	38	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10517	10522		10.1074/jbc.274.15.10517	http://dx.doi.org/10.1074/jbc.274.15.10517			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187844	hybrid			2023-01-03	WOS:000079663500083
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Designer Jell-O	SCIENCE			English	Editorial Material																		Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1872	1872						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206893				2023-01-03	WOS:000079228600034
J	Wang, C; Stewart, RJ; Kopecek, J				Wang, C; Stewart, RJ; Kopecek, J			Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains	NATURE			English	Article							PHASE-TRANSITION; GEL; HETERODIMER; SWITCH	Stimuli-sensitive polymer hydrogels, which swell or shrink in response to changes in the environmental conditions, have been extensively investigated and used as 'smart' biomaterials and drug-delivery systems(1,2). Most of these responsive hydrogels are prepared from a limited number of synthetic polymers and their derivatives, such as copolymers of (meth)acrylic acid, acrylamide and N-isopropyl acrylamide(3-12). Water-soluble synthetic polymers have also been crosslinked with molecules of biological origin, such as oligopeptides(13) and oligodeoxyribonudeotides(14), or with intact native proteins(15). Very often there are several factors influencing the relationship between structure and properties in these systems, making it difficult to engineer hydrogels with specified responses to particular stimuli. Here we report a hybrid hydrogel system assembled from water-soluble synthetic polymers and a well-defined protein-folding motif, the coiled coil. These hydrogels undergo temperature-induced collapse owing to the cooperative conformational transition of the coiled-coil protein domain. This system shows that well-characterized water-soluble synthetic polymers can be combined with well-defined folding motifs of proteins in hydrogels with engineered volume-change properties(16,17).	Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kopecek, J (corresponding author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.	Jindrich.Kopecek@m.cc.utah.edu						Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Ho CH, 1998, LANGMUIR, V14, P3889, DOI 10.1021/la980148k; HOCHULI H, 1990, GENET ENG, V12, P87; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; Hu ZB, 1998, NATURE, V393, P149, DOI 10.1038/30205; ISER PF, 1998, NATURE, V394, P459; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KOPECEK J, 1971, J POLYM SCI A1, V9, P2801, DOI 10.1002/pol.1971.150091005; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Langer R, 1998, NATURE, V392, P5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Nagahara S, 1996, POLYM GELS NETW, V4, P111, DOI 10.1016/0966-7822(96)00001-9; NG K, 1995, LANGMUIR, V11, P4048, DOI 10.1021/la00010a069; Obaidat AA, 1996, PHARM RES-DORDR, V13, P989, DOI 10.1023/A:1016090103979; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Peppas NA, 1997, CURR OPIN COLLOID IN, V2, P531, DOI 10.1016/S1359-0294(97)80103-3; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SUBR V, 1990, Journal of Biomaterials Science Polymer Edition, V1, P261; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; WANG C, 1998, ACS POLYM PREPRINTS, V39, P194; WANG C, 1998, P INT S CONTR REL BI, V25, P54; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	30	501	522	9	282	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 4	1999	397	6718					417	420		10.1038/17092	http://dx.doi.org/10.1038/17092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164KA	9989405				2023-01-03	WOS:000078461700042
J	MacArthur, C				MacArthur, C			What does postnatal care do for women's health?	LANCET			English	Editorial Material									Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham	MacArthur, C (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.			MacArthur, Christine/0000-0003-0434-2158				*AUD COMM, 1997, FIRST CLASS DEL IMPR; Billingham K, 1998, BRIT MED J, V316, P406, DOI 10.1136/bmj.316.7129.406; BORWN S, 1998, BRIT J OBSTET GYNAEC, V105, P156; Department of Health, 1993, CHANGING CHILDBIRTH; Enkin M., 1995, GUIDE EFFECTIVE CARE; Glazener CMA, 1997, BRIT J OBSTET GYNAEC, V104, P330, DOI 10.1111/j.1471-0528.1997.tb11463.x; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; Gunn J, 1998, BRIT J OBSTET GYNAEC, V105, P991, DOI 10.1111/j.1471-0528.1998.tb10263.x; MACARTHUR C, 1991, HLTH CHILDBIRTH; SHARIF K, 1993, J OBSTET GYNAECOL, V13, P251; SWEET B, 1997, MIDWIFERY TXB MIDWIV	11	30	30	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 30	1999	353	9150					343	344		10.1016/S0140-6736(05)74945-X	http://dx.doi.org/10.1016/S0140-6736(05)74945-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	163ZL	9950436				2023-01-03	WOS:000078437000006
J	Heath, I				Heath, I			A seamless service	BRITISH MEDICAL JOURNAL			English	Article									Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, London NW5 2UP, England.							*CTR ADV INT ED, 1996, PRINC INT ED; NEAL MM, 1992, NEEDLEWORK SCH	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1723	1724		10.1136/bmj.317.7174.1723	http://dx.doi.org/10.1136/bmj.317.7174.1723			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857147	Green Published			2023-01-03	WOS:000077742300037
J	Cherkin, DC; Deyo, RA; Battie, M; Street, J; Barlow, W				Cherkin, DC; Deyo, RA; Battie, M; Street, J; Barlow, W			A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH SURVEY SF-36; SPINAL MANIPULATION; NATURAL-HISTORY; NATIONAL SURVEY; PRIMARY-CARE; NECK PAIN; FOLLOW-UP; PHYSIOTHERAPY; MANAGEMENT; SYMPTOMS	Background and Methods There are few data on the relative effectiveness and costs of treatments for low back pain. We randomly assigned 321 adults with low back pain that persisted for seven days after a primary care visit to the McKenzie method of physical therapy, chiropractic manipulation, or a minimal intervention (provision of an educational booklet). Patients with sciatica were excluded. Physical therapy or chiropractic manipulation was provided for one month (the number of visits was determined by the practitioner but was limited to a maximum of nine); patients were followed for a total of two years. The bothersomeness of symptoms was measured on an 11-point scale, and the level of dysfunction was measured on the 24-point Roland Disability Scale. Results After adjustment for base-line differences, the chiropractic group had less severe symptoms than the booklet group at four weeks (P=0.02), and there was a trend toward less severe symptoms in the physical-therapy group (P=0.06). However, these differences were small and not significant after transformations of the data to adjust for their non-normal distribution. Differences in the extent of dysfunction among the groups were small and approached significance only at one year, with greater dysfunction in the booklet group than in the other two groups (P=0.05). For all outcomes, there were no significant differences between the physical-therapy and chiropractic groups and no significant differences among the groups in the numbers of days of reduced activity or missed work or in recurrences of back pain. About 75 percent of the subjects in the therapy groups rated their care as very good or excellent, as compared with about 30 percent of the subjects in the booklet group (P<0.001). Over a two year period, the mean costs of care were $437 for the physical-therapy group, $429 for the chiropractic group, and $153 for the booklet group. Conclusions For patients with low back pain, the McKenzie method of physical therapy and chiropractic manipulation had similar effects and costs, and patients receiving these treatments had only marginally better outcomes than those receiving the minimal intervention of an educational booklet. Whether the limited benefits of these treatments are worth the additional costs is open to question. (N Engl J Med 1998;339:1021-9.) (C) 1998, Massachusetts Medical Society.	Grp Hlth Ctr Hlth Studies, Dept Hlth Serv, Seattle, WA 98101 USA; Grp Hlth Ctr Hlth Studies, Dept Family Med, Seattle, WA 98101 USA; Grp Hlth Ctr Hlth Studies, Dept Med, Seattle, WA 98101 USA; Grp Hlth Ctr Hlth Studies, Dept Biostat, Seattle, WA 98101 USA; Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA; Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada	University of Washington; University of Washington Seattle; University of Alberta	Cherkin, DC (corresponding author), Grp Hlth Ctr Hlth Studies, Dept Hlth Serv, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Battie, Michele C/C-6155-2018	Battie, Michele C/0000-0001-8499-2040	AHRQ HHS [HS07915] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Assendelft W J, 1996, J Manipulative Physiol Ther, V19, P499; BATTIE MC, 1994, PHYS THER, V74, P219, DOI 10.1093/ptj/74.3.219; Bigos S, 1994, AHCPR PUBLICATION; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; COXHEAD CE, 1981, LANCET, V1, P1065; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; Donelson R, 1990, Orthop Rev, V19, P681; Fisher LD., 1997, BIOMETRICS, V53, P1182; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HALDEMAN S, 1991, ADULT SPINE PRINCIPL, V2, P1581; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; Mckenzie R, 1985, TREAT YOUR OWN BACK; MCKENZIE RA, 1981, LUMBAR SPINE MECH DI; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; *NAT CTRL HLTH STA, 1986, VIT HLTH STAT, V10; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SALKEVER DS, 1985, DHHS PUBLICATION; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; Sternbach RA, 1986, CLIN J PAIN, V2, P49, DOI DOI 10.1097/00002508-198602010-00008; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	33	405	413	0	58	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1021	1029		10.1056/NEJM199810083391502	http://dx.doi.org/10.1056/NEJM199810083391502			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126LL	9761803				2023-01-03	WOS:000076294800002
J	Wetzel, MS; Eisenberg, DM; Kaptchuk, TJ				Wetzel, MS; Eisenberg, DM; Kaptchuk, TJ			Courses involving complementary and alternative medicine at US medical schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Context.-With the public's increasing use of complementary and alternative medicine, medical schools must consider the challenge of educating physicians about these therapies. Objectives.-To document the prevalence, scope, and diversity of medical school education in complementary and alternative therapy topics and to obtain information about the organizational and academic features of these courses. Design.-Mail survey and follow-up letter and telephone survey conducted in 1997-1998. Participants.-Academic or curriculum deans and faculty at each of the 125 US medical schools. Main Outcome Measures.-Courses taught at US medical schools and administrative and educational characteristics of these courses. Results.-Replies were received from 117 (94%) of the 125 US medical schools. Of schools that replied, 75 (64%) reported offering elective courses in complementary or alternative medicine or including these topics in required courses. Of the 123 courses reported, 84 (68%) were stand-alone electives, 38 (31%) were part of required courses, and one (1%) was part of an elective. Thirty-eight courses (31%) were offered by departments of family practice and 14 (11%) by departments of medicine or internal medicine. Educational formats included lectures, practitioner lecture and/or demonstration, and patient presentations. Common topics included chiropractic, acupuncture, homeopathy, herbal therapies, and mind-body techniques. Conclusions.-There is tremendous heterogeneity and diversity in content, format, and requirements among courses in complementary and alternative medicine at US medical schools.	Beth Israel Deaconess Med Ctr, Dept Med, Ctr Alternat Med Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Off Educ Dev, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Wetzel, MS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Ctr Alternat Med Res, 330 Brookline Ave, Boston, MA 02215 USA.	mwetzel@warren.med.harvard.edu			NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM MED ASS COUNC, 1997, ENC MED STUD ED COMP; *ASS AM MED COLL, 1997, DIR AM MED ED; Association of American Medical Colleges, 1998, 1 ASS AM MED SCH, P7; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Berman B M, 1995, J Am Board Fam Pract, V8, P361; BERMAN BM, 1994, ALTERNATIVE MED EXPA; Blumberg D L, 1995, Altern Ther Health Med, V1, P31; Breedlove C, 1997, JAMA-J AM MED ASSOC, V278, P1702, DOI 10.1001/jama.1997.03550200078038; Carlston M, 1997, Fam Med, V29, P559; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; *FED STAT MED BOAR, 1997, REP HLTH CAR FRAUD S; Fox E, 1997, JAMA-J AM MED ASSOC, V278, P761; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; MARTIN JB, 1997, CAB PRIM CAR SER HAR; MUEHSAM PA, 1997, GEA CORRES       SPR, P10; MUEHSAM PA, 1998, GEA CORRES       SPR, P24; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113	18	275	282	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					784	787		10.1001/jama.280.9.784	http://dx.doi.org/10.1001/jama.280.9.784			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729989	Bronze			2023-01-03	WOS:000075609900006
J	Barrett-Connor, E				Barrett-Connor, E			Fortnightly review - Hormone replacement therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY-OF-LIFE; ESTROGEN REPLACEMENT; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; CONTROLLED TRIAL; RISK; BONE; METAANALYSIS; OSTEOPOROSIS; MORTALITY		Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Barrett-Connor, E (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.	ebarrettconnor@ucsd.edu						Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, IN PRESS CONTR CLIN; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Kanis JA, 1996, BONE, V19, pS185, DOI 10.1016/S8756-3282(96)00257-8; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LIMOUZINLAMOTHE MA, 1994, AM J OBSTET GYNECOL, V170, P618, DOI 10.1016/S0002-9378(94)70239-X; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; Newnham H.H., 1997, LANCET S1, V349, pS13; Newton KM, 1997, AM J EPIDEMIOL, V145, P269; Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18; OBrien JE, 1996, J AM COLL CARDIOL, V28, P1111, DOI 10.1016/S0735-1097(96)00306-3; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Porter M, 1996, BRIT J OBSTET GYNAEC, V103, P1025, DOI 10.1111/j.1471-0528.1996.tb09555.x; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; STEVENSON JC, 1996, MENOPAUSE, P243; Torgerson DJ, 1997, ARCH INTERN MED, V157, P2121, DOI 10.1001/archinte.157.18.2121; Tunstall-Pedoe H, 1998, LANCET, V351, P1425, DOI 10.1016/S0140-6736(97)11321-6; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; *WHO, 1996, WHO TECH REP SER, V866; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	40	125	132	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					457	461						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703530				2023-01-03	WOS:000075490200023
J	Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA				Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA		Eastern Cooperative Oncology Grp; N Cent Canc Treatment Grp; SW Oncology Grp	Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection	ANNALS OF INTERNAL MEDICINE			English	Article						surgical procedures, operative; colonic neoplasms; salvage therapy; outcome and process assessment (health care); disease-free survival	COLORECTAL-CARCINOMA; SURGICAL-TREATMENT; ADJUVANT THERAPY; POLYPS; FLUOROURACIL; LEVAMISOLE; METASTASES; LIVER	Background: Follow-up testing after surgery for colon cancer is recommended principally to identify resectable recurrences, but data on the efficacy of, outcomes of, and optimal strategies for this testing are limited. Objectives: To determine the relation between followup tests and salvage surgery, assess outcomes, and document surgical mortality. Design: Retrospective cohort study. Setting: A North American multi-institutional trial comparing postoperative chemotherapy plus follow-up with follow-up alone. Patients: 1247 patients with resected stage II and stage III colon cancer. Intervention: The protocol mandated follow-up testing that could be supplemented at the discretion of treating physicians. Indications of recurrent disease were documented. Measurements: Recurrence, resectable recurrence, surgical mortality, and survival were studied. Results: 548 patients had recurrence of colon cancer. Salvage surgery was attempted in 222 patients (41%). In 109 patients (20%), curative-intent surgery was done for hepatic recurrence (28 patients), pulmonary metastasis (20 patients), local recurrence (24 patients), or recurrence at other sites (37 patients). Most curative-intent surgical procedures were motivated by follow-up testing (36 patients), elevated carcinoembryonic antigen level (41 patients), or symptoms (27 patients). The median follow-up time after curative-intent surgery exceeded 5 years; the estimated 5-year disease-free survival rate was 23%. A solitary lesion was a favorable prognostic factor. The surgical mortality rate was 2%. Curative-intent resections were done in 15 patients with second primary colorectal cancer; 12 of these patients have survived disease-free. Conclusions: Second operations for colon cancer that are triggered by follow-up testing or symptoms are common and can result in long-term disease-free survival.	Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Grand Forks Clin Ltd, Grand Forks, ND 58201 USA	Mayo Clinic; Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Goldberg, RM (corresponding author), Mayo Clin, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	goldberg.richard@mayo.edu	Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013	Goldberg, Richard/0000-0003-3713-6895; 	NATIONAL CANCER INSTITUTE [U10CA025224, P01CA031224, U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31224, CA-37404, CA-25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BALLANTYNE GH, 1993, CANCER, V71, P4252, DOI 10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO;2-6; ECKARDT VF, 1988, CANCER, V61, P2552, DOI 10.1002/1097-0142(19880615)61:12<2552::AID-CNCR2820611227>3.0.CO;2-6; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; HUGHES KS, 1986, SURGERY, V100, P278; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCAFEE MK, 1992, ANN THORAC SURG, V53, P780, DOI 10.1016/0003-4975(92)91435-C; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; NELSON RL, 1993, CANCER-AM CANCER SOC, V71, P4298, DOI 10.1002/1097-0142(19930615)71:12+<4298::AID-CNCR2820711819>3.0.CO;2-9; NORFLEET RG, 1991, GASTROINTEST ENDOSC, V37, P531, DOI 10.1016/S0016-5107(91)70822-5; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; *SAS I INC, 1990, SAS STAT US GUID VER, P1027; STEELE G, 1993, CANCER, V71, P4225, DOI 10.1002/1097-0142(19930615)71:12+<4225::AID-CNCR2820711811>3.0.CO;2-C; TURK PS, 1993, CANCER-AM CANCER SOC, V71, P4267, DOI 10.1002/1097-0142(19930615)71:12+<4267::AID-CNCR2820711816>3.0.CO;2-O; WERNECKE K, 1991, AM J ROENTGENOL, V157, P731, DOI 10.2214/ajr.157.4.1892027; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301	19	226	229	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					27	+		10.7326/0003-4819-129-1-199807010-00007	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652996				2023-01-03	WOS:000074513300004
J	Hewson, MG				Hewson, MG			Traditional healers in southern Africa	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	One task of medical anthropologists is to search for similarities and differences among cultural conceptions of illness and healing. This search may identify common, if not universal, characteristics of healing and effective patient care. This paper describes traditional healing practices in southern Africa as related by six traditional healers. Despite the seemingly exotic nature of their practice, the traditional healers' underlying strategies (probing deeply into the psychological, spiritual, and social contexts of illness and using healing ceremonies and natural medicinal preparations) seem to be effective in certain circumstances. Perhaps more important, these strategies can leave both patient and practitioner with a sense of connection and satisfaction. A study of these strategies reveals some general qualities of the healing process that are more apparent in the absence of sophisticated technology.	Cleveland Clin Fdn, Div Educ, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hewson, MG (corresponding author), Cleveland Clin Fdn, Div Educ, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Cassel, 1991, NATURE SUFFERING GOA; Damasio AR, 1994, DESCARTESERROR EMOTI; Fadiman J. A., 1977, AFR STUD REV, V20, P87, DOI [10.2307/523864, DOI 10.2307/523864]; Frank J. D., 1973, PERSUASION HEALING C; Hewson MG, 1996, J GEN INTERN MED, V11, P481, DOI 10.1007/BF02599044; HEWSON MGA, 1985, ANTHROPOL EDUC QUART, V16, P31, DOI 10.1525/aeq.1985.16.1.05x0849q; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Levenstein J, 1989, COMMUNICATING MED PA; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; LIPKING M, 1995, MED INTERVIEW CLIN; MBITI JS, 1969, AFRICAN REL PHILOS; MCCALLUM TG, 1992, WHITE WOMAN WITCHDOC; NGUBANE H, 1992, SOCIAL BASIS HLTH HE; NOVACK DH, 1995, MED INTERVIEW CLIN C; OSLER W, 1910, BMJ-BRIT MED J, V2, P1470; RANTALA E, 1992, BASELINE STUDY HLTH; Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Sharma H.M., 1996, FUNDAMENTALS COMPLEM; Smith RC, 1996, PATIENTS STORY INTEG; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125	23	55	57	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1029	1034		10.7326/0003-4819-128-12_Part_1-199806150-00014	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625666				2023-01-03	WOS:000074201300010
J	Kuo, PY; Sherwood, JK; Saltzman, WM				Kuo, PY; Sherwood, JK; Saltzman, WM			Topical antibody delivery systems produce sustained levels in mucosal tissue and blood	NATURE BIOTECHNOLOGY			English	Article						drug delivery; controlled-release; passive immunization	MONOCLONAL-ANTIBODIES; CONTROLLED-RELEASE; GENITAL HERPES; VAGINA; MICE; ETHINYLESTRADIOL; CONTRACEPTION; ABSORPTION; TRANSPORT; ESTRIOL	Immunity at mucosal surfaces, which are ports of entry for many pathogens, is essential in preventing infections. But most current strategies for passive immunization involve injection of antibodies for systemic, not mucosal, protection. We measured mucosal and systemic antibody levels after controlled topical delivery to the vagina. Poly(ethylene-co-vinyl acetate) disks containing I-125-labeled monoclonal IgG or anti-lactate dehydrogenase-C, antibodies were placed in the vaginas of mice. High antibody levels (0.26-12 mu g/ml) were maintained at the mucosal surface for 7 days after disk insertion. Antibody molecules also penetrated into the vaginal epithelium, presumably by diffusing through the extracellular space, and entered the circulation. Biologically active antibodies were detected in the blood. The antibody concentration in the blood was approximately 1% of the concentration in the vagina. Although the permeability of the epithelium to macromolecules is low, high concentrations were maintained at the luminal surface for an extended period, permitting substantial systemic uptake of antibody.	Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	Cornell University; Johns Hopkins University	Saltzman, WM (corresponding author), Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043873] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43873] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTER D, 1990, CONTRACEPTION, V42, P285, DOI 10.1016/0010-7824(90)90016-O; BAXTER LT, 1994, CANCER RES, V54, P1517; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; BENZIGER DP, 1983, DRUG METAB REV, V14, P137, DOI 10.3109/03602538308991387; Castle PE, 1997, BIOL REPROD, V56, P153, DOI 10.1095/biolreprod56.1.153; CLAUSS MA, 1990, CANCER RES, V50, P3487; CONE RA, 1994, AM J REPROD IMMUNOL, V31, P1; Gude WD, 1982, HISTOLOGICAL ATLAS L, P17; Kuo PYP, 1996, CRIT REV EUKAR GENE, V6, P59, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.40; KUO PYP, 1996, THESIS J HOPKINS U B; MA JKC, 1990, ARCH ORAL BIOL, V35, pS115, DOI 10.1016/0003-9969(90)90140-6; Ogra PL., 1994, HDB MUCOSAL IMMUNOLO, P705; OHERN PA, 1995, BIOL REPROD, V52, P331, DOI 10.1095/biolreprod52.2.331; OKADA H, 1991, PEPTIDE PROTEIN DRUG, P633; OLSSON SE, 1990, CONTRACEPTION, V42, P563, DOI 10.1016/0010-7824(90)90083-8; Parr M, 1994, HDB MUCOSAL IMMUNOLO, P677; RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133; SALTZMAN WM, 1989, BIOPHYS J, V55, P163, DOI 10.1016/S0006-3495(89)82788-2; SALTZMAN WM, 1993, CRIT REV THER DRUG, V10, P111; SCHIFF I, 1980, AM J OBSTET GYNECOL, V138, P1137, DOI 10.1016/S0002-9378(16)32780-6; SCHIFF I, 1977, FERTIL STERIL, V28, P1063; SCHIFF I, 1978, FERTIL STERIL, V30, P278; Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468; Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264; SHERWOOD JK, 1996, THESIS J HOPKINS U B; SHERWOOD JK, 1993, THESIS J HOPKINS U B; TACKET CO, 1988, NEW ENGL J MED, V318, P1240, DOI 10.1056/NEJM198805123181904; WHALEY KJ, 1994, J INFECT DIS, V169, P647, DOI 10.1093/infdis/169.3.647; [No title captured]	29	26	28	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1998	16	2					163	167		10.1038/nbt0298-163	http://dx.doi.org/10.1038/nbt0298-163			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YV500	9487523				2023-01-03	WOS:000071831300029
J	Adam, J				Adam, J			ABC of palliative care - The last 48 hours	BRITISH MEDICAL JOURNAL			English	Article									Hunter Hill Marie Curie Ctr, Glasgow, Lanark, Scotland		Adam, J (corresponding author), Hunter Hill Marie Curie Ctr, Glasgow, Lanark, Scotland.								0	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1600	1603		10.1136/bmj.315.7122.1600	http://dx.doi.org/10.1136/bmj.315.7122.1600			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437282	Green Published			2023-01-03	WOS:000071021900032
J	Keane, FM; Munn, SE; du Vivier, AWP; Taylor, NF; Higgins, EM				Keane, FM; Munn, SE; du Vivier, AWP; Taylor, NF; Higgins, EM			Analysis of Chinese herbal creams prescribed for dermatological conditions	BRITISH MEDICAL JOURNAL			English	Article							ECZEMA	Objective To determine whether Chinese herbal creams used for the treatment of dermatological conditions contain steroids. Design 11 herbal creams obtained from patients attending general and paediatric dermatology outpatient clinics were analysed with high resolution gas chromatography and mass spectrometry Setting Departments of dermatology and clinical biochemistry Main outcome measure Presence of steroid. Results Eight creams contained dexamethasone at a mean concentration of 456 mu g/g (range 64 to 1500 mu g/g). All were applied to areas of sensitive skin such as face and flexures. Conclusion Greater regulation needs to be imposed on Chinese herbalists to prevent illegal and inappropriate prescribing of potent steroids.	Univ London Kings Coll Hosp, Dept Dermatol, London SE5 9RS, England; Univ London Kings Coll Hosp, Dept Clin Biochem, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Keane, FM (corresponding author), Univ London Kings Coll Hosp, Dept Dermatol, London SE5 9RS, England.							ALLEN BR, 1990, LANCET, V336, P177, DOI 10.1016/0140-6736(90)91696-8; HUGHES JR, 1994, BRIT J DERMATOL, V130, P261, DOI 10.1111/j.1365-2133.1994.tb02916.x; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; ODRISCOLL J, 1992, BRIT J DERMATOL, V127, P543, DOI 10.1111/j.1365-2133.1992.tb14859.x; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E	7	77	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 27	1999	318	7183					563	564		10.1136/bmj.318.7183.563	http://dx.doi.org/10.1136/bmj.318.7183.563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	173DQ	10037629	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000078966300024
